Scientific Report 2020

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz



START

Index

1 Introduction

2 Executive summary

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication and Public Engagement
- 2.13 Responsible Research and Innovation

3 Information Groups by Area

- 3.1 Neuroscience Area
- 3.2 Cardiovascular Area
- 3.3 Infectious Diseases and Immunity Area
- 3.4 Large System Pathologies Area
- 3.5 Cancer and Human Molecular Genetics Area
- 3.6 Surgery, Transplant and Health Technologies Area

4 Associated Clinicians

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

1 Introduction



Dr. Rafael Pérez-Santamarina Feijóo

Managing Director of HULP Chairman of the Board of FIBHULP



Dr. Eduardo López-Collazo

Scientific Director of IdiPAZ



2020 will be recorded in our memory for the devastating effects of the SARS CoV-2 pandemic, but it is also necessary to highlight the extraordinary response of scientific and health professionals who are part of our institution. The health, social and economic deep impact is still present in our days.

Therefore, the 2020 Scientific Report of IdiPAZ is a report of activities that provides us an opportunity to recognize these achievements of our researchers, who dedicated their tireless effort in trying to reduce the terrible impact of the pandemic to the society, despite of the difficulties, with their projects in the different research groups and areas.

To IdiPAZ changes also included the incorporation of the University Hospital of Getafe and the European University of Madrid inside to our health research institute accredited by the Health Institute Carlos III. The main goal of these union are to promote, develop and integrate the excellence research in Health Sciences. This new structure has provide an opportunity to create new synergies and reinforce several lines of existing research and creates new ones. For the future, IdiPAZ marks new horizons, promoting new research area of the institute, as health aging and frailty in the elderly, advances therapies or big data analysis for personalized medicine.

Throughout 2020, the IdiPAZ research groups have been working in other areas, contributing in a very important way to preserve the health of all citizens. This scientific report offers the opportunity to deepen the main lines of action of these centers and their impact society, always at the service of health and focused on the citizen's needs.

IdiPAZ has promoted the configuration of multidisciplinary teams capable of addressing several facets of translational research, with the mind always focused on the generation of innovation and the transfer of results to the healthcare system. Over the years, we have maintained a progressive growth of our scientific activity, which is structured into six research areas: neurosciences, cardiovascular, infectious diseases and immunity, large

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

system pathologies, cancer and human molecular genetics and surgery, transplants and health technologies.

Regarding to the transfer to society of the main achievements on innovation, we would like to point out the consolidation of a culture of innovation in the Institute that has led to the generation of a large community of innovative professionals. A wide and varied technological portfolio has been generated with high transfer capacity to the market; continuous and sustained growth of the transfer and exploitation rates of its technological portfolio. Generation of a wide and varied technological portfolio with a high capacity for transference to the market; a continuous and sustained growth of the transfer and exploitation rates of its technological portfolio; to be a pioneer in the creation of the first hospital spin-offs in the region of the Community of Madrid. The creation of a wide-ranging network of contacts and collaborators. At 31st of December 2020 the Innovation Support Unit had 214 innovation projects or ideas in active state, 21 of them were in the initial phase, 59 in the evaluation phase, 34 in development, 64 in transfer and 36 in the market. Also, we have done an effort to continue and improve our translational research with a direct application to the care of our patients, and in this strategic process, at less 364 new contracts for clinical trials were signed in this year. Finally, to improve the R&D&I, the IdiPAZ worked in the implementation of the certification of the Institute's R&D&I Management System that it includes, actually, 15 units or platforms in differents international norms.

The involvement of the university, in most of the research groups, has resulted in a high participation in graduate programs, generating more than 26 Doctoral Theses in this year; 4 of them has been qualified with an International Mention.



In addition, applying the principles of Responsible Research and Innovation (RRI), IdiPAZ professionals went a step further and became involved in the difficult task of transferring to society the science that was being generated around the world at great speed. In our interest to promote research and science to the Society, we hosted many scientific activities as the European Researchers' Night, the Science and Innovation Week, the International Day of Woman and Girl in Science, and different events of scientific dissemination organized with the objective of actively involving citizens in science, technology and innovation and, mainly aimed at the youngest public, to promote scientific vocations In parallel, our institution is making a great effort to promote IdiPAZ trademark and collaborations both national and internationally.

Once again we would like to thanks all the staff for their work, their effort, and dedication, essential for the fulfillment of the aims of the Institute, which they have been essential in contributing to the fight against the pandemic throughout 2020. They have demonstrate their ability to adapt and respond to the most urgent needs and to work for do better science for a better Society. To all of you, our sincere gratitude and appreciation for your daily work. Thank you very much.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2 Executive summary

2.1 Global Analysis
2.2 Research Structure
2.3 Training Report and Teaching
2.4 Innovation and Transfer Activities
2.5 Quality Committe
2.6 Clinical Trials
2.7 Platforms
2.8 Scientific Production
2.9 CIBERs and RETICs
2.10 Institutional Projects
2.11 Internationalization
2.12 Comunication and Public Engagement
2.13 Responsible Research and Innovation



Doctoral theses. European Mention

Covid-19

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.1 Global Analysis

2.1.1 Scientific Analysis

In 2020, the scientific production of IdiPAZ included more than 1,400 publications, with 8,511 points of total impact factor. It is the best impact factor for the last few years.


Nearly of 50% of the publications are IdiPAZ own documents, so the author the first, the last or the corresponding author of the publication is a researcher of the institute. The original articles by IdiPAZ researchers overcome the thousand and exceeding the 4,700-point threshold (4,711.54 points).

1,460 Publications


1,099 Originals

	Total	Impact Factor	Mean Impact Factor
Publications	**1,460**	8,511.17	5.83
Owned Publications	**693**	2,740.54	3.95
Un-owned Publications	**767**	5,770.64	7.52
Originals	**1,099**	6,572.54	5.98
Owned Originals	**452**	1,678.49	3.71
Un-owned Originals	**647**	4,894.05	7.56

Total Impact Factor between 2009-2020




Mean Impact Factor between 2009-2020




2.1 Global Analysis

2.1.1 Scientific Analysis


Total Impact Factor for original papers between 2009-2020




Mean Impact Factor for original papers between 2009-2019



Distribution of publications by quartile 2009-2020



Distribution of originals by quartile 2009-2020



It is important to highlight the quality of the journals in which the articles were published in 2020, more than 17% of them were published in journals of the first decile of their subject area, also the publication in journals in the first quartile overcome the 42%.


2.1 Global Analysis

2.1.1 Scientific Analysis


IdiPAZ researchers evidenced their participation in national and international scientific networks, with almost 84% of the total documents published in collaboration (83.56%), which 88.63% of the originals publications. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached almost 16% for all manuscripts and for originals.

The upward trend in scientific activity conducted by our groups is also reinforced by the analysis of originals belong to IdiPAZ researchers. In 2020, 452 original IdiPAZ articles were published, with a mean impact factor of 3.71. The growth rates achieved in previous years have been increased in both indexes.

Papers with international collaboration between 2009-2020



Owned originals between 2009-2020



COVID scientific activity

IdiPAZ researcher worked for up-date the scientific information about SARS-CoV-2 and to accelerate diagnostics, vaccines and therapeutics strategies to deliver quick results for sociecity and the COVID-19 patients.

The *Instituto de Salud Carlos III* granted 6 research project outstanding researchers of IdiPAZ in finding solutions to challenges posed by the novel coronavirus disease COVID-19 and other infectious diseases. Also, 19 research projects y 29 clinical trials were performed by the IdiPAZ researchers.

	Total	Impact Factor	Mean Impact Factor
Publications	**170**	1,591.27	9.36
Owned Publications	**90**	295.42	3.28
Un-owned Publications	**80**	1,295.85	16.20
Originals	**105**	1,245.60	11.86
Owned Originals	**47**	129.78	2.76
Un-owned Originals	**58**	1,115.83	19.24
1st. Decile	**31**	1,189.54	38.37
1st Quartile	**67**	1,385.07	20.67

Introduction

Executive summary

Information Groups by Area


Associated Clinicians

2.1.2 Annual Accounts

In accordance with the Law 19/2013, of December 9th, of transparency, access to public information and good governance, the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) makes their information public, with the objective of guaranteeing institutional transparency:

Transparency data on the web

Economic income 2020



Economic income overhead 2020



	2019	2020
Income		
Income from own activity	**16.568.199,67 €**	**16.568.199,67 €**
Financial income	**40.977,53 €**	**40.977,53 €**
Exceptional income	**- €**	**- €**
Exchange rate differences	**4.224,27 €**	**4.224,27 €**
TOTAL INCOME	**16.613.401,47 €**	**16.613.401,47 €**
Expenses		
Monetary aid and others	**105.888,34 €**	**105.888,34 €**
Procurement	**951.344,89 €**	**951.344,89 €**
Staff costs	**7.006.763,30 €**	**7.006.763,30 €**
Other exploitation costs	**4.740.556,15 €**	**4.740.556,15 €**
Amortizations	**1.181.479,16 €**	**1.181.479,16 €**
Financial cost	**126.899,48 €**	**126.899,48 €**
Exchange rate differences	**3.767,39 €**	**3.767,39 €**
Exceptional costs	**900,00 €**	**900,00 €**
Provision (endowment - excess)	**2.245.938,18 €**	**2.245.938,18 €**
TOTAL EXPENSES	**16.363.536,89 €**	**16.363.536,89 €**
RESULTS	**249.864,58 €**	**249.864,58 €**

In 2020, the foundation –FIBHULP- received a Nominative Transfer of the *Consejeria de Sanidad de la Comunidad de Madrid* in favor of charging the 312D program "Biomedical Research Foundations", to fund the following items:

- Researchers and personal of support of the I3, I3SNS, Miguel Servet I, Miguel Servet II, Río Hortega, Sara Borrell, Juan de la Cierva, Marie Skłodowska-Curie, and Juan Rodés Programs.
- Intensification Programs of health professionals.
- Activities of promotion and dissemination research and scientific culture.
- Accreditations of the research activity.
- Support to the Technical Units or Platforms for Research and Management of R+D+i

By the other hand, in 2020, the emergency situation caused by the SARS-CoV-2 has led the Consejeria de Sanidad to promote R+D+i in the COVID-19 disease, through a nominative transfer COVID-19 to the FIBHULP, for the development of research projects, clinical trials and other initiatives proposed by the research groups.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



mazars

C/ Alcalá, 57
28014 Madrid
+ 34 915 424 030
www.mazars.es

Informe de Auditoría de Cuentas Anuales emitido por un Auditor Independiente

Al Patronato de
Fundación para la Investigación Biomédica del Hospital Universitario La Paz

Opinión

Hemos auditado las cuentas anuales de la **Fundación para la Investigación Biomédica del Hospital Universitario La Paz** (la Fundación), que comprenden el balance a 31 de diciembre de 2020, la cuenta de resultados y la memoria correspondientes al ejercicio terminado en dicha fecha.

En nuestra opinión, las cuentas anuales adjuntas expresan, en todos los aspectos significativos, la imagen fiel del patrimonio y de la situación financiera de la Fundación a 31 de diciembre de 2020, así como de sus resultados y flujos de efectivo correspondientes al ejercicio terminado en dicha fecha, de conformidad con el marco normativo de información financiera que resulta de aplicación (que se identifica en la nota 2 de la memoria) y, en particular, con los principios y criterios contables contenidos en el mismo.

Fundamento de la opinión

Hemos llevado a cabo nuestra auditoría de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España. Nuestras responsabilidades de acuerdo con dichas normas se describen más adelante en la sección *Responsabilidades del auditor en relación con la auditoría de las cuentas anuales* de nuestro informe.

Somos independientes de la Fundación de conformidad con los requerimientos de ética, incluidos los de independencia, que son aplicables a nuestra auditoría de las cuentas anuales en España según lo exigido por la normativa reguladora de la actividad de auditoría de cuentas. En este sentido, no hemos prestado servicios distintos a los de la auditoría de cuentas ni han concurrido situaciones o circunstancias que, de acuerdo con lo establecido en la citada normativa reguladora, hayan afectado a la necesaria independencia de modo que se haya visto comprometida.


Consideramos que la evidencia de auditoría que hemos obtenido proporciona una base suficiente y adecuada para nuestra opinión.

Aspectos más relevantes de la auditoría

Los aspectos más relevantes de la auditoría son aquellos que, según nuestro juicio profesional, han sido considerados como los riesgos de incorrección material más significativos en nuestra auditoría de las cuentas anuales del periodo actual. Estos riesgos han sido tratados en el contexto de nuestra auditoría de las cuentas anuales en su conjunto, y en la formación de nuestra opinión sobre éstas, y no expresamos una opinión por separado sobre esos riesgos.

Oficinas en: Alicante, Barcelona, Bilbao, Madrid, Málaga, Valencia, Vigo

MAZARS Auditores, S.L.P. (Sociedad Social: Calle Diputació, 260, 08007 Barcelona
Registro Mercantil de Barcelona, Tomo 33.704, Folio 213, Hoja B-180111, Inscripción 1ª, C.I.F. B-81922382
Inscrita con el número 21149 en el Registro Oficial de Auditores de Cuentas (ROAC)



mazars

Inversiones financieras

El activo del balance adjunto a 31 de diciembre de 2020 presenta, en el epígrafe "Inversiones financieras a corto plazo", depósitos bancarios y fondos de inversión por importe de 19.474 miles de euros. Dado el importe significativo de estos activos sobre el total de activos de la Fundación, consideramos su naturaleza y valoración como un aspecto relevante de nuestra auditoría.

Nuestros procedimientos de auditoría han incluido, entre otros, (i) entendimiento y revisión en detalle de la composición de las inversiones, así como su clasificación para su valoración (ii) la confirmación con las entidades depositarias de la naturaleza y los importes de dichos activos financieros a 31 de diciembre de 2020, (iii) la evaluación del cumplimiento del Código de Conducta de las entidades sin ánimo de lucro para la realización de inversiones temporales, aprobado mediante Acuerdo del Consejo de la Comisión Nacional del Mercado de Valores, de fecha 20 de febrero de 2019 y (iv) la revisión de que la memoria adjunta, en las notas 4.7 y 8.1, incluye los desgloses de información que requiere el marco de información financiera aplicable.

Ingresos de la entidad por su actividad propia

La cuenta de resultados adjunta incluye, dentro del epígrafe "Ingresos de la entidad por su actividad propia", los ingresos derivados de ensayos clínicos, por un importe de 8.176 miles de euros, y los ingresos procedentes de subvenciones y donaciones, por un importe de 8.802 miles de euros. Los ingresos por ensayos clínicos se reconocen cuando el promotor del ensayo aprueba las visitas realizadas. Las subvenciones y donaciones se imputan a resultados en función del gasto ejecutado en los proyectos durante el ejercicio, junto con el overhead correspondiente. Dichos ingresos contienen diferentes condiciones de aplicación, uso y métodos de justificación que condicionan el registro contable de los mismos. Por ello, consideramos su valoración como un aspecto relevante en nuestra auditoría.

Nuestros procedimientos de auditoría han incluido, entre otros, (i) el entendimiento y la revisión del procedimiento seguido por la Fundación para el control de la gestión de los ensayos clínicos y los proyectos de investigación, (ii) la revisión en detalle de una muestra de ingresos para comprobar si las cantidades contabilizadas se corresponden con los importes acordados y cobrados, (iii) la comprobación del registro contable de dichos ingresos en el periodo correcto, (iv) la confirmación con una muestra de los entidades financiadoras de los importes pendientes de cobro a 31 de diciembre de 2020, (v) el análisis de la recuperabilidad de los saldos deudores a 31 de diciembre de 2020 y (vi) la revisión de que la memoria adjunta, en las notas 4.14, 17 Y 18, incluye los desgloses de información que requiere el marco de información financiera aplicable.


Importes pendientes de ejecutar en ensayos clínicos y proyectos de investigación

El pasivo corriente del balance adjunto presenta, en el epígrafe "Provisiones a corto plazo", la cantidad de 20.694 miles de euros. Dicho importe incluye 20.357 miles de euros, correspondientes a los importes pendientes de ejecutar a 31 de diciembre de 2020 en ensayos clínicos y proyectos de investigación, que se encuentran a disposición de los investigadores responsables, según lo estipulado en los contratos y acuerdos suscritos. Dado el importe significativo de este epígrafe sobre el pasivo corriente de la Fundación, consideramos su valoración como un aspecto relevante en nuestra auditoría.

Nuestros procedimientos de auditoría han incluido, entre otros, (i) el entendimiento y la revisión del procedimiento seguido por la Fundación para el control de los importes pendientes de ejecutar en ensayos clínicos y proyectos de investigación, (ii) la comprobación de que el saldo de la provisión a 31 de diciembre de 2020 coincida con el detalle de los ensayos clínicos y proyectos de investigación, y (iii) la revisión de que la memoria adjunta, en las notas 4.15 y 15, incluye los desgloses de información que requiere el marco de información financiera aplicable.

2

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



mazars

Responsabilidad de la Directora de la Fundación en relación con las cuentas anuales

La Directora de la Fundación es responsable de formular las cuentas anuales adjuntas, de forma que expresen la imagen fiel del patrimonio, de la situación financiera y de los resultados de la Fundación, de conformidad con el marco normativo de información financiera aplicable a la Fundación en España, y del control interno que considere necesario para permitir la preparación de cuentas anuales libres de incorrección material, debida a fraude o error.

En la preparación de las cuentas anuales, la Directora de la Fundación es responsable de la valoración de la capacidad de la Fundación para continuar como entidad en funcionamiento, revelando, según corresponda, las cuestiones relacionadas con la entidad en funcionamiento y utilizando el principio contable de entidad en funcionamiento excepto si el Patronato de la Fundación tiene intención de liquidar la Fundación o de cesar sus operaciones, o bien no existe otra alternativa realista.

Responsabilidades del auditor en relación con la auditoría de las cuentas anuales

Nuestros objetivos son obtener una seguridad razonable de que las cuentas anuales en su conjunto están libres de incorrección material, debida a fraude o error, y emitir un informe de auditoría que contiene nuestra opinión. Seguridad razonable es un alto grado de seguridad pero no garantiza que una auditoría realizada de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España siempre detecte una incorrección material cuando existe. Las incorrecciones pueden deberse a fraude o error y se consideran materiales si, individualmente o de forma agregada, puede preverse razonablemente que influyan en las decisiones económicas que los usuarios toman basándose en las cuentas anuales.

Como parte de una auditoría de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España, aplicamos nuestro juicio profesional y mantenemos una actitud de escepticismo profesional durante toda la auditoría. También:

- Identificamos y valoramos los riesgos de incorrección material en las cuentas anuales, debida a fraude o error, diseñamos y aplicamos procedimientos de auditoría para responder a dichos riesgos y obtenemos evidencia de auditoría suficiente y adecuada para proporcionar una base para nuestra opinión. El riesgo de no detectar una incorrección material debida a fraude es más elevado que en el caso de una incorrección material debida a error, ya que el fraude puede implicar colusión, falsificación, omisiones deliberadas, manifestaciones intencionadamente erróneas, o la elusión del control interno.
- Obtenemos conocimiento del control interno relevante para la auditoría con el fin de diseñar procedimientos de auditoría que sean adecuados en función de las circunstancias, y no con la finalidad de expresar una opinión sobre la eficacia del control interno de la Fundación.
- Evaluamos si las políticas contables aplicadas son adecuadas y la razonabilidad de las estimaciones contables y la correspondiente información revelada por la Directora de la Fundación.
- Concluimos sobre si es adecuada la utilización, por la Directora de la Fundación, del principio contable de entidad en funcionamiento y, basándonos en la evidencia de auditoría obtenida, concluimos sobre si existe o no una incertidumbre material relacionada con hechos o con condiciones que pueden generar dudas significativas sobre la capacidad de la Fundación para continuar como entidad en funcionamiento. Si concluimos que existe una incertidumbre material, se requiere que llamemos la atención en nuestro informe de auditoría sobre la correspondiente información revelada en las cuentas anuales o, si dichas revelaciones no son adecuadas, que expresemos una opinión modificada. Nuestras conclusiones se basan en la evidencia de auditoría obtenida hasta la fecha de nuestro informe de auditoría. Sin embargo, los hechos o condiciones futuros pueden ser la causa de que la Fundación deje de ser una entidad en funcionamiento.

3



mazars

- Evaluamos la presentación global, la estructura y el contenido de las cuentas anuales, incluida la información revelada, y si las cuentas anuales representan las transacciones y hechos subyacentes de un modo que logran expresar la imagen fiel.

Nos comunicamos con la Directora de la Fundación en relación con, entre otras cuestiones, el alcance y el momento de realización de la auditoría planificada y los hallazgos significativos de la auditoría, así como cualquier deficiencia significativa del control interno que identificamos en el transcurso de la auditoría.

Entre los riesgos significativos que han sido objeto de comunicación a la Directora de la Fundación, determinamos los que han sido de la mayor significatividad en la auditoría de las cuentas anuales del periodo actual y que son, en consecuencia, los riesgos considerados más significativos.

Describimos esos riesgos en nuestro informe de auditoría salvo que las disposiciones legales o reglamentarias prohíban revelar públicamente la cuestión.

Madrid, 23 de junio de 2021

MAZARS AUDITORES, S.L.P.
ROAC Nº S1189

Juan Antonio Giménez Miró
ROAC Nº 15.588

4

2.2 Research Structure

Scientific Director

Eduardo López-Collazo

Scientific Assistant Director

Ignacio Zapardiel Gutiérrez

Technical Assistant Director

Paloma Gómez Campelo

Governing Council

Chairman

Antonio Zapatero Gaviria. Healthcare vice Councilor CM

Deputy Chairman

Rafael Garesse Alarcón. Chancelor of UAM

Members

Rafael Pérez-Santamarina Feijoo. Managing Director of HULP, Chair of the Board of FIBHULP

Rodolfo Álvarez-Sala Walther. FIBHULP Patron

Teresa Chavarría Giménez. FIBHULP Patron

Juan José Ríos Blanco. FIBHULP Patron

Eduardo López-Collazo. IdiPAZ Scientific Director

Almudena Castro Conde. FIBHULP Patron

Exuperio Díez Tejedor. FIBHULP Patron

Francisco Javier García-Samaniego Rey. FIBHULP Patron

Antonio Pérez Martínez. FIBHULP Patron

Susana Noval Martín. HULP Representative

Francisco García Río. HULP Representative

Paloma Gómez Campelo. HULP Representative

Carlos Félix Sánchez Ferrer. UAM Representative

Luis del Peso Ovalle. UAM Representative

Esther López García. UAM Representative

Miguel Ángel Andrés Molinero. Managing Director of HUG

Óscar García López. UEM Representative

Secretary

Ana Coloma Zapatero. Director of FIBHULP

Executive Committee

Chairman

Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP; permanent delegation to Rodolfo Álvarez-Sala Walther.

Members

Eduardo López-Collazo. IdiPAZ Scientific Director/Stabilized Research

Francisco García Río. HULP Representative

Juan José Ríos Blanco. HULP Representative

Ignacio Zapardiel Gutiérrez. IdiPAZ Scientific Assistant Director

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Paloma Gómez Campelo. IdiPAZ Technical Assistant Director

Carlos Félix Sánchez Ferrer. UAM Representative

Francisco Arnalich Fernández. UAM Representative

Miguel Ángel Andrés Molinero. Managing Director of HUG

Rosa Carmen Fernández Lobato. HUG Representative

Óscar García López. UEM Representative

Secretary

Ana Coloma Zapatero. Director of FIBHULP

External Scientific Committee

Juan Tamargo Menéndez. Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC) - Complutense University of Madrid. Madrid

Reiner Albert Veitia. Professor. Université Denis Diderot, Paris VII. Group leader of the Molecular Oncology and Ovarian Pathologies, l'Institut Jacques Monod. Paris

Joaquín Arribas López. Preclinical Research Program Director and Principal Investigator of the VHIO Growth Factors Group. Vall d´Hebron Hospital. Barcelona. Chair of the Technical Committee on Cancer Screening Health Research Fund (FIS). Institute of Health Carlos III

Jacinta Cecilia Bustamante. Associate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris

Carlos Belmonte Martínez. Professor. Miguel Hernández University. Institute of Neurosciences. Alicante President of the International Brain Research Organization (IBRO)

Isabel Fabregat Romero. Research Group Coordinator. Centre d´Oncologia Molecular. L´Hospitalet, Barcelona IDIBELL- Bellvitge Biomedical Research Institute. Barcelona

Carmen Maroto Vela. Professor. Chief of Microbiology. Clinical Hospital University of Granada

Santiago Moreno Guillén. Chief of Infectious diseases Service. Ramón y Cajal Hospital. Madrid Professor. Alcalá University. Madrid

Juan Pedro Bolaños Hernández. Departament of Biochemistry and Molecular Biology. University of Salmanca. Institute of Functional Biology and Genomics. Salamanca.

Santiago Rodríguez de Córdoba. Professor. Cellular and Molecular Medicine Department. Center of Biological Research. CSIC. Madrid

Pablo Pelegrin Vivancos. Scientific Assistant Director. Principal Investigator in Group: Digestive Surgery, Endocrine and Abdominal Organ Transplantation. Virgen de la Arrixaca Biosanitary Research Institute. Murcia

Elisa Martí Gorostiza. Head researcher of Development of the Spinal Cord in health and disease. Instituto de Biología Molecular de Barcelona (CSIC). Barcelona



Animal Welfare Organ

Carmen Fernández Criado. Director of the Veterinary Office of the Faculty of Medicine of the UAM.Specialist in Animal Health and Welfare as an external consultant

Fernando Carceller Benito. Deputy Neurosurgery Service HULP as optional and researcher of the "Neurology and Cerebrovascular Disease" from IdiPAZ

Nuria Vilaboa Díaz. IdiPAz´s resercher. Internal consultant

Carlota Largo Aramburu. Head of the animal Service HULP Experimental Surgery Specialist in Animal Health and Welfare Center.

Technical Secretary

Mercedes Ruiz Balibrea

Lucia Medina Royo

Daniel Quijada Alcón

Documentation Service

Raúl Román Cañizares

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Internal Scientific Committee

Chairman

Eduardo López Collazo, Scientific Director

Secretary

Nora Butta Coll. HULP Representative

Members

Ignacio Zapardiel Gutiérrez. Scientific Assistant Director

Paloma Gómez Campelo. Technical Assistant Director

Javier de Castro Carpeño. Innovation Support Unit Coordinator

José Jonay Ojeda Feo. Quality Committee Coordinator

Bárbara Martínez de Miguel. Training Committee Coordinator

Alejandro Martín Quirós. Postdoctoral Representative

Karla Marina Montalbán. Predoctoral Representative

HULP representatives

Francisco García Río

Antonio Pérez Martínez

Jaime Feliu Batlle

José Luis Merino

María Gutiérrez Fernández

Nuria Vilaboa Díaz

Blanca Fuentes Gimeno

Inmaculada Ibáñez de Cáceres

María Auxiliadora Bajo

UAM representatives

María Carmen Sellán Soto

Esther López García

Mercedes Salaices Sánchez

Francisco Arnalich Fernández

Belén Pérez González

HUG representatives

Javier Sánchez-Rubio Ferrández

Andrés Maldonado Morillo

Raquel Herrero Hernández

UEM representatives

Óscar García López

FIBHULP

Director

Ana Coloma Zapatero

Human Reesources Manager

Head: Ana Gloria Herrera Puerta

María Quintanar Jaime

Private Projects Manager

Head: F. G. G.

Nathalia García Quero

Clinical Trial Manager

Head: Sara Moral Álamo

Desirée Hernández López

Public Projects Manager

Head: Silvia Arce Santamaría

Raquel Carmona del Mazo

Institutional Projects Manager

José Luis Narro Villanueva

Marisa Tejedor Botello

European Projects Manager

Santiago Rello Varona

Contracting Manager and Head of Legal Department

Sara Fernández Morata

Irene Montero Morales

Aitana López Redondo

Accountants

Head: Laura López Revuelta

Mónica García López

Researcher Reception and Attention

Carmen García Artiaga

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Ethics Committee

President

Almudena Castro Conde. Head of Section of Cardiology Department

Vicepresesident

Jesús Frías Iniesta. Head of the Clinical Pharmacology Department. Representative of Research Committee

Members

José Manuel Añón Elizalde. Head of Section of Intensive Medicine Department

José Ignacio Bernardino de la Serna. Assistant Physician-Internal Medicine Department

Nora Butta Coll. Head of Research Laboratory of Coagulopathies and Alterations of Haemostasis. Researcher of the IdiPAZ

Fernando Cabañas González. Head of Pediatrics and Neonatology Quiron Salud Madrid University Hospital. Researcher of the IdiPAZ

Filiberto Chuliá Fernández. Lawyer, Head of the legal Department

Mariana Díaz Almiron. Data analyst. Biostatistics Platform

María Dolores Diestro Tejeda. Assistant Physician-Gynaecology and Obstetrics Department

Jaime Fernández-Bujarrabal Villoslada. Assistant Physician-Pneumology Department

María Justa García-Matres Cortés. Assistant Physician–Urology Department. Representative of Clinical Ethics Committee

Mercedes Gasior Kabat. Assistant Physician-Hematology Department

Pedro Herranz Pinto. Head of Dermatology Department

Carlos Lahoz Rallo. Assistant Physician-Internal Medicine Department

Nuria Rodríguez Salas. Assistant Physician-Medical Oncology Department

Miriam Romero Portales. Assistant Physician-Digestive System Department

Filomena Trocoli González. Nurse. Supervisor of Nephrology Department

Alejandra Vilanova Sánchez. Assistant Physician-Pediatric Surgery Department

Elena Villamañán Bueno. Assistant Clinical Pharmacist-Pharmacy Department

Rosa Villanueva Peña. Assistant Physician-Psychiatry Department

Members from outside the institution

Evaristo Moliné Jorques. Layperson and Patient representative

Eva Prieto Utiel. Assistant Clinical Pharmacist of Primary Care-Pharmacy Department

Technical Secretary

Emma Fernandez Uzquiano. Head of Technical Secretary of Research Ethics Committee

Sol de Gracia García. Administrative Assistant

María Isabel Arribas Álvarez. Administrative

Elena García Méndez. Pharmacist

Quality Committee

Coordinator:

José Jonay Ojeda Feo

Members:

Blanca Fuentes Gimeno

Alberto Martin Vega

María Luisa Díaz Martínez

Gema Valles Pérez

Paloma Gómez Campelo

María Dolores Pérez Garre

Ana Coloma Zapatero

Unit of Scientific Culture and Innovation of IdiPAZ

Members

Bárbara Martínez de Miguel

Alejandro Martín Quirós

Paloma Gómez Campelo

María Dolores Pérez Garre

Rocío Buendía Domínguez

Gema Vallés Pérez

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Training Committee

President

Bárbara Martínez de Miguel. HULP representative

Secretary

Alejandro Martín Quirós. HULP representative

Members

Paloma Gómez Campelo. Direction representative

María Fernández Velasco. FIBHULP representative

Julián Nevado Blanco. HULP representative

Alberto Borobia Pérez. HULP representative

Inmaculada Ibáñez de Cáceres. FIBHULP representative

Rocío Rosas Alonso. FIBHULP representative

Mercedes Ruiz Balibrea. HULP representative

Lucía Medina Royo. FIBHULP representative

Ana Sastre Perona. FIBHULP representative

Ana Rodríguez Redondo. UAM representative

Pilar Sánchez-Corral Gómez. Employee representative

Equality and Diversity Committee

Members

Eduardo López Collazo. Scientific Director, FIBHULP representative

Paloma Gómez Campelo. FIBHULP representative

María Quintanar Jaime. FIBHULP representative

F. G. G. Employee representative

Nuria Vilaboa Díaz. Employee representative

Juan Ángel Fresno Vara. Employee representative

Contact

igualdadydiversidad@idipaz.es

23th July of 2019, we decided to join as the Equality and Diversity Committee in the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) because we think it is important to improve equality in the community respecting the differences, and to contribute to their promotion in science.

In a short period, this committee has achieved significant results:

- Prevention and action protocol against discriminatory harassment, moral, sexual harassment and harassment based on sex
- Equality and Diversity Plan

In addition, in December 2019, FIBHULP/IdiPAZ signed the diversity charter, the initiative of the Fundación Diversidad - of the European Institute of Diversity Management and the Alares Foundation with the support of the Spanish Ministry of Equal Opportunities, added at the European diversity Charter.

By signing this document, IdiPAZ/FIBHULP assumes the guidelines of its Decalogue of principles:

1. To sensitize employees in line with the values of equal opportunities and respect for diversity.
2. To advance in the construction of a diverse workforce
3. To promote the inclusion in the workplace
4. To consider policies to promote diversity in the workplace
5. To promote of work-life balance for employees
6. Recognition of the diversity of clients
7. To communicate the compromise around these principles to the employees.
8. To communicate the compromise around these principles to the suppliers.
9. To communicate the compromise around these principles to the public administrations, business organizations, trade unions and other stakeholders.
10. To highlighting activities in support of non-discrimination -and their results- in its Annual Report.

EU Platform of Diversity

CHARTER DIVERSIDAD

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Commission for Humanization and Social and Scientific Responsibility

Members

Ana Coloma Zapatero. Director of FIBHULP

Paloma Gómez Campelo. Technical Assistant Director – Coordinator of RSC

María Quintanar Jaime. FIBHULP representative – Responsable of RSC

Miguel Amengual Pliego. Assistant Director of Healthcare Community – HULP representative

Sara Gusi Gil. Environmental Management Technician. HULP representative

Gloria García. District Council representative

Concepción Velázquez-Gaztelu. NUPA President, Patient Association representantive

Contact

RSC@idipaz.es

IdiPAZ/FIBHULP has the certification of Corporate Social Responsibility through the IQNet SR10 standard, within the Integrated Management System of the Hospital Universitario La Paz.

In addition, we are working on joining the commitment to the Sustainable Development Goals defined by the United Nations, which includes 17 goals and 169 targets, including new areas such as climate change, economic inequality, innovation, sustainable consumption, peace and justice, among other priorities. To this end, we are working to establish a model that includes the SDGs and we have defined a survey to establish those aspects that are most relevant to our institution.

Thereby, we are immersed in a process of integration of the Sustainable Development Goals and that is why, through the Commission for Social and Scientific Responsibility of IdiPAZ, we have launched the project.



Health and Safety Committee

Compostion

Gema Vallés Pérez. FIBHULP Representative/ President

Sara Fernández Morata. FIBHULP Representative

Jesús Mingorance Cruz. FIBHULP Representative

Laura Saldaña Quero. Risk Prevention Delegate/Secretary

Berta Rodés Soldevilla. Risk Prevention Delegate

D. F. G. G. Workers' Representative

External Prevention Service

QUIRÓN PREVENCIÓN

Delegate of the External Prevention Servive

Ángel Martínez Blasco

Contact

CSS.FIBHULP@idipaz.es

Works Committee

Ángel Campos Barros

Juan Ángel Fresno Vara

Rocío López Vacas

Nuria Vilaboa Díaz

Rosa Rodríguez Pérez

D. F. G. G.

Laura Saldaña

Pilar Sánchez-Corral Gómez

Berta Rodés

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Areas

Neuroscience Area


Coordinator: **Exuperio Díez Tejedor**

GROUPS

Psychiatry and Mental Health
Director: **María Fe Bravo Ortiz**

Neurology and Cerebrovascular Diseases
Director: **Exuperio Díez Tejedor**

Neuroprotective Strategies in Neurodegenerative Diseases
Director: **Antonio Cuadrado Pastor**



Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies
Director: **Francisco Zafra Gómez**

Mechanisms and Biomarkers in Neurodegenerative Diseases
Director: **Isabel Lastres Becker**

Cardiovascular Area

Coordinator: **José Luis López-Sendón Hentschel**

GROUPS

Research on Invasive Clinical Cardiology – ICCI-Paz
Director: **José Luis López-Sendón Hentschel**

Cardiovascular Epidemiology and Nutrition
Director: **Fernando Rodríguez Artalejo**

Coagulopathies and Alterations of Haemostasis
Director: **Víctor Jiménez Yuste**

Vascular Physiology and Pharmacology
Director: **Mercedes Salaices Sánchez**

Vascular Pharmacology and Metabolism (FARMAVSM)
Director: **Carlos F. Sánchez Ferrer**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Infectious Diseases and Immunity Area

Coordinator: **Eduardo López-Collazo**

GROUPS

AIDS and Infectious Diseases
Director: **José Ramón Arribas López**

Molecular Microbiology
Director: **Jesús Mingorance Cruz**

Immuno-Rheumatology
Director: **María Eugenia Miranda Carús**



Innate Immune Response
Director: **Eduardo López-Collazo**

Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System
Directors: **Margarita López Trascasa**
Pilar Sánchez-Corral Gómez

Lymphocyte Pathophysiology in Immunodeficiencies
Director: **Eduardo López Granados**

Drug Hypersensibility and Innate Immune Response
Director: **Teresa Bellón Heredia**

Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response
Director: **Cristina Calvo Rey**

Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases
Director: **María José Mellado Peña**

Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy
Director: **Antonio Pérez Martínez**

Immunomediate Gastrointestinal Diseases and other Digestive Pathologies
Director: **María Dolores Martín Arranz**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Large System Pathologies Area

Coordinator: **Francisco García Río**

GROUPS

Internal Medicine and Systemic Diseases
Director: **Francisco Arnalich Férnandez**

Organic Dysfunction and Failure in the Aggression
Director: **Abelardo García de Lorenzo y Mateos**

Respiratory Diseases
Director: **Francisco García Río**

Regulation of Gene Expression and by Hypoxia
Director: **Luis del Peso Ovalle**

Nephrology
Director: **Maria Auxiliadora Bajo Rubio**

Neonatology
Director: **Adelina Pellicer Martínez**

Aging and Fragility in the Elderly
Director: **Juan Ignacio González Montalvo**

Molecular Hepatology
Director: **Paloma Jara Vega**

Diagnosis and Treatment of Allergic Diseases
Director: **Santiago Quirce Gancedo**

Gynecologic Oncology
Director: **Ignacio Zapardiel Gutiérrez**

Patient Blood Management
Director: **Manuel Quintana Díaz**

Urology
Director: **Luis Martínez-Piñeiro Lorenzo**

Health Care Nurses Research
Director: **Jesús Castro Toro**

Maternal and Fetal Medicine
Director: **José Luis Bartha Rasero**

Emergency and Critical Pathology
Director: **Alejandro Martín Quirós**

Hospital Pharmacy
Director: **Alicia Herrero Ambrosio**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Cancer and Human Molecular Genetics Area

Coordinator: **Gemma Moreno Bueno**

GROUP

INGEMM- Institute of Medical and Molecular Genetics
Director: **Pablo Lapunzina Badía**

Translational Oncology
Director: **Jaime Feliú Battle**

Experimental Therapies and Biomarkers in Cancer
Directors: **Inmaculada Ibáñez de Cáceres**
Javier de Castro Carpeño

Oto-Neurosurgery Research
Director: **Luis Lassaletta Atienza**

Cancer Molecular Pathology and Therapeutic Targets
Director: **David Hardisson Hernáez**

Mechanisms of Tumour Progression
Director: **Gemma Moreno Bueno**

Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells
Director: **Carmela Calés Bourguet**

Research and Diagnosis of Inherited Metabolic Diseases
Director: **María Belén Pérez González**

Regulation of Ciliary Structure and Function by Phosphoinositides
Director: **Francesc García Gonzalo**

Dyslipemias of Genetic Origin and Metabolic Diseases
Director: **Sonia Rodríguez Novoa**

Surgery, Transplant and Health Technologies Area

Coordinator: **Nuria Vilaboa Díaz**

GROUP

Bone Pathophysiology and Biomaterials
Director: **Nuria Vilaboa Díaz**

Cellular Engineering
Director: **María Paz de Miguel González**

Clinical Pharmacology
Director: **Jesús Frías Iniesta**

Osteoarticular Surgery Research – GICOA
Director: **Enrique Gómez Barrena**

Research in Oral and Maxillofacial Surgery
Director: **Juan Luis Cebrián Carretero**

Patients Safety and Quality Research
Director: **Elena Ramírez García**

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Public Research Contracts

Ramón y Cajal Stabilisation Contracts (I3) - CM

- Karen Elise Heath. INGEMM - Institute of Medical and Molecular Genetics Group
- Jesús Mingorance Cruz. Molecular Microbiology Group
- Rebeca Pérez de Diego. Innate Immune Response Group

Miguel Servet Stabilisation Contracts (I2) - ISCIII/ CM

- Teresa Bellón Heredia. Drug Hypersensibility and Innate Immune Response Group
- Juan Ángel Fresno Vara. Translational Oncology Group
- Ángel Campos Barros. INGEMM - Institute of Medical and Molecular Genetics Group
- María Paz de Miguel González. Cellular Engineering Group
- Eduardo López-Collazo. Innate Immune Response Group
- Juan Antonio Rey Herranz. Oto-Neurosurgery research Group
- Berta Rodés Soldevila. AIDS and Infectious Diseases Group
- Pilar Sánchez-Corral Gómez. Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group
- María Rosa Torres Jiménez. Metabolic-Vascular Unit Group
- David Vicent López. Molecular Hepatology Group
- Nuria Vilaboa Díaz. Bone Pathophysiology and Biomaterials Group
- Nora Viviana Butta Coll. Coagulopathies and Alterations of Haemostasis Group
- María Inmaculada Ibáñez de Cáceres. Experimental Therapies and Biomarkers in Cancer Group
- Rosa María Rodríguez Pérez. Diagnosis and Treatment of Allergic Diseases Group
- Laura Saldaña Quero. Bone Pathophysiology and Biomaterials Group
- María Fernández Velasco. Innate Immune Response Group

Miguel Servet Contracts Type I - ISCIII

- María Dolores Gutiérrez (MS15/00069). Neurology and Cerebrovascular Diseases Group
- Carolina Cubillos Zapata (MS18/00208). Respiratory Diseases Group
- Ana Sastre Perona (MS19/00033). Experimental Therapies and Biomarkers in Cancer Group
- Carlos del Fresno Sánchez (CP20/00106). Innate Immune Response Group
- Laura Otero Ortega (CP20/00024). Neurology and Cerebrovascular Diseases Group

Intensification Contracts - ISCIII

- Cristina Calvo (INT19/00009). Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- Francisco Javier Carcas Sanjuan (INT19/00082). Clinical Pharmacology Group
- Alberto M. Borobia Pérez (INT19/00055). Clinical Pharmacology Group
- José Ramón Arribas López (INT20/00041). AIDS and Infectious Diseases Group
- Francisco Javier García Río (INT20/00020). Respiratory Diseases Group

Río Hortega Contracts - ISCIII

- ·Carlos Grasa Lozano (CM19/00015). Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- Irene García García (CM19/00243). Clinical Pharmacology Group
- Julen Cadiñanos Loidi (CM19/00059). AIDS and Infectious Diseases Group
- Lorena Ostios García (CM19/00056). Translational Oncology Group
- Rocío Rosas Alonso (CM19/00100). Experimental Therapies and Biomarkers in Cancer Group
- Amelia Rodriguez Mariblanca (CM20/00009). Clinical Pharmacology Group
- Carmen Busca Arenzana (CM20/00157)
- Elisa Alonso López (CM20/00047)

Juan Rodés Contracts - ISCIII

- Rocío Montejano Sánchez (JR18/00039). AIDS and Infectious Diseases Group

Sara Borrell Contracts - ISCIII

- María Perez Mato (CD19/00063). Neurology and Cerebrovascular Diseases Group

Marie Skłodowska-Curie Actions - Horizon 2020. European Union

- María Cristina Murano. (CAREINTRIALS). Clinical Pharmacology Group

Predoctoral Fellowship - ISCIII

- Andrés Esteban Cantos (FI17/00192). AIDS and Infectious Diseases Group
- María del Carmen Gómez de Frutos (FI17/00188). Neurology and Cerebrovascular Diseases Group
- Fernando Laso Garcia (FI18/00026). Neurology and Cerebrovascular Diseases Group
- Carmen Mestre Duran (FI19/00176).Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group
- Miranda Burdiel Herencia (FI19/00061). Experimental Therapies and Biomarkers in Cancer Group
- Roberto Lozano Rodríguez (FI19/00334). Innate Immune Response Group
- Enrique Alfaro García (FI20/00059)

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Predoctoral Contract - Ministry of Science, Innovation and Universities

- Francisca Díaz González (FPU17/04055). INGEMM - Institute of Medical and Molecular Genetics

Predoctoral La Caixa Fundation Contracts

- Karla Marina Montalbán Hernández (INPhiNIT). Innate Immune Response Group

Technical Support Stabilisation Contracts - CM

- Francisco Gayá Moreno. AIDS and Infectious Diseases Group
- María Teresa Vallejo Cremades. Congenital Malformation Surgery Group
- Beatriz Sanz Minguela. Cell Culture Unit

Bioinformatics Technician Support Research Contract

- Mario Solis López. INGEMM - Institute of Medical and Molecular Genetics

Youth Guarantee Contracts - CM Graduate

- Lucía María Acero Riaguas (PEJ-2020-AI/BMD-17846).
- María Fuentes Andión (PEJ-2020-AI/BMD-19637)
- Andrea Bueno Sen (PEJ-2020-AI/BMD-18883)
- Cecilia Huarte Sebastián (PEJ-2020-AI/BMD-17656)

Technical Support

- Virginia Rufo Rabadán (PEJ-2017-TL/BMD-6201). INGEMM - Institute of Medical and Molecular Genetics
- Sonia Jiménez Rodríguez (PEJ-2017-TL/BMD-6939). Molecular Microbiology Group
- Marta Ramiro Rivera (PEJ-2017-TL/BMD-12199). Diagnosis and Treat-ment of Allergic Diseases Group
- Lidia Pertiñez Celestino (PEJ-2017-TL/BMD-12351). Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- Gabriel Saíz Medrano (PEJ-2017-TL/BMD-12514). AIDS and Infectious Diseases Group
- José Carlos Casalvilla Dueña (PEJ-2017-TL/BMD-13082). Innate Immune Response Group
- Sandra Gutiérrez García (PEJ-2017-TL/BMD-13791). Associated Clinicians

Youth Guarantee Contracts - MINECO Predoctoral

- Laura Clares Villa (PEJ2018-002874 P). Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Programme	Organisation	Total
Ramón y Cajal Stabilisation Contracts (I3)	CM	3
Miguel Servet Stabilisation Contracts (I2)	ISCIII/ CM	16
Technical Support Stabilisation Contracts	CM	3
	TOTAL ESTABLISHED	**22**
Miguel Servet Contracts CP Type 1	ISCIII	5
Intensification Contracts	ISCIII	5
Río Hortega Contracts	ISCIII	8
Juan Rodés Contracts	ISCIII	1
Marie Skłodowska-Curie Actions	European Union	1
Sara Borrell Contract	ISCIII	1
Predoctoral Fellowship	ISCIII	7
Predoctoral Contract	Ministry of Science, Innovation and Universities	1
Predoctoral La Caixa Fundation Contracts	La Caixa	1
Bioinformatics Technician Support Research Contracts	ISCIII	1
Youth Guarantee Contracts	MINECO	1
Youth Guarantee Contracts	CM	11
	TOTAL PROGRAMMES	**43**
	TOTAL ESTABLISHED + PROGRAMMES	**65**
UCICEC	CAIBER	13
FIS Projects	ISCIII	10
European Projects	EU	7
Research Network	ISCIII	6
Research Network	CM	1
SAF/MAT	MINECO	4
Biobank	ISCIII	2
Commercial clinical trials	EECC Promoters	36
Private projects	Pharmaceutical Industry	73
In-house Projects	FIBHULP	20
ITEMAS Network	ISCIII	2
RETOS	MINECO	2
Spin-off	CM	1
	TOTAL EMPLOYEES DEPENDET ON P.I.	**186**
Private projects	Pharmaceutical Industry	3
	TOTAL FELLOWS DEPENDET ON P.I.	**3**
	TOTAL STAFF DEPENDENT ON P.I.	**189**
Technical Unit Staff	FIBHULP	19
	TOTAL TECHNICAL UNIT	**19**
	TOTAL	**273**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Researcher profile


The following graphs show the classification of IdiPAZ researchers according to the EURAXES regulations proposed by the European Union. In addition, in the following image we can see the evolution of this classification that has occurred in the last year.



Euraxess Researcher Profile



Evolution of the Euraxess Researcher Profile



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.3 Training Report and Teaching

Some of the goals of IdiPAZ are to generate knowledge, to train specialists in the biomedical, to promote research and to transfer the knowledge not only to clinical practice but the society too.

2.3.1 Doctoral Theses

In 2020, 24 Doctoral Theses have been read and/or supervised by IdiPAZ researchers. 4 of them was a European theses ( ).

Doctoral Student	Title	Director	University
Teresa Olea Tejero	Infección por el virus de la hepatitis C oculto en varias situaciones de enfermedad renal crónica.	Dr. Rafael Selgas Gutiérrez	UAM
Alejandra Romero Martínez	Mecanismos antisenescentes de la angiotensina (1-7) en el endotelio vascular.	Dra. Concepción Peiró vallejo y Dr. Carlos F. Sánchez Ferrer	UAM
Beatriz Pola Bibián	Exacerbaciones de asma en el servicio de urgencias del Hospital Universitario La Paz.	Dr. Rodolfo Alvarez-Sala	UAM
José Avendaño Ortiz	Inmuno-checkpoints: PD-L1, una diana terapéutica más allá del cáncer.	Dr. Eduardo López Collazo	UAM
María Pérez López	Implicación funcional de Gasdermina B en dos contextos biológicos: cáncer e inflamación.	Dra. Gema Moreno Bueno y Dr. José David Sarrió López	UAM
Ana Martínez Feito	Monitorización de la terapia biológica en enfermedades inflamatorias inmunomediadas	Dr. Alejandro Balsa Criado y Dra. Dora Pascual-Salcedo Pascual	UAM
Ynay José De León Barrios	La influencia de la musicoterapia en procesos neurobioquímicos del desarrollo temprano.	Dra. Adelina Pellicer Martínez y Dra. Mª Jesús Del Olmo Barros	UAM
Olaia Rodríguez Fraga	Utilidad de la medición de biomarcadores cardíacos en pacientes adultos con cardiotoxicidad por terapia antineoplásica.	Dr. Antonio Buño Soto	UAM
Sergio Castrejón Castrejón	Eficacia y seguridad de la desconexión eléctrica de las venas pulmonares mediante aplicaciones de radiofrecuencia de alta potencia y corta duración en pacientes con fibrilación auricular.	Dr. José Luis Merino Llorens, y Dr. José Ángle Cabrera Rodríguez	UAM
Juan Ramón Rey Blas	Valoración funcional, cognitiva y seguimiento clínico de supervivientes a largo plazo tras una parada cardíaca extrahospitalaria.	Dr. José Luis Lopéz-Sendon	UAM

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.3.1 Doctoral Thesis

David Hernández Herrero	Establecimiento de un sistema de unidades relativas de valor como método de gestión de las consultas de intervencionismo en un servicio de Medicina Física y Rehabilitación de un hospital de tercer nivel de la Comunidad de Madrid.	Dr. Juan Carlos Miangolarra Page y Dra. Lucía Garvín Ocampos	URJC
Estefanía Alonso Rodríguez	Osteonecrosis de los maxilares relacionada con bifosfonatos. Aplicación de células madre derivadas de tejido adiposo en modelo experimental murino.	Dr. Miguel Burgueño García	UAM
Álvaro Briso-Montiano Pastrana	Desarrollo de modelos para la evaluación de terapias con chaperonas farmacológicas en aciduria metilmalónica y deficiencia en fosfomanomutasa.	Dra. Belén Pérez González	UAM
Nicolás Alejandro Suarez Rovira	Protocolos de Transfusión Masiva con esquemas predeterminados vs guiados por tests viscoelásticos: estudio comparativo y análisis de coste efectividad en pacientes con trauma grave.	Dr. Manuel Quintana-Díaz y Dr. José Antonio García-Erce	UAM
María Teresa Nuñez-Villaveiran Baselga	Considerations for a full facial allotransplantation including the temporo-mandibular joints: a radiological and anatomical cadaveric study.	Dr. Abelardo García de Lorenzo y Mateos	UAM
Raúl Honrubia López	Repercusión del tratamiento con antivirales de acción directa sobre la evolución clínica y la calidad de vida en pacientes con hepatitis crónica C tratados en un hospital terciario.	Dr. Javier García-Samaniego Rey y Dr. Antoio Madejón Seiz	UAM
Andrés de la Rocha Muñoz	Fisiopatología del transportador neuronal de glicina GlyT2: regulación y estudio de mutantes asociados a hiperplexia.	Dra. Beatriz López Corcuera	UAM
Jenifer Villa García	Análisis genómico de Enterobacterales productores de carbapenemasas de interés clínico en el Hospital Universitario 12 de Octubre.	Dr. Jesús Mingorance Cruz y Dr. Fernando Chaves	UAM
Esmeralda Alonso Barroso	Estudios fisiopatológicos para la búsqueda de nuevas dianas terapéuticas en acidemia propiónica mediante la caracterización del modelo murino y el desarrollo de nuevos modelos celulares humanos basados en iPSCs.	Dra. Lourdes Ruiz y Dra. Eva Richard	UAM
Raquel Gutiérrez Zúñiga	Impacto de la Diabetes Mellitus y su control metabólico en la evolución del infarto cerebral. Estudio de cohortes.	Dra. Blanca Fuentes Gimeno y Dr. Exuperio Díez Tejedor	UAM
Natalia García Vázquez	Validación del método de cribado automático del riesgo de desnutrición CONUT, su comparación con otros métodos de valoración y su capacidad de predicción de complicaciones, readmisiones y fallecimientos.	Dra. Carmen Gómez Candela y Dra. Elena Villamañán Bueno	UAM
Alejandro Fulgencio Covián	Investigación traslacional en las cardiomiopatías asociadas a la acidemia propiónica.	Dra. Lourdes Ruiz y Dra. Eva Richard	UAM
Luis Albeiro Mesa Galán	Utilidad clínica de la ecografía ocular en el diagnóstico de Síndrome de Terson en pacientes neurocríticos.	Dr. Manuel Quintana-Díaz	UAM
Raúl Galera Martinez	Efecto de la hiperinsuflación dinámica sobre la respuesta cardiovascular al ejercicio en pacientes con enfermedad pulmonar obstructiva crónica.	Dr. Francisco García Río y Dr. Rodolfo Álvarez-Sala	UAM
Sobrino Jiménez C.	Estudio de utilización del concentrado de complejo protrombónico en un servicio de urgencias.	Dr. José Antonio Romero Garrido y Dra. Juana Benedi González	UCM
Bilbao Gómez-Martino C	Análisis de los medicamentos implicados en errores de conciliación al ingreso hospitalario.	Dr. José Antonio Romero Garrido y Dra. Juana Benedi González	UCM

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.3.2 Scientific Training Plan

The Training Committee established a Training Plan, which specifies the training strategy for the institute´s human resources and covers the research training needs of their members. Annually it´s developed the training offer with several proposals to make up the plan. Also, it´s developed a residents training program have been started for residents doctors of the University Hospital La PAZ.

The own training offer is mainly based on a series of transversal courses in research methodology and courses related of the different lines of research.

The plan is complemented by several activities such as conferences, scientific seminars and other activities linked to these areas.

In addition, The Training Committee established a Residents training program for residents of the University Hospital la Paz.



Members

President
Bárbara Martínez de Miguel

Secretary
Alejandro Martín Quirós

Direction representative
Paloma Gómez Campelo

HULP representative
Julián Nevado Blanco
Alberto Borobia Pérez
Mercedes Ruiz Balibrea

FIBHULP representative
María Fernández Velasco
Rocío Rosas Alonso
Inmaculada Ibáñez de Cáceres
Lucía Medina Royo

UAM representative
Ana Rodríguez Redondo

Employee's representative
Pilar Sánchez-Corral Gómez

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Training courses conducted by IdiPAZ

Title	Head	Dates	articipants
Técnicas de escritura científica en inglés	María Fernández Velasco	20th-23rd January	40
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. I Edition.	Paloma Gómez Campelo	7th May	15
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. II Edition.	Paloma Gómez Campelo	15th May	15
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. III Edition.	Paloma Gómez Campelo	22sd May	15
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. IV Edition.	Paloma Gómez Campelo	4th June	15
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. V Edition.	Paloma Gómez Campelo	12sd June	15
Curso de Manejo de Muestras COVID-19: Capacitación para el trabajo en BSL2	Berta Rodés Soldevila	26th October	40
Protección de los trabajadores en el manejo de muestras de pacientes con sospecha o confirmación de COVID-19. VI Edition.	Paloma Gómez Campelo	29th October	15
Curso Manejo de Muestras COVID-19: Equipos de Protección Individual -EPIs-.	Alejandro Martín Quirós	30th October	40
Escritura de manuscritos de investigación	Pilar Sánchez-Corral Gómez	23rd-24th November	30
Técnicas de Laboratorio	María Fernández Velasco Víctor Toledano Real	14th-18th December	25



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Residents training programme

The training program has been designed to provide residents at IdiPAZ with scientific tools and skills, which are key for the development of their careers.

Because of the coronavirus situation, in 2020 only a single course was done

February-24th

Taller de Investigación en Simulación.
Head: Manuel Quintana Díaz
Participants: 26



Scientific Seminars

IdiPAZ Scientific Seminars program welcomes renowned researchers and clinical investigators to our Institute to share, discuss and debate latest insights, discovery and next directions in oncology with our students, postdocs and senior faculty from our research groups. In this year, Scientific Seminars of IdiPAZ was certified by "Acreditación de Actividades de Formación Continuada de las Profesiones Sanitarias" by the Community of Madrid procedure number nº07-AFOC-00901.4/2020 and 20 seminars were held.

Scientific Coordinators:

- **Paloma Gómez Campelo**, Innate Immune Response Group and Scientific Director of Biobank

Secretary:

- **Susana García Pérez**

Research Area	Speaker		Seminar title	Date
	Esteban Veiga Chacón Investigador del Centro Nacional de Biotecnología (CNB-CSIC)		Linfocitos entrenados con bacteria como nueva generación de inmunoterapias contra tumores	10th January 2020
	Salvador Iborra Investigador del Centro Nacional de Investigaciones Cardiovasculares (CNIC)		Células dendríticas, servicio de inteligencia responsable de la inmunidad en las barreras	17th January 2020

2.3.2 Scientific Initiatives

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Ignacio Zapardiel Gutiérrez Director del grupo de investigación de Ginecología Oncológica de IdiPAZ		Utilidades del verde de indocianina y la fluorescencia en cirugía	24th January 2020
Erika Guijarro Fernández FEA de la unidad de Trasplante Pediátrico del Hospital Universitario La Paz		Realidad virtual: tratamiento psicológico en niños y adultos	14th February 2020
Enrique Gómez Barrena Director del grupo de investigación de Cirugía Osteoarticular GICOA de IdiPAZ		Investigación Clínica en Terapia Celular y Regeneración Ósea	21st February 2020
Manuel Quintana Director del grupo de investigación de Gestión en el Paciente Sangrante de IdiPAZ		Sangre...sin sudor y lágrimas	28th February 2020
Lluís Montoliu Investigador del dpto. de Biología Molecular y Celular del Centro Nacional de Biotecnologia (CBN-CSIC)		¿Qué pueden aportar las herramientas CRISPR en la investigación sobre la COVID-19?	26th June 2020
Alberto Borobia FEA de Farmacología Clínica y Coordinador de la Unidad de Ensayos Clínicos del Hospital Universitario La Paz		Cohorte COVID@HULP. Resultados de la primera gran cohorte europea	3rd July 2020
Pepe Alcamí Investigador del Centro Nacional de Microbiología del ISCIII		Transportina 3, punto de encuentro entre el VIH y las distrofias musculares	10th July 2020
Elias Dahdouh Investigador del grupo de Microbiología Molecular del IdiPAZ		Quantification of the intestinal load of a targeted set of resistance genes to Monitor Antibiotic Resistance in paediatric transplant patients – qMAR	18th September 2020
Carolina Cubillos Investigadora Miguel Servet del grupo de Enfermedades Respiratorias del IdiPAZ		Efecto de la hipoxia intermitente en la inmunovigilancia: la apnea obstructiva del sueño	25th September 2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

	Alberto López Lera Investigador Postdoctoral CIBERER del grupo Diagnóstico y tratamiento de patologías asociadas a alteraciones del sistema del complemento de IdiPAZ		Angioedema Hereditario:Inmunodeficiencia o trombоinflamación	2nd October 2020
	Andrés Hidalgo Alonso Jefe del grupo de investigación de Imagen de la Inflamación Cardiovascular y la respuesta inmune del CNIC		Alondras, búhos e inflamación vascular	9th October 2020
	Francisco Javier Cubero Investigador Ramón y Cajal en el dpto. de Inmunología, Oftalmológica y ORL de la Facultad de Medicina de la Universidad Complutense de Madrid		A JUnk story of chronic liver injury	23th October 2020
	Mª Eugenia Fernández Directora de la Unidad de Producción Celular y Medicina Regenerativa (GMP) del IIS Gregorio Marañón		Experiencia en terapias avanzadas en el Hospital Gregorio Marañón	30th October 2020
	Alejandro Martín Quirós Director del grupo de Investigación Patología Urgente y Emergente del IdiPAZ		Grupo de patología urgente y emergente. Orden dentro del caos ¿es posible?	13rd November 2020
	Carolina García-Vidal Investigadora del dpto. de Enfermedades Infecciosas del Hospital Clínic de Barcelona		Inteligencia artificial y enfermedades infecciosas	27th November 2020
	Cristina Ferreras Investigadora del grupo de investigación traslacional en cáncer infantil, trasplante hematopoyético y terapia celular del IdiPAZ		Identificación de Linfocitos T memoria de donantes convalecientes contra SARS-CoV-2. Producción a gran escala y resultados del ensayo clínico fase I RELEASE	4th December 2020
	Isabel Fabregat Investigadora del IDIBELL, CIBERehd y de la Universidad de Barcelona		The TGF-b pathway: a pharmalogical target in the hepatocellular carcinoma?	11th December 2020
	Marta Feito Rodríguez Investigadora del IdiPAZ y FEA en el Servicio de Dermatología del Hospital Universitario La Paz		Perniosis y COVID	18th December 2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Neuroscience Area

Scientific Coordinator: Exuperio Díez Tejedor
Jefe de Servicio de Neurología del Hospital Universitario la Paz. Catedrático del Departamento de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

Speaker	Talk Title	Date	Place
Elisa López Dolado. Hospital Nacional de Parapléjicos. Toledo	Nuevas terapias en la reparación del daño medular traumático.	27th January 2020	Aula Jaso. H. Infantil H. Universitario la Paz
Carlos Calle de Migue. F.E.A. Neurología. Servicio de Neurología. Hospital Universitario. Fuenlabrada	Avances en el conocimiento de la nocicepción y el dolor neuropático.	18th November 2020	Webinar
Mariana H. G. Monje. Centro Integral de Neurociencias HM Cinac (Madrid).	Teoría patogénica cortical y somatotopia de la denervación nigroestriatal en la enfermedad de Parkinson.	1st December 2020	Webinar

Scientific clinical sessions - Hospital Universitario La Paz

Date	Talk Title	Speaker
4th March 2020	Manejo de Cardiopatías Congénitas	**Coordinators:** **Dr. José Luis Bartha,** Jefe de Servicio de Obstetricia y Ginecología **Dr. Federico Gutiérrez-Larraya,** Jefe de Servicio de Cardiología Infantil **Dr. Ángel Aroca,** Jefe de Servicio de Cirugía Cardiaca Pediátrica **Speakers:** **Dra. Eugenia Antolín,** Servicio de Obstetricia y Ginecología **Dra. Lucía Deiros,** Servicio de Cardiología Infantil **Dra. Fe García Santiago,** INGEMM **Dr. Raúl Sánchez,** Servicio de Cirugía Cardiaca Pediátrica
26th February 2020	Hombro Doloroso	**Coordinators:** **Dr. Jorge de las Heras,** Servicio de Traumatología **Speakers:** **Dr. Samuel Antuña,** Jefe de Sección de Traumatología **Dra. María Jesús Vazquez,** Servicio de Rehabilitación **Dra. Mar Tapia,** Servicio de Radiología **Dra. Gloria Talavera,** Servicio de Traumatología **Dr. Miguel Bernad,** Servicio de Reumatología **-Dr. Raúl Barco,** Servicio de Traumatología

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

19th February 2020	**Córticodependencia en asma grave**	**Coordinators:** **Dr. Santiago Quirce Gancedo,** Jefe de Sección de Alergología **Speaker:** **Dr. Javier Domínguez Ortega,** Servicio de Alergología
12nd February 2020	**Nuevo Coronavirus 2019**	**Coordinators:** **Dr. Jose Ramón Arribas,** Jefe de Sección Medicina Interna - Unidad de Infecciosas **Dra. Concepción Prados,** Jefa de Sección Neumología. Subdirectora Médica. Carlos III **Dr. Juan Carlos Figueira,** Médico adjunto de la Unidad de Cuidados Intensivos de adultos **Speakers:** **Dr. Nicolás García-Arenzana,** Servicio de Medicina Preventiva **Dra. Marta Mora,** Servicio de Medicina Interna - Unidad de Infecciosas **Dra. María Romero,** Servicio de Microbiología **Dra. Concepción Núñez,** Jefa de Servicio de Prevención de Riesgos de Laborales **Dr. Fernando de la Calle,** Servicio de Medicina Interna - Unidad de Tropicales **Dra. Cristina Calvo,** Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales
05th February 2020	**Las Comisiones Técnicas Consultivas del hospital, una nueva etapa**	**Coordinators:** **Dr. Juan José Ríos Blanco,** Director Médico y Presidente de la Junta Técnica Asistencial **Speakers:** **Dr. Joaquín Díaz Domínguez,** Jefe de Servicio de Cirugía General y del Aparato Digestivo **Dr. José Jonay Ojeda Feo,** Coordinador de Calidad del hospital
29th January 2020	**Manejo de Antitrombóticos pericirugía y periprocedimiento. QxAApp y registro**	**Coordinators:** **Dra. Inmaculada Roldán Rabadán,** Servicio de Cardiología **Dr. José Luis López Sendón,** Jefe de Servicio de Cardiología **Speakers:** **Dr. David Vivas Balcones,** Servicio de Cardiología del Hospital Clínico San Carlos **Dra. Raquel Ferrandis,** Servicio de Anestesia, Reanimación y Terapéutica del dolor del Hospital Universitario y Politécnico La Fe de Valencia
22th January 2020	**Complicación atípica en un paciente con trasplante multivisceral**	**Coordinators:** **Dra. Esther Ramos Boluda,** Servicio Gastroenterología **Speakers:** **Dra. Rocío González Sacristán,** Servicio Gastroenterología Pediátrica **Dra. Marta Mora Rillo,** Servicio Medicina Interna **Dr. José Ramón Arribas López,** Servicio Medicina Interna **Dra. Nerea Ibarra Soraluce,** Servicio Anatomía Patológica
15th January 2020	**Varón de 80 años con síndrome febril, insuficiencia respiratoria y radiografía de Tórax normal**	**Coordinators:** **- Dr. Francisco Arnalich Fernández,** Jefe de Servicio de Medicina Interna **Speaker:** **-Dr. Aquilino Sánchez Purificación,** Servicio de Medicina Interna **-Dr. Oscar Cerezo Aranda,** Servicio de Anatomía Patológica

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Another Scientific activities

18th November 2020: 2nd PhDay IdiPAZ



19th November 2020: Presentation Scientific Report 2019



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.3.3 Science and Society-Scientific Outreach Initiatives

The Unit of Scientific Culture and Innovation of IdiPAZ (UCC+i) has the aim of dissemination of science and innovation performed in our institution and as a key service to increase the scientific education and culture, to promote scientific vocations and innovative talent, to communicate researchers' findings, and to foster research among new generations, knowledge the population and patients.

Unit of Scientific Culture and Innovation of IdiPAZ

Members:

- Bárbara Martínez de Miguel
- Alejandro Martín Quirós
- Paloma Gómez Campelo
- María Dolores Pérez Garre
- Rocío Buendía Domínguez
- Gema Vallés Pérez

IdiPAZ toke participate in the International Day of Women and Girls in Science, the nineteen edition of the Madrid Science and Innovation Week with twenty one free activities and in the European Researchers' Night with six free activities which allow attendees to get to know first-hand the institution's R+D+I and researchers through talks, workshops, fast meeting, guided tours, etc. Finally, we collaborated in the 4° ESO+empresa workday, an event which offers the students the opportunity to get to know first-hand the work that healthworkers and Scientifics in a hospital carry out, their motivations and efforts.

11st February 2020: - International Day of Women and Girls in Science



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2-15th November – Science and Innovation Week



Due to the situation caused by the COVID-19, all the activities that were carried out were online.

Activity	Date	Organizated by
¿Qué es y qué hace un gestor de innovación? La gestión de la innovación como salida profesional	13th November 2020	**Unidad de Apoyo a la Innovación** Estela Sánchez Lola Pérez
¿Quieres conocer cómo investigamos en nuestro Instituto? Visita guiada edif. IdiPAZ y plataformas 	10th November 2020 12th November 2020	**Unidad de Cultivos Celulares** Gema Vallés Pérez
La patente como herramienta clave para la investigación y fuente de información estratégica para una organización	11th November	**Unidad de Apoyo a la Innovación** Estela Sánchez Lola Pérez

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Ceguera infantil hereditaria: cómo lograr el acceso a una terapia génica precoz 	11th November	**UMOG (Unidad Multidisciplinar de Oftalmogenética)** Elena Vallespín Responsable Sección Oftalmogenética Molecular del Instituto de Genética Médica y Molecular del Hospital La Paz Susana Noval Jefe de Sección de Oftalmología Infantil del Hospital La Paz María Nieves Adjunto de Oftalmología del Hospital La Paz Marta Naranjo Adjunto de Neurofisiología Clínica del Hospital La Paz Celia Fernández Alcalde R3 de Oftalmología del Hospital La Paz
Enfermería, microorganismos e higiene de manos: ¡ una lucha sin cuartel!"  	11th November	**Jesús Morente** Dirección de Enfermería del Hospital Universitario La Paz

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

DNA DAY 2020. Oftalmogenética: del paciente a la terapia génica 	03th November	**UMOG (Unidad Multidisciplinar de Oftalmogenética)** Elena Vallespín Responsable Sección Oftalmogenética Molecular del Instituto de Genética Médica y Molecular del Hospital La Paz Susana Noval Jefe de Sección de Oftalmología Infantil del Hospital La Paz María Nieves Adjunto de Oftalmología del Hospital La Paz Marta Naranjo Adjunto de Neurofisiología Clínica del Hospital La Paz Celia Fernández Alcalde R3 de Oftalmología del Hospital La Paz Pablo Lapunzina Director Científico del CIBERER.Jefe de Sección Sobrecrecimientos del Instituto de Genética Médica y Molecular del Hospital La Paz Javier García Asociación AMIRES Almudena Ávila Fernánez Adjunto Servicio de Genética de la Fundación Jiménez Díaz María Palomares Bralo Responsable Sección Trastornos del desarrollo neurológico del Instituto de Genética Médica y Molecular del Hospital La Paz Felix Armadá Jefe de Oftalmología Infantil Hospital La Paz
Luz y color para encontrar huellas microscópicas de los visitantes inesperados en nuestras células 	03th November	**Unidad de Imagen e Inmunohistoquímica** Mayte Vallejo Cremade Onys Camps Ortega

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Separar el grano de la paja: **Cómo encontrar un oasis en el desierto de la información**	03th November	**Documentalista** Raúl Román Cañizares
The future needs the best ... **biobanqueros!** 	05th November	**Biobanco de IdiPAZ** Paloma Gómez Campelo. Directora Marina Arranz Álvarez. Coordinadora Yaiza Pedroche. Técnico Sandra Nieto. Técnico
Visita guiada a la Plataforma de Biobanco 	5th November 12th November	**Biobanco de IdiPAZ** Paloma Gómez Campelo. Directora Marina Arranz Álvarez. Coordinadora Yaiza Pedroche. Técnico Sandra Nieto. Técnico

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.4 Innovation and Transfer Activities

2.4.1 Innovation and Transfer Activities

The Innovation Support Unit (or Innovation Unit)of FIBHULP was created in June 2010 within the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the Innovation Unit is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

Activities

The main aim of the Innovation Support Unit is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the Innovation Unit has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.
- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.
- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.
- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Its impact in the Hospital has been strengthened by the creation of both the Innovation Platform and the Innovation Committee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital's Management Board in order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mission of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.4.1 Innovation and Transfer Activities

establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. It also forms part of the Innovation Committee, a decision-making body on the ideas to be supported by FIBHULP.

Among the greatest achievements of the Innovation Support Unit are the following:


1 **The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.**

At December 31 2020 the UAI had 214 innovation projects or ideas in active state, 21of which were in the capture phase, 59 in the evaluation phase, 34 in development, 64 in transfer and 36 in the market. According to these data, it follows that 17% of the projects have been successfully exploited and positioned in the market, very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. In relation to the type of projects managed by the UAI, it is important to highlight that the number of Health ICT-type projects during 2020equals the number of Bio and Medical Device projects. Although the UAI has more than ten years of experience, most of the activity (122projects) and its achievements have taken place in the last five years, period 2016-2020.

UAI portfolio breakdown by project development phase (2016-2020)




UAI portfolio breakdown by project type (2016-2020)




2. **The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ's innovation community.**

During the period 2016-2020 the UAI filed 14 priority patents (7 Spanish patents,6 European patents and 1 US patent) and 11 PCT; 15 national or regional phase entry applications were filed (1 at the OEPM, 3 at the EPO, 3 at the USPTO and 8 at other patent offices) and 12 patents were granted (9 at the OEPM, 2 at the EPO and 1 at the USPTO).


Patent applications filed (2016-2020)



Priority patent applications filed (2016-2020)




Regional phase entry applications (2016-2020)



2.4.1 Innovation and Transfer Activities

Patents granted (2016-2020)



UAI's portfolio of patent families in active state during period 2016-2020 reached the figure of 37 patent families (28 of them with Spanish priority, 8 of them of European priority, and 1 of them has US priority).

As for the software, during the period 2016-2020 the UAI registered 28 computer applications.

Special mention should also be made to the UAI trademark portfolio. During the period 2016-2020, 13trademark applications were filed and 13 were granted.

It is important to note that these trademarks, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.


3. The UAI has prepared a catalogue of technology offers -based on specification sheets-, which includes the complete portfolio of exploitable IdiPAZ results.

This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.

4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio.

During the period 2016-2020, the UAI succeeded in signing 63 license agreements of intellectual property rights (copyright). On the other hand, during the same period the UAI managed to achieve the following values in terms of transfer: 9 patents, 28 software, 7 intellectual property works and 29 trademarks in use or in commercial exploitation, which meant a significant achievement in terms of economic return.

Patents granted (2016-2020)



5. Thanks to UAI's support and management it has been possible to create and consolidate the first technology-based company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid.

The spin-off concerned, Biomedical Molecular Medicine, exploits the research results in oncology –specifically, a genomic test to determine whether breast cancer patients should have chemotherapy – designed by some members of IdiPAZ.

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals.

Over the last year, its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc. Among all the promotional activities, the following stand out:

- Workshop "La patente como herramienta clave para la investigación y fuente de información estratégica para su organización". XX Semana de la Ciencia y la Innovación 2020, 11 de noviembre, 10:00-11:00h.
- Workshop: Qué es y qué hace un gestor de innovación. La gestión de la innovación como salida profesional. XX Semana de la Ciencia y la Innovación 2020, 13 de noviembre, 10:00-11:00h.
- WEBIN finance: evaluation of an innovation project", part of the Training sessions titled "INVERSIÓN EN TIEMPOS DE COVID-19" organised by Companies and Investors Working Group of ITEMAS Platform, 23 June 2020, 14:00h

In addition, the UAI has collaborated with important institutions and private entities to promote innovation, in particular, it has participated in various

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

forums and round tables organized by various stakeholders of the biomedical sector.

7. The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results, it is important to highlight the increasing amount of innovation projects managed by the Innovation Unit that has been awarded with prestigious awards and aids. The following are some of the projects that won grants or awards during 2020:

(a) Granting of the aid "Caixa Impulse Validate" to 2 innovation projects:
- Innovation project "First bio-Tool for Exosomal normalization in Liquid biopsy and its clinical applicability for Lung cancer patients stratification (Code CI: CI20-00182)" led by Inmaculada Ibañez de Caceres, Head of Head of Cancer Epigenetics Laboratory. INGEMM and Coordinator of the Experimental Therapies and Biomarkers in Cancer at IdiPAZ.
- Innovation project "ClearPap (Code CI: CI20-00251)" led by Dr. Jesus Manuel Muñoz Caro, Specialist in Oral and Maxillofacial Surgery at La Paz University Hospital.

(b) 6 innovation projects were selected to participate in the 5th edition of the HealthStart Program: (1) COMUNICAPP; (2) DISPOSITIVO PARA LACTANCIA MATERNA; (3) KIT QUIRÚRGICO; (4) MUT4CHILD, (5) NUTRINFATTY and (6) RELEASE. HealthStart is the program of the Madrimasd Knowledge Foundation (Madri+d Foundation) and the Medical Technology Innovation Platform (ITEMAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the acceleration of technological start-ups of the Community of Madrid in the healthcare sector

(c) The innovation project titled "RELEASE" was awarded in the HACKATON #VENCEALVIRUS aid.

(d) Granting of the aid "Desarrollo Tecnológico en Salud" Health Research Projects (AES 2020) to the innovation project titled "Validación del biomarcador epigenético MGMT en biopsia líquida como prueba no invasiva para diagnóstico y seguimiento de pacientes con gliomas de alto grado." (DTS20/00029).

(e) Granting of the aid RETOS-Colaboración R+D+i projects to the innovation project titled "Desarrollo de un Sistema Predictivo de Respuesta al Tratamiento con Derivados del Platino en Cáncer de Pulmón basado en Aptámeros (PREDIAPT)" RTC2019-007229-1

Organisation

Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.

The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and he's a member of the Medical Oncology Department of the La Paz University Hospital, Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The Innovation Unit also consists of a team of two experts in fostering innovation and protecting research results and technology transfer:

Estela Sánchez Simón, Law Graduate; and
María Dolores Pérez Garre, Bachelor of Chemical Sciences.

CONTACT
Coordinator
Javier de Castro Carpeño
javier.decastro@salud.madrid.org
Phone: (+34) 91 207 12 34
Members
Estela Sánchez Simón
innovacion.legal@idipaz.es
Phone: (+34) 91 207 12 34
María Dolores Pérez Garre
innovacion@idipaz.es
Phone: (+34) 91 207 12 34

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.4.2 Patents and trademarks

Neuroscience Area

Psychiatry and Mental Health Group

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.

Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.

Neurology and Cerebrovascular Diseases Group

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Gil Martínez A, author; FIBHULP, assignee. Brand name: Specular Face; ESM 4.022.981; 2019 June 10.

Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194; 2020 November 30.

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



Cardiovascular Area

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Vascular Physiology and Pharmacology Group

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14 .

León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino)metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01 .

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Brand name: leggie. ESM4044711; 2019 November 22 .

leggie

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Infectious Deseases and Immunity Area

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS,inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D´HEBRON - INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Innate Immune Response Group

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

Lumphocyte Pathophysiology in Immunodeficiencies Group

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Drug Hypersensibility and Innate Immune Response Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2] pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Pediatric systemic infections; hiv, tuberculosis, imported and emergent diseases

Mellado MJ, Piñeiro R, authors; ASOCIACION ESPAÑOLA DE PEDIATRIA (AEPED), assignee. Brand name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

Translational research in pediatric oncology, hematopoietic transplantation and cell therapy

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13.

Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees. Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (Publication Number pending); 2020 September 25.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Associated Clinician

Castán García P, Gil García AI, Madejón Seiz A, Montoya Miñano JJ, Sainz Martínez E, inventors; MIRNAX BIOSENS, S.L, applicants; Bivalent reverse primers. EP19382956.1 and EP20382336.4, PCT/EP2020/080999; 2019 November 04 and 2020 April 24.

Limones López GR, Madejón Seiz A, inventors; Biotools Biotechnological & Medical Laboratories, S.A., applicants; Method for the amplification by reverse transcription coupled to a nested or semi-nested reaction PCR in a single step, of a target RNA, and its applications in the identification of enterovirus and the discrimination between poliovirus and non-polio enterovirus. P200100567; 2001 March 12.

Madejón Seiz A, Vega Rocha S; inventors; Biotools Biotechnological & Medical Laboratories, S.A., applicants; Single stage amplification of DNA by semi nested PCR consists of contacting a Diana DNA fragment with a reaction mixture for pathogens identification. P200100568, 2001 March 12.

Franco de Sarabia Rosado PM, Limones López GR, Madejón Seiz A, Marín Alberdi MD; inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Procedimiento para la preparación de mezclas de reacción estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reacción y kits que las contienen. ARP020104835; 2002 December 12.

Franco de Sarabia Rosado PM, Limones López GR, Madejón Seiz A, Marín Alberdi MD, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Method for preparing stabilised reaction mixtures, which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures. P200100569, PCT/ES02/00109, AU2002246125B2, BR0204479A, BR0204479B1, CA2408857A1, EP1374827A2, EP1374827B1, IL152757A, JP2004519242A, JP4448280B2, KR20030036178A, US2003119042A1, US7919294B2; 2001 March 12.

De Grado Sanz M, Franco de Sarabia Rosado PM, Haro Castuera A, Limones López GR, Madejón Seiz A, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Stabilised composition for fluorimetric, colorimetric or chemoluminescent assays, kits containing same and production method thereof. P200300472, PCT/ES2004/000024, EP04703407.9; 2003 February 26.

Madejón Seiz A, Limones López GR, Calvo Macarro FJ, Rodríguez Gil S, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Nucleic acid detection method involving the direct generation of a measurable signal. PCT/ES2005/070093, AU2005333512A1, CA2579918A1, EP1892302A1, JP2008543300A, US2007292868A1, US7919244B2; 2005 June 16

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Large System Pathologies Area

Organic Dysfunction and Failure in the Agression Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14

Nephrology Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2] pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Diagnosis and Treatment of Allergic Diseases Group

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (EP3290438); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.In vitro method foridentifying severity levels in bronchial asthma patients. P201730739, PCT/ES2018/070390, EP3633050; 2017 May 29.

Gynecologic Oncology Group

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.

Urology

Botella Cubells LM, Albiñana Díaz V, Villar Gómez de las Heras K, inventors; CSIC, Alianza Española de Familias de Von Hippel-Lindau-VHL, assignees; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/EP2018/071220, CA3072389A1, EA202090452A1, EP3664788A1, US2020323798A1; 2017 August 07.

Sánchez-Puelles González-Carvajal JM, Botella Cubells LM, Aguado Sánchez T, Del Río Nechaevsky M, García Martín A, García Díez M, Larcher Laguzzi F, Carretero Trillo M, inventors; CSIC, UC3M, CIEMAT, assignees; Inhibitors of TGF-β1 and endoglin producers for use in the treatment of epidermolysis bullosa. P201831072, PCT/ES2019/070757; 2018 November 07.

Aguado Sánchez T, Albiñana Díaz V, Botella Cubells LM, Cuesta Martínez A, Sánchez-Puelles González-Carvajal JM, Villar Gómez-de las Heras K, inventors; Alianza Española De Familias De Von Hippel-Lindau–VHL, CSIC, Consorcio Centro de Investigación Biomédica en Red M.P., assignees; Treatment and prevention of glioblastoma. EP18382917A, PCT/EP2019/084822, CA3122640A1; 2018 December 12.

2.4.2 Patents and trademarks

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Large System Pathologies Area

Reyburn HT, Valés-Gómez M, inventors; assignees; Assay for the detection of the Cys-like protease (Mpro) of SARS-CoV-2. EP20382495.8; 2020 August.

Valés-Gómez M, inventors; assignees; Method for the detection and/or quantification of extracellular vesicles in fluid biological samples. EP16411562; 2020 August.

Emergency and critical pathology

Carballo Cardona C; author; FIBHULP, assignee. Brand name: Diagether. CM15869911, 2016 September 29.

Associated Clinician

de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Cancer and Human Molecular Genetics Area

INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM9.969.064; 2011 October 27, 2011 May 16.

INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM10.904.951; 2012 July 25, 2012 May 23.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.

Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee. Brand name: Pharma Genfinder; CM18332183; 2020 November 05.

Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP,

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH120, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP3353322B1, US20180346990, CN108174608, DE3353322, FR3353322, GB3353322; 2015 September 23.

Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.

Fernández Martos C.; Trilla Fuertes L.; Fresno Vara JÁ; Gámez Pozo A.; Ghanem Cañete I.; Feliu Battle J.. EP19382982.7. In vitro method for the prognosis of anal squamous cell carcinoma. 11/11/2019. Biomedica Molecular Medicine SL.

Gayá Moreno F.; Díaz Almirón M.; Trilla Fuertes L.; Fresno Vara J.A; Gámez Pozo A. Nuevo método de resolución de Gene-Protein-Reaction Associations. 30/08/2017. Biomedica Molecular Medicine SL.

Experimental Therapies and Biomarkers in Cancer Group

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828, IT1660.13, ES1660.13, FR1660.13, DE1660.13, GB1660.13; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (EP3681515), PCT/EP2018/068156, US16/647,368; 2017 September 15.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct; 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene 06-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (EP3725899), PCT/EP2020/060753 PCT Direct; 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending), PCT/EP2020/069659; 2019 July 19.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Mechanisms of Tumour Progression Group

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat deLleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

Research and Diagnosis of Inherited Metabolic Diseases Group


Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal MA, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, University of Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5, PCT/EP2017/069147; 2016 July 29.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



Surgery, Transplant and Health Technologies Area

Bone Pathophysiology and Biomaterials Group

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 62/495,501 and US62/499,650, PCT/EP2017/072930, EP3512602; 2016 September 16 and 2017 February 02.

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees. Compounds that induce protein unfolding and a mitigated response thereto, and methods of use thereof. US 62/764,569. 2018 August 08.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 62/495,501; 2016 September 16.

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

Clinical Pharmacology Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX; CM13.681.614; 2015 May 28.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

Osteoarticular Surgery Research- GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Associated Clinician

Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees. Brand name:VTR Virtual Transplant Reality; CM18.000.131;2018 December 14.

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.

Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic accessory.P201730569; 2017 March 31.

Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S; Julián García Rivera F, de la Quintana Jiménez P, inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP, assignees. Dispositivo de corte automático de discos de ostomía. P201830718, PCT/ES2019/070492. 2018 July 16.

Ramírez de Molina A, Tabernero Urbieta M, Reglero Rada G, Torres Olivares CF, Largo Aramburu C, Santamaría Ramiro M, Polo Paredes G, Ruiz Pérez D, de Miguel del Campo E, Álvarez Gómez de Segura I, inventors; Fundación IMDEA Alimentación, UAM, FIBHULP, IGENFARMA, assignees. Composición para la reducción del declive metabólico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lípidico. P201830740; 2018 July 20.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Other trademarks of IdiPAZ

FIBHULP, author; FIBHULP, assignee. Brand name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM 8.871.873; 2010 July 06, 2010 February 10.

FIBHULP, author; FIBHULP, assignee. Brand name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.


FIBHULP, author; FIBHULP, assignee. Brand name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.

Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Brand name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales; ESM 3.649.812-2; 2017 February 02.

De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: #OdeOstomía; CM 016922734; 2017 September 21

De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: CM 016922858; 2017 September 21

De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: Ostomía; CM 017131822; 2017 August 22.



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.5 Quality Committe

IdiPAZ maintains its goal, which is to become a reference centre for multidisciplinary translational biomedical research at national and european level. To achieve this objective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching.

IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management teams of the IdiPAZ institutions. To support and facilitate quality, the institution maintains a Quality Committee.

During 2020, the Quality Committee fostered these principles but also achieved specific goals. The previous work proved as an important milestone for the institutional reaccreditation process which took place in early 2020. After successfully adapting to the COVID-19 pandemic and according to the on-going working quality plan the IdiPAZ management system has been maintained once more under the requirements of the ISO 9001:2015 and the UNE 166002:2014 and its scope has been expanded to 5 new platforms/units/committees (https://www.aenor.com/certificacion/certificado/?codigo=170675). Moreover, our institution has achieved for the first time the certification of its Social Responsibility Management System (https://www.aenor.com/certificacion/subcertificado?codigo=212298).



Finally, considering that IdiPAZ is a continuously evolving organisation, the Quality activities of our institution has been enriched by the different achievements made by its member organizations.

The Hospital Universitario La Paz, despite the challenges brought by the COVID-19 pandemic, managed to develope and review several protocols, clinical pathways and clinical practice guidelines. The attached tables show the clinical pathways reviewed in 2020 as well as the protocols developed or updated in the same period. In addition, the staff members continuously collaborate in the improvement of the institution by participating in clinical committees and creating improvement groups, as well as implementing satisfaction surveys for patients and professionals. Also during 2020 hospital departments quality management systems are being consolidated in an overall management system according to the standards ISO 9001:2015, ISO 14001:2015, ISO 22000:2005, IQNet-SR10, UNE 179003 and UNE 15896. The hospital has also 25 accredited units within the Spanish National Accreditation System.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Protocol/Clinical pathway	Status
Acompañamiento parental en la inducción anestésica del paciente pediátrico	New
Actividad en consultas de Alergia durante la pandemia	New
Actividad en consultas de Dermatología durante la pandemia	New
Actuación ante trabajadores sintomáticos COVID-19	New
Actuación de los pacientes pediátricos trasplantados al inicio del curso escolar (dada la situación de pandemia)	New
Adaptación de la actividad en el Hospital de día de Hematooncología de adultos	New
Alerta de trasplante, selección de donante y receptor y preparación receptor trasplante renal	Review
Asistencia a parejas con muerte perinatal	Review
Atención a casos de fiebre del virus del nilo occidental	New
Atención a las crisis febriles en la Urgencia pediátrica	Review
Atención a pacientes con sospecha de infección transmisión sexual	New
Atención a pacientes con sospecha de ITS	Review
Atención a pacientes en situación de gravedad o últimos días y éxitus en la crisis de la COVID-19	New
Atención a pacientes infantiles con patología oftalmológica (Ptosis palpebral, Microftalmía y anoftalmía, Alteraciones palpebrales, Cataratas congénitas e infantiles, Queratoplastias en niños)	Review
Atención COVID-19 en el Hospital Maternal	New
Atención de la ascitis en urgencias	Review
Atención de la encefalopatía en urgencias	Review
Atención durante la pandemia a pacientes en la Unidad de Psiquiatría	New
Atención pediátrica integral de paciente COVID	New
Cambio de cánulas domiciliaria en pacientes con ELA	New
Circuito y atención al niño maltratado y niños refugiados	Review
Confort Acústico y protección del sueño en UCIP	Review
Contacto piel con piel y acompañamiento de familiares en partos por cesárea	Review
Control microbiológico de la Unidad de Terapia celular	New
Cribado COVID-119 de pacientes acompañantes en Hospital Infantil y Maternal	New
Custodia de pertenencias de pacientes fallecidos con COVID-19	New
Desinfección del módulo de normohipotermia del quirófano de Cirugía Cardiovascular Infantil	Review
Desinvaginación con control ecográfico para niños con invaginación intestinal	New
Donación de sangre de cordón umbilical	Review
Donación en asistolia controlada	Review
Errores a evitar en la práctica clínica cardiológica realizado especialmente para facilitar el manejo de pacientes enviados desde primaria	New
Indicación de punción de fistula arteriovenosa nativa en hemodiálisis	Review
Intervención temprana en psicosis	Review
Manejo antitrombótico en procedimientos de ablación compleja	Review
Manejo asistencial y gestión de pacientes en plantas de hospitalización COVID-19	New
Manejo de la inmunosupresión de pacientes con trasplante renal con infección por SARS-CoV-2 que requieren ingreso hospitalario	New
Manejo de la Insuficiencia Cardiaca en Urgencias	Review
Manejo de pacientes COVID-NO COVID en las urgencias	New
Manejo del hipoparatiroidismo postiroidectomía	New
Manejo multidisciplinar de la pancreatitis aguda	New
Manejo neonatal ante sospecha o confirmación de COVID-19	New
Manejo nutricional de pacientes COVID-19	New
Monitorización de la coagulación en ECMO y política transfusional en ECMO	New

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Obtención de muestras de cilindros de próstata vía transrectal	New
Obtención de muestras tisulares postmortem en pacientes SARS-CoV-2 positivo medinate biopsia con aguja gruesa ecoguiada	New
Obtención de Progenitores Hematopoyéticos de Médula Ósea de Donante Cadavérico	New
Plan de contingencia ante la pandemia de Oncología radioterápica	New
Plan de Emergencias y Desastres: Plan de Intervención del Programa Clínico de Trasplantes Pediátrico	New
Pretratamiento con anticoagulantes directos pre-cardioversión eléctrica o ablación de fibrilación/flutter auricular	Review
Producto de terapia celular y terapia avanzada con resultados positivos de cultivo microbiológico	New
Profilaxis de la enfermedad tromboembólica en pacientes quirúrgicos	Review
Profilaxis infecciosa en pacientes sometidos a TPH Alo y Auto	Review
Profilaxis y tratamiento de la enfermedad tromboembólica pediátrica	New
Protección esofágica post-ablación auricular izquierda	Review
Realización de eduación terapéutica grupal en diabetes durante la pandemia	New
Realización de tratamientos reproductivos durante la pandemia COVID-19	New
Reanudación de actividad asistencial del servicio de Endocrinología y Nutrición tras la fase de confinamiento	New
Reanudación de la actividad en cirugía oral durante la pandemia	New
Reanudación de la actividad en la unidad de broncoscopias durante la pandemia	New
Reanudación de la actividad en la unidad de hemodinamia durante la pandemia	New
Reanudación de la actividad en rehabilitación y logopedia durante la pandemia	New
Reanudación de la actividad quirúrgica paciente pediátrico en pandemia COVID	New
Recomendaciones para reanudar la actividad habitual en la Unidad de Endoscopias Digestivas y Unidad de Ecografías en el contexto de la pandemia	New
Recuperación intensificada (ERAS) en cirugía colorrectal	New
Regulación de acompañantes y prohibición de visitas durante la pandemia COVID-19	New
Rehabilitación cardiaca "virtual" de los distintos programas: cardiopatía isquémica, insuficiencia cardiaca y fibrilación auricular	New
Seguimiento remoto de pacientes portadores de dispositivos	Review
Transición del paciente con DM1 desde unidades de Reanimación a planta	New
Transición infantil-adulto en pacientes trasplantados cardiacos	Review
Traqueotomía percutánea en pacientes en pacientes COVID medidas para reducir aerosoles y salpicaduras	New
Traslado del paciente desde la Unidad de TPH a la UCI	Review
Tratamiento de los pacientes con sarcomas y tumores de partes blandas en pandemia COVID	New
Tratamiento del fracaso renal agudo en pediatría	Review
Tratamiento del linfedema primario y secundario	Review
Tratramiento de pacientes con cáncer ginecológico (Vulva, Vagina, Cérvix, Endometrio, Ovario/Peritoneo)	Review
Uso racional de la transfusión de componentes sanguíneos en el paciente pediátrico y neonatal	New

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.6 Clinical Trials

In 2020, the number of active clinical trials was 3,247. The number of trials signed in this year was 364.

Covid-19



Agrifoglio Rotaeche A. Estudio observacional de cohortes para caracterizar el uso actual de la nutrición parenteral y los resultados clínicos en pacientes adultos en estado crítico hospitalizados en unidades de cuidados intensivos en Europa.
Type: Study, phase: PASS-SP.
HULP code: PI-3777.
Sponsored´s protocol code: NScr-003-CNI.
Sponsored by: Fresenius Kabi Deutschland GMBH.
Signed date: 06/02/2020

Aguado Acín P. Factores asociados al descenso de densidad mineral ósea y a la incidencia de fracturas durante el periodo de descanso terapéutico con BF.
Type: Study, phase: PASS-OD.
HULP code: PI-3952.
Sponsored´s protocol code: FIB-ALE-2020-01.
Sponsored by: FIBHULP.
Signed date: 23/09/2020

Aguilar-Amat Prior MJ. Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de padsevonil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia fármacorresistente.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5026.
Sponsored´s protocol code: EP0091.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 01/10/2020

Aguilar-Amat Prior MJ. Estudio prospectivo, no intervencionista, observacional y multicéntrico para investigar la dosis, la eficacia y la seguridad de perampanel cuando se utiliza como primer tratamiento complementario en la asistencia clínica habitual de pacientes mayores de 12 años con crisis de inicio parcial con o sin generalización secundaria o con crisis tonico-clónicas generalizadas primarias asociadas a epilepsia generalizada idiopática.
Type: Study, phase: PASS-SP.
HULP code: PI-4301.
Sponsored´s protocol code: E2007-M044-512.
Sponsored by: Eisai Europe Limited.
Signed date: 31/08/2020

Alcobendas Rueda RM. Estudio de fase 3, multicéntrico, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes de entre 1 y menos de 18 años con artritis idiopática juvenil.
Type: Clinical Trials, phase: III.
HULP code: 5240.
Sponsored´s protocol code: I4V-MC-JAHX.
Sponsored by: Lilly S.A.
Signed date: 15/04/2020

Alcobendas Rueda RM. Estudio aleatorizado, con enmascaramiento doble y comparativo con un placebo, en el que se evalúan la eficacia, la seguridad y la retirada del tratamiento con baricitinib por vía oral en pacientes con artritis idiopática juvenil de entre 1 y menos de 18 años.
Type: Clinical Trials, phase: III.
HULP code: 5387.
Sponsored´s protocol code: I4V-MC-JAHU (JUVE-BALM).
Sponsored by: Lilly S.A.
Signed date: 13/02/2020

Alcolea Batres S. Estudio en fase III, prospectivo, multicéntrico, doble ciego, con doble simulación, aleatorizado, controlado con fármaco activo, de grupos paralelos, de grupos secuenciales, adaptativo y basado en acontecimientos para comparar la eficacia, la seguridad y la tolerabilidad de macitentán 75 mg frente a macitentán 10 mg en pacientes con hipertensión arterial pulmonar, seguido de un periodo de tratamiento abierto con macitentán 75 mg.
Type: Clinical Trials, phase: III.
HULP code: 5546.
Sponsored´s protocol code: AC-055-315 UNISUS.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 25/05/2020

Alonso Pacheco ML. Prueba de concepto para evaluar la eficacia y seguridad de una nueva pauta de tratamiento de guselkumab en pacientes con psoriasis en placas moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5687.
Sponsored´s protocol code: GUDERM.
Sponsored by: Herranz Pinto, Pedro.
Signed date: 30/11/2020

Alonso Prieto, MM. Estudio en fase I/II, abierto

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

y multicéntrico para evaluar la farmacocinética, seguridad y tolerabilidad de naldemedina en pacientes pediátricos que están recibiendo o van a recibir tratamiento con opioides
Type: Clinical Trials, phase: I.
HULP code: 5535.
Sponsored´s protocol code: 1907V21F.
Sponsored by: Shionogi B.V.
Signed date: 12/05/2020

Álvarez Maestro M. Quimioterapia neoadyuvante versus adyuvante en carcinoma urotelial del tracto urinario superior. Ensayo clínico randomizado de viabilidad fase II. URANOS.
Type: Clinical Trials, phase: II.
HULP code: 5582.
Sponsored´s protocol code: EUOG-2016-003.
Sponsored by: European Uro-Oncology Group.
Signed date: 28/09/2020

Álvarez Maestro M. Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma urotelial de tracto urinario resecable.
Type: Clinical Trials, phase: IV.
HULP code: 5053.
Sponsored´s protocol code: VitDURO-AECC17-01.
Sponsored by: CEIC Hospital Universitari Germans Trias I Pujol.
Signed date: 07/02/2020

Álvarez Maestro M. Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de durvalumab y el bacilo de Calmette-Guerin administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5344.
Sponsored´s protocol code: D419JC00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 20/04/2020

Álvarez Maestro M. Ensayo clínico de fase 3, aleatorizado y controlado con un comparador para estudiar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con el Bacilo de Calmette-Guérin (BCG) en participantes con cáncer de vejiga no músculo invasivo de alto riesgo que es persistente o recurrente tras un tratamiento de inducción con BCG (keynote-676).
Type: Clinical Trials, phase: III.
HULP code: 5493.
Sponsored´s protocol code: MK-3475-676.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 22/01/2020

Álvarez Román MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNTP) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave FVIII < 1 %.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4487.
Sponsored´s protocol code: 261203.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 12/05/2020

Álvarez Román MT. Estudio en fase I/II abierto y multinacional de seguridad y escalada de dosis de SHP648, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa el fix padua en sujetos con hemofilia B.
Type: Clinical Trials, phase: I.
HULP code: Appendix I 5382.
Sponsored´s protocol code: SHP648-101.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 21/07/2020

Álvarez Román MT. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos con una extensión abierta para evaluar la eficacia y la seguridad de rilzabrutinib por vía oral (PRN1008) en adultos y adolescentes con trombocitopenia inmunitaria persistente o crónica.
Type: Clinical Trials, phase: III.
HULP code: 5696.
Sponsored´s protocol code: PRN1008-018.
Sponsored by: Principia Biopharma Inc.
Signed date: 10/11/2020

Álvarez Román MT. Eficacia y seguridad del factor VIII recombinante (Novoeight®) en pacientes con hemofilia A sometidos a intervenciones quirúrgicas.
Type: Study, phase: PASS-SP.
HULP code: PI-4439.
Sponsored´s protocol code: MFL-TUR-2018-01.
Sponsored by: López Fernández, Maria Fernanda.
Signed date: 28/10/2020

Álvarez Román MT. Evaluación de la seguridad a largo plazo de adynovi/adynovate (factor antihemofílico [recombinante] pegilado, rurioctocog alfa pegol) en pacientes con hemofilia A: un estudio de seguridad posterior a la autorización (PASS) de adynovi/adynovate.
Type: Study, phase: PASS-LA.
HULP code: PI-4279.
Sponsored´s protocol code: TAK-660-403.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 01/10/2020

Álvarez-Sala Walther R. Estudio fundamental de 52 semanas de duración, aleatorizado, doble ciego, controlado con placebo en grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de dupilumab en pacientes con enfermedad pulmonar obstructiva crónica de moderada grave con inflamación tipo2.
Type: Clinical Trials, phase: III.
HULP code: 5539.
Sponsored´s protocol code: EFC15805.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 15/05/2020

Antorrena Miranda MI. Ensayo de colchicina en el SARS-COV2 coronavirus (Colcorona-covid-19).
Type: Clinical Trials, phase: III.
HULP code: 5578.
Sponsored´s protocol code: MHIPS-2020-01 COLCORONA.
Sponsored by: FIBHULP.
Signed date: 01/06/2020

Antorrena Miranda MI. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.
Type: Study, phase: Drugs.
HULP code: Appendix III PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 23/09/2020

Antorrena Miranda MI. Estudio observacional para evaluar el beneficio clínico neto de edoxaban en pacientes con fibrilación auricular no valvular, según práctica clínica habitual en España. Registro Benefit.
Type: Study, phase: PASS-OD.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



HULP code: PI-4283.
Sponsored´s protocol code: DSE-EDO-2020-01.
Sponsored by: Daiichi Sankyo España.
Signed date: 13/11/2020

Armada Romero E. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de Dalcetrapib sobre el riesgo cardiovascular en una población definida genéticamente con síndrome coronario agudo reciente: el ensayo DALI-GENE.
Type: Clinical Trials, phase: III.
HULP code: Appendeix I 4627.
Sponsored´s protocol code: DAL-301.
Sponsored by: Dalcor Pharma UK LTD.
Signed date: 02/12/2020

Arnalich Fernández F. Ensayo clínico del uso de anakinra (Anti il-1) en el síndrome de tormenta de citoquinas secundario a covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5589.
Sponsored´s protocol code: ANA-COVID-GEAS.
Sponsored by: Fundación Miguel Servet-Instituto de Investigaciones Biomédicas.
Signed date: 01/05/2020

Arribas López JR. Estudio fase 3 aleatorizado para evaluar la seguridad y la actividad antiviral de remdesevir GS-5734TM en participantes con infección grave por el covid-19.
Type: Clinical Trials, phase: III.
HULP code: 5537.
Sponsored´s protocol code: GS-US-540-5773.
Sponsored by: Gilead Sciences S.L.
Signed date: 16/03/2020

Arribas López JR. Estudio fase 3 aleatorizado para evaluar la seguridad y la actividad antiviral de remdesevir GS-5734TM en participantes con infección moderada por el covid-19.
Type: Clinical Trials, phase: III.
HULP code: 5538.
Sponsored´s protocol code: GS-US-540-5774.
Sponsored by: Gilead Sciences S.L.
Signed date: 16/03/2020

Arribas López JR. Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de tocilizumab en pacientes con neumonía grave en la enfermedad por el covid-19.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5566.
Sponsored´s protocol code: WA42380.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 23/07/2020

Arribas López JR. Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de tocilizumab en pacientes con neumonía grave en la enfermedad por el covid-19.
Type: Clinical Trials, phase: III.
HULP code: 5566.
Sponsored´s protocol code: WA42380.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 30/03/2020

Arribas López JR. Estudio adaptativo de fase 2/3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de sarilumab en pacientes hospitalizados por covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5562.
Sponsored´s protocol code: EFC16844.
Sponsored by: Sanofi Aventis S.A.
Signed date: 25/03/2020

Arribas López JR. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de MK-4482 en adultos hospitalizados con covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5692.
Sponsored´s protocol code: MK-4482-001.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 25/09/2020

Arribas López JR. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de MK-4482 en adultos no hospitalizados con covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5693.
Sponsored´s protocol code: MK-4482-002.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 25/09/2020

Arribas López JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de AD26.COV2.S para la prevención de covid-19 mediada por Sars-Cov-2 en adultos mayores de 18 años.
Type: Clinical Trials, phase: III.
HULP code: 5734.
Sponsored´s protocol code: VAC31518COV3009.
Sponsored by: Janssen Cilag International N.V.
Signed date: 11/12/2020

Arribas López JR. Estudio internacional observacional para la caraterización de adultos hospitalizados por las complicaciones de la gripe a pandémica H1N1.
Type: Study, phase: Drugs.
HULP code: Appendix II 3045.
Sponsored´s protocol code: INSIGHT 003.
Signed date: 24/01/2020

Asencio Durán M. Estudio de 12 meses, prospectivo, abierto, de fase 4 para evaluar la eficacia y seguridad de Ozurdex® (implante intravítreo de dexametasona) en pacientes sin tratamiento previo (según la práctica clínica estándar) con edema macular diabético.
Type: Clinical Trials, phase: IV.
HULP code: 5260.
Sponsored´s protocol code: CMO-MA-EYE-0603.
Sponsored by: Allergan Pharmaceuticals International Limited.
Signed date: 28/09/2020

Balsa Criado A. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de filgotinib en pacientes con artritis psoriásica activa que han presentado respuesta insuficiente o que son intolerantes al tratamiento con fármacos biológicos antirreumáticos modificadores de enfermedad.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5515.
Sponsored´s protocol code: GS-US-431-4567.
Sponsored by: Gilead Sciences Inc.
Signed date: 30/07/2020.

Balsa Criado A. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de filgotinib en pacientes con artritis psoriásica activa que han presentado respuesta insuficiente o que son intolerantes al tratamiento con fármacos bio-

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

lógicos antirreumáticos modificadores de enfermedad.
Type: Clinical Trials, phase: III.
HULP code: 5515.
Sponsored´s protocol code: GS-US-431-4567.
Sponsored by: Gilead Sciences Inc.
Signed date: 20/04/2020

Balsa Criado A. Programa de fase 3 aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de upadacitinib en pacientes adultos con espondiloartritis axial.
Type: Clinical Trials, phase: III.
HULP code: 5458.
Sponsored´s protocol code: M19-944.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 27/01/2020

Balsa Criado A. Estudio abierto y multicéntrico para pacientes que hayan completado un estudio previo con secukinumab patrocinado por novartis y que, a criterio del investigador, se estén beneficiando del tratamiento continuado con secukinumab.
Type: Clinical Trials, phase: III.
HULP code: 5710.
Sponsored´s protocol code: CAIN457A02001B.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 19/10/2020

Balsa Criado A. Estudio ciara: análisis del impacto del coste en pacientes con artritis reumatoide moderada severa que no responden a fármaco modificador de la enfermedad biológico o a fármaco modificador de la enfermedad sintético convencional.
Type: Study, phase: PASS-SP.
HULP code: PI-3779.
Sponsored´s protocol code: PFI-INF-2019-01.
Sponsored by: Pfizer S.L.U.
Signed date: 01/12/2020

Balsa Criado A. Estudio observacional transversal, sobre la facilidad de uso del dispositivo de inyección errosa pen.
Type: Study, phase: PASS-OD.
HULP code: PI-4167.
Sponsored´s protocol code: GR-TE-01-2019.
Sponsored by: Gedeon Ritcher Iberica S.A.U.
Signed date: 25/06/2020

Baltasar Tello P. Estudio de fase III, aleatorizado de zanubrutinib (BGB-3111) en comparación con ibruntinib en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas recidivante/resistente.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5223.
Sponsored´s protocol code: BGB-3111-305.
Sponsored by: Beigene USA Inc.
Signed date: 16/04/2020

Baltasar Tello P. Estudio de fase III, prospectivo, abierto, multicéntrico y aleatorizado para comparar la eficacia y la seguridad de una combinación de venetoclax y obinutuzumab frente a fludarabina, ciclofosfamida y rituximab (FCR)/bendamustina y rituximab (BR) en pacientes en buen estado con leucemia linfocítica crónica (LLC) no tratada previamente sin del (17P) ni mutación de tP53.
Type: Clinical Trials, phase: III.
HULP code: 5464.
Sponsored´s protocol code: C041685.
Sponsored by: Roche Farma S.A.
Signed date: 10/01/2020

Bartha Rasero JL. Ensayo en fase III, aleatorizado, doble ciego o con enmascaramiento para el observador, controlado con placebo, para evaluar la eficacia y seguridad de una vacuna de subunidad F prefusión contra el virus respiratorio sincitial (VRS) en lactantes nacidos de mujeres vacunadas durante el embarazo.
Type: Clinical Trials, phase: III.
HULP code: 5526.
Sponsored´s protocol code: C3671008.
Sponsored by: Pfizer S.L.U.
Signed date: 04/06/2020

Bernardino de la Serna JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir, doravirina y doravirina/islatravir, cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5532.
Sponsored´s protocol code: MK-8591A-019.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 03/12/2020

Bernardino de la Serna JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir, doravirina y doravirina/islatravir, cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.
Type: Clinical Trials, phase: III.
HULP code: 5532.
Sponsored´s protocol code: MK-8591A-019.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 28/02/2020

Bloise Sánchez I. Mapeo nacional de carbapenemasas en España. Estudio Carba-Map.
Type: Study, phase: PASS-OD.
HULP code: PI-4415.
Sponsored´s protocol code: MSD-CAR-2020-01.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 30/10/2020

Bonilla Hernán MG. Evaluación del riesgo cardiovascular, y de sus determinantes, en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica. Proyecto Carma.
Type: Study, phase: Drugs.
HULP code: Appendix II PI-011.
Sponsored´s protocol code: CARMA.
Sponsored by: Fundación Española de Reumatología.
Signed date: 29/07/2020

Bonilla Hernán MG. Evolución del lupus eritematoso sistémico en España.
Type: Study, phase: Drugs.
HULP code: Appendix I PI-1909.
Sponsored´s protocol code: RELESSER-PROS.
Sponsored by: Fundación Española de Reumatologia.
Signed date: 12/06/2020

Borobia Pérez A. Estudio fase I/IIA, de primera administración en humanos, aleatorizado, con observador ciego para evaluar la seguridad, reactogenicidad e inmunogenicidad de tres dosis diferentes de VAC52416 (EXPEC10V) en adultos de entre 60 y 85 años con un estado de salud estable.
Type: Clinical Trials, phase: I.
HULP code: 5569.
Sponsored´s protocol code: VAC52416BAC1001.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Sponsored by: Janssen-Cilag España S.A.
Signed date: 17/09/2020

Borobia Pérez A. Prevencion de enfermedad por Sars-Cov-2 (covid-19) mediante la profilaxis pre-exposición de emtricitabina /tenofovir disoproxilo e hidroxicloroquina en personal sanitario: ensayo clínico aleatorizado, controlado con placebo.
Type: Clinical Trials, phase: III.
HULP code: 5576.
Sponsored´s protocol code: PREP COVID-19.
Sponsored by: Ministerio de Sanidad, Consumo y Bienestar Social.
Signed date: 03/09/2020

Borobia Pérez A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunacion de AD26CCO-VS1 en adultos sanos de 18 a 55 años inclusive.
Type: Clinical Trials, phase: II.
HULP code: Appendix II 5630.
Sponsored´s protocol code: VAC31518COV2001.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 31/12/2020

Borobia Pérez A. Estudio fase 2a, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunacion de AD26CCO-VS1 en adultos sanos de 18 a 55 años inclusive.
Type: Clinical Trials, phase: II.
HULP code: 5630.
Sponsored´s protocol code: VAC31518COV2002 VAC31518.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 08/07/2020

Borobia Pérez A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de AD26CCO-VS1 en adultos sanos de 18 a 55 años inclusive.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5630.
Sponsored´s protocol code: VAC31518COV2002.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 20/10/2020

Caballero Molina MT. BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCX7353 como tratamiento oral para la prevención de ataques en pacientes con angioedema hereditario.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4984.
Sponsored´s protocol code: BCX7353-302.
Sponsored by: Biocryst Pharmaceuticals Inc.
Signed date: 19/02/2020

Caballero Molina MT. Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la eficacia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de C1 (C1-INH) normal y angioedema adquirido debido a déficit de C1-INH.
Type: Clinical Trials, phase: III.
HULP code: 5550.
Sponsored´s protocol code: SHP643-303.
Sponsored by: Dyax Corp.
Signed date: 18/11/2020

Cabrera Lafuente M. Ganancia de peso en niños prematuros de muy bajo peso, con fortificación individualizada versus fortificación ajustada: estudio aleatorio controlado.
Type: Study, phase: Drugs.
HULP code: 5704.
Sponsored´s protocol code: FORTIN.
Sponsored by: Cabrera Lafuente, Marta.
Signed date: 09/12/2020

Calvo Rey C. Estudio abierto, de un solo brazo para evaluar la farmacocinética, seguridad y tolerabilidad, y para explorar los resultados clínicos del tratamiento con dosis única o múltiple de zanamivir IV en neonatos e infantes menores de 6 meses con infección por gripe confirmada complicada.
Type: Clinical Trials, phase: II.
HULP code: 5641.
Sponsored´s protocol code: 200925.
Sponsored by: Glaxosmithkline S.A.
Signed date: 23/10/2020

Calvo Rey C. Estudio en fase IIB abierto para evaluar la seguridad, tolerabilidad e inmunogenicidad de Menab-cwy en lactantes sanos de 2 y 6 meses.
Type: Clinical Trials, phase: IIb.
HULP code: 5716.
Sponsored´s protocol code: C3511002.
Sponsored by: Pfizer S.L.U.
Signed date: 27/08/2020

Calvo Rey C. Estudio fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de rilematovir en lactantes y niños (≥28 días a ≤5 años de edad) y posteriormente en recién nacidos (<28 días de edad), hospitalizados con infección aguda respiratoria por virus sincitial respiratorio.
Type: Clinical Trials, phase: III.
HULP code: 5679.
Sponsored´s protocol code: 53718678RSV3001 DAISY.
Sponsored by: Janssen Cilag International N.V.
Signed date: 20/10/2020

Calvo Rey C. Estudio aleatorizado, controlado y doble ciego con grupo paralelo, en múltiples países para investigar la equivalencia de crecimiento y evaluar la seguridad y la tolerancia de la fórmula infantil con prebióticos y posbióticos derivados del proceso de fermentación de lactofidus TM en bebés a término sanos.
Type: Study, phase: Drugs.
HULP code: PI-3988.
Sponsored´s protocol code: EBB18FI23464.
Sponsored by: Nutricia Research B.V.
Signed date: 07/08/2020

Canales Albendea MA. Estudio de fase III randomizado, doble ciego y controlado con placebo, de itacitinib o placebo en combinación con corticosteroides para el tratamiento de primera línea de la enfermedad de injerto contra huésped en fase aguda.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4872.
Sponsored´s protocol code: INCB 39110-301.
Sponsored by: Incyte Corporation.
Signed date: 27/03/2020


Canales Albendea MA. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo de acalabrutinib en combinación con rituximab, ciclofosfamida, doxorrubicina, vincristina y prednisona (R-CHOP) en pacientes ≤65 años con linfoma difuso de células B grandes sin centro germinal no tratado previamente.
Type: Clinical Trials, phase: III.
HULP code: 5675.
Sponsored´s protocol code: ACE-LY-312.
Sponsored by: Acerta Pharma B.V.
Signed date: 29/10/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Canales Albendea MA. Estudio en fase II/III multicéntrico y aleatorizado de rituximab-gemcitabina-dexametasona-platino con o sin selinexor, en pacientes con linfoma difuso de células B grandes recidivante/resistente.
Type: Clinical Trials, phase: II.
HULP code: 5601.
Sponsored´s protocol code: XPORT-DLBCL-030.
Sponsored by: Karyopharm Therapeutics Inc.
Signed date: 22/09/2020

Canales Albendea MA. Estudio de fase III, abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de glofitamab combinado con gemcitabina más oxaliplatino en comparación con rituximab combinado con gemcitabina y oxaliplatino en pacientes con linfoma difuso de células B grandes en recaída/resistente.
Type: Clinical Trials, phase: III.
HULP code: 5628.
Sponsored´s protocol code: G041944.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

Canales Albendea MA. Estudio adaptativo de biomarcadores de fase IB/III, doble ciego, aleatorizado, controlado con principio activo, en 3 etapas de tazemetostat o placebo en combinación con lenalidomida más rituximab en pacientes con linfoma folicular recidivante/resistente al tratamiento.
Type: Clinical Trials, phase: I.
HULP code: 5671.
Sponsored´s protocol code: EZH-302.
Sponsored by: Epizyme Inc.
Signed date: 16/12/2020

Carcas Sansuán AJ. Evaluación de la farmacocinética de paracetamol en pacientes pediátricos según su status ponderal evaluado mediante IMC: normopeso, sobrepeso y obesidad.
Type: Clinical Trials, phase: IV.
HULP code: 5685.
Sponsored´s protocol code: PARA-OBES.
Sponsored by: Carcas Sansuán, Antonio J.
Signed date: 24/11/2020

Casado Sánchez C. Latitude: estudio prospectivo de cohorte europeo sobre el uso del láser urgotouch® para la prevención de cicatrices lineales anormales.
Type: Study, phase: PASS-SP.
HULP code: PI-3853.
Sponsored´s protocol code: EN/URGO/VTOUCH/2018.
Sponsored by: Laboratorios Urgo S.L.U.
Signed date: 03/02/2020

Castelo Fernández B. Estudio en fase 3, aleatorizado, doble ciego sobre avelumab combinado con la quimioradioterapia de referencia (cisplatino más radioterapia definitiva) en comparación con la quimiorradioterapia de referencia en el tratamiento de primera línea de pacientes con carcinoma epidermoide localmente avanzado de cabeza y cuello.
Type: Clinical Trials, phase: III.
HULP code: Appendix III 4861.
Sponsored´s protocol code: B9991016.
Sponsored by: Pfizer S.L.U.
Signed date: 05/08/2020

Castelo Fernández B. Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101B en el tratamiento de sujetos con cáncer orofaríngeo VPH-16 positivo resistente al platino.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5124.
Sponsored´s protocol code: ISA101B-HN-01-17.
Sponsored by: Isa Therapeutics B.V.
Signed date: 11/11/2020

Castelo Fernández B. Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con ret mutante y sin tratamiento anterior con inhibidores de quinasa (libretto-531).
Type: Clinical Trials, phase: III.
HULP code: 5441.
Sponsored´s protocol code: J2G-MC-JZJB.
Sponsored by: Lilly S.A.
Signed date: 05/02/2020

Castelo Fernández B. Estudio de fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metastásico con expresión de PD-L1.
Type: Clinical Trials, phase: II.
HULP code: 5492.
Sponsored´s protocol code: 209229.
Sponsored by: Glaxosmithkline S.A.
Signed date: 03/03/2020

Castelo Fernández B. Estudio de fase II/III aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 en combinación con pembrolizumab y quimioterapia con 5FU-platino frente a placebo en combinación con pembrolizumab y quimioterapia con 5FU-platino para el tratamiento en primera línea de carcinoma de células escamosas de cabeza y cuello recurrente/metastásico.
Type: Clinical Trials, phase: II.
HULP code: 5631.
Sponsored´s protocol code: 209227.
Sponsored by: Glaxosmithkline S.A.
Signed date: 06/08/2020

Castelo Fernández B. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (Trilynx).
Type: Clinical Trials, phase: III.
HULP code: 5602.
Sponsored´s protocol code: Debio 1143-SCCHN-301.
Sponsored by: Debiopharm S.A.
Signed date: 09/07/2020

Castillo Grau P. Estudio clínico de fase 3/4, multinacional, multicéntrico, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de aramchol en pacientes con esteatohepatitis no alcohólica (Estudio Armor).
Type: Clinical Trials, phase: III.
HULP code: 5434.
Sponsored´s protocol code: ARAMCHOL-018.
Sponsored by: Galmed Research and Developmente Ltd.
Signed date: 14/01/2020

Castro Conde A. Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (Surpass-CVOT).
Type: Clinical Trials, phase: I.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

HULP code: 5484.
Sponsored´s protocol code: 18F-MC-GPGN.
Sponsored by: Lilly S.A.
Signed date: 29/01/2020

Castro Conde A. Impacto del consenso español para la mejora de los objetivos LDL colesterol después de un síndrome coronario agudo.
Type: Study, phase: Drugs.
HULP code: PI-4420.
Sponsored´s protocol code: GOAL.
Sponsored by: Sociedad Española de Cardiología.
Signed date: 10/11/2020

Chaverri Rada MD. Estudio fase III, prospectivo, multicéntrico, randomizado, doble ciego, controlado con placebo y de grupos paralelos para comparar la eficacia y seguridad de masitinib en combinación con riluzol frente a placebo en combinación con riluzol para el tratamiento de pacientes con esclerosis lateral amiotrófica.
Type: Clinical Trials, phase: III.
HULP code: 5412.
Sponsored´s protocol code: AB19001.
Sponsored by: Abscience.
Signed date: 04/12/2020

Climent Alcalá FJ. Estudio abierto y comparativo con tratamiento activo, de la seguridad y la eficacia extrapolada en pacientes pediátricos que requieren anticoagulación para el tratamiento de un acontecimiento tromboembólico venoso.
Type: Clinical Trials, phase: III.
HULP code: APPENDIX II 4852.
Sponsored´s protocol code: v B0661037.
Sponsored by: Pfizer S.L.U.
Signed date: 13/11/2020

Climent Alcalá FJ. Ensayo de fase III, abierto, aleatorizado, multicéntrico y controlado para evaluar la farmacocinética y farmacodinámica de edoxabán y comparar la eficacia y seguridad de edoxabán con un tratamiento estándar anticoagulante en sujetos pediátricos desde el nacimiento hasta antes de los 18 años con tromboembolismo venoso confirmado.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4855.
Sponsored´s protocol code: DU176b-D-U312.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 17/02/2020

Condorhuamán Alvarado PY. Estudio observacional, prospectivo, del efecto de un suplemento nutricional hipercalórico e hiperproteico con HMB, de administración oral, en una población de edad avanzada desnutrida o en riesgo de desnutrición que ha sufrido una fractura de cadera.
Type: Study, phase: Drugs.
HULP code: PI-3505.
Sponsored´s protocol code: DA20.
Sponsored by: Abbott Laboratories S.A.
Signed date: 14/09/2020

Cruz Castellanos P. Estudio observacional prospectivo para identificar pacientes con CPNM avanzado/metastásico y translocación de ALK y conocer su manejo terapéutico (Estudio Idealk).
Type: Study, phase: PASS-SP.
HULP code: Appendix I PI-3438.
Sponsored´s protocol code: A8081057.
Sponsored by: Pfizer S.L.U.
Signed date: 13/11/2020

Custodio Carretero AB. Ensayo clínico exploratorio "Basket" de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino.
Type: Clinical Trials, phase: II.
HULP code: 5399.
Sponsored´s protocol code: GETNE-T1914.
Sponsored by: Grupo Español de Tumores Neuroendocrinos.
Signed date: 04/09/2020

Custodio Carretero AB. Ensayo clínico en fase III, multicéntrico, doble ciego, aleatorizado para evaluar la eficacia y la seguridad de sintilimab frente a placebo, en combinación con quimioterapia, para el tratamiento de primera línea del carcinoma escamoso de esófago irresecable, localmente avanzado, recurrente o metastásico (Orient-15).
Type: Clinical Trials, phase: III.
HULP code: 5595.
Sponsored´s protocol code: CIBI308A301.
Sponsored by: Innovent Biologics.
Signed date: 09/06/2020

de Andrés Ares J. Estudio en grupos paralelos, doble ciego, aleatorizado y controlado por placebo, para evaluar la eficacia y seguridad de AP-325 en pacientes con dolor neuropático periférico post-quirúrgico.
Type: Clinical Trials, phase: II.
HULP code: 5494.
Sponsored´s protocol code: AP-325.04.
Sponsored by: Algiax Pharmaceuticals GMBH.
Signed date: 22/01/2020

de Castro Carpeño J. Ensayo de fase III, abierto, multicéntrico de avelumab (MSB0010718C) frente al doblete con base de platino como tratamiento de primera línea del cáncer de pulmón no microcítico PD-L1+ recurrente o en estadio IV.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4889.
Sponsored by: Merck KGAA.
Signed date: 08/10/2020

de Castro Carpeño J. Estudio cesto, abierto, multicéntrico, global, en fase ii con entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes ntrk1/2/3, ros1 o alk.
Type: Clinical Trials, phase: II.
HULP code: Appendix III 4648.
Sponsored´s protocol code: G040782 (RXDX-101).
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 06/02/2020

de Castro Carpeño J. Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de met (metex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino.
Type: Clinical Trials, phase: II.
HULP code: Appendix III 4657.
Sponsored´s protocol code: MS200095-0022.
Sponsored by: Merck KGAA.
Signed date: 13/01/2020

de Castro Carpeño J. Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadío IIIB/IV con alteraciones por omisión del exón 14 de MET (Metex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino.
Type: Clinical Trials, phase: II.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

HULP code: Appendix IV 4657.
Sponsored´s protocol code: MS200095-022.
Sponsored by: Merck KGAA.
Signed date: 08/09/2020

de Castro Carpeño J. Estudio en paraguas de fase IB/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (Morpheus Pulmonar).
Type: Clinical Trials, phase: I.
HULP code: 5591.
Sponsored´s protocol code: B039610.
Sponsored by: Genentech Inc.
Signed date: 20/10/2020

de Castro Carpeño J. Resilient: estudio aleatorizado abierto en FSE III de irinotecán liposomal inyectable (onivyde®) frente a topotecán en pacientes con cáncer de pulmón microcítico que han progresado con o después del tratamiento de primera línea basado en platino.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5330.
Sponsored´s protocol code: MM-398-01-03-04.
Sponsored by: Ipsen Bioscience Inc.
Signed date: 06/04/2020

de Castro Carpeño J. Estudio exploratorio de los efectos biológicos y los biomarcadores de nivolumab en combinación con ipilimumab en pacientes con cáncer de pulmón no microcítico en estadio IV o recurrente sin tratamiento previo (Checkmate 592: evaluación de la vía del punto de control y de nivolumab en ensayos clínicos 592).
Type: Clinical Trials, phase: IV.
HULP code: Appendix II 5107.
Sponsored´s protocol code: CA209-592.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 13/02/2020

de Castro Carpeño J. Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (Canopy-1).
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4258.
Sponsored´s protocol code: CACZ885U2301.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 30/11/2020

de Castro Carpeño J. Ensayo de plataforma de fase 2 basado en biomarcardores en pacientes con cáncer de pulmón no microcítico avanzado cuya enfermedad ha progresado durante el tratamiento con osimertinib en primera línea.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5345.
Sponsored´s protocol code: D6186C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 04/08/2020

de Castro Carpeño J. Estudio pantumoral para el seguimiento a largo plazo de supervivientes de cáncer que han participado en ensayos de investigación de nivolumab.
Type: Clinical Trials, phase: II.
HULP code: 5551.
Sponsored´s protocol code: CA2098TT.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 23/09/2020

de Castro Carpeño J. Estudio aleatorizado de fase III de sitravatinib en combinación con nivolumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso avanzado con progresión de la enfermedad durante o después de la quimioterapia con platino y el tratamiento con inhibidor de punto de control (Sapphire).
Type: Clinical Trials, phase: III.
HULP code: 5556.
Sponsored´s protocol code: 516-005.
Sponsored by: Mirati Therapeutics Inc.
Signed date: 30/09/2020

de Castro Carpeño J. Estudio abierto, multicéntrico y global para evaluar la eficacia y la seguridad a largo plazo en pacientes que están recibiendo o que han recibido previamente durvalumab en otros protocolos (WAVE).
Type: Clinical Trials, phase: IV.
HULP code: 5419.
Sponsored´s protocol code: D910FC00001.
Sponsored by: Astrazeneca Ab.
Signed date: 27/02/2020

de Castro Carpeño J. Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar la eficacia de tak-788 como tratamiento de primera línea frente a quimioterapia a base de platino en pacientes con cáncer de pulmón no microcítico con mutaciones de EGFR por inserción en el exón 20.
Type: Clinical Trials, phase: III.
HULP code: 5454.
Sponsored´s protocol code: TAK-788-3001.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 03/02/2020

de Castro Carpeño J. Ensayo de fase 3, abierto, aleatorizado y multicéntrico que compara selpercatinib con una terapia basada en platino y pemetrexed, con o sin pembrolizumab, como tratamiento inicial del cáncer de pulmón no microcítico avanzado o metastásico, positivo para fusión de Ret.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5442.
Sponsored´s protocol code: J2G-MC-JZJC.
Sponsored by: Lilly S.A.
Signed date: 13/05/2020

de Castro Carpeño J. Ensayo de fase 3, abierto, aleatorizado y multicéntrico que compara selpercatinib con una terapia basada en platino y pemetrexed, con o sin pembrolizumab, como tratamiento inicial del cáncer de pulmón no microcítico avanzado o metastásico, positivo para fusión de ret.
Type: Clinical Trials, phase: III.
HULP code: 5442.
Sponsored´s protocol code: J2G-MC-JZJC.
Sponsored by: Lilly S.A.
Signed date: 17/02/2020

de Castro Carpeño J. Estudio de fase III multicéntrico, aleatorizado, abierto y con control activo de AMG 510 frente a docetaxel en el tratamiento de sujetos con cpnm tratado previamente, localmente avanzado y no resecable o metastásico con la mutación P.G12C en el KRAS.
Type: Clinical Trials, phase: III.
HULP code: 5545.
Sponsored´s protocol code: 20190009.
Sponsored by: Amgen S.A.
Signed date: 23/04/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



de Castro Carpeño J. Ensayo abierto de un solo brazo para evaluar la actividad antitumoral, la seguridad y la farmacocinética de SAR408701 utilizado en combinación con ramucirumab en pacientes con carcinoma pulmonar no microcítico no escamoso metastásico con tumores Ceacam5 positivos, tratados previamente con quimioterapia a base de platino y con un inhibidor de puntos de control inmunitario.
Type: Clinical Trials, phase: II.
HULP code: 5555.
Sponsored´s protocol code: ACT16525.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 09/06/2020

de Castro Carpeño J. Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparación con durvalumab en pacientes con cáncer de pulmón no microcítico localmente avanzado en estadio III irresecable que no han presentado progresión después de quimiorradioterapia con platino concomitante (Skyscraper-03).
Type: Clinical Trials, phase: III.
HULP code: 5590.
Sponsored´s protocol code: GO41854.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

de Castro Carpeño J. Estudio de fase III, multicéntrico, aleatorizado, abierto y controlado para evaluar la eficacia, la seguridad y la farmacocinética de atezolizumab en combinación con cabozantinib en comparación con docetaxel en monoterapia en pacientes con cáncer de pulmón no microcítico tratado previamente con un anticuerpo anti-PDL1/PD-1 y quimioterapia con platino.
Type: Clinical Trials, phase: III.
HULP code: 5568.
Sponsored´s protocol code: GO41892.
Sponsored by: Roche Farma S.A.
Signed date: 28/05/2020

de Castro Carpeño J. Estudio fase 3 abierto y aleatorizado de la combinación de la terapia amivantamab y carboplatino-pemetrexed, frente a carboplatino-pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con egfr mutado por inserciones en el Exon 20.
Type: Clinical Trials, phase: III.
HULP code: 5652.
Sponsored´s protocol code: 61186372NSC3001.
Sponsored by: Janssen Cilag International N.V.
Signed date: 10/09/2020

de Castro Carpeño J. Estudio fase 3 aleatorizado de la combinación de amivantamab y lazertinib frente a osimertinib como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación del EGFR. Mariposa.
Type: Clinical Trials, phase: III.
HULP code: 5636.
Sponsored´s protocol code: 73841937NSC3003.
Sponsored by: Janssen Cilag International N.V.
Signed date: 28/08/2020

de Castro Carpeño J. Ensayo clínico fase III de quimioterapia adyuvante versus quimoinmunoterapia en pacientes con cáncer de pulmón no microcítico estadio IB-IIIA con resección completa. Nadim Adjuvant.
Type: Clinical Trials, phase: III.
HULP code: 5690.
Sponsored´s protocol code: GECP20/05.
Sponsored by: Fundación GECP.
Signed date: 03/11/2020

de Castro Carpeño J. Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadío IIIB o IV.
Type: Clinical Trials, phase: III.
HULP code: 5665.
Sponsored´s protocol code: 213400.
Sponsored by: Glaxosmithkline S.A.
Signed date: 12/11/2020

de Castro Carpeño J. Estudio de fase II, aleatorizado, doble ciego y controlado con placebo de tiragolumab en combinación con atezolizumab más pemetrexed y carboplatino/cisplatino en comparación con pembrolizumab más pemetrexed y carboplatino/cisplatino en pacientes con cáncer de pulmón no microcítico no epidermoide avanzado no tratado previamente.
Type: Clinical Trials, phase: II.
HULP code: 5702.
Sponsored´s protocol code: BO42592.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 11/11/2020

de Castro Carpeño J. Estudio en el mundo real sobre la actividad TKI en mutaciones poco frecuentes y secuenciación Giotrif.
Type: Study, phase: PASS-OD.
HULP code: PI-3985.
Sponsored´s protocol code: 1200-0316.
Sponsored by: Boehringer Ingelheim International GMBH.
Signed date: 04/03/2020

de la Calle Fernández-Miranda M. Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al virus respiratorio sincitial, administrada por vía im a gestantes de 18 a 49 años de edad, para la prevención de la enfermedad vías respiratorias bajas asociada al VRS en sus hijos hasta los 6 meses de edad.
Type: Clinical Trials, phase: III.
HULP code: 5728B.
Sponsored´s protocol code: 212171 RSV MAT-009.
Sponsored by: Glaxosmithkline S.A.
Signed date: 18/11/2020

de la Quintana Jiménez P. Estudio BE1 Spain: capsule system for colostomates.
Type: Study, phase: Drugs.
HULP code: PI-3864.
Sponsored´s protocol code: Be1.
Sponsored by: B.Braun Medical S.A.
Signed date: 14/01/2020

de la Serna Blázquez O. Ensayo clínico aleatorizado, doble ciego, controlado con placebo para evaluar la exposición sistémica y seguridad de diferentes dosis de nintedanib oral añadido al tratamiento estándar durante 24 semanas, seguido de un tratamiento abierto con nintedanib de duración variable, en niños y adolescentes (6 a 17 años de edad) con enfermedad pulmonar intersticial fibrosante clínicamente significativa.
Type: Clinical Trials, phase: III.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

HULP code: Appendix I 5408.
Sponsored´s protocol code: 1199-0337.
Sponsored by: Boehringer Ingelheim España, S.A.
Signed date: 12/06/2020

de Lucas Laguna R. Estudio de fase III, aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar upadacitinib en combinación con corticosteroides tópicos en adolescentes y adultos con dermatitis atópica moderada o grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5145.
Sponsored´s protocol code: M16-047.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 30/06/2020

de Lucas Laguna R. Ensayo de fase III aleatorizado, doble ciego y multicéntrico para evaluar la eficacia, la seguridad y la tolerabilidad de brodalumab en comparación con el uso de placebo (ciego) y ustekinumab (abierto) en pacientes adolescentes (12-17 años de edad) con psoriasis en placas de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5572.
Sponsored´s protocol code: LP0160-1396.
Sponsored by: Leo Pharma A/S.
Signed date: 10/11/2020

de Lucas Laguna R. Estudio de extensión de fase 3b, multicéntrico, abierto y a largo plazo de apremilast (CC-10004) en pacientes pediátricos de 6 a 17 años con psoriasis en placas de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5512.
Sponsored´s protocol code: CC-10004-PPSO-004.
Sponsored by: Amgen S.A.
Signed date: 06/10/2020

de Paz Arias R. Estudio para evaluar imetelstat (GRN163l) en sujetos con síndrome mielodisplásico de riesgo IPSS bajo o intermedio-1 recurrente/refractario al tratamiento con agentes estimuladores de la eritropoyesis, dependientes de las transfusiones.
Type: Clinical Trials, phase: III.
HULP code: 4500.
Sponsored´s protocol code: 63935937MDS3001.
Sponsored by: Geron Corporation.
Signed date: 03/02/2020

Díaz García L. Interacción de los fármacos usados para el tratamiento de la infección por coronavirus (covid-19) sobre los niveles sanguíneos de los inmunosupresores en pacientes post trasplante.
Type: Study, phase: PASS-OD.
HULP code: PI-4528.
Sponsored´s protocol code: IDI-TAC-2020-01.
Sponsored by: Fundación Instituto de Investigación Marqués de Valdecilla.
Signed date: 27/11/2020

Díaz Menéndez M. Características clínicas y epidemiológicas de los pacientes hospitalizados por covid-19 en España.
Type: Study, phase: Drugs.
HULP code: PI-4088.
Sponsored´s protocol code: COVID-19/SEIMC-FSG.
Sponsored by: Fundación SEIMC-GESIDA.
Signed date: 23/06/2020

Díaz Pollán B. Ensayo clínico internacional, multicéntrico, adaptativo, doble ciego, aleatorizado, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de la inmunoglobulina hiperinmune intravenosa anti-coronavirus para el tratamiento de pacientes adultos hospitalizados al inicio de la progresión clínica de covid-19.
Type: Clinical Trials, phase: III.
HULP code: 5711.
Sponsored´s protocol code: INSIGTH.
Sponsored by: Regents of the University of Minnesota.
Signed date: 13/01/2020

Diestro Tejeda MD. Evaluación del método Osna para la detección rápida de metástasis en ganglios linfáticos en mujeres con cáncer endometrial.
Type: Study, phase: Drugs.
HULP code: PI-4275B.
Sponsored´s protocol code: CP-OSNA-EC-210.
Sponsored by: Sysmexeurope GMBH.
Signed date: 02/10/2020

Díez Tejedor E. Estudio internacional de fase 2, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, de BMS-986177, un inhibidor del factor xia oral, para la prevención de un nuevo caso de ictus isquémico o de re-infarto cerebral silente en pacientes tratados con aspirina y clopidogrel después de un ictus isquémico agudo o un accidente isquémico transitorio.
Type: Clinical Trials, phase: II.
HULP code: 5633.
Sponsored´s protocol code: CV010-031.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 11/08/2020

Díez Tejedor E. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de ravulizumab en pacientes adultos sin tratamiento previo con inhibidores del complemento con miastenia gravis generalizada.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5277.
Sponsored´s protocol code: ALXN1210-MG-306.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 20/02/2020

Díez Tejedor E. Reducción del riesgo de apoplejía en personas que tienen hemorragia intracraneal previa y fibrilación auricular.
Type: Clinical Trials, phase: IV.
HULP code: 5467.
Sponsored´s protocol code: ENRICH-AF.
Sponsored by: Hamilton Health Sciencies Corporation.
Signed date: 04/09/2020

Díez Tejedor E. Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD).
Type: Clinical Trials, phase: III.
HULP code: 5463.
Sponsored´s protocol code: ALXN1210-NMO-307.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 29/07/2020

Díez Tejedor E. Estudio de prueba de concepto, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de elezanumab en ictus isquémico agudo.
Type: Clinical Trials, phase: II.
HULP code: 5517.
Sponsored´s protocol code: M19-148.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 24/08/2020

Escobar Cervantes C. Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

de eventos cardiovasculares en Europa. Estudio multinacional observacional (Santorini).
Type: Study, phase: PASS-SP.
HULP code: PI-4163A.
Sponsored´s protocol code: DSE-HCL-01-19.
Sponsored by: Daiichi-Sankyo Europe GMBH.
Signed date: 12/06/2020

Espinosa Arranz E. Ensayo de fase 1b/3 multicéntrico de talimogene laherparepvec en combinación con pembrolizumab (MK-3475) para el tratamiento del melanoma en estadio IIIB a IVM1c no resecable.
Type: Clinical Trials, phase: IIIb.
HULP code: Appendix I 4636.
Sponsored´s protocol code: 20110265.
Sponsored by: Amgen S.A.
Signed date: 30/04/2020

Espinosa Arranz E. Estudio de fase IB multicéntrico, sin enmascaramiento para evaluar la seguridad y la eficacia de ipatasertib en combinación con atezolizumab y paclitaxel o NAB-paclitaxel en pacientes con cáncer de mama triple negativo localmente avanzado o metastásico.
Type: Clinical Trials, phase: I.
HULP code: Appendix II 5012.
Sponsored´s protocol code: CO40151.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 09/10/2020

Espinosa Arranz E. Estudio en fase II, multicéntrico, abierto y aleatorizado para evaluar la eficacia y seguridad de RO7198457 en combinación con pembrolizumab frente a pembrolizumab en pacientes con melanoma avanzado sin tratamiento previo.
Type: Clinical Trials, phase: II.
HULP code: 5585.
Sponsored´s protocol code: GO40558.
Sponsored by: Genentech Inc.
Signed date: 26/06/2020

Espinosa Arranz E. Describe-AD: Retrospective study of adjuvant dabrafenib and trametinib combination in patients with resected melanoma in Spain.
Type: Study, phase: PASS-OD.
HULP code: PI-4166.
Sponsored´s protocol code: GEM-1901.
Sponsored by: Grupo Español Multidisciplinar de Melanoma.
Signed date: 22/07/2020

Espinosa Arranz E. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España.
Type: Study, phase: PASS-SP.
HULP code: Appendix I PI-3208.
Sponsored´s protocol code: GEM-IPI-2018-01.
Sponsored by: Grupo Español Multidisciplinar de Melanoma.
Signed date: 05/11/2020.

Feliú Batlle J. Estudio en fase 1b/2 del tratamiento combinado con ibrutinib en tumores gastrointestinales y genitourinarios avanzados seleccionados.
Type: Clinical Trials, phase: I.
HULP code: Appendix I 4630.
Sponsored´s protocol code: PCYC-1128-CA.
Sponsored by: Pharmacyclics Llc.
Signed date: 16/09/2020

Feliú Batlle J. Estudio en fase II, multicéntrico y abierto, para investigar la eficacia, la seguridad y la farmacocinética del anticuerpo monoclonal anti-PD-1, BGB-A317, en pacientes con carcinoma hepatocelular irresecable tratado anteriormente.
Type: Clinical Trials, phase: II.
HULP code: Appendix II 4996.
Sponsored´s protocol code: BGB-317-208.
Sponsored by: Beigene USA Inc.
Signed date: 14/05/2020

Feliú Batlle J. Estudio de fase 3 aleatorizado para evaluar el uso de eryaspase en combinación con quimioterapia, comparada con quimioterapia sola como tratamiento de segunda línea en pacientes con adenocarcinoma pancreático.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5105.
Sponsored´s protocol code: GRASPANC 2018-01.
Sponsored by: Erytech Pharma S.A.
Signed date: 10/06/2020

Feliú Batlle J. Estudio en fase I-II, primero en humanos, de CX-2029 en adultos con linfomas difusos de linfocitos B grandes o tumores sólidos no resecables localmente avanzados o metastásicos (Proclaim-CX-2029).
Type: Clinical Trials, phase: I.
HULP code: Appendix I 5153.
Sponsored´s protocol code: CTMX-M-2029-001.
Sponsored by: Cytomx Thereapeutics Inc.
Signed date: 03/11/2020

Feliú Batlle J. Primer estudio en humanos de fase I/II de la seguridad y eficacia del IMC-C103C en monoterapia y en combinación con atezolizumab en pacientes con HLA-A*0201 positivo y cáncer positivo para Mage-A4 avanzado.
Type: Clinical Trials, phase: I.
HULP code: Appendix I 5423.
Sponsored´s protocol code: IMC-C103C-101.
Sponsored by: Immunocore Ltd.
Signed date: 14/09/2020

Feliú Batlle J. Primer estudio en humanos de fase I/II de la seguridad y eficacia del IMC-c103c en monoterapia y en combinación con atezolizumab en pacientes con HLA-a*0201 positivo y cáncer positivo para mage-a4 avanzado.
Type: Clinical Trials, phase: I.
HULP code: 5423.
Sponsored´s protocol code: IMC-C103C-101.
Sponsored by: Immunocore Ltd.
Signed date: 05/02/2020

Feliú Batlle J. Estudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarcinoma de páncreas metastásico.
Type: Clinical Trials, phase: III.
HULP code: 5490.
Sponsored´s protocol code: D-US-60010-001.
Sponsored by: Ipsen Bioscience Inc.
Signed date: 17/02/2020

Feliú Batlle J. Estudio de fase 1 para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de AMG 404, un anticuerpo de la muerte celular programada 1 (PD-1), en pacientes con tumores sólidos avanzados.
Type: Clinical Trials, phase: I.
HULP code: 5659.
Sponsored´s protocol code: 20180143.
Sponsored by: Amgen S.A.
Signed date: 09/09/2020

Feliú Batlle J. Estudio clínico de fase III aleatorizado, abierto, internacional, multicéntrico, del anticuerpo PD-1

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



SHR-1210 más mesilato de apatinib (rivoceranib) en comparación con sorafenib como tratamiento de primera línea en pacientes con carcinoma hepatocelular avanzado que no han recibido previamente tratamiento sistémico.
Type: Clinical Trials, phase: III.
HULP code: 5409.
Sponsored´s protocol code: SHR-1210-III-310.
Sponsored by: Jiangsu Heng Rui Medicine Co. Ltd.
Signed date: 11/05/2020

Feliú Batlle J. Estudio aleatorizado global, multicéntrico, doble ciego de fase III de carboplatino paclitaxel con INCMGA00012 o placebo para participantes con carcinoma escamoso localmente recurrente o metastásico inoperable del canal anal no tratado previamente con quimioterapia sistémica (POD1UM-303/Interaact).
Type: Clinical Trials, phase: III.
HULP code: 5627.
Sponsored´s protocol code: INCMGA0012-303.
Sponsored by: Incyte Corporation.
Signed date: 06/11/2020

Feliú Batlle J. Estudio fase 2, abierto, de múltiples cohortes para evaluar la eficacia y la seguridad del SAR408701 en pacientes con tumores sólidos avanzados positivos a CEACAM5.
Type: Clinical Trials, phase: II.
HULP code: 5720.
Sponsored´s protocol code: ACT16432.
Sponsored by: Sanofi Aventis S.A.
Signed date: 14/12/2020

Fernández Prieto AF. Protocolo básico de la plataforma del registro de vigilancia de productos neurovasculares.
Type: Study, phase: Medical Devices.
HULP code: 5648.
Sponsored´s protocol code: PSR NV INSPIRE.
Sponsored by: Medtronic Bakken Research Center B.V.
Signed date: 27/11/2020

Figueira Iglesias JC. Ensayo clínico de fase II, unicéntrico, doble ciego, aleatorizado, controlado con placebo para explorar la eficacia y seguridad de melatonina i.v. en pacientes con covid-19 ingresados en UCI (Estudio Melcovid).
Type: Clinical Trials, phase: II.
HULP code: 5609.
Sponsored´s protocol code: PHM-2020-001.
Sponsored by: Pharmamel S.L.
Signed date: 06/06/2020

Fuentes Gimeno B. Administración intravenosa de células troncales mesenquimales alogénicas de tejido adiposo en el infarto cerebral agudo. Ensayo clínico fase IIB multicéntrico y doble ciego controlado con placebo.
Type: Clinical Trials, phase: II.
HULP code: 5528.
Sponsored´s protocol code: AMASCIS-02.
Sponsored by: FIBHULP.
Signed date: 24/06/2020

Fuentes Gimeno B. Eficacia y seguridad de la trombectomía en el accidente cerebrovascular con lesión importante e intervalo de tiempo prolongado: un ensayo clínico comparativo (Tensión).
Type: Clinical Trials.
HULP code: 5506.
Sponsored´s protocol code: TENSION.
Sponsored by: .
Signed date: 16/09/2020

Fuentes Gimeno B. Ensayo clínico piloto dulcinea (Dubbing language-therapy cinema-based in aphasia post-stroke). A feasibility cross-over pilot-trial.
Type: Study, phase: Drugs.
HULP code: 5405.
Sponsored´s protocol code: DULCINEA.
Sponsored by: Fuentes Gimeno B.
Signed date: 11/03/2020

Fuentes Gimeno B. Epidemia covid19 e ictus agudo. Registro multicentrico Ictus.
Type: Study, phase: Drugs.
HULP code: PI-4107. Sponsored by: Fuentes Gimeno B.
Signed date: 23/06/2020

Gallego Martínez A. Estudio retrospectivo, multicéntrico de niraparib como terapia de mantenimiento en pacientes sensibles a platino con cáncer de ovario recurrente que han recibido niraparib dentro del programa de acceso expandido en España.
Type: Study, phase: PASS-OD.
HULP code: PI-4394.
Sponsored´s protocol code: GEICO88-R.
Sponsored by: Grupo Español de Investigacion Cáncer de Ovario.
Signed date: 07/10/2020

Gallego Martínez A. Registro clínico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario.
Type: Study, phase: Drugs.
HULP code: PI-3715.
Sponsored´s protocol code: GEICO 81-T.
Sponsored by: Grupo Español de Investigacion Cáncer de Ovario.
Signed date: 17/07/2020

Gandía González ML. Estudio fase 2, multicéntrico, doble ciego, multidosis, controlado con placebo, randomizado y de grupos paralelos para evaluar la eficacia y seguridad de biib093 intravenoso en pacientes con contusión cerebral.
Type: Clinical Trials, phase: III.
HULP code: 5276 5276.
Sponsored´s protocol code: 252BN201.
Sponsored by: Biogen Idec LTD.
Signed date: 08/06/2020

Gandía González ML. Estudio de prueba de concepto, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del elezanumab en la lesión aguda traumática de médula espinal cervical.
Type: Clinical Trials, phase: II.
HULP code: 5560.
Sponsored´s protocol code: M16-077.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 29/05/2020

García Córdoba C. Recopilación de datos retrospectivos sobre la fijación y estabilización de huesos largos y cortos tratados con el sistema de tornillos fixos.
Type: Study, phase: Medical Devices.
HULP code: PI-3700.
Sponsored´s protocol code: 16JAN2019 FIXOS SCREW.
Sponsored by: Stryker European Operations Limited.
Signed date: 18/11/2020

García García I. Identificación de factores clínicos y farmacogenéticos predictores de respuesta a nuevos anticoagulantes orales en el tratamiento de la fibrilación auricular no valvular.
Type: Study, phase: PASS-Public Founds.
HULP code: PI-4018.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Sponsored´s protocol code: SFC-NAC-2019-01.
Sponsored by: Fundación Hospital Universitario la Princesa.
Signed date: 19/05/2020

García Río FJ. Ensayo clínico fase II aleatorizado para explorar la eficacia del uso de células mesenquimales alogénicas de tejido de cordón umbilical en pacientes con afectación pulmonar grave por covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5586.
Sponsored´s protocol code: MESCEL-COVID19.
Sponsored by: Fundación Investigación Biomédica del Hospital Niño Jesús.
Signed date: 29/04/2020

García Sánchez A. Estudio clínico de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a lenvatinib en el tratamiento de primera línea de participantes con carcinoma hepatocelular avanzado (LEAP-002).
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5194.
Sponsored´s protocol code: MK7902-002.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 01/07/2020

García Sánchez A. Estudio de fase 3, doble ciego, con dos grupos, para evaluar la seguridad y la eficacia de pembrolizumab (MK-3475) frente a un placebo como tratamiento adyuvante en participantes con carcinoma hepatocelular y respuesta radiológica completa tras resección quirúrgica o ablación local.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5274.
Sponsored´s protocol code: MK-3475-937.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 20/01/2020

García-Guereta Silva L. Estudio multicéntrico para evaluar la seguridad y tolerabilidad a largo plazo de un tratamiento en abierto con sacubitrilo/valsartán en pacientes pediátricos con insuficiencia cardiaca debida a disfunción sistólica de ventrículo izquierdo sistémico, que han completado el estudio CLCZ696B2319.
Type: Clinical Trials, phase: III.
HULP code: 5440.
Sponsored´s protocol code: CLCZ696B2319E1.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 07/09/2020

García-Samaniego Rey J. Estudio fase IIB, aleatorizado, multicéntrico, de grupos paralelos, parcialmente ciego (promotor y participante ciegos, equipo investigador no ciego) para evaluar la eficacia y seguridad del tratamiento con GSK3228836 en sujetos con hepatitis B crónica (B-Clear).
Type: Clinical Trials, phase: II.
HULP code: 5593.
Sponsored´s protocol code: 209668.
Sponsored by: Glaxosmithkline S.A.
Signed date: 06/11/2020

Gasior Kabat M. Estudio de fase 3 aleatorizado y abierto para evaluar la eficacia y la seguridad de navitoclax combinado con ruxolitinib en comparación con el mejor tratamiento disponible en pacientes con mielofibrosis en recaída/refractario (TRANSFORM-2).
Type: Clinical Trials, phase: III.
HULP code: 5714.
Sponsored´s protocol code: M20-178.
Sponsored by: Abbvie Deutschland GMBH & co. Kg.
Signed date: 30/11/2020

Ghanem Cañete I. Estudio de fase 3, multicéntrico, abierto, aleatorizado y controlado de infigratinib oral frente a gemcitabina con cisplatino en sujetos con colangiocarcinoma avanzado/metastásico o inoperable con fusiones/translocaciones del gen FGFR2
Type: Clinical Trials, phase: III.
HULP code: 5347.
Sponsored´s protocol code: QBGJ398-301.
Sponsored by: Qed Therapeutics Inc.
Signed date: 31/03/2020

Ghanem Cañete I. Estudio para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de TRK-750 en pacientes con cáncer colorrectal que padecen neuropatía periférica inducida por la quimioterapia después de recibir quimioterapia que contiene oxaliplatino en adyuvancia.
Type: Clinical Trials, phase: II.
HULP code: 5497.
Sponsored´s protocol code: 750CNP01.
Sponsored by: Toray Industries Inc.
Signed date: 08/04/2020

Ghanem Cañete I. Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos.
Type: Study, phase: Drugs.
HULP code: PI-4330.
Sponsored´s protocol code: TTD-20-01.
Sponsored by: Grupo Tratamiento Tumores Digestivos.
Signed date: 28/08/2020

Ghanem Cañete I. Un estudio retrospectivo no intervencional sobre el tratamiento de primera línea para pacientes con cáncer colectivo metástico mutante BRAVF600E (MCRC).
Type: Study, phase: Drugs.
HULP code: PI-4371.
Sponsored´s protocol code: PFA-CET-2020-01.
Sponsored by: SAS Pierre Fabre Medicament.
Signed date: 22/09/2020

Gómez Candela C. Ensayo clínico nutricional para evaluar el consumo de una bebida funcional sobre la recuperación del esfuerzo físico en condiciones aeróbicas de un colectivo de deportistas.
Type: Study, phase: Medical Devices.
HULP code: 5504.
Sponsored´s protocol code: PROGRESO.
Sponsored by: Anfaco-Cecopesca.
Signed date: 24/03/2020

Gómez Candela C. Efecto del consumo habitual de un extracto de saccharomyces cerevisiae rico-glucanos y quitina-quitosano sobre la microbiota intestinal de personas con sobrepeso/obesidad.
Type: Study, phase: Medical Devices.
HULP code: 5519.
Sponsored by: AB-Biotics S.A.
Signed date: 30/04/2020

González García JJ. Estudio de fase IIA, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el VIH-1 MVA.HTI y CHADOX1.HTI, con el agonista de TLR7 vesatolimod (GS-9620), en infección por el VIH-1 tratada de forma precoz.
Type: Clinical Trials, phase II.
HULP code: Appendix I 5163.
Sponsored´s protocol code: AELIX-003.
Sponsored by: Aelix Therapeutics S.L.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Signed date: 22/10/2020

González García JJ. Estudio de fase IIA, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el VIH-1 mva.hti y chadox1.hti, con el agonista de TLR7 vesatolimod (GS-9620), en infección por el VIH-1 tratada de forma precoz.
Type: Clinical Trials, phase: II.
HULP code: 5163.
Sponsored´s protocol code: AELIX-003.
Sponsored by: Aelix Therapeutics S.L.
Signed date: 06/02/2020

González García JJ. Estudio de fase 2/3 para evaluar la seguridad y eficacia del inhibidor de la cápside de acción prolongada GS 6207 en combinación con un tratamiento de base optimizado en pacientes con infección por VIH-1 altamente tratados y con multirresistencia a fármacos.
Type: Clinical Trials, phase: II.
HULP code: 5491.
Sponsored´s protocol code: GS-US-200-4625.
Sponsored by: Gilead Sciences Inc.
Signed date: 03/03/2020

González García JJ. Ensayo clínico multicéntrico aleatorizado para evaluar la eficacia de melatonina en la profilaxis de la infección por Sars-Cov-2 en contactos de alto riesgo.
Type: Clinical Trials, phase: IV.
HULP code: 5573.
Sponsored´s protocol code: MECOVID.
Sponsored by: Borobia Pérez A.
Signed date: 01/06/2020

González García JJ. Estudio fase IIIB, aleatorizado, multicéntrico, con grupo control activo, de grupo paralelo, no inferioridad, abierto, que evalúa la eficacia, seguridad y tolerabilidad del cambio a cabotegravir de acción prolongada junto con rilpivirina de acción prolongada administrado cada dos meses desde un régimen de comprimido único de bictegravir / emtricitabina / tenofovir alafenamida en adultos infectados por VIH1 virológicamente suprimidos.
Type: Clinical Trials, phase: II.
HULP code: 5634.
Sponsored´s protocol code: 208379.
Sponsored by: Laboratorios Viiv Healthcare S.L.
Signed date: 08/10/2020

González García JJ. Prevalencia de personas que viven con VIH con pocas o no opciones para construir un régimen antiretroviral viable. Estudio Previar.
Type: phase: PASS-0D.
HULP code: PI-4259.
Sponsored´s protocol code: VII-DAR-2019.01.
Sponsored by: Laboratorios Viiv Healthcare S.L.
Signed date: 26/06/2020

González Martínez B. Estudio fase II, abierto, multicéntrico, de un brazo único, para determinar la seguridad y la eficacia de tisagenlecleucel en pacientes pediátricos diagnosticados de linfoma no Hodgkin de células B maduras en recaída/refractario (Bianca).
Type: Clinical Trials, phase: II.
HULP code: Appendix II 5138.
Sponsored´s protocol code: CCTL019C2202.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 07/09/2020

Guerra García MS. Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.
Type: Clinical Trials, phase: I.
HULP code: 5624.
Sponsored´s protocol code: 213406.
Sponsored by: Glaxosmithkline Research And Development Limited.
Signed date: 14/09/2020

Gutiérrez-Larraya Aguado F. Estudio post-autorización trevisio: estudio multicéntrico, no aleatorizado y de un solo grupo del Amplatzer™ Trevisio™ intravascular delivery system para facilitar la implantación percutánea y transcatéter de los oclusores amplatzer.
Type: Study, phase: Medical Devices.
HULP code: PI-4379A.
Sponsored´s protocol code: CRD-963/ABT-CIP-10319.
Sponsored by: Abbott Medical España S.A.
Signed date: 23/10/2020

Hardisson Hernáez D. Evaluación del método Osna para la detección rápida de metástasis en ganglios linfáticos en mujeres con cáncer endometrial.
Type: Study, phase: Drugs.
HULP code: PI-4275A.
Sponsored´s protocol code: CP-OSNA-EC-210.
Sponsored by: Sysmexeurope GMBH.
Signed date: 02/10/2020

Hardisson Hernáez D. Validación estudio Neovattl.
Type: Study, phase: Drugs.
HULP code: PI-3692 .
Sponsored´s protocol code: GES-NEO-2019-001.
Sponsored by: Fundación Española de Senología .
Signed date: 27/01/2020

Hernández Gutiérrez A. Randomized, double-blind and placebo-controlled trial to evaluate the effect of a probiotic mix on bacterial vaginosis in adult women.
Type: Study, phase: Medical Devices.
HULP code: 5502.
Sponsored´s protocol code: VAG/001/19 REProVag.
Sponsored by: Otcem Pharmaceuticals S.L.
Signed date: 27/01/2020

Herranz Pinto P. Estudio de fase 3, multicéntrico, doble ciego, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes adultos con dermatitis atópica.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4958.
Sponsored´s protocol code: I4V-MC-JAHN.
Sponsored by: Lilly S.A.
Signed date: 15/04/2020

Herranz Pinto P. Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego, controlado con principio activo de comparación (secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de bimekizumab en adultos con psoriasis (PSO) en placas crónica de grado moderado o severo.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5109.
Sponsored´s protocol code: PS0015.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 22/01/2020

Herranz Pinto P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5141.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Sponsored´s protocol code: B7451015.
Sponsored by: Pfizer Inc.
Signed date: 09/07/2020

Herranz Pinto P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5089.
Sponsored´s protocol code: B7451014.
Sponsored by: Pfizer S.L.U.
Signed date: 08/09/2020

Herranz Pinto P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 5089.
Sponsored´s protocol code: B7451014.
Sponsored by: Pfizer S.L.U.
Signed date: 26/10/2020

Herranz Pinto P. Estudio de fase III, aleatorizado, doble ciego,comparativo con vehículo, para evaluar la eficacia y seguridad del tratamiento de mantenimiento y reduccion de brote con el ungüento crisaborole al 2 %, una vez al dia durante 52 semanas en participantes pediátricos y adultos (a partir de 2 años de edad) con dermatitis atópica de leve a moderada, que respondieron al tratamiento con ungüento crisaborole al 2 % dos veces al día.
Type: Clinical Trials, phase: III.
HULP code: 5476.
Sponsored´s protocol code: C3291035.
Sponsored by: Pfizer S.L.U.
Signed date: 28/04/2020

Herranz Pinto P. Estudio de fase III, doble ciego, aleatorizado, controlado con placebo, de la eficacia y seguridad de la crema de ruxolitinib, seguido de un período de extensión en participantes con vitíligo.
Type: Clinical Trials, phase: III.
HULP code: 5513.
Sponsored´s protocol code: INCB 18424-307.
Sponsored by: Incyte Corporation.
Signed date: 26/03/2020

Herranz Pinto P. Estudio de fase 3b, multicéntrico, intervencionista y abierto de pacientes adultos con psoriasis en placas moderada o grave que presentan una respuesta insuficiente a secukinumab o ixekizumab y cambian a risankizumab.
Type: Clinical Trials, phase: III.
HULP code: 5468.
Sponsored´s protocol code: M19-164.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 14/01/2020

Herranz Pinto P. Estudio de fase III, abierto, multicentrico, a largo plazo, para investigar la seguridad y la eficacia de PF06651600 en participantes adultos y adolescentes con alopecia areata.
Type: Clinical Trials, phase: III.
HULP code: 5394.
Sponsored´s protocol code: B7981032.
Sponsored by: Pfizer S.L.U.
Signed date: 18/05/2020

Herranz Pinto P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficiencia y la seguridad de nemolizumab (CD14152) en sujetos con demartitis atópica de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5477.
Sponsored´s protocol code: RD.06.SPR.118161.
Sponsored by: Galderma S.A.
Signed date: 26/06/2020

Herranz Pinto P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (CD14152) en sujetos con dermatitis atópica de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5478.
Sponsored´s protocol code: RD.06.SPR.118163.
Sponsored by: Galderma S.A.
Signed date: 07/09/2020

Herranz Pinto P. Estudio aleatorizado, doble ciego, multicéntrico, de 24 semanas de duración de secukinumab subcutáneo para evaluar el tratamiento antiinterleuquina - 17a en pacientes con psoriasis en placas con Ehgna coexistente (Pinpoint).
Type: Clinical Trials, phase: III.
HULP code: 5661.
Sponsored´s protocol code: CAIN457ADE15.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 21/10/2020

Herranz Pinto P. Estudio de fase 3B, aleatorizado, doble ciego, con doble simulación, controlado con principio activo, multicéntrico, para evaluar la eficacia y la seguridad de abrocitinib en comparación con dupilumab en participantes adultos que reciben terapia tópica de base con dermatitis atópica de moderada a grave.
Type: Clinical Trials, phase: IIIb.
HULP code: 5503.
Sponsored´s protocol code: B7451050.
Sponsored by: Pfizer S.L.U.
Signed date: 12/06/2020

Herranz Pinto P. Ensayo aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de efgartigimod PH20 SC en pacientes adultos con pénfigo (vulgar o foliáceo).
Type: Clinical Trials, phase: III.
HULP code: 5663.
Sponsored´s protocol code: ARGX-113-1904.
Sponsored by: Argenx Bvba.
Signed date: 16/11/2020

Herranz Pinto P. Ensayo de seguimiento del ARGX-113-1904, abierto y multicéntrico para evaluar la seguridad, la tolerabilidad y la eficacia de efgartigimod PH20 SC en pacientes con pénfigo.
Type: Clinical Trials, phase: III.
HULP code: 5670.
Sponsored´s protocol code: ARGX-113-1905.
Sponsored by: Argenx Bvba.
Signed date: 16/11/2020

Herranz Pinto P. Estudio observacional internacional de resultados sanitarios durante 3 años sobre el tratamiento biológico de la psoriasis en placas de moderada a grave.
Type: Study, phase: PASS-SP.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

HULP code: PI-3507.
Sponsored´s protocol code: I1F-MC-B007.
Sponsored by: Eli Lilly Co Uk Ltd.
Signed date: 11/08/2020

Herranz Pinto P. Estudio observacional transversal y multicéntrico para la validación de la versión española del cuestionario Pure-4. Estudio Pure4.
Type: Study, phase: Drugs.
HULP code: PI-4483.
Sponsored´s protocol code: CAIN457AES15.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 03/12/2020

Herranz Pinto P. Estudio transversal mundial de la carga de la enfermedad en pacientes adolescentes y adultos con dermatitis atópica (measure ad).
Type: Study, phase: PASS-OD.
HULP code: PI-3941.
Sponsored´s protocol code: ABB-PIM-2019-01.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 18/05/2020

Hierro Llanillo L. Estudio abierto de extensión para evaluar la eficacia y la seguridad a largo plazo de A4250 en niños con colestasis intrahepática familiar progresiva de tipo 1 y 2.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4790.
Sponsored´s protocol code: 64294178HPC3001.
Sponsored by: Albireo Ab.
Signed date: 03/11/2020.

Hierro Llanillo L. Estudio de seguridad a largo plazo sobre el maralixibat, un inhibidor del transportador apical de ácidos biliares dependiente de sodio (ASBTI), para el tratamiento de pacientes con colestasis hepática que participaron previamente en un estudio sobre el aralixibat.
Type: Clinical Trials, phase: II.
HULP code: 5472.
Sponsored´s protocol code: MRX-800.
Sponsored by: Mirum Pharaceutical Inc.
Signed date: 08/01/2020

Higuera Gomez O. Estudio observacional prospectivo sobre el uso de citrato de fentanilo transmucosa en la práctica clínica habitual para el control de las crisis irruptivas de dolor en pacientes oncológicos.
Type: Study, phase: PASS-SP.
HULP code: PI-4057.
Sponsored´s protocol code: FABF-NIS-1901/FER-FEN.
Sponsored by: Ferrer Internacional S.A.
Signed date: 24/03/2020

Humala Barbier KK. Estudio en fase 3, multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar AG-120 en combinación con azacitidina en sujetos de 18 años de edad o más con leucemia mieloide aguda con una mutación de IDH1 sin tratamiento previo.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4866.
Sponsored´s protocol code: AG120-C-009.
Signed date: 08/05/2020

Iniesta Manjavacas AM. Estudio observacional ambispectivo para analizar el manejo evolutivo de los fármacos con efecto pronóstico en pacientes tratados con polipíldora como tratamiento de base al alta de un primer síndrome coronario agudo.
Type: Study, phase: PASS-SP.
HULP code: PI-4368.
Sponsored´s protocol code: PANDORA FER-AAS-2020-0.
Sponsored by: Ferrer Internacional S.A.
Signed date: 28/09/2020

Jiménez Martín C. Caracterización de las curvas dosis-respuesta y del funcionamiento clínico del inmunobiograma, un nuevo método de diagnóstico in vitro para evaluar el perfil de resistencia a inmunosupresores en una muestra representativa de pacientes con trasplante renal.
Type: Study, phase: Drugs.
HULP code: PI-4366.
Sponsored´s protocol code: BH-IMBG-TR-2020-002.
Sponsored by: Biohope Scientific Solutions for Human Health S.L.
Signed date: 21/09/2020

Jiménez Yuste VM. Estudio abierto de un producto no investigativo, multicéntrico, inicial para evaluar al menos 6 meses de eficacia prospectiva y datos seleccionados de seguridad de la terapia de reemplazo de profilaxis con factor IX (corrección) en el ámbito de atención habitual de moderadamente grave a grave hemofilia b en adultos sujetos (solución: c≤2%) quienes son negativos para neutralizar anticuerpos (NAB) a vector de virus adenoasociado (AAV)-Spark100.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5204.
Sponsored´s protocol code: C0371004.
Sponsored by: Pfizer S.L.U.
Signed date: 07/04/2020

Jiménez Yuste VM. Estudio abierto en pacientes adolescentes y adultos con hemofilia A o B grave (actividad del factor de coagulación <1 %) con o sin inhibidores para comparar el tratamiento estándar con la profilaxis con PF-06741086.
Type: Clinical Trials, phase: III.
HULP code: 5486.
Sponsored´s protocol code: B7841005.
Sponsored by: Pfizer S.L.U.
Signed date: 09/09/2020

Jiménez Yuste VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5401.
Sponsored´s protocol code: NN7415-4311.
Sponsored by: Novo Nordisk Pharma S.A.
Signed date: 16/01/2020

Jiménez Yuste VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 5401.
Sponsored´s protocol code: NN7415-4311.
Sponsored by: Novo Nordisk Pharma S.A.
Signed date: 15/09/2020

Jiménez Yuste VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5400.
Sponsored´s protocol code: NN7415-4307.
Sponsored by: Novo Nordisk A/S.
Signed date: 16/01/2020

Jiménez Yuste VM. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (MIM8) in healthy subjects and in subjects with haemophilia a with or without factor VIII inhibitors.
Type: Clinical Trials, phase: II.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

HULP code: 5514.
Sponsored´s protocol code: NN7769-4513.
Sponsored by: Novo Nordisk A/S.
Signed date: 10/11/2020

Jiménez Yuste VM. Estudio abierto multicéntrico de fase 3 sobre la seguridad, eficacia y farmacocinética del factor de coagulación recombinante intravenoso VIII FC-factor Von Willebrand-proteína de fusión XTEN (rfviiifc-vwf-xten; bivv001) en pacientes tratados previamente con ≥12 años con hemofilia a severa.
Type: Clinical Trials, phase: III.
HULP code: 5482.
Sponsored´s protocol code: EFC16293.
Sponsored by: Bioverativ Therapeutics Inc.
Signed date: 25/02/2020

Jiménez Yuste VM. Estudio de fase IIIB, multicéntrico, abierto y de un solo grupo para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica de emicizumab subcutáneo en pacientes desde el nacimiento hasta los 12 meses de edad con hemofilia A sin inhibidores.
Type: Clinical Trials, phase: IIIb.
HULP code: 5706.
Sponsored´s protocol code: M041787.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/11/2020

Jiménez Yuste VM. Ensayo clínico aleatorizado, abierto, para evaluar el efecto de dosis profilácticas o terapéuticas de bemiparina en pacientes con covid-19 (Bemicop).
Type: Clinical Trials, phase: IV.
HULP code: 5618.
Sponsored´s protocol code: BEMICOP.
Sponsored by: Universidad de Navarra.
Signed date: 30/10/2020

Jurado Roman A. Aterectomía rotacional, litotricia o láser para el tratamiento de lesiones (Roller Coaster).
Type: Study, phase: Drugs.
HULP code: PI-4293.
Sponsored´s protocol code: EPIC22.
Sponsored by: Fundación Epic.
Signed date: 13/11/2020

Jurado Roman A. Eficacia y seguridad del uso de láser coronario en lesiones incruzables ó indilatables.
Type: Study, phase: Medical Devices.
HULP code: 5501.
Sponsored´s protocol code: LUDICO.
Sponsored by: Jurado Roman, Alfonso.
Signed date: 22/09/2020

Jurado Roman A. Registro prospectivo, de brazo único, multicéntrico, observacional de litotricia coronaria para el tratamiento de lesiones calcificadas en España (Estudio Réplica).
Type: Study, phase: Drugs.
HULP code: PI-4286.
Sponsored´s protocol code: EPIC18.
Sponsored by: Fundación Epic.
Signed date: 06/11/2020

Jurado Roman A. Tratamiento de la infraexpansion de stent: láser excimer versus dilatacion a alta presión (láser expand).
Type: Study, phase: Drugs.
HULP code: PI-4258.
Sponsored´s protocol code: EPIC18.
Sponsored by: Fundación Epic.
Signed date: 31/08/2020

Labrandero de Lera C. Estudio multicéntrico, abierto, aleatorizado, basado en acontecimientos, para evaluar la eficacia, la seguridad y la farmacocinética de macitentán frente al tratamiento de referencia en niños con hipertensión arterial pulmonar.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4744.
Sponsored´s protocol code: AC-055-312.
Sponsored by: Actelion Pharmaceuticals Ltd.
Signed date: 16/07/2020

Lara Lara M. Opciones para el alivio de la migraña en pediatría: estudio aleatorio, doble ciego de lasmiditan frente a placebo para tratar el episodio agudo de migraña: Pioneer-Peds.
Type: Clinical Trials, phase: III.
HULP code: 5604.
Sponsored´s protocol code: H8H-MC-LAHV.
Sponsored by: Lilly S.A.
Signed date: 08/10/2020

Lara Lara M. Estudio en fase 3, de 12 meses de tratamiento abierto con lasmiditan en pacientes pediátricos con migraña: Pioneer-Peds2.
Type: Clinical Trials, phase: III.
HULP code: 5603.
Sponsored´s protocol code: H8H-MC-LAHW.
Sponsored by: Lilly S.A.
Signed date: 08/10/2020

Lara Lara M. Estudio intervencionista, aleatorizado, doble ciego, de grupos paralelos y controlados con placebo con un período de extensión para evaluar la eficacia y la seguridad del eptinezumab para la prevención de la migraña en pacientes contratamientos preventivos previos sin éxito.
Type: Clinical Trials.
HULP code: 5552.
Sponsored´s protocol code: 18898A.
Sponsored by: Lundbueck A/S.
Signed date: 19/11/2020

Leal García A. Satisfacción y adherencia del tratamiento en mujeres con atrofia vulvovaginal. Estudio transversal. Estudio Creta.
Type: Study, phase: PASS-OD.
HULP code: PI-4069.
Sponsored´s protocol code: SHI-OSP-2019-01.
Sponsored by: Shionogi S.L.
Signed date: 23/04/2020

Lluch Bernal, MM. Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia al polen de gramíneas.
Type: Clinical Trials, phase: II.
HULP code: 5553.
Sponsored´s protocol code: SL-51A.
Sponsored by: Roxall Medicina España S.A (Bial Industrial Farmacéutica S.A.).
Signed date: 10/09/2020

López Carrasco A. Estudio de extensión, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de linzagolix a largo plazo en pacientes con dolor de moderado a intenso asociado a endometriosis.
Type: Clinical Trials, phase: III.
HULP code: 5522.
Sponsored´s protocol code: 190BE2109-006.
Sponsored by: Obseva S.A.
Signed date: 08/06/2020

López Cavanillas B. Ensayo clínico Paloma II: ensayo clínico aleatorizado, abierto, multicéntrico de grupos paralelos y con grupo control, para explorar la eficacia del

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

gel vaginal Papilocare® en la reparación de la mucosa cervical con lesiones causadas por virus papiloma humano de alto riesgo.
Type: Clinical Trials, phase: II.
HULP code: 5678.
Sponsored´s protocol code: PALOMA II.
Sponsored by: Procare Health Iberia S.L.
Signed date: 01/10/2020

López de la Guía A. Estudio de fase 3, multicéntrico, aleatorizado y abierto, de venetoclax y dexametasona en comparación con pamalidomina y dexametasona en sujetos con mieloma múltiple en recidiva o refractario con T (11;14).
Type: Clinical Trials, phase: III.
HULP code: 5548.
Sponsored´s protocol code: M13-494.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 25/05/2020

López de la Guía A. Estudio observacional para describir la repercusión de los anticuerpos monoclonales como tratamiento de primera línea frente a otros regímenes estándar en pacientes con mieloma múltiple de nuevo diagnóstico que no sean candidatos a trasplante. Datos de práctica clínica habitual en España (Carinae).
Type: Study, phase: PASS-SP.
HULP code: PI-4065.
Sponsored´s protocol code: 54767414MMY4024.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 27/03/2020



López de Sá Areses E. Estudio en fase IIB, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de Medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona N-terminal natriurético cerebral.
Type: Clinical Trials, phase: II.
HULP code: 5637.
Sponsored´s protocol code: D4920C00002.
Sponsored by: Astrazeneca Ab.
Signed date: 28/09/2020

López Gutiérrez JC. Estudio de revisión retrospectiva de historias clínicas de pacientes con síndrome de sobrecrecimiento asociado a PIK3CA que han recibido alpelisib a través de un programa de uso compasivo (EPIK-P1).
Type: Study, phase: PASS-OD.
HULP code: PI-4213.
Sponsored´s protocol code: NOV-ALP-2020-01.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 15/07/2020

López-Sendón Hentschel JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLIC como un nuevo biomarcador de isquemia.
Type: Study, phase: Drugs.
HULP code: Appendix I PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 20/01/2020

López-Sendón Hentschel JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.
Type: Study, phase: Drugs.
HULP code: Appendix II PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 09/07/2020

Magallanes García L. Marcadores genéticos, transcriptómicos y celulares de respuesta a terapia biológica en enfermedad inflamatoria intestinal pediátrica.
Type: Study, phase: PASS-Public Founds.
HULP code: PI-4024.
Sponsored´s protocol code: FG-2019-01 (LAL-TNF-20).
Sponsored by: López Fernández, Luis Andrés.
Signed date: 28/02/2020

Martín Arranz MD. Estudio multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de ABT-494 para el tratamiento de inducción y mantenimiento en pacientes con colitis ulcerosa de moderada a grave.
Type: Clinical Trials, phase: II.
HULP code: 5450.
Sponsored´s protocol code: M14-234.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 14/01/2020

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de upadacitinib (ABT 494) en pacientes con colitis ulcerosa de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5452.
Sponsored´s protocol code: M14-675.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 14/01/2020

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4937.
Sponsored´s protocol code: M16-006.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/05/2020

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave sin respuesta al tratamiento biológico previo.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4935.
Sponsored´s protocol code: M15-991.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/05/2020

Martín Arranz MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn que respondan al tratamiento de inducción en los Study M16-006 o M15-991.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 4936.
Sponsored´s protocol code: M16-000.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/05/2020

Martín Arranz MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risan-

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

kizumab en sujetos con colitis ulcerosa que respondan al tratamiento de inducción en los estudios M16-067 o M16-065.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5057.
Sponsored´s protocol code: M16-066.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/05/2020

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta al tratamiento biológico previo.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5058.
Sponsored´s protocol code: M16-067.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 21/05/2020

Martín Arranz MD. Estudio de seguridad posautorización para evaluar la seguridad y la eficacia a largo plazo de la administración repetida de darvadstrocel en pacientes con enfermedad de Crohn y fístulas perianales complejas.
Type: Clinical Trials, phase: IV.
HULP code: 5465.
Sponsored´s protocol code: Alofisel-4001.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 28/09/2020

Martín Arranz MD. Estudio de extensión abierto para evaluar etrasimod cuando se administra a sujetos con colitis ulcerosa activa moderada o grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5368.
Sponsored´s protocol code: APD-334-303.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 25/06/2020

Martín Arranz MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ABBV-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.
Type: Clinical Trials, phase: II.
HULP code: Appendix II 5246.
Sponsored´s protocol code: M15-722.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 29/10/2020

Martín Arranz MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ABBV-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5246.
Sponsored´s protocol code: M15-722.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 28/05/2020

Martín Arranz MD. Estudio fase 3b, aleatorizado, doble ciego, multicéntrico para evaluar la seguridad y la eficacia de la terapia de reinducción intravenosa con ustekinumab en pacientes con enfermedad de Crohn activa moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5427.
Sponsored´s protocol code: CNT01275CRD3008 (POWER).
Sponsored by: Janssen Cilag International N.V.
Signed date: 15/09/2020

Martín Arranz MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5366.
Sponsored´s protocol code: APD334-301.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 02/07/2020

Martín Arranz MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5367.
Sponsored´s protocol code: APD334-302.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 26/06/2020

Martín Arranz MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.
Type: Clinical Trials, phase: III.
HULP code: 5367.
Sponsored´s protocol code: APD334-302.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 22/01/2020

Martín Arranz MD. Estudio fase 2b/3 aleatorizado, doble-ciego, controlado con placebo, grupo paralelo, multicéntrico, para evaluar la eficacia y seguridad de guselkumab en pacientes con colitis ulcerosa activa de moderada a severa.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5393.
Sponsored´s protocol code: CNT01959UC03001 (QUASAR).
Sponsored by: Janssen Cilag International N.V.
Signed date: 06/07/2020

Martín Arranz MD. Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de varias dosis para evaluar la eficacia, seguridad y farmacocinética de PF06480605 en participantes adultos con colitis ulcerosa de moderada a severa.
Type: Clinical Trials, phase: II.
HULP code: 5507.
Sponsored´s protocol code: B7541007.
Sponsored by: Pfizer Inc.
Signed date: 14/04/2020

Martín Arranz MD. Ensayo clínico multicéntrico de fase IB/IIA (prueba de concepto) aleatorizado, con doble ciego y controlado con placebo para evaluar la seguridad, farmacocinética y eficacia del tratamiento oral con OST-122 en pacientes con colitis ulcerosa de moderada a severa.
Type: Clinical Trials, phase: I.
HULP code: 5473.
Sponsored´s protocol code: CT– OST – 122 – 02.
Sponsored by: Oncostellae S.L.
Signed date: 04/03/2020

Martín Arranz MD. Estudio fase 3, multicéntrico, aleatorizado, con enmascaramiento para los evaluadores de la eficacia de risankizumab en comparación con ustekinumab para el tratamiento de sujetos adultos con enfermedad de Crohn de moderada a grave sin respuesta al tratamiento con terapia antiTNF.
Type: Clinical Trials, phase: III.

HULP code: 5658.
Sponsored´s protocol code: M20-259.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 02/10/2020

Martín Carbonero L. Estudio clínico de fase 3, aleatorizado, abierto y comparativo con tratamiento activo para evaluar el cambio de tratamiento a doravirina/islatravir una vez al día en pacientes infectados por el VIH-1 con supresión virológica durante el tratamiento antirretroviral.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5471.
Sponsored´s protocol code: MK-8591A-017.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 09/09/2020

Martín Quirós A. Estudio descriptivo de pacientes con síndrome gripal atendidos en un servicio de urgencias de un hospital terciario.
Type: Study, phase: Drugs.
HULP code: PI-3889.
Sponsored´s protocol code: GRIPE 19.
Sponsored by: Martín Quirós, Alejandro.
Signed date: 15/05/2020

Martín Salces M. Ensayo en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efgartigimod (ARGX 113) 10 mg/kg por vía intravenosa en pacientes adultos con trombocitopenia inmune primaria.
Type: Clinical Trials, phase: III.
HULP code: 5430.
Sponsored´s protocol code: ARGX-113-1801.
Sponsored by: Argenx Bvba.
Signed date: 29/01/2020

Martín Salces M. Ensayo en fase III multicéntrico, sin enmascaramiento y a largo plazo para evaluar la seguridad y la eficacia de 10 mg/kg de efgartigimod (ARGX-113) por vía intravenosa en pacientes adultos con trombocitopenia inmunitaria primaria.
Type: Clinical Trials, phase: III.
HULP code: 5480.
Sponsored´s protocol code: ARGX-113-1803.
Sponsored by: Argenx Bvba.
Signed date: 13/05/2020

Maseda Garrido E. Ensayo fundamental de fase III multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y con dos grupos paralelos para investigar la eficacia y la seguridad de la fosfatasa alcalina recombinante humana para el tratamiento de pacientes con lesión renal aguda asociada a la sepsis.
Type: Clinical Trials, phase: III.
HULP code: 5625.
Sponsored´s protocol code: AP-recAP-AKI-03-01.
Sponsored by: Am-Pharma B.V.
Signed date: 23/07/2020

Maseda Garrido E. Sedación con sevoflurano versus propofol en pacientes con síndrome de distrés respiratorio agudo causado por la infección covid-19.
Type: Clinical Trials, phase: IV.
HULP code: Appendix I 5575.
Sponsored´s protocol code: SEVO-COVID19.
Sponsored by: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana.
Signed date: 10/05/2020

Maseda Garrido E. Sedación con sevoflurano versus propofol en pacientes con síndrome de distrés respiratorio agudo causado por la infección covid-19.
Type: Clinical Trials, phase: IV.
HULP code: 5575.
Sponsored´s protocol code: SEVO-COVID19.
Sponsored by: Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana.
Signed date: 08/04/2020

Maseda Garrido E. SEUR: Estudio retrospectivo para evaluar el uso de recursos asociado al manejo de pacientes que hayan adquirido una infección producida por un microorgansmo Gram-negativo resistente a los carbapenemes.
Type: Study, phase: Drugs.
HULP code: PI-4207.
Sponsored´s protocol code: SEUR.
Sponsored by: Shionogi S.L.
Signed date: 03/03/2020

Mayoral Arenal M. Estudio de seguridad postautorización no intervencionista, multinacional y multicéntrico para evaluar la seguridad a largo plazo y la tolerabilidad de Odomzo® (Sonidegib) administrado en pacientes con carcinoma basocelular localmente avanzado.
Type: Study, phase: PASS-LA.
HULP code: PI-4222.
Sponsored´s protocol code: CLDE225A2404.
Sponsored by: Teva Pharmaceutical Industries Ltd.
Signed date: 29/12/2020

Mellado Peña MJ. Ensayo en fase III, aleatorizado, doble ciego para evaluar la seguridad de una vacuna conjugada antineumocócica 20-valente en lactantes sanos.
Type: Clinical Trials, phase: III.
HULP code: 5557.
Sponsored´s protocol code: B7471013.
Sponsored by: Pfizer S.L.U.
Signed date: 27/08/2020

Mellado Peña MJ. Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al virus respiratorio sincitial, administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la enfermedad vías respiratorias bajas asociada al VRS en sus hijos hasta los 6 meses de edad.
Type: Clinical Trials, phase: III.
HULP code: 5728.
Sponsored´s protocol code: 212171 (RSV MAT-009).
Sponsored by: Glaxosmithkline S.A.
Signed date: 18/11/2020

Méndez Echavarría AM. Estudio de fase 2/3 abierto y de un solo brazo que evalúa la seguridad, tolerabilidad, farmacocinética y eficacia de remdesivir (GS-5734TM) en participantes con covid-19 de 0 a <18 años de edad.
Type: Clinical Trials, phase: III.
HULP code: 5615.
Sponsored´s protocol code: GS-US-540-5823.
Sponsored by: Gilead Sciences S.L.
Signed date: 16/09/2020

Mendieta Azcona C. Estudio observacional para evaluar el manejo clínico y la adecuación de las estrategias terapéuticas utilizadas en pacientes con enfermedad aterosclerótica estable y el uso de los tratamientos recomendados de acuerdo a las guías clínicas. Estudio Apalusa.
Type: Study, phase: PASS-OD.
HULP code: PI-3815A.
Sponsored´s protocol code: SEC-ATE-2019-01.
Sponsored by: Fundación Casa del Corazón.
Signed date: 22/05/2020

Pérez Valero I. Estudio de fase III, aleatorizado, mul-

Introduction

Executive summary


Information Groups by Area

Associated Clinicians

ticéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el VIH-1 con supresión virológica.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5354.
Sponsored by: VIIV Healthcare Uk Limited.
Signed date: 02/07/2020

Merino Llorens JL. Estudio observacional para evaluar el manejo clínico y la adecuación de las estrategias terapéuticas utilizadas en pacientes con enfermedad aterosclerótica estable y el uso de los tratamientos recomendados de acuerdo a las guías clínicas. Estudio Apalusa.
Type: Study, phase: PASS-OD.
HULP code: PI-3815B.
Sponsored´s protocol code: SEC-ATE-2019-01.
Sponsored by: Sociedad Española de Cardiología.
Signed date: 14/07/2020

Mora Rillo M. Ensayo clínico aleatorizado para evaluar la eficacia de diferentes tratamientos en pacientes con covid19 que requieren hospitalización.
Type: Clinical Trials, phase: III.
HULP code: 5559.
Sponsored´s protocol code: PANCOVID19.
Sponsored by: FIBHULP.
Signed date: 28/03/2020



Mora Rillo M. Seguridad y utilización en práctica clínica del plasma convaleciente en pacientes ingresados por covid-19. Estudio observacional PlasMadrid.
Type: Study, phase: Drugs.
HULP code: 5645.
Sponsored´s protocol code: PLASMADRID.
Sponsored by: Centro de Transfusion.
Signed date: 21/09/2020

Morado Arias M. Estudio de extensión, abierto, multicéntrico de AG -348 en sujetos adultos con deficiencia de piruvato cinasa incluidos previamente en estudios con AG-348.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5237.
Sponsored´s protocol code: AG348-C-011.
Sponsored by: Agios Pharmaceuticals Inc.
Signed date: 13/01/2020

Morado Arias M. Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de crovalimab frente a eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna no tratada previamente con inhibidores del complemento.
Type: Clinical Trials, phase: III.
HULP code: 5707.
Sponsored´s protocol code: BO42162.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 29/12/2020

Moreno Gómez JR. Estudio post-autorización trevisio: estudio multicéntrico, no aleatorizado y de un solo grupo del Amplatzer™ Trevisio™ intravascular delivery system para facilitar la implantación percutánea y transcatéter de los oclusores amplatzer.
Type: Study, phase: Medical Devices.
HULP code: PI-4379B.
Sponsored´s protocol code: CRD-963/ABT-CIP-10319.
Sponsored by: Abbott Medical España S.A.
Signed date: 23/10/2020

Mostaza Prieto JM. Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa. Estudio multinacional observacional (Santorini).
Type: Study, phase: PASS-SP.
HULP code: PI-4163B.
Sponsored´s protocol code: DSE-HCL-01-19.
Sponsored by: Alpha Bioresearch S.L.
Signed date: 18/06/2020

Olveira Martín A. Estudio multicéntrico de fase III, doble ciego, aleatorizado, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4999.
Sponsored´s protocol code: 747-304.
Sponsored by: Intercept Pharmaceuticals Inc.
Signed date: 22/10/2020

Olveira Martín A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, confirmatorio y de dos partes para evaluar la eficacia y seguridad de VAY736 en pacientes con hepatitis autoinmunitaria con respuesta incompleta o intolerancia al tratamiento estándar (Amber).
Type: Clinical Trials, phase: II.
HULP code: Appendix I 5232.
Sponsored´s protocol code: CVAY736B2201.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 17/06/2020

Olveira Martín A. Estudio en fase IIB/III internacional, sin interrupciones, adaptativo, doble ciego, aleatorizado, controlado con placebo, multicéntrico, en el que se evalúa la eficacia y la seguridad de belapectin (GR-MD-02) para la prevención de las varices esofágicas en la cirrosis por EH.
Type: Clinical Trials, phase: II.
HULP code: 5660.
Sponsored´s protocol code: GT-031 NASH-RX.
Sponsored by: Galectin Therapeutics Inc.
Signed date: 23/09/2020

Olveira Martín A. Evaluación de la eficacia, la seguridad y la tolerabilidad de NGM282 (aldafermina) en un estudio fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo de pacientes con cirrosis compensada por esteatohepatitis no alcohólica (Alpine 4).
Type: Clinical Trials, phase: II.
HULP code: 5547.
Sponsored´s protocol code: 282-CC-207.
Sponsored by: NGM Biopharmaceuticals Inc.
Signed date: 24/09/2020

Palma Milla S. Cuidado nutricional en pacientes críticos hospitalizados por el covid-19: estudio observacional de seguimiento de 1 año.
Type: Study, phase: Drugs.
HULP code: PI-4396.
Sponsored´s protocol code: NUTRICOV.
Sponsored by: Outcomes´10 S.L.U.
Signed date: 23/10/2020

Parra Ramírez PA. Ensayo de 78 semanas para comparar el efecto y la seguridad de la insulina Icodec una vez a la semana y de insulina Glargina 100 unidades/ml una vez al dia, ambas en combinación con tratamiento antidiabético no insulínico, en pacientes con diabetes tipo 2 no tratados previamente con insulina.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Type: Clinical Trials, phase: III.
HULP code: 5651.
Sponsored´s protocol code: NN1436-4477.
Sponsored by: Novo Nordisk A/S.
Signed date: 16/10/2020

Pascual Pascual SI. Estudio de extensión del seguimiento internacional, multicéntrico, doble ciego de 9 meses de duración para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-Tooth de tipo 1A.
Type: Clinical Trials, phase: III.
HULP code: Appendix III 4768.
Sponsored´s protocol code: CLN-PXT3003-03.
Sponsored by: Pharnext.
Signed date: 24/08/2020

Pascual Pascual SI. Estudio de continuación, doble ciego, controlado con placebo, aleatorizado, multicéntrico, dividido en dos partes para investigar la seguridad, tolerabilidad, farmacocinética, farmacodinámica y eficacia de RO7034067 en pacientes con atrofia muscular espinal de tipo 2 y 3.
Type: Clinical Trials, phase: II.
HULP code: Appendix II 4664.
Sponsored´s protocol code: BP39055.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/10/2020

Pascual Pascual SI. Efectos de N-acetil-l-leucina en la ataxiatelangiectasia: un ensayo en fase II multinacional, multicéntrico, sin enmascaramiento para los pacientes y con enmascaramiento para los evaluadores.
Type: Clinical Trials, phase: II.
HULP code: 5621.
Sponsored´s protocol code: IB1001-203.
Sponsored by: Intrabio Ltd.
Signed date: 13/10/2020

Pascual Pascual SI. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne capaces de caminar.
Type: Clinical Trials, phase: III.
HULP code: 5619.
Sponsored´s protocol code: NS-065/NCNP-01-301.
Sponsored by: NS Pharma Inc.
Signed date: 06/08/2020

Pascual Pascual SI. Estudio controlado, aleatorizado y de aumento gradual de la dosis de nusinersén (BIIB058) en participantes con atrofia muscular espinal.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5466.
Sponsored´s protocol code: 232SM203.
Sponsored by: Biogen Idec Research Limited.
Signed date: 01/10/2020

Pascual Pascual SI. Estudio controlado, aleatorizado y de aumento gradual de la dosis de nusinersén (BIIB058) en participantes con atrofia muscular espinal.
Type: Clinical Trials, phase: III.
HULP code: 5466.
Sponsored´s protocol code: 232SM203.
Sponsored by: Biogen Idec Research Limited.
Signed date: 20/04/2020

Pascual Pascual SI. Diseño y validación psicométrica de un conjunto de cuestionarios "Toolbox" para evaluar los resultados de salud en atrofia muscular espinal desde el punto de vista del paciente. Estudio SMA-Tool.
Type: Study, phase: Drugs.
HULP code: PI-4398.
Sponsored´s protocol code: ML41962/ ROC-AME2020-0.
Sponsored by: Roche Farma S.A.
Signed date: 24/09/2020

Pellicer Martínez A. An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic insufficiency in the immediate postnatal period.
Type: Clinical Trials.
HULP code: 5533.
Sponsored´s protocol code: NeoCirc-003 TRIAL.
Sponsored by: FIBHULP.
Signed date: 05/06/2020

Peña Conde L. Comportamiento de edoxabán en pacientes con fibrilación auricular no valvular e insuficiencia cardíaca en España. Estudio Emayic.
Type: Study, phase: PASS-SP.
HULP code: PI-4458.
Sponsored´s protocol code: SEC-EDO-2020-01.
Sponsored by: Sociedad Española de Cardiología.
Signed date: 15/12/2020

Peralta Calvo J. Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090.
Type: Clinical Trials, phase: III.
HULP code: 5338.
Sponsored´s protocol code: BAY 86-5321 / 20275.
Sponsored by: Bayer Ag.
Signed date: 06/05/2020

Pérez Martínez A. Infusion de células natural killer aloreactivas o estimuladaas con IL-15 ex vivo tras trasplante haploidéntico de progenitores hematopoyéticos en pacientes pediátricos con neoplasias hematológicas.
Type: Clinical Trials, phase: I.
HULP code: 5521.
Sponsored´s protocol code: PHINK-01/2019.
Sponsored by: FIBHULP.
Signed date: 28/09/2020

Pérez Martínez A. A phase I/II dose-escalation multi center study to evaluate the safety of infusion of natural killer cells or memory t cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia.
Type: Clinical Trials, phase: I.
HULP code: 5579.
Sponsored´s protocol code: RELEASE.
Sponsored by: Pérez Martínez, Antonio.
Signed date: 29/09/2020

Pérez Valero I. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el VIH-1 con supresión virológica.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5354.
Sponsored´s protocol code: 208090.
Sponsored by: VIIV Healthcare Uk Limited.
Signed date: 02/07/2020

Pérez Valero I. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide.
Type: Clinical Trials, phase: III.
HULP code: 5470.
Sponsored´s protocol code: MK-8591A-018.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 15/01/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Pinto Marín A. Estudio de fase III, estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4699.
Sponsored´s protocol code: M029983.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 24/02/2020

Pinto Marín A. Un ensayo multicéntrico, abierto, fase 1b/2 de lenvatinib (e7080) más pembrolizumab en sujetos con tumores sólidos seleccionados.
Type: Clinical Trials, phase: I.
HULP code: Appendix II 5046.
Sponsored´s protocol code: E7080-A001-111.
Sponsored by: Covance Inc.
Signed date: 18/03/2020

Pinto Marín A. Estudio de fase IB de aumento escalonado de la dosis de cabozantinib (XL184) en combinación con atezolizumab en pacientes con tumores sólidos localmente avanzados o metastásicos.
Type: Clinical Trials, phase: I.
HULP code: 5583.
Sponsored´s protocol code: XL184-021.
Sponsored by: Exelixis Inc.
Signed date: 13/05/2020

Pinto Marín A. Estudio de fase 3 aleatorizado de cistectomía más pembrolizumab perioperatorio frente a cistectomía sola en participantes con cáncer de vejiga con invasión muscular que no son aptos para recibir cisplatino (KEYNOTE-905).
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5304.
Sponsored´s protocol code: MK-3475-905.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 27/11/2020

Pinto Marín A. Estudio de fase II, abierto, aleatorizado y multicéntrico para evaluar la eficacia y la seguridad de pemigatinib más pembrolizumab en comparación con pemigatinib solo y con el tratamiento de referencia como tratamiento de primera línea para el carcinoma urotelial metastásico o no resecable en participantes no aptos para cisplatino, cuyos tumores expresan mutación o reordenamiento de FGFR3 (Fight-205).
Type: Clinical Trials, phase: II.
HULP code: 5439.
Sponsored´s protocol code: INCB 54828-205.
Sponsored by: Incyte Corporation.
Signed date: 25/02/2020

Pinto Marín A. Ensayo de fase III, multicéntrico, doble ciego, aleatorizado y controlado con placebo de infigratinib para el tratamiento adyuvante de sujetos con carcinoma urotelial invasivo con alteraciones del gen FGFR3 sensibles.
Type: Clinical Trials, phase: III.
HULP code: 5481.
Sponsored´s protocol code: QBGJ398-302.
Sponsored by: Qed Therapeutics Inc.
Signed date: 26/02/2020

Pinto Marín A. Estudio de fase III multicéntrico, aleatorizado, abierto para evaluar la eficacia y seguridad de atezolizumab administrado en combinación con cabozantinib frente a cabozantinib en monoterapia en pacientes con carcinoma de células renales localmente avanzado o metastásico inoperable que han presentado progresión tumoral radiológica durante o después del tratamiento con un inhibidor de puntos de control inmunitario.
Type: Clinical Trials, phase: III.
HULP code: 5677.
Sponsored´s protocol code: W041994.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

Pinto Marín A. Fase II, ensayo multicéntrico, no aleatorio, de un solo brazo, abierto, de atezolizumab en combinación de dosis divididas de gemcitabina más cisplatino en pacientes con carcinoma urotelial metastásico localmente avanzado. Phase II, multicenter, nonrandomized, single-arm, open-label trial of atezolizumab in combination of split-doses of gemcitabine plus cisplatin in patients with locally advanced or metastatic urothelial carcinoma.
Type: Clinical Trials, phase: II.
HULP code: 5662.
Sponsored´s protocol code: SOGUG-2020-IEC(VEJ)-1.
Sponsored by: Grupo Sogug.
Signed date: 23/11/2020

Pinto Marín A. Preferencias de pacientes y oncólogos por las características del tratamiento de carcinoma de células renales en España y Portugal. Código de protocolo CA209-9W6. Código de clasificación de la AEMPS BMS-INM2018-01.
Type: Study, phase: PASS-OD.
HULP code: PI-4025.
Sponsored´s protocol code: CA209-9W6.
Sponsored by: Bristol Myers Squibb S.A.U.
Signed date: 24/04/2020

Prados Sánchez C. Ensayo clínico con enmascaramiento doble, multicéntrico y controlado con placebo para investigar la eficacia y seguridad de 12 meses de terapia con Promixin® inhalado (colistimetato de sodio) para el tratamiento de pacientes con bronquiectasia no debida a fibrosis quística con infección crónica por pseudomonas aeruginosa.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 4779.
Sponsored´s protocol code: Z7224L01.
Sponsored by: Zambon, S.A.
Signed date: 05/10/2020

Prados Sánchez C. Estudio en fase III y abierto para evaluar la seguridad a largo plazo del tratamiento combinado VX-445 en sujetos con fibrosis quística.
Type: Clinical Trials, phase: III.
HULP code: 5383.
Sponsored´s protocol code: VX18-445-113.
Sponsored by: Vertex Pharmaceuticals Incorporated.
Signed date: 24/01/2020

Prieto Nieto I. Premas Study. Prevalence of malnutrition in gastrointestinal surgical oncology patients (prevalencia de la desnutrición en pacientes oncológicos sometidos a cirugía gastrointestinal).
Type: Study, phase: Drugs.
HULP code: PI-4285.
Sponsored´s protocol code: FRE-NUL-2020-01.
Sponsored by: Sanidad y Ediciones S.L.
Signed date: 10/09/2020

Quintana Díaz M. A multicenter, randomized, open-label, parallel group pilot study to evaluate safety and efficacy of convalescent methylene blue treated (MBT) plasma from donors recovered from coronavirus disease 2019 (covid-19) with standard medical treatment (SMT) versus SMT alone in subjects with covid-19 requiring admission to the intensive care unit (ICU).
Type: Study, phase: Drugs.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

HULP code: 5581.
Sponsored´s protocol code: GC2003.
Sponsored by: Grifols Worldwide Operations, Ltd.
Signed date: 17/04/2020

Quirce Gancedo SE. Real world effectiveness study of mepolizumab in severe eosinophilic asthma in Spain. Redes study.
Type: Study, phase: PASS-OD.
HULP code: PI-3885.
Sponsored´s protocol code: GLA-MEP-2019-01.
Sponsored by: Glaxosmithkline S.A.
Signed date: 09/01/2020

Ramos Boluda ME. Registro multicéntrico prospectivo para pacientes con síndrome del intestino corto.
Type: Study, phase: PASS-LA.
HULP code: APPENDIX I PI-3299.
Sponsored´s protocol code: TED-R13-002.
Sponsored by: Takeda Pharmaceutical International AG.
Signed date: 20/10/2020

Redondo Sánchez A. Ensayo de fase II aleatorizado, doble ciego, controlado con placebo, de dicloruro de radio-223 en combinación con exemestano y everolimús frente a placebo en combinación con exemestano y everolimús, administrado a pacientes con cáncer de mama metastásico negativo para HER2 y positivo para los receptores hormonales, con metástasis óseas.
Type: Clinical Trials, phase: II.
HULP code: Appendix II 4263.
Sponsored by: Bayer Pharma Ag.
Signed date: 30/06/2020



Redondo Sánchez A. Atezolizumab en combinación con bevacizumab y quimioterapia versus bevacizumab y quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de fase III.
Type: Clinical Trials, phase: III.
HULP code: Appendix I 5305.
Sponsored´s protocol code: 0 AGO-OVAR 2.29.
Sponsored by: Ago Research GMBH.
Signed date: 28/04/2020

Redondo Sánchez A. Atezolizumab en combinación con bevacizumab y quimioterapia versus bevacizumab y quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de fase III.
Type: Clinical Trials, phase: III.
HULP code: 5305.
Sponsored´s protocol code: AGO-OVAR 2.29.
Sponsored by: Ago Research GMBH.
Signed date: 03/02/2020

Redondo Sánchez A. Estudio de fase 1/2, aleatorizado, sin enmascaramiento, en el que se evalúa ramucirumab en pacientes menores de edad y en adultos jóvenes con tumores desmoplásicos de células pequeñas y redondas recidivantes, recurrentes o resistentes al tratamiento.
Type: Clinical Trials, phase: I.
HULP code: 5278.
Sponsored´s protocol code: J1S-MC-JV01.
Sponsored by: Lilly S.A.
Signed date: 20/02/2020

Redondo Sánchez A. Estudio de fase 2, aleatorizado, sin enmascaramiento, en el que se evalúa ramucirumab en pacientes menores de edad y en adultos jóvenes con sarcoma sinovial recidivante, recurrente o resistente al tratamiento.
Type: Clinical Trials, phase: I.
HULP code: 5279.
Sponsored´s protocol code: J1S-MC-JV02.
Sponsored by: Lilly S.A.
Signed date: 20/02/2020

Redondo Sánchez A. Ensayo clínico aleatorizado fase I/II de selinexor más gemcitabina en determinados sarcomas de partes blandas y osteosarcomas avanzados.
Type: Clinical Trials, phase: I.
HULP code: 5541.
Sponsored´s protocol code: GEIS-67.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 08/07/2020

Redondo Sánchez A. Estudio fase II para evaluar la seguridad y eficacia de tiragolumab más atezolizumab y de atezolizumab en monoterapia en pacientes con cáncer de cérvix metastásico y/o recurrente PD-L1 positivo.
Type: Clinical Trials, phase: II.
HULP code: 5700.
Sponsored´s protocol code: WO42017.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 19/11/2020

Redondo Sánchez A. Estudio en fase III de grupo único sobre mirvetuximab soravtansina en cáncer epitelial de ovario, peritoneal primario o de las trompas de falopio de alto grado avanzado con expresión elevada del receptor de folato α.
Type: Clinical Trials, phase: III.
HULP code: 5564.
Sponsored´s protocol code: IMGN853-0417.
Sponsored by: Immunogen Inc.
Signed date: 05/06/2020

Remesal Camba A. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, seguido de una fase de tratamiento activo para evaluar la eficacia y seguridad de apremilast en niños de 2 a menos de 18 años con úlceras bucales activas asociadas a la enfermedad de Behçet (Bean).
Type: Clinical Trials, phase: III.
HULP code: 5666.
Sponsored´s protocol code: 20190530.
Sponsored by: Amgen S.A.
Signed date: 16/11/2020

Remesal Camba A. Los nuevos criterios de Printo para la clasificación de la artritis idiopática juvenil. Un proyecto basado en la evidencia científica para la revisión de los criterios de la liga internacional contra el reumatismo (ILAR).
Type: Study, phase: Drugs.
HULP code: PI-3816.
Sponsored by: Instituto Giannina Gaslini.
Signed date: 28/09/2020

Riera del Moral LF. Ensayo clínico multicéntrico, aleatorizado, de búsqueda de dosis, de grupos paralelos, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de la administración intramuscular de células mesenquimalesalogénicas derivadas de tejido adiposo en pacientes diabéticos con isquemia crítica de miembros inferiores sin posibilidad de revascularización.
Type: Study, phase: Drugs.
HULP code: 5426.
Sponsored´s protocol code: NOMA.
Sponsored by: Instituto Investigacion Sanitaria Fjd.
Signed date: 18/06/2020

Ríos González E. Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical.
Type: Clinical Trials, phase: III.
HULP code: Appendix II 5226.
Sponsored´s protocol code: 56021927pcr3011.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 16/11/2020

Ríos González E. Estudio aleatorizado, doble ciego, controlado con placebo de fase III de niraparib en combinación con acetato de abiraterona y prednisona frente a acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico sensible a la castración con mutaciones deletéreas en la línea germinal o somáticas en los genes de reparación por recombinación homóloga.
Type: Clinical Trials, phase: III.
HULP code: 5654.
Sponsored´s protocol code: 676520000PCR3002.
Sponsored by: Janssen Cilag International N.V.
Signed date: 27/08/2020

Rivas Becerra B. Estudio postautorización de seguridad multicéntrico y no intervencionista de 6 anos de duración realizado en pacientes a los que se ha recetado Jinarc® debido a poliquistosis renal autosómica dominante.
Type: Study, phase: PASS-LA.
HULP code: Appendix I PI-2881.
Sponsored´s protocol code: 156-12-299.
Sponsored by: Otsuka Pharmaceutical Development & Commercializacion Inc.
Signed date: 27/08/2020

Robles Marhuenda AJ. Estudio piloto multicéntrico, aleatorizado, abierto y con grupos paralelos para evaluar la seguridad y eficacia de la inmunoglobulina intravenosa (IGIV) a altas dosis junto con tratamiento médico estándar (TME) en comparación con el TME solo en sujetos hospitalizados con covid-19.
Type: Clinical Trials, phase: II.
HULP code: 5722.
Sponsored´s protocol code: GC2004.
Sponsored by: Grifols Worldwide Operations, Ltd.
Signed date: 06/11/2020

Roda Frade JM. Estudio fase 2, multicéntrico, doble ciego, multidosis, controlado con placebo, randomizado y de grupos paralelos para evaluar la eficacia y seguridad de BIIB093 intravenoso en pacientes con contusión cerebral.
Type: Clinical Trials, phase: II.
HULP code: 5276.
Sponsored´s protocol code: 252BN201.
Sponsored by: Biogen Idec Research Limited.
Signed date: 08/06/2020

Rodríguez de Rivera Garrido FJ. Estudio de fase 2, aleatorizado y controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de TAK-079 en pacientes con miastenia grave generalizada.
Type: Clinical Trials, phase: II.
HULP code: 5498.
Sponsored´s protocol code: TAK-079-1005.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 24/02/2020

Rodriguez Salas N. Estudio de fase II, multicéntrico y sin enmascaramiento para evaluar la seguridad y la eficacia de U3-1402 en sujetos con cáncer colorrectal avanzado o metastásico.
Type: Clinical Trials, phase: II.
HULP code: 5613.
Sponsored´s protocol code: U31402-A-U202.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 25/11/2020

Rodriguez Salas N. Ensayo en fase III global, multicéntrico, aleatorizado y controlado con placebo para comparar la eficacia y la seguridad de fruquintinib, más los mejores cuidados paliativos frente a placebo, más los mejores cuidados paliativos en pacientes con cáncer de colorrectal metastásico resistente (Fresco2).
Type: Clinical Trials, phase: III.
HULP code: 5592.
Sponsored´s protocol code: 2019-013-GLOB1.
Sponsored by: Hutchison Medipharma Limited.
Signed date: 09/09/2020

Rodriguez Salas N. Estudio de fase II de un solo grupo para investigar el tepotinib en combinación con cetuximab en pacientes con cáncer colorrectal metastásico del lado izquierdo sin mutaciones RAS/BRAF que han adquirido resistencia al tratamiento frente al anticuerpo anti-EGFR debido a la amplificación de MET.
Type: Clinical Trials, phase: II.
HULP code: 5629.
Sponsored´s protocol code: MS202202-0002.
Sponsored by: Merck Healthcare KGAA.
Signed date: 03/11/2020

Rodriguez Salas N. A multi-center observational retrospective study to evaluate the clinical management of patients diagnosed with colorectal metastatic tumors and to characterize the management of DMMR and MSI-H in Spain.
Type: Study, phase: PASS-OD.
HULP code: PI-4315 .
Sponsored´s protocol code: 8621 (COMISH).
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 07/10/2020

Romero Ribate D. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar el efecto de dupilumab en la inflamación de las vías respiratorias a través de evaluaciones de la función pulmonar, taponamiento mucoso y otros parámetros de imagen pulmonar en pacientes con asma.
Type: Clinical Trials, phase: IV.
HULP code: 5536.
Sponsored´s protocol code: LPS15834.
Sponsored by: Sanofi Aventis S.A.
Signed date: 03/07/2020

Romero Ribate D. Estudio sobre la carga que supone para el sistema sanitario y los pacientes la tos crónica refractaria o inexplicada.
Type: Study, phase: PASS-OD.
HULP code: PI-4393.
Sponsored´s protocol code: BURDEN/ID VEAP: 8614.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 06/11/2020

Rubio Aparicio PM. An international multicenter phase II randomised trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemotherapy a siopen study.
Type: Clinical Trials, phase: II.
HULP code: 5096.
Sponsored´s protocol code: VERITAS.
Sponsored by: Instituto Investigacion Sanitaria Hospital La Fe.
Signed date: 12/02/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Rubio Aparicio PM. Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.
Type: Clinical Trials, phase: II.
HULP code: Appendix I 4854.
Sponsored´s protocol code: GEIS-52.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 06/05/2020

Sáenz de Pipaón Marcos M. Comparación entre nutrición parenteral individualizada y estándar en recién nacidos prematuros, con edad gestacional de menos de 37+0 semanas, y un peso al nacimiento superior a 1250 gramos: ensayo clínico aleatorizado.
Type: Clinical Trials, phase: IV.
HULP code: 5381.
Sponsored´s protocol code: SP-PP18.
Sponsored by: Virgilio P. Carnielli.
Signed date: 23/10/2020

Saenz de Pipaón Marcos M. Efecto de la suplementación temprana con ácido docosahexanoico y ácido araquidónico sobre la incidencia de displasia broncopulmonar en niños extremadamente prematuros.
Type: Study, phase: Medical Devices.
HULP code: 4840.
Sponsored´s protocol code: Estudio DHA.
Sponsored by: Sáenz de Pipaon Marcos, Miguel.
Signed date: 30/11/2020



Sainz Costa T. Estudio de ampliación abierto con rilpivirina en combinación con una pauta de base que contiene otros antirretrovirales en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 que participaron en estudios pediátricos con rilpivirina.
Type: Clinical Trials, phase: II.
HULP code: 5611.
Sponsored´s protocol code: TMC278I-FD3004.
Sponsored by: Janssen Sciences Ireland U.C.
Signed date: 29/09/2020

Sánchez Purificación A. Estudio fase 3 multicéntrico, ciego, aleatorizado, de grupos paralelos, con aprocitentán en pacientes con hipertensión arterial resistente.
Type: Clinical Trials, phase: III.
HULP code: 5469.
Sponsored´s protocol code: ID-080A301.
Sponsored by: Idorsia Pharmaceuticals Ltd.
Signed date: 03/03/2020

Sánchez Torres AM. Estudio observacional prospectivo multicéntrico sobre el fracaso del soporte respiratorio no invasivo precoz en recién nacidos prematuros con síndrome de distrés respiratorio en las unidades de cuidados intensivos neonatales españolas de nivel III.
Type: Study, phase: PASS-SP.
HULP code: PI-3948.
Sponsored´s protocol code: CHI-SFT-2019-01.
Sponsored by: Chiesi España S.A.
Signed date: 08/01/2020

Sánchez Vadillo I. Estudio fase II con aleatorizacion 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con lma de nuevo diagnóstico con el GEN FLT3 no mutado.
Type: Clinical Trials, phase: II.
HULP code: 5334.
Sponsored´s protocol code: QUIWI.
Sponsored by: Fundación Pethema.
Signed date: 12/06/2020

Sánchez Vadillo I. Estudio de fase 3, aleatorizado y abierto para evaluar la seguridad y la eficacia de venetoclax en combinación con azacitidina después de un alotrasplante de células progenitoras en pacientes con leucemia mielógena aguda.
Type: Clinical Trials, phase: III.
HULP code: 5554.
Sponsored´s protocol code: M19-063.
Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
Signed date: 25/05/2020

Sánchez Vadillo I. Estudio aleatorizado y abierto para evaluar la eficiacion y seguridad del tratamiento de mantenimiento de Galinpepimut-s (GPD) en monoterapia, en comparación con el mejor tratamiento disponible seleccionado por el investigador, en sujetos con leucemia mieloide aguda que han alcanzado la remisión completa tras un tratamiento de rescate de segunda línea.
Type: Clinical Trials, phase: III.
HULP code: 5620.
Sponsored´s protocol code: SLSG18-301.
Sponsored by: Sellas Life Sciences.
Signed date: 09/09/2020

Santos Simarro F. Phase II, open-label, dose-escalation and dose-expansion study of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in children with achondroplasia: Propel 2.
Type: Clinical Trials, phase: II.
HULP code: 5596.
Sponsored´s protocol code: QBGJ398-201.
Sponsored by: Qed Therapeutics Inc.
Signed date: 01/10/2020

Santos Simarro F. Achieve: estudio multicéntrico, longitudinal y observacional de niños con acondroplasia.
Type: Study, phase: Drugs.
HULP code: PI-3832.
Sponsored´s protocol code: TCC-NHS-01.
Sponsored by: Ascendis Pharma Growth Disorders.
Signed date: 04/02/2020

Santos Simarro F. Estudio de evaluacion clínica prospectiva en niños con acondroplasia: el ensayo Propel.
Type: Study, phase: Drugs.
HULP code: PI-4027.
Sponsored´s protocol code: QBGJ398-001.
Sponsored by: Qed Therapeutics Inc.
Signed date: 25/02/2020

Sastre Urguelles A. Ensayo clínico fase 1/2 de un brazo para evaluar la seguridad y la eficacia del mesilato de eribulina en combinación con irinotecán en niños con tumores sólidos refractarios o recurrentes.
Type: Clinical Trials, phase: I.
HULP code: Appendix II 5125.
Sponsored´s protocol code: E7389-G000-213.
Sponsored by: Eisai Europe Limited.
Signed date: 26/11/2020

Sastre Urguelles A. Estudio en fase 2, multicéntrico, abierto y aleatorizado para comparar la eficacia y la seguridad de lenvatinib en combinación con ifosfamida y etopósido frente a ifosfamida y etopósido en niños, adolescentes y adultos jóvenes con osteosarcoma recidivante o resistente (OLIE).
Type: Clinical Trials, phase: II.
HULP code: 5500.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Sponsored´s protocol code: E7080-G000-230.
Sponsored by: Eisai Europe Limited.
Signed date: 25/02/2020

Sisinni L. Estudio en fase I/II de búsqueda de dosis y de la eficacia y seguridad de ibrutinib en pacientes pediátricos con enfermedad del injerto contra el huésped crónica.
Type: Clinical Trials, phase: I.
HULP code: Appendix I 5313.
Sponsored´s protocol code: PCYC-1146-IM.
Sponsored by: Pharmacyclics Llc.
Signed date: 16/10/2020

Soto Abanades CI. Estudio clínico de fase 3 prospectivo, multicéntrico, doble ciego, aleatorizado, controlado con producto activo, triple simulado, de grupo paralelo, secuencial y adaptativo para comparar la eficacia y seguridad de las monoterapias de Macitentán y Tadalafilo con la combinación de dosis fija correspondiente en pacientes con hipertensión arterial pulmonar, seguidas de un periodo de tratamiento abierto con una combinación de dosis fija de Macitentán y Tadalafilo.
Type: Clinical Trials, phase: III.
HULP code: Appendix 5319.
Sponsored´s protocol code: AC-077A301(DUE).
Sponsored by: Janssen-Cilag España S.A.
Signed date: 14/09/2020

Soto Abanades CI. Estudio en fase III, prospectivo, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos y flexibles con ampliación abierta para evaluar la eficacia y la seguridad de macitentán 75 mg en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente.
Type: Clinical Trials, phase: III.
HULP code: 5543.
Sponsored´s protocol code: 67896062CTP3001.
Sponsored by: Actelion Pharmaceuticals Ltd.
Signed date: 22/04/2020

Tirado Requero P. Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo, de grupos paralelos para comparar la eficacia, la seguridad y la tolerabilidad de la administración subcutánea de fremanezumab, comparado con placebo como tratamiento preventivo de las migrañas crónicas en niños de entre 6 y 17 años.
Type: Clinical Trials, phase: III.
HULP code: 5682.
Sponsored´s protocol code: TV48125-CNS-30082.
Sponsored by: Teva Branded Pharmaceutical Products R&D Inc.
Signed date: 14/09/2020

Tirado Requero P. Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo, de grupos paralelos para comparar la eficacia, la seguridad y la tolerabilidad de la administración subcutánea de fremanezumab, comparado con placebo como tratamiento preventivo de las migrañas episódicas en niños de entre 6 y 17 años.
Type: Clinical Trials, phase: III.
HULP code: 5683.
Sponsored´s protocol code: TV48125-CNS-30083.
Sponsored by: Teva Branded Pharmaceutical Products R&D Inc.
Signed date: 14/09/2020

Tirado Requero P. Estudio multicéntrico, abierto, para evaluar la seguridad, la tolerabilidad y la eficacia a largo plazo de la administración subcutánea mensual de fremanezumab, como tratamiento preventivo de las migrañas crónicas y episódicas en niños de entre 6 y 17 años.
Type: Clinical Trials, phase: III.
HULP code: 5684.
Sponsored´s protocol code: TV48125-CNC-30084.
Sponsored by: Teva Branded Pharmaceutical Products R&D Inc.
Signed date: 14/09/2020

Torres Santos-Olmo RM. Evaluación del consumo de oxígeno en botellas en urgencias.
Type: Study, phase: Drugs.
HULP code: PI-4461.
Sponsored´s protocol code: OXIURG.
Sponsored by: Vulpis Box S.A.
Signed date: 11/11/2020

Valencia Ortega E. Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo.
Type: Clinical Trials, phase: III.
HULP code: 5483.
Sponsored´s protocol code: MK-8591A-020.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 03/01/2020

Varas Mayoral M. Estudio abierto de fase II para evaluar la eficacia y tolerabilidad del tratamiento con vafidemstat en combinación con el tratamiento estándar para prevenir el síndrome de distrés respiratorio agudo en pacientes adultos graves con covid-19.Study Escape.
Type: Clinical Trials, phase: II.
HULP code: 5719.
Sponsored´s protocol code: CL08-ORY-2001.
Sponsored by: Oryzon Genomics S.A.
Signed date: 02/12/2020"

Viejo Llorente A. Estudio de fase IB, no aleatorizado, abierto, multicéntrico y de dosis única que evalúa la seguridad, tolerabilidad y actividad de BIVV020 en adultos con enfermedad por crioaglutininas.
Type: Clinical Trials, phase: IB.
HULP code: 5540.
Sponsored´s protocol code: PDY16370.
Sponsored by: Sanofi Aventis S.A.
Signed date: 23/11/2020

Villanueva Peña R. Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de seltorexant 20 mg como tratamiento complementario a los antidepresivos en pacientes adultos y de edad avanzada con trastorno depresivo mayor con síntomas de insomnio que respondieron de manera inadecuada al tratamiento con antidepresivos y un tratamiento de extensión de seguridad abierto a largo plazo con seltorexant.
Type: Clinical Trials, phase: III.
HULP code: 5643.
Sponsored´s protocol code: 42847922MDD3001.
Sponsored by: Janssen Pharmaceutica N.V.
Signed date: 05/10/2020

Villanueva Peña R. A 12-month observational prospective cohort study to analyze cardiometabolic profile changes to switch to lurasidone in patients with schizophrenia.
Type: Study, phase: PASS-SP.
HULP code: PI-4416.
Sponsored´s protocol code: ANG-LUR-2020-01.
Sponsored by: Angelini Farmaceutica.
Signed date: 04/11/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Zamora Auñón P. Estudio ventana de oportunidad con pelareorep en cáncer de mama en estadio temprano (Aware-1).
Type: Clinical Trials, phase: I.
HULP code: 5256.
Sponsored´s protocol code: RE0027.
Sponsored by: Oncolytics Biotech Inc.
Signed date: 13/02/2020

Zamora Auñón P. Ensayo clínico de fase III, doble ciego y aleatorizado, para evaluar la eficacia y seguridad de capivasertib + paclitaxel en comparación con un placebo + paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo localmente avanzado (inoperable) o metastásico, confirmado histológicamente.
Type: Clinical Trials, phase: III.
HULP code: 5549.
Sponsored´s protocol code: D3614C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 04/05/2020

Zamora Auñón P. Estudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormonal positivo, receptor del factor de crecimiento epidérmico humano 2 negativo (hr+/her2–) después de la recurrencia o la progresión durante o después del tratamiento con un inhibidor de la aromatasa (capitello-291).
Type: Clinical Trials, phase: III.
HULP code: 5516.
Sponsored´s protocol code: D3615C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 11/03/2020

Zamora Auñón P. Ensayo en fase 3, randomizado, multicéntrico con tratamiento abierto de trastuzumab deruxtecán (T-DXD; DS-8201A) frente a quimioterapia a elección del investigador en pacientes con cáncer de mama con expresión baja del receptor del factor de crecimiento epidérmico-2 (HER2-LOW) y receptores hormonales positivos, cuya enfermedad ha progresado durante el tratamiento endocrino en el contexto metastásico (DestinyBREAST06).
Type: Clinical Trials, phase: III.
HULP code: 5632.
Sponsored´s protocol code: D9670C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 14/10/2020


Zamora Auñón P. Estudio fase II multicéntrico, aleatorizado, abierto, con dos brazos de tratamiento neoadyuvante, para evaluar la eficacia, seguridad y farmacocinética de GDC-9545 más palbociclib comparado con anastrozol más palbociclib en mujeres posmenopáusicas con cáncer de mama precoz no tratado, con receptor de estrógeno-positivo y HER2-negativo.
Type: Clinical Trials, phase: II.
HULP code: 5656.
Sponsored´s protocol code: WO42133.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 02/12/2020

Zamora Auñón P. Estudio fase 3, aleatorizado, multicéntrico, doble ciego de SAR439859 más palbociclib en comparación con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama RE(+), HER2(–) que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada.
Type: Clinical Trials, phase: III.
HULP code: 5644.
Sponsored´s protocol code: EFC15935.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 08/10/2020

Zamora Auñón P. Estudio observacional retrospectivo para evaluar el perfil demográfico y clinicopatológico y el manejo de pacientes con cáncer de mama precoz HER2-positivo y enfermedad residual tratados con trastuzumab emtansina en España: estudio Karma.
Type: Study, phase: PASS-OD.
HULP code: PI-4029.
Sponsored´s protocol code: ML41735.
Sponsored by: Roche Farma S.A.
Signed date: 28/02/2020

Zapardiel Gutiérrez, I. Follow-up in gynecological cancer survivors: an eortc qlg-gcg survivorship study.
Type: Study, phase: Drugs.
HULP code: PI-3676.
Sponsored´s protocol code: 1514-QLQ-GCG.
Sponsored by: Eortc Accounting Department.
Signed date: 23/04/2020

Zarauza Santoveña, A. Identificación de biomarcadores ómicos y su variabilidad inter e intraindividual que permitan la mejora en la individualización de tacrolimus: ensayo clínico no controlado en pacientes pediátricos con trasplante renal.
Type: Clinical Trials, phase: IV.
HULP code: 5520.
Sponsored´s protocol code: TRACO-OMICS.
Sponsored by: FIBHULP.
Signed date: 22/07/2020



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.7 Platforms

The Scientific Support Platforms are services with the aim of providing a scientific, technical or technological support to research or innovation projects. They have been created to provide services of advice, methodological support, biostatistical or epidemiological analysis within others and they give the scientific and technical support that researchers need to carry out the research projects.

2.7.1 Biobank
2.7.2 Biostatistic
2.7.3 Experimental Surgery
2.7.4 Documentalist
2.7.5 UICEC
2.7.6 International
2.7.7 Flow Cytometer Laboratory
2.7.8 Cell Culture Unit
2.7.9 Molecular Imaging and Immunohistochemistry
2.7.10 Radioisotope
2.7.11 BSL2-Virology
2.7.12 Traditional Sequencing
2.7.13 Bioinformatics Service
7.2.14 Pain Platform
2.7.15 Food, Nutrition and Health
2.7.16 Simulation Platform (CEASEC)
2.7.17 Tissue Engineering and 3D Printing



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.1 Biobank

The Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank which works to obtain, store, manage and distribute large collections of human biological samples of diseases of interest for researchers.

In 2020, the Biobank increases its capacity with the incorporation of new scientific-technical services, and as result the platform has been renamed as **Platform for Biobanks and Biomodels of IdiPAZ**.

This service is created with the collaboration of the University Hospital La Paz, the Foundation for Biomedical Research of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz –IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684.

The **Platform for Biobanks and Biomodels of IdiPAZ** (PT20/004) belongs to the National Biobank Network (RNBB) (http://www.redbiobancos.es) to support research in Biomedicine and Health Sciences from Strategic Health Action 2017-20203 of the Carlos III Health Institute.

The Biobank of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate IdiPAZ Number ES-0512/2018.

Objectives

The main objective of the IdiPAZ Biobank is to promote biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the Royal Decree of Biobanks 1716/2011. This guarantees the confidentiality of the samples and associated data.

The IdiPAZ Biobank provides researchers with an agile channel to access samples, their products and data associated with quality assurances and ethical-legal adaptation.

The obtaining, and if necessary the revocation, of the patient's informed consent is controlled, giving the same all the required information. Special attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results.

Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank is favored. In addition, the activity of the IdiPAZ Biobank is made known and valued to society and, especially, in the field of patient and affected associations.

The IdiPAZ Biobank will provide benefits at different levels, starting with donors, patients, society in general and the clinicians and researchers involved. It also aims to facilitate communication and cooperation of different groups with common interests both nationally and internationally.

All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all patients (Organic Law 3/2018 and Regulation General Data Protection 2016/679).

Composition

Scientific Director

Paloma Gómez Campelo (PhD)

Coordinator

Marina Arranz Álvarez

Senior Experts in Pathology and Cytology

Sandra NietoTorrero

Yaiza Pedroche Just

HUB Organoids Manager

Laura Córdoba García

Contact

biobanco.hulp@salud.madrid.org

biobanco@idipaz.es

Phone: Biobank Laboratory (+34) 91 207 11 91

Secretary

Susana García Pérez

Phone: (+34) 91 207 15 12

investigacion.hulp@salud.madrid.org



Introduction

Executive summary

Information Groups by Area


Associated Clinicians

2.7.1 Biobank

Scientific Committee

David Hardisson Hernáez (MD, PhD)
Francisco Arnalich Fernández (MD, PhD)
Inmaculada Ibáñez de Cáceres (PhD)
Enrique Espinosa Arranz (MD, PhD)
Eduardo López Granados (MD, PhD)
Alicia Hernández Gutiérrez (MD, PhD)

Platform for Biobank and Biomodels of IdiPAZ



Equipment

- Eight -80°C deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes
- Combined refrigerator of 4° C y – 20° C
- Cryostat to cut frozen samples
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector
- Biological safety cabins IIA
- Centrifuge with capacity to process samples in tubes and Eppendorfs
- Automatic platform to manipulate and trace liquids
- One mini coolers to freeze inclined biological samples below 1°C
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentame samples
- Vortex Mixer /agitator
- Spectrophotometer (Nanodrop®)
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, and cells.
- Printer/photocopier/scanner
- 3 computers and a management computer system
- Label printing system and a bar code reader connected to the management software

Portfolio of services

Technical and scientific assessment

- Collection and management of new collection
- Work Methodology/ Methods
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system
- Training and advice on the use of Biobank management software (Bio-e-Bank).
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank
- Training of trainees (FCTs) of training cycles

Sample/collection management

- Coordinating a collection of samples in multiple study/research centers
- Storage of pre-existing collections under LIB 14/2007
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree
- Management and control of Informed Consent (CI) and/or clinic's regarding samples
- Aliquot of blood/salines/plasma/other liquids
- Sample reception and codification

Histology techniques

- Making paraffin block
- Making frozen tissue blocks
- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)

2.7.1 Biobank

- Other kinds of stains
- Laser microdissection

Cell techniques

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques

- DNA and RNA quantification via spectrophotometer (NANODROP)

Organoid models


IdiPAZ's Biobank is working on the establishment of a living biobank of organoid models directly generated from patient biopsies. The in vitro organoid system is a critical tool for the study of a wide range of physiology processes and for drug screening studies to provide personalized treatment options to patients.


Areas of application:

- Studies of tissue morphogenesis and organ development
- Oncology and immuno-oncology
- Infectious diseases
- Genetic and inflammatory diseases
- Drug screening for toxicity and efficacy


Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject. Also, researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

Biobank's scientific indicators






Finally, the recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) and its rapid national and international spread pose, have provided the IdiPAZ Biobank the opportunity of have started a COVID-19 Collection.



Publications in 2020 with the mention of IdiPAZ Biobank authorship attribution



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.2 Biostatistic

The Biostatistics Section has the mission of giving methodological support to the professionals of the "La Paz" University Hospital and, in general, to the IdiPaz professionals, and to provide technical solutions for the optimization of clinical processes by incorporating the necessary technologies for this.

Composition

Coordinator

Mariana Díaz Almirón

Email: mariana.diaz@idipaz.es

Tel: (+34): 912071791

Clinical Biostatistics

Itsaso Losantos García

Email: itsaso.losantos@salud.madrid.org

Tel: (+34): 912071791

Bioengineer

Francisco Gayá Moreno

Email: francisco.gaya@salud.madrid.org


Tel: (+34): 912071791

Portfolio of services

- Study design
- Creation of data collection systems (such as ms Access)
- Technical support in the development of studies.
- Support for the design and analysis of observational epidemiological studies.
- Assistance in the design, analysis and interpretation of validation studies of diagnostic tests in the clinical hospital context.
- Development of information processing systems (clinical image, readings of measuring devices, implementation of statistical methods ...). Analysis of results: Multivariate Analysis (Discriminant Analysis, Correspondence Analysis, Factor Analysis, Survival Analysis, Analysis with competitive risks. ..), Generalized Linear Models including Models with Mixed Effects and Generalized Equation Models, development of Risk Models for classification and prediction, construction of Scoring Systems for Risk Assessment, Analysis of Growth Curves, Clinical Trial Methodology, Methods of Sequential Data Analysis, Analysis of High-dimensional Data (Analysis of microarrays). Biclúster Analysis. Resampling Methods (Bootstrap, Jackknife).
- Presentation and dissemination of results
- Realization of training activities

Activity carried out during 2019

Distribution by Center



Distribution by Research




Introduction
Executive summary
Information Groups by Area
Associated Clinicians


2.7.2 Biostatistic




Distribution by Required Support



Distribution by Research Statement



Pertaining to a Research Line



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.3 Experimental Surgery

The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine-tunes procedures for new diagnostic and therapeutic techniques that use laboratory animals. In the teaching field, the Section organises and supports training courses in surgical, microsurgical, laparoscopic and anaesthetic techniques.

Composition

Section Head

Manuel Quintana
Manuel.quintana@salud.madrid.org
Phone: (+34) 91 20715 81

Veterinarian

Carlota Largo Aramburu
carlota.largo@salud.madrid.org
Phone: (+34) 91 207 15 81

Secretary

Irene Cuevas Gordo
irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54

Technicians and assistants

Sonsoles Jimenez Mediano
Isabel Rodríguez Martín
Mar Varona
Pablo Llorente
Pedro Gallego
Daniel Gómez Barroso



Equipment

The Section consists of two microsurgery rooms, an operating room and an animal facility. The microsurgery room has surgical loupes and microscopes, as well as inhalers anaesthesia systems for rodents. All experimental procedures with rodents are performed in this room. Its layout, with fixed and mobile posts, allows for the implementation of microsurgical and laparoscopic courses with simulators.

The operating room is equipped with double team surgical tables and anaesthesia stations with monitoring equipment, which allow for two surgeries to be performed simultaneously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray equipment. All procedures performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques. The animal facility has a total of five rooms for conventional accommodation of animals, in both the breeding phase and for experimentation. Two of these rooms have modular enclosures for housing large species such as pigs, sheep and rabbits. The remaining three accommodate rodents (rat, mouse and gerbil). The housing of rodents has controlled ventilation systems (a ventilated rack for mice and another for rats) and conventional systems in shelves. It also has a sealed positive and negative pressure room.

Animal facility

The research and teaching at IdiPAZ involving the use of laboratory animals is managed via the animal platform of IdiPAZ, and is overseen by Rd. Carlota Largo Aram Buru. In this department we develop biomedical research projects, training courses specific to the various specialties as well as procedures for putting in place new diagnostic techniques or therapies that involve the use of experimental animals. In addition, the animal facility works with the Ethics Committee for Animal Wellbeing, whose authorisations is required for all procedures.

The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental phases, two rooms for animal handling and experimental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressure based washing system, and several storage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Surgery where there is a double operating theatre, a microsurgery room and various additional rooms (dressing areas, offices, and store rooms).

The species typically used include: rodents (rats, mice and gerbils), rabbits, pigs, sheep and goats, and occasionally dogs, cats or guinea pigs. Recently, a fish housing unit has been established (zebra fish). To avoid contamination and permit a good workflow, the rooms for housing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the interior while avoiding the unnecessary entrance of unauthorised personnel.

The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage is includes stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to encourage the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects. For the cleanliness of the room and the animals, there are hot and cold water connections via a hose.

The rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position.

2.7.3 Experimental Surgery

The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room.

The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, gloves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish. There is a storeroom for feed and shavings and a room for handling and the performance of procedures.

In addition to two large areas of animals, the animal facility includes:

- A washroom equipped with a cage washer (Hobart), a stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it.
- A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray.
- Store room (clean material).
- Control room with computers for environmental control.

The animal facility complies with all current legislation and is registered with number ES-280790001941.

Portfolio of services

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

2.7.4 Documentalist

Objectives

The documentalist platform is responsible for the analysis, maintenance and dissemination of the scientific production generated by the Institute. This production is collected both in the bibliometric reports that are published on the IdiPAZ website as well as in the Institute's Research Report which is published annually and in which all the research activity of our research groups is collected. Also key is the support of the unit to the scientific management when carrying out internal evaluations of researchers or research groups.

The platform provides support to all IdiPAZ researchers when performing bibliographic searches, managing ORCID, CVN or different researcher profiles, advising on scientific evaluation, advising on quality criteria for scientific publications and any training related to this service.

This platform has also played a key role in publicizing and promoting open access policies, as well as participating in the initiatives carried out by public institutions for the creation of institutional repositories.

Through the documentalist, IdiPAZ members can print the posters that will be used to disseminate the results of their research at the congresses of their specialties.

The main objectives of the platform are:

- To show society the relevance of scientific research conducted at IdiPAZ.
- Facilitate transparency and maximize the impact of the scientific production of the institute.
- Collaborate in the transmission of knowledge generated in the IdiPAZ environment.

Composition

Head

Raúl Román Cañizares
documentalista@idipaz.es
Phone: (+34) 91 727 75 76

Portfolio of services

- Draw up of IdiPAZ's Annual Research Report
- Support to researchers in their access and use of databases, literature searches, etc.
- Design and creation of tools to control the scientific production
- Development of Bibliometric Reports
- Evaluation of researchers
- Bibliometric assessment of Research Groups
- Advice on literature search tools
- Advice on the use of bibliometric techniques
- Poster printing for congress

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.7.2 UICEC

La Paz Research and Clinical Trials Unit (Unidad de Investigación Clínica y Ensayos Clínicos del Hospital La Paz, HULP-UICEC), is one of the IdiPAZ supported research platforms. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UCICEC is the coordinator of the Spanish Clinical Research Network (SCReN), research platform of Instituto de Salud Carlos III.

Its wide portfolio of services provides support to researchers in design, set-up (including IRBs and Competent Authority approvals), management, data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the preparation of feasibility and financial reports, administrative tasks (i.e., investigators coordination, schedule of visits), as well as projects development and research, particularly in the recruitment and follow-up of patients and data collection, assistance in audit, inspections and adverse drug reactions management according to regulatory procedures, among other tasks. We also perform nursing activities and laboratory management, obtaining, processing and shipping the samples to central laboratories. All operations are GCP compliant as needed.

HULP-UCICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows harbour early phase clinical trials both in healthy volunteers and patients (children and adults).

Composition

Head
Jesús Frías Iniesta (MD, PhD)
jesus.frias@salud.madrid.org

UCICEC Manager
Alberto M. Borobia Pérez (MD, PhD)
alberto.borobia@salud.madrid.org
Phone: (+34) 912 071 466

Scientific Coordinator
Antonio J. Carcas Sansuán (MD, PhD)
antonio.carcas@salud.madrid.org

Clinical Pharmacologist
Elena Ramírez García (MD, PhD)
Irene García García (MD)
Alicia Marín Candón (MD)
Javier Queiruga (MD)
Amelia Rodriguez Mariblanca (MD)
Lucía Martínez de Soto (MD)

International Project Manager
Paloma Moraga Alapont (MSc)
Paula Valle Simon (MSc)
Paula Prieto (MSc)

National Project Manager
Rocío Prieto (PhD)

Project Manager Paediatrics Oncology Trials
Pilar Guerra García (MD)
Cristina Blasco (MsC)

Clinical Research Associate
Marina Aparicio Marlasca (PhD)
Francisco Borrel (MsC)
Mª Luisa de Frías (PhD)
Pablo Molina (MsC)

Bioestaticians
María Jiménez González
Vega Rey Mauleón

Technical Secretary of SCReN
Victoria Hernández Rubio
María José Rubira Touriño
Gema del Prado Marugán
Victor Alelú Hernández
Sánchez Correa Amparo

Data Entry
Silvia Llorente
Beatriz Llorente Robledo

Clinical Trials Nurses
Vega Mauleón Martínez (MsC)
Raquel de Madariaga Castell
Laura Vitón Vara (MSc)
Cristina López Crespo (MsC)
Paula de la Rosa Veja (MsC)
Marta Sanz García



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.7.2 UICEC

Nursing supervisor

Patricia Luna Castaño

Receptionist /Clinical Trials Assistant

Cristina Miragall Roig

Marisol Díaz Guerra

ucicec.hulp@salud.madrid.org
Phone: (+34) 912 071 466

Facilities

- 6 Work offices (28 work stations)
- 1 Meeting room (with audiovisual and teleconference systems)
- 1 Archive room
- Phase I/II Clinical Trial Unit:
  - A hospital ward with eight beds and four chairs (children and adults)
  - 1 Doctor's office
  - 1 Central point for sample collection
  - 1 Sitting room
- Carlos III Satellite Unit
  - 1 Work office and doctor´s office
  - 1 Laboratory

Equipment

- 1 ECG
- 1 Centrifuge (Carlos III Satellite Unit)
- 2 Refrigerated centrifuge
- 1 Refrigerator
- 1 Room temperature chamber (Carlos III Satellite Unit)
- 3 -20°C freezers (1 in Carlos III Satellite Unit)
- 2 -80°C deep freezer
- 4 Vital signs monitors
- Defibrillator
- Temperature recording system
- Digital clocks synchronised by GPS
- 2 medical scales (1 in Carlos III Satellite Unit)
- Digital blood pressure monitors and pulse oximeters
- Digital timers
- Crash trolley
- 2 Cure trolleys
- Video surveillance system
- 11 patient calling devices
- 4 patient surveillance cameras

Portfolio of services

The portfolio of services includes more than 80 tasks grouped into:

- Methodologic support
- Clinical trial pre-study activities
- Study development
- Finalization and closure tasks
- Pharmacovigilance
- Statistics and data management
- Medical and nursing tasks

Research activity of UICEC

During 2020, the platform has provided assistance and support in start-up, coordination, data-management, laboratory management or nursing tasks in more than 150 commercial clinical trials of 46 Research Groups and more than 40 independent clinical research projects. In this period, 6 audits have been conducted and have been successfully overcome. In 2017 UCICEC was certified to the ISO 9001:2015 and has been recertified in 2018, 2019 and 2020.

HULP-UICEC has also provided methodological support in almost 150 clinical independent projects, including advice on study requirements and documentation, protocol development and design and preparation of application reports for competitive projects. HULP-UCICEC is the leader of clinical work packages (WP) or is the National Coordination (NC) of 4 European projects (IMI and H2020).

Finally, more than 10 early phase trials have been conducted in our Phase I.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.6 International

The Internationalisation Platform of IdiPAZ is the office in charge of dynamising, promoting and managing the international projection of the research groups. Our objective is to promote the different research groups that make up the institute at an international level, identifying possible synergies between groups and centres, new partners and sources of funding, as well as the formation of strategic alliances. To this end, we try to maintain a continuous dialogue not only with our researchers but also with the centres from which the future of research is designed and planned, particularly in the European Union.

Throughout 2020, the Platform has relied on the efforts of

José Luis Narro Villanueva, MBA

Marisa Tejedor Botello, MSc

Santi Rello Varona, PhD


The pandemic situation due to the COVID-19 outbreak represented a challenge to everyone. In the Internationalisation Platform we were used to virtual communications and multi-tasking and that helped us to successfully pass the year. Besides, multiple emergency calls were issued by the international funders representing an extra, urgent, work to help IdiPAZ researchers to position themselves in this new panorama. From that efforts three projects participating by IdiPAZ were granted: CARE, EU-RESPONSE and RESPOND.

We have attended 43 events, workshops and information days on the future of research programmes, at which the priorities of the Union's next framework programme for research and innovation are being designed: Horizon Europe, which came into force in January 2021.


In 2020, we have submitted 35 proposals to the EU H2020 framework programme, the same number than 2019. Our success rate along H2020 has been the 25 % in mean. Those data speaks for our capacity and the quality of our researchers. Moreover, in 2020 IdiPAZ was granted the first EU-funded project as coordinator: a Marie Skłodowska-Curie Actions ("Excellent Science" pillar of H2020) Research and Innovation Staff Exchange project RISEinFAMILY (starting in September 2021).

We also keep doing our job in supporting the European Reference Network in paediatric transplantation, coordinated by the HULP.

Applications to H2020



EU funding returns during H2020



Financed and active international projects- 2020

Project		Program	Logo
AIMED	Antimicrobial Integrated Methodologies for orthopaedic applications	H2020-MSCA	AIMed Antimicrobial Integrated Methodologies

2.7.6 International

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

CARE	Corona Accelerated R&D in Europe	H2020-IMI	
COMBACT-CARE	A new public-private funded project to combat carbapenem resistance	H2020-IMI	
EJP -RD	European Joint Programme on Rare Diseases	H2020	
ENABLE	European Gram-negative Antibacterial Engine	H2020-IMI	
EpiAD	Effect of early and adult-life stress on the brain epigenome: relevance for the occurrence of Alzheimer's Disease.	ERA-NET JPND	
ERA4TB	European Tuberculosis Regimen Accelerator	H2020-IMI	
ERN RARE-LIVER	European Reference Network on hepatological diseases	EU Health Programme	
ERN TransplantChild (Coordinado por el HULP)	European Reference Network on transplantation in children	EU Health Programme	
	Integration systems for specific dataset, e-learning and support of ERN Core Services in the ERN TransplantChild	CEF programme	
	PaEdiatric Transplantation European Registry - PETER	EU Health Programme	
EU-RESPONSE	European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases	H2020	
ID-EPTRI	European Paediatric Translational Research Infrastructure	H2020	
IMPROVE PD	Identification and Mangement of Patients at Risk-Outocome and Vascular Events in Peritoneal Dialysis	H2020-MSCA	
iProcureSecurity	Strategic Partnership of Emergency Medical Service Practitioners for Coordination of Innovation Procurement	H2020	

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

NIH-11808SUB	Craniofacial Microsomia: Genetic Causes and Pathway Discovery	NIH-R01	
ORTHOUNION	ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs	H2020	ORTHOunion
PREDIRA	PRediction mEdical DevIce for Rheumatoid Arthritis	EIT-Health	PREDIRA
qMAR	Quantification of the intestinal load of a targeted set of resistance genes to Monitor Antibiotic Resistance in paediatric transplant patients	H2020-MSCA	qMAR
RESPOND	Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic	H2020	RESPOND
SHARP	Strengthened Health Regulations and Preparedness in EU	EU Health Programme	SHARP
VIRUSCAN	Optomechanics for Virology	H2020	ViruScan



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.7 Flow Cytometry Laboratory

The Flow Cytometry Core is an integrated facility into the Hospital La Paz Institute for Health Research (IdiPAZ), that provides all its members and external groups access to affordable and high-quality flow cytometry services, along with decisively scientific expertise using this technology in research.

We highlight a wide variety of flow cytometry applications: phenotypic analysis of cellular subpopulations using extracellular and intracellular staining, preliminary studies for subsequent clinical application, complex multicolor flow cytometry analysis, etc. This technology is an indispensable biomedicine tool, promoting symbiosis between clinical and basic researchers, as well as cooperation with external institutions.

The services provided include:

- Training and technical support.
- Experimental design, data analysis and interpretation assistance.
- Development of novel multicolor flow cytometry techniques assistance.

Composition



Head

Kilian Gutiérrez Viñas

kilian.gutierrez@idipaz.es

Phone: (+34) 91 727 00 00 (ext. 441021)

Secretary

Susana García Pérez

investigcion.hulp@salud.madrid.org

Phone: (+34) 912 071

Equipment

Currently, the unit has four analyzers:

- **One Beckman Coulter Navios™ cytometer analyser:**

  A clinical system that delivers analytical excellence by coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. With superior detection capabilities, Navios Cytometer provides accurate measurements, especially for rare events, which are critical to clinical diagnosis and monitoring.

  This analyser has three lasers: Blue solid state Diode (5 detectors), Red solid state Diode (3 detectors) and Violet solid state Diode (2 detectors), with which Navios can analyse ten colors simultaneously.

- **Two Becton Dickinson FACSCalibur™ cytometer analysers:**

  A system that supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.

  Each analyser has two lasers: Blue argon laser (3 detectors), and Red solid state Diode (1 detector), with which FACSCalibur™ can analyse four colors simultaneously.

- **One Becton Dickinson FACSCelesta™ cytometer analyser:**


  It is designed to make multicolored flow cytometry more accessible and allow researchers to benefit from new equipment and reagent technological innovations. These optical and reagent technology parallel advances allow multi-laser equipment to complement with new bright fluorochromes, providing a deeper and more powerful insight into cell analysis.

  This analyser has three lasers: Blue solid state Diode (4 detectors), Violet solid state Diode (6 detectors), and Ultra Violet solid state Diode (2 detectors), with which FACSCelesta™ can analyse twelve colors simultaneously.


  These support a wide range of flow cytometry applications, and the possibility of developing new ones responding to facility needs and/or upon users demand. Also during 2020, the Flow Cytometry Core endured quality levels required according to ISO 9001:2015 standard.

Indicators


Cytometry Core Activity




Cytometers Activity



Groups Activity (%)



Cytometers Activity Distribution



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.8 Cell Culture Unit

The Cell Culture Unit has been established as a core support division integrated and supported by Hospital La Paz Institute for Health Research (IdiPAZ) and La Paz University Hospital. This unit facilitates the establishment and management of in vitro model systems and experimental-related techniques for different applications and purposes including the study of biochemical processes, the elucidation of the molecular and cellular mechanisms involved in a biological process, the prediction of the cellular and tissue responses to a specific microenvironment and/or the identification and development of novel drugs, compounds and/or therapeutic targets. Therefore, this platform provides a fundamental basis for the development of research initiatives in the field of Biomedical and Pharmacological Research and Health Sciences.

Objetives

The Cell Culture Unit accomplishes its mission by providing users with assistance and support at scientific, technical and instrumental level through access to knowledge, equipment, material and human resources. According to IdiPAZ strategic plan and other institutional guidelines, this division contributes to the translation of biomedical research by fostering the synergies and cooperation between clinic- and basic- oriented research groups belonging to IdiPAZ as well as to external institutions. It also provides a dynamic and shared operational environment offering a convenient basis for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as the creation of collaborations and alliances between researchers of various categories and disciplines. Moreover, the association and proximity with other core facilities such as the Molecular Imaging and Immunohistochemistry Unit, the Flow Cytometry Unit or the BSL2-Virology laboratory, enable users to develop complementary techniques, to explore and upgrade research hypotheses and to extend and/or improve their objectives.

Composition

Coordinator

Gema Vallés Pérez (PhD)
gema.valles@salud.madrid.org
Phone: (+34) 917277000 (ext. 1576)

Technician

Beatriz Sanz Minguela
Phone: (+34) 917277000 (ext. 2142)

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

Equipment and facilities

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory is fitted with the following equipment:

Cabinets

- 4 Telstar Bio-II-A biological safety cabinets
- 1Telstar Bio-II Advanced 3 biological safety cabinets
- 2 Nuaire NU-437-400E biological safety cabinets
- 1 Heraeus HS-12 biological safety cabinets
- 1 Faster BH-EN 2004 biological safety cabinet
- 1 Gelaire BSB 4A biological safety cabinet
- 1 Esco Class II BSC biological safety cabinet
- 2 Faster BIO 48 vertical laminar flow cabinets
- 1 Faster TWO 30 vertical laminar flow cabinet

Incubators

- 3 Thermo Forma Scientific incubators
- 2 HERAcell incubators
- 1 Biotech Galaxy S incubators
- 3 Nuaire Autoflow incubators
- 1 Sanyo 02/C02 incubator

This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of C02 and N2.

Microscopes

- 1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.
- 1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.
- 1 Optika inverted light microscope
- 1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics
- 1 Lan Optics inverted light microscope

Centrifuges

- 2 Eppendorf 5810R refrigerated centrifuges
- 2 Eppendorf 5804 centrifuge
- 1 Hettich Universal 32R refrigerated centrifuge
- 1 Kubota 2010 centrifuge

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.8 Cell Culture Unit

Cell Separation System

1 Milteny Biotec autoMACS cell separation system

Freezing systems

2 Liebherr refrigerator (4°C and -20°C)
1 Balay refrigerator (4°C and -20°C)
1 Whirlpool refrigerator (4°C and -20°C)
1 Beko refrigerator (4°C and -20°C)

Other equipment

1 Presoclave 75 P-Selecta autoclave
1 Millipore water purification system
1 Heidolph Reax 2000 vortex
1 Raypa thermostatic waterbath
1 Memmert thermostatic waterbath
2 Precisterm thermostatic waterbath
1 Grant JB Aqua 12 Plus thermostatic waterbath

Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc ....

The cryopreservation room is equipped with

2 Statebourne Biorack 3000 liquid nitrogen tank
1 Thermo Locator 6 Plus liquid nitrogen tank
1 10 K Taylor Wharton liquid nitrogen tank
1 MVE cryosystem 4000 liquid nitrogen tank
1 Cryo Diffusion B2016 liquid nitrogen tank
1 Cryo diffusion B2048 liquid nitrogen tank
1 Cryo Diffusion B2011 liquid nitrogen tank
1 SEO GT40 liquid nitrogen tank
1 MVE XLC 511 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen 02 detector coupled to a mechanical ventilation system.

Portfolio of services

In general, this Division offers support for experimental approaches on an extensive range of matters including cell experimentation, consumables and reagents, equipment and laboratory area, technical assistance, training and research.

The main aspects of this support includes:


- Scientific and technical advice, personalized support and consultation: guidance in experimental setup and design, study planning, optimization of techniques and protocols, reagents and material acquisition, cells supply, troubleshooting, analysis and interpretation of results...
- Basic training and hands-on experiments (implementation of the self-service mode) according to biosafety, waste disposal and good laboratory practice guidelines.
- Access to specific facilities including instrumentation, equipment, materials and reagents.
- Preparation and supply of certain materials, reagents and sterile solutions.
- Management and general supervision including good laboratory practices and work habits, cleaning and waste disposal and operation and maintenance of the equipment.
- Performance of experimental procedures: cell separation, cell isolation for cultivation, maintenance and propagation of cell lines and primary cultures, cryopreservation and resuscitation, viability and proliferation, etc...
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guidelines, operating procedures, reports and other required mandatory documentation.
- Detection, identification and treatment of contaminations in cell cultures.

The Cell Culture Unit was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ Number ES-0512/2018.


The personnel associated to the Unit are indebted to the users and other joint staff who directly and indirectly has contributed to this highlight.

Cell Culture Unit´s scientific indicators

USERS: Distribution according to profile



USERS: Distribution according to research area



Projects according to Research Area



COLLABORATIONS: Networks & CIBER

Cell Culture Unit IdiPAZ

ciber-bbn isciii · ciberes isciii · cibercv isciii · AENOR · RIER · INVICTUS

International collaborations

UNI FREIBURG · UNIVERSITY OF LIVERPOOL · Université Joseph Fourier · UiO · Institut Cochin · UNIVERSITY OF MICHIGAN · UNIVERSITY OF EASTERN FINLAND · UF College of Medicine UNIVERSITY of FLORIDA

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.9 Molecular Imaging and Immunohistochemistry

The mission of the Molecular Image and Immunohistochemistry Unit is to provide a centralized service equipped with the highest quality histology, immunohistochemistry and imaging equipment, as well as scientific and technical support to researchers. This core is open to all investigators, including; IdiPaz and their affiliates, commercial and not-for-profit biotechnology companies, and other academic institutions. Image and Immunohistochemistry Unit, as a part of the network of IdiPAZ core facilities, play an essential role in enabling scientists and clinicians to realise their projects creating a link between basic and clinical research. The Unit activities are encompassed in the improvement of the quality management, education and innovation criteria ruled by IdiPaz strategic plan.

Specialized staff provides histological and molecular technical support to the researchers' requirements, which in turn produces high quality data interpretation to support grant applications and national and international scientific publications. Currently a broad range of techniques ranging from classical histology, to molecular techniques as immunohistochemistry, immunofluorescence and image and digital analysis are available at the facility. The general rules of the platform is that trained and authorized users have free access to the platform; IdiPaz staff in a Do-It-yourself manner and in a fee-for-service manner to all the rest.

The Unit, located in the IdiPaz building at the La Paz University Hospital, consists of two sections, the Immunohistochemistry and the Microscopy laboratories. Immunohistochemistry laboratory, housed in the first floor of IdiPaz building, offers protocols and automated high-throughput equipment allowing citospines, fixation techniques (paraffined or freezed), sectioning of tissues (microtomes and cryostats), and classical or advanced immuno-staining (Dako Autostainer). Microscopy Lab is in the -1 floor of IdiPaz building and offers facilities to perform a range of real time and end-point assays, including cell number, proliferation, apoptosis, cell size, and shape and viability measures. The equipment of Microscopy's lab allows to do conventional, fluorescence, confocal and high-content microscopy, includes a Leica TCS SPE inverted confocal, Leica DM6000 inverted fluorescence microscope, a microscope inverted Nikon Eclipse Ti with in vivo incubation system and a microscope Nanosight with a system of tracking nanoparticles. In addition, the lab offers image analysis programmes (NIS Elements AR, Nanosight 3.1, LASAF, Image ProPlus and ImageJ.

Composition

Head

María Teresa Vallejo Cremades (PhD)
tvallejo.hulp@salud.madrid.org
Phone: (+34) 917277526

Technician

Onys Camps Ortega
onys.camps.ortega@idipaz.es
ext. 42148

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

Resources, equipment and management of the laboratory

The services of the ImageM_IHQ core facility are available to all scientists in different models; collaboration, Do-It-Yourself (DiY) or in a fee (in this case, it must be consulted the head of the laboratory, the lab will support the service depending on staff availability). DiY users are allowed to access the facilities ONLY after training by the lab staff, training sessions can be scheduled at any time of the year. In addition, the lab provides fee-for-service model of use to external institutions and private companies. Access to the Immunohistochemistry Lab is free but access to the Microscopy requires the magnetic individual identification card.

The laboratory staff will give the basic rules to new users for good practices and safety work in the laboratory. Users should not use the equipment until the laboratory personnel have checked their correct training. Users must schedule the time of work in any equipment and booking reserve it is mandatory in all the facility.

Equipment of Molecular Image and Immunohistochemistry Unit

Immunohistochemistry Laboratory:

- Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TP1020)
- Embedding unit for high quality paraffin blocking (Leica EG1160)
- Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature from ambient to 100 °C
- 2 microtomes for specimen sectioning Leica RM2255
- 1 microtome for specimen sectioning Shandon AS325
- Leica EG 1150C Cold plate
- 2 thermostatic water Leica HI 1210 baths
- 1 thermostatic water Selecta Thermofn bath
- Automated Immunohistochemistry autostainer (Autostainer Plus DAKO)
- 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)
- PTLink DAKO
- Crison pH meter

2.7.9 Molecular Imaging and Immunohistochemistry

- Liebher upright freezer (-20°C and 4°C)
- Liebher economy freezer (-20°C)
- Shandon Cytospin 2
- Memmert BE 500 and UN30 oven.
- Selecta Agimatic-E magnetic stirrer with heating
- Olympus CH microscope, for practical laboratory applications
- Gilson pipette sets
- NUAIRE laboratory fume hood.

Staining area with manual options for Do-It-Yourself staining and cover slipping.

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be asked to the head of these laboratories.

The Microscopy laboratory equipment includes:

- Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Illumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.
  - NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
  - Camera IMAGING SOURCE
  - Camera Camera ANDOR Neo SCHOS refrigerated.
  - Lauda Ecoline Star incubator edition 003
  - Hotplate (OKO LAB)
  - D gas (Okolab)
  - Microscope culture plates adapter
- Leica DMI6000B inverted microscope. Filter cubes: A4 (UV), L5 (green), N3 (red) and Y5 (far red)
- Olympus BX41 (Bright feld) upright microscope with an attached Digital camera
- Zeiss Axioplan 2 upright microscope with fve objectives from 5x to 100x, phase contrast and fluorescent capabilities
- Zeiss Axio Lab.Al microscope fve objectives from 5x to100x. ERC5S Axocan camera.
- Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles' size based on the scattering of light, includes a microscope, a LM10 viewing unit, a Marlin camera, an objective x20 and is connected to an image analysis software.
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LAS AF image analysis software
- Analysis work station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.
- Nanosight NTA 3.1 analytical software.

The laboratory is equipped with shared facility from Neuroscience group (Leica TCS SPE inverted confocal).

Portfolio of services

- Collection and processing for fixing and decalcification of samples.
- Sample processing in paraffin by hand or automatic.
  - Complete paraffin embedding processing.
  - Serial cut in microtome and tissue assembly.
- Antibodies' validation.
- Buffer preparation and distribution of consumables.
- Sample processing frozen.
  - Preparation of freeze blocks.
  - Serial sections of blocks freeze and cuts collected on slides or floating.
- Staining.
- Hematoxylin - eosin.
- Masson trichrome.
- PAS.
  - Cytochemical and immunohistochemical techniques.
- Decalcification of samples required.
- Dewaxing cuts, performing staining.
- Immunohistochemical staining automated system Autostainer.
- Protocols for Immunofluorescence in frozen tissue and paraffin.
- Dehydration and slide assembly.
- Image acquisition. Viewing and digital format acquisition.
  - Light microscopy.
  - Light microscopy with phase contrast.
  - Epifluorescence.
  - Confocal microscopy.
  - Advanced Microscopy in living cell.
- Fluorescence colocalization by confocal microscopy.
- 3D reconstruction.
- In vivo image acquisition of biological samples (incubation system for the temperature and CO 2).
- Morphometry in biological samples.
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence.
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.



2.7.9 Molecular Imaging and Immunohistochemistry

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research highlights

In 2020, Image unit maintained their quality standards in order to support and collaborate with the groups belonging to the research areas of IdiPAZ; Neurosciences, Infectious disease and immunity, Cancer and human molecular genetics, Cardiovascular, Organ system pathologies and Surgery, transplant and health technologies. The collaboration are reflected in scientific dissemination as congress presentations and high impact international publications.

Jaén RI, Fernández-Velasco M, Terrón V, Sánchez-García S, Zaragoza C, Canales-Bueno N, Val-Blasco A, Vallejo-Cremades MT, Boscá L, Prieto P. BML-111 treatment prevents cardiac apoptosis and oxidative stress in a mouse model of autoimmune myocarditis. FASEB J. 2020 Aug; 34 (8):10531-10546.


Despite the special circumstances experienced during 2020, the level of Image unit activity has been maintained on the platform similar to that observed in the previous three years. Although the use of equipment decreased slightly in 2020, in proportion it has reached almost the same value as in 2019 and has matched the use in 2018. The unit is committing to supporting the role of science in this pandemic by promoting and assisting our research community in finding a scientific solution to this problem.

Equipment usage ratio



In the last year, we have increased the number of users. The most of inner users are interested in both facilities, Microscopy and Immunohistochemistry labs. The External users are interested mainly in the Immunohistochemistry facility.

Number of users



In December 2020 we renewed the certification according to the ISO2001 quality standard. The Image and Immunohistochemistry Unit has the certified scope of quality by AENOR referring to its processes according to the guidelines of the UNE-EN ISO 9001: 2015 Standard.

The platform is also committed with the diffusion of science, collaboration with similar facilities and formation of future scientist. To achieve the collaboration objective, the platform belongs to the Spanish Network of Advanced Optical Microscopy (REMOA) and participated at the virtual SPAOM2020 Spanish-Portuguese Meeting for Advanced Optical Microscopy organized by the Spanish Network of Advanced Optical Microscopy (REMOA) in Valencia with a communication:

*"Image analysis of neural and immune markers during the inner ear development of rat fetuses with congenit diaphragmatic hernia" Tejeda González, B1, Martínez Martinez L2,3 , Camps-Ortega O1, Tovar JA2,3, Vallejo-Cremades MT1,2**

Participation in the virtual workshop "Light and colour to know our cells. Visit-workshop to the Imaging Unit" during the XX Science Week organized by the CAM allows us to disseminate the scientific activity carried out in our platform. And finally, the platform participates in training activities as a laboratory tutor for Anatomic Pathology students who need this training to obtain their Higher Certificate of Studies (HNC) in Anatomic Pathology laboratory. In this sense, collaboration agreements have been renewed with vocational training center in Madrid, in the field of anatomic pathology laboratory work.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.10 Radioisotope

The radioisotope laboratory of IdiPAZ is a second category radioactive facility authorized by the Nuclear Safety Council for the use of non-encapsulated radioactive sources. The radioisotopes authorized at the facility are: ^{3}H, ^{33}P, ^{32}P, ^{125}I, ^{14}C, ^{51}Cr.

The laboratory, in addition to the counter, has equipment and working space for the performance of molecular biology and biochemical procedures and experiments with cell cultures. Currently the most common procedures are cell proliferation tests with tritiated thymidine.

The use of the facility both by staff of the institution and by external users requires prior authorization by those responsible for the facility that approves both the technical suitability of the users to work with radioactivity, and the procedures to be employed. The HULP Radiation Protection Service is responsible for control of the facility and of the radioactive wastes generated.

Composition

Head laboratory

Nuria Vilaboa Díaz
nuria.vilaboa@salud.madrid.org
Phone: 912 071 034

David Vicent López
david.vicent@salud.madrid.org
Phone: 91 207 10 30

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: 91 207 15 12

2.7.11 BSL2-Virology

The BSL2-Virology laboratory is an IdiPAZ platform created in September 2019 to support the Institute's research. Several research groups have benefited from the platform to conduct their research safely, since working with samples infected with a certain type of pathogen requires facilities with an adequate level of biosafety. The BSL2-Virology laboratory was certified according to ISO 9001 quality management standard within the scope of IQNet.

Composition

Coordinator

Berta Rodés Soldevila
berta.rodes@salud.madrid.org
Phone: 912 071 022

Secretary

Susana García Pérez
Investigación.hulp@salud.madrid.org
Phone: 912 071 512

Objetives

The BSL2-virology laboratory has been adapted to work with human samples infected with the HIV, HBV and HCV viruses; as well as GMOs of risk group 1 and 2. It also allows performance of certain experimental processes with other viral pathogens that require a biosafety level 2. The laboratory provides researchers with the necessary equipment to perform their own experimental processing and analysis, as well as training and assistance.

Resources

The BSL2-Virology Laboratory consists of an experimental laboratory and a compartment with a watertight door. All facilities are located in the IdiPAZ building.

The experimental laboratory is equipped with the following equipment:

Type II Biological Safety Cabinets (BSC)
1 BSC Telstar BIO-II-A/D

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.11 BSL2-Virology

2 BSC Telstar BIO-II-A/P
1 BSC Neuroaire CSB120

CO2 incubators
2 HERAEUS BB-6220 incubators

Centrifuges
1 HERAEUS Biofuge primor refrigerated centrifuge
1 HERAEUS Labofugue 400 non-refrigerated
1 Hettich Universal 320 non-refrigerated centrifuge


Microscope
1 NIKON Eclipse TS100 Inverted Optical Microscope

Refrigeration systems
1 Liebherr upright freezer (-20°C)
1 Liebherr profi line fridge (4°C)

Other equipment
1 P-Selecta Precisterm thermostatic waterbath
1 Inteliwasher 3D-IW8 BIOSAN

Permitted techniques

- Processing of different types of blood cells.
- Preparation of samples from HIV+ patients for cytometry.
- Studies of cellular polyfunctionality in the immune response against HIV.
- Handling and experimental processes of cell cultures.
- Measurement of the impact of antiretroviral drugs on mitochondrial function in PBMCs.
- Construction of viral protein expression vectors in eukaryotic expression vectors.
- ELISA techniques.
- In May 2020 the laboratory was authorized for the use of blood samples from patients with covid-19 and certain related processes.




BSL2-virology laboratory management indicators


nº new and unsuscribed users per month



Persons taking a biosafety course/capacity-building



Lab use 2020 (hours/month)



Introduction

Executive summary

Information Groups by Area


Associated Clinicians

2.7.12 Sequencing Platform

Composition

Head

María del Rocío Mena de la Cruz
mariarocio.mena@salud.madrid.org
Phone: +34 912071214



2.7.12.1 Traditional Sequencing

Research support activity is one of the basic cornerstones of the institute and our laboratory is proud to participate in this strategic line. So, a service in the area of genomics was necessary to enable state-of-the-art research within the institute's lines of precision medicine research. The laboratory also supports the different diagnostic units of the hospital that have incorporated the advances obtained in research. So, we have always characterized ourselves as a clear example of translational research.

Our laboratory owns the necessary equipment and infrastructure for performing tasks such as conventional sequencing (Sanger method), marker DNA genotyping, and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates into the genetic analysers. Therefore, we are able to detect more than 30 polymorphic markers per sample. The knowledge of staff, allows offering design, protocol development, and data analysis support and training to tasks in genomics techniques.

With the aim of keeping services updated, new synergies are currently being created to offer researchers the necessary support in Next Generation Sequencing techniques.

During the last year, the close interaction with research groups at different levels (initial brainstorming, sample processing, ...) have resulted in co-authoring 2 international journal papers, and contributing to about 30 others by offering sequencing services.

As part of the strategic line of promoting quality technical support in research, we annually participate in external international evaluations within the European Molecular Genetics.

Quality Network (EMQN). In addition, we maintain the certification according to ISO 9001: 2015 quality management system standard within the scope of IQNet RESEARCH INSTITUTE Certificate SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ Number ES-0512/2018.

Composition

Head

María del Rocío Mena de la Cruz
mariarocio.mena@salud.madrid.org
Phone: +34 912071214

Technical Staff

María Fernández Elvira
mfelvira@salud.madrid.org

Ruth Rodríguez García
mruth.rodriguez@salud.madrid.org



Equipment

- Eppendrof 5415D Centrifuge.
- Veriti Termocycler(Applied Biosystems).
- Genetics Analyzers 3130xl y 3730xl (Applied Biosystems-Life Technologies).

Software

- Sequencing Analysis v5.3.1
- Sequence Scanner v1.0
- GeneMapper v4.0
- Peak Scanner v1.0
- Variant report v1.0

2.7.12 Traditional Sequencing

Introduction
Executive summary
Information Groups by Area
Associated Clinicians


Portfolio of services

- Nucleic Acid quantitation (Tecan, Nanodrop).
- PCR purification for Sanger sequencing (Exosap).
- Sanger Sequencing.
- Fragments Analysis:
  - QF-PCR.
  - MLPAs (multiplex ligation-dependent probe amplification).
    - Microsatellite instability (MSI).
    - AZF.
    - SnapShot.
    - TP-PCR.


2020 Facility Activity

Research Area	Genotyping Products		Sanger Sequencing Products		Sanger Sequencing		Total
Infectious diseases and immunity	1895	16,32%	7195	20,77%	49	7,99%	9139
Cardiovascular	1	0,01%	1793	5,18%	0	0,00%	1794
Organ system pathologies	1720	14,81%	703	2,03%	0	0,00%	2423
Cancer and human molecular genetics	7994	68,85%	24939	71,99%	564	92,01%	33497
Total	**11610**		**34640**		**613**		**46863**

Research areas



Services



Publications

1. *Peces R, **Mena R**, Martín Y, Hernández C, Peces C, Tellería D, Cuesta E, Selgas R, Lapunzina P, Nevado J. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2. Mol Genet Genomic Med. 2020 Aug;8(8):e1321. doi: 10.1002/mgg3.1321. Epub 2020 Jun 13.*

2. *Peces R, **Mena R**, Peces C, Cuesta E, Selgas R, Barruz P, Lapunzina P, Nevado J. Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression. Clin Genet. 2020 Jun;97(6):857-868. doi: 10.1111/cge.13738. Epub 2020 Mar 25.*

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.12.2 Genomic Analysis

Composition

Head

Rebeca Pérez de Diego
rebeca.perez@idipaz.es
Phone: +34 912071032


The Genomic Analysis platform aims to offer the comprehensive analysis of mass sequencing panels of Primary Immunodeficiency, whole exome sequencing (WES) and whole genome sequencing (WGS) in samples from patients with suspected Primary Immunodeficiency (PIDs). This platform allows customers to benefit from the knowledge and experience of the Laboratory of Immunogenetics of Diseases (www.lighd.org) belonging to the Innate Immune Response Group, obtaining a report of candidate genes responsible for pathology by filtering the list of variants provided by the massive sequencing tools.

The working team of the platform is formed by Dr. Rebeca Pérez de Diego, responsible of the platform, who performs the genomic analysis and the report of results; and the laboratory technician Ana Maria Van Den Rym in charge of the validation by Sanger of the selected variants.

It is a recently created platform that has not yet started its activity in 2020 and is going to carry out the corresponding accreditation in 2021.

The platform allows the genomic analysis of patients with suspected PID, which will allow both the genetic counseling of patients with known genetic defect, as well as the detection of new genetic etiologies in PIDs, which is of great scientific and clinical interest. In the second case, the platform allows connecting these patients and their clinicians with research in this area where patients can be characterized and become part of the laboratory's own research project studies. This type of analysis is part of personalized medicine that allows a genetic diagnosis for patients and their families, allowing an optimization of their treatments.

Figure WES analysis



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.13 Bioinformatics Platform

Objetives

Research bioinformatic support platform whose main objective is to promote the development of any DNA / RNA study on a massive scale, either in humans or in other organisms. The activity of the platform is aimed at advising scientists and researchers on the possibilities and benefits obtained from the application of computational biology techniques in their research. In addition, researchers will be supported in the analysis and interpretation of data obtained using high-throughput experimental techniques.

Composition

Coordinator

Alejandro Pascual Iglesias
Alejandro.pascual.iglesias@idipaz.es
Phone: 91 207 15 12

Portfolio of services

1. Experimental design. Advice to decide the sample size, the design of the study and the planning of the methodology.
2. Data analysis. The bioinformatic processing of the data obtained is carried out in various high-performance technological platforms used in the field of genomics. These analyzes include normalization, statistical analysis, and representation of the results. The most common analyzes are:
    I. Differential expression of genes, miRNAs or lncRNAs. The technology of origin of the experiments can be microarrays (Affymetrix, Agilent) or RNA-seq (Illumina, Ion Torrent).
    II. Protein-DNA interactions from immunuprecipitation and microarray (ChIP-chip) or sequencing (ChIP-seq) experiments.
    III. Helps to interpret results. Once the genes of interest have been selected, biological-functional assignment studies are carried out, such as the study of functional enrichment of gene / protein lists.
    IV. Design, implementation and administration of databases (eg of patients, samples, etc.).
    V. Individualized training activities: Training for users (scientific / technical) in the main theoretical and practical foundations for handling results and their interpretation.

Functioning

The procedure to follow is as follows:

- Fill in the "Job Application" form and send it to carolina.rubio.martin@idipaz.es. Fill in what you want to do by means of a short memory in which the primary objective of the study and the secondary objectives, if any, are clearly specified.
- Meeting with the Bioinformatics Platform to share questions such as the sample size with which it is going to work, the statistical power to be obtained and the variables to be analyzed.
- Preparation and delivery of the data to be analyzed in the format previously agreed between both parties.
- Carrying out the analysis.
- Delivery of results in the pertinent formats.

Equipment

- High technical computer
- Intel Core i9 9900K
- Gigabyte Z390 D ATX 1151 1
- MEMORY HYPERX FURY 16GB

Activity in 2020

All the projects based on the work of bioinformatic platform are actually resulting in several research papers:

- Cellular and humoral functional responses after BNT162b2 SARS-CoV-2 mRNA vaccination differ between naïve and COVID-19-recovered individuals.
- The immune checkpoints storm in COVID-19: role as severity markers at emergency department admission
- Soluble SIGLEC5: A new prognosis marker in colorectal cancer
- The immune checkpoints storm in COVID-19: role as severity markers at emergency department admission
- Intertwined leukocytes balances in tumours and peripheral blood as robust predictors of right and left colorectal cancer survival

Introduction

Executive summary

Information Groups by Area

Associated Clinicians


2.7.13 Bioinformatics Platform

- Also, during 2020, the platform offered help in other projects such as the study of Target Linkage between Interesting miRNAs and Gene Group in human complement, coagulation, or focal adhesion molecular cascades.

Study of Target Linkage between Interesting miRNAs and Gene Group




Complement and coagularion cascades



Other projects:

Development of new machine learning strategies and set up to represent large amounts of data, using Omiq platform. Those strategies are tSNE (T-distributed stochastic neighbour embedding) with all new variants like tSNE-CUDA, opt-tSNE, for dimensionality reduction that is particularly well suited for the visualization of high-dimensional datasets. and UMAP (Uniform Manifold Approximation and Projection), as the evolution of Principal Component Analysis (PCA).



UMAP is a nonlinear dimensionality reduction method, it is very effective for visualizing clusters or groups of data points and their relative proximities.

The significant difference with TSNE is scalability, it can be applied directly to sparse matrices thereby eliminating the need to applying any Dimensionality reduction such as PCA or Truncated SVD(Singular Value Decomposition) as a prior pre-processing step (McInnes, L., & Healy, J. (2018). UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. ArXiv e-prints).

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.14 Pain Platform

Objetives

The Early-Stage Researcher Support Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a recently created service that aims to promote the design and development of research projects in health areas. Focused in our early-stage professional researchers, training and research development will be encouraged to achieve our clinicians a better performance in competitive calls.

Composition

Head

Paloma Gómez Campelo
pgomezc@salud.madrid.org
Phone: (+34) 91 207 15 12

Staff

Daniel Quijada Alcón
daniel.quijada.alcon@idipaz.es
Phone: (+34) 91 207 17 40

Lucía Medina Royo
comunicacion@idipaz.es
Phone: (+34) 91 727 75 76

Mentor Program

IdiPAZ, with the support of HULP, has launched a Mentor Program with the purpose of supporting our clinical researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "AcciónEstratégica en Salud (AES)", granted by Instituto de Salud Carlos III.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it will take into account the experience and scientific knowledge from our senior researchers to help our early-stage researchers from the beginning of their research carrear.

The objectives of the program are:

- **Increasing the number of clinical research in IDIPAZ.**
- **Avoiding a generational leap of clinical researchers.**
- **Strengthening the research profile of our clinical staff.**
- **Becoming IDIPAZ a clinical research model, as the same level that IDIPAZ is in the clinical trials.**
- **Performing an internal cultural change in clinical research.**



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.15 Food, Nutrition and Health

The IdiPAZ Food, Nutrition and Health Platform (NUTRinvest) is a structure created to provide scientific-technical service and support in Human Research and Specialized Advice in Nutrition and Food issues.

The Platform provide service of Specialized Advice in Nutrition and Food at 3 levels:

1. .Industries (agro-food or pharmaceutical sector) interesting in the new products development with an improved nutritional profile.
2. Companies interested in creating new technological tools to facilitate the acquisition of guidelines and healthy habits (web, app, etc.) and healthy habits.
3. Individual interested in knowing their nutritional status through a precision and individualized nutritional assessment

Composition

Scientific-Technical coordinator

Bricia López Plaza, PhD, MSc.
bricia.plaza@idipaz.es

Project manager

Samara Palma Milla, PhD, MD.
samara.palma@salud.madrid.org

Clinical Research Associate

Cristina Santurino Fontecha, PhD.
cristina.santurino@idipaz.es

Edwin Fernández Cruz, PhD.
edwin.fernandez.cruz@idipaz.es

Marlhyn Valero Pérez (Nutricionist).
marlhyn.valero@idipaz.es

Natalia García Vázquez (Pharmacist)
ngarcia.hulp@salud.madrid.org

Marina Morato Martínez (Nutricionist)
marina.morato@salud.madrid.org

Marta Clavero Fraile (Nutricionist)
marta.clavero.fraile@idipaz.es

Lucía Arcos Castellanos (Nutricionist)
larcoscastellanos@gmail.com

Main sectors

- Agri-food/pharmaceutical industries interested in designing or validating the effectiveness of new products.
- Institutions/government agencies with an interest in expanding knowledge in the area of nutrition for the generation/implementation of political measures in Public Health.
- Public or private institutions that want to develop computer applications, or information or communication programs in the field of Nutrition of interest to health professionals, consumers or patients.
- Researchers with interest in the inclusion of nutritional variables in their research projects.
- Individuals interested in obtain information about their nutritional health and who wish to receive precision and individualized nutrition through detailed analysis.

Portfolio of services

- Scientific advice to improve nutritional profiles of foods or nutritional formulas.
- Scientific-technical support in the area of Human Nutrition research:
  - Create well designed Project Plan for Clinical Trials and other human studies.
  - Management and Submission of applications to the Ethics Committee: The platform prepares and management all the documents required by obtain the approval of the Ethics Committee (Informed consent form, Letters from ethics committees. Study questionnaire (copies of any questionnaires or draft questionnaires), Case Record Forms (CRFs), Budget details, etc.)
  - Field work execution (all activities are carried out by members of the platform team with consolidated qualifications in the area):
    - Individualized ietary studies: through the use of validated tools (Food records (24h, 3-7 days), Food Frequency Questionnaires, Weighted food records, DIAL software, calorimetry ...)
    - Diagnostic and screening nutritional studies: using validated methodology (Subjective Global Assessment (SGA), Nutritional Status Assessment (NSA), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment (MNA).
    - Anthropometric studies: Weight, Height, Circumferences, Folds, Bioelectrical Impedance, DXA...
    - Biochemical studies (blood, urine, feces): measurements of health markers related to the area of nutrition (glucose metabolism parameters, curves for calculating the glycemic index, lipid metabolism, inflammation, oxidationa and hormonal biomarkers...)
    - Physical activity studies: through the use of validated questionnaires (IPAQ, MINNESOTA...).
    - Evaluate the use of sensors, control devices and monitoring support (blood glucose, weight, eating disorders, food photographs, physical activity, etc.).
    - Evaluate the use of specific nutrient modules, oral nutritional supplements and highly specialized artificial nutrition (enteral and parenteral).
    - Functional capacity studies: through dynamometry and validated questionnaires.
    - Sensory perception studies: through the use of validated questionnaires
    - Satiety control studies: using biochemical markers and handling of validated questionnaires
    - Quality of life studies: through the use of validated questionnaires.
      - Tolerance Studies: through the use of validated questionnaires.
      - Nutrigenetics and Metabolic Studies with our collaborating centers.
  - Production of scientific and technical report

2.7.15 Food, Nutrition and Health

- Development of computer applications for websites or mobile apps in the nutrition/food area.
- Individual nutritional status evaluations and proposals for individualized nutrition intervention programs.
- To contribute and design components for nutrition education strategies and programs

Equipment

- Absorciometría de rayos X de energía dual (DXA). Dual-energy x-ray absorptiometry (DXA)
- Impedancia Bioeléctrica (BIA) para la medida de composición corporal a través del dispositivo Inbody. Bioelectric Impedance System (BIA) for body composition measurement through Inbody device.
- Ecógrafo para el diagnóstico avanzado de alta resolución. Ultrasound machine for advanced high resolution diagnosis.
- Lipocalibres Holtain para medidas de pliegues corporales. Holtain Skinfold Calipers
- Balanzas sanitarias digitales TANITA. Tanita digital healthcare scales
- Cintas métricas reglamentadas para medidas de circunferencias. Executive Diameter Tape
- Calorimetría indirecta. Indirect calorimetry
- Acelerómetros. Accelerometers

Activity indicators

ARTICLES

1. *Castro EA, Carraça EV, Cupeiro R, López-Plaza B, Benito JP, González-Lamuño D and Peinado AB on behalf of the PRONAF Study Group. The effects of the type of exercise and physical activity on eating behavior and body composition in overweight and obese subjects. Nutrients 2020,12, 557; doi:10.3390/nu12020557.*
2. *López-Plaza B, Benito PJ, Bermejo LM, Peinado AB, Cupeiro R, Butragueño J, Rojo-Tirado MA, González-Lamuño D and Gómez-Candela C on behalf of the PRONAF Study Group. Strength plus endurance training and individualized diet reduce fat mass in overweight subjects: a randomized clinical trial. Int J Environ Res Public Health 2020, 17, 2596; doi:10.3390/ijerph17072596.*
3. *Santurino C, López-Plaza B, Fontecha J, Calvo MV, Bermejo LM, Gómez-Andrés D and Carmen Gómez-Candela. Consumption of goat cheese naturally rich in omega-3 and conjugated linoleic acid improves the cardiovascular and inflammatory biomarkers of overweight and obese subjects: a randomized controlled trial. Nutrients 2020, 12, 1315; doi:10.3390/nu12051315*
4. *Valero-Pérez M, Bermejo LM, López-Plaza B, Aguiló García M, Palma- Milla S and Gómez- Candela C. Regular consumption of lipigo® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program. Nutrients 2020, 12, 1960; doi:10.3390/nu12071960*
5. *Morato-Martínez M, López-Plaza B, Santurino C, Palma-Milla S and Gómez-Candela C. A dairy product to reconstitute enriched with bioactive nutrients stops bone loss in high-risk menopausal women without pharmacological treatment. Nutrients 2020, 12, 2203; doi:10.3390/nu12082203*
6. *García-Vázquez N, Palma Milla S, López-Plaza B, Valero-Pérez M, Morato-Martínez M y Gómez-Candela C. Comparación del método CONUT con la VGS y el VEN para la predicción de complicaciones, estancia hospitalaria, readmisiones y mortalidad. Nutr Hosp 2020;37(4):799- 806. http://dx.doi.org/10.20960/nh.03062.*
7. *Morato-Martínez M, Santurino C, López-Plaza B, Arcos-Castellanos L, Clavero-Fraile M, Valero-Pérez M, Palma-Milla S, Gómez-Candela C. A standardized, integral nutritional intervention and physical activity program reduces body weight in women newly diagnosed with breast cancer. Nutr Hosp. 2021 Apr 5. doi: 10.20960/nh.03409. Online ahead of print.*
8. *Morales D, Shetty S, López-Plaza B, Gómez-Candela C, Smidt H, Marín FR, Soler-Rivas C. Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan- enriched extract obtained from Lentinula edodes. Eur J Nutr 2021 Feb 12. doi: 10.1007/s00394-021-02504-4. Online ahead of print.*

BOOKS

Gómez Candela C, Palma Milla S, Morato Martínez M, Bruzos Calvo C, López Plaza B. I. Introducción a la Nutrición clínica. Nutrición artificial órgano específica. Universidad Nacional de Educación a Distancia. Madrid, 2021. P.13-52. ISBN: 978-84-362-7678-7.

EXTERNAL USERS

Food industry

1. AB Biotics, S.A.
2. Nutricia S.R.L.
3. Go Fruselva, S.L.
4. Persán Distribuciones Farmacéuticas S.R.L.
5. Adventia Pharma, S.L.
6. Asociación Nacional de Fabricantes de Conservas de Pescados y Mariscos y Centro Técnico Nacional de Conservación de Productos de la pesca (ANFACO-CECOPESCA).
7. Alga Energy S.A.

Pharmaceutical laboratories

1. Abbott Laboratories S.A
2. Baxter S.L.
3. B. Braun Medical S.A.
4. Nestlé España S.A.
5. Cantabria Lab Nutrición Médica S.L.
6. Nutricia S.R.L.
7. Persán Distribuciones Farmacéuticas S.R.L.

To implement clinical trials or epidemiological studies well designed in the area of human nutrition, in order to validate the activity and efficacy of bioactive compounds, nutrients, foods, dietary patterns or artificial nutrition, on different parameters related to the health promotion, the disease prevention or its therapeutic activity.

Introduction

Executive summary

Information Groups by Area


Associated Clinicians

2.7.16 Simulation Platform (CEASEC)

Objectives

The IdiPAZ/FIBHULP Simulation Centre offers professionals from various fields the following possibilities:

- Learning and training on the approach for patients in critical clinical conditions: cardiopulmonary resuscitation, shock of various origins, acute respiratory failure of various aetiologies, multiple trauma, arrhythmias, complicated births, difficult airways, safety, and leadership.
- Ongoing training of teams who treat patients in critical conditions: ICU, anaesthesia, emergency department, surgery.
- Learning and training on managing patients with technology-dependent conditions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, haemodialysis and hemofiltration and external ventricular assistance.
- Learning and training on managing technology for diagnostic and therapeutic use: echocardiography, abdominal ultrasonography, catheterisation, laparoscopic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy.
- Learning the use of invasive techniques: arterial and central venous cannulation, nasogastric and vesical catheterisation, suturing, thoracentesis, paracentesis, tracheostomy, nerve blocks.
- Learning to perform a correct medical history review and physical examination and communicating and contacting patients, using actors and advanced simulators.



Composition

Governing Council

Dr. Javier Cobas Gamallo
Dª. Ana Coloma Zapatero
Dra. Carlota Largo Aramburu
Dª Elena Martín de Castro
Dr. Juan Vázquez Estévez
Dª. Alicia Portas
Dr. Manuel Quintana Díaz
Dr. Pedro de la Oliva Senovilla
Dr. Ramón Cantero Cid
Dra. Ana Mª Sánchez Torres
Dra. Emilia Guash Arévalo
Dr. Esteban López de Sá y Areses
Dr. Ignacio Zapadiel Gutierrez
Dra. Esther Rey Cuevas
Dr. Juan José Ríos Blanco
Dra. Dolores Elorza

Chairman Governing Council

Dr. Manuel Quintana Díaz

Secretary Governing Council

Dª Ana Coloma Zapatero
Dª Estela Sánchez Simón

Contact

Dña. Irene Cuevas
irene.cuevas@salud.madrid.org
Phone: 91 207 71 54

Clinical Simulation Technician

Javier Rubio Bolívar

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.7.17 Tissue Engineering and 3D Printing Platform

The Tissue Engineering and 3D Printing Platform purpose is to promote the development of biomedical research and solutions based on tissue engineering and bioprinting and offer different services as 3D printing technologies, computer imaging, virtual planning and computer aided design to the professionals.

Research and activity areas of the platform are:

- Synthetic biology, bioprinting of tissues and organs → development of a skin model
- Establishment of a live organoid biobank from patients' samples
- Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Tissue engineering approaches to develop tissue models and organs
- Development of new medical devices (biomodels, surgical guides, prosthesis and implants) based on emerging technologies as 3D printing
- Computer imaging, virtual planning and 3D printing to plan surgeries

Composition

Director

Ramón Cantero Cid

Scientific advisor

Maria P. De Miguel González

Equipment

- Bioprinter Unit (V1 REGEMAT 3D) for thermoplastics, microextrusion, UV curing, temperature control and injection of cell laden biomaterials
- Fused deposition modelling (FDM) 3D printer for prototyping

Portfolio of services

- Bioprinting of meshes structures with or without cells
- 3D cell cultures
- Cell viability and proliferation assays to assess biocompatibility of reactives and materials
- Development of biofabrication processes
- Development of Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Computer imaging and tissue segmentation from TAC and MRI
- 3D virtual planning
- Computer Aided Design (CAD)
- 3D printing of biomodels, surgical guides, prosthesis and implants in polymers and metals
- Biomaterials processing and manufacturing
- Education and training in the areas of activities



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8 Scientific Production

2.8.1 Journal Analysis

The journals whose titles are in **bold type** belong to the first decile of their category

Journal	ISSN	Total of documents	Impact factor	Quartile
2020 Computing in Cardiology	2325-8861	1	not indexed	
A & A Practice	2325-7237	1	not indexed	
Academic Emergency Medicine	1069-6563	1	3,451	Q1
ACS Applied Nano Materials	2574-0970	1	5,097	Q2
ACS Infectious Diseases	2373-8227	1	5,084	Q1
ACS Omega	2470-1343	1	3,512	Q2
Acta Cytologica	0001-5547	1	2,319	Q3
Acta Neurochirurgica	0001-6268	1	2,216	Q3
Acta Obstetricia et Gynecologica Scandinavica	0001-6349	1	3,636	Q1
Acta Orthopaedica Belgica	0001-6462	1	0,5	Q4
Acta Otorrinolaringológica Española	0001-6519	2	not indexed	
Acta Paediatrica	0803-5253	2	2,299	Q2
Acta Pediátrica de México	0186-2391	1	not indexed	
Actas Dermo-Sifiliográficas	0001-7310	6	not indexed	
Actas Españolas de Psiquiatría	1139-9287	1	1,196	Q4
Actas Urológicas Españolas	0210-4806	12	0,994	Q4
Addiction	**0965-2140**	**1**	**6,526**	**Q1**
Advances in Therapy	0741-238X	4	3,845	Q2
Aging Cell	**1474-9718**	**1**	**9,304**	**Q1**
Aids	0269-9370	2	4,177	Q3
AIDS Research and Therapy	1742-6405	1	2,25	Q4
Aids Reviews	1139-6121	1	2,5	Q3
Alcoholism-Clinical and Experimental Research	0145-6008	1	3,455	Q3
Alimentary Pharmacology & Therapeutics	**0269-2813**	**4**	**8,171**	**Q1**
Allergologia et Immunopathologia	0301-0546	2	1,667	Q4



2.8.1 Journal Analysis

Allergy	**0105-4538**	**9**	**13,146**	**Q1**
American Heart Journal	0002-8703	1	4,479	Q2
American Journal of Cardiology	0002-9149	1	2,778	Q3
American Journal of Clinical Nutrition	0002-9165	2	7,045	Q1
American Journal of Critical Care	1062-3264	1	2,228	Q2
American Journal of Emergency Medicine	0735-6757	1	2,469	Q2
American Journal of Hematology	**0361-8609**	**1**	**10,047**	**Q1**
American Journal of Human Genetics	**0002-9297**	**4**	**11,025**	**Q1**
American Journal of Medical Genetics Part A	1552-4825	4	2,802	Q3
American Journal of Medicine	0002-9343	2	4,965	Q1
American Journal of Ophthalmology	**0002-9394**	**1**	**5,258**	**Q1**
American Journal of Physiology-Renal Physiology	1931-857X	1	3,377	Q2
American Journal of Surgical Pathology	**0147-5185**	**2**	**6,394**	**Q1**
American Journal of Transplantation	**1600-6135**	**3**	**8,086**	**Q1**
American Journal of Tropical Medicine and Hygiene	0002-9637	3	2,345	Q2
Anales de Pediatría	2341-2879	23	1,5	Q4
Analytical Chemistry	**0003-2700**	**1**	**6,986**	**Q1**
Andrologia	0303-4569	1	2,775	Q3
Angiogenesis	**0969-6970**	**1**	**9,596**	**Q1**
Angiología	0003-3170	2	not indexed	
Annals of Allergy Asthma & Immunology	1081-1206	2	6,347	Q1
Annals of Clinical and Translational Neurology	2328-9503	4	4,511	Q2
Annals of Emergency Medicine	**0196-0644**	**2**	**5,721**	**Q1**
Annals of Hematology	0939-5555	2	3,673	Q2
Annals of Internal Medicine	**0003-4819**	**1**	**25,391**	**Q1**
Annals of Medicine	0785-3890	1	4,709	Q1
Annals of Physical and Rehabilitation Medicine	**1877-0657**	**1**	**4,919**	**Q1**
Annals of Plastic Surgery	0148-7043	1	1,539	Q4
Annals of Surgical Oncology	1068-9265	1	5,344	Q2
Annals of the Rheumatic Diseases	**0003-4967**	**3**	**19,103**	**Q1**
Annals of Translational Medicine	2305-5839	1	3,932	Q3
Annals of Vascular Surgery	0890-5096	1	1,466	Q4
Antibodies	2073-4468	1	not indexed	
Antimicrobial Agents and Chemotherapy	0066-4804	1	5,191	Q1
Antioxidants	**2076-3921**	**9**	**6,312**	**Q1**
Antiviral Research	0166-3542	2	5,97	Q1
Antiviral Therapy	1359-6535	1	not indexed	
Archives of Biochemistry and Biophysics	0003-9861	1	4,013	Q2
Archives of Bone and Joint Surgery	2345-4644	5	not indexed	
Archives of Disease in Childhood	0003-9888	3	3,791	Q1
Archives of Gerontology and Geriatrics	0167-4943	1	3,25	Q3
Archives of Gynecology and Obstetrics	0932-0067	1	2,344	Q3
Archives of Pathology & Laboratory Medicine	0003-9985	1	5,534	Q1
Archivos Argentinos de Pediatría	0325-0075	1	0,635	Q4
Archivos de Bronconeumología	0300-2896	13	4,872	Q2
Archivos Españoles de Urología	0210-4806	20	0,436	Q4
Arteriosclerosis Thrombosis and Vascular Biology	1079-5642	1	8,311	Q1
Arthritis Care & Research	2151-464X	3	4,794	Q2
Arthritis Research & Therapy	1478-6354	1	5,156	Q2
Arthroscopy Techniques	2212-6287	1	not indexed	
Asia-Pacific Journal of Ophthalmology	2162-0989	1	2,827	Q2
Atherosclerosis	0021-9150	2	5,162	Q2
Australasian Journal of Dermatology	0004-8380	1	2,875	Q3
Autoimmunity Reviews	**1568-9972**	**3**	**9,754**	**Q1**
Biochemia Medica	1330-0962	1	2,313	Q3
Biochimica et Biophysica Acta-General Subjects	0304-4165	1	3,77	Q2
Biochimica et Biophysica Acta-Molecular Basis of Disease	0925-4439	2	5,187	Q1
Biochimica et Biophysica Acta-Reviews On Cancer	**0304-419X**	**1**	**10,68**	**Q1**
Biochimie	0300-9084	1	4,079	Q2
Bioinformatics	**1367-4803**	**1**	**6,937**	**Q1**
Biology of Blood and Marrow Transplantation	1083-8791	1	5,742	Q1
Biomaterials	**0142-9612**	**1**	**12,479**	**Q1**
Biomedicines	2227-9059	2	6,081	Q1
Biomolecules	2218-273X	2	4,879	Q2
BJU International	1464-4096	1	5,588	Q1
Blood	**0006-4971**	**1**	**22,113**	**Q1**
Blood Cancer Journal	**2044-5385**	**1**	**11,037**	**Q1**
Blood Coagulation & Fibrinolysis	0957-5235	2	1,276	Q4
Blood Reviews	0268-960X	1	8,25	Q1
BMC Cancer	1471-2407	1	4,43	Q2
BMC Geriatrics	1471-2318	1	3,921	Q1
BMC Health Services Research	1472-6963	2	2,655	Q3
BMC Infectious Diseases	1471-2334	1	3,09	Q3
BMC Medicine	**1741-7015**	**1**	**8,775**	**Q1**

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

BMC Musculoskeletal Disorders	1471-2474	1	2,362	Q2
BMC Nephrology	1471-2369	1	2,388	Q3
BMC Psychology	2050-7283	1	not indexed	
BMC Urology	1471-2490	1	2,264	Q3
BMJ Open	2044-6055	5	2,692	Q2
BMJ Paediatrics Open	2399-9772	2	not indexed	
Boletin de Pediatría	0214-2597	1	not indexed	
Bone Marrow Transplantation	0268-3369	1	5,483	Q1
Brain	**0006-8950**	**1**	**13,501**	**Q1**
Brain & Development	0387-7604	1	1,961	Q3
Brain Communications	2632-1297	1	not indexed	
Brain Sciences	2076-3425	1	3,394	Q3
Brazilian Journal of Physical Therapy	1413-3555	1	3,377	Q1
Breast Cancer Research and Treatment	0167-6806	1	4,872	Q2
British Journal of Cancer	0007-0920	1	7,64	Q1
British Journal of Dermatology	**0007-0963**	**2**	**9,302**	**Q1**
British Journal of Haematology	0007-1048	2	6,998	Q1
British Journal of Neurosurgery	0268-8697	1	1,596	Q4
British Journal of Nutrition	0007-1145	2	3,718	Q3
British Journal of Ophthalmology	0007-1161	1	4,638	Q1
British Journal of Oral & Maxillofacial Surgery	0266-4356	1	1,651	Q3
British Journal of Pharmacology	**0007-1188**	**2**	**8,739**	**Q1**
British Journal of Sports Medicine	**0306-3674**	**1**	**13,8**	**Q1**
British Journal of Surgery	**0007-1323**	**2**	**6,939**	**Q1**
Burns	0305-4179	3	2,744	Q3
Ca-A Cancer Journal for Clinicians	**0007-9235**	**1**	**508,702**	**Q1**
Cancer	0008-543X	1	6,86	Q1
Cancer Biology & Medicine	2095-3941	1	4,248	Q2
Cancer Cytopathology	1934-662X	1	5,284	Q1
Cancer Medicine	2045-7634	1	4,452	Q2
Cancer Research	**0008-5472**	**3**	**12,701**	**Q1**
Cancers	2072-6694	12	6,639	Q1
Carbohydrate Polymers	**0144-8617**	**1**	**9,381**	**Q1**
Cardiology	0008-6312	1	1,869	Q4
Cardiology Journal	1897-5593	2	2,737	Q3
Cardiovascular & Hematological Disorders Drug Targets	2212-4063	2	not indexed	
Cardiovascular Diabetology	**1475-2840**	**1**	**9,951**	**Q1**
Case Reports in Oncology	1662-6575	1	not indexed	
Case Reports in Pediatrics	2090-6803	1	not indexed	
Catheterization and Cardiovascular Interventions	1522-1946	2	2,692	Q3
Cell	**0092-8674**	**1**	**41,582**	**Q1**
Cell Calcium	0143-4160	2	6,817	Q1
Cell Reports	2211-1247	1	9,423	Q1
Cells	2073-4409	7	6,6	Q2
Cellular and Molecular Life Sciences	1420-682X	1	9,261	Q1
Cellular and Molecular Neurobiology	0272-4340	1	5,046	Q2
Central European Journal of Urology	2080-4806	4	not indexed	
Circulation	**0009-7322**	**2**	**29,69**	**Q1**
Circulation-Heart Failure	1941-3289	1	8,79	Q1
Cirugía Cardiovascular	1134-0096	1	not indexed	
Cirugía Española	0009-739X	5	1,653	Q3
Cirugía Pediátrica	2445-2807	2	not indexed	
Cirugía y Cirujanos	0009-7411	1	0,361	Q4
Clínica Chimica Acta	0009-8981	1	3,786	Q1
Clínica e Investigacion en Arteriosclerosis	0214-9168	1	not indexed	
Clinical & Translational Oncology	1699-048X	16	3,405	Q3
Clinical and Experimental Allergy	0954-7894	3	5,018	Q2
Clinical and Experimental Rheumatology	0392-856X	7	4,473	Q2
Clinical and Translational Allergy	2045-7022	1	5,871	Q2
Clinical Cancer Research	**1078-0432**	**1**	**12,531**	**Q1**
Clinical Case Reports	2050-0904	1	not indexed	
Clinical Chemistry	**0009-9147**	**2**	**8,327**	**Q1**
Clinical Chemistry and Laboratory Medicine	1434-6621	3	3,694	Q2
Clinical Drug Investigation	1173-2563	1	2,859	Q3
Clinical Epigenetics	1868-7075	1	6,551	Q1
Clinical Gastroenterology and Hepatology	**1542-3565**	**1**	**11,382**	**Q1**
Clinical Genetics	0009-9163	3	4,438	Q2
Clinical Genitourinary Cancer	1558-7673	1	2,872	Q3
Clinical Immunology	1521-6616	3	3,969	Q3
Clinical Infectious Diseases	**1058-4838**	**1**	**9,079**	**Q1**
Clinical Journal of the American Society of Nephrology	**1555-9041**	**1**	**8,237**	**Q1**
Clinical Kidney Journal	2048-8505	3	4,452	Q1
Clinical Medicine	1470-2118	1	2,659	Q2
Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders	1179-5441	1	not indexed	
Clinical Microbiology and Infection	**1198-743X**	**3**	**8,067**	**Q1**
Clinical Nuclear Medicine	**0363-9762**	**1**	**7,794**	**Q1**
Clinical Nutrition	**0261-5614**	**6**	**7,324**	**Q1**

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

Clinical Ophthalmology	1177-5483	1	not indexed	
Clinical Research in Cardiology	1861-0684	1	5,46	Q1
Clinical Rheumatology	0770-3198	1	2,98	Q3
Clinical Science	0143-5221	1	6,124	Q1
Clinical Transplantation	0902-0063	1	2,863	Q2
Clinicoeconomics and Outcomes Research	1178-6981	1	not indexed	
Clinics in Plastic Surgery	0094-1298	1	2,017	Q3
Cochlear Implants International	1754-7628	1	not indexed	
Colorectal Disease	1462-8910	3	3,788	Q1
Communications Biology	**2399-3642**	**2**	**6,268**	**Q1**
Contact Dermatitis	**0105-1873**	**1**	**6,6**	**Q1**
Contraception	0010-7824	1	3,375	Q2
Critical Care	1466-609X	4	9,097	Q1
Critical Care Medicine	0090-3493	1	7,598	Q1
Cureus	2168-8184	1	not indexed	
Current Medical Research and Opinion	0300-7995	1	2,58	Q2
Current Medicinal Chemistry	0929-8673	1	4,53	Q2
Current Oncology Reports	1523-3790	1	5,075	Q2
Current Opinion in Anesthesiology	0952-7907	3	2,706	Q3
Current Opinion in Organ Transplantation	1087-2418	1	2,64	Q3
Current Opinion in Pulmonary Medicine	1070-5287	1	3,155	Q3
Current Opinion in Urology	0963-0643	1	2,309	Q3
Current Pharmaceutical Design	1381-6128	2	3,116	Q3
Current Rheumatology Reports	1523-3774	1	4,592	Q2
Current Topics in Behavioral Neurosciences	1866-3370	1	not indexed	
Cytokine	1043-4666	1	3,861	Q3
Cytopathology	0956-5507	2	2,073	Q3
Dermatologic Surgery	1076-0512	1	3,398	Q2
Diabetes Research and Clinical Practice	0168-8227	1	5,602	Q1
Diagnostic Cytopathology	8755-1039	2	1,582	Q4
Disaster Medicine and Public Health Preparedness	1938-744X	1	1,385	Q4
Disease Models & Mechanisms	1754-8403	1	5,758	Q2
Ear and Hearing	**0196-0202**	**1**	**3,57**	**Q1**
Ebiomedicine	2352-3964	2	8,143	Q1
Ecancermedicalscience	1754-6605	1	not indexed	
Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques	0742-2822	2	1,724	Q4
Efort Open Reviews	2396-7544	6	4,618	Q1
EJC Supplements	**1359-6349**	**2**	**9,386**	**Q1**
Embo Molecular Medicine	**1757-4676**	**1**	**12,137**	**Q1**
Emergencias	1137-6821	2	3,881	Q1
Emergency Radiology	1070-3004	1	not indexed	
Emerging Infectious Diseases	**1080-6040**	**1**	**6,883**	**Q1**
Endocrine	1355-008X	1	3,633	Q3
Endocrine Connections	2049-3614	1	3,335	Q3
Endocrinologia Diabetes y Nutricion	2530-0180	5	1,417	Q4
Enfermedades Infecciosas y Microbiología Clínica	0213-005X	11	1,731	Q4
Enfermeria Intensiva	1130-2399	1	not indexed	
Environment International	**0160-4120**	**2**	**9,621**	**Q1**
Environmental Pollution	**0269-7491**	**1**	**8,071**	**Q1**
Environmental Research	**0013-9351**	**1**	**6,498**	**Q1**
Epidemiology	1044-3983	1	4,822	Q1
Epigenomics	1750-1911	1	4,778	Q2
Epilepsia	0013-9580	2	5,864	Q1
ESC Heart Failure	2055-5822	1	4,411	Q2
Eurointervention	1774-024X	3	6,534	Q1
Europace	1099-5129	4	5,214	Q2
European Annals of Allergy and Clinical Immunology	1764-1489	2	not indexed	
European Food Research and Technology	1438-2377	1	2,998	Q2
European Heart Journal	**0195-668X**	**6**	**29,983**	**Q1**
European Heart Journal-Acute Cardiovascular Care	2048-8726	1	4,696	Q2
European Heart Journal-Cardiovascular Imaging	**2047-2404**	**3**	**6,875**	**Q1**
European Heart Journal-Case Reports	2514-2119	1	not indexed	
European Journal of Anaesthesiology	0265-0215	1	4,33	Q2
European Journal of Applied Physiology	1439-6319	1	3,078	Q2
European Journal of Cancer	0959-8049	3	9,162	Q1
European Journal of Clinical Investigation	0014-2972	1	4,686	Q1
European Journal of Clinical Microbiology & Infectious Diseases	0934-9723	2	3,267	Q3
European Journal of Gastroenterology & Hepatology	0954-691X	1	2,566	Q4
European Journal of Haematology	0902-4441	1	2,997	Q3
European Journal of Heart Failure	**1388-9842**	**6**	**15,534**	**Q1**
European Journal of Human Genetics	1018-4813	1	4,246	Q2
European Journal of Internal Medicine	0953-6205	4	4,487	Q1
European Journal of Lipid Science and Technology	1438-7697	1	2,679	Q3

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

European Journal of Medical Genetics	1769-7212	2	2,708	Q3
European Journal of Medicinal Chemistry	**0223-5234**	**1**	**6,514**	**Q1**
European Journal of Neurology	**1351-5101**	**2**	**6,089**	**Q1**
European Journal of Nutrition	1436-6207	1	5,614	Q1
European Journal of Obstetrics & Gynecology and Reproductive Biology	0301-2115	1	2,435	Q3
European Journal of Pain	1090-3801	2	3,931	Q2
European Journal of Pediatric Surgery	0939-7248	4	2,191	Q3
European Journal of Pediatrics	0340-6199	1	3,183	Q1
European Journal of Physical and Rehabilitation Medicine	1973-9087	1	2,874	Q2
European Journal of Preventive Cardiology	2047-4873	1	7,804	Q1
European Journal of Radiology	0720-048X	2	3,528	Q2
European Psychiatry	0924-9338	1	5,361	Q1
European Public Law	1354-3725	1	not indexed	
European Radiology	0938-7994	1	5,315	Q1
European Respiratory Journal	**0903-1936**	**1**	**16,671**	**Q1**
European Respiratory Review	0905-9180	1	8,839	Q1
European Spine Journal	0940-6719	5	3,134	Q2
European Stroke Journal	2396-9873	1	not indexed	
European Urology	**0302-2838**	**11**	**20,096**	**Q1**
European Urology Focus	2405-4569	2	5,996	Q1
European Urology Oncology	**2588-9311**	**3**	**7,479**	**Q1**
Eurosurveillance	**1560-7917**	**4**	**6,307**	**Q1**
Experimental Gerontology	0531-5565	1	4,032	Q2
Experimental Hematology & Oncology	2162-3619	1	5,133	Q2
Expert Opinion On Drug Discovery	1746-0441	1	6,098	Q1
Expert Review of Hematology	1747-4086	5	2,929	Q3
Expert Review of Molecular Diagnostics	1473-7159	1	5,225	Q1
Eye	0950-222X	1	3,775	Q1
Farmacia Hospitalaria	1130-6343	2	not indexed	
Faseb Journal	0892-6638	3	5,191	Q1
Febs Journal	1742-464X	1	5,542	Q1
Food Control	0956-7135	1	5,548	Q1
Foods	2304-8158	1	4,35	Q2
Frontiers in Bioengineering and Biotechnology	2296-4185	2	5,89	Q1
Frontiers in Cardiovascular Medicine	2297-055X	1	6,05	Q1
Frontiers in Cellular and Infection Microbiology	2235-2988	1	5,293	Q1
Frontiers in Cellular Neuroscience	1662-5102	1	5,505	Q1
Frontiers in Endocrinology	1664-2392	1	5,555	Q1
Frontiers in Genetics	1664-8021	2	4,599	Q2
Frontiers in Immunology	1664-3224	7	7,561	Q1
Frontiers in Medicine	2296-858X	2	5,091	Q1
Frontiers in Microbiology	1664-302X	2	5,64	Q1
Frontiers in Neuroanatomy	1662-5129	1	3,856	Q2
Frontiers in Neurology	1664-2295	4	4,003	Q2
Frontiers in Neuroscience	1662-453X	1	4,677	Q2
Frontiers in Nutrition	2296-861X	1	6,576	Q1
Frontiers in Oncology	2234-943X	1	6,244	Q2
Frontiers in Pediatrics	2296-2360	6	3,418	Q1
Frontiers in Pharmacology	1663-9812	4	5,81	Q1
Frontiers in Physiology	1664-042X	4	4,566	Q1
Frontiers in Psychiatry	1664-0640	1	4,157	Q2
Future Cardiology	1479-6678	3	not indexed	
Gaceta Sanitaría	0213-9111	3	2,139	Q3
Gastroenterología y Hepatología	0210-5705	3	2,102	Q4
Gastrointestinal Endoscopy	0016-5107	1	9,427	Q1
General Hospital Psychiatry	0163-8343	1	3,238	Q2
Genes	2073-4425	4	4,096	Q2
Genetics in Medicine	**1098-3600**	**1**	**8,822**	**Q1**
Gland Surgery	2227-684X	1	2,953	Q2
Gut Pathogens	1757-4749	1	4,181	Q2
Gynecologic and Obstetric Investigation	0378-7346	1	2,031	Q3
Gynecologic Oncology	**0090-8258**	**3**	**5,482**	**Q1**
Gynecology and Minimally Invasive Therapy	2213-3070	1	not indexed	
Haematologica	0390-6078	2	9,941	Q1
Haemophilia	1351-8216	7	4,287	Q1
Headache	0017-8748	1	5,887	Q1
Heart	1355-6037	1	5,994	Q1
Heliyon	2405-8440	4	not indexed	
Hepatology	**0270-9139**	**3**	**17,425**	**Q1**
Hip International	1120-7000	2	2,135	Q3
HIV Medicine	1464-2662	3	3,18	Q3
Hormone Research in Paediatrics	1663-2818	1	2,852	Q2
Hormones and Behavior	0018-506X	1	3,587	Q1
Hospital Practice (1995)	2154-8331	1	not indexed	
HSS Journal	1556-3316	1	not indexed	
Human & Experimental Toxicology	0960-3271	1	2,903	Q3
Human Genetics	0340-6717	1	4,132	Q2

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

Human Molecular Genetics	0964-6906	1	6,15	Q1
Human Mutation	1059-7794	5	4,878	Q2
Human Vaccines & Immunotherapeutics	2164-5515	1	3,452	Q2
Hypertension Research	0916-9636	1	3,872	Q2
IJC Heart & Vasculature	2352-9067	1	not indexed	
Immunology and Cell Biology	0818-9641	1	5,126	Q2
Immunology Letters	0165-2478	1	3,685	Q3
Indian Journal of Dermatology Venereology & Leprology	0378-6323	1	2,545	Q3
Indian Journal of Orthopaedics	0019-5413	1	1,251	Q4
Infection and Drug Resistance	1178-6973	1	4,003	Q2
Infectious Diseases	2374-4235	1	3,404	Q3
Infectious Diseases in Clinical Practice	1056-9103	1	not indexed	
Infectious Diseases of Poverty	**2095-5162**	**2**	**4,52**	**Q1**
Inflammatory Bowel Diseases	1078-0998	2	5,325	Q2
Injury-International Journal of The Care of The Injured	0020-1383	3	2,586	Q2
Intensive Care Medicine	**0342-4642**	**2**	**17,44**	**Q1**
International Brazilian Journal of Urology	1677-5538	1	1,541	Q4
International Journal of Audiology	1499-2027	1	2,117	Q2
International Journal of Biological Sciences	1449-2288	1	6,58	Q1
International Journal of Cancer	0020-7136	1	7,396	Q1
International Journal of Cardiology	0167-5273	1	4,164	Q2
International Journal of Clinical Practice	1368-5031	1	2,503	Q2
International Journal of Dermatology	0011-9059	1	2,736	Q3
International Journal of Environmental Research and Public Health	1660-4601	6	3,39	Q1
International Journal of Epidemiology	**0300-5771**	**2**	**7,196**	**Q1**
International Journal of Gynecological Cancer	1048-891X	5	3,437	Q2
International Journal of Infectious Diseases	1201-9712	3	3,623	Q2
International Journal of Medical Sciences	1449-1907	1	3,738	Q2
International Journal of Molecular Sciences	1422-0067	11	5,923	Q1
International Journal of Oncology	1019-6439	2	5,65	Q2
International Journal of Ophthalmology	2222-3959	1	1,779	Q4
International Journal of STD & AIDS	0956-4624	1	1,359	Q4
International Journal of Surgery	**1743-9191**	**6**	**6,071**	**Q1**
International Journal of Surgery Protocols	2468-3574	1	not indexed	
International Journal of Tuberculosis and Lung Disease	1027-3719	1	2,373	Q4
International Journal of Urology	0919-8172	1	3,369	Q2
International Journal of Vascular Medicine	2090-2824	1	not indexed	
Investigative Ophthalmology & Visual Science	0146-0404	1	4,799	Q1
JAAD Case Reports	2352-5126	1	not indexed	
JACC-Basic to Translational Science	2452-302X	1	8,648	Q1
JAIDS-Journal of Acquired Immune Deficiency Syndromes	1525-4135	2	3,731	Q2
JAMA Cardiology	**2380-6583**	**1**	**14,676**	**Q1**
JAMA Oncology	**2374-2437**	**2**	**31,777**	**Q1**
JAMA Surgery	**2168-6254**	**1**	**14,766**	**Q1**
Jama-Journal of The American Medical Association	**0098-7484**	**2**	**56,272**	**Q1**
JBJS Case Connector	2160-3251	1	not indexed	
JCO Global Oncology	2687-8941	1	not indexed	
JIMD Reports	2192-8304	1	not indexed	
Journal de Mycologie Medicale	1156-5233	1	2,391	Q4
Journal Der Deutschen Dermatologischen Gesellschaft	1610-0379	3	5,584	Q1
Journal for Immunotherapy of Cancer	**2051-1426**	**1**	**13,751**	**Q1**
Journal of Advanced Research	2090-1232	1	10,479	Q1
Journal of Affective Disorders	0165-0327	1	4,839	Q2
Journal of Aging and Physical Activity	1063-8652	1	1,961	Q3
Journal of Allergy and Clinical Immunology	**0091-6749**	**2**	**10,793**	**Q1**
Journal of Allergy and Clinical Immunology-In Practice	2213-2198	8	8,861	Q1
Journal of Alzheimers Disease	1387-2877	1	4,472	Q2
Journal of Antimicrobial Chemotherapy	0305-7453	9	5,79	Q1
Journal of Arrhythmia	1880-4276	1	not indexed	
Journal of Asthma and Allergy	1178-6965	3	4,258	Q2
Journal of Biological Chemistry	0021-9258	1	5,157	Q1
Journal of Biological Regulators and Homeostatic Agents	0393-974X	1	1,711	Q4
Journal of Cardiovascular Pharmacology and Therapeutics	1074-2484	1	2,457	Q3
Journal of Cardiovascular Translational Research	1937-5387	1	4,132	Q2
Journal of Clinical Endocrinology & Metabolism	0021-972X	3	5,958	Q1
Journal of Clinical Immunology	0271-9142	1	8,317	Q1
Journal of Clinical Medicine	2077-0383	25	4,241	Q1
Journal of Clinical Psychiatry	0160-6689	1	4,384	Q1
Journal of Clinical Virology	1386-6532	1	3,168	Q3

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

Journal of Comparative Effectiveness Research	2042-6305	1	1,744	Q4
Journal of Critical Care	0883-9441	1	3,425	Q2
Journal of Crohns & Colitis	1873-9946	1	9,071	Q1
Journal of Cystic Fibrosis	1569-1993	1	5,482	Q1
Journal of Dermatological Science	0923-1811	1	4,563	Q1
Journal of Dermatology	0385-2407	1	4,005	Q2
Journal of Drug Assessment	1369-9474	1	not indexed	
Journal of Emergency Medicine	0736-4679	2	1,484	Q3
Journal of Endocrinology	0022-0795	1	4,286	Q2
Journal of Endourology	0892-7790	1	2,942	Q2
Journal of Epidemiology and Community Health	0143-005X	1	3,71	Q1
Journal of Family & Reproductive Health	1735-8949	1	not indexed	
Journal of Functional Foods	1756-4646	1	4,451	Q1
Journal of Gastroenterology and Hepatology	0815-9319	1	4,029	Q2
Journal of Global Health	2047-2978	1	4,413	Q1
Journal of Headache and Pain	1129-2369	1	7,277	Q1
Journal of Heart and Lung Transplantation	**1053-2498**	**1**	**10,247**	**Q1**
Journal of Hematology & Oncology	**1756-8722**	**2**	**17,388**	**Q1**
Journal of Hepatology	**1600-0641**	**5**	**25,083**	**Q1**
Journal of Hospital Infection	0195-6701	2	3,926	Q2
Journal of Human Genetics	1434-5161	1	3,172	Q3
Journal of Human Lactation	0890-3344	1	2,219	Q2
Journal of Hypertension	0263-6352	2	4,844	Q2
Journal of Immunology	0022-1767	1	5,422	Q2
Journal of Infection	0163-4453	4	6,072	Q1
Journal of Infection and Public Health	1876-0341	1	3,718	Q2
Journal of Infectious Diseases	0022-1899	1	5,226	Q1
Journal of Intellectual Disability Research	0964-2633	1	2,424	Q2
Journal of Invasive Cardiology	1042-3931	4	2,022	Q3
Journal of Investigational Allergology and Clinical Immunology	1018-9068	10	4,333	Q2
Journal of Investigative Dermatology	**0022-202X**	**1**	**8,551**	**Q1**
Journal of Manipulative and Physiological Therapeutics	0161-4754	1	1,437	Q3
Journal of Maternal-Fetal & Neonatal Medicine	1476-7058	2	2,398	Q3
Journal of Medical Genetics	0022-2593	1	6,318	Q1
Journal of Medical Internet Research	**1438-8871**	**1**	**5,428**	**Q1**
Journal of Neonatal Nursing	1355-1841	1	not indexed	
Journal of Neural Engineering	1741-2560	1	5,379	Q1
Journal of Neuroengineering and Rehabilitation	**1743-0003**	**1**	**4,262**	**Q1**
Journal of Neurointerventional Surgery	**1759-8478**	**1**	**5,836**	**Q1**
Journal of Neurology	0340-5354	3	4,849	Q1
Journal of Neuroscience Methods	0165-0270	1	2,39	Q3
Journal of Neurosurgery-Pediatrics	1933-0707	1	2,375	Q3
Journal of Neurosurgery-Spine	1547-5654	1	3,602	Q1
Journal of Nutrition	0022-3166	2	4,798	Q2
Journal of Nutrition Health & Aging	1279-7707	1	4,075	Q2
Journal of Obstetrics and Gynaecology Research	1341-8076	1	1,73	Q4
Journal of Ophthalmology	2090-004X	1	1,909	Q3
Journal of Oral Rehabilitation	0305-182X	2	3,837	Q1
Journal of Parenteral and Enteral Nutrition	0148-6071	3	4,016	Q2
Journal of Parkinsons Disease	1877-7171	1	5,568	Q1
Journal of Pathology	**0022-3417**	**1**	**7,996**	**Q1**
Journal of Pediatric Gastroenterology and Nutrition	0277-2116	3	2,839	Q2
Journal of Pediatric Genetics	2146-4596	1	not indexed	
Journal of Pediatric Ophthalmology & Strabismus	0191-3913	1	1,402	Q4
Journal of Pediatric Orthopaedics	0271-6798	1	2,324	Q2
Journal of Pediatric Surgery	0022-3468	2	2,545	Q2
Journal of Pediatric Urology	1477-5131	1	1,83	Q3
Journal of Pediatrics	**0022-3476**	**1**	**4,406**	**Q1**
Journal of Perinatal Medicine	0300-5577	1	1,901	Q3
Journal of Physical Activity & Health	1543-3080	1	2,592	Q2
Journal of Pineal Research	**0742-3098**	**1**	**13,007**	**Q1**
Journal of Proteomics	1874-3919	1	4,044	Q2
Journal of Rheumatology	0315-162X	1	4,666	Q2
Journal of Sexual Medicine	1743-6095	1	3,802	Q2
Journal of Shoulder and Elbow Surgery	1058-2746	1	3,019	Q2
Journal of Sleep Research	0962-1105	1	3,981	Q2
Journal of Stroke	2287-6391	1	6,967	Q1
Journal of Surgical Case Reports	2042-8812	1	not indexed	
Journal of Surgical Research	0022-4804	1	2,192	Q3
Journal of The American Academy of Dermatology	**0190-9622**	**5**	**11,527**	**Q1**

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.8.1 Journal Analysis

Journal of the American College of Cardiology	**0735-1097**	**4**	**24,094**	**Q1**
Journal of The American Heart Association	2047-9980	2	5,501	Q1
Journal of the American Medical Directors Association	1525-8610	2	4,669	Q2
Journal of The Brazilian Chemical Society	0103-5053	1	1,838	Q3
Journal of The European Academy of Dermatology and Venereology	0926-9959	5	6,166	Q1
Journal of The Franklin Institute-Engineering and Applied Mathematics	0016-0032	1	4,504	Q1
Journal of The International Aids Society	1758-2652	1	5,396	Q1
Journal of the Neurological Sciences	1878-5883	1	3,181	Q3
Journal of The Pediatric Infectious Diseases Society	2048-7193	1	3,164	Q1
Journal of The Saudi Heart Association	1016-7315	1	not indexed	
Journal of Thrombosis and Haemostasis	1538-7933	1	5,824	Q1
Journal of Translational Medicine	1479-5876	1	5,531	Q2
Journal of Travel Medicine	**1195-1982**	**4**	**8,49**	**Q1**
Journal of Urology	0022-5347	1	7,45	Q1
Journal of Vascular Surgery-Venous and Lymphatic Disorders	2213-333X	3	2,859	Q2
Journal of Viral Hepatitis	1352-0504	2	3,728	Q2
Journals of Gerontology Series A-Biological Sciences and Medical Sciences	**1079-5006**	**2**	**6,053**	**Q1**
Kardiologia Polska	0022-9032	1	3,108	Q2
Kidney International	**0085-2538**	**1**	**10,612**	**Q1**
Kidney International Reports	2468-0249	1	4,164	Q1
Knee Surgery Sports Traumatology Arthroscopy	0942-2056	2	4,342	Q1
Lancet Child & Adolescent Health	**2352-4642**	**1**	**11,288**	**Q1**
Lancet Haematology	**2352-3026**	**3**	**18,959**	**Q1**
Lancet HIV	**2352-3018**	**3**	**12,767**	**Q1**
Lancet Infectious Diseases	**1473-3099**	**2**	**25,071**	**Q1**
Lancet Neurology	**1474-4422**	**1**	**44,182**	**Q1**
Lancet Oncology	**1470-2045**	**2**	**41,316**	**Q1**
Lancet Public Health	**2468-2667**	**1**	**21,648**	**Q1**
Lancet Respiratory Medicine	**2213-2600**	**3**	**30,7**	**Q1**
Leukemia	**0887-6924**	**1**	**11,528**	**Q1**
Liver International	1478-3223	1	5,828	Q2
Materials Chemistry and Physics	0254-0584	1	4,094	Q2
Maturitas	0378-5122	1	4,342	Q1
Med	2666-6340	1	not indexed	
Medical Microbiology and Immunology	0300-8584	1	3,402	Q3
Medical Mycology	**1369-3786**	**1**	**4,076**	**Q1**
Medicina Clínica	0025-7753	17	1,725	Q3
Medicina de Familia-Semergen	1138-3593	9	not indexed	
Medicina Intensiva	0210-5691	8	2,491	Q3
Medicina Oral Patologia Oral y Cirugía Bucal	1698-6946	2	2,407	Q3
Medicina-Buenos Aires	0025-7680	1	0,653	Q4
Medicine	0025-7974	3	1,889	Q3
Methods in Molecular Biology (Clifton, N.J.)	1940-6029	1	not indexed	
Methodsx	2215-0161	1	not indexed	
Microbial Drug Resistence	1076-6294	1	3,431	Q3
Minerva Anestesiologica	0375-9393	2	3,051	Q3
Minerva Urológica e Nefrológica	0393-2249	5	3,72	Q2
Minimally Invasive Therapy & Allied Technologies	1364-5706	1	2,442	Q2
Modern Pathology	**0893-3952**	**3**	**7,842**	**Q1**
Molecular & Cellular Proteomics	1535-9476	1	5,911	Q1
Molecular Biology Reports	0301-4851	2	2,316	Q4
Molecular Genetics & Genomic Medicine	2324-9269	1	2,183	Q3
Molecules	1420-3049	1	4,411	Q2
Multiple Sclerosis and Related Disorders	2211-0348	1	4,339	Q2
Mycoses	0933-7407	1	4,377	Q1
Nanomedicine	1743-5889	1	5,307	Q1
Nature	**0028-0836**	**1**	**49,962**	**Q1**
Nature Communications	**2041-1723**	**1**	**14,919**	**Q1**
Nature Ecology & Evolution	**2397-334X**	**1**	**15,46**	**Q1**
Nature Medicine	**1078-8956**	**2**	**53,44**	**Q1**
Nature Protocols	**1754-2189**	**1**	**13,491**	**Q1**
Nature Reviews Molecular Cell Biology	**1471-0072**	**1**	**94,444**	**Q1**
Nefrología	0211-6995	3	2,033	Q3
Nephrology Dialysis Transplantation	0931-0509	1	5,992	Q1
Neurobiology of Aging	0197-4580	1	4,763	Q2
Neurocirugía	1130-1473	2	0,553	Q4
Neurología	0213-4853	7	3,109	Q3
Neurological Sciences	1590-1874	1	3,307	Q2
Neurology	**0028-3878**	**1**	**9,91**	**Q1**
Neurology-Neuroimmunology & Neuroinflammation	**2332-7812**	**1**	**8,485**	**Q1**
Neuro-Oncology Advances	2632-2498	1	not indexed	
Neurourology and Urodynamics	0733-2467	1	2,696	Q3
New England Journal of Medicine	**0028-4793**	**5**	**91,245**	**Q1**

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.8.1 Journal Analysis

Nucleic Acids Research	**0305-1048**	**1**	**16,971**	**Q1**
Nucleosides Nucleotides & Nucleic Acids	1525-7770	1	1,381	Q4
Nutrición Clínica y Dietética Hospitalaria	0211-6057	1	not indexed	
Nutrición Hospitalaria	0212-1611	4	1,057	Q4
Nutrients	2072-6643	13	5,717	Q1
Obesity	1930-7381	1	5,002	Q1
Obesity Surgery	0960-8923	1	4,129	Q1
Oncoimmunology	2162-402X	1	8,11	Q1
Oncologist	1083-7159	3	not indexed	
Open Forum Infectious Diseases	2328-8957	3	3,835	Q3
Ophthalmologica	0030-3755	1	3,25	Q2
Oral Oncology	**1368-8375**	**1**	**5,337**	**Q1**
Orphanet Journal of Rare Diseases	1750-1172	7	4,123	Q2
Osteoporosis International	0937-941X	2	4,507	Q2
Otology & Neurotology	1531-7129	1	2,311	Q3
Oxidative Medicine and Cellular Longevity	1942-0900	1	6,543	Q1
Pain Medicine	1526-2375	5	3,75	Q2
Pain Physician	1533-3159	1	4,965	Q1
Pain Practice	1530-7085	1	3,183	Q3
Pancreatology	1424-3903	1	3,996	Q2
Pathogens	2076-0817	1	3,492	Q2
Pathogens and Disease	2049-632X	1	3,166	Q3
Pathogens and Global Health	2047-7724	1	2,894	Q2
Pathology & Oncology Research	1219-4956	1	3,201	Q2
Pediatric Allergy Immunology and Pulmonology	2151-321X	1	1,349	Q4
Pediatric Blood & Cancer	1545-5009	5	3,167	Q1
Pediatric Critical Care Medicine	1529-7535	1	3,624	Q1
Pediatric Dermatology	0736-8046	6	1,588	Q3
Pediatric Infectious Disease Journal	0891-3668	6	2,129	Q3
Pediatric Nephrology	0931-041X	1	3,714	Q1
Pediatric Pulmonology	8755-6863	2	3,039	Q2
Pediatric Research	0031-3998	7	3,756	Q1
Pediatric Transplantation	1397-3142	2	1,502	Q4
PEERJ	2167-8359	1	2,984	Q2
Permanente Journal	1552-5775	1	not indexed	
Pharmaceutics	1999-4923	2	6,321	Q1
Pharmacogenomics	1462-2416	1	2,533	Q3
Pharmacogenomics Journal	1470-269X	1	3,55	Q2
Pharmacological Research	**1043-6618**	**1**	**7,658**	**Q1**
Pharmacological Reviews	**0031-6997**	**1**	**25,468**	**Q1**
Physica Medica-European Journal of Medical Physics	1120-1797	1	1,316	Q3
Physical Therapy	0031-9023	2	not indexed	
Physiological Reports	2051-817X	1	not indexed	
Physiology & Behavior	0031-9384	1	1,04	Q2
Physiotherapy Theory and Practice	0959-3985	1	2,279	Q2
Pituitary	1386-341X	1	4,107	Q2
Plastic and Reconstructive Surgery	0032-1052	3	4,73	Q1
Plos Medicine	**1549-1277**	**1**	**11,069**	**Q1**
Plos Neglected Tropical Diseases	1935-2735	1	4,411	Q1
Plos One	1932-6203	13	3,24	Q2
Point of Care	1533-029X	1	not indexed	
Polymers	2073-4360	1	4,329	Q1
Practical Laboratory Medicine	2352-5517	1	not indexed	
Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health	2210-7789	1	2,899	Q2
Proceedings of The National Academy of Sciences of The United States of America	0027-8424	1	11,205	Q1
Progres en Urologie	1166-7087	1	0,915	Q4
Progress in Cardiovascular Diseases	0033-0620	1	8,194	Q1
Prostaglandins & Other Lipid Mediators	1098-8823	1	3,072	Q3
Psychiatry Research	0165-1781	1	3,222	Q3
Public Health Nutrition	1368-9800	1	4,022	Q2
Quality of Life Research	0962-9343	1	4,147	Q1
Radiation Physics and Chemistry	**0969-806X**	**1**	**2,858**	**Q1**
Radiología	0033-8338	1	not indexed	
Rational Pharmacotherapy in Cardiology	1819-6446	1	not indexed	
Redox Biology	**2213-2317**	**3**	**11,799**	**Q1**
Rehabilitacion	1578-3278	1	not indexed	
Reproductive Biomedicine Online	1472-6483	1	3,828	Q1
Reproductive Toxicology	0890-6238	1	3,143	Q3
Respiratory Medicine	0954-6111	2	3,415	Q2
Respiratory Research	1465-993X	1	5,631	Q1
Reumatologia Clínica	1699-258X	5	not indexed	
Revista Alergia México (Tecamachalco, Puebla, Mexico : 1993)	0002-5151	1	not indexed	
Revista Chilena de Infectología	0716-1018	1	0,52	Q4
Revista Chilena de Pediatría-Chile	0370-4106	1	not indexed	
Revista Clínica Española	0014-2565	9	1,556	Q3
Revista Colombiana de Cancerología	0123-9015	1	not indexed	
Revista de Neurología	0210-0010	4	0,87	Q4

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.8.1 Journal Analysis

Revista de Osteoporosis y Metabolismo Mineral	1889-836X	1	not indexed	
Revista de Psicoterapia	1130-5142	1	not indexed	
Revista de Psiquiatría y Salud Mental	1888-9891	2	3,318	Q2
Revista Española de Anestesiología y Reanimación	0034-9356	7	not indexed	
Revista Española de Cardiología	0014-2565	26	4,753	Q2
Revista Española de Cirugía Oral y Maxilofacial	2173-9161	4	not indexed	
Revista Española de Comunicacion en Salud	1989-9882	1	not indexed	
Revista Española de Enfermedades Digestivas	1130-0108	7	2,086	Q4
Revista Española de Geriatría y Gerontología	1578-1747	4	not indexed	
Revista Española de Medicina Nuclear e Imagen Molecular	2253-654X	1	1,359	Q4
Revista Española de Patología	1988-561X	2	not indexed	
Revista Española de Quimioterapia	0214-3429	5	1,553	Q4
Revista Española de Salud Pública	1135-5727	4	0,756	Q4
Revista Internacional de Andrología	1698-031X	1	1,063	Q4
Rheumatology	1462-0324	7	7,58	Q1
Rheumatology and Therapy	2198-6576	1	3,494	Q3
RMD Open	2056-5933	2	5,117	Q2
RNA	1355-8382	1	4,942	Q2
Scandinavian Journal of Medicine & Science in Sports	0905-7188	3	4,221	Q1
Scientific Reports	2045-2322	25	4,379	Q1
Seminars in Arthritis and Rheumatism	0049-0172	5	5,532	Q1
Seminars in Neurology	0271-8235	1	3,42	Q2
Seminars in Pediatric Surgery	1055-8586	2	2,754	Q2
Shoulder & Elbow	1758-5732	1	not indexed	
Skin Research and Technology	0909-752X	1	2,365	Q3
Sleep	0161-8105	1	5,849	Q1
Sleep Medicine Reviews	**1087-0792**	**1**	**11,609**	**Q1**
Somatosensory and Motor Research	0899-0220	2	1,111	Q4
Spanish Journal of Psychology	1138-7416	1	1,264	Q3
Spine	0362-2436	1	3,468	Q1
Spine Deformity	2212-134X	1	not indexed	
Statistics in Medicine	0277-6715	1	2,373	Q3
Stem Cell Research	1873-5061	1	2,02	Q4
Stem Cell Research & Therapy	1757-6512	2	6,832	Q1
Stem Cells Translational Medicine	2157-6564	1	6,94	Q1
Stroke	**0039-2499**	**2**	**7,914**	**Q1**
Surgical Endoscopy and Other Interventional Techniques	0930-2794	1	4,584	Q1
Surgical Infections	1096-2964	1	2,15	Q3
Theranostics	**1838-7640**	**1**	**11,556**	**Q1**
Therapeutic Advances in Gastroenterology	1756-283X	1	4,409	Q2
Therapeutic Advances in Infectious Disease	2049-9361	1	not indexed	
Therapeutic Advances in Musculoskeletal Disease	1759-720X	1	5,346	Q1
Thoracic Cancer	1759-7706	1	3,5	Q2
Thorax	0040-6376	1	9,139	Q1
Thrombosis and Haemostasis	0340-6245	3	5,249	Q2
Thrombosis Research	0049-3848	3	3,944	Q2
Thyroid	1050-7256	1	6,568	Q1
Toxicology Letters	0378-4274	1	4,372	Q2
Toxins	2072-6651	1	4,546	Q1
Transfusion	0041-1132	2	3,157	Q3
Transfusion and Apheresis Science	1473-0502	1	1,764	Q4
Translational and rology and Urology	2223-4683	1	3,15	Q2
Translational Oncology	1936-5233	1	4,243	Q2
Translational Research	**1931-5244**	**1**	**7,012**	**Q1**
Translational Stroke Research	1868-4483	1	6,829	Q1
Transplant Infectious Disease	1398-2273	1	2,228	Q4
Transplant International	0934-0874	1	3,782	Q2
Transplantation	0041-1337	2	4,939	Q1
Transplantation Proceedings	0041-1345	6	1,066	Q4
Travel Medicine and Infectious Disease	**1477-8939**	**3**	**6,211**	**Q1**
Trends in Food Science & Technology	**0924-2244**	**1**	**12,563**	**Q1**
Trends in Pharmacological Sciences	**0165-6147**	**1**	**14,819**	**Q1**
Trials	1745-6215	7	2,279	Q4
Ultrasound in Medicine and Biology	0301-5629	1	2,998	Q1
United European Gastroenterology Journal	2050-6406	1	4,623	Q2
Vaccine	0264-410X	3	3,641	Q3
Vaccines	2076-393X	1	4,422	Q2
Veterinary Research	**0928-4249**	**1**	**3,683**	**Q1**
Viruses-Basel	1999-4915	2	5,048	Q2
World Journal of Emergency Surgery	**1749-7922**	**2**	**5,469**	**Q1**
World Journal of Surgery	0364-2313	1	3,352	Q2
World Journal of Surgical Oncology	1477-7819	1	2,754	Q2
World Journal of Urology	0724-4983	4	4,226	Q1
World Neurosurgery	1878-8750	1	2,104	Q3
Xenotransplantation	1064-3745	1	not indexed	

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.8.2 High Impact Publications

Neuroscience Area

Rodríguez-Pardo J, Riera-López N, Fuentes B, Alonso de Leciñana M, Secades-Garcia S, Álvarez-Fraga J, Busca-Ostolaza P, Carneado-Ruiz J, Díaz-Guzmán J, Egido-Herrero J, Gil-Núñez A, Masjuan-Vallejo J, Real-Martínez V, Vivancos-Mora J, **Díez-Tejedor E.** Prehospitalselection of thrombectomycandidates-beyondlargevesselocclusion: M-DIRECT scale. Neurology. 2020; 94(8): E851-60. Article. IF: 9.91; D1

Diekhorst L, Gómez-de Frutos MC, Laso-García F, Otero-Ortega L, Fuentes B, Jolkkonen J, Detante O, Moisan A, Leyva L, Martínez-Arroyo A, Díez-Tejedor E, **Gutiérrez-Fernández M.** Mesenchymal stem cells from adipose tissue do not improve functional recovery after ischemic stroke in hypertensiverats. Stroke. 2020; 51(1): 342-6. Article. IF: 7.914; D1

Otero-Ortega L, Laso-García F, Gómez-de Frutos MG, Diekhorst L, Martínez-Arroyo A, Alonso-López E, García-Bermejo ML, Rodríguez-Serrano M, Arrue-Gonzalo M, Díez-Tejedor E, Fuentes B, **Gutiérrez-Fernández M**. Low dose of extracellular vesicles identified that promote recovery after ischemic stroke. Stem Cell Res Ther. 2020; 11(1): 70. Article. IF: 6.832; Q1

Robledinos-Antón N, Escoll M, Guan KL, **Cuadrado A.** TAZ represses the neuronal commitment of neural stem cells. Cells. 2020; 9(10): 2230. Article. IF: 6.6; Q2

Llorente P, Martins S, Sastre I, Aldudo J, Recuero M, Adjaye J, **Bullido MJ**. Matrix metalloproteinase 14 mediates app proteolysis and lysosomal alterations induced by oxidative stress in human neuronal cells. Oxid Med Cell Longev. 2020: 5917187. Article. IF: 6.543; Q1

Cardiovascular Area

López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Albendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, González-Juanatey JR, Monzonis AM, Prieto PG, González-Costello J, Antolín JMS, Chamorro RC, **Fernández TL**. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-9. Article. IF: 29.983; D1

Martínez-Gómez D, Esteban-Cornejo I, López-García E, García-Esquinas E, Sadarangani KP, Veiga OL, **Rodríguez-Artalejo F**. Physical activity less than the recommended amount may prevent the onset of major biological risk factors for cardiovascular disease: a cohort study of 198 919 adults. Brit J Sport Med. 2020; 54(4): 238-4. Article. IF: 13.8; D1

Moreno-Fernández S, Garcés-Rimón M, **Miguel M.** Egg-derived peptides and hydrolysates: A new bioactive treasure for cardiometabolic diseases. Trends Food Sci Tech. 2020; 104: 208-18. Article. IF: 12.563; D1

Struijk EA, Rodríguez-Artalejo F, Fung TT, Willett WC, Hu FB, **López-García E**. Sweetened beverages and risk of frailty among older women in the Nurses' Health Study: A cohort study. Plos Med. 2020; 17(12): e1003453. Article. IF: 11.069; D1

Donat-Vargas C, Moreno-Franco B, Laclaustra M, Sandoval-Insausti H, Jarauta E, **Guallar-Castillón P.** Exposure to dietary polychlorinated biphenyls and dioxins, and its relationship with subclinical coronary atherosclerosis: The Aragon Workers' Health Study. Environ Int. 2020; 136: 105433. Article. IF: 9.621; D1

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



Infectious Deseases and Immunity Area


Bellón T, Rodríguez-Martín S, Cabañas R, Ramírez E, Lerma V, González-Herrada C, González O, Sendagorta E, Fiandor A, **de Abajo FJ**. Assessment of drug causality in SJS/TEN: Concordance between lymphocyte transformation test and ALDEN. Allergy. 2020; 75(4): 956-9. Article. IF: 13.146; D1

Pérez-Martínez A, Ferreras C, Pascual A, González-Vicent M, Alonso L, Badell I, Navarro JMF, Regueiro A, Plaza M, Hurtado JMP, Benito A, Beléndez C, Couselo JM, Fuster JL, Díaz-Almirón M, Bueno D, Mozo Y, Marsal J, López AG, Sisinni L, de Heredia CD, Díaz MA. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020; 95(1): 28-37. Article. IF: 10.047; D1

Tamayo M, Martín-Nunes L, Val-Blasco A, M-Piedras MJG, Navarro-Garcia JA, Lage E, Prieto P, Ruiz-Hurtado G, **Fernández-Velasco M**, Delgado C. Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. Br J Pharmacol. 2020; 177(14): 3273-90. Article. IF: 8.739; D1

Van Den Rym A, Taur P, Martínez-Barricarte R, Lorenzo L, Puel A, González-Navarro P, Pandrowala A, Gowri V, Safa A, Toledano V, Cubillos-Zapata C, López-Collazo E, Vela M, Pérez-Martínez A, Sánchez-Ramón S, Recio MJ, Casanova JL, Desai MM, **de Diego RP**. Human BCL10 deficiency due to homozygosity for a rare allele. J Clin Immunol. 2020; 40(2): 388-98. Article. IF: 8.317; Q1

De Miguel R, Rial-Crestelo D, Domínguez-Domínguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, García-Álvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadinanos J, Mayoral M, Castro JM, Moreno V, Martín-Carbonero L, Delgado R, Rubio R, Pulido F, **Arribas JR**. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine. 2020; 55: 102779. Article. IF: 8.143; Q1



Large System Pathologies Area

Rivas JG, Socarras MR, Somani B, Uvin P, Vásquez JL, Henningsohn L, Pearce I, Zondervan P, Van Poppel H, Palou J. Undergraduate education for urology in Europe. Where do we stand? Eur Urol. 2020; 78(3): 381-4. Article. IF: 20.096; D1

Marqués M, Tranchant R, Risa-Ebri B, Suárez-Solis ML, Fernández LC, Carrillo-de-Santa-Pau E, del Pozo N, de Villarreal JM, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, **Real FX**. Combined MEK and PI3K/p110 beta inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 2020; 80(4): 843-56. Article. IF: 12.701; D1

Valino-Rivas L, Cuarental L, Núñez G, Sanz AB, Ortiz A, **Sánchez-Niño MD**. Loss of NLRP6 expression increases the severity of acute kidney injury. Nephrol Dial Transplant. 2020; 35(4): 587-98. Article. IF: 5.992; Q1

Díaz R, Sandoval P, Rodrigues-Díez RR, del Peso G, Jiménez-Heffernan JA, Ramos-Ruiz R, Llorens C, Laham G, Álvarez-Quiroga M, López-Cabrera M, Ruiz-Ortega M, Bajo MA, **Selgas R**. Increased miR-7641 levels in peritoneal hyalinizing vasculopathy in long-term peritoneal dialysis patients. Int J Mol Sci. 2020; 21(16): 5824. Article. IF: 5.923; Q1

Cubillos-Zapata C, Almendros I, Díaz-García E, Toledano V, Casitas R, Galera R, López-Collazo E, Farre R, Gozal D, **García-Rio F**. Differential effect of intermittent hypoxia and sleep fragmentation on PD-1/PD-L1 upregulation. Sleep. 2020; 43(5): zsz285. Article. IF: 5.849; Q1

Introduction
Executive summary
Information Groups by Area
Associated Clinicians



Cancer and Human Molecular Genetics Area

Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma XW, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang HW, Shah J, Shacham S, Kauffman M, Van den Neste E, **Canales MA.** Selinexor in patients with relapsed or refractory diffuse large B cell lymphoma (SADAL): a single -arm, multinational, multicentre, open label, phase 2 trial. Lancet Haematol. 2020; 7(7): E509-22. Article. IF: 18.959; D1


Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, **Zapata JM**. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. J Hematol Oncol. 2020; 13(1): 32. Article. IF: 17.388; D1

Font-Tello A, Kesten N, Xie YT, Taing L, Vareslija D, Young LS, Hamid AA, Van Allen EM, Sweeney CJ, Gjini E, Lako A, Hodi FS, Bellmunt J, Brown M, **Cejas P**, Long HW. FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat Protoc. 2020; 15(8): 2503-18. Article. IF: 13.491; D1

Palencia-Campos A, Aoto PC, Machal EMF, Rivera-Barahona A, Soto-Bielicka P, Bertinetti D, Baker B, Vu L, Piceci-Sparascio F, Torrente I, Boudin E, Peeters S, Hul WV, Huber C, Bonneau D, Hildebrand MS, Coleman M, Bahlo M, Bennett MF, Schneider AL, Scheffer IE, Kibaek M, Kristiansen BS, Issa MY, Mehrez MI, Ismail S, Tenorio J, Li GY, Skalhegg BS, Otaify GA, Temtamy S, Aglan M, Jonch AE, de Luca A, Mortier G, Cormier-Daire V, Ziegler A, Wallis M, Lapunzina P, Herberg FW, Taylor SS, **Ruiz-Perez VL**. Germline and Mosaic Variants in PRKACA and PRKACB Cause a Multiple Congenital Malformation Syndrome. Am J Hum Genet. 2020; 107(5): 977-88. Article. IF: 11.025; D1

Mota A, Oltra S, **Moreno-Bueno G**. Insight updating of the molecular hallmarks in ovarian carcinoma. EJC Suppl. 2020; 15: 16-26. Article. IF: 9,386; D1

Heredia-Soto V, López-Guerrero JA, Redondo A, **Mendiola M**. The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. EJC Suppl. 2020; 15: 49-55. Article. IF: 9.386; D1



Surgery, Transplant and Health Technologies Area

Sánchez-Casanova S, Martín-Saavedra FM, Escudero-Duch C, Uceda MIF, Prieto M, Arruebo M, Acebo P, Fabiilli ML, Franceschi RT, **Vilaboa N**. Local delivery of bone morphogenetic protein-2 from near infrared-responsive hydrogels for bone tissue regeneration. Biomaterials. 2020; 241: 119909. Article. IF: 12.479; D1

Valles G, Bensiamar F, Maestro-Paramio L, García-Rey E, Vilaboa N, **Saldaña L**. Influence of inflammatory conditions provided by macrophages on osteogenic ability of mesenchymal stem cells. Stem Cell Res Ther. 2020; 11(1): 57. Article. IF: 6.832; Q1

Ramírez E, Urroz M, Rodríguez A, González-Muñoz M, Martín-Vega A, Villán Y, Seco E, Monserrat J, Frías J, Carcas AJ, **Borobia AM**. Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: Cautionary Data. Front Pharmacol. 2020; 11: 602841. Article. IF: 5.81; Q1

Borobia AM, Collado SG, Cardona CC, Pueyo RC, Alonso CF, Torres IP, González MC, Codesido JRC, Betegón MA, Barcela LA, Andicoechea AO, Testa AF, Colina JT, Dorribo AC, Galán CD, Ávila JCM, Lugilde ST, **Sansuán AJC**. Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: INMEDIATE: A randomized controlled trial in emergency departments. Ann Emerg Med. 2020; 75(3): 315-28. Article. IF: 5.721; D1

Morato-Martínez M, López-Plaza B, Santurino C, Palma-Milla S, **Gómez-Candela C**. A dairy product to reconstitute enriched with bioactive nutrients stops bone loss in high-risk menopausal women without pharmacological treatment. Nutrients. 2020; 12(8): 2203. Article. IF: 5.717; Q1

2.9 CIBERs and RETICs

2.9.1 CIBER- Biomedical Research Networking Centers

Throughout 2020, IdiPAZ has participated in the following thematic networks and research consortiums legally recognized.

Project	Acronym	CIBER	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
	CIBERNED	Networked Biomedical Research Center for Neurodegenerative Diseases	Carlos III Health Institute	**Bullido Gómez-Heras, María Jesús**	Neurology and cerebrovascular diseases	31/12/2020
			Carlos III Health Institute	**Cuadrado Pastor, Antonio**	Neuroprotective Strategies in Neurodegenerative Diseases	31/12/2020
CB15/00037	CIBERES	Networked Biomedical Research Center for Respiratory Diseases	Carlos III Health Institute	**García Río, Francisco**	Respiratory Diseases	31/12/2021
CB06/01/0049	CIBER-BBN	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Carlos III Health Institute	**Vilaboa Díaz, Nuria Elda**	Bone Pathophysiology and biomaterials	3/12/2020
CB06/04/0083	CIBEREHD	Networked Biomedical Research Center for Hepatic and Digestive Diseases	Carlos III Health Institute	**García-Samaniego Rey, Javier**	Associated Clinician	31/12/2020
CB06/07/1033	CIBERER	Networked Biomedical Research Center for Rare Diseases	Carlos III Health Institute	**Caballero Soto, María Soto**	Diagnosis and Treatment of Allergic Diseases	31/12/2020
CB06/07/1005			Carlos III Health Institute	**Lapunzina Badía, Pablo**	Cell Therapy and Gene Metastasis	31/12/2020
CB06/07/0004			Carlos III Health Institute	**Pérez González, María Belén**	Research and Diagnosis of Inherited Metabolic Diseases	31/12/2020
CB06/07/1021			Carlos III Health Institute	**Varela Nieto, María Isabel**	Oto-Neurosurgery Research	31/12/2022
CB06/07/0038			Carlos III Health Institute	**Botella Cubells, Luisa María**	Urology	31/12/2021
CB19/07/00042			Carlos III Health Institute	**López Granados, Eduardo**	Lymphocyte Pathophysiology in Immunodecficiencies	31/12/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.9.1 CIBER- Biomedical Research Networking Centers

CB06/02/0001	CIBERESP	Networked Biomedical Research Center for Public Health and Epidemiology	Carlos III Health Institute	**Rodríguez Artalejo, Fernando**	Cardiovascular Epidemiology and Nutrition	31/12/2020
CB16/11/00286	CIBERCV	Networked Biomedical Research Center for Cardiovascular Diseases	Carlos III Health Institute	**Salaices Sánchez, Mercedes**	Vascular Physiology and Pharmacology	31/12/2022
CB16/12/00295	CIBERONC	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	**Moreno Bueno, Gema**	Mechanisms of Tumour Progression	31/12/2022
CB16/12/00273			Carlos III Health Institute	**Muñoz Terol, Alberto**	Mechanisms of Tumour Progression	31/12/2022
CB16/12/00398			Carlos III Health Institute	**Feliú Batlle, Jaime**	Trasnlational Oncology	31/12/2022

2.9.2 RETICs- Networks for Cooperative Research in Health

The Thematic Networks for Cooperative Research in Health (RETICS) are organizational structures formed by the association of different Biomedical Research groups at the Carlos III Health Institute and, throughout 2020, IdiPAZ has participated in 10 out of 17 networks.

Project	Acronym	Network	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
PT17/0005/0025	ITEMAS	Plataforma ITEMAS	Carlos III Health Institute	**de Castro Carpeño, Javier**	Experimental Therapies and Biomarkers in Cancer	31/12/2020
PT17/0015/0025	RNBB	Red de Biobancos	Carlos III Health Institute	**Gómez Campelo, Paloma**	Innate Immune Response	31/12/2020
PT17/0017/0013	SCReN	Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos	Carlos III Health Institute	**Frías Iniesta, Jesús**	Clinical Pharmacology	31/12/2020

2.9.1 CIBER- Biomedical Research Networking Centers

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

RD16/0019/0005	**INVICTUS PLUS**	Vascular and Cerebral Diseases Network	Carlos III Health Institute	**Díez Tejedor, Exuperio**	Neurology and Cerebrovascular Diseases	31/12/2021
RD16/0025/0018	**RIS**	Research Network for AIDS	Carlos III Health Institute	**González García, Juan**	AIDS and Infectious Diseases	31/12/2021
RD16/0006/0033	**ARADYAL**	Asthma, Adverse and Allergic Reactions	Carlos III Health Institute	**Laguna Martínez, José Julio**	Associated Clinician	31/12/2021
RD16/0022/0004	**SAMID**	Research Network for Maternal and Child Health and Development	Carlos III Health Institute	**Cabañas González, Fernando**	Congenital Malformation Surgery	31/12/2021
RD16/0022/0006			Carlos III Health Institute	**Martínez Martínez, Leopoldo**	Congenital Malformation Surgery	31/12/2021
RD16/0027/0002	**RICET**	Tropical Disease Cooperative Research Network	Carlos III Health Institute	**Mora Rillo, Marta**	AIDS and infectious diseases	31/12/2021
RD16/0009/0008	**REDINREN**	Research Network for Renal Diseases	Carlos III Health Institute	**Selgas Gutiérrez, Rafael**	Nephrology	31/12/2021
RD16/0012/0012	**RIER**	Investigational Network in Inflammation and Rheumatic Diseases	Carlos III Health Institute	**Miranda Carús, María Eugenia**	Immuno-Rheumatology	31/12/2021

2.10 Institutional Projects

2.10.1 Mentor Program

IdiPAZ, in collaboration with the HULP, has implemented a mentoring program principal focusing on support clinical researchers to apply to national competitive calls, especially the main call for health research projects: "Acción Estratégica en Salud (AES)" of the Institute of Health Carlos III.

The objectives of the program are: increasing the number of clinical research in the Institute, avoiding a generational leap of clinical researchers, strengthening the research profile of our clinical staff and becoming a clinical research model, as the same level that in the clinical trials.

To achieve the goals of the program is necessary to start some action plans focusing on different weakness that have been detected: creation of curriculum in official format, enable synergies to create research groups, support from the different platforms of IdiPAZ, services of medical writing and stand out the impact and the strategic priorities of the projects for the National Health System.



2.10.2 Transversal Research Projects

IdiPAZ's Strategic Plan has, among its priorized lines of action, the promotion of research of excellence through the consolidation of the research areas and groups that make up the scientific structure. For this, the model of interrelation between the research areas and groups of the Institute is key and directly impacts the generation of synergies and the development of joint collaborative projects.

The main objective of the Transversal Research Projects is to strengthen the configuration of multidisciplinary research teams, participated by IdiPAZ research groups (both excellent, consolidated and emerging as young researchers).

Two Transversal Research Projects have been implemented:

- **Study of pathogen-host interaction: implementation of a logistic for the development of infectious disease projects.**
- **Biomodels for the study of multiple diseases: a tool for the development and implementation of therapies.**

Approach of these Transversal Research Projects included:

- Translational vision, interrelation between the scientific areas of IdiPAZ and orientation to the clinical practice setting.
- Participatory research projects in which collaboration between research groups from different Areas is promoted.
- Projects coordinated by a person in charge who encourages participation and collaboration between groups for the development of projects.
- Evaluation with monitoring indicators based on standards of excellence, focused on obtaining funding, scientific production and / or results in clinical practice.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.10.3 TransplantChild

During this year we face the fifth year of the coordination of the European Reference Network (ERN) TransplantChild (www.transplantchild.eu). The ERN tackle a low prevalence complex procedure and condition as the paediatric transplantation of all kind of solid organ (kidney, liver, heart, intestine and lung) and hematopoietic stem cell transplantation.

New members have joined the network, reaching now 42 healthcare providers in 22 European countries.



The involvement of the multidisciplinary team at IdiPAZ-La Paz University Hospital, make possible the development of important activities focused on the specific topics related to paediatric transplantation, such us minimisation of immunosuppression, transition to adulthood, tolerance induction, vaccination or the effect of Covid-19 outbreak.

After the progress in the development of the Clinical Practice Guideline on the minimisation of the immunosuppression, we focused on the preparation of a experts consensus document on the Transition, as the process of the preparation of the young adult to transit from the paediatric care to the adult care, taking into consideration the training and self-conscious of the young adult and a smooth transfer to the professionals in adult care. Members of TransplantChild (Children's Memorial Health Institute in Poland, Papa Giovanni XXII in Italy and Karolinska Institute in Sweden) together with collaborators from The Hospital for Sick Children in Canada, Sevilla University, Magna Graecia University in Italy and the support of policymakers representatives from Spain and Italy and European Patients Advocacy Groups, have submitted a research proposal to the CARE call of Horizon Europe: "Graft Meets World: Enhancing Transfer Experience to Adult Health Care for Paediatric Transplant Recipients" (P-TRANSFER). The aim of the project is ensure an efficient and effective continuity of care during the transfer process to achieve the best conditions for the patient at clinical and maturity level, increase adherence to medication, reduce the risk of rejection and improve the patient's quality of life.

Unfortunately, the Covid-19 outbreak impacted on paediatric transplantation activity across Europe. The consequences on patients, professionals and healthcare were published in Clinical Transplantation "Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare" (DOI: 10.1111/ctr.14063).

The results of other studies and activities carried out in TransplantChild have been published as well:

- "Current Practices on Diagnosis, Prevention and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Patients after Solid Organ Transplantation: Results of ERN TransplantChild Healthcare Working Group Survey" (DOI: 10.3390/children8080661)
- "Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis" (DOI: 10.1136/bmjopen-2020-037721)
- "ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network" (DOI: 10.3390/children8090760)
- "Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild" (DOI: 10.1186/s13023-020-1293-0)
- "Social Resources for Transplanted Children and Families in European Union Hospitals of ERN TransplantChild" (DOI: 10.3390/children8090723)

On November 2020 ERN TransplantChild organised with success the II Workshop on Translational Research: "Novel strategies in paediatric transplantation" with general and parallel sessions for clinicians, surgeons and nurses.

2.11 Internationalization

America

Argentina
Brazil
Canada
Chile
Colombia
Costa Rica
Guatemala
Mexico
Panama
United States of America
Uruguay
Venezuela

Europe

Belgium
Croatia
Czech Republic
Denmark
Finland
France
Germany
Greece
Hungary
Italy
Netherlands
North Macedonia
Norway
Poland
Portugal
Serbia
Slovakia
Slovenia
Sweden
Switzerland
United Kingdom

Africa

Egypt

Asia

India
Iran
Israel
Japan
Lebanon
Malaysia
People's Republic of China
Russia
Saudi Arabia
Singapore
South Korea
Taiwan
Thailand
Turkey
United Arab Emirates

Oceania

Australia
New Zealand



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.12 Comunication and Public Engagement

The communication of biomedical research allows the population to know and understand biomedical progress or possible application in human health, making the citizen more knowledgeable about the diseases that affect society. IdiPAZ uses its tool to carry out this task, the newsletter "IdiPAZ Informa". In 2020, 221 newsletter were sent to our researchers.

IdiPAZ has been present in different media, both written and digital press (radio, TV, etc.), which contributed to highlight the activity developed by the Institute throughout 2020. IdiPAZ appears in 40 publications on mass media.

In our website, "IdiPAZ in the media" is included a coverage of 178 digital press mentions along this year:

http://www.idipaz.es/PaginaDinamica.aspx?IdPag=665&Lang=ES.

Also, 19 news were published at the website of the Institute (www.idipaz.es), and the website of Consejería de Sanidad de la Comunidad de Madrid has published 21 news from IdiPAZ researchers (https://www.comunidad.madrid/actualidad):



Hemos tratado a 41 pacientes con terapias avanzadas contra el cáncer

09/01/2020. La Comunidad de Madrid ha tratado hasta la fecha a 41 pacientes con las nuevas terapias avanzadas CAR-T contra el cáncer hematológico, 26 con los fármacos comercializados y otros 15 en el marco de ensayos clínicos. Aunque es pronto para evaluar la eficacia de estos tratamientos en la práctica clínica habitual, a fecha de hoy, de los pacientes tratados, seis han alcanzado la remisión completa. Dos de estos seis pacientes fueron dados de alta el pasado mes de diciembre en la Unidad Infanto-juvenil del Hospital La Paz.



El Hospital Universitario La Paz cuenta con la primera Unidad de Predisposición Genética a Cáncer Infantil de la Comunidad de Madrid

26/01/2020. La Unidad de Ginecología Oncológica del Hospital Universitario la Paz ha conseguido el Certificado en Cirugía de Cáncer de Ovario Avanzado de la Sociedad Europea de Ginecología Oncológica (ESGO, del inglés European Society of Gynecological Oncology). Esta certificación supone un reconocimiento a la calidad en el tratamiento de esta enfermedad por parte del hospital y sus profesionales.



El Hospital La Paz cuenta con la primera Unidad de Predisposición Genética a Cáncer Infantil

28/01/2020. A día de hoy, al menos el 10% de los cánceres infantiles tienen su explicación en alteraciones genéticas que acontecen en la llamada línea germinal, es decir, alteraciones presentes en el ADN de todas las células de un individuo. Esta situación puede ayudar a diagnosticar en estadios tempranos de la enfermedad, a ofrecer un consejo genético, y a plantear terapias génicas futuras.



El Hospital La Paz lidera los ensayos clínicos de un proyecto europeo contra la tuberculosis

03/02/2020. El Servicio de Farmacología Clínica y la Unidad de Investigación Clínica y Ensayos Clínicos del Hospital Universitario La Paz cooordinarán los ensayos clínicos de la primera administración en humanos, de antibióticos contra la tuberculosis. Concretamente en infecciones multirresistentes, mejorando la eficacia de los antibióticos, así como la calidad de vida de los pacientes. El Acelerador Europeo de Regímenes Contra la Tuberculosis es uno de los mayores proyectos científicos europeos en este área de investigación.



El Hospital La Paz emplea por primera vez en España la técnica REBOA en una paciente obstétrica

18/02/2020. El Servicio de Obstetricia y Ginecología del Hospital Universitario La Paz ha realizado por primera vez en una cesárea por placenta previa y acretismo placentario, la técnica endovascular REBOA (Resuscitative Endovascular Ballon Occlusión of the Aorta-Reboa), siendo la primera vez que se utiliza en España en una paciente obstétrica. La técnica REBOA es un procedimiento endovascular mínimamente invasivo que permite el control de la hemorragia.



La Paz crea una Unidad de Atención a las profesionales víctimas de violencia de género

24/02/2020. El Servicio de Asesoría Jurídica del Hospital Universitario La Paz crea la primera Unidad de Atención a las profesionales del centro víctimas de violencia de género en un Hospital del Sistema Nacional de Salud. La función de esta unidad es escuchar, informar y asesorar a las profesionales del centro sobre los medios y servicios, tanto locales y autonómicos como estatales, disponibles para las víctimas de violencia de género, de manera confidencial.



La Unidad de Nutrición del Hospital La Paz apuesta por la nutrición de precisión

26/02/2020. El Hospital Universitario La Paz de Madrid ha acogido hoy la jornada sobre nutrición de precisión Controversias alrededor del uso de módulos proteicos específicos. La Jornada, que ha sido inaugurada por el director gerente del centro madrileño, Rafael Pérez-Santamarina, y la jefa de la Unidad de Nutrición, Carmen Gómez Candela, ha sido una puesta en común de expertos en nutrición de precisión y sobre las modalidades de soporte nutricional que los profesionales tienen a su disposición.



Información sobre el coronavirus a través de un vídeo difundido por redes sociales

03/03/2020. El doctor José Ramón Arribas, jefe de Sección de Medicina Interna-Enfermedades Infecciosas del Hospital La Paz-Carlos III, ofrece en el vídeo información práctica para el ciudadano sobre la transmisión, prevención y sintomatología del coronavirus, entre otros temas. Además, el médico explica que ante síntomas de coronavirus, el ciudadano debe quedarse en casa y contactar con los servicios sanitarios por teléfono.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



La Comunidad de Madrid reorganiza la Atención Pediátrica Urgent

21/03/2020. La Consejería de Sanidad de la Comunidad de Madrid ha reorganizado la atención de la Urgencia pediátrica, Cuidados Intensivos y hospitalización pediátrica centralizando las necesidades actuales en los hospitales Universitarios La Paz e Infantil Universitario Niño Jesús. El SUMMA 112 realizará los traslados pediátricos al Hospital Universitario La Paz como al Hospital Infantil Universitario Niño Jesús, según las necesidades clínicas de los pacientes, su cercanía y disposición.



La Comunidad reorganiza la atención Obstétrica, Ginecológica y Neonatológic

23/03/2020. La Consejería de Sanidad de la Comunidad de Madrid ha reorganizado, desde el día de hoy, la atención urgente de Obstetricia, Ginecología y Neonatología, centralizando la urgencia en los hospitales Universitarios La Paz, Gregorio Marañón, 12 de Octubre y Puerta de Hierro-Majadahonda, con el objetivo de evitar posibles contagios por coronavirus (COVID-19) a los pacientes.



Los hospitales públicos madrileños inician investigaciones sobre tratamientos para el COVID-19

31/03/2020. Los hospitales públicos de la Comunidad de Madrid están realizando varios ensayos clínicos para investigar los medicamentos más efectivos para tratar la infección por coronavirus (COVID-19). En el primero de estos ensayos, con la participación de los hospitales Ramón y Cajal, La Paz y Gregorio Marañón, se comprueba la eficacia y seguridad de Sarilumab (del laboratorio Sanofi Aventis) en pacientes graves o críticos por COVID-19.




Los resultados del Estudio ISCHEMIA publicados en la revista New England Journal of Medicine

01/04/2020. La prestigiosa revista New England Journal of Medicine acaba de publicar una serie de artículos en los que se rebelan los resultados de un estudio internacional de efectividad comparativa financiado por el Instituto Nacional del Corazón, Pulmón y Sangre (NHLBI) de los Institutos Nacionales de Salud (NIH) para determinar la mejor manera de manejar la cardiopatía isquémica estable. El Dr. López-Sendón, director del grupo Investigación en Cardiología Clínica E Invasiva de IdiPAZ, lidera el grupo del estudio en el Hospital Universitario La Paz.



Dos investigadoras de IdiPAZ publican en NEJM datos del uso de REMDESIVIR en pacientes SARS-CoV-2

04/06/2020. Más de 60 documentos han sido publicados por investigadores del IdiPAZ en revistas de impacto. Cabe destacar dos publicaciones en una de las revistas más prestigiosas en medicina New England Journal of Medicine, la revista n° 1 en el campo de la medicina interna según el JCR del año 2018. En el equipo investigador de ambas publicaciones se encuentran dos investigadoras del IdiPAZ, la dra. Marta Mora Rillo y la dra. Rocío Montejano Sánchez. En ambas publicaciones se analizan los resultados del tratamiento con Remdesivir.



El Hospital La Paz lidera la primera cohorte de pacientes infectados por COVID-19 de Europa

25/06/2020. El Hospital Universitario La Paz lidera la primera gran cohorte de pacientes hospitalizados por Covid-19 en Europa. La denominada "Cohorte COVID@HULP" está coordinada por el doctor José Ramón Arribas, Jefe de la Unidad de Enfermedades Infecciosas y el doctor Alberto Borobia, Coordinador de la Unidad Central de Investigación Clínica y Ensayos Clínicos.



El doctor Santiago Quirce Gancedo ha sido galardonado con el premio Clemens Von Pirquet 2020

30/06/2020. El doctor Santiago Quirce, investigador del IdiPAZ y jefe del Servicio de Alergología del Hospital La Paz, ha recibido el Premio Clemens Von Pirquet 2020 que otorga la Academia Europea de Alergología e Inmunología Clínica por su investigación clínica en el campo de la Alergología. Se trata de la distinción más alta que otorga la Academia Europea a aquellos científicos que han contribuido de manera muy significativa en el campo de la Alergología y la Inmunología Clínica.



El Hospital La Paz recibió consultas acerca de 1.100 personas mayores

01/07/2020. El Hospital Universitario La Paz ha sido uno de los hospitales de la red madrileña con una mayor presión asistencial en los días más duros de la pandemia de la COVID-19 en nuestro país. Uno de los mayores retos a los que se ha enfrentado el hospital ha sido gestionado a través del equipo de Geriatría de Enlace, que ha servido de nexo de unión entre el hospital y las 40 residencias de personas mayores de su área de influencia, ofreciendo atención a las más de 4.000 personas institucionalizadas en estos centros.



El Hospital La Paz recupera el 'piel con piel' del recién nacido tras la cesárea

01/07/2020. El Hospital Universitario La Paz recupera la práctica "piel con piel" entre la madre y el recién nacido tras una cesárea, así como el acompañamiento de un familiar durante la intervención de la paciente en quirófano, práctica que durante el pico de contagios de la pandemia por COVID-19 había sido suspendida por motivos de salud y seguridad del recién nacido. De marzo a mayo de 2020 se han atendido en el centro 1.500 partos de los cuales 120 han sido casos en los que la madre era positiva en infección por coronavirus Sars-Cov2.



Inmunólogos de La Paz participan en un nuevo test de detección de anticuerpos frente a la COVID-19

17/07/2020. Investigadores del Consejo Superior de Investigaciones Científicas (CSIC) han desarrollado un nuevo ensayo de detección de anticuerpos frente al SARS-CoV-2 de gran fiabilidad, según estudios realizados en colaboración con los Servicios de Inmunología del Hospital Universitario La Paz y del Hospital de La Princesa. Este nuevo ensayo de ELISA permite realizar de forma automatizada, la determinación de anticuerpos de tipo IgM, IgA e IgG frente a tres tipos de antígenos.



El Hospital La Paz coordinará a nivel nacional el desarrollo de ensayos clínicos Covid-19

19/07/2020. El Servicio de Farmacología Clínica y la Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC) del Hospital Universitario La Paz serán los responsables de coordinar a nivel nacional el desarrollo de los ensayos clínicos de primera administración en humanos, en el marco de la mayor iniciativa europea para acelerar el desarrollo de terapias para COVID-19 y futuras amenazas de Coronavirus.



El proyecto RELEASE elegido en la V edición del Programa HealthStart

22/07/2020. RELEASE es un proyecto de Terapia Celular con Linfocitos T de memoria en pacientes graves de COVID19. El proyecto consiste en generar una linfoteca, un biobanco de células que contienen linfocitos con capacidad memoria frente al SARS-COV2 que pueda ser utilizado para el tratamiento de pacientes infectados por SARS-CoV-2 que presentan enfermedad de COVID-19 con pronóstico moderado/severo. Release podría aplicarse a las infecciones provocadas por cualquier tipo de virus.



El suplemento nutricional, Nutrinfatty, desarrollado por investigadores del IdiPAZ, ha sido seleccionado en la V edición del Programa HealthStart

22/07/2020. Nutrinfatty (NUTRitional supplement for pre-term INfants based on FATTY acids), es un suplemento nutricional para prevenir las consecuencias de la prematuridad. Nutrinfatty consigue reducir la incidencia de las enfermedades provocadas por la prematuridad y fomenta el crecimiento del prematuro (peso, longitud y perímetro encefálico) además de mejorar su microbiota intestinal. Esta nueva solución favorece su absorción por parte del intestino incrementando su respuesta en el crecimiento, la tolerancia alimentaria y el desarrollo del prematuro a todos los niveles.



El proyecto Mut4child ha sido elegido la V edición del Programa HealthStart

22/07/2020. El proyecto Mut4child consiste en el desarrollo y la comercialización de un Kit de diagnóstico genético para la optimización del diagnóstico precoz, pronóstico y tratamiento del cáncer infantil. Se trata de un panel de secuenciación masiva que permitirá la detección precoz y la mejora en la precisión del diagnóstico de niños que presentan un mayor riesgo de desarrollar cáncer así como optimizar el tratamiento convencional a través del uso de fármacos dirigidos acercándonos así a una medicina de precisión.



El Kit quirúrgico universal ha sido seleccionado en la V edición del Programa HealthStart

22/07/2020. El Kit quirúrgico universal, imprimible desde la nube, permite mejorar la asistencia médica en zonas remotas o de bajos recursos (zonas de conflicto, campos de refugiados, estaciones espaciales...). El kit cuenta con instrumental desechable o reesterilizable, de bajo coste que permite llevar a cabo intervenciones quirúrgicas, con mayor seguridad de los pacientes y calidad de la atención médica. El material desechable o reesterilizable, evitará procesos de limpieza y esterilización post-quirúrgica del instrumental.



Un dispositivo para lactancia materna, desarrollado en el IdiPAZ, ha sido seleccionado en la V edición del Programa HealthStart

22/07/2020. Un dispositivo asociado a una aplicación de móvil utilizado para valorar la cantidad de leche materna ingerida durante la lactancia, especialmente en niños con lactancia materna exclusiva. Esto da lugar en determinadas ocasiones a situaciones de angustia para los familiares que provocan, incluso, el abandono de dicho método por parte de la madre. Esta solución no solo sería usada por los padres, sino también por el propio personal sanitario para asegurar adecuados aportes y evitar complicaciones secundarias a su déficit.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



El proyecto ComunicaAPP-Afasia del IdiPAZ ha sido elegido para participar en la V edición del Programa HealthStart

22/07/2020. El Proyecto ComunicAPP-Afasia consiste en una herramienta digital creada para mejorar la comunicación y fomentar la recuperación de los pacientes que presentan alteraciones del lenguaje (afasia) como consecuencia de enfermedad cerebrovascular (ictus). ComunicAPP-afasia permite un inicio precoz del tratamiento y utilización ilimitada. Combina imagen, lectura y sonido, agrupadas en categorías y con un código de colores, que favorece la conectividad cerebral mediante estímulos múltiples.



Programa pionero de Simulación en Emergencias y Urgencias Obstétricas en el Hospital La Paz

27/07/2020. El Servicio de Ginecología y Obstetricia en colaboración con el Centro Avanzado de Simulación y Entrenamiento Clínico (CEASEC) del Hospital Universitario La Paz, ha iniciado recientemente un Programa de Simulación en Obstetricia, pionero en España, cuyo objetivo es mejorar la coordinación entre los distintos equipos involucrados en la atención a la gestante, así como mejorar la seguridad tanto de las pacientes como de los profesionales que las atienden.



EL proyecto ClearPap del IdiPAZ ha sido seleccionado por el Programa Caixa Impulse Validate

27/07/2020. El Proyecto ClearPap, liderado por el dr. Jesús Manuel Muñoz, desarrolla un dispositivo para el tratamiento de las lesiones preneoplásicas del virus del papiloma humano (VPH) mediante la aplicación de terapia fotodinámica concurrente y un fármaco fotosensibilizante. ClearPap consigue superar las limitaciones de la terapia fotodinámica pues aplica y difunde la luz de manera homogénea en toda la cavidad que se va a tratar consiguiendo una mayor eficacia de la terapia.



El proyecto STELLA del IdiPAZ ha sido seleccionado por el Programa Caixa Impulse Validate

27/07/2020. El Proyecto STELLA dirigido por la dra. Inmaculada Ibáñez de Cáceres consiste en una prueba capaz de normalizar el contenido de miRNAs exosomales en muestras de distintos tipos de pacientes y permite pronosticar la respuesta del paciente con cáncer de pulmón avanzado a los tratamientos con cisplatino y detectar el riesgo de progresión a cáncer de pulmón en pacientes con enfermedad pulmonar obstructiva crónica (EPOC).



Iniciamos la vacunación de voluntarios del primer ensayo clínico contra el COVID-19 en España

15/09/2020. La Comunidad de Madrid comienza la vacunación de los participantes madrileños en el ensayo clínico en fase 2 de la primera vacuna contra el COVID-19 en España, de la compañía farmacéutica Janssen. Los hospitales madrileños La Paz y La Princesa son, junto con el Hospital Marqués de Valdecilla en Santander, los tres centros que participan este ensayo clínico. Los voluntarios madrileños son 150 personas (75 por hospital), 100 de entre 18 y 55 años y 50 mayores de 65 años, que, hasta el 22 de septiembre, realizarán la visita de vacunación en las Unidades de Ensayos Clínicos.



La Unidad de Nutrición de La Paz premiada por la Medical Nutrition International Industry

25/09/2020. El premio ha sido otorgado por la Medical Nutrition International Industry (MNI) y evaluado por la European Society for Parenteral and Enteral Nutrition (ESPEN) con una cuantía de 30.000€, dirigido a iniciativas y proyectos de investigación relacionados con el cuidado nutricional. El proyecto presentado por la Unidad de Nutrición y Dietética del Hospital Universitario La Paz busca identificar la herramienta más efectiva y rápida para la diagnosis de la desnutrición en pacientes hospitalizados.



Científicos descubren la existencia de causas genéticas e inmunológicas de la COVID-19 grave

30/09/2020. Una investigación del Consorcio internacional COVID Human Genetic Effort, del que forma parte el Hospital Universitario La Paz a través de su Instituto de Investigación (IdiPAZ), ha descubierto la existencia de causas genéticas e inmunológicas en el desarrollo de la forma más grave de COVID-19.



Tres servicios médicos del Hospital La Paz entre los 50 mejores del mundo

06/10/2020. Tres servicios del Hospital Universitario La Paz se encuentran entre los 50 mejores de su especialidad en el mundo, según el medio especializado Newsweek. La edición sanitaria estadounidense en colaboración con Stadista ha publicado su ranking hospitalario elaborado por una junta de expertos médicos globales. En esta ocasión han analizado los servicios de Oncología y Cardiología de entre los 200 mejores hospitales del mundo y Endocrinología de entre los 100 mejores.



La Paz realiza el primer implante en España de un nuevo sistema de estimulación de médula espinal

16/10/2020. El Servicio de Neurocirugía del Hospital Universitario La Paz ha realizado con éxito el primer implante de un novedoso sistema de Estimulación de Médula Espinal contra el dolor crónico. El paciente tiene Síndrome de cirugía de Espalda Fallida o FBSS, una afección muy dolorosa e incapacitante. Esta gama de dispositivos son compatibles con Resonancias magnéticas de cuerpo entero y combinan opciones terapéuticas para una analgesia personalizada. Este nuevo sistema ha demostrado su eficacia contra el dolor crónico.



Laboratorio de Inmunogenética de las Enfermedades premiado a la mejor comunicación por E-Poster del congreso del ESID 2020

19/10/2020. El Laboratorio de Inmunogenética de las Enfermedades dirigido por la Dra. Rebeca Pérez de Diego ha recibido el premio a la mejor presentación E-Poster en el congreso de la Sociedad Europea de Inmunodeficiencias (ESID). El trabajo premiado ha expuesto sus investigaciones en la identificación del segundo paciente con una inmunodeficiencia primaria causada por deficiencia en el gen que codifica a BCL10 y contado con la colaboración del Dr Mukesh Desai del Bai Jerbai Wadia Hospital for Children.



El Hospital Universitario La Paz y la ONCE investigan conjuntamente la base genética de las cataratas congénitas

17/11/2020. La ONCE colabora con el Instituto de Genética Médica y Molecular (INGEMM) del Instituto de Investigación Sanitaria del Hospital La Paz-IdiPAZ en un proyecto coordinado por la investigadora Elena Vallespín, que tiene como objetivo el diseño y desarrollo de una estrategia de cribado integral basada en la secuenciación masiva para todos los genes y loci –lugares donde se sitúan dichos genes– responsables de catarata congénita bilateral (CCB). La catarata congénita bilateral (CCB) no sindrómica es la causa de ceguera congénita reversible con mayor prevalencia a nivel mundial.



El doctor Francisco García Río ha sido elegido presidente de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR)

19/11/2020. El doctor Francisco García Río, exdirector científico de IdiPAZ y director del grupo de investigación Enfermedades Respiratorias de IdiPAZ ha sido elegido presidente de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). La elección se ha dado a conocer en la asamblea de socios que se celebró en el 53 Congreso virtual.



El doctor Víctor Jiménez Yuste nuevo vicepresidente de la Sociedad Española de Hematología y Hemoterapia (SEHH)

19/11/2020. La Sociedad Española de Hematología y Hemoterapia (SEHH) ha renovado su junta directiva en las elecciones celebradas en su LXII Congreso Nacional que se ha celebrado de manera virtual. En estas elecciones ha sido elegido como vicepresidente segundo de la Sociedad el doctor Jiménez Yuste. Víctor Jiménez Yuste es Jefe de Servicio del Hospital Universitario la Paz y director del grupo de investigación Coagulopatías y Alteraciones de la Hemostasia.



Hemos mantenido la actividad de trasplantes, incluso durante los momentos más complejos del COVID

23/11/2020. Médicos del Hospital Universitario La Paz, a través de una técnica innovadora, han llevado a cabo el primer trasplante multivisceral y de progenitores hematopoyéticos en el mundo. El paciente, un menor de 15 años que padece displasia epitelial intestinal, había recibido dos trasplantes anteriormente, con rechazo, y con este nuevo trasplante de estómago, intestino delgado y grueso, páncreas e hígado y de médula para sustituirle precursores hematopoyéticos sanos (médula ósea), se redujo el riesgo de rechazo y se consiguió un caso de éxito, pionero en el mundo.



Hemos mantenido la actividad de trasplantes, incluso durante los momentos más complejos del COVID

23/11/2020. IdiPAZ ha batido sus propios records un año más, alcanzando los 5.900 puntos de factor de impacto global, superando el umbral de los 5.000 puntos por segunda vez en su historia y los 5.599 conseguidos el año 2018. En 10 años el Instituto de Investigación de La Paz ha pasado de los 2.500 puntos a 5.900 puntos en 2019. Este año, además ha obtenido la segunda reacreditación como Instituto de Investigación Sanitaria del Instituto de Salud Carlos III. La acreditación inicial fue en 2009 y la primera reacreditación en 2015.



Dos publicaciones con participación del IdiPAZ han sido seleccionadas por la revista Nature entre los 10 mejores descubrimientos del 2020

17/12/2020. Las dos publicaciones científicas donde se descubre la existencia de causas genéticas e inmunológicas de la COVID-19 grave han sido seleccionadas por la revista Nature como uno de los 10 mejores descubrimientos del 2020 para todos los campos científicos www.nature.com/articles/d41586-020-03514-8.


Introduction

Executive summary

Information Groups by Area

Associated Clinicians

The website is one of the other main task, to carry out the communication. In 2020, the number of visitors to the webpage were:



On the other hand, news that includes the work of our researchers, data about courses, grants, and other news of interest to the public, are published on the main social networks, where IdiPAZ has its own profile since October 2018.

In 2020, IdiPAZ opened a channel on Youtube to spread the webinars and other news.

Twitter: **@IdipazScience**	Facebook: **facebook.com/IdiPAZ**	Instagram: **@Idipaz**	YouTube: **youtube.com/IdiPAZ**
Followers: 1,621	Followers: 228	Followers: 436	Followers: 14
Publications: 252	Publications: 136	Publications: 96	Publications: 25



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2.13 Responsible Research and Innovation

Responsible Research and Innovation (RRI) is the key action of the Science with and for Society an approach that anticipates and assesses potential implications and societal expectations with regard to research and innovation, with the aim to Foster the design of inclusive and sustainable research and innovation. Based in RRI principles, IdiPAZ is growing to imply societal actors to work together for the research process in order to align both the process and its outcomes with the values, needs and expectations of society.

IdiPAZ has continued and development new several RRI actions:

Ethics and Research Integrity

- Human Resources Strategy for Researchers- HRS4R: endorsed the Charter and Code principles, gap analysis, OTM-R and action Plan design. In 2020, the European Commission recognizes with the 'HR Excellence in Research Award' to the institution.
- Own Ethic Committee: Research Ethics Committee with Medical Products and Animal Welfare Organ
- International Organization for Standardization (ISO) 9001 Certification for Committees and Platforms of IdiPAZ.
- Good Practice Recommendations Guidelines.

Open Access

- Own Open access Guideline of IdiPAZ
- To encourage researchers to participate in the institutional Open-Access Repositories with papers and research data: as Repisalud of the Institute of Health Carlos III, Institutional Repository of the Regional Health System of the Community of Madrid, and Biblos-e Archivo of the Autonomous University of Madrid
- Scientific Seminar, with online video recording to connect to scientific community and the society.
- In 2020, IdiPAZ was included as member of the European Open Science Cloud (EOSC) Association, to advance Open Science, to accelerate the creation of new knowledge, inspire education, spur innovation and promote accessibility and transparency.
- Workshop to promote and create the ORCID code use between IdiPAZ researchers (03/11/2020).
- Workshop to create the normalized curriculum in CVN format (05/02/2021)
- Workshop of the Institutional Repository of the Regional Health System of the Community of Madrid to promote the

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

use between IdiPAZ researchers (15/03/2021) to collect, preserve and make available to any interested person the scientific production generated by the professionals of all the centers and services of the Ministry of Health as result of their assistance, research and teaching activity, thus guaranteeing their conservation and open access and promoting their visibility and dissemination.

- Act 19/2013, of December 9, 2013, on transparency, access to public information and good governance. In accordance with the provisions of Article 66 paragraphs 1 and 2 of Law 10/2019 of April 10, 2009, and Article 2.1 of Law 10/2019 of April 10, 2009, and with the aim of publicizing our entity and the relevant information about it, the FIBHULP is registered in the Transparency Register of the Community of Madrid since March 4, 2021 with registration number 202100170.
- European Union Transparency Register. The Interinstitutional Agreement between the European Parliament and the European Commission sets out the rules and principles on which the Transparency Register is based. The first Agreement (signed in June 2011) was reviewed after two years. The revised Agreement was adopted in April 2014. FIBHULP is currently listed in the European Union Register as of May 10, 2021 under registration number 86699642652-90.

Science Education

- Scientific divulgation activities:
  - International Day of Women and Girls in Science
  - Science and Innovation Week
  - European Researchers´ Night
  - "4º ESO+empresa" Day
- Scientific Culture and Innovation Unit of IdiPAZ

Public engagement

- Current information about Clinical Trials research studies in different phases for Patients
- The society has the opportunity to collaborate with IdiPAZ via sponsorship and our Patronage Strategy - Pazito: colabora
- IdiPAZ+i News is an information bulletin focus to translated the society that the hospital is not only a place to treat the patients otherwise the researchers try to improve the health and wellbeing of our population with the research and innovation projects.

Governance

- Participative Governance: European Reference Network on paediatric transplantation (ERN TransplantChild), coordinated by our institution, TransplantChild Patients Committee.
- Research Ethics Committee with Medical Products
- Commission for Humanization and Social and Scientific Responsibility of IdiPAZ

Gender Equality

- Design of the Equality and Diversity Plan. Registered with REGCON (Registro y Depósito de Convenios Colectivos, acuerdos colectivos de trabajo y Planes de Igualdad)- Code 28109182112021.
- Creation of the Equality and Diversity Committee.
- Protocol for the prevention of and action against discriminatory harassment, moral and sexual harassment and harassment based on gender which has been developed by IdiPAZ's Commission for Equality and Diversity, to recognize, prevent, and if necessary, eradicate all those behaviors and organizational factors that reveal violent behavior in the workplace and promote a healthy work environment and climate, both physically and psychologically.
- Human Resources Strategy for Researchers- HRS4R: endorsed the Charter and Code principles, gap analysis, OTM-R and action Plan design.
- Participation in the International Day of Women and Girls in Science.



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

2.13.1 Social Responsibility

In 2020, IdiPAZ/FIBHULP get the international certification thought IQNet SR10, as a mark of confidence to shareholders and other stakeholders that reliable, recognized and value focus management practices are in place.



2.13.2 Goals to Transform Our World

In line with Social Responsibility Strategy, IdiPAZ begin to work in Sustainable Development Goals proposed by the 2030 Agenda for Sustainable Development, adopted by all United Nations Member States. Its provides a shared blueprint for peace and prosperity for people and the planet, now and into the future, and 17 Sustainible Development Goals (SDGs) were proposed.

A materiality study was performed through a process of questionnaire send to all the researchers, identify and mapping all of the research lines and projects of the Institute. As a result of the analysis, IdiPAZ priorized four Sustainible Development Goals that were included in their Strategic research and innovation Plan as follows::

IdiPAZ Sostenible

Strategic ODS:

3. Good Health
5. Gender Equality
8. Decent work and Economic Growth
9. Innovation and Infrastructure
10. Reduced inequalities
12. Responsible consumption and production
17. Partnerships for the goals

Relevant ODS:

4. Quality education
7. Affordable and clean energy
13. Climate action
16. Peace, justice and strong institutions

2.13.2 Goals to Transform Our World

In the next years, IdiPAZ will contribute to the implementation of the SDGs through its work on the four priorized goals and targets:



- **3.3** By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.
- **3.4** By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
- **3.5** Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.
- **3.7** By 2030, ensure universal access to sexual and reproductive healthcare services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes.
- **3.B** Support the research and development of vaccines and medicines for the communicable and noncommunicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all.
- **3.C** Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.
- **3.D** Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.



- **5.1** End all forms of discrimination against all women and girls everywhere
- **5.2** Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation
- **5.4** Recognize and value unpaid care and domestic work through the provision of public services, infrastructure and social protection policies and the promotion of shared responsibility within the household and the family as nationally appropriate
- **5.5** Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision making in political, economic and public life
- **5.B** Enhance the use of enabling technology, in particular information and communications technology, to promote the empowerment of women
- **5.C** Adopt and strengthen sound policies and enforceable legislation for the promotion of gender equality and the empowerment of all women and girls at all levels



- **8.3** Promote development-oriented policies that support productive activities, decent job creation, entrepreneurship, creativity and innovation, and encourage the formalization and growth of micro-, small- and medium-sized enterprises, including through access to financial services
- **8.5** By 2030, achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal value
- **8.6** By 2020, substantially reduce the proportion of youth not in employment, education or training
- **8.7** Take immediate and effective measures to eradicate forced labour, end modern slavery and human trafficking and secure the prohibition and elimination of the worst forms of child labour, including recruitment and use of child soldiers, and by 2025 end child labour in all its forms
- **8.8** Protect labour rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants, and those in precarious employment

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

9 INNOVATION AND INFRASTRUCTURE

- **9.1** Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all
- **9.5** Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending
- **9.B** Support domestic technology development, research and innovation in developing countries, including by ensuring a conducive policy environment for, inter alia, industrial diversification and value addition to commodities
- **9.C** Significantly increase access to information and communications technology and strive to provide universal and affordable access to the Internet in least developed countries by 2020

10 REDUCED INEQUALITIES

- **10.2** By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status
- **10.3** Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard
- **10.4** Adopt policies, especially fiscal, wage and social protection policies, and progressively achieve greater equality

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

- **12.2** By 2030, achieve the sustainable management and efficient use of natural resources
- **12.4** By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment
- **12.5** By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse
- **12.8** By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature
- **12.A** Support developing countries to strengthen their scientific and technological capacity to move towards more sustainable patterns of consumption and production
- **12.B** Develop and implement tools to monitor sustainable development impacts for sustainable tourism that creates jobs and promotes local culture and products

17 PARTNERSHIPS FOR THE GOALS

- **17.6** Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, in particular at the United Nations level, and through a global technology facilitation mechanism
- **17.17** Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3 Information Groups by Area

3.1 Neuroscience Area
3.2 Cardiovascular Area
3.3 Infectious Diseases and Immunity Area
3.4 Large System Pathologies Area
3.5 Cancer and Human Molecular Genetics Area
3.6 Surgery, Transplant and Health Technologies Area



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3 Information Groups by Area

3.1 Neuroscience Area

Documents:	136	IF:	576.^{299}
Originals:	104	IF:	394.^{639}
D1:	17	Q1:	48

3.2 Cardiovascular Area

Documents:	231	IF:	2187.^{492}
Originals:	186	IF:	1902.^{735}
D1:	48	Q1:	113

3.3 Infectious Diseases and Immunity Area

Documents:	341	IF:	1994.^{06}
Originals:	272	IF:	1636.^{377}
D1:	60	Q1:	169

3.4 Large System Pathologies Area

Documents:	451	IF:	2390.^{844}
Originals:	310	IF:	1700.^{748}
D1:	74	Q1:	174

3.5 Cancer and Human Molecular Genetics Area

Documents:	206	IF:	1454.^{196}
Originals:	171	IF:	1139.^{106}
D1:	55	Q1:	101

3.6 Surgery, Transplant and Health Technologies Area

Documents:	196	IF:	651.461
Originals:	139	IF:	460.849
D1:	21	Q1:	62

Doctoral theses. European Mention

Covid-19

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.1 Neuroscience Area

Exuperio Díez Tejedor

Documents:	136	IF:	576.[299]
Originals:	104	IF:	394.[639]
D1:	17	Q1:	48



3.1.1 Psychiatry and Mental Health Group

3.1.2 Neurology and Cerebrovascular Diseases Group


3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases Group

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group

3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases Group

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.1 Neuroscience Area



Strategic Objectives	Development forecast for the coming years	Actions
Neuroscience Area is composed of 5 research groups and has as general objectives the promotion of teaching, research and dissemination of knowledge in the field of neurosciences and neurological diseases, particularly in relation to clinical neurosciences.	Cohesion between different disciplines (biomedical research, engineering).	**Performing annual workshops and seminars science.**
	Encourage and promote research among the healthcare staff who sometimes perceive research as something negative.	**Training in research methodology in specialized health personnel and in training.**
	Innovation and technology transfer.	**Innovation promotion program that involves health organizations, research institutions and companies.**

3.1.1 Psychiatry and Mental Health Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	12
Impact Factor:	40.592
Q1:	3



María Fe Bravo Ortiz. Jefe de Servicio de Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Consuelo de Dios Perrino. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Blanca Amador Sastre. Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz

Jorge Andreo Jover. Investigador Predoctoral. FIBHULP

Carmen Bayón Pérez. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Susana Cebolla Lorenzo. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Eduardo Fernández Jiménez. Psicólogo Interno Residente. Hospital Universitario La Paz

Nieves González Suárez. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Ana Hospital Moreno. Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz

Eduardo Jiménez Sola. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Jesús Martí Esquitino. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Gonzalo Martínez-Ales García. Investigador Postdoctoral. Universidad de Columbia

Roberto Mediavilla Torres. Investigador Predoctoral. Hospital Universitario La Paz

Ainoa Muñoz San José. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Óscar Pajares González-Gallego. Enfermero Especialista en Salud Mental CSM Fuencarral. Hospital Universitario La Paz

Ángela Palao Tarrero. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Pau Pérez Sales. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Cristina Rocamora González. Psicologa. Residencia Asistida San Camilo

Beatriz Rodríguez Vega. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

María Paz Vidal Villegas. Técnico de Apoyo. Hospital Universitario La Paz

Rosa Villanueva Peña. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Strategic Objective

The group is devoted to assess the efficacy of psychotherapeutic techniques as adjunctive to other therapeutic measures in mental disorders and other medical diseases.

Their main areas of investigation are: research in bipolar disorder, severe mental disorder, and other medical disorders such as multiple sclerosis, cancer and chronic pain.

We participate in clinical trials on new treatments and specific therapies in order to improve the prognosis of these disorders.

Moreover, the group is involved in the evaluation of new treatments or new indications in mental disorders through the participation in clinical trials.

We are specially focused in the assessment of the efficacy and effectiveness of techniques such as Mindfulness and we evaluate hypothetical mediators of response, such as neurotrophic factors or factors related to inflammatory response.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Psychotherapeutic interventions in mental disorders
- Suicide prevention
- Psychological and social impact of the COVID-19 pandemic
- e-Health interventions
- Mindfulness-based interventions

Research Activity

Doctoral theses

Mediavilla Torres R. Mindfulness y cognición social en psicosis: Prueba de concepto, estudio piloto de aplicabilidad y ensayo controlado aleatorizado[dissertation]. Madrid: UAM: 2020 (27/02/2020)

Directors: Díaz García MI
Bravo Ortiz MF

Martínez Ales G. Contact maintenance strategies and brief psychotherapeutic intervention for suicide prevention: an implementation, effectiveness, and cost-effectiveness study[dissertation]. Madrid: UAM: 2020 (11/05/2020).

Directors: Bravo Ortiz MF
Baca García E

Publications

- Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020, 192: 152-60. Review. IF: 3.944, Q2
- Arenas-Castaneda PE, Aroca Bisquert F, Martínez-Nicolas I, Castillo Espindola LA, Barahona I, Maya-Hernández C, Lavana Hernández MM, Manrique Miron PC, Alvarado Barrera DG, Trevino Aguilar E, Barrios Núñez A, de Jesús Carlos G, Vildosola Garcés A, Flores Mercado J Barrigón ML, Artes A, de Leon S, Molina-Pizarro CA, Rosado Franco A, Pérez-Rodríguez M, Courtet P, Martínez-Ales G, Baca-García E. Universal mental health screening with a focus on suicidal behaviour using smartphones in a Mexican rural community: protocol for the SMART-SCREEN population-based survey. Bmj Open. 2020, 10(7): e035041. Article. IF: 2.692, Q2
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Rios JJ, Hernan MA, Frías J, Arribas JR. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. J Clin Med. 2020, 9(6): 1733. Article. IF: 4.241, Q1
- Hernández-Calle D, Martínez-Ales G, Mediavilla R, Aguirre P, Rodríguez-Vega B, Bravo-Ortiz MF. Trends in Psychiatric Emergency Department Visits due to Suicidal Ideation and Suicide Attempts During the COVID-19 Pandemic in Madrid Spain. J Clin Psychiat. 2020, 81(5): 20113419. Editorial Material. IF: 4.384, Q1
- Hernández-Calle D, Martínez-Ales G, Román-Mazuecos E, Rodríguez-Vega B, Bravo-Ortiz MF. Prevention over prediction: the psychiatrist challenge of suicide risk assessment in the emergency department. Rev Psiquiatr Salud Ment. 2020, 13(4): 232-3. Letter. IF: 3.318, Q2
- Martínez-Ales G, Hernández-Calle D, Khauli N, Keyes KM. Why Are Suicide Rates Increasing in the United States? Towards a Multilevel Reimagination of Suicide Prevention. Curr Top Behav Neurosci. 2020, 46: 1-23. Review. Not indexed
- Martínez-Ales G, López-Cuadrado T, Olfson M, Bouza C. Use and outcomes of mechanical ventilation for people with severe mental disorders admitted due to natural causes: A nationwide population-based study. Gen Hosp Psychiat. 2020, 65: 15-20. Article. IF: 3.238, Q2
- Mediavilla R, Fernández-Jiménez E, Rodríguez-Vega B, Gotor-Martínez L, Rivelles-Sevilla RV, Rojano-Capilla P, Bravo-Ortiz MF. Adapting mental health care after the COVID-19 outbreak: Preliminary findings from a public general hospital in Madrid (Spain). Psychiat Res. 2020, 289: 113077. Letter. IF: 3.222, Q3
- Mediavilla R, Muñoz-Sanjosé A, Rodríguez-Vega B, Bayón C, Palao A, Vidal-Villegas MP, Bravo-Ortiz MF. Clinical trials of psychological interventions cancelled due to the COVID-19 outbreak: how should we respond? Actas Esp Psiquiatri. 2020, 48(5): 233. Letter. IF: 1.196, Q4
- Reinares M, Pacchiarotti I, Sole B, García-Estela A, Rosa AR, Bonnin CM, De Dios C, Torres I, Varo C, Montejo L, Valls E, Mur-Mila E, Hidalgo-Mazzei D, Jiménez E, Torrent C, Goikolea JM, Martínez-Aran A, Pérez-Sola V, Vieta E, Colom F. A prospective longitudinal study searching for predictors of response to group psychoeducation in bipolar disorder. J Affect Disorders. 2020, 274: 1113-21. Article. IF: 4.839, Q2
- Rodríguez-Vega B, Palao A, Muñoz-Sanjosé A, Torrijos M, Aguirre P, Fernández A, Amador B, Rocamora C, Blanco L, Marti-Esquitino J, Ortiz-Villalobos A, Alonso-Sanudo M, Cebolla S, Curto J, Villanueva R, de-la-Iglesia MJ, Carracedo D, Casado C, Vidal E, Trigo D, Iglesias N, Cabanas D, Mellado L, García D, Fernández-Encinas C, Navarro R, Mediavilla R, Vidal-Villegas MP, Bravo-Ortiz MF, Bayón C. Implementation of a Mindfulness-Based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid Spain. Front Psychiatry. 2020, 11: 562578. Article. IF: 4.157, Q2
- Wasserman D, Apter G, Baeken C, Bailey S, Balazs J, Bec C, Bienkowski P, Bobes J, Ortiz MFB, Brunn H, Boke O, Camilleri N, Carpiniello B, Chihai J, Chkonia E, Courtet P, Cozman D, David M, Dom G, Esanu A, Falkai P, Flannery W, Gasparyan K, Gerlinger G, Gorwood P, Gudmundsson O, Hanon C, Heinz A, Dos Santos MJH, Hedlund A, Ismayilov F, Ismayilov N, Isometsa ET, Izakova L, Kleinberg A, Kurimay T, Reitan SK, Lecic-Tosevski D, Lehmets A, Lindberg N, Lundblad KA, Lynch G, Maddock C, Malt UF, Martín L, Martynikhin I, Maruta NO, Matthys F, Mazaliauskiene R, Mihajlovic G, Peles AM, Miklavic V, Mohr P, Ferrandis MM, Musalek M, Neznanov N, Ostorharics-Horvath G, Pajevic I, Popova A, Pregelj P, Prinsen E, Rados C, Roig A, Kuzman MR, Samochowiec J, Sartorius N, Savenko Y, Skugarevsky O, Slodecki E, Soghoyan A, Stone DS, Taylor-East R, Terauds E, Tsopelas C, Tudose C, Tyano S, Vallon P, van der Gaag RJ, Varandas P, Vavrusova L, Voloshyn P, Wancata J, Wise J,

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Zemishlany Z, Oncu F, Vahip S. Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. Eur Psychiat. 2020, 63(1): e82. Review. IF: 5.361, Q1

Research projects

Bravo Ortiz MF. Impacto de la pandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico. The covid-19 heroes study (COV20/00988). ISCIII. 2020-2021.

Managment centre: FIBHULP

Bravo Ortiz MF. Contrato garantía juvenil de ayuda investigación (PEJ-2017-AI/SAL-5716 CONTRATO). CM. 2018-2020.

Managment centre: FIBHULP

Bravo Ortiz MF. Contrato predoctoral (PEJD-2018-PRE/SAL-9039 CONTRAT). CM. 2019-2020.

Managment centre: FIBHULP

Bravo Ortiz MF. Intervenciones basadas en mindfulness para mejorar la cognición social en pacientes con un primer episodio psicótico (PI17/00768). ISCIII. 2018-2021.

Managment centre: FIBHULP

Bravo Ortiz MF. Ambiente y genes en esquizofrenia (S2017/BMD-3740 AGES-CM 2-CM). CM. 2018-2021.

Managment centre: FIBHULP

de Dios Perrino C. Eficacia de un programa de actividad física aeróbica como intervención coadyuvante en pacientes bipolares estables con sobrepeso. Proyecto Aerobip (PI17/01554). ISCIII. 2018-2020.

Managment centre: FIBHULP

Rodríguez Vega B. Prevención e intervención en suicidio (SURVIVE): estudio de cohorte y ensayos clínicos controlados anidados de programas de prevención secundaria para intentos de suicidio (PI19/00941). ISCIII. 2020-2022.

Managment centre: FIBHULP

Bravo Ortiz MF. Impacto de lapandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico: the COVID-19 Heroes Study (PI-4099-BRAVO ORTIZ). Sociedad Española de Psiquiatría. 2020-Ongoing.

Managment centre: FIBHULP

de Dios Perrino C. Regulación epigenética del sistema oxitocina-vasopresina y prosociabilidad en la manía bipolar (PI-1946 GRUPOS EMERGENTES 2014). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2015-Ongoing.

Managment centre: FIBHULP

Rodríguez Vega B. Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos (Lundbeck-Rodríguez Vega). Lundbeck España S. A. 2007-Ongoing.

Managment centre: FIBHULP

Rodríguez Vega B. Traducción y validación de los instrumentos reflective functioning questionnaire e inventary of personality onganization (RODRIGUEZ VEGA PI-2956). Fundación Vasca de Innovacion e Investigación Sanitarias. 2018-Ongoing.

Managment centre: FIBHULP

Bravo Ortiz MF. Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic (RESPOND). UE. 2020-2023.

Managment centre: FIBHULP

Clinical trials

Villanueva Peña R. Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de seltorexant 20 mg como tratamiento complementario a los antidepresivos en pacientes adultos y de edad avanzada con trastorno depresivo mayor con síntomas de insomnio que respondieron de manera inadecuada al tratamiento con antidepresivos y un tratamiento de extensión de seguridad abierto a largo plazo con seltorexant.

Type: EECC, phase III.
HULP code: 5643.
Sponsored´s protocol code: 42847922MDD3001.
Sponsored by: Janssen Pharmaceutica
N.V. Signed date: 05/10/2020

Villanueva Peña R. A 12-month observational prospective cohort study to analyze cardiometabolic profile changes to switch to lurasidone in patients with schizophrenia.

Type: Estudios, phase EPA-SP.
HULP code: PI-4416
Sponsored´s protocol code: ANG-LUR-2020-01.
Sponsored by: Angelini Farmaceutica.
Signed date: 04/11/2020

Patents and trademarks

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.



Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.;



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.1.2 Neurology and Cerebrovascular Diseases Group

Publications:	82
Impact Factor:	301.652
Q1:	27



Exuperio Díez Tejedor. Jefe de Servicio de Neurología. Hospital Universitario La Paz. Catedrático del Departamento de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

María José Aguilar-Amat Prior. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Elda María Alba Suárez. Investigador Predoctoral. Hospital Universitario La Paz

María Alonso de Leciñana Cases. Facultativo Especialista de Área en Neurología . Hospital Universitario La Paz

Francisco Javier Arpa Gutiérrez. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María Jesús Bullido Gómez-Heras. Profesor Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM "Severo Ochoa"

Fernando Carceller Benito. Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Elena de Celis Ruiz. Investigadora Predoctoral. Hospital Universitario La Paz

Sebastián Cerdán García-Esteller. Investigador Postdoctoral. Laboratorio de Imagen y Espectroscopia por Resonancia Magnética. IIB "Alberto Sols"

María Delia Chaverri Rada. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Jorge Eduardo Collazos Castro. Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos de Toledo

Francisco Javier Díaz de Terán Velasco. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Lucas Diekhorst. Investigador Predoctoral. Hospital Universitario La Paz

Josué Fernández Carnero. Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitarios La Salle

Andrés Francisco Fernández Prieto. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Mireya Fernández-Fournier Fernández. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Raúl Ferrer Peña. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Ana Frank García. Jefe de Sección en Servicio de Neurología. Hospital Universitario La Paz. Profesora Titular de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

Remedios Frutos Martínez. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Blanca Fuentes Gimeno. Jefa de Sección en Neurología. Hospital Universitario La Paz

María Luisa Gandía González. Facultativa Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Iván García Suárez. Facultativo Especialista de Área en Urgencias. Hospital Universitario San Agustín

María del Carmen Gómez de Frutos. Investigadora Predoctoral. Hospital Universitario La Paz

Ana Cristina Guadaño Ferraz. Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. IIB "Alberto Sols"

Alfonso Gil Martínez. Fisioterapeuta. Hospital Universitario La Paz

María Dolores Gutiérrez Fernández. Investigadora Postdoctoral. Contrtato Miguel Servet tipo I. Laboratorio de Neurociencias y Enfermedades Cerebrovasculares. Hospital Universitario La Paz

María Hernández Barral. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

David Hernández Herrero. Facultativo Especialista de Área en Rehabilitación y Medicina Física. Hospital Universitario La Paz

Vicente Iváñez Mora. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Roy La Touche Arbizu. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Laura Lacruz Ballester. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Manuel Lara Lara. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Fernando Laso García. Investigador Predoctoral. Hospital Universitario La Paz

Jesús María López Arrieta. Jefe de Sección de Geriatría. Hospital de Cantoblanco – Hospital Universitario La Paz. Profesor Asociado de Prácticas. Facultad de Psicología. Universidad Autónoma de Madrid

María Pilar López Larrubia. Científica Titular. CSIC. IBB "Alberto Sols"

Ibai López de Uralde Villanueva. Investigador Predoctoral. Centro Superior de Estudios Universitarios La Salle

Begoña Marín Aguilera. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Juan Andrés Martín Gonzalo. Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE

Ángel Martín Montes. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Arturo Martínez Arroyo. Técnico de Laboratorio. Hospital Universitario La Paz

Mercedes Martínez Moreno. Facultativo Especialista de Área en Medicina Física y Rehabilitación. Hospital Universitario La Paz

Susana Moraleda Pérez. Jefe de Sección de Medicina Física y Rehabilitación. Hospital Universitario La Paz

Pedro Navía Álvarez. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Pilar Negredo Madrigal. Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. Universidad Autónoma de Madrid

Susana Noval Martín. Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz

Jesús Oliván Palacios. Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz

Laura Otero Ortega. Investigadora Postdoctoral. Contrato Juan de la Cierva. Hospital Universitario La Paz

Joaquín Pardo Montero. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Alba París Alemany. Profesora. Investigadora Predoctoral. Centro Superior de Estudios Universitarios La Salle

Samuel Ignacio Pascual Pascual. Jefe de Sección de Neurología Pediátrica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

José Francisco Paz Solís. Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Inmaculada Puertas Muñoz. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Estrella Rausell Tamayo. Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. Universidad Autónoma de Madrid

José María Roda Frade. Jefe de Servicio de Neurocirugía. Hospital Universitario La Paz

Irene Rodríguez Andonaegui. Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE

Jorge Rodríguez de Pardo de Donlebún. Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz

Francisco Javier Rodríguez de Rivera Garrido. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Aranzazu Royo Orejas. Jefe de Sección de Radiología. Hospital Universitario La Paz

Gerardo Ruiz Ares. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

María Teresa Salas Campos. Técnico Superior Psicología. Servicio de Neurología. Hospital Universitario La Paz

Susana Santiago Pérez. Facultativo Especialista de Área en Neurofisiología. Hospital Universitario La Paz

Soledad Serrano López. Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz

Antonio Tallón Barranco. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Gema Torrijos Barbero. Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-Hospital Universitario La Paz

Arturo Ugalde Canitrot. Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz

Francisco Vivancos Matellano. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Strategic Objective

CEREBROVASCULAR

- Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To analyze the influence of hyperglycemia, diabetes and glycemic variability in the evolution of stroke.To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic factors, extracellular vesicles and remyelinizating drugs. To analyze the contribution of comorbidities in the mechanisms that occur after stroke, and the effect of therapies (protective, reparative ...) in animal models of stroke associated with hypertension and hyperglycemia.
- Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).
- Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, exosomes) in the ischemic area.
- Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients.
- Study of the clinical (neurological and neuropsy-chological) and anthropological factors influencing functional recovery and reintegration of stroke pa tients as well as the compliance with the recommendations for secondary stroke prevention.
- To analyze the recovery of post-stroke aphasia through a dubbing tool for television series and the development of a communication app. To evaluate the use of virtual reality in the recovery of motor and cognitive sequelae post-stroke, as well as the computational analysis of movement.
- To evaluate the effectiveness of keeping oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

- To discover factors anticipating the development of atrial fibrillation through EKG and echocardiographic abnormalities in criptogenic stroke.
- Impact of COVID-19 pandemic in stroke care and in stroke outcomes

HEADACHES AND NEUROPATHIC PAIN

- Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.
- Central Sensitization and pain perception in patients with cluster headache.
- Features and outcome of migraine in patients with fibromyalgia.
- Response to OnabotulinumtoxinA in High Frequency Episodic Migraine.
- Refractory migraine database.
- Short Term Prophylaxis of Cluster Headache: A Comparative Study.
- Study of neuropathic and chronic craniofacial pain
- Photophobia management using greater occipital nerve blocks in migraine patients
- CGRP-pathway drugs in patients with refractory migraine and medication overuse headache
- CGRP-pathway drugs in patients with refractory migraine and autoinmune diseases
- CGRP-pathway drugs in elderly patients with refractory migraine
- Multicentric colaboration in post-COVID related headache investigation
- Features and outcome of chronic refractory cluster headache treated with greater occipital nerve stimulation

NEURODEGENERATIVE DISEASES

Alzheimer´s disease

- Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer's disease.
- Study of genetic polymorfism related with PSP in the context of a multicentre Genome Wide Association study (GWAS)

Parkinson´s disease

- Tremor as a negative predictive factor in developing dementia associated with Parkinson's disease.
- Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson's disease.

Hereditary ataxias

- Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.
- Participation in the Registry of the European Consortium EFACTS (European Friedreich's Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedrich's Ataxia.

NEUROIMMUNOLOGY/NEUROINFLAMMATION

Multiple sclerosis

- Analysis of extracellular vesicles as biomarkers in multiple sclerosis patients.
- Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.
- Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.
- Development of parametric test in multiple sclerosis by fotometric strategies.

Autoinmune encephalitis and other autoinmune neurological diseases

- Neurological syndromes associated to antiGAD antibodies
- Paraneoplasic syndromes and other neurological diseases associated to antibodies.

Infectious diseases

- Study of neurological symptoms after COVID19 recovery in patients refer to specific consutation
- Analysis of brain volumetry in patients with cognitive symptoms after COVID19
- COVID-19 associated encephalopathy. Risk factors and outcomes

AUTONOMIC NERVOUS SYSTEM

- Evaluation of the Autonomic Nervous System in movement disorders.
- Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.

NEUROMUSCULAR DISEASES

- Observational study of the clinical course of patients with Charcot-Marie-Tooth disease. Identification of prognostic factors.
- Efficacy of evaluation of Eslicarbazepine acetate in neuropathic pain in patients with peripheral neuropathies.
- Develop a hand thermography tool for the diagnosis of fine fiber neuropathy.

Amyotrophic Lateral Sclerosis (ALS)

- Analysis of the different profiles of cognitive impairment in ALS patients.Adaptation and validation of cognitive ALS specific scales for Spanish patients .Study of cognitive potentials for identification of possible specific EEG endophenotypes in ALS patients.
- Study of biomarkers in ALS and other motor neuron diseases.Genetic,metabolomic and proteomic profiling combined with clinical parameters .
- Participation In Project MinE: International program analyzing the genoma of 15000 patients and controls by the same genotyping platform.
- Functional study of Autonomic Nervous System in Amyotrophic Lateral Sclerosis. Identification of differential patterns of the disease presentation and their impact on clinical outcome .

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

SLEEP

- Development and evaluation of intervention protocols in childhood insomnia treatment.
- Analysis of sleep microstructure in newborns with Prader Willi Syndrome.
- Study on the efficacy of child insomnia treatment with oral iron supplements against placeb.

EPILEPSY

- Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsia.
- Analysis of neuropsychological disorders in the primary generalized epilepsy.

* Obstructive sleep apnea in Epilepsy.

- Impact of perampanel in patients with epileptic encephalopathies. A multicentric study.
- Approach to refractory status epilepticus. Analysis of the different anesthetic agents commonly used in an intensive care unit
- Epilepsy in the elderly patient: peculiarieties and treatment alternatives, with a special focus in refractory cases.

DIGITAL TECHNOLOGIES APPLIED TO NEUROLOGICAL DISEASES.

- Objective assessment of motor or other functional deficits (stroke, movement disorders, multiple sclerosis)
- Environmental enrichment to promote early stroke recovery
- Virtual reality in promoting cognitive and motor recovery
- New applications of ultrasound for diagnosis and research in neurological diseases

NEUROSTIMULATION

- Neurostimulation in brain and spinal cord injuries

BRAIN DEVELOPMENT DISORDERS

- Study and functional classification of the gait of pediatric patients with cerebral palsy.
- Study and functional classification of the gait of patients with familial spastic parapa- resis.
- Gait analysis as a tool for the differential diagnosis bet - ween child cerebral palsy and PEF in paediatric patients.

Research lines

- Cerebrovascular diseases.
- Headache and neuropathic pain.
- Neurodegenerative diseases: cognitive disorders, movement disorders and spinocere- bellar ataxias.
- Neuroimmunology. Multiple sclerosis.
- Neuromuscular diseases. Motor neuron diseases Amyotrophic lateral sclerosis.
- Digital Technologies applied to neurological diseases
- Neurostimulation in brain and spinal cord injuries
- Developmental disorders and neurological maturation (TRADESMA).



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research Activity

Doctoral theses

Gutiérrez Zúñiga R. Impacto de la Diabetes Mellitus y su control metabólico en la evolución del infarto cerebral. Estudio de cohortes [dissertation]. Madrid: UAM: 2020 (26/11/2020).

Directors: Fuentes Gimeno B
Díez Tejedor E

Hernandez Herrero D. Establecimiento de un sistema de unidades relativas de valor como método de gestión de las consultas de intervencionismo en un servicio de Medicina Física y Rehabilitación de un hospital de tercer nivel de la Comunidad de Madrid[dissertation]. Mostoles: URJC: 2020 (17/07/2020).

Directors: Miangolarra Page JC
Garvin Ocampos L

Publications

- Armario P, Brotons C, Elosua R, de Leciñana MA, Castro A, Clara A, Cortes O, Rodríguez AD, Herranz M, Justo S, Lahoz C, Pedro-Botet J, Pérez AP, Santamaría R, Tresserras R, Lain SA, Royo-Bordonada MA. Statement of the spanish interdisciplinary vascular prevention committee on the updated European Cardiovascular Prevention Guidelines. Rev Esp Salud Publica. 2020; 94: e202009102. Article. IF: 0.756; Q4
- Benayas B, Sastre I, López-Martín S, Oo A, Kim B, Bullido MJ, Aldudo J, Yánez-Mo M. Tetraspanin CD81 regulates HSV-1 infection. Med Microbiol Immun. 2020; 209(4): 489-98. Article. IF: 3.402; Q3
- Carda S, Invernizzi M, Bavikatte G, Bensmail D, Bianchi F, Deltombe T, Draulans N, Esquenazi A, Francisco GE, Gross R, Jacinto LJ, Pérez SM, O'Dell MW, Reebye R, Verduzco-Gutiérrez M, Wissel J, Molteni F. The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. Ann Phys Rehabil Med. 2020; 63(6): 554-6. Letter. IF: 4.919; D1
- Cuenca-Martínez F, Herranz-Gómez A, Madronero-Miguel B, Reina-Varona A, La Touche R, Angulo-Díaz-Parreno S, Pardo-Montero J, del Corral T, López-de-Uralde-Villanueva I. Craniocervical and cervical spine features of patients with temporomandibular disorders: A systematic review and meta-analysis of observational studies. J Clin Med. 2020; 9(9): 2806. Review. IF: 4.241; Q1
- Cuenca-Martínez F, Suso-Mart L, Leon-Hernández JV, La Touche R. Effects of movement representation techniques on motor learning of thumb-opposition tasks. Sci Rep-Uk. 2020; 10(1): 12267. Article. IF: 4.379; Q1
- Cuenca-Martínez F, Suso-Martí L, Leon-Hernández JV, La Touche R. The role of movement representation techniques in the motor learning process: A neurophysiological hypothesis and a narrative review. Brain Sci. 2020; 10(1): 27. Review. IF: 3.394; Q3
- de Vidania S, Palomares-Pérez I, Frank-García A, Saito T, Saido TC, Draffin J, Szaruga M, Chavez-Gutiérrez L, Calero M, Medina M, Guix FX, Dotti CG. Prodromal Alzheimer's Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimer's Pathology. Front Neurosci. 2020; 14: 562581. Article. IF: 4.677; Q2
- del Corral T, La Touche R, Iranzo MACI, Olmos R, Blanco-Royano F, López-de-Uralde-Villanueva I. Development and validation of the AdT-Physio scale: A tool to assess adherence and perception of physical therapist intervention in patients with cystic fibrosis. Phys Ther. 2020; 100(11): 2063-74. Article. Not indexed
- Díaz-Sáez MC, Gil-Martínez A, González II, Lee JK, de-Vera JLDCP, Carretero JLC, Beltrán-Alacreu H. A novel mobile application to determine mandibular and tongue laterality discrimination in women with chronic temporomandibular disorder. Med Oral Patol Oral. 2020; 25(6): E775-83. Article. IF: 2.407; Q3
- Diekhorst L, Gómez-de Frutos MC, Laso-García F, Otero-Ortega L, Fuentes B, Jolkkonen J, Detante O, Moisan A, Leyva L, Martínez-Arroyo A, Díez-Tejedor E, Gutiérrez-Fernández M. Mesenchymal stem cells from adipose tissue do not improve functional recovery after ischemic stroke in hypertensive rats. Stroke. 2020; 51(1): 342-6. Article. IF: 7.914; D1
- Elizagaray-García I, Beltrán-Alacreu H, Angulo-Díaz S, Garrigos-Pedron M, Gil-Martínez A. Chronic primary headache subjects have greater forward head posture than asymptomatic and episodic primary headache sufferers: Systematic review and meta-analysis. Pain Med. 2020; 21(10): 2465-80. Review. IF: 3.75; Q2
- Ferrer-Peña R, Calvo-Lobo C, La Touche R, Fernández-Carnero J. Hip-joint posture and movement alterations are associated with high interference of pain in the life of patients with greater trochanteric pain syndrome. J Manip Physiol Ther. 2020; 43(6): 612-9. Article. IF: 1.437; Q3
- Flores AP, Gutiérrez JS, Reyes JRB, Tamayo JS, Benito FC. Risk factors associated with conversion of an Ommaya reservoir to a permanent cerebrospinal fluid shunt in preterm posthemorrhagic hydrocephalus. J Neurosurg-Pediatr. 2020; 25(4): 417-24. Article. IF: 2.375; Q3
- Flores AP, Sánchez CV, Roda JM, Cerdán S, Barríos AJ, Utrilla C, Royo A, González MLG. Assessment of pre-operative measurements of tumor size by MRI methods as survival predictors in wild type IDH glioblastoma. Front Oncol. 2020; 10: 1662. Article. IF: 6.244; Q2
- Fuentes B, de Leciñana MA, Calleja-Castano P, Carneado-Ruiz J, Egido-Herrero J, Gil-Núñez A, Masjuan-Vallejo J, Vivancos-Mora J, Rodríguez-Pardo J, Riera-López N, Ximénez-Carrillo A, Cruz-Culebras A, Gómez-Escalonilla C, Díez-Tejedor E. Impact of the COVID-19 pandemic on the organisation of stroke care. Madrid Stroke Care Plan. Neurología. 2020; 35(6): 363-71. Article. IF: 3.109; Q3
- Fuentes B, Gutiérrez-Zúñiga R, Díez-Tejedor E. It's time to say goodbye to the ESUS construct. Front Neurol. 2020; 11: 653. Editorial Material. IF: 4.003; Q2
- Fuentes B, Pastor-Yborra S, Gutiérrez-Zuniga R, de Villar NGP, de Celis E, Rodríguez-Pardo J, Gómez-de Frutos MC, Laso-García F, Gutiérrez-Fernández M, Ortega-Casarrubios M, Soto A, López-Fernández M, Santamaría M, Díez-González N, Freijo MM, Zandio B, Delgado-Mederos R, Calleja A, Portilla-Cuenca JC, Lisbona A, Otero-Ortega L, Díez-Tejedor E. Glycemic variability: prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study. J Transl Med. 2020; 18(1): 414. Article. IF: 5.531; Q2
- Gago-Veiga AB, de Terán JD, González-García N, González-Oria C, González-Quintanilla V, Minguez-Olaondo A, Santos-Lasaosa S, Romero JV, Pozo-Rosich P. How and when to refer patients diagnosed with secondary headache and other craniofacial pain in the Emergency Department and Primary Care: Recommendations of the Spanish Society of Neurology's Headache Study Group. Neurología. 2020; 35(5): 323-31. Review. IF: 3.109; Q3
- Gandía-González ML, Sáez-Alegre M, Roda JM. Neurosurgeons on the frontline of COVID-19: no place for surgery? Acta Neurochir. 2020; 162(7): 1503-4. Letter. IF: 2.216; Q3
- García Castro J, Rodríguez-Pardo J, Díaz de Terán J. Eclampsia-induced posterior reversible encephalopathy syndrome in a donor oocyte recipient. Family Reprod Health. 2020; 14(4): 269-72. Article. Not indexed
- García-Feijoo P, Isla A, Díez-Tejedor E, Mansilla B, Flores AP, Sáez-Alegre M, Vivancos C. Decompressive craniectomy in malignant middle cerebral artery infarction: family perception, outcome and prognostic factors. Neurocirugía. 2020; 31(1): 7-13. Article. IF: 0.553; Q4
- García-Magro N, Martín YB, Palomino-Antolín A, Egea J, Negredo P, Avendaño C. Multiple morphometric assessment of microglial cells in deafferented spinal trigeminal nucleus. Front Neuroanat. 2020; 13: 103. Article. IF: 3.856; Q2
- García-Magro N, Negredo P, Martín YB, Núñez A, Avendano C. Modulation of mechanosensory vibrissal responses in the trigeminocervical complex by stimulation of the greater occipital nerve in a rat model of trigeminal neuropathic

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

pain. J Headache Pain. 2020; 21(1): 96. Article. IF: 7.277; Q1

- García-Pastor A, Gil-Núñez A, Ramirez-Moreno JM, González-Nafria N, Tejada J, Moniche F, Portilla-Cuenca JC, Martínez-Sánchez P, Fuentes B, Gamero-García MA, de Lecinana MA, Masjuan J, Canovas D, Aladro Y, Parkhutik V, Lago A, De Arce AM, Usero-Ruiz M, Delgado-Mederos R, Pampliega A, Ximénez-Carrillo A, Bartulos-Iglesias M, Castro-Reyes E. Progression of carotid near-occlusion to complete occlusion: related factors and clinical implications. J Neurointerv Surg. 2020; 12(12): 1180-5. Article. IF: 5.836; D1
- García-Pastor A, Gil-Núñez A, Ramírez-Moreno JM, González-Nafria N, Tejada J, Moniche F, Portilla-Cuenca JC, Martínez-Sánchez P, Fuentes B, Gamero-García MA, de Leciñana MA, Canovas-Verge D, Aladro Y, Lago-Martín A, de Arce-Borda AM, Usero-Ruiz M, Arenillas JF, Delgado-Mederos R, Pampliega A, Ximenez-Carrillo A, Bartulos-Iglesias M, Castro-Reyes E. Comment on the article "Symptomatic carotid near-occlusion causes a high risk of recurrent ipsilateral ischemic stroke" by Gu et al. J Neurol. 2020; 267(3): 849-51. Letter. IF: 4.849; Q1
- Gómez A, Cerdán S, Pérez-Laso C, Ortega E, Pasaro E, Fernández R, Gómez-Gil E, Mora M, Marcos A, del Cerro MCR, Guillamon A. Effects of adult male rat feminization treatments on brain morphology and metabolomic profile. Horm Behav. 2020; 125: 104839. Article. IF: 3.587; Q1
- Gómez-de Frutos MC, García-Suárez I, Laso-García F, Diekhorst L, Otero-Ortega L, Alonso-López E, Díez-Tejedor E, Gutiérrez-Fernández M, Ruiz-Ares G. Identification of brain structures and blood vessels by conventional ultrasound in rats. J Neurosci Meth. 2020; 346: 108935. Article. IF: 2.39; Q3
- Grande-Alonso M, Garrigos-Pedron M, Cuenca-Martínez F, Vidal-Quevedo C, Prieto-Aldana M, La Touche R, Gil-Martínez A. Influence of the generation of motor mental images on physiotherapy treatment in patients with chronic low back pain. Pain Physician. 2020; 23(4): E399-E408. Article. IF: 4.965; Q1
- Grande-Alonso M, Muñoz-García D, Cuenca-Martínez F, Delgado-Sanz L, Prieto-Aldana M, La Touche R, Gil-Martínez A. Relationship between healthcare seeking and pain expansion in patients with nonspecific chronic low back pain. PEERJ. 2020; 8: e8756. Article. IF: 2.984; Q2
- Grande-Alonso M, Ortega-López F, Vittecoq R, Mayo-Fernández E, Navarro-Fernández G, Cuenca-Martínez F, La Touche R, París-Alemany A. Auditory and visual distraction improve muscle endurance: a randomised controlled trial. Somatosens Mot Res. 2020; 37(4): 334-42. Article. IF: 1.111; Q4
- Gutiérrez GG, Díaz-Manera J, Almendrote M, Azriel S, Barcena JE, García PC, Salas AC, Rodríguez CC, Cobo AM, Guardiola PD, Fernández-Torron R, Petit MPG, Pavia PG, Gallego MG, Martínez AJG, Jerico I, García SK, Arregui ALD, Martorell L, de la Tassa GM, Zabaleta RM, Muñoz-Blanco JL, Roldan JO, Pascual SIP, Peinado RP, Pérez H, Aldea JJP, Rabasa M, Ramos A, Bartolome AR, Pérez MAR, Urtizberea JA, Zapata-Wainberg G, Gutiérrez-Rivas E. Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease. Neurología. 2020; 35(3): 185-206. Article. IF: 3.109; Q3
- Gutiérrez-Zúñiga R, Rigual R, Torres-Iglesias G, Sánchez-Velasco S, de Leciñana MA, Masjuán J, Velasco RA, Navas I, Izquierdo-Esteban L, Fernández-Ferro J, Rodríguez-Pardo J, Ruiz-Ares G, Zapata-Wainberg G, Fuentes B, Díez-Tejedor E. Long-term anticoagulation in secondary ischemic stroke prevention: The prospective multicenter RESTAIC Registry. Front Neurol. 2020; 11: 575634. Article. IF: 4.003; Q2
- Henríquez-Recine, Noval S, Zafra B, de Manuel S, Contreras I. Ocular emergencies in children: Demographics, origin, symptoms, and most frequent diagnoses. J Ophthalmol. 2020; 2020: 6820454. Article. IF: 1.909; Q3
- Herruzo R, Herruzo I. Antimicrobial efficacy of a very stable hypochlorous acid formula compared with other antiseptics used in treating wounds: in-vitro study on micro-organisms with or without biofilm. J Hosp Infect. 2020; 105(2): 289-94. Article. IF: 3.926; Q2
- Indelicato E, Nachbauer W, Eigentler A, Amprosi M, Gothe RM, Giunti P, Mariotti C, Arpa J, Durr A, Klopstock T, Schols L, Giordano I, Burk K, Pandolfo M, Didszdun C, Schulz JB, Boesch S. Onset features and time to diagnosis in Friedreich's Ataxia. Orphanet J Rare Dis. 2020; 15(1): 198. Article. IF: 4.123; Q2
- La Touche R, Cuenca-Martínez F, Suso-Marti L, García-Vicente A, Navarro-Morales B, París-Alemany A. Tactile trigeminal region acuity in temporomandibular disorders: A reliability and cross-sectional study. J Oral Rehabil. 2020; 47(1): 9-18. Article. IF: 3.837; Q1
- La Touche R, García SM, García BS, Acosta AP, Juárez DA, Pérez JJF, Angulo-Díaz-Parreno S, Cuenca-Martínez F, París-Alemany A, Suso-Marti L. Effect of manual therapy and therapeutic exercise applied to the cervical region on pain and pressure pain sensitivity in patients with temporomandibular disorders: A systematic review and meta-analysis. Pain Med. 2020; 21(10): 2373-84. Article. IF: 3.75; Q2
- La Touche R, Herranz-Gómez A, Destenay L, Gey-Seedorf I, Cuenca-Martínez F, París-Alemany A, Suso-Marti L. Effect of brain training through visual mirror feedback, action observation and motor imagery on orofacial sensorimotor variables: A single-blind randomized controlled trial. J Oral Rehabil. 2020; 47(5): 620-35. Article. IF: 3.837; Q1
- La Touche R, Pardo-Montero J, Cuenca-Martínez F, Visscher CM, París-Alemany A, López-de-Uralde-Villanueva I. Cross-cultural adaptation and psychometric properties of the spanish version of the tampa scale for kinesiophobia for temporomandibular disorders. J Clin Med. 2020; 9(9): 2831. Article. IF: 4.241; Q1
- La Touche R, París-Alemany A, Suso-Martí L, Martín-Alcocer N, Mercado F, Cuenca-Martínez F. Pain memory in patients with chronic pain versus asymptomatic individuals: A prospective cohort study. Eur J Pain. 2020; 24(9): 1741-51. Article. IF: 3.931; Q2
- La Touche R, Pérez JJF, Acosta AP, Campodonico LG, García SM, Juárez DA, García BS, Angulo-Díaz-Parreo S, Cuenca-Martínez F, Suso-Marti L, París-Alemany A. Is aerobic exercise helpful in patients with migraine? A systematic review and meta-analysis. Scand J Med Sci Spor. 2020; 30(6): 965-82. Review. IF: 4.221; Q1
- La Touche R, Pérez JJF, García SM, Cuenca-Martínez F, López-de-Uralde-Villanueva I, Suso-Marti L. Hypoalgesic effects of aerobic and isometric motor imagery and action observation exercises on asymptomatic participants: A randomized controlled pilot trial. Pain Med. 2020; 21(10): 2186-99. Article. IF: 3.75; Q2
- Lassaletta L, Morales-Puebla JM, Altuna X, Arbizu A, Aristegui M, Batuecas A, Cenjor C, Espinosa-Sánchez JM, García-Iza L, García-Raya P, González-Otero T, Manos M, Martin C, Moraleda S, Roda JM, Santiago S, Benitez J, Cavalle L, Correia V, Estevez JM, Gómez J, González R, Jiménez J, Lacosta JL, Lavilla MJ, Penarrocha J, Polo R, García-Purrinos F, Ramos F, Tomas M, Uzcanga M, Vallejo LA, Gavilán J. Facial paralysis: Clinical practice guideline of the Spanish Society of Otolaryngology. Acta Otorrinolaringol Esp. 2020; 71(2): 99-118. Article. Not Indexed
- Lassaletta L, Morales-Puebla JM, González-Otero T, Moraleda S, Roda JM, Gavilan J. The experience of a facial nerve unit in the treatment of patients with facial paralysis following skull base surgery. Otol Neurotol. 2020; 41(10): E1340-9. Review. IF: 2.311; Q3
- Llorente P, Martins S, Sastre I, Aldudo J, Recuero M, Adjaye J, Bullido MJ. Matrix metalloproteinase 14 mediates APP proteolysis and lysosomal alterations induced by oxidative stress in human neuronal cells. Oxid Med Cell Longev. 2020; 2020: 5917187. Article. IF: 6.543; Q1
- López-de-Uralde-Villanueva I, Beltrán-Alacreu H, Fernández-Carnero J, La Touche R. Pain management using a multimodal physiotherapy program including a biobehavioral approach for chronic nonspecific neck pain: a randomized controlled trial. Physiother Theory Pract. 2020; 36(1): 45-62. Article. IF: 2.279; Q2
- Lubrini G, Periáñez JA, Fernández-Fournier M, Barranco AT, Díez-Tejedor E, García AF, Ríos-Lago M. Identifying perceptual, motor, and cognitive components contributing to slowness of information processing in multiple sclerosis with and without depressive symptoms. Span J Psychol. 2020; 23: e21. Article. IF: 1.264; Q3
- Lupo V, Won S, Frasquet M, Schnitzler MS, Komath SS, Pascual-Pascual SI, Espinós C, Svaren J, Sevilla T. Bi-allelic mutations inEGR2cause autosomal recessive demyelinating neuropathy by disrupting the EGR2-NAB complex. Eur J Neurol. 2020; 27(12): 2662-7. Article. IF: 6.089; D1
- Mantegazza R, O'Brien FL, Yountz M, Howard JF (Díez Tejedor E, Fernández-Fournier M, Rodriguez de Rivera FJ, Fernández-Fournier M). Consistent improvement with eculizumab across

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020; 7(8): 1327-39. Article. IF: 4.511; Q2

- Martínez-Alarcón L, Ríos A, Gutiérrez PR, Gómez FJ, Santaines-Borreda E, Agras-Suárez MC, Iriarte J, Canadas-De la Fuente GA, Herruzo R, Hurtado-Pardos B, Blanco G, Barcena-Calvo C, Llorca FJ, Perello-Campaner C, Asunsolo A, Arribas-Marin JM, Sánchez P, García-Mayor S, Fernández A, Soto-Ruiz MN, de Jesus MT, Navalon JC, Lana A, Bertran-Noguer C, Fuentes L, Pena-Amaro MP, Hernández JR, Jimenez-Herrera MF, Virseda J, Blanco-Sánchez R, Yelamos J, Calvo-Sánchez MD, Bondia JA, Prado-Laguna MC, González-García A, Martínez-Rodríguez A, Bas-Sarmiento P, Faus-Gabande F, Muinos-Alvarez A, Peyro-Gregori L, Hernández-Martínez H, López-Navas AI, Parrilla P, Ramirez P. Organ donation related with attitude toward the law of presumed consent: Spanish University Medical and nursing students study. Transpl P. 2020; 52(2): 439-42. Article. IF: 1.066; Q4
- Martínez-Alarcón L, Ríos A, Gutiérrez PR, Gómez FJ, Santaines-Borreda E, Agras-Suárez MC, Iriarte J, Canadas-De la Fuente GA, Herruzo R, Hurtado-Pardos B, Blanco G, Barcena-Calvo C, Llorca JF, Perello-Campaner C, Asunsolo A, Marin JMA, Sánchez P, Mayor-García S, Fernández A, Soto-Ruiz MN, de Jesús MT, Navalón JC, Lana A, Noguer CB, Fuentes L, Amaro MPP, Hernández JR, Jiménez-Herrera MF, Virseda J, Blanco-Sánchez R, Yelamos J, Calvo-Sánchez MD, Bondia JA, Laguna MCP, González-García A, Martínez-Rodríguez A, Bas-Sarmiento P, Faus-Gabande F, Muinos-Alvarez A, Peyro-Gregori L, Hernández-Martínez H, López-Navas AI, Parrilla P, Ramirez P. Confident perception of primary care physicians correlates to the attitude toward donation and organ transplantation: A multicenter study of medical and nursing Spanish students. Transpl P. 2020; 52(2): 491-5. Article. IF: 1.066; Q4
- Martínez-Alarcón L, Ríos A, Gutiérrez PR, Santaines-Borreda E, Gómez FJ, Agras-Suárez MC, Iriarte J, Canadas-De la Fuente GA, Herruzo R, Hurtado-Pardos B, Blanco G, Barcena-Calvo C, Llorca FJ, Perello-Campaner C, Asunsolo A, Arribas-Marin JM, Sánchez P, García-Mayor S, Fernández A, Soto-Ruiz MN, de Jesus MT, Navalon JC, Lana A, Bertran-Noguer C, Fuentes L, Pena-Amaro MP, Hernández JR, Jimenez-Herrera MF, Virseda J, Blanco-Sánchez R, Yelamos J, Calvo-Sánchez MD, Bondia JA, Prado-Laguna MC, González-García A, Martínez-Rodríguez A, Bas-Sarmiento P, Faus-Gabande F, Muinos-Alvarez A, Peyro-Gregori L, Hernández-Martínez H, López-Navas AI, Parrilla P, Ramírez P. Exploring health science students? Notions on organ donation and transplantation: A multicenter study. Transpl P. 2020; 52(5): 1428-31. Article. IF: 1.066; Q4
- Martínez-Fernández A, Vega MR, Quintás S, Heras MD, de Terán JD, González GL, García OT, Mora JV, Gago-Veiga AB. Psychosocial repercussion of migraine: is it a stigmatized disease? Neurol Sci. 2020; 41(8): 2207-13. Article. IF: 3.307; Q2
- Matías-Guiu J, Matías-Guiu JA, Álvarez-Sabín J, Ara JR, Arenillas J, Casado-Naranjo I, Castellanos M, Jiménez-Hernández MD, Laínez-Andrés JM, Moral E, Morales A, Rodríguez-Antigüedad A, Segura T, Serrano-Castro P, Díez-Tejedor E. Will neurological care change over the next 5 years due to the COVID-19 pandemic? Key informant consensus survey. Neurología. 2020; 35(4): 252-7. Review. IF: 3.109; Q3
- Membrilla JA, de Lorenzo I, Sastre M, de Terán JD. Headache as a cardinal symptom of coronavirus disease 2019: A cross-sectional study. Headache. 2020; 60(10): 2176-91. Article. IF: 5.887; Q1
- Michalska P, Buendía I, Duarte P, Fernández Mendivil C, Negredo P, Cuadrado A, López MG, Leon R. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacol Res. 2020; 152: 104597. Article. IF: 7.658; D1
- Miró JUM, Matellano FV. Chorea following extracorporeal circulation in adults: A case report and brief literature review. Neurología. 2020; 35(7): 519-21. Letter. IF: 3.109; Q3
- Noval S, Henríquez-Recine MA, Contreras I, Galdós M, Zafra B, Barrio-Barrio J, Carceller F. Macular ganglion cell complex thinning in children with visual field defects due to central nervous system pathology. Eye. 2020; 34(9): 1570-6. Article. IF: 3.775; Q1
- Ntaios G, Michel P, Georgiopoulos G, Guo YT, Li WC, Xiong J, Calleja P, Ostos F, González-Ortega G, Fuentes B, de Lecinana MA, Díez-Tejedor E, García-Madrona S, Masjuan J, DeFelipe A, Turc G, Goncalves B, Domigo V, Dan GA, Vezeteu R, Christensen H, Christensen LM, Meden P, Hajdarevic L, Rodríguez-López A, Díaz-Otero F, García-Pastor A, Gil-Núñez A, Maslias E, Strambo D, Werring DJ, Chandratheva A, Benjamin L, Simister R, Perry R, Beyrouti R, Jabbour P, Sweid A, Tjoumakaris S, Cuadrado-Godia E, Campello AR, Roquer J, Moreira T, Mazya MV, Bandini F, Matz K, Iversen HK, González-Duarte A, Tiu C, Ferrari J, Vosko MR, Salzer HJF, Lamprecht B, Dunser MW, Cereda CW, Quintero ABC, Korompoki E, Soriano-Navarro E, Soto-Ramirez LE, Castaneda-Mendez PF, Bay-Sansores D, Arauz A, Cano-Nigenda V, Kristoffersen ES, Tiainen M, Strbian D, Putaala J, Lip GYH. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke the global COVID-19 stroke registry. Stroke. 2020; 51(9): E254-8. Article. IF: 7.914; D1
- Otero-Ortega L, Laso-García F, Gómez-de Frutos MG, Diekhorst L, Martínez-Arroyo A, Alonso-López E, García-Bermejo ML, Rodríguez-Serrano M, Arrue-Gonzalo M, Díez-Tejedor E, Fuentes B, Gutiérrez-Fernández M. Low dose of extracellular vesicles identified that promote recovery after ischemic stroke. Stem Cell Res Ther. 2020; 11(1): 70. Article. IF: 6.832; Q1
- Paz JF, Sanz MDS, Paz-Domingo MV, Gandía-González ML, Santiago-Pérez S, Frade JMR. The use of transcranial motor-evoked potentials, somatosensory-evoked potentials and free-run electromyography for proper placement of paddle leads in chronic pain. Brit J Neurosurg. 2020; 34(4): 465-9. Article. IF: 1.596; Q4
- Prieto I, Alarcón CR, García-Gómez R, Berdún R, Urgel T, Portero M, Pamplona R, Martínez-Ruiz A, Ruiz-Sanz JI, Ruiz-Larrea MB, Jove M, Cerdán S, Monsalve M. Metabolic adaptations in spontaneously immortalized PGC-1 alpha knock-out mouse embryonic fibroblasts increase their oncogenic potential. Redox Biol. 2020; 29: 101396. Article. IF: 11.799; D1
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Paño-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae. Gut Pathog. 2020; 12(1): 15. Article. IF: 4.181; Q2
- Real MS, de Terán JD. OnabotulinumtoxinA is an effective treatment for chronic migraine in patients with comorbid fibromyalgia. Front Neurol. 2020; 11: 575130. Article. IF: 4.003; Q2
- Ríos A, López-Navas A, Gutiérrez PR, Gómez FJ, Iriarte J, Herruzo R, Blanco G, Llorca FJ, Asunsolo A, Sánchez P, Fernández A, De Jesus MT, Lana A, Fuentes L, Hernández JR, Virseda J, Yelamos J, Bondia JA, Carrillo J, Sánchez A, Alarcón LM, Parrilla P, Ramirez P. What reasons lead Spanish medical students not to be in favor of organ donation? Transpl P. 2020; 52(2): 443-5. Article. IF: 1.066; Q4
- Ríos A, López-Navas A, Gutiérrez PR, Gómez FJ, Iriarte J, Herruzo R, Blanco G, Llorca FJ, Asunsolo A, Sánchez P, Fernández A, de Jesús MT, Lana A, Fuentes L, Hernández JR, Virseda J, Yelamos J, Bondia JA, Carrillo J, Sánchez A, Alarcón LM, Parrilla P, Ramirez P. Are medical students of non-spanish nationality studying in Spain as sensitized to transplantation as those of spanish nationality? Transpl P. 2020; 52(2): 435-8. Article. IF: 1.066; Q4
- Ríos A, López-Navas A, Gutiérrez PR, Gómez FJ, Iriarte J, Herruzo R, Blanco G, Llorca FJ, Asunsolo A, Sánchez P, Fernández A, De Jesús MT, Lana A, Fuentes L, Hernández JR, Virseda J, Yelamos J, Bondia JA, Carrillo J, Sánchez A, Alarcón LM, Parrilla P, Ramírez P. Information about donation and organ transplantation among Spanish medical students. Transpl P. 2020; 52(2): 446-8. Article. IF: 1.066; Q4
- Rodríguez-Izquierdo I, Serramia MJ, Gómez R, de la Mata FJ, Bullido MJ, Muñoz-Fernández MA. Gold nanoparticles crossing blood-brain Barrier prevent HSV-1 infection and reduce herpes associated amyloid-beta secretion. J Clin Med. 2020; 9(1): 155. Article. IF: 4.241; Q1
- Rodríguez-Pardo J, Fuentes B, de Leciñana MA, Campollo J, Castano PC, Ruiz JC, Herrero JE, Leal RG, Núñez AG, Cerezo JFG, Martínez AM, Vallejo JM, Aguado BP, López NR, de las Heras RS, Mora JV, Tejedor ED. Acute stroke care during the COVID-19 pandemic. Ictus Madrid Program recommendations. Neurologia. 2020; 35(4):

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

258-63. Review. IF: 3.109; Q3

- Rodríguez-Pardo J, Plaza Herraiz A, Lobato-Pérez L, Ramirez-Torres M, De Lorenzo I, Alonso de Leciñana M, Díez-Tejedor E, Fuentes B. Influence of oral anticoagulation on stroke severity and outcomes: A propensity score matching case-control study. J Neurol Sci. 2020; 410: 116685. Article. IF: 3.181; Q3
- Rodríguez-Pardo J, Riera-López N, Fuentes B, Alonso de Leciñana M, Secades-García S, Álvarez-Fraga J, Busca-Ostolaza P, Carneado-Ruiz J, Díaz-Guzman J, Egido-Herrero J, Gil-Núñez A, Masjuan-Vallejo J, Real-Martínez V, Vivancos-Mora J, Díez-Tejedor E. Prehospital selection of thrombectomy candidates beyond large vessel occlusion: M-DIRECT scale. Neurology. 2020; 94(8): E851-60. Article. IF: 9.91; D1
- Rodríguez-Pardo J, Secades-García S, Riera-López N, de Leciñana MA, Real-Martínez V, Carneado-Ruiz J, Díaz-Guzmán J, Díez-Tejedor E, Egido-Herrero J, Gil-Núñez A, Matute-Lozano MC, Trillo S, Vera-Lechuga R, Vivancos-Mora J, Ximénez-Carrillo A, Fuentes B. Contraindications to intravenous thrombolysis in prehospital triage of thrombectomy candidates. Eur J Neurol. 2020; 27(12): 2439-45. Article. IF: 6.089; D1
- Rodríguez-Sanz A, Pena-Llamas E, Alonso-Canovas A, Alonso-Frech FA, Borrue-Fernández C, Catalán MJ, Fanjul-Arbos S, García-Cobos E, García-Ramos R, Ruiz-Espiga PG, Herreros-Rodríguez J, Kurtis-Urra M, López-Lozano JJ, López-Manzanares L, Martínez-Castrillo JC, Martínez-Fernández R, Mata M, Pérez-Sánchez JR, Posada IJ, Rojo A, Romero-Munoz JP, Ruiz-Huete C, Sánchez-Alonso MP, Vivancos-Matellano F. Clinical experience in the treatment of motor fluctuation in Parkinson's disease. Delphi consensus of a group of experts in movement disorders. Rev Neurologia. 2020; 71(11): 407-20. Article. IF: 0.87; Q4
- Ruiz-Ruiz C, García-Magro N, Negredo P, Avendaño C, Bhattacharya A, Ceusters M, García AG. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1(G93A) female mice. Dis Model Mech. 2020; 13(10): dmm045732. Article. IF: 5.758; Q2
- Salas T, Radakovic R, Rodríguez-Castillo V, Marín S, Chaverri D, Rodríguez-Santos F. Spanish adaptation of the dimensional apathy Scale (DAS) in amyotrophic lateral sclerosis. Front Neurol. 2020; 11: 562837. Article. IF: 4.003; Q2
- Sobrino T, Rodríguez-Yánez M, Campos F, Iglesias-Rey R, Millán M, de la Ossa NP, Dávalos A, Delgado-Mederos R, Martínez-Domeno A, Martí-Fabregas J, Castellanos M, Serena J, Lago A, Díez-Tejedor E, Castillo J. Association of high serum levels of growth factors with good outcome in ischemic stroke: a multicenter study. Transl Stroke Res. 2020; 11(4): 653-63. Article. IF: 6.829; Q1
- Soto-Insuga V, Oses M, Castaño-De la Mota C, Martínez-Bermejo A, Giraldez BG, Losada-Del Pozo R, Rodrigo-Moreno M, Martínez-Cayuelas E, Díaz-Gómez E, Serratosa JM. Breath-holding spell or epileptic seizure? A description of three girls with epileptic seizures triggered by anoxia. Rev Neurologia. 2020; 71(8): 313-4. Letter. IF: 0.87; Q4
- Suso-Martí L, La Touche R, Angulo-Díaz-Parreo S, Cuenca-Martínez F. Effectiveness of motor imagery and action observation training on musculoskeletal pain intensity: A systematic review and meta-analysis. Eur J Pain. 2020; 24(5): 886-901. Review. IF: 3.931; Q2
- Suso-Martí L, París-Alemany A, La Touche R, Cuenca-Martínez F. Effects of mental and physical orofacial training on pressure pain sensitivity and tongue strength: A single-blind randomized controlled trial. Physiol Behav. 2020; 215: 112774. Article. IF: 1.04; Q2
- Tejera DM, Beltrán-Alacreu H, Cano-de-la-Cuerda R, Hernández JVL, Martín-Pintado-Zugasti A, Calvo-Lobo C, Gil-Martínez A, Fernández-Carnero J. Effects of virtual reality versus exercise on pain, functional, somatosensory and psychosocial outcomes in patients with non-specific chronic neck pain: A randomized clinical Trial. Int J Env Res Pub He. 2020; 17(16): 5950. Article. IF: 3.39; Q1
- Tejera DM, Fernández-Carnero J, Suso-Martí L, Cano-de-la-Cuerda R, Lerín-Calvo A, Remón-Ramiro L, La Touche R. Comparative study of observed actions, motor imagery and control therapeutic exercise on the conditioned pain modulation in the cervical spine: a randomized controlled trial. Somatosens Mot Res. 2020; 37(3): 138-48. Article. IF: 1.111; Q4
- Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020; 267(7): 1991-2001. Article. IF: 4.849; Q1

Research projects

Alonso de Leciñana Cases M. Exosomas circulantes y mecanismos de reparación en ictus hemorrágico. Estudio traslacional (PI17/01922). ISCIII. 2018-2022.

Managment centre: FIBHULP

Alonso de Leciñana Cases M. Identificación de proteínas implicadas en la neuroreparación tras la isquemia cerebral. Estudio clínico-experimental. Fundación Hospital Ramon y Cajal. 2016-Ongoing.

Managment centre: FIBHULP

Alonso de Leciñana Cases M; Gutierrez Fernández M. Exosomas circulantes y mecanismos de reparación en ictus hemorrágico. Estudio traslacional. (PI 17/01922). ISCIII. 2018-Ongoing.

Managment centre: FIBHULP

Chaverri Rada MD. Recogida y envío de muestras de ADN genómico de pacientes con ELA para su estudio dentro del proyecto Mine (CHAVERRI RADA-ELA PI-3354). FUNDELA. 2020-Ongoing.

Managment centre: FIBHULP

Díaz de Terán Velasco FJ, Aguilar-Amat Prior MJ. Registro de pacientes en una clínica de primera crisis epiléptica. Allergan S. A. 2016-Ongoing.

Managment centre: FIBHULP

Díaz de Terán Velasco FJ. Influencia del estrés como factor precipitante de la crisis en pacientes con epilepsia. Ucb Pharma S. A. 2015-Ongoing.

Managment centre: FIBHULP

Díaz de Terán Velasco FJ. Sensibilización central y percepción del dolor en pacientes con cefalea en racimos. Allergan S. A. 2019-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. AMASCIS-02. Alogenic adipose tissue-derived mesenchymal stem cells in ischemic stroke. A phase IIB multicenter double blind placebo controllled clinical trial (PIC18/00016). ISCIII. 2019-2022.

Managment centre: FIBHULP

Díez Tejedor E. Analysis of the protectiv effect of olmesartan administrated pre or post-cerebral infarction in an animal model. Pfizer S. L. U. 2011-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Aplicación de nano partículas lipídicas biomodales sectorizadas hacia la zona de preinfarto en la reparación mediada por citicolina en el tratamiento de la isquemia cerebral. Modelo en ratas. Ferrer Farma S. A. 2009-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Brain repair therapy with exosomes derived mesenchymal stem cells in experimental intreacerebral hemorrhage model. Roche Farma S. A. 2016-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Efecto de los factores tróficos (cerebrolisina) y terapia con células madre en isquemia cerebral focal. Estudio experimental en ratas II. Ever Neuro Pharma GMBH. 2010-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con Lemtrada(Alemtuzumab) en pacientes con

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

formas recidivantes de Esclerosis Múltiple. Sanofi Aventis S. A. 2015-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Informatización de la gestión de pacientes. Unidad de Neuroinmunología y esclerosis múltiple en el Hospital Universitario La Paz. Sanofi Aventis S. A. 2014-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta a tratamientos biológicos. Fundación Biogen Idec. 2013-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta al natalizumab. Schering España S. A. Schering España S. A. 2011-Ongoing.

Managment centre: FIBHULP

Díez Tejedor E. Red de Enfermedades Vasculares Cerebrales. Invictus Plus (RD16/0019/0005). ISCIII. 2017-2021.

Managment centre: FIBHULP

Díez Tejedor E. Registro clínico para el seguimiento de tratamiento anticoagulante en prevención secundaria tras un ictus cardioembólico. Boehringer Ingelheim España S. A. 2011-Ongoing.

Managment centre: FIBHULP

Frank García A. Análisis antropológico de la sobrecarga del cuidador principal de personas con demencia. Estrategias de comunicación. Various financiers. 2018-2021.

Managment centre: FIBHULP

Frank García A. Evaluación de la satisfacción e impacto de los talleres formativo-informativos sobre ictus realizados por el Servicios de Neurología y Centro de Ictus del Hospital Universitario La Paz. Various financiers. 2018-Ongoing.

Managment centre: FIBHULP

Frank García A. Fffect of early and adult-life stress on the brain epigenome: relevance for the occurrence of Álzheimer´s disease (AC17/00120). ISCIII. 2018-2021.

Managment centre: FIBHULP

Fuentes Gimeno B. Ensayo clínico piloto dulcinea (dubbing language-therapy cinema-based in aphasia post-stroke. a feasibility cross-over pilot-trial). Fundación Bancaria Caixa D'Estalvis I Pensions de Barcelona la Caixa. 2019-Ongoing.

Managment centre: FIBHULP

Fuentes Gimeno B. Terapia reparadora con exosomas de células troncales mesenquimales en el infarto cerebral con daño subcortical en un modelo animal experimental (PI15/01318). ISCIII. 2016-2020.

Managment centre: FIBHULP

Fuentes Gimeno B. Variabilidad glucémica: impacto pronóstico en el infarto cerebral agudo e influencia del tratamiento corrector de la hiperglucemia. Estudio GLIAS-3 (PI18/00991). ISCIII. 2019-2021.

Managment centre: FIBHULP

Gil Martínez A, de Castro Carpeño J. Face Mirro. Fundación para la Innovacion y la Prospectiva en Salud en España. 2018-Ongoing.

Managment centre: FIBHULP

Gil Martínez A. Efectividad de un programa de ejercicios en pacientes con enfermedad de COVID-19 ingresados en planta del Hospital Universitario La Paz. Colegio Oficial de Fisioterapeutas de la Comunidad de Madrid. 2020-Ongoing.

Managment centre: FIBHULP

Gil Martínez A. Sistema de interacción natural para análisis y rehabilitación de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE). Fundación I+D del Software Libre. 2016-Ongoing.

Managment centre: FIBHULP

Gómez de Frutos MC. Contrato predoctoral (FI17/00188). ISCIII. 2018-2021.

Managment centre: FIBHULP

Gutierrez Fernández M, Alonso de Leciñana Cases M. Descifrando el papel de las vesículas extracelulares como moduladores de la respuesta inmunológica para promover la recuperación funcional tras la hemorragia cerebral. Estudio traslacional. (PI 20/00243). ISCIII. 2021-Ongoing.

Managment centre: FIBHULP

Gutiérrez Fernández MD. Exosomes as predictive biomarkers in acute ischemic stroke patients: a translational research approach (CP15/00069). ISCIII. 2016-2021.

Managment centre: FIBHULP

Laso García F. Contrato predoctoral (FI18/00026). ISCIII. 2019-2022.

Managment centre: FIBHULP

Moraleda Pérez S. Pacientes con parálisis facila periférica: Registro de características clínicas antes y después del tratamiento con toxina butolínica tipo A y reeducación neuromuscular facial. Allergan S. A. 2014-Ongoing.

Managment centre: FIBHULP

Muñoz y Ramón JM, Frank García A. Formación de personal investigador en colaboración con instituciones públicas y privadas. Various financiers. 2013-Ongoing.

Managment centre: FIBHULP

Noval Martín S. Estudio multicéntrico de tres años de duración para evaluar la tomografía de coherencia óptica como medida de valoración en pacientes con esclerosis múltiple. Novartis Farmacéutica S. A. 2012-Ongoing.

Managment centre: FIBHULP

Noval Martín S. Identificación de factores pronósticos de recuperación visual tras la cirugía de tumores de la región selar. Novartis Farmacéutica S. A. 2010-Ongoing.

Managment centre: FIBHULP

Otero Ortega L. Estrategias terapéuticas para el infarto cerebral (IJCI-2017-33505). MINECO. 2019-2020.

Managment centre: FIBHULP

Otero Ortega L. Proyecto Juan de la Cierva (IJCI-2017-33505p). MINECO. 2019-2020.

Managment centre: FIBHULP

Pascual Pascual SI. Estudio de la eficacia de la toxina botulínica en el pie equino espástico de la parálisis cerebral y de los factores que influyen en la misma. Allergan S. A. 2008-Ongoing.

Managment centre: FIBHULP

Pascual Pascual SI. Longitudinal data collection from patients with spinal muscular atrophy in spain a nationwide Registry-Cuidame. Fundación Sant Joan de Deu. 2020-Ongoing.

Managment centre: FIBHULP

Pascual Pascual SI. Safety evaluation on the use of botulinum toxin type a for the treatment of spasticity in children after 20 years of experience 1996-2015. A retrospective monocenter observacional study based on a data base containing over 1000 children. Ipsen Innovation. 2017-Ongoing.

Managment centre: FIBHULP

Puertas Muñoz I. Parametrización del modelo Estandarizado de Nine-Peg-Hole Test(NPHT) para estudio de discapacidad en miebros superiores en pacientes con Esclerosis Múlitple. Fundación Merck Salud. 2020-Ongoing.

Managment centre: FIBHULP

Roda Frade JM. Estudio multicéntrico del in-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

teractoma metabólico y genético en gliomas humanos. Implicaciones diagnósticas y pronósticas (PI17/00361). ISCIII. 2018-2022.

Managment centre: FIBHULP

Roda Frade JM. Imagen multimodal de la respuesta terapeutica a estrategias multidiana en enfermedades neurológicas (S2017/BMD-3688). CM. 2018-2021.

Managment centre: FIBHULP

Roda Frade JM. Programa de formación de un becario para el estudio del paciente diagnosticado con dolor crónico y/o trastornos del movimiento candidato a tratamiento con neuromodulación medular y cerebral. Boston Scientific Iberica S. A. 2017-Ongoing.

Managment centre: FIBHULP

Rodríguez de Rivera Garrido FJ. Estudio doble ciego, controlado con placebo, de grupos paralelos, aleatorizado, multicéntrico de la eficacia y seguridad de nicotinamida en pacientes con ataxia de Friedreich (AC16/00082). ISCIII. 2017-2021.

Managment centre: FIBHULP

Ruíz Ares G. Influencia de factores clínicos, bioquímicos y ultrasográficos asociados al pronóstico de la hemorragia intracerebral parenquimatosa. Estudio traslacional (PI16/01052). ISCIII. 2017-2021.

Managment centre: FIBHULP

Vivancos Matellano F. Análisis de la diferente evolución clínica de pacientes con enfermedad de Parkinson con tratamiento adyuvante asociado de un inhibidor de la dopa decarboxilasa y un inhibidor de la COMT. Lundbeck España S. A. 2008-Ongoing.

Managment centre: FIBHULP

Vivancos Matellano F. Programa de formación científica en la profundización del conocimiento de la enfermedad de Parkinson. Abbvie Spain S. L. U. 2020-Ongoing.

Managment centre: FIBHULP

Vivancos Matellano F. Proyecto de desarrollo para la mejora clínico-asistencial de pacientes con enfermedad de Parkinson avanzada tras el confinamiento. Abbvie Spain S. L. U. 2020-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Bullido Gómez-Heras MJ. Centro de Investigación en Red de Enfermedades neurodegenerativas. (CIBERNED). ISCIII. (31/12/2020).

Managment centre: FIBHULP

Díez Tejedor E. Vascular and Cerebral Diseases Network. (INVICTUS PLUS). ISCIII. (31/12/2021).

Managment centre: FIBHULP

Clinical trials

Aguilar-Amat Prior MJ. Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de padsevonil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia fármacorresistente.

Type: EECC, phase II.
HULP code: Anexo 1 5026.
Sponsored´s protocol code: EP0091.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 01/10/2020

Aguilar-Amat Prior, MJ. Estudio prospectivo, no intervencionista, observacional y multicéntrico para investigar la dosis, la eficacia y la seguridad de perampanel cuando se utiliza como primer tratamiento complementario en la asistencia clínica habitual de pacientes mayores de 12 años con crisis de inicio parcial con o sin generalización secundaria o con crisis tonicoclónicas generalizadas primarias asociadas a epilepsia generalizada idiopática.



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Type: Estudios, phase EPA-SP.
HULP code: PI-4301.
Sponsored´s protocol code: E2007-M044-512.
Sponsored by: Eisai Europe Limited.
Signed date: 31/08/2020

Chaverri Rada, MD. Estudio fase III, prospectivo, multicéntrico, randomizado, doble ciego, controlado con placebo y de grupos paralelos para comparar la eficacia y seguridad de masitinib en combinación con riluzol frente a placebo en combinación con riluzol para el tratamiento de pacientes con esclerosis lateral amiotrófica.

Type: EECC, phase III.
HULP code: 5412.
Sponsored´s protocol code: AB19001.
Sponsored by: Abscience.
Signed date: 04/12/2020

Díez Tejedor, E. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de ravulizumab en pacientes adultos sin tratamiento previo con inhibidores del complemento con miastenia gravis generalizada.

Type: EECC, phase III.
HULP code: Anexo 1 5277.
Sponsored´s protocol code: ALXN1210-MG-306.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 20/02/2020

Díez Tejedor, E. Estudio de prueba de concepto, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de elezanumab en ictus isquémico agudo.

Type: EECC, phase II.
HULP code: 5517.
Sponsored´s protocol code: M19-148.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 24/08/2020

Díez Tejedor, E. Estudio internacional de fase 2, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, de BMS-986177, un inhibidor del factor xia oral, para la prevención de un nuevo caso de ictus isquémico o de re-infarto cerebral silente en pacientes tratados con aspirina y clopidogrel después de un ictus isquémico agudo o un accidente isquémico transitorio.

Type: EECC, phase II.
HULP code: 5633.
Sponsored´s protocol code: CV010-031.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 11/08/2020

Díez Tejedor, E. Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD).

Type: EECC, phase III.
HULP code: 5463.
Sponsored´s protocol code: ALXN1210-NMO-307.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 29/07/2020

Díez Tejedor, E. Reducción del riesgo de apoplejía en personas que tienen hemorragia intracraneal previa y fibrilación auricular.

Type: EECC, phase IV.
HULP code: 5467.
Sponsored´s protocol code: ENRICH-AF.
Sponsored by: Hamilton Health Sciencies Corporation.
Signed date: 04/09/2020

Fernández Prieto, AF. Protocolo básico de la plataforma del registro de vigilancia de productos neurovasculares.

Type: Estudios, phase Producto Sanitario.
HULP code: 5648.
Sponsored´s protocol code: PSR NV INSPIRE.
Sponsored by: Medtronic Bakken Research Center B.V.
Signed date: 27/11/2020

Fuentes Gimeno, B. Administración intravenosa de células troncales mesenquimales alogénicas de tejido adiposo en el infarto cerebral agudo. Ensayo clínico fase IIB multicéntrico y doble ciego controlado con placebo.

Type: EECC, phase II.
HULP code: 5528.
Sponsored´s protocol code: AMASCIS-02.
Sponsored by: FIBHULP.
Signed date: 24/06/2020

Fuentes Gimeno, B. Eficacia y seguridad de la trombectomía en el accidente cerebrovascular con lesión importante e intervalo de tiempo prolongado: un ensayo clínico comparativo (Tensión).

Type: EECC, phase .
HULP code: 5506.
Sponsored´s protocol code: TENSION.
Sponsored by: .
Signed date: 16/09/2020

Fuentes Gimeno, B. Ensayo clínico piloto dulcinea (Dubbing language-therapy cinema-based in aphasia post-stroke). A feasibility cross-over pilot-trial.

Type: Estudios, phase No EPA.
HULP code: 5405.
Sponsored´s protocol code: DULCINEA.
Sponsored by: Fuentes Gimeno, Blanca.
Signed date: 11/03/2020

Fuentes Gimeno, B. Epidemia covid-19 e ictus agudo. Registro multicentrico Ictus.

Type: Estudios, phase No EPA.
HULP code: PI-4107.
Sponsored by: Fuentes Gimeno, Blanca.
Signed date: 23/06/2020

Gandia Gonzalez, ML. Estudio de prueba de concepto, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del elezanumab en la lesión aguda traumática de médula espinal cervical.

Type: EECC, phase II.
HULP code: 5560.
Sponsored´s protocol code: M16-077.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 29/05/2020

Gandía Gonzalez, ML. Estudio fase 2, multicéntrico, doble ciego, multidosis, controlado con placebo, randomizado y de grupos paralelos para evaluar la eficacia y seguridad de biib093 intravenoso en pacientes con contusión cerebral.

Type: EECC, phase III.
HULP code: 5276 5276.
Sponsored´s protocol code: 252BN201.
Sponsored by: Biogen Idec LTD.
Signed date: 08/06/2020

Lara Lara, M. Estudio en fase 3, de 12 meses de tratamiento abierto con lasmiditan en pacientes pediátricos con migraña: Pioneer-Peds2.

Type: EECC, phase III.
HULP code: 5603.
Sponsored´s protocol code: H8H-MC-LAHW.
Sponsored by: Lilly S.A.
Signed date: 08/10/2020

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, de grupos paralelos y controlados con placebo con un período de extensión para evaluar la eficacia y la seguridad del eptinezumab para la prevención de la migraña en pacientes contratamientos preventivos previos sin éxito.

Type: EECC, phase .
HULP code: 5552.
Sponsored´s protocol code: 18898A.
Sponsored by: Lundbueck A/S .
Signed date: 19/11/2020

Lara Lara, Manuel. Opciones para el alivio de la migraña en pediatría: estudio aleatorio, doble ciego de lasmiditan frente a placebo

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

para tratar el episodio agudo de migraña: Pioneer-Peds.

Type: EECC, phase III.
HULP code: 5604.
Sponsored´s protocol code: H8H-MC-LAHV.
Sponsored by: Lilly S.A.
Signed date: 08/10/2020

Pascual Pascual, Samuel Ignacio. Diseño y validación psicométrica de un conjunto de cuestionarios "Toolbox" para evaluar los resultados de salud en atrofia muscular espinal desde el punto de vista del paciente. Estudio SMA-Tool.

Type: Estudios, phase No EPA.
HULP code: PI-4398.
Sponsored´s protocol code: ML41962/ROC-AME2020-0.
Sponsored by: Roche Farma S.A.
Signed date: 24/09/2020

Pascual Pascual, Samuel Ignacio. Efectos de N-acetil-l-leucina en la ataxiatelangiectasia: un ensayo en fase II multinacional, multicéntrico, sin enmascaramiento para los pacientes y con enmascaramiento para los evaluadores.

Type: EECC, phase II.
HULP code: 5621.
Sponsored´s protocol code: IB1001-203.
Sponsored by: Intrabio Ltd.
Signed date: 13/10/2020

Pascual Pascual, Samuel Ignacio. Estudio controlado, aleatorizado y de aumento gradual de la dosis de nusinersén (BIIB058) en participantes con atrofia muscular espinal.

Type: EECC, phase III.
HULP code: 5466.
Sponsored´s protocol code: 232SM203.
Sponsored by: Biogen Idec Research Limited.
Signed date: 20/04/2020

Pascual Pascual, Samuel Ignacio. Estudio controlado, aleatorizado y de aumento gradual de la dosis de nusinersén (BIIB058) en participantes con atrofia muscular espinal.

Type: EECC, phase III.
HULP code: Anexo 1 5466.
Sponsored´s protocol code: 232SM203.
Sponsored by: Biogen Idec Research Limited.
Signed date: 01/10/2020

Pascual Pascual, Samuel Ignacio. Estudio de continuación, doble ciego, controlado con placebo, aleatorizado, multicéntrico, dividido en dos partes para investigar la seguridad, tolerabilidad, farmacocinética, farmacodinámica y eficacia de RO7034067 en pacientes con atrofia muscular espinal de tipo 2 y 3.

Type: EECC, phase II.
HULP code: Anexo 2 4664.
Sponsored´s protocol code: BP39055.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/10/2020

Pascual Pascual, Samuel Ignacio. Estudio de extensión del seguimiento internacional, multicéntrico, doble ciego de 9 meses de duración para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-Tooth de tipo 1A.

Type: EECC, phase III.
HULP code: Anexo 3 4768.
Sponsored´s protocol code: CLN-PXT3003-03.
Sponsored by: Pharnext.
Signed date: 24/08/2020

Pascual Pascual, Samuel Ignacio. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne capaces de caminar.

Type: EECC, phase III.
HULP code: 5619.
Sponsored´s protocol code: NS-065/NCNP-01-301.
Sponsored by: NS Pharma Inc.
Signed date: 06/08/2020

Roda Frade, José María. Estudio fase 2, multicéntrico, doble ciego, multidosis, controlado con placebo, randomizado y de grupos paralelos para evaluar la eficacia y seguridad de BIIB093 intravenoso en pacientes con contusion cerebral.

Type: EECC, phase II.
HULP code: 5276.
Sponsored´s protocol code: 252BN201.
Sponsored by: Biogen Idec Research Limited.
Signed date: 08/06/2020

Rodriguez De Rivera Garrido, Francisco Javier. Estudio de fase 2,aleatorizado y controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de TAK-079 en pacientes con miastenia grave generalizada.

Type: EECC, phase II.
HULP code: 5498.
Sponsored´s protocol code: TAK-079-1005.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 24/02/2020

Patents and trademarks

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Gil-Martínez A, inventors; FIBHULP, assignees.Specular Face. 4022981/5. 2019 December 10.

Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194; 2020 November 30.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases Group

Publications:	10
Impact Factor:	88.^{483}
Q1:	6

Antonio Cuadrado Pastor. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

María Antón Valadés. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Isabel Escoll Guerrero. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Raquel Fernández Ginés. Investigadora Predoctoral. Universidad Autónoma de Madrid

Ángel Juan García Yagüe. Investigador Postdoctoral. CIBERNED

Nadia Giselle Innamorato. Investigadora Predoctoral. Universidad Autónoma de Madrid


Diego Lastra Martínez. Investigador Predoctoral. Universidad Autónoma de Madrid

Ángela Martínez Valverde. Investigadora Postdoctoral. CSIC. IIB "Alberto Sols"

Patricia Rada Llano. Investigadora Postdoctoral. IIB "Alberto Sols"

Natalia Robledinos Antón. Investigador Predoctoral. Universidad Autónoma de Madrid

Ana Isabel Rojo Sanchís. Profesora Ayudante Doctor. Universidad Autónoma de Madrid



Strategic Objective

Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response ould be regulated pharmacologically to provide a therapeutic benefit in these diseases.

To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor Nrf2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress. For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson's and Alzheimer's disease as well as co-morbid retinopathy and type II diabetes

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases.
- The transcription factor Nrf2 as a new therapeutic target in Parkinson's and Alzheimer's disease
- Molecular basis of the role of Nrf2 in type 2 diabetes and its complications (diabetic retinopathy and nephropathy).

Research Activity

Publications

- Casas AI, Nogales C, Mucke HAM, Petraina A, Cuadrado A, Rojo AI, Ghezzi P, Jaquet V, Augsburger F, Dufrasne F, Soubhye J, Deshwal S, Di Sante M, Kaludercic N, Di Lisa F, Schmidt HHHW. On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacol Rev. 2020; 72(4): 801-28. Review. IF: 25.468; D1
- Robledinos-Antón N, Escoll M, Guan KL, Cuadrado A. TAZ Represses the Neuronal Commitment of Neural Stem Cells. Cells. 2020; 9(10): 2230. Article. IF: 6.6; Q2
- Escoll M, Lastra D, Robledinos-Antón N, Wandosell F, Antón IM, Cuadrado A. WIP modulates oxidative stress through NRF2/KEAP1 in glioblastoma cells. Antioxidants. 2020; 9(9): 773. Article. IF: 6.312; D1
- Cuadrado A, Pajares M, Benito C, Jiménez-Villegas J, Escoll M, Fernández-Gines R, Yagüe AJG, Lastra D, Manda G, Rojo AI, Dinkova-Kostova AT. Can activation of NRF2 be a strategy COVID-19? Trends Pharmacol Sci. 2020; 41(9): 598-610. Review. IF: 14.819; D1
- Cuadrado A, Perello C, Cabezas J, Llerena S, Llop E, Escudero MD, Hernández-Conde M, Puchades L, Redondo C, Fortea JI, de Miguel AG, Serra MA, Calleja JL, Crespo J. Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. J Viral Hepatitis. 2020; 27(11): 1261-5. Article. IF: 3.728; Q2
- Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson's disease: Mechanisms and therapeutic implications. Cells. 2020; 9(7): 1687. Review. IF: 6.6; Q2
- Martín-Hurtado A, Lastres-Becker I, Cuadrado A, García-Gonzalo FR. NRF2 and primary cilia: An emerging partnership. Antioxidants. 2020; 9(6): 475. Review. IF: 6.312; D1
- Herrera-Arozamena C, Estrada-Valencia M, Pérez C, Lagartera L, Morales-García JA, Pérez-Castillo A, Franco-González JF, Michaiska P, Duarte P, Leon R, López MG, Mills A, Gago F, García-Yagüe AJ, Fernández-Ginés R, Cuadrado A, Rodríguez-Franco MI. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. Eur J Med Chem. 2020; 190: 112090. Article. IF: 6.514; D1.
- Michalska P, Buendía I, Duarte P, Fernández Mendivil C, Negredo P, Cuadrado A, López MG, Leon R. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacol Res. 2020; 152: 104597. Article. IF: 7.658; D1
- Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong SJ, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattlecker M, Dobson R, Cuadrado A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, ten Kate M, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleo A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frolich L, Legido-Quigley C, Barkhof F, Blennow K, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R, Nielsen SF, Soininen H, Vellas B, Kloszewska I, Mecocci P, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Bertram L, Nevado-Holgado AJ, Lovestone S. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. J Alzheimers Dis. 2020; 77(3): 1353-68. Article. IF: 4.472; Q2

Research projects

Martínez Valverde A. Mecanismos moleculares y comunicación intertisular en la resistencia a la insulina (B2017/BMD-3684 MOIR2-CM). CAM. 2018-2020.

Managment centre: CISC

Cuadrado A; Lastres-Becker I. Papel de NRF2 en la función y el destino del cerebro con Alzheimer (SAF2016-76520-R). Ministerio de Ciencia e Innovacion. 2017-2020.

Managment centre: UAM

Cibers and Retics

Cuadrado Pastor A. Networked Biomedical Research Center for Neurodegenerative Diseases. (CIBERned). ISCIII. (31/12/2020).

Managment centre: UAM

Patents and trademarks

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group

Publications:	1
Impact Factor:	1.838
Q1:	0



Francisco Zafra Gómez. Catedrático. Facultad de Ciencias. Universidad Autónoma de Madrid

Enrique Núñez Balbuena. Titulado Técnico Superior. Universidad Autónoma de Madrid

María del Carmen Aragón Rueda. Catedrática. Facultad de Ciencias. Universidad Autónoma de Madrid

Eva María Porlan Alonso. Investigador Programa Ramón y Cajal. Universidad Autónoma de Madrid

Beatriz Fuensanta López Corcuera. Profesora Titular. Facultad de Ciencias. Universidad Autónoma de Madrid

Strategic Objective

Role of glutamate and glycine transporters in physiological and pathological aspects of glutamatergic and glycinergic neurotransmission.

Involvement of glutamate transporters in excitotoxicity, ischemia and traumatic brain injury.

Pathologies of glycinergic neurotransmission such as hyperekplexia and pain

Role of the adult neurogenesis in neurorepair.

Role of microRNAs in ischemic tolerance.

Research lines

The group studies the physiological and pathological aspects of glutamate fuxes in brain as potential targets to prevent excitotoxicity, associated with brain disfunctions like ischemia, o traumatic brain injury:

1. Identification and characterization of new GlyT2 mutations (SLC6A5 gene) associated to human hyperekplexia. Effects of the mutations on transporter structure, function, proteostasis and glycinergic neurotransmission. Role in presynaptic hyperekplexia of different genes related to GlyT2 trafficking, interactoma, posttranslational modifications. Rescue interventions.
2. Study of plastic adaptations affecting glycine transporters in physiological and pathological nociception. Regulation of GlyTs by receptors modulating nociceptive signaling (P2XR, P2YR, mAch, nAch, a2 adrenergic, 5-HT). Signaling pathways.
3. Neuron-glia crosstalk through microRNAS and exosomes
4. The group studies the physiological and pathological aspects Neuronal reparation by adult neurogenesis:
   A) Identification of novel regulatory mechanisms of adult neurogenesis by kinases.
   B) Identification of novel regulatory mechanisms of adult neurogenesis by microRNAs and other non-coding RNAs.


Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity



Doctoral theses

de la Rocha Muñoz A. Fisiopatología del transportador neuronal de glicina GlyT2: regulación y estudio de mutantes asociados a hiperplexia[dissertation]. Madrid: UAM: 2020(05/10/2020).

Director: López Corcuera B.

Publications

- da Silva VD, Silva RR, Neto JG, López-Corcuera B, Guimaraes MZ, Noel F, Buarque CD. New alpha-Hydroxy-1,2,3-triazoles and 9H-Fluorenes-1,2,3-triazoles: Synthesis and Evaluation as Glycine Transporter 1 Inhibitors. J Brazil Chem Soc. 2020; 31(6): 1258-69. Article. IF: 1.838; Q3

Research projects

López Corcuera B. El transportador neuronal de. glicina glyt2 en patologias. humanas: hiperplexia y dolor (SAF2017-84235-R). MINECO. 2018-2020.

Managment centre: UAM

Zafra Gómez F. Papel de los microRNAs y los exosomas en la inducción de la tolerancia isquémica en el cerebro (RTI2018-098712-B-I00). MINECO. 2019-2021.

Managment centre: UAM

Porlan Alonso E. Nuevos reguladores farmacológicos de la neurogénesis adulta y la reprogramación directa (PID2019-104763RB-I00). Ministerio de Ciencia e Innovación. 2020-2023.

Managment centre: UAM

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases Group

Publications:	3
Impact Factor:	16.[121]
Q1:	1

Isabel Lastres Becker. Profesora Titular. Universidad Autónoma de Madrid

Marina Arribas Blázquez. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Irene Chaves Coira. Profesor Ayudante Doctor. Universidad Autónoma de Madrid

Sara Castro Sánchez. Investigadora Predoctoral. Universidad Autónoma de Madrid

Rosana Hernández Sierra. Técnico Especialista. Universidad Autónoma de Madrid



Strategic Objective

The aging of the population poses a growing burden in society. This is associated with the increase in disability and diseases that have a high impact on health care, on patients and their families. Likewise, aging is associated with the appearance of different neurodegenerative diseases, among which include Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). Therefore, the development of advanced biological markers, new drugs and appropriate technology is the key to establishing a treatment for these diseases, which is currently an important social challenge. In our laboratory we study the molecular basis of neurodegeneration. The research projects we develop have a multidisciplinary approach that combines basic and translational research, using cell culture techniques, murine models and postmortem samples from patients with AD, PD and ALS.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Implication of alterations at the mitochondrial and mitophagy level in Parkinson's Disease
- New therapeutic strategies for diseases with alterations in the TAU protein, such as Alzheimer's disease. We have two different approaches to this:
  - Modulation at the epigenetic level: miRNAs
  - Involvement of the cannabinoid system: CB2 receptor
- Development of new therapeutic strategies for amyotrophic lateral sclerosis. We have three different aprroaches:
  - Design of new drugs
  - Analysis of RNA metabolism and stress granule formation
  - Implication of the kinases RIPK1 and SGK1 in the pathology

Research Activity

Publications

- Castro-Sánchez S, Zaldívar-Diez J, Luengo E, López MG, Gil C, Martínez A, Lastres-Becker I. Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiol Aging. 2020; 96: 148-54. Article. IF: 4.763; Q2
- Galán-Ganga M, del Río R, Jiménez-Moreno N, Díaz-Guerra M, Lastres-Becker I. Cannabinoid CB2 receptor modulation by the transcription factor NRF2 is specific in microglial cells. Cell Mol Neurobiol. 2020; 40(1): 167-77. Article. IF: 5.046; Q2
- Martín-Hurtado A, Lastres-Becker I, Cuadrado A, García-Gonzalo FR. NRF2 and primary cilia: An emerging partnership. Antioxidants. 2020; 9(6): 475. Review. IF: 6.312; D1

Research projects

Martínez A; Lastres-Becker I. Diseño y desarrollo de fármacos innovadores para el tratamiento de la esclerosis lateral amiotrófica (B2017/BMD-3813). CM. 2018-2022.

Managment centre: CSIC-UAM

Cuadrado A; Lastres-Becker I. Papel de NRF2 en la función y el destino del cerebro con Alzheimer (SAF2016-76520-R). Ministerio de Ciencia e Innovacion . 2017-2020.

Managment centre: UAM

Lastres-Becker I. Análisis del transporte de gránulos de RNA y traducción de proteínas in situ en ELA: ¿implicación de SATUFEN y TDP-43? (2019/00325/001). FUNDELA. 2019-2021.

Managment centre: UAM

Martínez A; Lastres-Becker I. Aging and neurodegeneration targeting by protein kinase small molecules inhibitors (PID2019-105600RB-I00). Ministerio de Ciencia e Innovacion . 2020-2023.

Managment centre: CSIC

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.2 Cardiovascular Area

José Luis López-Sendón Hentschel

Documents:	231	IF:	2187.[492]
Originals:	186	IF:	1902.[735]
D1:	48	Q1:	113

3.2.1 Research on Invasive Clinical Cardiology – ICCI-Paz Group

3.2.2 Cardiovascular Epidemiology and Nutrition Group

3.2.3 Coagulopathies and Alterations of Haemostasis Group


3.2.4 Vascular Physiology and Pharmacology Group

3.2.5 Vascular Pharmacology and Metabolism Group (FARMAVSM)



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.2 Cardiovacular Area



Strategic Objectives	Development forecast for the coming years	Actions
Cardiovascular Area is composed of 6 groups that carry out basic, experimental and clinical research in the fields of cardiology and cardiovascular risk factors. The area has an important activity in the performance of international clinical trials of wide impact and applicability. The scientific production of the cardiovascular area is supported by a high impact factor. The groups also have extensive experience in training researchers.	To merge the groups by research lines in order to avoid the duplicities that make the group lose strength and competitiveness and to bet on being more competitive and to take better advantage of the resources.	**Foster and support translational research lines.**
	The area should be focused on consolidated and multidisciplinary research lines rather than structured by pathologies. The collaboration with research groups from other organizations should be the norm.	**Establish relationships/ collaboration/alliances with other IdiPAZ research groups and with groups from other institutions and maintain those already started.**
	Resources should be focused on priorities established by the researchers themselves, or directly by IdiPAZ after analyzing the scientific production of each group.	**Analyze the scientific production of each group.**
	Clinical research through the resources it provides (clinical trials) should guide basic research projects in order to offer the ideal field for translational medicine. This type of research also provides a stronger link between international research groups.	**Encourage participation in clinical trials of researchers.**

3.2.1 Research on Invasive Clinical Cardiology - ICCI-PAZ Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	73
Impact Factor:	1273.^{343}
Q1:	27



José Luis López-Sendón Hentschel.
Jefe de Servicio de Cardiología. Hospital Universitario La Paz

Isabel Antorrena Miranda. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Eduardo Armada Romero. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Almudena Castro Conde. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Regina Dalmau González-Gallarza. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Francisco Javier Domínguez Melcón. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Carlos Escobar Cervantes. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Jaime Fernández de Bobadilla Osorio. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Javier Fuertes Beneítez. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Guillermo Galeote García. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Elvira Ana González García. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Teresa González Gallego. Investigadora Senior (Contrato Ramón y Cajal). IIB "Alberto Sols"

Gabriela Guzmán Martínez. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Ángel Manuel Iniesta Manjavacas. Facultativo Especialista de Área en Cardiología Hospital Universitario La Paz

Santiago Jiménez Valero. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Teresa López Fernández. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Esteban López de Sá y Areses. Jefe de Sección de Cuidados Intensivos Cardiológicos. Hospital Universitario La Paz

José Luis Merino Llorens. Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. Hospital Universitario La Paz

José Raúl Moreno Gómez. Jefe de Sección de Hemodinámica. Hospital Universitario La Paz

María del Mar Moreno Yangüela. Jefe de Sección de Imagen Cardiaca. Hospital Universitario La Paz

Rafael Peinado Peinado. Jefe de Sección de Arritmias y Electrofisiología. Hospital Universitario La Paz

Esther Pérez David. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Juan Ramón Rey Blas. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Luis Riera del Moral. Facultativo Especialista de Área en Angiología y Cirugía Vascular. Hospital Universitario La Paz. Profesor Asociado Departamento de Cirugía. Universidad Autónoma de Madrid

Inmaculada Roldán Rabadán. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

José Ruiz Cantador. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Silvia Cayetana Valbuena López. Médico Interno Residente en Cardiología. Hospital Universitario La Paz

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

The group consists of various healthcare units of the Department of Cardiology at Hospital La Paz: Clinic/Coronary Unit, interventional cardiology, cardiac imaging, electrophysiology, rehabilitation and adult congenital heart disease.

The main research lines focus on providing clinical responses, with local research protocols and direct participation in clinical trials and international multicentre registries. Moreover, clinical translational potential is reinforcedthrough an institutional relationship with the CNIC.

Research lines

- Myocardial ischaemia. Acute and chronic. Diagnosis, prognosis and treatment.
- Cardiac arrhythmias. Catheter navigation systems.
- Diagnosis and treatment. Post cardiac arrest hypothermia.
- Heart Failure. Diagnosis and treatment. Cardiotoxicity of antineoplastic agents.
- Cardiac diagnostic imaging.
- Aortic stenosis. Diagnosis and treatment.
- Adult congenital heart diseases.
- Endovascular therapy and new cellular therapies in peripheral vascular disease.

Research Activity

Publications

- Argos CM, Fernández TL, López CV. Severe stenosis due to prosthetic thrombosis evaluated with TrueVue. Rev Esp Cardiol. 2020; 73(6): 499. Editorial Material. IF: 4,753; Q2
- Arribas F, Brugada J, Almendral J, Arbelo E, Infante ED, García-Cosio F, Lospitao S, Merino JL, Ormaetxe JM, Osca J, Tercedor L, Pedrote A, Lahuerta AA, Barón G, Escobar C, Fiol M, Fortuny E, Torrecilla EG, Font ER, Granel RR, Arribas F, Congost GB, Bueno H, Evangelista A, Ferreira-González I, Navarro MJ, Marin F, de Isla LP, Sambola A, Vazquez R, Viana-Tejedor A, Ibanez B, Alfonso F. Comments on the 2019 ESC guidelines on supraventricular tachycardia. Rev Esp Cardiol. 2020; 73(6): 445-51. Editorial Material. IF: 4.753; Q2
- Arroyo-Ucar E, Gómez RM, Vazquianez MR, Saura FT. Quo vadis, coronary lithoplasty. Rev Esp Cardiol. 2020; 73(5): 430. Letter. IF: 4.753; Q2
- Barrios V, Cosín-Sales J, Bravo M, Escobar C, Gámez JM, Huelmos A, Cortes CO, Egocheaga I, García-Pinilla JM, Jiménez-Candil J, López-de-Sa E, Llergo JT, Obaya JC, Pallares-Carratala V, Sanmartin M, Vidal-Pérez R, Cequier A. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol. 2020; 73(11): 910-8. Article. IF: 4.753; Q2
- Barrios V, Escobar C. Reply to 'On the quality of life questionnaires in atrial fibrillation'. Rev Clin Esp. 2020; 220(2): 146-7. Letter. IF: 1.556; Q3
- Barrios V, Escobar C. Atrial fibrillation, an equivalent of cardiovascular disease risk. Eur Heart J. 2020; 41(48): 4599. Editorial Material. IF: 29.983; D1
- Barrios V, Escobar C. May we apply results data from classical hypertension clinical trials to all beta-blockers?. J Hypertens. 2020;38(12):-. Letter. IF: 4,844; Q2
- Barrios V, Escobar C, Arrarte V, García E, Fernández MR, Rincón LM, Roldán C. First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. Clin Investig Arterioscler. 2020; 32(6): 231-41. Article. Not indexed
- Barrios V, Escobar C, Arrarte V, Roldan C. First national registry of evolocumab in clinical practice in cardiology units in Spain. The RETOSS-CARDIO study. Rev Esp Cardiol. 2020; 73(6): 513-5. Letter. IF: 4.753; Q2
- Barrios V, Escobar C, Barón G, Gómez-Doblás J, Recalde E, Segura L, Álvarez P, Alonso F, Toril J, Chopo JM. Quality of life, medication adherence and satisfaction with anticoagulant treatment (dabigatran vs vitamin K antagonists) according to thromboembolic risk. Data from the CAPANA study. Int J Clin Pract. 2020; 74(11): e13605. Letter. IF: 2.503; Q2
- Barrios V, Escobar C, Cortes CO, Sales JC, Figal DAP, Marimón XGM. Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. Rev Clin Esp. 2020; 220(6): 339-49. Article. IF: 1.556; Q3
- Barrios V, Escobar C, Gómez-Doblas JJ, Fernández-Dueñas J, Garrido RR, Rodríguez JP, Sánchez JU, Arellano-Rodrigo E, Donado E. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists. J Comp Eff Res. 2020; 9(9): 615-25. Article. IF: 1.744; Q4
- Biscaglia S, Guiducci V, Santarelli A, Santos IA, Fernández-Avilés F, Lanzilotti V, Varbella F, Fileti L, Moreno R, Giannini F, Colaiori I, Menozzi M, Redondo A, Ruozzi M, Ibanes EG, Gil JLD, Maietti E, Zoccai GB, Escaned J, Tebaldi M, Barbato E, Dudek D, Colombo A, Campo G. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. Am Heart J. 2020; 229: 100-9. Article. IF: 4.479; Q2
- Bonanad Lozano C, Díez-Villanueva P, Blas SG, Ayesta A, Ibars S, Ariza-Sole A, Ferreiro JL, Moreno R, Roldán I, Marín F, Carol Ruiz A, García Pardo H, Sanchis J, Cruz-González I, Anguita M, Cequier A, Ruiz García J, Martínez-Selles M. Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischaemic heart disease. Atrial Fibrillation and Ischemic Heart Disease in the Elderly. Rev Esp Geriatr Gerontol. 2020; 55(6): 338-42. Article. Not indexed
- Cantor WJ, Lavi S, Dzavik V, Cairns J, Cheema AN, Della Siega A, Moreno R, Stankovic G, Kedev S, Natarajan MK, Levi Y, Yuan F, Jolly SS. Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. Catheter Cardio Inte. 2020; 96(3): 519-25. Article. IF: 2.692; Q3
- Celutkiene J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, Bucciarelli-Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS, Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jaarsma T, Mullens W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F, Zamorano

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsen T, Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020; 22(9): 1504-24. Article. IF: 15.534; D1

- Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Mollmann H, Roffi M, Tavazzi G, Ferre JM, Windecker S, Dudek D, Baumbach A. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. Eurointervention. 2020; 16(3): 233-46. Article. IF: 6.534; Q1
- Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Mollmann H, Roffi M, Tavazzi G, Ferre JM, Windecker S, Dudek D, Baumbach A. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. Eur Heart J. 2020; 41(19): 1839-51. Article. IF: 29.983; D1
- Dangas GD, Tijssen JGP, Wohrle J, Sondergaard L, Gilard M, Mollmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimaraes AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schafer U, Seeger J, Tchetche D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S. A Controlled trial of rivaroxaban after transcatheter aortic-valve replacement. New Engl J Med. 2020; 382(2): 120-9. Article. IF: 91.245; D1
- De Luca G, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, Ferrer GRI, Ganyukov V, Wojakowski W, von Birgelen C, Versaci F, Ten Berg J, Laine M, Dirksen M, Casella G, Kala P, Gil JLD, Becerra V, De Simone C, Carrill X, Scoccia A, Lux A, Kovarnik T, Davlouros P, Gabrielli G, Rios XF, Bakraceski N, Levesque S, Guiducci V, Kidawa M, Marinucci L, Zilio F, Galasso G, Fabris E, Menichelli M, Manzo S, Caiazzo G, Moreu J, Fores JS, Donazzan L, Vignali L, Teles R, Ojeda FB, Lehtola H, Camacho-Freiere S, Kraaijeveld A, Antti Y, Boccalatte M, Martínez-Luengas IL, Scheller B, Alexopoulos D, Uccello G, Faurie B, Barrios AG, Wilbert B, Cortese G, Moreno R, Parodi G, Kedhi E, Verdoia M. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovasc Diabetol. 2020; 19(1): 215. Article. IF: 9.951; D1
- De Luca G, Verdoia M, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, Ferrer GR, Ganyukov V, Wojakowski W, Kinnaird T, van Birgelen C, Cottin Y, IJsselmuiden A, Tuccillo B, Versaci F, Royaards KJ, Ten Berg J, Laine M, Dirksen M, Siviglia M, Casella G, Kala P, Gil JLD, Banning A, Becerra V, De Simone C, Santucci A, Carrillo X, Scoccia A, Amoroso G, Lux A, Kovarnik T, Davlouros P, Mehilli J, Gabrielli G, Rios XF, Bakraceski N, Levesque S, Cirrincione G, Guiducci V, Kidawa M, Spedicato L, Marinucci L, Ludman P, Zilio F, Galasso G, Fabris E, Menichelli M, García-Touchard A, Manzo S, Caiazzo G, Moreu J, Fores JS, Donazzan L, Vignali L, Teles R, Benit E, Agostoni P, Ojeda FB, Lehtola H, Camacho-Freiere S, Kraaijeveld A, Antti Y, Boccalatte M, Deharo P, Martínez-Luengas IL, Scheller B, Alexopoulos D, Moreno R, Kedhi E, Uccello G, Faurie B, Barrios AG, Di Uccio FS, Wilbert B, Smits P, Cortese G, Parodi G, Dudek D. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. J Am Coll Cardiol. 2020; 76(20): 2321-30. Article. IF: 24.094; D1
- Divison-Garrote JA, Prieto-Diaz MA, Alonso-Moreno FJ, Velilla-Zancada SM, Escobar-Cervantes C, Llisterri-Caro JL, Cinza-Sanjurjo S, Rodríguez-Roca GC, Polo-García J, Pallares-Carratala V. Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study. Semergen. 2020; 46(2): 107-14. Article. Not Indexed
- Escobar C, Anguita M, Arrarte V, Barrios V, Cequier A, Cosin-Sales J, Egocheaga I, de Sa EL, Masana L, Pallares V, de Isla LP, Pinto X, Juanatey JRG, Zamorano JL. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol. 2020; 73(2): 161. Article. IF: 4,753; Q2
- Escobar C, Borras X, Freire RB, González-Juanatey C, Morillas M, Munoz AV, Gómez-Doblas JJ. A Delphi consensus on the management of oral anticoagulation in patients with nonvalvular atrial fibrillation in Spain: ACOPREFERENCE study. Plos One. 2020; 15(6): e0231565. Article. IF: 3.24; Q2
- Escobar C, Varela L, Palacios B, Capel M, Sicras A, Sicras A, Hormigo A, Alcazar R, Manito N, Botana M. Costs and healthcare utilisation of patients with heart failure in Spain. Bmc Health Serv Res. 2020; 20(1): 964. Article. IF: 2.655; Q3
- Ezhov MV, Catapano A, Escobar C, Kukharchuk VV, Voevoda MI, Drapkina OM, Shalnova SA, Starodubova AV, Gurevich VS, Shaposhnik II, Bolshakova OO, Oynotkinova OS, Alieva AS. The role of red yeast rice based preparations for non-pharmacological correction of dyslipidemia in patients with low and moderate cardiovascular risk (Expert Opinion). Ration Pharmacother Cardiol. 2020; 16(1): 147-55. Article. Not Indexed
- Farkowski MM, Jubele K, Marin F, Gandjbakhch E, Ptaszynski P, Merino JL, Lenarczyk R, Potpara TS. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace. 2020; 22(1): 162-9. Article. IF: 5.214; Q2
- Gaitán RM, Vicent L, Rodríguez-Queralto O, López-de-Sa E, Elorriaga A, Pastor G, Baneras J, Lorenzo B, García-Rubira JC, Corbi M, Ariza A, Martínez-Selles M. Dexmedetomidine in medical cardiac intensive care units. Data from a multicenter prospective registry. Int J Cardiol. 2020; 310: 162-6. Article. IF: 4.164; Q2
- Goette A, Lip GYH, Jin J, Heidbuchel H, Cohen AA, Ezekowitz M, Merino JL. Differences in thromboembolic complications between paroxysmal and persistent atrial fibrillation patients following electrical cardioversion (From the ENSURE-AF Study). Am J Cardiol. 2020;131: 27-32. Article. IF: 2.778; Q3
- Goette A, Merino JL, De Caterina R, Huber K, Heidbuchel H, Jin J, Lip GYH. Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. Clin Res Cardiol. 2020; 109(11): 1374-80. Article. IF: 5.46; Q1
- González-García A, Hernández-Matamoros H, Jiménez-Valero S, Jurado-Román A, Galeote G, Moreno R, López-Sendón JL. Coronary thrombosis from superficial calcific sheet. J Invasive Cardiol. 2020; 32(10): E266. Editorial Material. IF: 2.022; Q3
- González-García A, Hernández-Matamoros H, Jurado-Román A, Galeote G, Jiménez-Valero S, Moreno R. Valve in valve procedure and left main stent: To deliver or not to deliver. Cardiol J. 2020; 27(1): 87-8. Editorial Material. IF: 2.737; Q3
- González-García A, Jurado-Román A, Hernández-Matamoros H, Jiménez-Valero S, Galeote G, Moreno R, López-Sendón JL. Iatrogenic atrial septal defect after percutaneous mitral valve repair with MitraClip: Should we consider closing them routinely? J Invasive Cardiol. 2020; 32(11): E295-7. Article. IF: 2.022; Q3
- Gutiérrez GG, Díaz-Manera J, Almendrote M, Azriel S, Barcena JE, García PC, Salas AC, Rodríguez CC, Cobo AM, Guardiola PD, Fernández-Torrón R, Petit MPG, Pavia PG, Gallego MG, Martínez AJG, Jerico I, García SK, Arregui ALD, Martorell L, de la Tassa GM, Zabaleta RM, Muñoz-Blanco JL, Roldán JO, Pascual SIP, Peinado RP, Pérez H, Aldea JJP, Rabasa M, Ramos A, Bartolome AR, Pérez MAR, Urtizberea JA, Zapata-Wainberg G, Gutiérrez-Rivas E. Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease. Neurología. 2020; 35(3): 185-206. Article. IF: 3.109; Q3
- Hernández JMD, Camarero TG, Alonso JAB, Gómez-Hospital JA, Fernández GV, Hwang DHL, Laso FS, Recalde AS, de Prado AP, Martínez-Luengas IL, Hernández FH, Lizarbe SG, Alonso LG, Zueco J, Alfonso F. Outcomes of predefined optimisation criteria for intravascular ultrasound guidance of left main stening. Eurointervention. 2020; 16(3): 210-7. Article. IF: 6.534; Q1
- Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Wallentin L. Association of different estimates of renal function With cardiovascular mortality and bleeding in atrial fibrillation. J Am Heart Assoc. 2020; 9(18): e017155. Article. IF: 5.501; Q1


Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Íñiguez A, Chevalier B, Richardt G, Neylon A, Jiménez VA, Kornowski R, Carrie D, Moreno R, Barbato E, Serra-Penaranda A, Guiducci V, Valdés-Chavarri M, Yajima J, Wijns W, Saito S. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. Catheter Cardio Inte. 2020; 95(2): 175-84. Article. IF: 2.692; Q3
- Jurado-Román A, Hernández H, Jiménez-Valero S, Martín-Polo L, Galeote G, Gonzálvez A, Moreno R, López-Sendón JL. Coronary perforation after excimer laser coronary angioplasty at a calcium nodule. J Invasive Cardiol. 2020; 32(8): E226-7. Editorial Material. IF: 2.022; Q3
- Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R, López-Sendón JL. Very long-term outcome of coronary covered stents. Not all covered stents are the same. Eurointervention. 2020;15(14):1297-1297. Letter. IF: 6,534; Q1
- Kontny F, Andersen T, Ueland T, Akerblom A, Lakic TG, Michelsen AE, Aukrust P, Bertilsson M, Becker RC, Himmelmann A, James SK, Siegbahn A, Storey RF, Wallentin L. Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2020; 9(4): 313-22. Article. IF: 4.696; Q2
- Koziel M, Merino JL, de Caterina R, Huber K, Jin JM, Melino M, Goette A, Lip GYH. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. Eur J Clin Invest. 2020; 50(5): e13221. Article. IF: 4.686; Q1
- Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. Ca-Cancer J Clin. 2020; 70(6): 480-504. Article. IF: 508.702; D1
- Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, Rockhold FW, Elghamaz A, López-Sendón JL, Farsky PS, Chernyavskiy AM, Diaz A, Phaneuf D, De Belder MA, Ma YT, Guzmán LA, Khouri M, Sionis A, Hausenloy DJ, Doerr R, Selvanayagam JB, Maggioni AP, Hochman JS, Maron DJ. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction insights from the ISCHEMIA trial. Circulation. 2020; 142(18): 1725-35. Article. IF: 29.69; D1
- López-Fernández T. Cardiac imaging in oncology patients in Europe: a model for advancement of CV safety and development of comprehensive CV care. J Cardiovasc Transl. 2020; 13(3): 490-4. Review. IF: 4.132; Q2
- López-Fernández T, López-Sendón JL. Heart failure after treatment for breast cancer: old cancer therapies, new clinical data. What do we need to complete the puzzle? Eur J Heart Fail. 2020; 22(2): 375-7. Editorial Material. IF: 15.534; D1
- López-Honrubia V, Hidalgo-Olivares VM, Dobon-Roux M, Marti-Laosa MM, Castro-Larefors S, Fernández-Lopee J, Andrés I, Roche O, Roviro-sa A, Arenas M, Martínez-Terol F, Fernández TL, Sabater S. Radiotherapy is safe in patients with implantable cardiac devices. Analysis of a systematic interrogation follow-up. Clin Transl Oncol. 2020; 22(12): 2286-92. Article. IF: 3.405; Q3
- López-Mínguez JR, Nogales-Asensio JM, De Oliveira EI, Santos L, Ruiz-Salmeron R, Arzamendi-Aizpurua D, Costa M, Gutiérrez-García H, Fernández-Diaz JA, Freixa X, Cruz-González I, Moreno R, Iniguez-Romo A, Alfonso-Manterola F. Major bleeding predictors in patients with left atrial appendage closure: The Iberian Registry II. J Clin Med. 2020; 9(7): 2295. Article. IF: 4.241; Q1
- López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Albendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, González-Juanatey JR, Monzonis AM, Prieto PG, González-Costello J, Antolin JMS, Chamorro RC, Fernández TL. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-+. Article. IF: 29.983; D1
- Lucas MF, Ruiz-Roso G, Merino JL, Sánchez R, Bouarich H, Herrero JA, Muriel A, Zamora J, Collado A. Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial. Trials. 2020; 21(1): 206. Article. IF: 2.279; Q4
- Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojko-



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

vic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from theCardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020 ;22(11): 1945-60. Article. IF: 15.534; D1

- Manolis AJ, Kallistratos MS, Poulimenos LE, Ambrosio G, Dechend R, López-Sendón J, Rosano G, Collins P. The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind? Eur J Intern Med. 2020; 72: 5-8. Review. IF: 4.487; Q1
- Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y. Initial invasive or conservative strategy for stable coronary disease. New Engl J Med. 2020; 382(15): 1395-407. Article. IF: 91.245; D1
- Martínez-Losas P, de Sa EL, Armada E, Rosillo S, Monedero MC, Rey JR, Caro-Codon J, Soto AB, Sendón JPLL. Neuron-specific enolase kinetics: an additional tool for neurological prognostication after cardiac arrest. Rev Esp Cardiol. 2020; 73(2): 123-30. Article. IF: 4.753; Q2
- Martin-García A, López-Fernández T, Mitroi C, Chaparro-Munoz M, Moliner P, Martín-García AC, Martínez-Monzonis A, Castro A, López-Sendón JL, Sánchez PL. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. Esc Heart Fail. 2020; 7(2): 763-7. Article. IF: 4.411; Q2
- Merino JL, Martínez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejón-Castrejón S. COVID-19 andQT interval prolongation: more than just drug toxicity? Europace. 2020; 22(10): 1479. Editorial Material. IF: 5.214; Q2
- Ojeda S, Romaguera R, Cruz-González I, Moreno R. Spanish cardiac catheterization and coronary intervention registry. 29th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2019). Rev Esp Cardiol. 2020; 73(11): 927-36. Article. IF: 4.753; Q2
- Pascual-Tejerina V, Sánchez-Recalde A, Cantador JR, González AE, Gutiérrez-Larraya F, Oliver JM. Long-term follow-up of patients with repaired coarctation of the aorta who develop hemoptysis. Rev Esp Cardiol. 2020; 73(3): 265-7. Letter. IF: 4.753; Q2
- Quevedo PJ, Pan M, Moreno R, de Prado AP. Scientific evidence versus expert opinion. Should we modify clinical practice guidelines? Rev Esp Cardiol. 2020; 73(2): 187-9. Letter. IF: 4.753; Q2
- Refoyo E, Troya J, Trigo E, Guzmán-Martínez G, Valbuena-López S, Caro-Codon J, Rosillo S, Moreno-Yanguela M, Tamargo J, Arribas JR, Acquatella H, López-Sendón J. Comparison of noninvasive cardiac test strategies for newly diagnosed chagas disease in a non-endemic zone. Am J Trop Med Hyg. 2020; 103(4): 1480-6. Article. IF: 2.345; Q2
- Rey JR, Caro-Codón J, Pineda DP, Merino JL, Iniesta AM, López-Sendón JL. Arterial thrombotic complications in hospitalized patients with COVID-19. Rev Esp Cardiol. 2020; 73(9): 769-71. Letter. IF: 4.753; Q2
- Rey JR, Caro-Codón J, Sotelo LR, López-de-Sa E, Rosillo SO, Fernández OG, de Bobadilla JF, Iniesta AM, Conde LP, Miranda IA, Armada E, Cantador JR, López-Sendón JL. Long term clinical outcomes in survivors after out-of-hospital cardiac arrest. Eur J Intern Med. 2020; 74: 49-54. Article. IF: 4.487; Q1
- Rey JR, Valero SJ, Pinedo DP, Merino JL, López-Sendón JL, Caro-Codon J. COVID-19 and simultaneous thrombosis of two coronary arteries. Rev Esp Cardiol. 2020; 73(8): 676-8. Letter. IF: 4.753; Q2
- Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, Picard MH, Kwong RY, Bairey-Merz CN, Cyr DD, Lopes RD, López-Sendón JL, Held C, Szwed H, Senior R, Gosselin G, Nair RG, Elghamaz A, Bockeria O, Chen JY, Chernyavskiy AM, Bhargava B, Newman JD, Hinic SB, Jaroch J, Hoye A, Berger J, Boden WE, O'Brien SM, Maron DJ, Hochman JS. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients With moderate or severe ischemia secondary analysis of the ISCHEMIA randomized clinical trial. Jama Cardiol. 2020; 5(7): 773-86. Article. IF: 14.676; D1
- Rodríguez-Leor O, Cid-Alvarez B, de Prado AP, Rossello X, Ojeda S, Serrador A, López-Palop R, Martin-Moreiras J, Rumoroso JR, Cequier A, Ibáñez B, Cruz-González I, Romaguera R, Moreno R. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Rev Esp Cardiol. 2020; 73(12): 994-1002. Article. IF: 4.753; Q2
- Sánchez-Salado JC, Burgos V, Ariza-Sol A, Sionis A, Canteli A, Bernal JL, Fernández C, Castrillo C, Ruiz-Lera M, López-de-Sa E, Lidon RM, Worner F, Martínez-Selles M, Segovia J, Viana-Tejedor A, Lorente V, Alegre O, Llao I, González-Costello J, Manito N, Cequier A, Bueno H, Elola J. Trends in cardiogenic shock management and prognostic impact of type of treating center. Rev Esp Cardiol. 2020; 73(7): 546-53. Article. IF: 4.753; Q2
- Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S, Schwalm JD, Velianou JL, Valettas N, Sibbald M, Rodes-Cabau J, Ducas J, Cohen EA, Bagai A, Rinfret S, Newby DE, Feldman L, Laster SB, Lang IM, Mills JD, Cairns JA, Mehta SR. Nonculprit lesion severity and outcome of revascularization in patients with STEMI and multivessel coronary disease. J Am Coll Cardiol. 2020; 76(11): 1277-86. Article. IF: 24.094; D1
- Sicras-Mainar A, Escobar-Cervantes C, Mico-Pérez RM, Llisterri-Caro JL. Clinical and economic consequences in patients initiating therapy with clopidogrel brand-name vs. generic: A real-life retrospective study. Semergen. 2020; 46(1): 16-26. Article. Not indexed
- Solano-López J, Zamorano JL, Sanz AP, Amat-Santos I, Sarnago F, Ibanes EG, Sanchis J, Blas JRR, Gómez-Hospital JA, Martínez SS, Maneiro-Melón NM, Gaitán RM, D'Gregorio JG, Salido L, Mestre JL, Sanmartín M, Sánchez-Recalde A. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Rev Esp Cardiol. 2020; 73(12): 985-93. Article. IF: 4.753; Q2
- Tyl B, Sendón JL, Borer JS, De Sa EL, Lerebours G, Varin C, De Montigny A, Pannaux M, Komajda M. Comparison of outcome adjudication by Investigators and by a central end point committee in heart failure trials experience of the SHIFT heart failure study. Circ-Heart Fail. 2020; 13(7): e006720. Article. IF: 8.79; Q1
- Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L, (López Sendón JL). ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 2020; 293: 35-41. Article. IF: 5.162; Q2
- Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Ghapar AKA, Selvara K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbiocchi F, Pasupati S, Kim HS, Aminian A, Tie C, Wlodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. New Engl J Med. 2020;3 82(13): 1208-18. Article. IF: 91.245; D1
- Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimón L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Gómez JCP, Scott J, Suter TM, Minotti G. The cancer patient and cardiology. Eur J Heart Fail. 2020; 22(12): 2290-309. Review. IF: 15.534; D1
- Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. (López Sendón JL). Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020; 75(10): 1145-55. Article. IF: 24.094; D1

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research projects

Castro Conde A. Rehab+ (R+). EIT-Health. 2020-2021.

Managment centre: FIBHULP

Galeote García G. Aterectomia rotacional electiva vs de rescate en pacientes con lesiones coronarias calcificadas graves e insuficiencia renal crónica. Boston Scientific International S. A. 2020-Ongoing.

Managment centre: FIBHULP

Guzmán Martínez G. Marcadores precoces de disfunción ventricular derecha y alteraciones de la circulación pulmonar en pacientes afectos de hipertensión pulmonar. Siemens Heatlhcare S. L. 2018-Ongoing.

Managment centre: FIBHULP

Jiménez Valero S. Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: Estudio IVI. Abbott Laboratories S. A. 2009-Ongoing.

Managment centre: FIBHULP

Jiménez Valero S. Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S. L. 2015-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL, Antorrena Miranda MI. Colchicine cardiovascular outcome trial. Montreal Heart Institute. 2017-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Antorrena Miranda MI. Colchicine coronavirus Sars-Cov2 trial. Colcorona-COVID-19. Montreal Heart Institute. 2020-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Antorrena Miranda MI. International study of comparative health effectiveness with medical and invasive approaches. Estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. New York University School of Medicine. 2013-2021.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Biomarcadores en la cardiotoxicidad por agentes antineoplás: rendimiento diagnóstico. Boehringer Ingelheim España S. A. 2015-Ongoing.

Managment centre: FIBHULP

López-Sendón Hentschel JL. Investigación traslacional en arritmias cardiacas hereditarias (S2017/BMD-3738). CM. 2018-2021.

Managment centre: FIBHULP

Merino Llorens JL. Actividades formativas de investigación en cirugía cardiaca pediátrica. Magnetecs Corp. 2006-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS). UE. 2020-2026.

Managment centre: FIBHULP

Merino Llorens JL. El vectorcaidiograma como herramienta de caracterización no invasiva de la dinámica de activación y de I-A presencia y locauzación de zonas de conducción lenta en los circuitos de Flijter auricular atípico izquierdo mediante vectorcardiograma. Arrhythmia Network Technology S. L. 2018-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Formación en investigación en electrofisiología cardiaca. European Society of Cardiology. 2015-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrecuency power for faster and safer pulmonary veins ablation trial (Power FAST II) (PI18/01522). ISCIII. 2019-2021.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrequency power for faste and safe pulmonary veins ablastion-a pilot observational study (Power Fast I). Arrhythmia Network Technology S. L. 2018-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Hospital Smart development based on AI (HosmartAI). UE. 2020-2024.

Managment centre: FIBHULP

Merino Llorens JL. Innovación tecnológica en cardiología: mapas tridimensionales de ciclo de retorno para la ablación de taquicardias macroreentrantes. Medtronic Iberica S. A. 2007-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Registro retrospectivo de identificación de factores cardiovasculares de mal pronóstico en pacientes COVID 19. Medtronic Iberica S. A. 2020-Ongoing.

Managment centre: FIBHULP

Moreno Gómez JR. Evaluación clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Subproyecto: análisis de expresión de mirnas relacionados con el proceso angiogénico en cáncer mama. Abbott Laboratories S. A. 2011-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Comparación de un cateter multielectrodo frente a un cateter de ablación de punta irrigada para crear mapas de voltaje y activación en pacientes con taquicardias auriculares macroreentrantes. Medtronic Iberica S. A. 2019-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Medtronic Iberica S. A. 2009-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Registro de pacientes con cardipatía congénita del adulto portadores de un sistema de terapia de resincronización cardiaca (RETRACCA). Medtronic Iberica S. A. 2017-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Fundación Casa del Corazón. 2008-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Utilidad de los algoritmos de diagnóstico diferencial electrocardiográfico de las taquicardias regulares de QRS ancho en pacientes con cardiopatías congénitas de adulto. Medtronic Iberica S. A. 2019-Ongoing.

Managment centre: FIBHULP

Riera del Moral LF. Tratamiento celular de los aneurismas de aorta abdominal en un modelo murino. Riera del Moral, Luis Felipe. 2017-Ongoing.

Managment centre: FIBHULP

Clinical trials

Antorrena Miranda, MI. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.

Type: Estudios, phase No EPA.
HULP code: Anexo 3 PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 23/09/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Antorrena Miranda, MI. Ensayo de colchicina en el SARS-COV2 coronavirus (Colcorona-covid-19).
Type: EECC, phase III.
HULP code: 5578.
Sponsored´s protocol code: MHIPS-2020-01 COLCORONA.
Sponsored by: FIBHULP.
Signed date: 01/06/2020

Antorrena Miranda, MI. Estudio observacional para evaluar el beneficio clínico neto de edoxaban en pacientes con fibrilación auricular no valvular, según práctica clínica habitual en España. Registro Benefit.
Type: Estudios, phase EPA-OD.
HULP code: PI-4283 .
Sponsored´s protocol code: DSE-EDO-2020-01.
Sponsored by: Daiichi Sankyo España.
Signed date: 13/11/2020

Castro Conde, A. Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (Surpass-CVOT).
Type: EECC, phase I.
HULP code: 5484.
Sponsored´s protocol code: 18F-MC-GPGN.
Sponsored by: Lilly S.A.
Signed date: 29/01/2020

Castro Conde, A. Impacto del consenso español para la mejora de los objetivos LDL colesterol después de un síndrome coronario agudo.
Type: Estudios, phase No EPA.
HULP code: PI-4420 .
Sponsored´s protocol code: GOAL.
Sponsored by: Sociedad Española de Cardiología.
Signed date: 10/11/2020

Escobar Cervantes, C. Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa. Estudio multinacional observacional (Santorini).
Type: Estudios, phase EPA-SP.
HULP code: PI-4163A .
Sponsored´s protocol code: DSE-HCL-01-19.
Sponsored by: Daiichi-Sankyo Europe Gmbh.
Signed date: 12/06/2020

Iniesta Manjavacas, AM. Estudio observacional ambispectivo para analizar el manejo evolutivo de los fármacos con efecto pronóstico en pacientes tratados con polipíldora como tratamiento de base al alta de un primer síndrome coronario agudo.
Type: Estudios, phase EPA-SP.
HULP code: PI-4368 .
Sponsored´s protocol code: PANDORA FER-AAS-2020-0.
Sponsored by: Ferrer Internacional S.A.
Signed date: 28/09/2020

López De Sá Areses, E. Estudio en fase IIB, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de Medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona N-terminal natriurético cerebral.
Type: EECC, phase II.
HULP code: 5637.
Sponsored´s protocol code: D4920C00002.
Sponsored by: Astrazeneca Ab.
Signed date: 28/09/2020

López-Sendón Hentschel, JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLIC como un nuevo biomarcador de isquemia.
Type: Estudios, phase No EPA.
HULP code: Anexo 1 PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 20/01/2020

López-Sendón Hentschel, JL. Detección precoz de isquemia miocárdica compatible con síndrome coronario agudo mediante APO J-GLYC como un nuevo biomarcador de isquemia.
Type: Estudios, phase No EPA.
HULP code: Anexo 2 PI-3647.
Sponsored´s protocol code: EDICA-2019.
Sponsored by: Glycardial Diagnostics S.L.
Signed date: 09/07/2020

Merino Llorens, JL. Estudio observacional para evaluar el manejo clínico y la adecuación de las estrategias terapéuticas utilizadas en pacientes con enfermedad aterosclerótica estable y el uso de los tratamientos recomendados de acuerdo a las guías clínicas. Estudio Apalusa.
Type: Estudios, phase EPA-OD.
HULP code: PI-3815B .
Sponsored´s protocol code: SEC-ATE-2019-01.
Sponsored by: Sociedad Española de Cardiología.
Signed date: 14/07/2020

Moreno Gómez, JL. Estudio post-autorización trevisio: estudio multicéntrico, no aleatorizado y de un solo grupo del Amplatzer™ Trevisio™ intravascular delivery system para facilitar la implantación percutánea y transcatéter de los oclusores amplatzer.
Type: Estudios, phase Producto Sanitario.
HULP code: PI-4379B .
Sponsored´s protocol code: CRD-963/ABT-CIP-10319.
Sponsored by: Abbott Medical España S.A.
Signed date: 23/10/2020

Pérez Valero, I. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el VIH-1 con supresión virológica.
Type: EECC, phase III.
HULP code: Anexo 1 5354.
Sponsored´s protocol code: .
Sponsored by: VIIV Healthcare Uk Limited.
Signed date: 02/07/2020

Riera Del Moral, LF. Ensayo clínico multicéntrico, aleatorizado, de búsqueda de dosis, de grupos paralelos, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de la administración intramuscular de células mesenquimalesalogénicas derivadas de tejido adiposo en pacientes diabéticos con isquemia crítica de miembros inferiores sin posibilidad de revascularización.
Type: Estudios, phase No EPA.
HULP code: 5426.
Sponsored´s protocol code: NOMA.
Sponsored by: Instituto Investigacion Sanitaria Fjd.
Signed date: 18/06/2020

Patents and trademarks

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.2.2 Cardiovascular Epidemiology and Nutrition Group

Publications:	40
Impact Factor:	298.^{843}
Q1:	27



Fernando Rodríguez Artalejo.
Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

José Ramón Banegas Banegas. Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Auxiliadora Graciani Pérez-Regadera. Profesora Contratada de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Pilar Guallar Castillón. Profesora Titular de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Juan Luis Gutiérrez Fisac. Profesor Asociado de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Esther López García. Profesora Contratada. Doctora de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Strategic Objective

Our strategic objective is to produce relevant information to support clinical and population-based policies aimed at controlling CVD. The results of our studies have been explicitly incorporated into the National Strategy for Ischemic Heart Disease Control and into the National Strategy for Obesity Prevention and Control, elaborated by the Ministry of Health.

Moreover, our research results have also supported the development of clinical guidelines in this field; specifically, the guidelines of the Spanish Society for Arterial Hypertension, and guidelines of the Spanish Society of Family Medicine, the leading society devoted to primary health care in Spain.

Research lines

- Cardiovascular and nutritional epidemiology.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Publications

- Andre P, Proctor G, Driollet B, García-Esquinas E, López-García E, Gómez-Cabrero D, Neyraud E, Rodríguez-Artalejo F, Morzel M, Feart C. The role of overweight in the association between the Mediterranean diet and the risk of type 2 diabetes mellitus: a mediation analysis among 21 585 UK biobank participants. Int J Epidemiol. 2020; 49(5):1582-90. Article. IF: 7.196. D1
- Arias-Fernandez L, Struijk EA, Rodríguez-Artalejo F, López-García E, Lana A. Habitual dietary fat intake and risk of muscle weakness and lower-extremity functional impairment in older adults: A prospective cohort study. Clin Nutr. 2020; 39(12): 3663-70. Article. IF: 7.324. D1
- Ballesteros JM, Struijk EA, Rodríguez-Artalejo F, López-García E. Mediterranean diet and risk of falling in community-dwelling older adults. Clin Nutr. 2020; 39(1): 276-81. Article. IF: 7.324. D1
- Banegas JR, Townsend RR. Arterial stiffness and reference values. Rev Esp Cardiol. 2020; 73(1): 11-3. Editorial Material. IF: 4.753. Q1
- Banegas JR. The IBERICAN Project. Progressing in the knowledge of cardiovascular risk in primary care in Spain. Semergen. 2020; 46(1): 1-3. Editorial Material. Not Indexed
- Caballero FF, Ballesteros JM, García-Esquinas E, Struijk EA, Ortola R, Rodríguez-Artalejo F, López-García E. Are legume-based recipes an appropriate source of nutrients for healthy ageing? A prospective cohort study. Brit J Nutr. 2020; 124(9):943-51. Article. IF: 3.718. Q1
- Cabañas-Sánchez V, Artero EG, Lavie CJ, Higueras-Fresnillo S, García-Esquinas E, Sadarangani KP, Ortola R, Rodríguez-Artalejo F, Martínez-Gómez D. Prediction of cardiovascular health by non-exercise estimated cardiorespiratory fitness. Heart. 2020; 106(23):1832-8. Article. IF: 5.994. Q1
- Cabañas-Sánchez V, Esteban-Cornejo I, Migueles JH, Banegas JR, Graciani A, Rodríguez-Artalejo F, Martínez-Gómez D. Twenty four-hour activity cycle in older adults using wrist-worn accelerometers: The seniors-ENRICA-2 study. Scand J Med Sci Spor. 2020; 30(4):700-8. Article. IF: 4.221. Q1
- Divison-Garrote JA, de la Cruz JJ, de la Sierra A, Vinyoles E, Gorostidi M, Escobar-Cervantes C, Segura J, Barrios V, Ruilope LM, Banegas JR. Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. Hypertens Res. 2020; 43(7): 696-704. Article. IF: 3.872. Q1
- Donat-Vargas C, Moreno-Franco B, Laclaustra M, Sandoval-Insausti H, Jarauta E, Guallar-Castillón P. Exposure to dietary polychlorinated biphenyls and dioxins and its relationship with subclinical coronary atherosclerosis: The Aragon Workers' Health Study. Environ Int. 2020; 136: 105433. Article. IF: 9.621. D1
- Estrada-deLeon DB, Struijk EA, Caballero FF, Sotos Prieto M, Rodríguez-Artalejo F, López-García E. Prolonged nightly fasting and lower-extremity functioning in community-dwelling older adults. Br J Nutr. 2020: 1-8. Article. IF: 3.718. Q1
- Fung TT, Struijk EA, Rodríguez-Artalejo F, Willett WC, López-García E. Fruit and vegetable intake and risk of frailty in women 60 years old or older. Am J Clin Nutr. 2020; 112(6): 1540-6. Article. IF: 7.045, Q1
- García-Esquinas E, Carrasco-Ríos M, Navas-Acien A, Ortola R, Rodríguez-Artalejo F. Cadmium exposure is associated with reduced grip strength in US adults. Environ Res. 2020; 180: 108819. Article. IF: 6.498. D1
- González-Guerrero JL, Paredes-Galan E, Ferrero-Martínez AI, Galán MC, Hornillos-Calvo M, Menéndez-Colino R, Torres-Torres I, Rodríguez-Artalejo F, Rodríguez-Pascual C. Characteristics and one-year outcomes in elderly patients hospitalised with heart failure and preserved mid-range and reduced ejection fraction. Rev Esp Geriatr Gerontol. 2020; 55(4): 195-200. Article. Not Indexed
- Haeberer M, Leon-Gómez I, Pérez-Gómez B, Téllez-Plaza M, Pérez-Ríos M, Schiaffino A, Rodríguez-Artalejo F, Galan I. Social inequalities in tobacco-attributable mortality in Spain. The intersection between age sex and educational level. Plos One. 2020; 15(9): e0239866. Article. IF: 3.24. Q1
- Haeberer M, Leon-Gómez I, Pérez-Gómez B, Tellez-Plaza M, Rodríguez-Artalejo F, Galan I. Social inequalities in cardiovascular mortality in Spain from an intersectional perspective. Rev Esp Cardiol. 2020; 73(4): 282-9. Article. IF: 4.753. Q1
- Laclaustra M, Rodríguez-Artalejo F, Guallar-Castillón P, Banegas JR, Graciani A, García-Esquinas E, López-García E. The inflammatory potential of diet is related to incident frailty and slow walking in older adults. Clin Nutr. 2020; 39(1): 185-91. Article. IF: 7.324. D1
- Lana A, Struijk EA, Ortola R, Rodríguez-Artalejo F, López-García E. Longitudinal association between sodium and potassium intake and physical performance in older adults. J Gerontol A-Biol. 2020; 75(12): 2379-86. Article. IF: 6.053. Q1
- Laosa O, Pedraza L, Álvarez-Bustos A, Carnicero JA, Rodríguez-Artalejo F, Rodríguez-Manas L. Rapid assessment at hospital admission of mortality risk from COVID-19: The role of functional status. J Am Med Dir Assoc. 2020; 21(12): 1798-802. Article. IF: 4.669. Q1
- Machado-Fragua MD, Hoogendijk EO, Struijk EA, Rodríguez-Artalejo F, López-García E, Beulens JW, van Ballegooijen AJ. High dephospho-uncarboxylated matrix Gla protein concentrations a plasma biomarker of vitamin K in relation to frailty: the Longitudinal Aging Study Amsterdam. Eur J Nutr. 2020; 59(3): 1243-51. Article. IF: 5.614. Q1
- Machado-Fragua MD, Struijk EA, Caballero FF, Ortola R, Lana A, Banegas JR, Rodríguez-Artalejo F, López-García E. Dairy consumption and risk of falls in 2 European cohorts of older adults. Clin Nutr. 2020; 39(10): 3140-6. Article. IF: 7.324. D1
- Martínez-Gómez D, Esteban-Cornejo I, López-García E, García-Esquinas E, Sadarangani KP, Veiga OL, Rodríguez-Artalejo F. Physical activity less than the recommended amount may prevent the onset of major biological risk factors for cardiovascular disease: a cohort study of 198 919 adults. Brit J Sport Med. 2020; 54(4): 238-44. Article. IF: 13.8. Q1
- Martínez-Gómez D, Hamer M, Ortega FB, Cabanas-Sánchez V, Sadarangani KP, Lavie CJ, Rodríguez-Artalejo F. Association of changes in physical activity and incidence and remission of overall and abdominal obesity in 113950 adults. Obesity. 2020; 28(3): 660-8. Article. IF: 5.002. Q1
- Martínez-Gómez D, Lavie CJ, Hamer M, Cabañas-Sánchez V, García-Esquinas E, Pareja-Galeano H, Struijk E, Sadarangani KP, Ortega FB, Rodríguez-Artalejo F. Physical activity without weight loss reduces the development of cardiovascular disease risk factors - a prospective cohort study of more than one hundred thousand adults. Prog Cardiovasc Dis. 2020; 62(6): 522-30. Review. IF: 8.194. Q1
- Montero-Salazar H, Donat-Vargas C, Moreno-Franco B, Sandoval-Insausti H, Civeira F, Laclaustra M, Guallar-Castillón P. High consumption of ultra-processed food may double the risk of subclinical coronary atherosclerosis: the Aragon Workers' Health Study (AWHS). Bmc Med. 2020; 18(1): 235. Article. IF: 8.775. D1
- Moreno-Franco B, Pérez-Esteban A, Civeira F, Guallar-Castillón P, Casasnovas JA, Mateo-Gallego R, Jarauta E, Malo S, Laclaustra M. Association between alcohol consumption and subclinical femoral atherosclerosis in smoking and non-smoking men: the AWHS study. Addiction. 2020; 115(9): 1754-1761. Article. IF: 6.526. D1
- Ortola R, Carballo-Casla A, García-Esquinas E, López-García E, Banegas JR, Rodríguez-Artalejo F. Health decline is associated with reports of no coffee consumption years after reporting coffee consumption among older adults in Spain. J Nutr. 2020; 150(7): 1916-23. Article. IF: 4.798. Q1

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

- Ortola R, Struijk EA, García-Esquinas E, Rodríguez-Artalejo F, López-García E. Changes in dietary intake of animal and vegetable protein and unhealthy aging. Am J Med. 2020; 133(2): 231-9. Article. IF: 4.965. Q1
- Pérez-Calahorra S, Civeira F, Guallar-Castillón P, Pinto X, Banegas JR, Pedro-Botet J, Suarez-Tembra M, Mauri M, Soler C, Rodríguez-Artalejo F, Laclaustra M. Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. Eur J Prev Cardiol. 2020; 27(15): 1649-60. Article. IF: 7.804. Q1
- Pérez-Tasigchana RF, Sandoval-Insausti H, Donat-Vargas C, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Combined impact of traditional and nontraditional Healthy behaviors on frailty and disability: A prospective cohort study of older adults. J Am Med Dir Assoc. 2020; 21(5):710.e1-9. Article. IF: 4.669. Q1
- Rey-García J, Guallar-Castillón P, Donat-Vargas C, Moreno-Iribas C, Barricarte A, Rodríguez-Barranco M, Colorado-Yohar S, Huerta JM, Chirlaque MD, Lasheras C, Amiano P, Imaz L, Agudo A, Sánchez MJ. Fried-food consumption does not increase the risk of stroke in the spanish cohort of the european prospective investigation into cancer and nutrition (EPIC) Study. J Nutr. 2020; 150(12): 3241-8. Article. IF: 4.798. Q1
- Sandoval-Insausti H, Blanco-Rojo R, Graciani A, López-García E, Moreno-Franco B, Laclaustra M, Donat-Vargas C, Ordovas JM, Rodríguez-Artalejo F, Guallar-Castillón P. Ultra-processed Food Consumption and Incident Frailty: A Prospective Cohort Study of Older Adults. J Gerontol A-Biol. 2020; 75(6): 1126-33. Article. IF: 6.053. Q1
- Sandoval-Insausti H, Jiménez-Onsurbe M, Donat-Vargas C, Rey-García J, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Ultra-processed food consumption is associated with abdominal obesity: A prospective cohort study in older adults. Nutrients. 2020; 12(8): 2368. Article. IF: 5.717. Q1
- Soldevila N, Vinyoles E, Tobias A, Banegas JR, De La Sierra A, Gorostidi M, Segura J, De La Cruz JJ, Munoz-Pérez MA, Querol X, Ruilope LM. How do ultrafine particles in urban air affect ambulatory blood pressure? J Hypertens. 2020; 38(5): 845-9. Article. IF: 4.844. Q1
- Sotos-Prieto M, Ruiz-Canela M, Song YQ, Christophi C, Mofatt S, Rodríguez-Artalejo F, Kales SN. The effects of a mediterranean diet intervention on targeted plasma metabolic biomarkers among US firefighters: A pilot cluster-randomized trial. Nutrients. 2020; 12(12): 3610. Article. IF: 5.717. Q1
- Struijk EA, Hagan KA, Fung TT, Hu FB, Rodríguez-Artalejo F, López-García E. Diet quality and risk of frailty among older women in the Nurses' Health Study. Am J Clin Nutr. 2020; 111(4): 877-83. Article. IF: 7.045. Q1
- Struijk EA, Rodríguez-Artalejo F, Fung TT, Willett WC, Hu FB, López-García E. Sweetened beverages and risk of frailty among older women in the Nurses' Health Study: A cohort study. Plos Med. 2020; 17(12): e1003453. Article. IF: 11.069. D1
- Taddei C, Jackson R, Zhou B, Bixby H, Danaei G, Di Cesare M, Kuulasmaa K, Hajifathalian K, Bentham J, Bennett JE, Aekplakorn W, Cifkova R, Dallongeville J, DeBacquer D, Giampaoli S, Gudnason V, Khang YH, Laatikainen T, Mann JI, Marques-Vidal P, Mensah GA, Muller-Nurasyid M, Ninomiya T, Petkeviciene J, Rodríguez-Artalejo F, Servais J, Soderberg S, Stavreski B, Wilsgaard T, Zdrojewski T, Zhao D, Stevens GA, Savin S, Cowan MJ, Riley LM, Ezzati M, Adams RJ, Ahrens W, Amouyel P, Amuzu A, Anderssen SA, Ariansen I, Arveiler D, Aspelund T, Auvinen J, Avdicova M, Banach M, Bandosz P, Banegas JR, Barbagallo CM, Bata I, Baur LA, Beaglehole R, Bernotiene G, Bi YF, Bienek A, Bjorkelund C, Bo S, Boehm BO, Bonaccio M, Bongard V, Borchini R, Borghs H, Breckenkamp J, Brenner H, Bruno G, Busch MA, de Leon AC, Capuano V, Casanueva FF, Casas JP, Caserta CA, Censi L, Chen FF, Chen SH, Chirlaque MD, Cho BL, Cho YM, Chudek J, Claessens F, Clarke J, Clays E, Cooper C, Costanzo S, Cottel D, Cowell C, Crujeiras AB, Cui LF, D'Arrigo G, Dauchet L, De Backer G, De Bacquer D, de Gaetano G, De Henauw S, De Smedt D, Dennison E, Deschamps V, Di Castelnuovo A, Dobson AJ, Donfrancesco C, Doring A, Drygas W, Du Y, Dziankowska-Zaborszczyk E, Eggertsen R, Ekelund U, Elosua R, Eriksson JG, Evans A, Faeh D, Felix-Redondo FJ, Fernandez-Berges D, Ferrari M, Ferrieres J, Finn JD, Forslund AS, Forsner M, Frontera G, Fujita Y, Gaciong Z, Galvano F, Gao JL, García-de-la-Hera M, Garnett SP, Gaspoz JM, Gasull M, Gates L, Gianfagna F, Gill TK, Giovannelli J, Giwercman A, Goltzman D, Gross MG, Gottrand F, Graff-Iversen S, Grafnetter D, Gregor RD, Grodzicki T, Grosso G, Gruden G, Gu DF, Guallar-Castillón P, Gudmundsson EF, Guessous I, Gunnlaugsdottir J, Gutzwiller F, Hardy R, Hata J, Haugsgjerd T, Hayes AJ, He J, He YN, Herrala S, Hihtaniemi IT, Hobbs M, Hopman WM, Huerta JM, Huybrechts I, Iacoviello L, Iannone AG, Ikeda N, Iwasaki M, Jamrozik K, Janszky I, Jarvelin MR, Jasienska G, Jennings G, Jeong SL, Jiang CQ, Joffres M, Jokelainen JJ, Jonas JB, Jozwiak J, Kajantie EO, Kauhanen J, Keil U, Keinanen-Kiukaanniemi S, Kersting M, Kiechl-Kohlendorfer U, Kiechl S, Kim J, Kim YY, Klumbiene J, Knoflach M, Ko S, Kolle E, Korpelainen R, Koskinen S, Kouda K, Kratzer W, Kriemler S, Krokstad S, Kujala UM, Kurjata P, Lam TH, Lanska V, Lappas G, Laugsand LE, Lee J, Lehtimaki T, Li YP, Lilly CL, Lin X, Lind L, Lissner L, Liu J, López-García E, Lorbeer R, Lozano JE, Luksiene D, Lundqvist A, Lundqvist R, Lytsy P, Ma GS, Machi S, Maggi S, Magliano DJ, Manzato E, Mathiesen EB, McLachlan S, McLean RM, McLean SB, Meirhaeghe A, Meisinger C, Metcalf P, Mi J, Miller JC, Moreno LA, Morin SN, Mossakowska M, Muiesan ML, Mursu J, Nakamura H, Namesna J, Nauck M, Navarrete-Munoz EM, Neal WA, Nenko I, Niiranen TJ, Ning G, Noale M, Norie S, Noto D, O'Neill T, O'Reilly D, Oh K, Olafsson O, Paccaud FM, Pajak A, Palmieri L, Panza F, Parnell WR, Peltonen M, Peters A, Petersmann A, Pigeot I, Pilotto L, Piwonska A, Plans-Rubio P, Porta M, Price JF, Puder JJ, Puhakka SE, Radisauskas R, Raitakari O, Ramos R, Redon J, Rigo F, Rodríguez-Pérez MD, Romaguera D, Ronkainen K, Rosengren A, Roy JGR, Ruidavets JB, Rutkowski M, Salanave B, Salmeron D, Salomaa V, Salonen JT, Salvetti M, Sans S, Saramies JL, Saum KU, Scheidt-Nave C, Schienkiewitz A, Schipf S, Schmidt CO, Schottker B, Sebert S, Sen A, Shaw JE, Shibuya K, Shin DW, Shiri R, Simons J, Simons LA, Sjostrom M, Slowikowska-Hilczer J, Slusarczyk P, Solfrizzi V, Sonestedt E, Soumare A, Staessen JA, Stathopoulou MG, Steene-Johannessen J, Stehle P, Stieber J, Stockl D, Stokwiszewski J, Sundstrom J, Suriyawongpaisal P, Tamosiunas A, Tan EJ, Taylor A, Tell G, Thijs L, Tolonen HK, Topor-Madry R, Tormo MJ, Torrent M, Tsugane S, Tuomainen TP, Tuomilehto J, Tzourio C, Uusitalo HMT, Van Herck K, Vanderschueren D, Vanuzzo D, Vatten L, Vega T, Veronesi G, Vioque J, Virtanen JK, Visvikis-Siest S, Vollenweider P, Voutilainen S, Vrijheid M, Wagner A, Wagner A, Wang MD, Wang Q, Wang YX, Wannamethee SG, Wei WB, Whincup PH, Wiecek A, Willeit J, Willeit P, Wojtyniak B, Wong A, Woodward M, Wu FC, Wu SL, Xu HQ, Xu L, Yan WL, Yang XG, Ye XW, Yoshihara A, Zambon S, Zhao WH. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol. 2020; 49(1):173-92. Article. IF: 7.196. D1
- Taddei C, Zhou B, Bixby H, Carrillo-Larco RM, Danaei G, Jackson R, Farzadfar F, Sophiea MK, Di Cesare M, Iurilli MLC, Martínez AR, Asghari G, Dhana K, Gulayin P, Kakarmath S, Santero M, Voortman T, Riley LM, Cowan MJ, Savin S, Bennett JE, Stevens GA, Paciorek CJ, Aekplakorn W, Cifkova R, Giampaoli S, Kengne AP, Khang YH, Kuulasmaa K, Laxmaiah A, Margozzini P, Mathur P, Nordestgaard BG, Zhao D, Aadahl M, Abarca-Gómez L, Rahim HA, Abu-Rmeileh NM, Acosta-Cazares B, Adams RJ, Agdeppa IA, Aghazadeh-Attari J, Aguilar-Salinas CA, Agyemang C, Ahluwalia TS, Ahmad NA, Ahmadi A, Ahmadi N, Ahmed SH, Ahrens W, Ajlouni K, Alarouj M, AlBuhairan F, AlDhukair S, Ali MM, Alkandari A, Alkerwi A, Aly E, Amarapurkar DN, Amouyel P, Andersen LB, Anderssen SA, Anjana RM, Ansari-Moghaddam A, Aounallah-Skhiri H, Araujo J, Ariansen I, Aris T, Arku RE, Arlappa N, Aryal KK, Aspelund T, Assuncao MCF, Auvinen J, Avdicova M, Azevedo A, Azizi F, Azmin M, Balakrishna N, Bamoshmoosh M, Banach M, Bandosz P, Banegas JR, Barbagallo CM, Barcelo A, Barkat A, Bata I, Batieha AM, Batyrbek A, Baur LA, Beaglehole R, Belavendra A, Ben Romdhane H, Benet M, Benn M, Berkinbayev S, Bernabe-Ortiz A, Bernotiene G, Bettiol H, Bhargava SK, Bi YF, Bienek A, Bikbov M, Bista B, Bjerregaard P, Bjertness E, Bjertness MB, Bjorkelund C, Bloch KV, Blokstra A, Bo S, Boehm BO, Boggia JG, Boissonnet CP, Bonaccio M, Bongard V, Borchini R, Borghs H, Bovet P, Brajkovich I, Breckenkamp J, Brenner H, Brewster LM, Bruno G, Bugge A, Busch MA, de Leon AC, Cacciottolo J, Can G, Candido APC, Capanzana

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

MV, Capuano E, Capuano V, Cardoso VC, Carvalho J, Casanueva FF, Censi L, Chadjigeorgiou CA, Chamukuttan S, Chaturvedi N, Chen CJ, Chen FF, Chen SH, Cheng CY, Cheraghian B, Chetrit A, Chiou ST, Chirlaque MD, Cho BL, Cho YM, Chudek J, Claessens F, Clarke J, Clays E, Concin H, Confortin SC, Cooper C, Costanzo S, Cottel D, Cowell C, Crujeiras AB, Csilla S, Cui LF, Cureau FV, D'Arrigo G, d'Orsi E, Dallongeville J, Damasceno A, Dankner R, Dantoft TM, Dauchet L, Davletov K, De Backer G, De Bacquer D, de Gaetano G, De Henauw S, de Oliveira PD, De Ridder D, De Smedt D, Deepa M, Deev AD, Dehghan A, Delisle H, Dennison E, Deschamps V, Dhimal M, Di Castelnuovo AF, Dika Z, Djalalinia S, Dobson AJ, Donfrancesco C, Donoso SP, Doring A, Dorobantu M, Dragano N, Drygas W, Du Y, Duante CA, Duda RB, Dzerve V, Dziankowska-Zaborszczyk E, Eddie R, Eftekhar E, Eggertsen R, Eghtesad S, Eiben G, Ekelund U, El Ati J, Eldemire-Shearer D, Eliasen M, Elosua R, Erasmus RT, Erbel R, Erem C, Eriksen L, Eriksson JG, Escobedo-de la Pena J, Eslami S, Esmaeili A, Evans A, Faeh D, Fall CH, Faramarzi E, Farjam M, Fattahi MR, Felix-Redondo FJ, Ferguson TS, Fernandez-Berges D, Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Foger B, Foo LH, Forslund AS, Forsner M, Fouad HM, Francis DK, Franco MD, Franco OH, Frontera G, Fujita Y, Fumihiko M, Furusawa T, Gaciong Z, Galvano F, Gao JL, García-de-la-Hera M, Garnett SP, Gaspoz JM, Gasull M, Gazzinelli A, Geleijnse JM, Ghanbari A, Ghasemi E, Gheorghe-Fronea OF, Ghimire A, Gianfagna F, Gill TK, Giovannelli J, Gironella G, Giwercman A, Goltzman D, Goncalves H, González-Chica DA, González-Gross M, González-Rivas JP, González-Villalpando C, González-Villalpando ME, González AR, Gottrand F, Graff-Iversen S, Gregor RD, Grodzicki T, Grontved A, Grosso G, Gruden G, Gu DF, Guallar-Castillón P, Guan OP, Gudmundsson EF, Gudnason V, Guerrero R, Guessous I, Gunnlaugsdottir J, Gupta R, Gutierrez L, Gutzwiller F, Ha S, Hadaegh F, Haghshenas R, Hakimi H, Hambleton IR, Hamzeh B, Hantunen S, Kumar RH, Hashemi-Shahri SM, Hata J, Haugsgjerd T, Hayes AJ, He J, He Y, Hendriks ME, Henriques A, Herrala S, Heshmat R, Hill AG, Ho SY, Ho SC, Hobbs M, Hofman A, Homayounfar R, Hopman WM, Horimoto ARVR, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT,



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Htet AS, Htike MMT, Huerta JM, Huhtaniemi IT, Huisman M, Hunsberger ML, Husseini AS, Huybrechts I, Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Wong NI, Iglesia I, Ikeda N, Ikram MA, Iotova V, Irazola VE, Ishida T, Islam M, Ismail AA, Iwasaki M, Jacobs JM, Jaddou HY, Jafar T, James K, Jamrozik K, Janszky I, Janus E, Jarvelin MR, Jasienska G, Jelakovic A, Jelakovic B, Jennings G, Jensen GB, Jeong SL, Jha AK, Jiang CQ, Jiménez RO, Jockel KH, Joffres M, Jokelainen JJ, Jonas JB, Jorgensen T, Joshi P, Joukar F, Jozwiak J, Juolevi A, Kafatos A, Kajantie EO, Kalter-Leibovici O, Kamaruddin NA, Kamstrup PR, Karki KB, Katz J, Kauhanen J, Kaur P, Kavousi M, Kazakbaeva G, Keil U, Keinanen-Kiukaanniemi S, Kelishadi R, Keramati M, Kerimkulova A, Kersting M, Khader YS, Khalili D, Khateeb M, Kheradmand M, Khosravi A, Kiechl-Kohlendorfer U, Kiechl S, Killewo J, Kim HC, Kim J, Kim YY, Klumbiene J, Knoflach M, Ko S, Kohler HP, Kohler IV, Kolle E, Kolsteren P, Konig J, Korpelainen R, PaulKorrovits, Kos J, Koskinen S, Kouda K, Kowlessur S, Kratzer W, Kriemler S, Kristensen PL, Krokstad S, Kromhout D, Kujala UM, Kurjata P, Kyobutungi C, Laamiri FZ, Laatikainen T, Lachat C, Laid Y, Lam TH, Lambrinou CP, Lanska V, Lappas G, Larijani B, Latt TS, Laugsand LE, Lazo-Porras M, Lee J, Lee J, Lehmann N, Lehtimaki T, Levitt NS, Li YP, Lilly CL, Lim WY, Lima-Costa MF, Lin HH, Lin X, Lin YT, Lind L, Linneberg A, Lissner L, Liu J, Loit HM, López-García E, López T, Lotufo PA, Lozano JE, Luksiene D, Lundqvist A, Lundqvist R, Lunet N, Ma GS, Machado-Coelho GLL, Machado-Rodrigues AM, Machi S, Madar AA, Maggi S, Magliano DJ, Magriplis E, Mahasampath G, Maire B, Makdisse M, Malekzadeh F, Malekzadeh R, Rao KM, Manios Y, Mann JI, Mansour-Ghanaei F, Manzato E, Marques-Vidal P, Martorell R, Mascarenhas LP, Mathiesen EB, Matsha TE, Mavrogianni C, McFarlane SR, McGarvey ST, McLachlan S, McLean RM, McLean SB, McNulty BA, Mediene-Benchekor S, Mehdipour P, Mehlig K, Mehrparvar A, Meirhaeghe A, Meisinger C, Menezes AMB, Menon GR, Merat S, Mereke A, Meshram II, Metcalf P, Meyer HE, Mi J, Michels N, Miller JC, Minderico CS, Mini GK, Miquel JF, Miranda JJ, Mirjalili MR, Mirrakhimov E, Modesti PA, Moghaddam SS, Mohajer B, Mohamed M, Mohammad K, Mohammadi Z, Mohammadifard N, Mohammadpourhodki R, Mohan V, Mohanna S, MohdYusoff MF, Mohebbi I, Mohebi F, Moitry M, Mollehave LT, Mller NC, Molnar D, Momenan A, Mondo CK, Monterrubio-Flores E, Moosazadeh M, Morejon A, Moreno LA, Morgan K, Morin SN, Moschonis G, Mossakowska M, Mostafa A, Mota J, Motlagh ME, Motta J, Msyamboza KP, Muiesan ML, Muller-Nurasyid M, Mursu J, Mustafa N, Nabipour I, Naderimagham S, Nagel G, Naidu BM, Najafi F, Nakamura H, Nang EEK, Nangia VB, Nauck M, Neal WA, Nejatizadeh A, Nenko I, Nervi F, Nguyen ND, Nguyen QN, Nieto-Martínez RE, Nihal T, Niiranen TJ, Ning G, Ninomiya T, Noale M, Noboa OA, Noto D, Al Nsour M, Nuhoglu I, O'Neill TW, O'Reilly D, Ochoa-Aviles AM, Oh K, Ohtsuka R, Olafsson O, Olie V, Oliveira IO, Omar MA, Onat A, Ong S, Ordunez P, Ornelas R, Ortiz PJ, Osmond C, Ostojic SM, Ostovar A, Otero JA, Owusu-Dabo E, Paccaud FM, Pahomova E, Pajak A, Palmieri L, Pan WH, Panda-Jonas S, Panza F, Parnell WR, Patel ND, Peer N, Peixoto SV, Peltonen M, Pereira AC, Peters A, Petersmann A, Petkeviciene J, Peykari N, Pham ST, Pichardo RN, Pigeot I, Pilav A, Pilotto L, Piwonska A, Pizarro AN, Plans-Rubio P, Plata S, Pohlabeln H, Porta M, Portegies MLP, Poudyal A, Pourfarzi F, Poustchi H, Pradeepa R, Price JF, Providencia R, Puder JJ, Puhakka SE, Punab M, Qorbani M, Bao TQ, Radisauskas R, Rahimikazerooni S, Raitakari O, Rao SR, Ramachandran A, Ramos E, Ramos R, Rampal L, Rampal S, Redon J, Reganit PFM, Revilla L, Rezaianzadeh A, Ribeiro R, Richter A, Rigo F, de Wit TFR, Rodriguez-Artalejo F, Rodriguez-Perez MD, Rodriguez-Villamizar LA, Roggenbuck U, Rojas-Martínez R, Romaguera D, Romeo EL, Rosengren A, Roy JGR, Rubinstein A, Ruidavets JB, Ruiz-Betancourt BS, Russo P, Rust P, Rutkowski M, Sabanayagam C, Sachdev HS, Sadjadi A, Safarpour AR, Safiri S, Saidi O, Saki N, Salanave B, Salmeron D, Salomaa V, Salonen JT, Salvetti M, Sanchez-Abanto J, Sans S, Santaliestra-Paisas AM, Santos DA, Santos M, Santos R, Saramies JL, Sardinha LB, Sarrafzadegan N, Saum KU, Savva SC, Sawada N, Sbaraini M, Scazufca M, Schaan BD, Schargrodsky H, Scheidt-Nave C, Schienkiewitz A, Schipf S, Schmidt CO, Schottker B, Schramm S, Sebert S, Sein AA, Sen A, Sepanlou SG, Servais J, Shakeri R, Shalnova SA, Shamah-Levy T, Sharafkhah M, Sharma SK, Shaw JE, Shayanrad A, Shi ZM, Shibuya K, Shimizu-Furusawa H, Shin DW, Shin Y, Shirani M, Shiri R, Shrestha N, Si-Ramlee K, Siani A, Siantar R, Sibai AM, Silva DAS, Simon M, Simons J, Simons LA, Sjostrom M, Skaaby T, Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Snijder MB, Soderberg S, Soemantri A, Sofat R, Solfrizzi V, Somi MH, Sonestedt E, Sorensen TIA, Jerome CS, Soumare A, Sozmen K, Sparrenberger K, Staessen JA, Stathopoulou MG, Stavreski B, Steene-Johannessen J, Stehle P, Stein AD, Stessman J, Stevanovic R, Stieber J, Stockl D, Stokwiszewski J, Stronks K, Strufaldi MW, Suarez-Medina R, Sun CA, Sundstrom J, Suriyawongpaisal P, Sy RG, Sylva RC, Szklo M, Tai ES, Tamosiunas A, Tan E, Tarawneh MR, Tarqui-Mamani CB, Taylor A, Taylor J, Tell GS, Tello T, Thankappan KR, Thijs L, Thuesen BH, Toft U, Tolonen HK, Tolstrup JS, Topbas M, Topor-Madry R, Tormo MJ, Tornaritis MJ, Torrent M, Torres-Collado L, Traissac P, Trinh OTH, Truthmann J, Tsugane S, Tulloch-Reid MK, Tuomainen TP, Tuomilehto J, Tybjaerg-Hansen A, Tzourio C, Ueda P, Ugel E, Ulmer H, Unal B, Uusitalo HMT, Valdivia G, Valvi D, van Dam R, van der Schouw YT, Van Herck K, Van Minh H, Rossem L, Van Schoor NM, van Valkengoed IGM, Vanderschueren D, Vanuzzo D, Varbo A, Varona-Perez P, Vasan SK, Vatten L, Vega T, Veidebaum T, Velasquez-Melendez G, Venero-Fernandez SJ, Veronesi G, MoniqueVerschuren WM, Victora CG, Vidiawati D, Viet L, Villalpando S, Vioque J, Virtanen JK, Visvikis-Siest S, Viswanathan B, Vlasoff T, Vollenweider P, Voutilainen A, Wade AN, Wagner A, Walton J, Bebakar WMW, WanMohamud WN, Wang MD, Wang NL, Wang Q, Wang YX, Wang YW, Wannamethee SG, Wedderkopp N, Wei WB, Whincup PH, Widhalm K, Widyahening IS, Wiecek A, Wijga AH, Wilks RJ, Willeit J, Willeit P, Wilsgaard T, Wojtyniak B, Wong-McClure RA, Wong A, Wong TY, Woo J, Woodward M, Wu FC, Wu SL, Xu HQ, Xu L, Yan WL, Yang XG, Yasuharu T, Ye XW, Yeow TP, Yiallouros PK, Yoosefi M, Yoshihara A, You SL, Younger-Coleman NO, Yusoff AF, Zainuddin AA, Zakavi SR, Zali MR, Zamani F, Zambon S, Zampelas A, KoZaw K, Zdrojewski T, Vrkic TZ, Zhang ZY, Zhao WH, Zhen SQ, Zheng YF, Zholdin B, Zhussupov B, Zoghlami N, Cisneros JZ, Gregg EW, Ezzati M. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020; 582(7810): 73-7. Article. IF: 4.9962. D1

- Wu YT, Daskalopoulou C, Terrera GM, Niubo AS, Rodríguez-Artalejo F, Ayuso-Mateos JL, Bobak M, Caballero FF, de la Fuente J, de la Torre-Luque A, García-Esquinas E, Haro JM, Koskinen S, Koupil I, Leonardi M, Pajak A, Panagiotakos D, Stefler D, Tobias-Adamczyk B, Prince M, Prina AM. Education and wealth inequalities in healthy ageing in eight harmonised cohorts in the ATHLOS consortium: a population-based study. Lancet Public Health. 2020; 5(7): E386-94. Article. IF: 2.1648. D1

Research projects

Rodríguez Artalejo F. Patrones dietéticos, composición corporal, deterioro físico y cognitivo en los ancianos españoles. CIBE-Resp. 2018-Ongoing.

Managment centre: FIBHULP

Rodríguez Artalejo F. El síndrome de fragilidad y los factores psicosociales en la trayectorias de envejecimiento saludable: una cohorte comunicatira de adultos mayores en España. CIBEResp. 2016-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Rodríguez Artalejo F. Networked Biomedical Research Center for Public Health and Epidemiology (CIBEResp). ISCIII. (31/12/2020)

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.2.3 Coagulopathies and Alterations of Haemostasis Group

Publications:	26
Impact Factor:	134.[676]
Q1:	16



Víctor Manuel Jiménez Yuste. Jefe de Servicio de Hematología. Hospital Universitario La Paz

María Teresa Álvarez Román. Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz

Nora Viviana Butta Coll. Investigadora Senior (Contrato Miguel Servet - Tipo 2). Jefa de Laboratorio. Hospital Universitario La Paz

Raquel Fernández Morata. Técnico de Laboratorio. Hospital Universitario La Paz

Elena García Arias-Salgado. Investigadora asociada. Advanced Medical Projects Madrid

Sara García Barcenilla. Coordinadora de Estudios. Hospital Universitario La Paz

Mónica Martín Salces. Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz

Isabel Rivas Pollmar. Médico Adjunto en Hematología. Hospital Universitario La Paz

Strategic Objective

This group's research activities address various relevant questions in the area of haematology and focus on the characterisation of the genetic and molecular basis of coagulation and haemostatic function. Our group investigates physiological processes such as coagulation, haemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signalling, with special emphasis on their relevance to pathological processes.

In addition, we perform epidemiological studies to facilitate patient data analysis and therapeutic treatment.

Research lines

1- Haemophilia A and B:

- Genetic and molecular studies in patients with haemophilia A and B
- Risk factors for the development of factor FVIII/FIX inhibitors in patients with haemophilia A and B. Individualised treatment adaptation based on the nature of antigenic epitopes
- Epidemiological studies of congenital haemophilia A and B, acquired haemophilia A and von Willebrand's disease

2-Haemostasis disorders:

- Haemostasis in thrombocytopenic diseases (immune thrombocytopenic purpura and myelodysplastic syndromes)
- Haemostasis in inflammatory diseases

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Publications

- Álvarez-Román MT, García-Barcenilla S, Cebanu T, González-Zorrilla E, Butta NV, Fernández-Bello I, Martín-Salces M, Rivas-Pollmar MI, Jiménez-Yuste V. Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. Haemophilia. 2020; 26(5): E245-7. Letter. IF: 4.287; Q1
- Bonanad S, García-Dasi M, Aznar JA, Mingot-Castellano ME, Jiménez-Yuste V, Calle MV, Palma A, López-Fernández MF, Marco P, Paloma MJ, Fernández-Mosteirin N, Galmes B, Sanabria M, Álvarez MP. Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia. 2020; 26(5):.800-8. Article. IF: 4.287; Q1
- Borras N, García-Martínez I, Batlle J, Perez-Rodríguez A, Parra R, Altisent C, López-Fernández MF, Pinto JC, Batlle-López F, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández-Mosteirin N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo A, Quismondo NC, Inigo B, Nieto MD, Vidal R, Martínez MP, Aguinaco R, Tenorio M, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobon M, Aguilar C, Corrales I, Vidal F. Unraveling the influence of common von Willebrand factor variants on von Willebrand disease phenotype: An exploratory study on the molecular and clinical profile of von Willebrand disease in Spain cohort. Thromb Haemostasis. 2020; 120(3): 437-48. Article. IF: 5.249; Q2
- Bury L, Megy K, Stephens JC, Grassi L, Greene D, Gleadall N, Althaus K, Allsup D, Bariana TK, Bonduel M, Butta NV, Collins P, Curry N, Deevi SVV, Downes K, Duarte D, Elliott K, Falcinelli E, Furie B, Keeling D, Lambert MP, Linger R, Mangles S, Mapeta R, Millar CM, Penkett C, Perry DJ, Stirrups KE, Turro E, Westbury SK, Wu J, Gomez K, Freson K, Ouwehand WH, Gresele P, Simeoni I. Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Hum Mutat. 2020; 41(1): 277-90. Article. IF: 4.878; Q2
- de la Corte-Rodríguez H, Álvarez-Román MT, Rodríguez-Merchán EC, Jiménez-Yuste V. What COVID-19 can mean for people with hemophilia beyond the infection risk. Expert Rev Hematol. 2020; 13(10): 1073-9. Review. IF: 2.929; Q3
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Jiménez-Yuste V. Intra-articular injections in people with haemophilia in the COVID-19 era. Haemophilia. 2020; 26(5): E248-50. Letter. IF: 4.287; Q1
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Martín-Salces M, Martinoli C, Jiménez-Yuste V. HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare?. Blood Coagul Fibrin. 2020; 31(6): 387-92. Article. IF: 1.276; Q4
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Martín-Salces M, Jiménez-Yuste V. 'Do not do' recommendations in hemophilia. Cardiovasc Hematol Disord Drug Targets. 2020; 20(3): 168-174. Review. Not indexed
- de la Cruz-Benito B, Lázaro-del Campo P, Ramírez-López A, de Soto-Álvarez T, Sánchez-Vadillo I, García-Pérez E, Dos Santos-Ortas A, Humala-Barbier K, López-de la Guía A, Casado-Abad G, Jiménez-Yuste V, Canales-Albendea M. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Brit J Haematol. 2020; 191(3): 386-9. Article. IF: 6.998; Q1
- García-Martínez I, Borrás N, Martorell M, Parra R, Altisent C, Ramírez L, Álvarez-Román MT, Núñez R, Megías-Vericat JE, Corrales I, Alonso S, Vidal F. Common genetic variants in ABO and CLEC4M modulate the pharmacokinetics of recombinant FVIII in severe hemophilia A patients. Thromb Haemostasis. 2020; 120(10): 1395-406. Article. IF: 5.249; Q2
- García-Suárez J, de la Cruz J, Cedillo A, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JA, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colas-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Alaez-Uson MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herraez R, Pascual A, Gomez E, Perez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martin-Buitrago LN, Canales M, González-Gascon I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Díez-Martín JL, Martínez-López J. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020; 13(1): 133. Article. IF: 17.388; D1
- Hay CRM, Shima M, Makris M, Jiménez-Yuste V, Oldenburg J, Fischer K, Iorio A, Skinner MW, Santagostino E, von Mackensen S, Kessler CM. Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia. 2020; 26(6): 966-74. Article. IF: 4.287; Q1
- Hernández-Maraver D, Viejo A, Kerguelen AE, Jiménez-Yuste V. Transfusion medicine during COVID-19 outbreak in the hotspot of Spain. Transfusion. 2020; 60(11): 2767-9. Letter. IF: 3.157; Q3
- López-Medina M, Hernández-Navarro F, Mtz-Enríquez AI, Oliva AI, Rodríguez-González V, Camarillo-García JP, Aguilar-Ortiz CO, Flores-Zuniga H, Oliva J. Enhancing the capacity and discharge times of flexible graphene batteries by decorating their anodes with magnetic alloys NiMnMx (M-x=Ga, In, Sn). Mater Chem Phys. 2020; 256: 123660. Article. IF: 4.094; Q2
- Manzano EM, Fernández-Bello I, Sanz RJ, Marhuenda AR, López-Longo FJ, Acuna P, Román MTA, Yuste VJ, Butta NV. Insights into the procoagulant profile of patients with systemic lupus erythematosus without antiphospholipid antibodies. J Clin Med. 2020; 9(10): 3297. Article. IF: 4.241; Q1
- Manzano EM, Román MTA, Sanz RJ, Bello IF, Hernández D, Salces MM, Valor L, Pollmar IR, Butta NV, Yuste VJ. Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. Brit J Haematol. 2020; 189(5): 943-53. Article. IF: 6.998; Q1
- Mareque M, Mingot-Castellano ME, López-Fernández MF, Álvarez-Román MT, Oyaguez I. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. Eur J Haematol. 2020; 105(1): 94-100. Article. IF: 2.997; Q3
- Maseda R, Martínez-Santamaría L, Sacedón R, Butta N, de Arriba MD, García-Barcenilla S, García M, Illera N, Pérez-Conde I, Carretero M, Jiménez E, Melen G, Borobia AM, Jiménez-Yuste V, Vicente A, del Río M, de Lucas R, Escámez MJ. Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: A case report. Front Med (Lausanne). 2020; 7: 576558. Article. IF: 5.091; Q1
- Oldenburg J, Shima M, Kruse-Jarres R, Santagostino E, Mahlangu J, Lehle M, Bienz NS, Chebon S, Asikanius E, Trask P, Mancuso ME, Jiménez-Yuste V, von Mackensen S, Levy GG. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020; 67(10): e28474. Article. IF: 3.167; Q1
- Paciullo F, Bury L, Noris P, Falcinelli E, Melazzini F, Orsini S, Zaninetti C, Abdul-Kadir R, Obeng-Tuudah D, Heller PG, Glembotsky AC, Fabris F, Rivera J, Lozano ML, Butta N, Favier R, Cid AR, Fouassier M, Podda GM, Santoro C, Grandone E, Henskens Y, Nurden P, Zieger B, Cuker A, Devreese K, Tosetto A, de Candia E, Dupuis A, Miyazaki K, Othman M, Gresele P. Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Hae-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

matologica. 2020; 105(7): 1948-56. Article. IF: 9.941; Q1

- Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, Salces MM, García-Barcenilla S, Jiménez-Yuste V. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis. J Thromb Haemost. 2020; 18(9): 2202-4. Article. IF: 5.824; Q1
- Román MTA, Coll NB, Barcenilla SG, González LP, Collazo ID, Rodríguez HD, Garrido JAR, Salces MM, Pollmar MIR, Cebanu T, González-Zorrilla E, Acuña P, Manzano EM, Merchán ECR, Martínez RT, Banares MJB, Alvarino MG, Yuste VJ. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia. 2020; 26(5): 773-8. Article. IF: 4.287; Q1
- Tiede A, Bonanad S, Santamaria A, Goldmann G, Canaro M, Palomero A, Frade LJG, Megías-Vericat JE, Martínez F, Candel FG, Yuste VJ, Sparber-Sauer M, Halimeh S, Adolf D, Hukauf M, Reichmann J, Oldenburg J. Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. Haemophilia. 2020; 26(6): 999-1008. Article. IF: 4.287; Q1
- Tiede A, Cid AR, Goldmann G, Jiménez-Yuste V, Pluta M, Lissitchkov T, May M, Matytsina I, Miljic P, Pabinger I, Persson P. Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. Thromb Haemostasis. 2020; 120(2): 277-88. Article. IF: 5.249; Q2
- Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, Di Minno G, D'Oiron R, Salaj P, Jiménez-Yuste V, Huth-Kuhne A, Giangrande P. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7): 1791-801. Article. IF: 9.941; Q1
- Yaish H, Matsushita T, Belhani M, Jiménez-Yuste V, Kavakli K, Korsholm L, Matytsina I, Philipp C, Reichwald K, Wu RH. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia. 2020; 26(1): 64-72. Article. IF: 4.287; Q1



Research projects

Álvarez Román MT. Experiencias reales en la práctica clínica con Elocta. Swedish Orphan Biovitrum AB. 2019-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Hemolution. Estudio observacional ambisprectivo para evaluar la efectividad y seguridad del tratamiento con emicizumab de pacientes con hemofilia a en condiciones de practica clínica habitual. Roche Losada, Olga. 2019-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Manejo de la patología urgente en pacientes con hemofilia en el ambito extrahospitalario. Desarrollo de un protocolo de actuación extrahospitalario. Desarrollo de un protocolo de actuación coordinado entre el SUMMA 112 y el servicio de trombosis y hemostasia del Hospital La Paz en la Comunidad de Madrid. Antares Consulting S. A.. 2014-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Programa del tratamiento multidisciplinario del paciente con hemofilia. Omnix Pharma S. L. 2017-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Puesta en marcha y realización del estudio clínico ml40944. Hemolife: un estudio observacional de calidad de vida en personas con hemofilia a y cuidadores (no definitivo) y el estudio Hemolution: estudio observacional ambispectivo para evaluar la eficacia y seguridad del tratamiento en emicizumab de pacientes con hemofilia a en condiciones práctica clínica habitual (no definitivo). Roche Farma S. A. 2018-Ongoing.

Managment centre: FIBHULP

Butta Coll NV. Determinación de los niveles y actividad de TFPI en el plasma de pacientes con alteración hemostática no filiada. Novo Nordisk Pharma S. A. 2020-Ongoing.

Managment centre: FIBHULP

Butta Coll NV. Estudio de la hemostasia en la enfermedad de Behçet. Baxter S. L. 2011-Ongoing.

Managment centre: FIBHULP

Butta Coll NV. Estudio prospectivo de pacientes con trombocitopenia inmune: identificación de mecanismos fisiopatológicos que condicionan el fenotipo clínico y la respuesta a la terapia (PI15/01457). ISCIII. 2016-2020.

Managment centre: FIBHULP

Butta Coll NV. Role of platelet glicosylation on platelet function and inmune response in inmmune thrombocytopenia patients (PI19/00772). ISCIII. 2020-2022.

Managment centre: FIBHULP

Fernández Bello I, Álvarez Román MT. Individualización del tratamiento para el control del sangrado agudo en pacientes con hemofilia grave en tratamiento profiláctico con emizumab y concizumab que es subproyecto de evaluación in vitro de la función procoagulante de diferentes moléculas clásicas con actividad anti-hemofílica en pacientes con hemofilia en profilaxis con emicizumab o concizumab. Real Fundación Victoria Eugenia. 2018-Ongoing.

Managment centre: FIBHULP

Fernández Bello I, Butta Coll NV. Desarrollo de nanosistemas para eliminar la respuesta inmune contra el factor VIII en ratones con

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

hemofilia grave e inhibidores:un estudio de prueba de concepto para el diseño de nuevos protocolos de tolerancia inmune en pacientes con hemofilia. Real Fundación Victoria Eugenia. 2018-Ongoing.

Managment centre: FIBHULP

García Barcenilla S. Puesta en marcha del estudio clinico con codigo: ML42270: Estudio observacional para evaluar las estrategias de afrontamiento del dolor crónico en pacientes con hemofilia A desde el punto de vista de enfermería (no definitivo). Roche Farma S. A. 2020-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Case-control pilot study of the immune modulating effect of feiba on patients with haemophilia a and inhibitors. Baxter Healthcare Corporation. 2013-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Desarrollo de un nuevo método de laboratorio de alta sensibilidad para la detección cuantitativa de anticuerpos contra el factor VIII. Pfizer S. L. U. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Estudio de efecto procoagulante del emicizumab y de su combinación con concentrados de factor para el tratamiento de sangrados en pacientes con hemofilia A grave (PI19/00631). ISCIII. 2020-2022.

Managment centre: FIBHULP

Jiménez Yuste VM. Estudio del papel de los biomarcadores de daño endotelial, hepatocelular y fibrosis hepatica y la elastografia de transicion en el diagnóstico del síndrome de obstruccion sinusoidal. Jazz Pharmaceuticals Iberia S. L. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Estudio in vitro del efecto procoagulante de factor VII recombinante activado y vatreptacog alfa en sangre de pacientes con hemofilia grave mediante tromboelastografía y test de generación de tromina. Fundación SETH. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Estudio in vitro del efecto procoagulante de feibar en pacientes en profilaxis con emicizumab. Takeda Pharmaceutical International Ag. 2020-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Field study to evaluate the activity a site specific of b-domain deleted (bdd) pegylated recombinant FVIII protein (BAY94-9024) in plasma samples measured with both chromogenic and one stage assays used in clínical laboratories. Bayer Hispania S. L. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Head-Us mobile APP: desingn and implementation. Pfizer Inc. 2017-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Individualizacion de la profilaxis: estudio de los niveles valles mediante técnicas globales e impacto de la actividad física. World Federation of Hemophilia. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Individualización del régimen profiláctico con agentes baipás en pacientes con hemofilia e inhibidor de alta respuesta mediante tromboelastometría y trominografía. Antares Consulting S. A. 2014-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Iniciativas Confihe: profilaxis personalizada: estudios prospectivos de la influencia de los parámetros farmacocinéticos individuales, test globales de la coagulación y actividad deportiva en la eficacia de la profilaxis. Mk Media S. L. 2017-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Monitorización del tratamiento con agentes "Bypass", en pacientes con hemofilia e inhibidor mediante tres métodos de evaluación global de la hemostasia. Sanofi Aventis S. A. 2017-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. One-year training and research scholarship programme in haemophilia and other haemostatic disorders. Novo Nordiks Health Care Ag. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Sinovitis post-hemartros. Estudio clínico, biológico y ecográfico. Post-hemarthrosis sinovitis markers on patients with haemophilia on prophilaxis. clínical, biological and ultrasonographic styd. Comunidad de Madrid. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste VM. Tailoring prophylaxis in children with severe haemophilia: impact of the trough procoagulant state on the incidence of breakthrough bleeding. Novo Nordiks Health Care Ag. 2015-Ongoing.

Managment centre: FIBHULP

Rivas Pollmar MI. Evaluación de la carga asistencial de enfermería durante el uso de bombas de infusión intravenosa programables para la administración frecuente de bolos de RFVIIA. Novo Nordisk Pharma S. A. 2020-Ongoing.

Managment centre: FIBHULP

Rivas Pollmar MI. Individualización de la profilaxis en pacientes pediátricos con hemofilia A grave mediante estudio farmacocinético y farmacodinámico en tratamiento con productos de vida media estándar y vida media extendida. Swedish Orphan Biovitrum S. L. 2020-Ongoing.

Managment centre: FIBHULP

Clinical trials

Álvarez Román, MT. Eficacia y seguridad del factor VIII recombinante (Novoeight®) en pacientes con hemofilia A sometidos a intervenciones quirúrgicas.

Type: Estudios, phase EPA-SP.
HULP code: PI-4439 .
Sponsored´s protocol code: MFL-TUR-2018-01.
Sponsored by: Lopez Fernandez, Maria Fernanda.
Signed date: 28/10/2020

Álvarez Román, MT. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos con una extensión abierta para evaluar la eficacia y la seguridad de rilzabrutinib por vía oral (PRN1008) en adultos y adolescentes con trombocitopenia inmunitaria persistente o crónica.

Type: EECC, phase III.
HULP code: 5696.
Sponsored´s protocol code: PRN1008-018.
Sponsored by: Principia Biopharma Inc.
Signed date: 10/11/2020

Álvarez Román, MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNTP) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave FVIII < 1 %.

Type: EECC, phase III.
HULP code: Anexo 1 4487.
Sponsored´s protocol code: 261203.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 12/05/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Álvarez Román, MT. Estudio en fase I/II abierto y multinacional de seguridad y escalada de dosis de SHP648, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa el fix padua en sujetos con hemofilia B.

Type: EECC, phase I.
HULP code: Anexo 1 5382.
Sponsored´s protocol code: SHP648-101.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 21/07/2020

Álvarez Román, MT. Evaluación de la seguridad a largo plazo de adynovi/adynovate (factor antihemofílico [recombinante] pegilado, rurioctocog alfa pegol) en pacientes con hemofilia A: un estudio de seguridad posterior a la autorización (PASS) de adynovi/adynovate.

Type: Estudios, phase EPA-LA.
HULP code: PI-4279 .
Sponsored´s protocol code: TAK-660-403.
Sponsored by: Baxalta Innovations GMBH.
Signed date: 01/10/2020

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores.

Type: EECC, phase III.
HULP code: Anexo 1 5401.
Sponsored´s protocol code: NN7415-4311.
Sponsored by: Novo Nordisk Pharma S.A.
Signed date: 16/01/2020

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores.

Type: EECC, phase III.
HULP code: Anexo 2 5401.
Sponsored´s protocol code: NN7415-4311.
Sponsored by: Novo Nordisk Pharma S.A.
Signed date: 15/09/2020

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.

Type: EECC, phase III.
HULP code: Anexo 1 5400.
Sponsored´s protocol code: NN7415-4307.
Sponsored by: Novo Nordisk A/S.
Signed date: 16/01/2020

Jiménez Yuste, VM. Ensayo clínico aleatorizado, abierto, para evaluar el efecto de dosis profilácticas o terapéuticas de bemiparina en pacientes con covid-19 (Bemicop).

Type: EECC, phase IV.
HULP code: 5618.
Sponsored´s protocol code: BEMICOP.
Sponsored by: Universidad de Navarra.
Signed date: 30/10/2020

Jiménez Yuste, VM. Estudio abierto de un producto no investigativo, multicéntrico, inicial para evaluar al menos 6 meses de eficacia prospectiva y datos seleccionados de seguridad de la terapia de reemplazo de profilaxis con factor IX (corrección) en el ámbito de atención habitual de moderadamente grave a grave hemofilia b en adultos sujetos (solución: c≤2%) quienes son negativos para neutralizar anticuerpos (NAB) a vector de virus adenoasociado (AAV)-Spark100.

Type: EECC, phase III.
HULP code: Anexo 1 5204.
Sponsored´s protocol code: C0371004.
Sponsored by: Pfizer S.L.U.
Signed date: 07/04/2020

Jiménez Yuste, VM. Estudio abierto en pacientes adolescentes y adultos con hemofilia A o B grave (actividad del factor de coagulación <1 %) con o sin inhibidores para comparar el tratamiento estándar con la profilaxis con PF-06741086.

Type: EECC, phase III.
HULP code: 5486.
Sponsored´s protocol code: B7841005.
Sponsored by: Pfizer S.L.U.
Signed date: 09/09/2020

Jiménez Yuste, VM. Estudio abierto multicéntrico de fase 3 sobre la seguridad, eficacia y farmacocinética del factor de coagulación recombinante intravenoso VIII FC-factor Von Willebrand-proteína de fusión XTEN (rfviiifc-vwf-xten; bivv001) en pacientes tratados previamente con ≥12 años con hemofilia a severa.

Type: EECC, phase III.
HULP code: 5482.
Sponsored´s protocol code: EFC16293.
Sponsored by: Bioverativ Therapeutics Inc.
Signed date: 25/02/2020

Jiménez Yuste, VM. Estudio de fase IIIB, multicéntrico, abierto y de un solo grupo para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica de emicizumab subcutáneo en pacientes desde el nacimiento hasta los 12 meses de edad con hemofilia A sin inhibidores.

Type: EECC, phase IIIb.
HULP code: 5706.
Sponsored´s protocol code: M041787.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/11/2020

Jiménez Yuste, VM. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (MIM8) in healthy subjects and in subjects with haemophilia a with or without factor VIII inhibitors.

Type: EECC, phase II.
HULP code: 5514.
Sponsored´s protocol code: NN7769-4513.
Sponsored by: Novo Nordisk A/S.
Signed date: 10/11/2020

Martín Salces, Ma. Ensayo en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efgartigimod (ARGX 113) 10 mg/kg por vía intravenosa en pacientes adultos con trombocitopenia inmune primaria.

Type: EECC, phase III.
HULP code: 5430.
Sponsored´s protocol code: ARGX-113-1801.
Sponsored by: Argenx Bvba.
Signed date: 29/01/2020

Martín Salces, M. Ensayo en fase III multicéntrico, sin enmascaramiento y a largo plazo para evaluar la seguridad y la eficacia de 10 mg/kg de efgartigimod (ARGX-113) por vía intravenosa en pacientes adultos con trombocitopenia inmunitaria primaria.

Type: EECC, phase III.
HULP code: 5480.
Sponsored´s protocol code: ARGX-113-1803.
Sponsored by: Argenx Bvba. Signed date: 13/05/2020

3.2.4 Vascular Physiology and Pharmacology Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	18
Impact Factor:	113.[133]
Q1:	13



Mercedes Salaices Sánchez. Catedrática. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid

María Jesús Alonso Gordo. Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

María Teresa Barrús Ortiz. Profesora Contratada Doctor. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Javier Blanco Rivero. Profesor Contratado Doctor. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid

Ana María Briones Alonso. Profesora Titular. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid

Constanza Ballesteros Martínez. Inestigadora Predoctoral. Universidad Autónoma de Madrid

Ana Belén García Redondo. Profesora Ayudante Doctor. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid

María González Amor. Inestigadora Predoctoral. Universidad Autónoma de Madrid

Zoe González Carnicero. Investigadora Predoctoral. Universidad Rey Juan Carlos

Raquel Hernanz Martín. Profesora Titular. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Ángela Martín Cortes. Profesora Contratada Doctor. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Marta Martínez Casales. Investigadora Predoctoral. Universidad Autónoma de Madrid

Marta Miguel Castro. Investigador Científico. Instituto de Investigación en Ciencias de la Alimentación. Consejo Superior de Investigaciones Científicas

Roberto Palacios Ramírez. Investigador Posdoctoral. Universidad Rey Juan Carlos

Raquel Rodrígues Díez. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Lucía Serrano Díaz del Campo. Inestigadora Predoctoral. Hospital Universitario La Paz

Strategic Objective

Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension.

The group is located at the Faculty of Medicine (UAM) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cellbased studies combined with physiological, pharmacological and molecular biology techniques. In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in the role of prostanoids derived from the inducible isoform of cyclooxygenase (COX-2) and reactive oxygen species (and their interaction among each other or with other mediators such as nitric oxide) in inflammatory conditions that resemble those found in cardiovascular pathologies. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Inflammation and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies.
- Adipose tissue and vascular alterations in cardiovascular pathologies.
- Neural control of vascular tone.
- Cardiovascular effects of heavy metals.
- Antioxidant and antihypertensive properties of food bioactive compounds.
- Resolution of inflammation as a therapeutic approach for cardiovascular diseases

Research Activity

Publications

- D Aller MA, Arias J, Blanco-Rivero J. Letter to the Editor: The Porto-Hepatic Spectrum of Cirrhotic Encephalopathy. Hepatology. 2020; 71(1): 394-5. Letter. IF: 17.425; D1
- Beck L, Su JJ, Comerma-Steffensen S, Pinilla E, Carlsson R, Hernanz R, Sheykhzade M, Danielsen CC, Simonsen U. Endothelial dysfunction and passive changes in the aorta and coronary arteries of diabetic db/db Mice. Front Physiol. 2020; 11: 667. Article. IF: 4.566; Q1
- Blanco-Rivero J, Xavier FE. Therapeutic potential of phosphodiesterase inhibitors for endothelial dysfunction-related diseases. Curr Pharm Design. 2020; 26(30): 3633-51. Review. IF: 3.116; Q3
- Caracuel L, Sastre E, Callejo M, Rodrigues-Díez R, García-Redondo AB, Prieto I, Nieto C, Salaíces M, Aller MA, Arias J, Blanco-Rivero J. Hepatic encephalopathy-associated cerebral vasculopathy in acute-on-chronic liver failure: Alterations on endothelial factor release and influence on cerebrovascular Function. Front Physiol. 2020; 11: 593371. Article. IF: 4.566; Q1
- de Vega MJP, Moreno-Fernández S, Pontes-Quero GM, González-Amor M, Vázquez-Lasa B, Sabater-Muñoz B, Briones AM, Aguilar MR, Miguel M, González-Muniz R. Characterization of novel synthetic polyphenols: Validation of antioxidant and vasculoprotective activities. Antioxidants. 2020; 9(9): 787. Article. IF: 6.312; D1
- de Yébenes VG, Briones AM, Martos-Folgado I, Mur SM, Oller J, Bilal F, González-Amor M, Méndez-Barbero N, Silla-Castro JC, Were F, Jiménez-Borreguero LJ, Sánchez-Cabo F, Bueno H, Salaíces M, Redondo JM, Ramiro AR. Aging-associated miR-217 aggravates atherosclerosis and promotes cardiovascular dysfunction. Arterioscl Throm Vas. 2020; 40(10): 2408-24. Article. IF: 8.311; Q1
- Escobar AG, Rizzetti DA, Piagette JT, Pecanha FM, Vassallo DV, Miguel M, Wiggers GA. Antioxidant properties of egg white hydrolysate prevent mercury-induced vascular damage in resistance arteries. Front Physiol. 2020; 11: 595767. Article. IF: 4.566; Q1
- González-Amor M, Vila-Bedmar R, Rodrigues-Díez R, Moreno-Carriles R, Arcones AC, Cruces-Sande M, Salaíces M, Mayor F, Briones AM, Murga C. Myeloid GRK2 regulates obesity-induced endothelial dysfunction by modulating inflammatory responses in perivascular adipose tissue. Antioxidants. 2020; 9(10): 953. Article. IF: 6.312; D1
- Isac-Torrente L, Fernández-Gomez B, Miguel M. Coffee capsules: implications in antioxidant activity, bioactive compounds, and aluminum content. Eur Food Res Technol. 2020; 246(11): 2335-47. Article. IF: 2.998; Q2
- Llevenes P, Rodrigues-Díez R, Cros-Brunso L, Prieto MI, Casani L, Balfagón G, Blanco-Rivero J. Beneficial effect of a multistrain synbiotic prodefen[(R)] plus on the systemic and vascular alterations associated with metabolic syndrome in rats: The role of the neuronal nitric oxide synthase and protein kinase A. Nutrients. 2020; 12(1): 117. Article. IF: 5.717; Q1
- López-Moreno M, López MTI, Miguel M, Garces-Rimon M. Physical and psychological effects related to food habits and lifestyle changes derived from COVID-19 home confinement in the Spanish population. Nutrients. 2020; 12(11): 3445. Article. IF: 5.717; Q1
- Miguel M, Vassallo DV, Wiggers GA. Bioactive peptides and hydrolysates from egg proteins as a new tool for protection against cardiovascular problems. Curr Pharm Design. 2020; 26(30): 3676-83. Review. IF: 3.116; Q3
- Moreno-Fernández S, Garcés-Rimón M, Miguel M. Egg-derived peptides and hydrolysates: A new bioactive treasure for cardiometabolic diseases. Trends Food Sci Tech. 2020; 104: 208-18. Article. IF: 12.563; D1
- Nguyen VT, Farman N, Palacios-Ramírez R, Sbeih M, Behar-Cohen F, Aractingi S, Jaisser F. Cutaneous wound healing in diabetic mice is improved by topical mineralocorticoid receptor blockade. J Invest Dermatol. 2020; 140(1): 223-34. Article. IF: 8.551; D1
- Orejudo M, García-Redondo AB, Rodrigues-Díez RR, Rodrigues-Díez R, Santos-Sánchez L, Muñoz AT, Egido J, Selgas R, Salaíces M, Briones AM, Ruiz-Ortega M. Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation. Clin Sci. 2020; 134(5): 513-27. Article. IF: 6.124; Q1
- Pinheiro JEG, Martínez CS, Moraes PZ, Stasiaki JE, Trost ME, Vassallo DV, Barbosa F, Pecanha FM, Cibin FWS, Miguel M, Wiggersa GA. Egg white hydrolysate prevents reproductive impairments induced by cadmium in rats. J Funct Foods. 2020; 67: 103823. Article. IF: 4.451; Q1
- Pinheiro JEG, Moraes PZ, Rodríguez MD, Simoes MR, Cibin F, Pinton S, Barbosa F, Pecanha FM, Vassallo DV, Miguel M, Wiggers GA. Cadmium exposure activates NADPH oxidase, renin-angiotensin system and cyclooxygenase 2 pathways in arteries, inducing hypertension and vascular damage. Toxicol Lett. 2020; 333: 80-9. Article. IF: 4.372; Q2
- Piotrowicz IBB, Garcés-Rimón M, Moreno-Fernández S, Aleixandre A, Salas-Mellado M, Miguel-Castro M. Antioxidant, angiotensin-converting enzyme inhibitory properties and blood-pressure-lowering effect of rice bran protein hydrolysates. Foods. 2020; 9(6): 812. Article. IF: 4.35; Q2

Research projects

Alonso Gordo MJ. Modulacion por NRF2 del daño vascular asociado a la patología hipertensiva. Relación con TLR4 (SAF2015-69294-R). MINECO. 2016-2020.

Managment centre: URJC

Briones Alonso AM. Interferon stimulated gene 15 (ISG15) as a novel mediator of car-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

diovascular damage. Bayer Grants4Targets. 2020-2021.

Managment centre: UAM

Garcia-Redondo AB. Interferon stimulated gene 15 (ISG15) as a new mediator of aortic aneurysms (SI1-PJI-2019-321). CAM-UAM. 2020-2022.

Managment centre: UAM

Miguel Castro M. Hidrólisis de proteínas vegetales de alto valor biológico: obtención de péptidos antioxidantes y nuevas texturas culinarias para la elaboración de productos sin gluten (AGL-2017-89213). MINECO. 2018-2021.

Managment centre: CSIC

Rodrigues Díez R. Contrato Juan de la Cierva (IJCI-2017-31399). MINECO. 2019-2021.

Managment centre: UAM

Salaices Sánchez M, Briones Alonso AM. Novel inflammatory mechanisms of vascular damage in hypertension and obesity. Role of pro-resolving lipid mediators as possible therapeutic strategy. (SAF2016-80305-P). MINECO. 2017-2021.

Managment centre: UAM

Salaices Sánchez M. Mediadores y mecanismos moleculares de patologías aórticas y valvulares (B2017/BMD-3676). CAM. 2018-2021.

Managment centre: UAM

Cibers and Retics

Salaices Sánchez M. Networked Biomedical Research Center for Cardiovascular Diseases CIBERCV (CB16/11/00286). ISCIII. (31/12/2022)

Patents and trademarks

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08 .

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14 .

León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino)metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j] quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01 .

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Brand name: leggie. ESM4044711; 2019 November 22.

leggie

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.2.5 Vascular Pharmacology and Metabolism (FARMAVSM) Group

Publications:	7
Impact Factor:	85.[206]
Q1:	6



Carlos Félix Sánchez Ferrer. Catedrático de Farmacología. Universidad Autónoma de Madrid

Elena Cercas Alonso. Técnico Especialista en Análisis Clínico. Universidad Autónoma de Madrid

Fernando de la Cuesta Marina. Investigador Postdoctoral. Universidad Autónoma de Madrid

Pilar Dongil Sánchez. Ayudante de Investigación. Universidad Autónoma de Madrid

Marta Menéndez Ribes. Ayudante de Investigación. Universidad Autónoma de Madrid

Concepción Peiró Vallejo. Profesora Titular de Farmacología. Universidad Autónoma de Madrid

Álvaro San Hipólito Luengo. Investigador Predoctoral. Universidad Autónoma de Madrid

Licia Shamoon. Investigador Predoctoral. Universidad Autónoma de Madrid

Inés Valencia Fernández. Investigador Predoctoral. Universidad Autónoma de Madrid

Jorge Francisco Gómez Cerezo. Jefe de Servicio de Medicina Interna. Hospital Universitario Infanta Sofía

Strategic Objective

Understanding vascular ageing, both in healthy and pathological conditions, like obesity ant diebetes mellitus.

Research lines

- Mechanisms of human vascular ageing
- Mechanisms for vascular damage in diabetes mellitus
- Obesity, adipokines, insulin resistance, and vascular dysfunction
- Role for the angiotensin-(1-7)/Mas receptor axis on vascular function and inflammation.
- Development of novel extracellular vesicle-based therapies for cardiovascular diseases

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Doctoral theses

Romero Martínez A. Mecanismos antisenescentes de la angiotensina (1-7) en el endotelio vascular[dissertation]. Madrid: UAM: 2020(15/07/20209.

Directors: Peiró Callejo C
Sánchez Ferrer CF.

Publications

- Lumpuy-Castillo J, Lorenzo-Almoros A, Pello-Lázaro AM, Sánchez-Ferrer C, Egido J, Tuñon J, Peiró C, Lorenzo O. Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. Int J Mol Sci. 2020;21(18):-6471. Review. IF: 5,923; Q1
- McCracken IR, Taylor RS, Kok FO, de la Cuesta F, Dobie R, Henderson BEP, Mountford JC, Caudrillier A, Henderson NC, Ponting CP, Baker AH. Transcriptional dynamics of pluripotent stem cell-derived endothelial cell differentiation revealed by single-cell RNA sequencing. Eur Heart J. 2020;41(9):1024-+. Article. IF: 29,983; D1
- Peiró C, Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?. Circulation. 2020;141(21):1665-1666. Editorial Material. IF: 29,69; D1
- Rodríguez-Pardo J, Fuentes B, de Leciñana MA, Campollo J, Castaño PC, Ruiz JC, Herrero JE, Leal RG, Núñez AG, Cerezo JFG, Martínez AM, Vallejo JM, Aguado BP, López NR, de las Heras RS, Mora JV, Tejedor ED. Acute stroke care during the COVID-19 pandemic. Ictus Madrid Program recommendations. Neurologia. 2020;35(4):258-263. Review. IF: 3,109; Q3
- Romacho T, Valencia I, Ramos-González M, Vallejo S, López-Esteban M, Lorenzo O, Cannata P, Romero A, San Hipolito-Luengo A, Gómez-Cerezo JF, Peiró C, Sánchez-Ferrer CF. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Sci Rep-Uk. 2020;10(1):-5386. Article. IF: 4,379; Q1
- Sánchez-Rodríguez C, Peiró C, Rodríguez-Manas L, Nevado J. Polyphenols Attenuate Highly-Glycosylated Haemoglobin-Induced Damage in Human Peritoneal Mesothelial Cells. Antioxidants. 2020;9(7):-572. Article. IF: 6,312; D1
- Valencia I, Peiro C, Lorenzo O, Sánchez-Ferrer CF, Eckel J, Romacho T. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?. Front Pharmacol. 2020;11():-1161. Review. IF: 5,81; Q1

Research projects

de la Cuesta Marina F. Developing novel nanotherapies for atherosclerosis by delivering senolytics to the plaque using mesenchymal stem cell-derived extracellular vesicles (2019-T1/IND-13794). CM. 2020-2024.

Managment centre: UAM

Peiró Vallejo C, Sánchez Ferrer CF. Adipoquinas: nuevas dianas farmacológicas para prevenir el envejecimiento vascular (SAF2017-84776-R). MINECO. 2018-2021.

Managment centre: UAM

Sánchez Ferrer CF. Citómetro Separador Sorter (EQC2018-005059-P). Ministerio de Ciencia, Innovación y Universidades. 2019-2020.

Managment centre: UAM



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.3 Infectious Diseases and Immunity Area

Eduardo López-Collazo

Documents:	341	IF:	1994.06
Originals:	272	IF:	1636.377
D1:	60	Q1:	169

3.3.1 AIDS and Infectious Diseases Group
3.3.2 Molecular Microbiology Group
3.3.3 Immuno-Rheumatology Group
3.3.4 Innate Immune Response Group
3.3.5 Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System Group
3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies Group
3.3.7 Drug Hypersensibility and Innate Immune Response Group
3.3.8 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
3.3.9 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases Group
3.3.10 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group
3.3.11 Immunomediate Gastrointestinal Diseases and other Digestive Pathologies Group



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.3 Infectious Diseases and Immunity Area



Strategic Objectives	Development forecast for the coming years	Actions
Infectious Diseases and Immunity Area is composed of 11 groups focused on the study of diseases related to the immune system such as HIV, autoimmune diseases, cancer, etc., as well as the molecular mechanisms that explain the phenomena associated with these pathologies.	To identify priority research topics in our area and if necessary expand some of them.	**Promote the priority research line identified.**
	To generate and develop scientific research projects that allow the production of knowledge in the biomedical area.	**Obtain national and international scientific research projects in biomedical area.**
	To generate a significant number of research products/results, such as publications in nationally and internationally indexed journals, journals that contribute to the social appropriation of knowledge.	**Improve the annual number of publications in the first quartile and decile, and total impact factor of the area.**
	To socialize the research resultsby presenting papers at national and international events.	**Increase the presence of area researchers in national and international events.**
	To establish agreements and strategic alliances with other communities of knowledge that allow academic discussion and project development.	**Search for synergies with other groups with similar and complement research lines.**
	To promote the training of young researchers and undergraduate and graduate students.	**Training in research methodology undergraduate, predoctoral and postdoctoral personal.**
	To develop a good system of applied research so that everything studied in the laboratory has repercussions on both our patients and our entities.	**Promote the synergies of translational researchers and clinical researchers, and their incorporation into groups.**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.1 AIDS and Infectious Diseases Group

Publications:	57
Impact Factor:	368.[287]
Q1:	3



José Ramón Arribas López. Facultativo Especialista de Área en Medicina Interna (Contrato de Intensificación). Unidad de VIH. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Marta Arsuaga Vicente. Médico Adjunto en Medicina Interna. Hospital Universitario La Paz

José Ignacio Bernardino de la Serna. Facultativo Especialista de Área en Medicina Interna. Unidad VIH. Hospital Universitario La Paz

Julén Cadiñanos Loidi. Facultativo Especialista de Área Medicina Interna. Contrato Río Hortega. Hospital Universitario La Paz

Fernando de la Calle Prieto. Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz. Profesor Colaborador. Universidad Autónoma de Madrid

Andrés Esteban Cantos. Investigador Predoctoral. Hospital Universitario La Paz

Rosa de Miguel Buckley. Facultativo Especialista Adjunto en Medicina Interna. Hospital Universitarios La Paz

Marta Díaz Menéndez. Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz

Marta Gálvez Charro. Enfermera. Unidad de VIH. Hospital Universitario La Paz

Francisco Gayá Moreno. Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). Hospital Universitario La Paz

Juan Julián González García. Facultativo Especialista de Área en Medicina Interna. Unidad de VIH. Hospital Universitario La Paz

Pedro Herranz Pinto. Facultativo Especialista de Área en Dermatología. Jefe de Sección. Hospital Universitario La Paz

Víctor Hontañón Antoñana. Investigador predoctoral. Hospital Universitario La Paz

María Concepción Ladrón de Guevara García. Facultativo Especialista de Área en Microbiología y Parasitología. Hospital Universitario La Paz

Luz Martín Carbonero. Facultativo Especialista de Área. Hospital Universitario La Paz

María del Mar Lago Núñez. Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz

Mario Mayoral Muñoz. Enfermero. Hospital Universitario La Paz

Beatriz Mena Garay. Técnico de Grado Superior. Hospital Universitario La Paz

Juan José Miguel Castro. Enfermero. Hospital Universitario La Paz

Rocío Montejano Sánchez. Investigadora Predoctoral (Contrato Río Hortega). Hospital Universitario La Paz

María Luisa Montes Ramírez. Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. Hospital Universitario La Paz

Marta Mora Rillo. Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz

Juan Carlos Ramos Ramos. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Francisco Moreno Ramos. Farmacéutico. Hospital Universitario La Paz

José María Peña Sánchez de Rivera. Jefe de Sección de Plaza Vinculada. Catedrático. Hospital Universitario La Paz. Universidad Autónoma de Madrid

Berta Rodés Soldevila. Investigadora Senior (Contrato Miguel Servet- I2). Hospital Universitario La Paz

Javier Rodríguez Centeno. Investigador postdoctoral. Hospital Universitario La Paz

Elena Sendagorta Cudós. Facultativo Especialista de Área de Dermatología. Hospital Universitario La Paz

Lucía Serrano Morago. Investigadora predoctoral. Hospital Universitario La Paz

Eulalia Valencia Ortega. Facultativo Especialista de Área en Medicina Interna. Hospital Univeristario La Paz

Gabriel Saiz Medrano. Técnico de Grado Superior. Hospital Universitario La Paz

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

TAlthough great progress has been made, HIV infection remains an incurable disease. Even under the best circumstances, HIV-infected patients who receive current antiretroviral therapy have a survival disadvantage compared with the general non-infected population, which is estimated to be a life expectancy of 15 years less than the general population.

HIV infection is highly prevalent in Spain. Among western European countries, Spain has the second highest prevalence. An important local characteristic of the HIV-infected population in Spain is the high prevalence of hepatitis C coinfection.

This research line covers four main topics of research in HIV infection: antiretroviral treatment, HIV-HCV coinfection, metabolic complications and HIV-resistance to antiretroviral drugs. In addition, we are planning to start another research project on infections other than HIV.

The group has started a new research line regarding the aging and HIV Infection.

Tropical diseases are increasing as a consequence of global travel. These diseases continue to be relatively rare however, and therefore, often sub-optimal treated if managed by non-speciaslists. Furthermore, every year an increasing amount of special travelers (pregnants, comorbidities, immunossupressed) travel abroad, adding complexity in terms of a timely and effective diagnosis and management. The Tropical and Travel Medicine Unit provide both pre and postravel assistance in imported infectious diseases. The aim of this Unit is to provide efficient and effecrive specialist care with proven or suspected tropical disease and a specific preventative travel advice, togheter with international vaccines recommended for the trip.

Research lines

- Antiretroviral therapy & resistance.
- Metabolic complications of antiretroviral therapy.
- Liver disease.
- Neurocognitive impairment.
- Paediatric HIV infection and MTCT.
- Epigenetic and cellular factors related to HIV progression
- Optimisation of antibiotic therapy (ID no HIV)
- Tropical diseases
- Emerging and re-emerging virus
- Molecular and cellular biomarkers of aging

Research Activity

Publications

- Alejos B, Suárez-García I, Rava M, Bautista-Hernández A, Gutiérrez F, Dalmau D, Sagastagoitia I, Rivero A, Moreno S, Jarrin I. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. J Antimicrob Chemother. 2020; 75(10): 3004-14. Article. IF: 5.79; Q1
- Álvarez-Troncoso J, Larrauri MZ, Vega MDM, Vallano RG, Peláez EP, Rojas-Marcos PM, Martín-Luengo F, del Campo PL, Gil CRH, Esteban ET. Case Report: COVID-19 with bilateral adrenal hemorrhage. Am J Trop Med Hyg. 2020; 103(3): 1156-7. Article. IF: 2.345; Q2
- Andaluz I, Arcos MD, Montero MD, Castillo P, Martín-Carbonero L, García-Samaniego J, Romero M, García A, Busca C, González J, Montes ML, Olveira A. Patients with hepatitis C lost to follow-up: ethical-legal aspects and search results. Rev Esp Enferm Dig. 2020; 112(7): 532-7. Article. IF: 2.086; Q4
- Arias-Rivera, S, López-López, C, Frade-Mera, MJ, Via-Clavero, G, Rodríguez-Mondejar, JJ, Sánchez-Sánchez, MM, Acevedo-Nuevo, M, Gil-Castillejos, D, Robleda, G, Cachon-Pérez, M, Latorre-Marco, I, Mera, MJF, Rivera, SA, Vega, VB, Lavela, JE, Basurto, FP, Monzo, VM, Sánchez, MDS, Olivares, JCQ, Mancera, AIN, Jaen, SH, Díaz, NR, Rodríguez-Rey, LFC, García, MDH, López, CL, Sanz, TRV, de la Ventana, ABS, Martínez, MG, Olivera, MJT, Sánchez, LG, Gozalo, MJ, Pena, JAT, Domínguez, SR, Cobo, MCM, Fernández, OH, Mora, MA, González, MDB, López, JM, Ayala, AC, Blanco, RG, Rodríguez-Palmero, LMM, Nuevo, MA, Marco, IL, González, SG, Fernández, AC, Santos, CF, García, SD, Sevillano, MCA, Mondejar, JJR, Molina, AR, Celdran, DL, López, NDE, García, ABG, Sanz, LN, Rojo, FJM, Hernández, AF, González, SA, Viguria, RG, Oroz, AM, Berardo, BMM, Roig, MAZ, Ortiz, MDG, Orue, PA, Gallano, JB, Gómez, YG, Salazar, MLM, Nunez, CR, Martínez, MM, Aguado, GL, Hervas, PP, Marmaneu, MM, Artola, MMA, Cisternas, ES, Gimeno, YM, Calvo, AR, Tato, JLT, Carbonell, JI, Talavera, DV, Jara, MS, Martínez, JM, Sánchez, BM, Ceron, MY, Pagan, MCP. Assessment of analgesia, sedation, physical restraint and delirium in patients admitted to Spanish intensive care units. Proyecto ASCyD. Enferm Intensiva (Engl Ed). 2020; 31(1): 3-18. Article. Not Indexed
- Arsuaga M, de Miguel R, Trigo E, Barreiro P, de la Calle F, Tarin EJ, Loli-Ausejo D, Díaz M. A case of acute generalized exanthematous pustulosis caused by exposure to Atovaquone/proguanil. J Travel Med. 2020; 27(6): taaa034. Editorial Material. IF: 8.49; D1
- Balas A, Ramírez E, Trigo E, Cabañas R, Fiandor A, Arsuaga M, Lerma V, Sanz B, LuisVicario J, Herranz P, de Abajo F, Bellon T. HLA-A*68, -A*11:01, and -A*29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS. J. Allergy Clin Immunol-Pract. 2020; 8(9): 3198-200. Letter. IF: 8.861; Q1
- Berenguer J, Ryan P, Rodríguez-Bano J, Jarrin I, Carratala J, Pachon J, Yllescas M, Arriba JR. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020; 26(11): 1525-36. Article. IF: 8.067; D1
- Bernardino JI, Arribas JR. Is Spain doing enough to reduce the cardiovascular risk of patients with Human Immnodeficiency Virus infection? Rev Clin Esp. 2020; 220(3): 182-3. Editorial Material. IF: 1.556; Q3

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Brochado-Kith O, Martínez I, Berenguer J, Medrano LM, González-García J, García-Broncano P, Jimenez-Sousa MA, Carrero A, Hontañón V, Muñoz-Fernández MA, Fernández-Rodríguez A, Resino S. Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study. AIDS. 2020; 34(13): 1891-7. Article. IF: 4.177; Q3
- Buckley RD, Trigo E, de la Calle-Prieto F, Arsuaga M, Díaz-Menéndez M. Social distancing to combat COVID-19 led to a marked decrease in food-borne infections and sexually transmitted diseases in Spain. J Travel Med. 2020 ;27(8): taaa134. Letter. IF: 8.49; D1
- Cabañas R, Ramírez, E, Sendagorta, E, Alamar, R, Barranco, R, Blanca-López, N, Dona, I, Fernández, J, García-Nunez, I, García-Samaniego, J, López-Rico, R, Marín-Serrano, E, Merida, C, Moya, M, Ortega-Rodríguez, NR, Becerra, BR, Rojas-Pérez-Ezquerra, P, Sánchez-González, MJ, Vega-Cabrera, C, Vila-Albelda, C, Bellon, T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-Naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. JAIDS. 2020; 83(3): 310-8. Article. IF: 3.731; Q2
- Carrasco I, Sainz T, Frick MA, de Ory SJ, Fortuny C, Burgos J, Montero M, Gavilán C, Falcon MD, Couceiro JA, Bernardino JI, Bisbal O, Guerrero C, Aldámiz-Echevarría MT, Berenguer J, Navarro ML. Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients. J Viral Hepatitis. 2020; 27(9): 955-8. Article. IF: 3.728; Q2
- Carrascosa JM, Belinchón I, Rivera R, Ara M, Bustinduy M, Herranz P. The use of apremilast in psoriasis: A delphi study. Actas Dermo-Sifilogr. 2020; 111(2): 115-34. Article. Not Indexed
- Carrero A, Berenguer J, Hontañón V, Navarro J, Hernández-Quero J, Galindo MJ, Quereda C, Santos I, Téllez MJ, Ortega E, Sanz J, Medrano LM, Pérez-Latorre L, Bellón JM, Resino S, Bermejo J, González-García J. Effects of eradication of HCV on cardiovascular risk and preclinical atherosclerosis in HIV/HCV-coinfected patients. JAIDS. 2020; 83(3): 292-300. Article. IF: 3.731; Q2
- Casado JL, Vizcarra P, Blanco JL, Montejano R, Negredo E, Espinosa N, Montero M, Mena A, Palacios R, López JC, Vergas J, Galindo MJ, Cabello A, Deltoro MG, De Santiago AD. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. Int J STD AIDS. 2020; 31(5): 467-73. Article. IF: 1.359; Q4
- Chalouni M, Rodríguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, Knobel H, Zucman D, Ferreras BA, Autran B, Thiebaut R, Raffi F, Arribas JR. Correlation between blood telomere length and CD4+CD8+T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals. PLoS One. 2020; 15(4): e0230772. Article. IF: 3.24; Q2
- Crespillo-Andújar C, López-Vélez R, Trigo E, Norman F, Díaz-Menéndez M, Monge-Maillo B, Arsuaga M, Pérez-Molina JA. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Clin Microbiol Infect. 2020; 26(3): 384.e1-4 . Article. IF: 8.067; D1
- Crespillo-Andújar C, Díaz-Menéndez M, Trigo E, Arsuaga M, De la Calle F, Lago M, de Guevara MCL, Barreiro P, Montero D, García-Bujalance S, Alvarado EA, de la Calle M, Sánchez-Seco MP, de Ory F, Vázquez A, Arribas JR, La Paz-Carlos III, García J, Martín-Boado E, Martínez-Sánchez N, Rodríguez R, Herrero B, López F, Bartha JL, Elorza MD, Lafuente MC, Hortelano MG. Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. Travel Med Infect Dis. 2020; 33: 101543. Article. IF: 6.211, D1
- de Miguel R, Rial-Crestelo D, Domínguez-Domínguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, García-Álvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadinanos J, Mayoral M, Castro JM, Moreno V, Martín-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine. 2020; 55: 102779. Article. IF: 8.143; Q1
- del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrin I, Hernan MA. Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. Epidemiology. 2020; 31(6): E49-51. Letter. IF: 4.822; Q1
- del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrin I, Hernan MA. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy a cohort study. Ann Intern Med. 2020;1 73(7): 536-41. Article. IF: 25.391; D1
- Díaz-Menéndez, M; Crespillo-Andújar, C; Trigo, E; de la Calle-Prieto, F; Arsuaga, M. Rabies postexposure prophylaxis in international travellers: Results from a Spanish travellers referral unit. Med Clin (Barc). 2020; 154(2): 55-8. Article. IF: 1.725; Q3
- Díaz-Menéndez M, Esteban ET, Ujiie M, Calleri G, Rothe C, Malvy D, Nicastri E, Bissinger AL, Grandadam M, Alpern JD, Gobbi F, Schlagenhauf P, Duvignaud A, Javelle E, Nakamoto T, Antinori S, Hamer DH. Travel-associated chikungunya acquired in Myanmar in 2019. Euro Surveill. 2020; 25(1): 5-11. Article. IF: 6.307; D1
- Dickinson L, Gurjar R, Stohr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Faetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M, (Arribas JR, Bernardino de la Serna JI). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. J Antimicrob Chemother. 2020; 75(3): 628-39. Article. IF: 5.79; Q1
- Díez C, Berenguer J, Ibáñez-Samaniego L, Llop E, Pérez-Latorre L, Catalina MV, Hontañón V, Jiménez-Sousa MA, Aldamiz-Echevarría T, Martínez J, Calleja JL, Albillos A, Bellón JM, Resino S, González-García J, Banares R. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis. Clin Infect Dis. 2020; 71(10): 2726-9. Article. IF: 9.079; D1
- Dudouet P, Gautret P, Larsen CS, Díaz-Menéndez M, Trigo E, von Sonnenburg F, Gobbi F, Grobusch MP, Malvy D, Field V, Asgeirsson H, Souto IO, Hamer DH, Parola P, Javelle E. Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in 2019-2020: A GeoSentinel case series. Travel Med Infect Dis. 2020; 36: 101814. Article. IF: 6.211; D1
- Gaborit BJ, Bergmann JF, Mussini C, Arribas JR, Behrens G, Walmsley S, Pozniak A, Raffi F. Plea for multitargeted interventions for severe COVID-19. Lancet Infect Dis. 2020; 20(10): 1122-3. Letter. IF: 25.071; D1
- García IG, Rodríguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1): 466. Letter. IF: 2.279; Q4
- García-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, González-García J, Jiménez-Sousa A, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Resino S, Carrero A, Miralles P, López JC, Parras F, Padilla B, Aldamiz-Echevarria T, Tejerina F, Díez C, Pérez-Latorre L, Fanciulli C, Gutiérrez I, Ramírez M, Carretero S, Bellón JM,

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Bermejo J, Berenguer J, Hontañón V, Arribas JR, Montes ML, Bernardino I, Pascual JF, Zamora F, Peña JM, Arnalich F, Díaz M, González-García J, Domingo P, Guardiola JM, Van den Eynde E, Pérez M, Ribera E, Crespo M, Casado JL, Dronda F, Moreno A, Pérez-Elias MJ, Sanfrutos MA, Moreno S, Quereda C, Arranz A, Casas E, de Miguel J, Schroeder S, Sanz J, Santos I, Bustinduy MJ, Iribarren JA, Rodríguez-Arrondo F, Von-Wichmann MA, Vergas J, Téllez MJ, Vinuesa D, Muñoz L, Hernández-Quero J, Ferrer A, Galindo MJ, Ortiz L, Ortega E, Montero M, Blanes M, Cuellar S, Lacniz J, Salavert M, López-Aldeguer J, Pérez G, Gaspar G, Yllescas M, Crespo P, Aznar E, Esteban H. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. J Infect. 2020; 80(1): 99-110. Article. IF: 6,072; Q1

- Gautret P, Díaz-Menéndez M, Goorhuis A, Wallace RM, Msimang V, Blanton J, Dacheux L, Parize P, Blumberg L, Bourhy H, Grobusch MP. Epidemiology of rabies cases among international travellers, 2013-2019: A retrospective analysis of published reports. Travel Med Infect Dis. 2020; 36: 101766. Article. IF: 6.211; D1
- González-Cordón A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F, Katlama C, Masia M, Bernardino JI, Saumoy M, Pozniak A, Gatell JM, Martínez E. Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. J Antimicrob Chemother. 2020; 75(11): 3334-43. Article. IF: 5.79; Q1
- Guédez-López GV, Alguacil-Guillen M, González-Donapetry P, Bloise I, Tornero-Marín C, González-García J, Mingorance J, García-Rodríguez J. Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020; 39(12): 2289-97. Article. IF: 3.267; Q3
- Latasa P, de Ory F, Arribas JR, Sánchez-Uriz MA, Sánchez-Arcilla I, Ordobas M, Negredo A, Trigo E, Delgado P, Marzola M, López MA, Sánchez-Seco MP, de la Calle-Prieto F, Ferrera P, Rodríguez E, Martín A, del Cerro MF, Córdoba E, Mora-Rillo M, Esteban MJ. Absence of IgG antibodies among high-risk contacts of two confirmed cases of Crimean-Congo haemorrhagic fever in the autonomous region of Madrid (Spain). J Infect Public Health. 2020; 13(10): 1595-8. Article. IF: 3.718; Q2
- Mayor-Ibarguren A, Feito-Rodríguez M, Castanedo LQ, Ruiz-Bravo E, Vega DM, Herranz-Pinto P. Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report. J Eur Acad Dermatol Venereol. 2020; 34(10): E541-2. Letter. IF: 6.166; Q1
- Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA, Martins M, Cahn PE, Lopardo GD, Porteiro N, Bloch MT, Baker DA, Roth N, Moore RJ, Finlayson RJ, McMahon J, Rieger A, Zoufaly A, Hartl S, Zangerle R, Smaill F, Walmsley SL, Conway B, Rachlis A, Smith GHR, Pérez C, Afani A, Barker MIEC, Chahin CE, Reyes MW, Gerstoft J, Weis N, Laursen AL, Molina JM, Yazdanpanah Y, Cotte L, Raffi F, Morlat P, Girard PM, Katlama C, Rockstroh JK, Arasteh K, Esser S, Stoehr A, Stellbrink HJ, Stoll M, Schuermann D, Faetkenheuer G, Bogner J, Lutz T, Baumgarten A, Jaeger H, Gori A, Coltan G, Constandis F, Erscoiu SM, Prisacariu LJ, Rugina S, Streinu-Cercel A, Pokrovsky VV, Zakharova NV, Shuldyakov AA, Ryamova EP, Kulagin VV, Tsybakova OA, Orlova-Morozova E, Nagimova F, Voronin E, Shimonova TE, Kozyrev OA, Orrell C, Lombaard JJ, Botes ME, Segorb JP, Gatell JM, Elias MJP, López JRA, Puigmal EN, Palter DP, Ortega FP, García JT, De los Santos I, Berenguer J, Williams IG, Johnson MA, Schembri G, Clarke A, Gompels M, Fox JM, Taylor SJ, Dockrell DH, Kegg S, Hagins DP, Osiyemi OO, Prelutsky DJ, Ramgopal MN, Scarsella AJ, Dretler R, DeJesus E, Bettacchi CJ, Sims J, Clay PG, Bellos NC, Thompson MA, Montero J, McDonald CK, Creticos C, Shamblaw D, Terrelonge AE, Valdes M, Tashima KT, Robbins WJ, Felizarta FA, Elion RA, Slim J, Lalla-Reddy SN, Win SS, Ruane PJ, Mills A, Cade JL, Dietz CA, Mayer C, Rondon JC, Cook PP, Daar E, Kumar PN, Swindells S, Castro JG, Morales-Ramirez JO, Santiago L, Santana-Bagur JL, (Arribas López JR) . Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised double-blind non-inferiority phase 3 trial. Lancet HIV. 2020; 7(1): E16-26. Article. IF: 12.767; D1
- Molina-Carrión S, Brochado-Kith S, González-García J, Berenguer J, Díez C, Llop E, Hontañón V, Ibáñez-Samaniego L, Montes ML, Resino S, Fernández-Rodríguez A, Jimenez-Sousa MA. Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals. J Clin Med. 2020; 9(8): 2407. Article. IF: 4.241; Q1
- Mostaza JM, García-Iglesias F, González-Alegre T, Blanco F, Varas M, Hernández-Blanco C, Hontañón V, Jaras-Hernández MJ, Martínez-Prieto M, Menéndez-Saldana A, Cachan ML, Estirado E, Lahoz C, de Miguel R, Romero M, Lago M, García-Quero C, Plaza C, Sainz-Costa T, Rivas-Vila S, Sánchez B, Torres CG, Martínez-Tobar L, Hernández-Pérez M, Racionero P, Mir-Ihara P, Pena-López J, Bautista-Barea M, Benítez AP, Rodríguez-Merlos P, Barcenilla M, San Basilio M, Valencia M, Romero-Martin R, de los Bueis AB, de la Hoz-Polo A, del Pino-Cidad M, Coca-Robinot J, González-Ferrer B, Fernández-Pérez P, Mogollon I, Montoro-Romero MS, Villalain I, del Hierro-Zarzuelo A, Hernández-Martin I, Domínguez J, Luna A, Montoro S, Sánchez-Orgaz M, Amorena G, Lavin-Dapena C, Negreiros AZ. Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. Arch Gerontol Geriatr. 2020; 91: 104204. Article. IF: 3.25; Q3
- Muehlenbein MP, Angelo KM, Schlagenhauf P, Chen L, Grobusch MP, Gautret P, Duvignaud A, Chappuis F, Kain KC, Bottieau E, Epelboin L, Shaw M, Hynes N, Hamer DH, Wu HR, Waggoner J, Piyaphanee W, Silachamroon U, Coyle C, Schwartz E, Blumberg L, de Frey A, Siu H, Valdez LM, Beadsworth M, Beeching N, Libman M, Yansouni C, McCarthy A, Saio M, Menéndez MD, Jordon S, Vinnemeier C, Asgeirsson H, Glans H, Hochberg N, Gobbi F, Rossanese A, Gkrania-Klotsa E, Connor B, van Genderen P, Anderson S, Licitra C, Thomas A, Lim PL, Wejse C, Jespersen S, Mockenhaupt F, Harms-Zwingenberger G, Kelly P, Phu TH, Chan J, Yuen KY, Yates J, Johnston V, Field V, Viscoli C, Toscanini F, Pandey P, Amatya B, Mavunda K, Contiguglia-Akcan D, Leder K, Torresi J, Alpern J, Stauffer B, von Sonnenburg F, Rothe C, Hagmann S, Sood S, Wyler B, Cahill J, Caumes E, Plewes K, Ghesquiere W, Leung D. Traveller exposures to animals: a GeoSentinel analysis. J Travel Med. 2020; 27(7): taaa010. Article. IF: 8.49; D1
- Navarro J, González-Cordón A, Casado JL, Bernardino JI, Domingo P, Portilla J, Llibre JM, Colomer J, Rial-Crestelo D, Vizcarra P, Curran A, Martínez E, Ribera E. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. J Antimicrob Chemother. 2020; 75(7): 1955-60. Article. IF: 5.79; Q1
- Norman FF, Henríquez-Camacho C, Díaz-Menéndez M, Chamorro S, Pou D, Molina I, Goikoetxea J, Rodríguez-Guardado A, Calabuig E, Crespillo C, Oliveira I, Pérez-Molina JA, López-Vélez R. Imported arbovirus infections in Spain, 2009-2018. Emerg Infect Dis. 2020; 26(4): 658-66. Article. IF: 6.883; D1
- Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang HL, Acosta R, Brainard DM, Collins SE, Martin H. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020; 7(6): E389-400. Article. IF: 12.767; D1
- Puente S, Lago M, Subirats M, Sanz-Esteban I, Arsuaga M, Vicente B, Alonso-Sardón M, Belhassen-García M, Muro A. Imported Mansonella perstans infection in Spain. Infect Dis Poverty. 2020; 9(1): 105. Article. IF: 4.52; D1
- Puente S, Ramírez-Olivencia G, Lago M, Subirats M, Bru F, Pérez-Blázquez E, Arsuaga M, de Guevara CL, de la Calle-prieto F, Vicente B, Alonso-Sardón M, Belhassen-García M, Muro A. Loiasis in sub-Saharan migrants living in Spain with emphasis of cases from Equatorial Guinea. Infect Dis Poverty. 2020; 9(1): 16. Article. IF: 4.52; D1
- Quintana-Castanedo L, Maseda-Pedrero R, Herranz-Pinto P. Erosive and crusty plaque located in the ear of a patient with a childhood burn history. Rev Clin Esp. 2020; 220(2): 139-40. Editorial Material. IF: 1.556; Q3

- Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, Chiloeches-Fernández C, Sendagorta-Cudos E, Herranz-Pinto P. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020; 6(6): 498-9. Article. Not Indexed
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Pano-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae. Gut Pathogens. 2020; 12(1): 15. Article. IF: 4.181; Q2
- Refoyo E, Troya J, Trigo E, Guzmán-Martínez G, Valbuena-López S, Caro-Codon J, Rosillo S, Moreno-Yanguela M, Tamargo J, Arribas JR, Acquatella H, López-Sendon J. Comparison of noninvasive cardiac test strategies for newly diagnosed Chagas disease in a non-endemic zone. Am J Trop Med Hyg. 2020; 103(4): 1480-86. Article. IF: 2.345; Q2
- Ryom L, Cotter A, de Miguel R, Beguelin C, Podlekareva D, Arribas JR, Marzolini C, Mallón PGM, Rauch A, Kirk O, Molina JM, Guaraldi G, Winston A, Bhagani S, Cinque P, Kowalska JD, Collins S, Battegay M. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020; 21(10): 617-24. Article. IF: 3.18; Q3
- Salguero S, Medrano LM, González-García J, Berenguer J, Montes ML, Díez C, García-Broncano P, Llop-Herrera E, Pérez-Latorre L, Bellono JM, Jiménez-Sousa MA, Resino S. Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. Sci Rep. 2020; 10(1): 10384. Article. IF: 4.379; Q1
- Salguero S, Rojo D, Berenguer J, González-García J, Fernández-Rodríguez A, Brochado-Kith O, Díez C, Hontañón V, Virseda-Berdices A, Martínez J, Ibáñez-Samaniego L, Llop-Herrera E, Barbas C, Resino S, Jiménez-Sousa MA. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. Liver Int. 2020; 40(9): 2215-27. Article. IF: 5.828; Q2
- Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao HY, Blair C, Wang HY, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn Y, Sanyal AJ, Huhn G, Marty FM. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 a randomized clinical trial. JAMA-J Am Med Assoc. 2020; 324(11): 1048-57. Article. IF: 56.272; D1
- Suárez-García I, Moreno C, Ruiz-Alguero M, Pérez-Elías MJ, Navarro M, Martínez MD, Viciana P, Pérez-Martínez L, Gorgolas M, Amador C, de Zarraga MA, Jarrin I, (González-Garcia JJ, Arnalich F, Arribas JR, Bernardino de la Serna JI, Herranz P, Hontañón V, González-Baeza A, Martín-Carbonero ML, Montejano R, Montes ML). Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS Res Ther. 2020; 17(1): 45. Article. IF: 2.25; Q4
- Suárez-García I, Alejos B, Delgado E, Rivero M, Pineda JA, Jarrin I, Moreno S, del Amo J, Dalmau D, Navarro ML, González MI, Blanco JL, García F, Rubio R, Iribarren JA, Gutiérrez F, Vidal F, Berenguer J, González J, Jarrin I, Hernando V, Alejos B, Sanz N, Moreno C, Munoz-Fernández MA, Fernández IC, Fuentes JLJ, Rico CG, de la Fuente JG, Concejo PP, Azpilicueta EM, (González-García J, Arnalich F, Arribas JR, Bernardino I, de Miguel R, González-Baeza A, Herranz P, Hontañón V, Martín-Carbonero L, Montejano R, Montes ML, Peña JM, Pérez-Valero I, Rodés B, Sendagorta E). How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. HIV Med. 2020; 21(2): 128-34. Article. IF: 3.18; Q3
- Suárez-García I, Ruiz-Alguero M, Yubero CG, Moreno C, Belza MJ, Estebánez M, de los Santos I, Masia M, Abad GS, Sánchez JM, Omar M, Jarrín I, (González-García J, Arnalich F, Arribas JR, Bernardino I, de Miguel R, González-Baeza A, Herranz P, Hontañón V, Martín-Carbonero L, Montejano R, Montes ML, Peña JM, Pérez-Valero I, Rodés B, Sendagorta E). Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. J Antimicrob Chemother. 2020; 75(2); 466-72. Article. IF: 5.79; Q1
- Valencia ME, Montejano R, Moreno V, Carbonero LM, Bernardino JI, Serrano L. Helicobacter pylori infection in the HIV plus population: a comorbidity to think about. Rev Esp Quim. 2020; 33(1): 68-72. Article. IF: 1.553; Q4

Research projects

Andrés Esteban EM. Valores pronósticos. Recursos consumidos y coste hospitalario de pacientes ingresados por infección Sars-Cov-2 según su fragilidad (COV20/00519). ISCIII. 2020-2021.

Managment centre: FIBHULP

Arribas López JR. Ensayo clínico aleatorizado para evaluar la eficacia de diferentes tratamientos en paciente con COVID que requieren hospitalización (COV20/00023). ISCIII. 2020-2021.

Managment centre: FIBHULP

Arribas López JR. Estudio de longitud telomérica en pacientes infectados por el VIH expuestos a dos estrategias de tratamiento atirretroviral diferente. Telomere Lenght Substudy . The European Treatment Network For Hiv, Hepatitis and Global Infectious Diseases. 2016-Ongoing.

Managment centre: FIBHULP

Arribas López JR. EU-RESPONSE . UE. 2020-2025.

Managment centre: FIBHULP

Arribas López JR. Impacto de abacavir y tenofovir en la recuperación a largo plazo del estado de inmunosenescencia en una cohorte prospectiva de adultos de avirímicos infrectador por el VIH (PI19/00294). ISCIII. 2020-2022.

Managment centre: FIBHULP

Arribas López JR. Tratamiento antiretroviral guiado por genotipo proviral: ensayo clínico piloto de prueba de concepto (TAR-PRO) (PI16/00837). ISCIII. 2017-2020.

Managment centre: FIBHULP

Bernardino de la Serna JI. Biological age and cardiovascular ischemic events or diabtes in HIV-infected patients . Gilead Sciences S. L. 2017-Ongoing.

Managment centre: FIBHULP

Bernardino de la Serna JI. Enfermedad coronaria obstruida asintomática en pacientes VIH. Papel de la metilación del ADN y la activación monocitaria en la progresión de la ateromatosis coronaria (PI18/01327). ISCIII. 2019-2021.

Managment centre: FIBHULP

Bernardino de la Serna JI. Programa de actualización sobre investigación en pacientes infectados por el VIH ¿qué hay de nuevo? nuevos pacientes, nuevos retos, nuevos investigadores . Gilead Sciences S. L. 2018-Ongoing.

Managment centre: FIBHULP

Cadiñanos Loidi J. Contrato Río Hortega (CM19/00059). ISCIII. 2020-2021.

Managment centre: FIBHULP

Díaz Menéndez M. Evaluación de la patología adquirida por viajeros de riesgo durante un viaje internacional: estudio prospectivo en un centro de referencia . International Society of Travel Medicine. 2017-Ongoing.

Managment centre: FIBHULP

Esteban Cantos A. Contrato predoctoral (FI17/00194). ISCIII. 2018-2021.

Managment centre: FIBHULP

Gayá Moreno F. Contrato técnico de apoyo a estabilizado (ECA07/013). CM. 2008-2025.

Managment centre: FIBHULP

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Gonzalez García JJ. Morbilidad y mortalidad a largo plazo tras la erradicación del VHC en pacientes coinfectados por VIH/VHC con fibrosis hepática avanzada/cirrosis (PI17/00903). ISCIII. 2018-2022.

Managment centre: FIBHULP

Herranz Pinto P, Casado Jiménez M. Terapia biológica con artritis psoriásica y psoriasis y su investigación asociada . Merck Sharp and Dohme de España S. A. 2005-Ongoing.

Managment centre: FIBHULP

Herranz Pinto P, de Lucas Laguna R. Dermatitis atópica y patología alergica en dermatología: actualización y perspectivas futuras para médicos y pacientes: de la investigación a la práctica clínica . Sanofi Aventis S. A. 2020-2020.

Managment centre: FIBHULP

Herranz Pinto P. Formación específica de dermatólogos y reumatólogos sobre el manejo de la psoriasis y artirtis psoriásica con el fin de contribuir a la mejora holística de la patología . Amgen S. A. 2021-Ongoing.

Managment centre: FIBHULP

Herranz Pinto P. Formación específica de dermatólogos y reumatólogos sobre el manejo de la psoriasis y artritis psoriásica con el fin de contribuir a la mejora holística de la pagología . Amgen S. A. 2021-2021.

Managment centre: FIBHULP

Herrero Ambrosio A, Fernández-Cuervo Alonso P, González García JJ. Desarrollo de un sistema de gestión de medicamentos en investigación. Sanofi Aventis S. A. 2008-Ongoing.

Managment centre: FIBHULP

Montejano Sánchez R. Contrato Juan Rodés (JR18/00039). ISCIII. 2019-2022.

Managment centre: FIBHULP

Montes Ramírez ML. Estudio de hepatopatías en pacientes infectados por VIH sin hepatitis víricas que reciben tratamiento antirretroviral. Abbvie Spain S. L. U. 2016-Ongoing.

Managment centre: FIBHULP

Montes Ramírez ML. Estudio de la enfermedad hepática no vírica en pacientes con infección por VIH. Impacto de la esteatohepatitis no alcohólica y su relación con la microbiótica y el microbioma intestinal local (PI17/01218). ISCIII. 2018-2021.

Managment centre: FIBHULP

Portas A, González García JJ, Pérez Blanco JJ, Izura Berruezo A. Ris Pack . Amgen S. A. 2009-Ongoing.

Managment centre: FIBHULP

Ríos Blanco JJ, Arnalich Fernández F. Estudio de disfunción ventricular precoz en pacientes con esclerodermia . Glaxosmithkline S. A. 2011-Ongoing.

Managment centre: FIBHULP

Ríos Blanco JJ. Estudio de hipertensión pulmonar en la cohorte de pacientes con infección VIH del Hospital La Paz . Actelion Pharmaceuticals España. 2010-Ongoing.

Managment centre: FIBHULP

Rodés Soldevila B. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-5831). CM. 2018-2020.

Managment centre: FIBHULP

Rodés Soldevila B. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12514). CM. 2020-2021.

Managment centre: FIBHULP

Rodés Soldevila B. Contrato Miguel Servet Categoria A (CES11/021). ISCIII. 2007-2025.

Managment centre: FIBHULP

Rodés Soldevila B. Convenio Marco: prácticas de María de Frrutos del Pozo: Máster Microbiologia. 450 horas totales. Universidad Complutense de Madrid. 2016-Ongoing.

Managment centre: FIBHULP

Rodés Soldevila B. Estrategias de tratamiento antirretroviral y su efecto en la edad epigenética en pacientes VIH positivos con supresión virológica (PI18/00569). ISCIII. 2019-2021.

Managment centre: FIBHULP

Cibers and Retics

González García J. Research Network for AIDS (RD16/0025/0018). ISCIII. (31/12/2021)

Díaz Menendez M. Tropical Disease Cooperative Research Network (RD16/0027/0002). ISCIII. (31/12/2021)

Clinical trials

Arribas López, JR. Estudio fase 3 aleatorizado para evaluar la seguridad y la actividad antiviral de remdesevir GS-5734TM en participantes con infección grave por el covid-19.

Type: EECC, phase III.
HULP code: 5537.
Sponsored´s protocol code: GS-US-540-5773.
Sponsored by: Gilead Sciences S.L.
Signed date: 16/03/2020

Arribas López, JR. Estudio fase 3 aleatorizado para evaluar la seguridad y la actividad antiviral de remdesevir GS-5734TM en participantes con infección moderada por el covid-19.

Type: EECC, phase III.
HULP code: 5538.
Sponsored´s protocol code: GS-US-540-5774.
Sponsored by: Gilead Sciences S.L.
Signed date: 16/03/2020

Arribas López, JR. Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de tocilizumab en pacientes con neumonía grave en la enfermedad por el covid-19.

Type: EECC, phase III.
HULP code: Appendix 1 5566.
Sponsored´s protocol code: WA42380.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 23/07/2020

Arribas López, JR. Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la seguridad y la eficacia de tocilizumab en pacientes con neumonía grave en la enfermedad por el covid-19.

Type: EECC, phase III.
HULP code: 5566.
Sponsored´s protocol code: WA42380.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 30/03/2020

Arribas López, JR. Estudio adaptativo de fase 2/3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de sarilumab en pacientes hospitalizados por covid-19.

Type: EECC, phase II.
HULP code: 5562.
Sponsored´s protocol code: EFC16844.
Sponsored by: Sanofi Aventis S.A.
Signed date: 25/03/2020

Arribas López, JR. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de MK-4482 en adultos hospitalizados con covid-19.

Type: EECC, phase II.
HULP code: 5692.
Sponsored´s protocol code: MK-4482-001.
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 25/09/2020

Arribas López, JR. Estudio clínico de fase

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de MK-4482 en adultos no hospitalizados con covid-19.

Type: EECC, phase II.
HULP code: 5693.
Sponsored´s protocol code: MK-4482-002.
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 25/09/2020

Arribas López, JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de AD26.COV2.S para la prevención de covid-19 mediada por Sars-Cov-2 en adultos mayores de 18 años.

Type: EECC, phase III.
HULP code: 5734.
Sponsored´s protocol code: VAC-31518COV3009.
Sponsored by: Janssen Cilag International N.V.
Signed date: 11/12/2020

Arribas López, JR. Estudio internacional observacional para la caraterización de adultos hospitalizados por las complicaciones de la gripe a pandémica H1N1.

Type: Estudios, phase No EPA.
HULP code: Appendix 2 3045.
Sponsored´s protocol code: INSIGHT 003.
Sponsored by: .
Signed date: 24/01/2020

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir, doravirina y doravirina/islatravir, cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: EECC, phase III.
HULP code: Appendix 1 5532 5532.
Sponsored´s protocol code: MK-8591A-019.
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 03/12/2020

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir, doravirina y doravirina/islatravir, cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: EECC, phase III.
HULP code: 5532.
Sponsored´s protocol code: MK-8591A-019.
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 28/02/2020

Díaz Menéndez, M. Características clínicas y epidemiológicas de los pacientes hospitalizados por covid-19 en España.

Type: Estudios, phase No EPA.
HULP code: PI-4088.
Sponsored´s protocol code: COVID-19/SEIMC-FSG.
Sponsored by: Fundación SEIMC-GESIDA.
Signed date: 23/06/2020

Gonzalez García, JJ. Estudio de fase IIA, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el VIH-1 MVA.HTI y CHADOX1.HTI, con el agonista de TLR7 vesatolimod (GS-9620), en infección por el VIH-1 tratada de forma precoz.


Type: EECC, phase II.
HULP code: Appendix 1 5163.
Sponsored´s protocol code: AELIX-003.
Sponsored by: Aelix Therapeutics S.L.
Signed date: 22/10/2020

Gonzalez García, JJ. Estudio de fase IIA, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el VIH-1 mva.hti y chadox1.hti, con el agonista de TLR7 vesatolimod (GS-9620), en infección por el VIH-1 tratada de forma precoz.

Type: EECC, phase II.
HULP code: 5163.
Sponsored´s protocol code: AELIX-003.
Sponsored by: Aelix Therapeutics S.L.
Signed date: 06/02/2020

Gonzalez García, JJ. Estudio de fase 2/3 para evaluar la seguridad y eficacia del inhibidor de la cápside de acción prolongada GS 6207 en combinación con un tratamiento de base optimizado en pacientes con infección por VIH-1 altamente tratados y con multirresistencia a fármacos.

Type: EECC, phase II.
HULP code: 5491.
Sponsored´s protocol code: GS-US-200-4625.
Sponsored by: Gilead Sciences Inc.
Signed date: 03/03/2020



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Gonzalez García, JJ. Ensayo clínico multicéntrico aleatorizado para evaluar la eficacia de melatonina en la profilaxis de la infección por Sars-Cov-2 en contactos de alto riesgo.

Type: EECC, phase IV.
HULP code: 5573.
Sponsored´s protocol code: MECOVID.
Sponsored by: Borobia Pérez, Alberto.
Signed date: 01/06/2020

Gonzalez García, JJ. Estudio fase IIIB, aleatorizado, multicéntrico, con grupo control activo, de grupo paralelo, no inferioridad, abierto, que evalúa la eficacia, seguridad y tolerabilidad del cambio a cabotegravir de acción prolongada junto con rilpivirina de acción prolongada administrado cada dos meses desde un régimen de comprimido único de bictegravir / emtricitabina / tenofovir alafenamida en adultos infectados por VIH1 virológicamente suprimidos.

Type: EECC, phase II.
HULP code: 5634.
Sponsored´s protocol code: 208379.
Sponsored by: Laboratorios Viiv Healthcare S.L.
Signed date: 08/10/2020

Gonzalez García, JJ. Prevalencia de personas que viven con VIH con pocas o no opciones para construir un régimen antiretroviral viable. Estudio Previar.

Type: Estudios, phase EPA-OD.
HULP code: PI-4259.
Sponsored´s protocol code: VII-DAR-2019.01.
Sponsored by: Laboratorios Viiv Healthcare S.L.
Signed date: 26/06/2020

Herranz Pinto, P. Estudio de fase 3, multicéntrico, doble ciego, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes adultos con dermatitis atópica.

Type: EECC, phase III.
HULP code: Appendix 2 4958.
Sponsored´s protocol code: I4V-MC-JAHN.
Sponsored by: Lilly S.A.
Signed date: 15/04/2020

Herranz Pinto, P. Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego, controlado con principio activo de comparación (secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de bimekizumab en adultos con psoriasis (PSO) en placas crónica de grado moderado o severo.

Type: EECC, phase III.
HULP code: Appendix 1 5109.
Sponsored´s protocol code: PS0015.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 22/01/2020

Herranz Pinto, P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.

Type: EECC, phase III.
HULP code: Appendix 1 5141.
Sponsored´s protocol code: B7451015.
Sponsored by: Pfizer Inc.
Signed date: 09/07/2020

Herranz Pinto, P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.

Type: EECC, phase III.
HULP code: Appendix 1 5089.
Sponsored´s protocol code: B7451014.
Sponsored by: Pfizer S.L.U.
Signed date: 08/09/2020

Herranz Pinto, P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.

Type: EECC, phase III.
HULP code: Appendix 2 5089.
Sponsored´s protocol code: B7451014.
Sponsored by: Pfizer S.L.U.
Signed date: 26/10/2020

Herranz Pinto, P. Estudio de fase III, aleatorizado, doble ciego,comparativo con vehículo, para evaluar la eficacia y seguridad del tratamiento de mantenimiento y reduccion de brote con el ungüento crisaborole al 2 %, una vez al dia durante 52 semanas en participantes pediátricos y adultos (a partir de 2 años de edad) con dermatitis atópica de leve a moderada, que respondieron al tratamiento con ungüento crisaborole al 2 % dos veces al día.

Type: EECC, phase III.
HULP code: 5476.
Sponsored´s protocol code: C3291035.
Sponsored by: Pfizer S.L.U.
Signed date: 28/04/2020

Herranz Pinto, P. Estudio de fase III, doble ciego, aleatorizado, controlado con placebo, de la eficacia y seguridad de la crema de ruxolitinib, seguido de un período de extensión en participantes con vitíligo.

Type: EECC, phase III.
HULP code: 5513.
Sponsored´s protocol code: INCB 18424-307.
Sponsored by: Incyte Corporation.
Signed date: 26/03/2020

Herranz Pinto, P. Estudio de fase 3b, multicéntrico, intervencionista y abierto de pacientes adultos con psoriasis en placas moderada o grave que presentan una respuesta insuficiente a secukinumab o ixekizumab y cambian a risankizumab.

Type: EECC, phase III.
HULP code: 5468.
Sponsored´s protocol code: M19-164.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 14/01/2020

Herranz Pinto, P. Estudio de fase III, abierto, multicentrico, a largo plazo, para investigar la seguridad y la eficacia de PF06651600 en participantes adultos y adolescentes con alopecia areata.

Type: EECC, phase III.
HULP code: 5394.
Sponsored´s protocol code: B7981032.
Sponsored by: Pfizer S.L.U.
Signed date: 18/05/2020

Herranz Pinto, P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficiencia y la seguridad de nemolizumab (CD14152) en sujetos con demartitis atópica de moderada a grave.

Type: EECC, phase III.
HULP code: 5477.
Sponsored´s protocol code: RD.06.SPR.118161.
Sponsored by: Galderma S.A.
Signed date: 26/06/2020

Herranz Pinto, P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (CD14152) en sujetos con dermatitis atópica de moderada a grave.

Type: EECC, phase III.

HULP code: 5478.
Sponsored´s protocol code: RD.06. SPR.118163.
Sponsored by: Galderma S.A.
Signed date: 07/09/2020

Herranz Pinto, P. Estudio aleatorizado, doble ciego, multicéntrico, de 24 semanas de duración de secukinumab subcutáneo para evaluar el tratamiento antiinterleuquina - 17a en pacientes con psoriasis en placas con Ehgna coexistente (Pinpoint).
Type: EECC, phase III.
HULP code: 5661.
Sponsored´s protocol code: CAIN457A-DE15.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 21/10/2020

Herranz Pinto, P. Estudio de fase 3B, aleatorizado, doble ciego, con doble simulación, controlado con principio activo, multicéntrico, para evaluar la eficacia y la seguridad de abrocitinib en comparación con dupilumab en participantes adultos que reciben terapia tópica de base con dermatitis atópica de moderada a grave.
Type: EECC, phase IIIb.
HULP code: 5503.
Sponsored´s protocol code: B7451050.
Sponsored by: Pfizer S.L.U.
Signed date: 12/06/2020

Herranz Pinto, P. Ensayo aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de efgartigimod PH20 SC en pacientes adultos con pénfigo (vulgar o foliáceo).
Type: EECC, phase III.
HULP code: 5663.
Sponsored´s protocol code: ARGX-113-1904.
Sponsored by: Argenx Bvba.
Signed date: 16/11/2020

Herranz Pinto, P. Ensayo de seguimiento del ARGX-113-1904, abierto y multicéntrico para evaluar la seguridad, la tolerabilidad y la eficacia de efgartigimod PH20 SC en pacientes con pénfigo.
Type: EECC, phase III.
HULP code: 5670.
Sponsored´s protocol code: ARGX-113-1905.
Sponsored by: Argenx Bvba.
Signed date: 16/11/2020

Herranz Pinto, P. Estudio observacional internacional de resultados sanitarios durante 3 años sobre el tratamiento biológico de la psoriasis en placas de moderada a grave.
Type: Estudios, phase EPA-SP.
HULP code: PI-3507 .
Sponsored´s protocol code: I1F-MC-B007.
Sponsored by: Eli Lilly Co Uk Ltd.
Signed date: 11/08/2020

Herranz Pinto, P. Estudio observacional transversal y multicéntrico para la validación de la versión española del cuestionario Pure-4. Estudio Pure4.
Type: Estudios, phase No EPA.
HULP code: PI-4483.
Sponsored´s protocol code: CAI-N457AES15.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 03/12/2020

Herranz Pinto, P. Estudio transversal mundial de la carga de la enfermedad en pacientes adolescentes y adultos con dermatitis atópica (measure ad).
Type: Estudios, phase EPA-OD.
HULP code: PI-3941 .
Sponsored´s protocol code: ABB-PIM-2019-01.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 18/05/2020

Martín Carbonero, L. Estudio clínico de fase 3, aleatorizado, abierto y comparativo con tratamiento activo para evaluar el cambio de tratamiento a doravirina/islatravir una vez al día en pacientes infectados por el VIH-1 con supresión virológica durante el tratamiento antirretroviral.
Type: EECC, phase III.
HULP code: Appendix 1 5471.
Sponsored´s protocol code: MK-8591A-017.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 09/09/2020

Mora Rillo, M. Ensayo clínico aleatorizado para evaluar la eficacia de diferentes tratamientos en pacientes con covid19 que requieren hospitalización.
Type: EECC, phase III.
HULP code: 5559.
Sponsored´s protocol code: PANCOVID19.
Sponsored by: FIBHULP.
Signed date: 28/03/2020

Mora Rillo, M. Seguridad y utilización en práctica clínica del plasma convaleciente en pacietnes ingresados por covid-19. Estudio observacional PlasMadrid.
Type: Estudios, phase No EPA.
HULP code: 5645.
Sponsored´s protocol code: PLASMADRID.
Sponsored by: Centro de Transfusion.
Signed date: 21/09/2020

Pérez Valero, Ignacio. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el VIH-1 con supresión virológica.
Type: EECC, phase III.
HULP code: Appendix 1 5354.
Sponsored´s protocol code: 208090.
Sponsored by: VIIV Healthcare Uk Limited.
Signed date: 02/07/2020

Pérez Valero, I. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide.
Type: EECC, phase III.
HULP code: 5470.
Sponsored´s protocol code: MK-8591A-018.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 15/01/2020

Valencia Ortega, E. Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo.
Type: EECC, phase III.
HULP code: 5483.
Sponsored´s protocol code: MK-8591A-020.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 03/01/2020

Patents and trademarks

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacións Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.2 Molecular Microbiology Group

Publications:	53
Impact Factor:	257.[728]
Q1:	29



Jesús Mingorance Cruz. Investigador Senior (Contrato Ramón y Cajal - I3). Hospital Universitario La Paz

Emilio Cendejas Bueno. Investigador Postdoctoral (Contrato Juan Rodes). Hospital Universitario La Paz

María Teresa Corcuera Pindado. Técnico Grado Superior. Hospital Universitario La Paz

Elias Dahdouh. Investigador Postdoctoral Marie Curie. Hospital Universitario La Paz

Manuela de Pablos Gómez. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Silvia García Bujalance. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Jesús García García. Catedrática del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

Julio García Rodríguez. Jefe de Servicio de Microbiología. Hospital Universitario La Paz

Paulino Gómez Puertas. Científico Titular CSIC. Profesor Honorario. CBM "Severo Ochoa". Universidad Autónoma de Madrid

María Rosa Gómez-Gil Mira. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Sonia Jiménez Rodríguez. Ténico de Laboratorio. Hospital Universitario La Paz

Fernando Lázaro Perona. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Belén Loeches Yagüe. Médico Adjunto. Unidad de Enfernedades Infecciosas. Hospital Universitario La Paz

Carmen Menéndez Gómez. Profesora Contratada Doctora del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

Dolores Montero Vega. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Arturo Noguerado Asensio. Jefe de Servicio de Medicina Interna. Hospital de Cantoblanco-Hospital Universitario La Paz

Verónica Pérez Blanco. Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz

Rafael Carlos Prados Rosales. Profesor Contratado Doctor del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

María Inmaculada Quiles Melero. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Alicia Rico Nieto. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Pilar Romero Gómez. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Guillermo Ruiz Carrascoso. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Carlos Toro Rueda. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Strategic Objective

The Molecular Microbiology research group is integrated into the Department of Microbiology at Hospital La Paz, and a significant number of its members are physicians in the department devoted to microbiological diagnostic work. This integration determines the group's strategic approach and therefore, the different lines of research revolve around several aspects of clinical microbiology and infectious diseases.

An important line of activity (Clinical Microbiology) is the result of the routine activities provided by the department, but goes further and deeper into the methodological, epidemiological and pathological challenges encountered in the daily routine.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

One research line derived from the former is the development of methods for the molecular characterisation of pathogenic microorganisms, including microbiological diagnosis and epidemiological analysis, and more recently, microbial genomics.

Another line focuses on the study of the evolution of pathogenic microorganisms. As a model of opportunistic pathogens, we study Escherichia coli, a microorganism that is well characterised at the genetic level and that is clinically relevant as the primary cause of urinary tract infections and one of the most frequently involved in bacteraemia.

As a model of viral pathogens, we study the dynamics of HIV viral populations over time and in terms of the response to antiretroviral treatment.

The taxonomy of the Mycobacteria and the study of Mycobacterium tuberculosis persistence are research lines developed jointly by the UAM and Hospital members of the group.

The Group includes a CSIC research scientist especialized in biocomputing and molecular dynamics.

Research lines

- Molecular epidemiology and evolution of pathogens
- Molecular methods for diagnostics of infectious diseases
- Microbial genomics
- Tuberculosis and other Mycobacteria
- Clinical Microbiology

Research Activity

Doctoral theses

Villa García J. Análisis genómico de Enterobacterales productores de carbapenemasas de interés clínico en el Hospital Universitario 12 de Octubre[dissertation]. Madrid: UAM: 2020(09/10/2020).

Directors: Mingorance Cruz J, Chaves Sánchez F

Publications

- Aguilera A, Trastoy R, Rodríguez-Frías F, Muñoz-Bellido JL, Melón S, Súarez A, Orduna A, Viciana I, Bernal S, García-Bujalance S, Montiel N, Molina JM, Basaras M, Fernández-Cuenca F, García-Arata I, Reina G, Ocete MD, Fuentes A, Navarro-de la Cruz D, Nieto L, de Castro AB, Buti M, Álvarez M, García F. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). J Infection. 2020; 81(4): 600-6. Article. IF: 6.072; Q1
- Alejos B, Súarez-García I, Rava M, Bautista-Hernández A, Gutiérrez F, Dalmau D, Sagastagoitia I, Rivero A, Moreno S, Jarrin I. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. J Antimicrob Chemoth. 2020; 75(10): 3004-14. Article. IF: 5.79; Q1
- Alonso B, Fernández-Barat L, Di Domenico EG, Marín M, Cercenado E, Merino I, de Pablos M, Muñoz P, Guembe M. Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia. BMC Infect Dis. 2020; 20(1): 909. Article. IF: 3.09; Q3
- Álvarez-Troncoso J, Larrauri MZ, Vega MDM, Vallano RG, Peláez EP, Rojas-Marcos PM, Martín-Luengo F, del Campo PL, Gil CRH, Esteban ET. Case Report: COVID-19 with Bilateral Adrenal Hemorrhage. Am J Trop Med Hyg. 2020; 103(3): 1156-7. Article. IF: 2.345; Q2
- Andaluz I, Arcos MD, Montero MD, Castillo P, Martín-Carbonero L, García-Samaniego J, Romero M, García A, Busca C, González J, Montes ML, Olveira A. Patients with hepatitis C lost to follow-up: ethical-legal aspects and search results. Rev Esp Enferm Dig. 2020; 112(7): 532-7. Article. IF: 2.086; Q4
- Bloise I, Gómez-Arroyo B, García-Rodríguez J. Detection of SARS-CoV-2 on high-touch surfaces in a clinical microbiology laboratory. J Hosp Infect. 2020; 105(4): 784-6. Letter. IF: 3.926; Q2
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buno A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernán MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Bouza E, Almirante B, Rodríguez JG, Garnacho-Montero J, Salavert M, Muñoz P, Sanguinetti M. Biomarkers of fungal infection: Expert opinion on the current situation. Rev Esp Quim. 2020; 33(1): 1-10. Review. IF: 1.553; Q4
- Candel FJ, Barreiro P, San Román J, Abanades JC, Barba R, Barberán J, Bibiano C, Canora J, Cantón R, Calvo C, Carretero M, Cava F, Delgado R, García-Rodríguez J, del Castillo JG, de Villaumbrosia CG, Hernández M, Losa JE, Martínez-Peromingo FJ, Molero JM, Muñoz P, Onecha E, Onoda M, Rodríguez J, Sánchez-Celaya M, Serra JA, Zapatero A. Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. Rev Esp Quim. 2020; 33(6): 466-84. Article. IF: 1.553; Q4
- Chrissian C, Camacho E, Fu MS, Prados-Rosales R, Chatterjee S, Cordero RJB, Lodge JK, Casadevall A, Stark RE. Melanin deposition in two Cryptococcus species depends on cell-wall composition and flexibility. J Biol Chem. 2020; 295(7): 1815-28. Article. IF: 5.157; Q1
- Crespillo-Andújar C, Diaz-Menéndez M, Trigo E, Arsuaga M, de la Calle F, Lago M, de Guevara MCL, Barreiro P, Montero D, García-Bujalance S, Alvarado EA, de la Calle M, Sánchez-Seco MP, de Ory F, Vázquez A, Arribas JR, La Paz-Carlos III, García J, Martin-Boado E, Martínez-Sánchez N,

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Rodríguez R, Herrero B, López F, Bartha JL, Elorza MD, Lafuente MC, Hortelano MG. Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. Travel Med Infect Di. 2020; 33: 101543. Article. IF: 6.211; D1

- del Rosal T, Caminoa MB, González-Guerrero A, Falces-Romero I, Romero-Gómez MP, Baquero-Artigao F, Sainz T, Méndez-Echevarría A, Escosa-García L, Aracil FJ, Calvo C. Outcome of severe bacterial pneumonia in the era of pneumococcal vaccination. Front Pediatr. 2020; 8: 576519. Article. IF: 3.418; Q1
- del Rosal T, Méndez-Echevarría A, García-Vera C, Escosa-García L, Agud M, Chaves F, Román F, Gutiérrez-Fernández J, de Gopegui ER, Ruiz-Carrascoso G, Ruiz-Gallego MD, Bernet A, Quevedo SM, Fernández-Verdugo AM, Díez-Sebastián J, Calvo C. Staphylococcus aureus nasal colonization in spanish children. The COSACO Nationwide Surveillance Study. Infect Drug Resist. 2020; 13: 4643-51. Article. IF: 4.003; Q2
- Díaz-García J, Arendrup MC, Cantón R, García-Rodríguez J, Gómez A, Gómez E, Orden B, Parisi G, Pemán J, Posteraro B, Sanguinetti M, Da Matta DA, Colombo AL, Muñoz P, Sánchez-Carrillo C, Guinea J, Escribano P. Candidemia Candida albicans clusters have higher tendency to form biofilms than singleton genotypes. Med Mycol. 2020; 58(7): 887-95. Article. IF: 4.076; D1
- Escudero-Sánchez R, Senneville E, Digumber M, Soriano A, del Toro MD, Bahamonde A, del Pozo JL, Guio L, Murillo O, Rico A, García-Pais MJ, Rodríguez-Pardo D, Iribarren JA, Fernández M, Benito N, Fresco G, Muriel A, Ariza J, Cobo J. Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infec. 2020; 26(4): 499-505. Article. IF: 8.067; D1
- Falcés-Romero I, Jiménez-Rodríguez S, Rico-Nieto A. Soft tissue infection due to catalase-negative Staphylococcus lugdunensis: First case reported in Europe. Med Clin-Barcelona. 2020; 155(7): 322-3. Letter. IF: 1.725; Q3
- Falcés-Romero I, Ruiz-Bastián M, Díaz-Pollán B, Maseda E, García-Rodríguez J. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital. Mycoses. 2020; 63(11): 1144-8. Article. IF: 4.377; Q1
- García-Arenzana N, Redondo-Bravo L, Espinel-Ruiz MA, Borrego-Prieto P, Ruiz-Carrascoso G, Quintas-Viqueira A, Sánchez-Calles A, Robustillo-Rodela A. Carbapenem-resistant enterobacteriaceae outbreak in a medical ward in Spain: epidemiology, control strategy, and importance of environmental disinfection. Microb Drug Resist. 2020; 26(1): 54-9. Article. IF: 3.431; Q3
- Gómez-Arroyo B, González-Donapetry P, Rico-Nieto A, Falces-Romero I. Leclercia adecarboxylata isolates in a tertiary-care hospital: A propos of the first case of prosthetic joint infection. Enferm Infec Micr Cl. 2020; 38(10): 503-5. Letter. IF: 1.731; Q4
- Guédez-López GV, Alguacil-Guillén M, González-Donapetry P, Bloise I, Tornero-Marín C, González-García J, Mingorance J, García-Rodríguez J. Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2. Eur J Clin Microbiol. 2020; 39(12): 2289-97. Article. IF: 3.267; Q3
- Guerrero-Beltrán C, Martínez-Sanz J, Álvarez M, Olalla J, García-Álvarez M, Iribarren JA, Masia M, Montero M, García-Bujalance S, Blanco JR, Rivero M, García-Fraile LJ, Espinosa N, Rodríguez C, Aguilera A, Vidal-Ampurdanes MC, Martínez M, Iborra A, Ímaz A, Gómez-Sirvent JL, Peraire J, Portilla J, Caballero E, Alejos B, García F, Moreno S. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. J Antimicrob Chemoth. 2020; 75(5): 1294-300. Article. IF: 5.79; Q1
- Guinea J, Arendrup MC, Cantón R, Canton E, García-Rodríguez J, Gómez A, de la Pedrosa EGG, Hare RK, Orden B, Sanguinetti M, Pemán J, Posteraro B, Ruiz-Gaitan A, Parisi G, Da Matta DA, Colombo AL, Sánchez-Carrillo C, Reigadas E, Muñoz P, Escribano P. Genotyping reveals high clonal diversity and widespread genotypes of candida causing candidemia at distant geographical areas. Front Cell Infect Mi. 2020; 10: 166. Article. IF: 5.293; Q1
- Krab LC, Marcos-Alcalde I, Assaf M, Balasubramanian M, Andersen JB, Bisgaard AM, Fitzpatrick DR, Gudmundsson S, Huisman SA, Kalayci T, Maas SM, Martínez F, McKee S, Menke LA, Mulder PA, Murch OD, Parker M, Pie J, Ramos FJ, Rieubland C, Mokry JAR, Scarano E, Shinawi M, Gómez-Puertas P, Tumer Z, Hennekam RC. Delineation of phenotypes and genotypes related to cohesin structural protein RAD21. Hum Genet. 2020; 139(5): 575-92. Article. IF: 4.132; Q2
- Latorre-Pellicer A, Ascaso A, Trujillano L, Gil-Salvador M, Arnedo M, Lucia-Campos C, Antonanzas-Pérez R, Marcos-Alcalde I, Parenti I, Bueno-Lozano G, Musio A, Puisac B, Kaiser FJ, Ramos FJ, Gómez-Puertas P, Pie J. Evaluating Face2Gene as a tool to identify cornelia de lange syndrome by facial henotypes. Int J Mol Sci. 2020; 21(3): 1042. Article. IF: 5.923; Q1
- Lázaro-Perona F, Dandouh E, Román-Soto S, Jiménez-Rodríguez S, Rodríguez-Antolín C, de la Calle F, Agrifoglio A, Membrillo FJ, García-Rodríguez J, Mingorance J. Metagenomic detection of two vientoviruses in a human sputum sample. Viruses-Basel. 2020; 12(3): 327. Article. IF: 5.048; Q2
- Lazo PA, García JL, Gómez-Puertas P, Marcos-Alcalde I, Arjona C, Villarroel A, González-Sarmiento R, Fons C. Novel dominant KCNQ2 exon 7 partial in-frame duplication in a complex epileptic and neurodevelopmental delay syndrome. Int J Mol Sci. 2020; 21(12): 4447. Article. IF: 5.923; Q1
- Llorca-Otero L, Toro-Rueda C. Diagnosis of Helicobacter pylori infection: Progress and challenges. Enferm Infec Micr Cl. 2020; 38(9): 407-9. Editorial Material. IF: 1.731; Q4
- López-Medrano F, Silva JT, Fernández-Ruiz M, Vidal E, Origuen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jironda-Gallegos C, Escudero R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Arminanzas C, González-Rico C, Farinas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andres A, Aguado JM. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort. Am J Transplant. 2020; 20(2): 451-62. Article. IF: 8.086; D1
- López-Roa P, Aznar E, Cacho J, Cogollos-Agruna R, Domingo D, García-Arata MI, Millán R, Páez M, Pérez-Cecilia E, Ruiz-Serrano MJ, Simon M, Tato M, Toro C, Valverde JF, Esteban J. Epidemiology of non-tuberculous mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. Eur J Clin Microbiol. 2020; 39(6): 1089-94. Article. IF: 3.267; Q3
- Marcos AT, Martin-Doncel E, Morejón-García P, Marcos-Alcalde I, Gómez-Puertas P, Segura-Puimedón M, Armengol L, Navarro-Pando JM, Lazo PA. VRK1 (Y213H) homozygous mutant impairs Cajal bodies in a hereditary case of distal motor neuropathy. Ann Clin Transl Neurol. 2020; 7(5): 808-18. Article. IF: 4.511; Q2
- Marcos-Alcalde I, López-Viñas E, Gómez-Puertas P. MEPSAnd: minimum energy path surface analysis over n-dimensional surfaces. Bioinformatics. 2020; 36(3): 956-8. Article. IF: 6.937; D1
- Mayor-Ibarguren A, Feito-Rodríguez M, Castanedo LQ, Ruiz-Bravo E, Vega DM, Herranz-Pinto P. Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report. J Eur Acad Dermatol. 2020; 34(10): E541-2. Letter. IF: 6.166; Q1
- Montalvo-Quirós S, Vallet-Regi M, Palacios A, Anguita J, Prados-Rosales RC, González B, Luque-García JL. Mesoporous silica nanoparticles as a potential platform for vaccine development against tuberculosis. Pharmaceutics. 2020; 12(12): 1218. Article. IF: 6.321; Q1
- Muñoz-Gallego I, Viedma E, Esteban J, Manchenо-Losa M, García-Canete J, Blanco-García A, Rico A, García-Perea A, Garbajosa PR, Escudero-Sánchez R, Somolinos MS, Arriaza MM, Romanyk J, Barbero JM, Vilela AA, Romo FG, Pérez-Jorge C, Arana DM, Monereo A, Domingo D, Cordero J, Romero MIS, Viejo MAG, Lora-Tamayo J, Chaves F. Genotypic and phenotypic characteristics of staphylococcus aureus prosthetic joint infections: Insight on the pathogenesis and prognosis of a multicenter prospective cohort. Open Forum Infect Dis. 2020; 7(9): ofaa344. Article. IF: 3.835; Q3
- Nogueira López J, Grasa Lozano C, Ots Ruiz C, Alonso García L, Falces-Romero I, Calvo C, García-López Hortelano M. Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. An Pediatr (Engl Ed). 2020; 2(2): 30476-8. Article. IF: 1.5; Q4

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Pascual-Itoiz MA, Peña-Cearra A, Martín-Ruiz I, Lavín JL, Simo C, Rodríguez H, Atondo E, Flores JM, Carreras-González A, Tomás-Cortázar J, Barriales D, Palacios A, García-Canas V, Pellón A, Fullaondo A, Aransay AM, Prados-Rosales R, Martín R, Anguita J, Abecia L. The mitochondrial negative regulator MCJ modulates the interplay between microbiota and the host during ulcerative colitis. Sci Rep-Uk. 2020; 10(1): 572. Article. IF: 4.379; Q1
- Peláez EC, Estévez MC, Mongui A, Menéndez MC, Toro C, Herrera-Sandoval OL, Robledo J, García MJ, del Portillo P, Lechuga LM. Detection and quantification of HspX antigen in sputum samples using plasmonic biosensing: Toward a real point-of-care (POC) for tuberculosis diagnosis. Acs Infect Dis. 2020; 6(5): 1110-20. Article. IF: 5.084; Q1
- Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, Abdala E, Magalhaes MR, Mularoni A, Monaco F, Pierrotti LC, Freire MP, Iyer RN, Steinke SM, Calvi EG, Tumbarello M, Falcone M, Fernández-Ruiz M, Costa-Mateo JM, Rana MM, Strabelli TMV, Paul M, Farinas MC, Clemente WT, Roilides E, Muñoz P, Dewispelaere L, Loeches B, Lowman W, Tan BH, Escudero-Sánchez R, Bodro M, Grossi PA, Soldani F, Gunseren F, Nestorova N, Pascual A, Martínez-Martínez L, Aguado JM, Rodríguez-Bano J, Torre-Cisneros J, Song ATW, Andraus W, D'Albuquerque LAC, David-Neto E, de Paula FJ, Rossi F, Ostrander D, Avery R, Rizzi M, Losito AR, Raffaelli F, Del Giacomo P, Tiseo G, Lora-Tamayo J, San-Juan R, Gracia-Ahufinger I, Castón J, Ruiz YA, Altman DR, Campos SV, Bar-Sinai N, Koppel F, Almajano FAD, Rico CG, Martínez MF, Mourao PHO, Neves FA, Ferreira J, Pyrpasopoulou A, Iosifidis E, Romiopoulos I, Minero MV, Sánchez-Carrillo C, Lardo S, Coussement J, Dodemont M, Jiayun K, Martin-Davila P, Fortun J, Almela M, Moreno A, Linares L, Gasperina DD, Balsamo ML, Rovelli C, Concia E, Chiesi S, Salerno DN, Ogunc D, Pilmis B, Seminari EM, Carratala J, Dominguez A, Cordero E, Lepe JA, Montejo M, de Lucas EM, Eriksson BM, van Delden C, Manuel O, Arslan H, Tufan ZK, Kazak E, David M, Lease E, Cornaglia G, Akova M. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. Am J Transplant. 2020; 20(6): 1629-41. Article. IF: 8.086; D1
- Pericas JM, Llopis J, Muñoz P, Gálvez-Acebal J, Kestler M, Valerio M, Hernández-Meneses M, Goenaga MA, Cobo-Belaustegui M, Montejo M, Ojeda-Burgos G, Sousa-Regueiro MD, de Alarcon A, Ramos-Martínez A, Miro JM. A Contemporary picture of enterococcal endocarditis. J Am Coll Cardiol. 2020; 75(5): 482-94. Article. IF: 24.094; D1
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Paño-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae. Gut Pathog. 2020; 12(1): 15. Article. IF: 4.181; Q2
- Rodríguez H, Prados-Rosales R, Lavín JL, Mazzone M, Anguita J. Editorial: Macrophage metabolism and immune responses. Front Immunol. 2020; 11: 1078. Editorial Material. IF: 7.561; Q1
- Román MTA, Coll NB, Barcenilla SG, González LP, Collazo ID, Rodríguez HD, Garrido JAR, Salces MM, Pollmar MIR, Cebanu T, González-Zorrilla E, Acuña P, Manzano EM, Merchán ECR, Martínez RT, Banares MJB, Alvarino MG, Yuste VJ. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia. 2020; 26(5): 773-8. Article. IF: 4.287; Q1
- Román-Soto S, Romero-Gómez MP, Montero-Vega MD, Cendejas-Bueno E. Clinical and microbiological diagnosis of nonprimary cytomegalovirus infection in pregnancy with symptomatic congenital cytomegalovirus infection. Infect Dis Clin Pract (Baltim Md). 2020; 28(2): 94-5. Article. Not Indexed
- Romera D, Aguilera-Correa JJ, García-Coca M, Mahillo-Fernández I, Vinuela-Sandoval L, García-Rodríguez J, Esteban J. The Galleria meilonella infection model as a system to investigate the virulence of Candida auris strains. Pathog Dis. 2020; 78(9): ftaa067. Article. IF: 3.166; Q3
- Rubio-Pérez I, Badía JM, Mora-Rillo M, Quirós AM, Rodríguez JG, Balibrea JM. COVID-19: Key concepts for the surgeon. Cir Espan. 2020; 98(6): 310-9. Article. IF: 1.653; Q3
- Ruiz-Carrascoso G, Fogeda-Moreno M, García-Rodríguez J. Syndromic panel-based real-time PCR versus selenite enrichment broth for the detection of Salmonella spp. in fecal samples. Enferm Infec Micr Cl. 2020; 38(4): 201. Letter. IF: 1.731; Q4



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Ruiz-Márvez E, Ramírez CA, Rodríguez ER, Flórez MM, Delgado G, Guzmán F, Gómez-Puertas P, Requena JM, Puerta CJ. Molecular characterization of Tc964, a novel antigenic protein from trypanosoma cruzi. Int J Mol Sci. 2020; 21(7): 2432. Article. IF: 5.923; Q1
- Ruiz-Velázquez E, García-Rodríguez J, Quiroz G, Femat R. Robust mu-synthesis: Towards a unified glucose control in adults, adolescents and children with T1DM. J Franklin I. 2020; 357(14): 9633-53. Article. IF: 4.504; Q1
- Salmanton-García J, Koehler P, Kindo A, Falces-Romero I, García-Rodríguez J, Racil Z, Chen SCA, Klimko N, Desoubeaux G, Thompson GR, Benítez-Penuela MA, Rodríguez JY, Sheppard DC, Hoenigl M, Le Govic Y, Badali H, Baddley JW, Chander J, Ingram PR, Pakstis DL, Mellinghoff SC, Atici S, Cesaro S, Chakrabarti A, Dupont D, González GM, Hatvani L, Herbrecht R, Klyasova G, Lass-Florl C, Mares M, Mullane K, Vinh DC, Wisplinghoff H, Lackner M, Cornely OA, Seidel D. Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope (R)-Global Registry for Emerging Fungal Infections. J Infection. 2020; 81(5): 802-15. Article. IF: 6.072; Q1
- Saralegui C, Ponce-Alonso M, Pérez-Viso B, Alegre LM, Escribano E, Lazaro-Perona F, Lanza VF, de Pipaon MS, Rodríguez JM, Baquero F, del Campo R. Genomics of serratia marcescens isolates causing outbreaks in the same pediatric unit 47 years apart: Position in an updated phylogeny of the species. Front Microbiol. 2020; 11: 451. Article. IF: 5.64; Q1
- Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zarraga MA, Vivancos MJ, Moreno S. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV. 2020; 7(8): E565-73. Article. IF: 12.767; D1
- Súarez-García I, Ruiz-Alguero M, Yubero CG, Moreno C, Belza MJ, Estebánez M, de los Santos I, Masia M, Abad GS, Sánchez JM, Omar M, Jarrin I. Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. J Antimicrob Chemoth. 2020; 75(2): 466-72. Article. IF: 5.79; Q1
- Urban JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martin CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutiérrez RS, Santovena AZ, Hijosa MM, Camblor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frias J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? Transpl Infect Dis. 2020; 22(6): e13432. Article. IF: 2.228; Q4

Research projects

Cendejas Bueno E. Desarrollo y validación de métodos para la detección y cuantificación de antifúngicos sistémicos en suero mediante MALDI-TOF (PI17/01444). ISCIII. 2018-2022.

Managment centre: FIBHULP

Dadouh E. qMAR: Quantification of the intestinal load of a targeted set of resistance genes to Monitor Antibiotic Resistance in paediatric transplant patients (796084). H2020-EU. 2018-2020.

Managment centre: FIBHULP

García García MJ. Latencia y Adaptación: papel de Mycobacterium tuberculosis silente en la enfermedad (PI19/00666). ISCIII. 2020-2022.

Managment centre: UAM

García Rodríguez J, Calleja M. VIRUSCAN, Optomechanics for Virology (731868). H2020-EU. 2016-2022.

Managment centre: FIBHULP

García Rodríguez J. Estudio poblacional de las especies de candida invasoras. Astellas Pharma S. A.. 2010-2020.

Managment centre: FIBHULP

Gómez Puertas P. COMPUDRUG: Development of a new and efficient drug design system based on computational dynamic calculation of macromolecular structures (RTC-2017-6494-1). Agencia Nacional de Investigación. 2018-2021.

Managment centre: CBMSO-CSIC

Gómez Puertas P. DRUGCOHESIN: New drugs for chromosome biology. Design of specific inhibitors of the Cohesin complex (RTI2018-094434-B-I00). Agencia Nacional de Investigación. 2019-2022.

Managment centre: CBMSO-CSIC

Mingorance Cruz J. Análisis cuantitativo de la colonización intestinal por enterobacterias productoras de carbapenemasas (PI16/01209). ISCIII. 2017-2020.

Managment centre: FIBHULP

Mingorance Cruz J. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-6939). CM. 2018-2021.

Managment centre: FIBHULP

Mingorance Cruz J. Contrato I3 Estabilizado (CESI311). CM. 2011-2025.

Managment centre: FIBHULP

Mingorance Cruz J. Mecanismos moleculares de la heteroresistencia y la heterogénea susceptibilidad a carbapenémicos en enterobacterias productoras de carbapenemesas (PI19/01356). ISCIII. 2020-2022.

Managment centre: FIBHULP

Prados-Rosales R. Connection between vesiculation and antibiotic tolerance in Mycobacterium tuberculosis (PID2019-110240RB-100). Agencia Nacional de Investigación. 2020-2023.

Managment centre: UAM

Prados-Rosales R. Research Network of Mycobacterial Systems Biology (RED2018-102677-T). Agencia Nacional de Investigación. 2019-2021.

Managment centre: UAM

Ruíz Carrascoso G. Evaluación y validaciónd el sistema de inteligencia analítica Biwer Anlytics como herramienta de mejora en el seguimiento de brotes por Sars-Cov-2. Werfen España S. A. U. 2020-Ongoing.

Managment centre: FIBHULP

Patents and trademarks

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.3 Immuno-Rheumatology Group

Publications:	39
Impact Factor:	219.[349]
Q1:	21



María Eugenia Miranda Carús.
Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Pilar Aguado Acín. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Alejandro Balsa Criado. Jefe de Servicio de Reumatología. Profesor Asociado. Facultad de Medicina. Hospital Universitario La Paz. Universidad Autónoma de Madrid

María Gema Bonilla Hernán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Ana Castilla Plaza. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Eugenio de Miguel Mendieta. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Francisco de Borja Hernández de Breijo. Investigador Postdoctoral. Hospital Universitario La Paz

Paula Fortea Gordo. Investigadora Predoctoral. Hospital Universitario La Paz

Sara García Carazo. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Emilio Martín Mola. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Ana Martínez Feito. Investigadora Predoctoral. Hospital Universitario La Paz

Irene Monjo Henry. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

María Victoria Navarro Compán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Laura Nuño Nuño. Médico Adjunto Interino en Reumatología. Hospital Universitario La Paz

María Dora Pascual-Salcedo Pascual. Químico Adjunto en Inmunología. Hospital Universitario La Paz

Chamaida Plasencia Rodríguez. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Diana Peiteado López. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Alejandro Villalba Yllán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Strategic Objective

Our objective is to investigate the pathogenesis and evolution of rheumatic diseases, specifically focusing on imaging, genetics, metabolic pathways and immunopathogenesis.

Research lines

- Immunopathogenesis, genetic, evolution, prognosis and biomarkers of inflammatory and autoimmune arthritis
- Imaging of inflammatory and autoimmune arthritis
- Immunopathogenesis and genetics of osteoporosis
- Immunogenicity of biological therapies with monoclonal antibodies

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Doctoral theses

Martínez Feito A. Monitorización de la terapia biológica en enfermedades inflamatorias inmunomediadas[dissertation]. Madrid: UAM: 2020(26/06/2020).

Directors: Balsa Criado A, Pascual-Salcedo Pascual D.

Publications

- Acebes C, Andréu JL, Balsa A, Batlle E, de Toro-Santos J, Llorente FG, Hernández MV, Fernández-Gutiérrez B, Hidalgo-Calleja C, Mayordomo L, Naredo E, Narváez FJ, Ortiz AM, Pablos JL, Pérez-Sandoval T, Rodríguez-Lozano C, Sánchez-Pernaute O, Uson J, Negron JB, Loza E, Carmona L, Castro SG, Álvarez MM. There is something you must see: breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective. Clin Exp Rheumatol. 2020; 38(1): 82-7. Article. IF: 4.473; Q2
- Almódovar R, Joven B, Almaraz ER, Melchor S, Rabadán E, Villaverde V, Navio T, Méndez LC, Oliveira LL, Prada A, González L, Navarro-Compán V, Loza E, Zarco P. Implementation of an assessment checklist for patients with spondyloarthritis in daily practice. Clin Exp Rheumatol. 2020; 38(1): 115-21. Article. IF: 4.473; Q2
- Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Wiedon A, Behrens F. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial. Bmc Musculoskel Dis. 2020; 21(1): 767. Article. IF: 2.362; Q2
- Benavent D, Plasencia-Rodríguez C, Franco-Gomez K, Nieto R, Monjo-Henry I, Peiteado D, Balsa A, Navarro-Compán V. Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum? Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20971889. Article. IF: 5.346; Q1
- Fernández EF, Núñez DB, Hernan GB, Henry IM, Carazo SG, Pineda MB, Criado AB, Acin PA. Multiple vertebral fractures following discontinuation of denosumab treatment: Ten clinical cases report. Reumatol Clin. 2020; 16(6): 480-4. Article. Not Indexed
- Fernández-Díaz C, Castaneda S, Melero-González RB, Ortiz-Sanjuan F, Juan-Mas A, Carrasco-Cubero C, Casafont-Sole I, Olive A, Rodríguez-Muguruza S, Almodovar-González R, Castellanos-Moreira R, Rodríguez-García SC, Aguilera-Cros C, Villa I, Ordonez-Palau S, Raya-Álvarez E, Morales-Garrido P, Ojeda-García C, Moreno-Ramos MJ, Hernan MGB, Rodríguez IH, López-Corbeto M, Andreu JL, de Aberasturi JRDJ, Ruibal-Escribano A, Exposito-Molinero R, Pérez-Sandoval T, López-Robles AM, Carreira-Delgado P, Mena-Vazquez N, Urruticoechea-Arana A, Peralta-Gines C, Arboleya-Rodríguez L, García FJN, Palma-Sánchez D, Pérez ECC, Maiz-Alonso O, Álvarez-Rivas MN, Fernández-Melon J, Casasempere PV, Cabezas-Rodríguez I, Castellvi-Barranco I, González-Montagut C, Blanco-Madrigal J, Del Val-Del Amo N, Fito MC, Rodríguez-Gomez M, Salgado-Pérez E, García-Magallon B, Hidalgo-Calleja C, López-Sánchez R, Fernández-Aguado S, Fernández-López JC, Castro-Oreiro S, Serrano-García I, García-Valle A, Romero-Yuste S, Expósito-Pérez L, Pérez-Albadalejo L, García-Aparicio A, Quillis-Marti N, Bernal-Vidal JA, Loricera-García J, Hernández JL, González-Gay MA, Blanco R. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology. 2020; 59(12): 3906-16. Article. IF: 7.58; Q1
- Fernández-Fernández E, Monjo-Henry I, Bonilla G, Plasencia C, Miranda-Carus ME, Balsa A, de Miguel E. False positives in the ultrasound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology. 2020; 59(9): 2443-7. Article. IF: 7.58; Q1
- Fortea-Gordo P, Villalba A, Nuño L, Santos-Bórnez MJ, Peiteado D, Monjo I, Puig-Kroger A, Sánchez-Mateos P, Martín-Mola E, Balsa A, Miranda-Carús ME. Circulating CD19+CD24(hi) CD38(hi) regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis. Rheumatology. 2020; 59(10): 3081-91. Article. IF: 7.58; Q1
- Freites-Núñez D, Baillet A, Rodríguez-Rodríguez L, Nguyen MVC, González I, Pablos JL, Balsa A, Vazquez M, Gaudin P, Fernández-Gutierrez B. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA). Trials. 2020; 21(1): 755. Article. IF: 2.279; Q4
- García-Magallón B, Castro-Villegas C, Rosello-Pardo R, Salvador-Oliván JA, Navarro-Compán V. Is the new ASDAS nomenclature in agreement with therapeutic decision making in patients with axial spondyloarthritis? Semin Arthritis Rheu. 2020; 50(5): 854-7. Article. IF: 5,532; Q1
- Garrido-Cumbrera M, Chacón-García J, Navarro-Compán V, Gratacos J, Sanz-Gómez S, Collantes-Estévez E. Does belonging to a patient association is of help for patients with axial spondyloarthritis? Results from the Atlas Survey. Curr Rheumatol Rep. 2020; 22(6): 22. Article. IF: 4.592; Q2
- González-Serna D, Ochoa E, López-Isac E, Julia A, Degenhardt F, Ortego-Centeno N, Radstake TRDJ, Franke A, Marsal S, Mayes MD, Martín J, Márquez A. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. Sci Rep-Uk. 2020; 10(1): 1862. Article. IF: 4.379; Q1
- Kiltz U, Landewe RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2020; 79(2): 193-201. Article. IF: 19.103; D1
- Kvien TK, Balsa A, Betteridge N, Buch MH, Dúrez P, Favalli EG, Favier G, Gabay C, Geenen R, Gouni-Berthold I, van den Hoogen F, Kent A, Klareskog L, Ostergaard M, Pavelka K, Pereira JP, Semb AG, Skold M, Dougados M. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open. 2020; 6(2): e001211. Article. IF: 5.117; Q2
- López-Mejías R, Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Rozas SMF, Llorca J, Fernández DI, Cuesta VMM, Ortego-Centeno N, Gómez NP, Mera-Varela A, Martínez-Barrio J, López-Longo FJ, Mijares V, Lera-Gómez L, Usetti MP, Laporta R, Pérez V, Gafas AD, González MAA, Calvo-Alen J, Romero-Bueno F, Sánchez-Pernaute LO, Nuño L, Bonilla G, Balsa A, Hernández-González F, Grafia I, Prieto-González S, Narváez J, Trallero-Araguas E, Selva-OCallaghan A, Gualillo O, Castaneda S, Cavagna LL, Cifrian JM, González-Gay MA. Influence of MUC5B gene on antisynthetase syndrome. Sci Rep-Uk. 2020; 10(1): 1415. Article. IF: 4.379; Q1
- Macía-Villa C, de Miguel E. Updating the use of the Madrid Sonographic Enthesis Index (MASEI): a systematic review of the literature. Rheumatology. 2020; 59(5): 1031-40. Review. IF: 7.58; Q1
- Martínez Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, Nozal P, Angeles González M, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A. Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. Semin Arthritis Rheum. 2020; 50(1):E1-2. Article. IF: 5.532; Q1
- Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Díez J, García-Ramírez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín- Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

patients with inflammatory bowel disease: originator vs. biosimilar. Sci Rep-Uk. 2020; 10(1): 17099. Article. IF: 4.379; Q1

- Marzo-Ortega H, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Dougados M, Combe B, Wei JCC, Baraliakos X, Hunter T, Sandoval D, Li XQ, Zhu BJ, Bessette L, Deodhar A. Impact of Ixekizumab on work productivity in patients with ankylosing spondylitis: Results from the COAST-V and COAST-W trials at 52 Weeks. Rheumatol Ther. 2020; 7(4): 759-74. Article. IF: 3.494; Q3
- Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, Galindo M, Melissa-Anzola A, Uriarte-Isacelay E, Olive-Márques A, Aurrecoechea E, Freire M, Tomero E, García-Villanueva MJ, Stoye C, Salas-Heredia E, Bernal-Vidal JA, Salgado E, Blanco R, Novoa FJ, Ibáñez-Barceló M, Torrente-Segarra V, Narváez J, Calvet J, Morales CM, Vázquez-Rodríguez TR, de la Pena PG, Bohórquez C, Andreu-Sánchez JL, Cobo-Ibáñez T, Bonilla G, Lozano-Rivas N, Montilla C, Toyos FJ, de la Fuente JLM, Expósito L, Ruiz-Lucea ME, Vals E, Manero-Ruiz J, Bernal-Vidal JA, Rua-Figueroa I. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology. 2020; 59(8): 2043-51. Article. IF: 7.58; Q1
- Molina JT, Criado AB, García FB, Alonso RB, Bustabad S, Alen JC, Corominas H, Nebro AF, Ivorra JAR, Sanmarti R. Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis. Reumatol Clin. 2020; 16(4): 272-81. Article. Not Indexed
- Navarro F, Martínez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, Gómez S, de Andrés-Nogales F, Casado MA, Oyaguez I. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020; 39(10): 2919-30. Article. IF: 2.98; Q3
- Navarro-Compán V, Oton T, Loza E, Almodovar R, Ariza-Ariza R, Bautista-Molano W, Burgos-Vargas R, Collantes-Estevez E, de Miguel E, González-Fernández C, Gratacos J, Ibáñez S, Juanola X, Maldonado-Cocco J, Molto A, Mulero J, Pacheco-Tena C, Ramos-Remus C, Sanz-Sanz J, Valle-Onate R, Zarco P, Marzo-Ortega H. Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis. Reumatol Clin. 2020; 16(5): 333-8. Article. Not Indexed
- Nieto RE, Rodríguez CP, López DP, Yllán AV, Criado AB, Navarro-Compán V. Are we treating women patients with real axial spondyloarthritis? Semin Arthritis Rheu. 2020; 50(3): 432-5. Article. IF: 5.532; Q1
- Novella-Navarro M, Plasencia C, Tornero C, Navarro-Compán V, Cabrera-Alarcon JL, Peiteado-López D, Nuño L, Monjo-Henry I, Franco-Gomez K, Villalba A, Balsa A. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020; 22(1): 284. Article. IF: 5.156; Q2
- Nuño L, Navarro MN, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, Monjo I, Tornero C, Villalba A, Miranda-Carús ME, de Miguel E, Bogas P, Castilla-Plaza A, Bernad-Pineda M, García-Lorenzo E, Rodríguez-Araya T, Balsa A. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020; 79(12): 1659-61. Letter. IF: 19.103; D1
- Ogdie A, Duarte-García A, Hwang M, Navarro-Compán V, van der Heijde D, Mease P. Measuring outcomes in axial spondyloarthritis. Arthrit Care Res. 2020; 72: 47-71. Article. IF: 4.794; Q2
- Ortolan A, Navarro-Compán V, Sepriano A, Landewe RBM, van der Heijde D, Ramiro S. Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. Rheumatology. 2020; 59(12): 3990-92. Letter. IF: 7.58; Q1
- Regueiro C, Rodríguez-Rodríguez L, López-Mejías R, Nuño L, Triguero-Martínez A, Pérez-Pampin E, Corrales A, Villalba A, López-Golan Y, Abasolo L, Remuzgo-Martínez S, Ortiz AM, Herranz E, Martínez-Feito A, Conde C, Mera-Varela A, Balsa A, González-Alvaro I, González-Gay MN, Fernández-Gutierrez B, González A. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Sci Rep-Uk. 2020; 10(1): 3355. Article. IF: 4.379; Q1
- Rodríguez-Martín E, Nieto-Ganan I, Hernández-Breijo B, Sobrino C, García-Hoz C, Bachiller J, Martínez-Feito A, Navarro-Compán V, Lapuente-Suanzes P, Bonilla G, Pascual-Salcedo D, Roy G, Jurado T, Nozal P, Vázquez-Díaz M, Balsa A, Villar LM, Plasencia-Rodríguez C. Blood lymphocyte subsets for early identification of non-remission to TNF inhibitors in rheumatoid arthritis. Front Immunol. 2020; 11: 1913. Article. IF: 7.561; Q1
- Rodríguez-Martínez L, Bang H, Regueiro C, Nuno L, Triguero-Martínez A, Peiteado D, Ortiz AM, Villalba A, Martínez-Feito A, Balsa A, González-Alvaro I, González A. Improved classification of rheumatoid arthritis with a score including anti-



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

acetylated ornithine antibodies. Sci Rep-Uk. 2020; 10(1): 19263. Article. IF: 4.379; Q1

- Rosas J, Martín-López M, Oton T, Balsa A, Calvo-Alen J, Sanmartí R, Tornero J, Carmona L. Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. Reumatol Clin. 2020; 16(5): 378-85. Article. Not Indexed
- Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vazquez A, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Mendez V, García-Aparicio A, Veroz-González R, Jovani V, Peiteado D, Sánchez-Orgaz M, Tomero E, De Miera FJTS, Pinillos V, Aurrecoechea E, Mora A, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazon I, Hernández JL, Castaneda S, González-Gay MA, Blanco R. Anti-IL-6 receptor tocilizumab in refractory graves' orbitopathy: National multicenter observational study of 48 patients. J Clin Med. 2020; 9(9): 2816. Article. IF: 4.241; Q1
- Serrano J, López-Pintor RM, Ramírez L, Fernández-Castro M, Sanz M, Melchor S, Peiteado D, Hernández G. Risk factors related to oral candidiasis in patients with primary Sjogren's syndrome. Med Oral Patol Oral. 2020; 25(5): E700-5. Article. IF: 2.407; Q3
- Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li ZG, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6): 685-99. Review. IF: 19.103; D1
- Tornero C, Navarro-Compán V, Tenorio JA, García-Carazo S, Buno A, Monjo I, Plasencia-Rodríguez C, Iturzaeta JM, Lapunzina P, Heath KE, Balsa A, Aguado P. Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia? Orphanet J Rare Dis. 2020; 15(1): 51. Article. IF: 4.123; Q2
- Torrente-Segarra V, Salmán-Monte TC, Rua-Figueroa I, del Campo V, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, Olive-Marqués A, Mourino-Rodríguez C, Horcada L, Bohórquez C, Montilla C, Salgado E, Díez-Álvarez E, Blanco R, Andreu JL, Fernández-Berrizbeitia O, Expósito L, Gantes M, Hernández-Cruz B, Pecondon-Espanol A, Lozano-Rivas N, Bonilla G, Iglesias AL, Rubio-Muñoz P, Ovalles J, Tomero E, Boteanu A, Narváez J, Freire M, Vela P, Quevedo-Vila V, Mas AJ, Muñoz-Fernández S, Raya E, Moreno M, Velloso-Feijoo ML, Soler G, Vázquez-Rodríguez TR, Pego-Reigosa JM. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). Semin Arthritis Rheu. 2020; 50(4): 657-62. Article. IF: 5.532; Q1
- van Bentum RE, Vodnizza SEI, de la Fuente MPP, Aldridge FV, Navarro-Compán V, Rusman TR, ter Wee MM, Letelier OV, van Weely SFE, van der Horst-Bruinsma IE. The ankylosing spondylitis performance index: reliability and feasibility of an objective test for physical functioning. J Rheumatol. 2020; 47(10): 1475-82. Article. IF: 4.666; Q2
- Zegarra-Mondragón S, López-González R, Martín-Martínez MA, García-Gomez C, Sánchez-Alonso F, González-Juanatey C, Arija SM, Hernán GB, Pardo SM, Escribano AR, García EP, Frías ED, Redondo JR, Sánchez MD, Cambrón ABR, Ramos MJM, Montero SAR, Marco MTN, Valle MM, González JG, Corral JB, Llorca J, Castaneda S, González-Gay MA. Association of apolipoprotein B/apolipoprotein AI ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study. Clin Exp Rheumatol. 2020; 38(4): 662-9. Article. IF: 4.473; Q2

Research projects

Aguado Acín P. Caracterización e historia natural de la hipofosfatasia en pacientes adultos con confirmacion genetica frente a pacientes con fosfatasa alcalina baja y test genético negativo. Hipofosfatasia del adulto. Alexion Pharmaceutical Inc. 2017-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Desarrollo de biochips para monitorización de infliximab y la presencia de anticuerpos frente a infliximab en sangre. IMG Pharma Biotech. 2017-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Estudio de las comorbilidades en la artritis reumatoide. Roche Farma S. A. 2011-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Estudio para determinar la correlación entre la calprotectina sérica y la actividad de la artritis reumatoide. Arepaz. 2010-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Preceptorship: Actualización en manejo clínico de patología reumática: artritis reumatoide y espondiloartritis: de la investigación a la práctica clínica. UCB de México S. A. 2019-2020.

Managment centre: FIBHULP

Balsa Criado A. Relación entre los niveles de fármaco circulante, la aparición de anticuerpos anti idiotipo y la respuesta clínica, en pacientes con enfermedades articulares inflamatorias (artritis reumatoide, artritis idiopática juvenil, artritis psoriática, enfermedad de Still y espondiloartropatías) que reciben tratamiento biológico. Pfizer S. L. U. 2011-Ongoing.

Managment centre: FIBHULP

de Miguel Mendieta E. Factores de riesgo de progresión radiográfica en columna de pacientes con espondilitis anquilosante. Influencia de los tratamientos actuales (PI17/01840). ISCIII. 2018-2022.

Managment centre: FIBHULP

Miranda Carús ME. Efecto del metotrexato en la frecuencia y función de las células T helper foliculares; implicaciones patogénicas y pronósticas. Laboratorios Gebro Pharma S. A. 2020-Ongoing.

Managment centre: FIBHULP

Miranda Carús ME. Frecuencia y función de las células T helper foliculares circulantes y plasmablastos en pacientes con artritis reumatoide, y su relación con los niveles de autoanticuerpos: odificaciones asociadas con el bloqueo de la coestimulación por Abatacept. Bristol Myers Squibb S. A. U. 2016-Ongoing.

Managment centre: FIBHULP

Miranda Carús ME. Frecuencia, fenotipo y función de las células B reguladoras (BREG) en pacientes con artritis reumatoide preclínica, temprana y establecida (PI16/01189). ISCIII. 2017-2021.

Managment centre: FIBHULP

Pascual-Salcedo Pascual MD; Herranz Pinto P. Identificación precoz de buenos respondedores primarios a las terapias biológicas en la psoriasis moderada a grave. Laboratorios Leo Pharma S. A. 2014-Ongoing.

Managment centre: FIBHULP

Plasencia Rodríguez C. Identificación precoz de respuesta clínica a la terapia anti-TNF en la artritis reumatoide (PI16/00474). ISCIII. 2017-2021.

Managment centre: FIBHULP

Plasencia Rodríguez C. Identificación precoz de respuesta clínica a la terapia anti-TNF en la artritis reumatoide. Sociedad de Reumatología de la Comunidad de Madrid. 2018-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Miranda Carús ME. Investigational Network in Inflammation and Rheumatic Diseases. (RIER). Carlos III Health Institute. (31/12/2021).

Clinical trials

Aguado Acín, Pilar. Factores asociados al descenso de densidad mineral ósea y a la incidencia de fracturas durante el periodo de descanso terapéutico con BF.

Type: Estudios, phase EPA-OD.
HULP code: PI-3952 .
Sponsored´s protocol code: FIB-ALE-2020-01.
Sponsoredby: FIBHULP.
Signed date: 23/09/2020

Balsa Criado, Alejandro. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de filgotinib en pacientes con artritis psoriásica activa que han presentado respuesta insuficiente o que son intolerantes al tratamiento con fármacos biológicos antirreumáticos modificadores de enfermedad.

Type: EECC, phase III.
HULP code: Anexo 1 5515.
Sponsored´s protocol code: GS-US-431-4567.
Sponsoredby: Gilead Sciences Inc.
Signed date: 30/07/2020.

Balsa Criado, Alejandro. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de filgotinib en pacientes con artritis psoriásica activa que han presentado respuesta insuficiente o que son intolerantes al tratamiento con fármacos biológicos antirreumáticos modificadores de enfermedad.

Type: EECC, phase III.
HULP code: 5515 .
Sponsored´s protocol code: Anexo 1.
Sponsoredby: .
Signed date: 12/07/2020

Balsa Criado, Alejandro. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de filgotinib en pacientes con artritis psoriásica activa que han presentado respuesta insuficiente o que son intolerantes al tratamiento con fármacos biológicos antirreumáticos modificadores de enfermedad.

Type: EECC, phase III.
HULP code: 5515.
Sponsored´s protocol code: GS-US-431-4567.
Sponsoredby: Gilead Sciences Inc.
Signed date: 20/04/2020

Balsa Criado, Alejandro. Programa de fase 3 aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de upadacitinib en pacientes adultos con espondiloartritis axial.

Type: EECC, phase III.
HULP code: 5458.
Sponsored´s protocol code: M19-944.
Sponsoredby: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 27/01/2020

Balsa Criado, Alejandro. Estudio abierto y multicéntrico para pacientes que hayan completado un estudio previo con secukinumab patrocinado por novartis y que, a criterio del investigador, se estén beneficiando del tratamiento continuado con secukinumab.

Type: EECC, phase III.
HULP code: 5710.
Sponsored´s protocol code: CAIN457A02001B.
Sponsoredby: Novartis Farmacéutica S.A.
Signed date: 19/10/2020

Balsa Criado, Alejandro. Estudio ciara: análisis del impacto del coste en pacientes con artritis reumatoide moderada severa que no responden a fármaco modificador de la enfermedad biológico o a fármaco modificador de la enfermedad sintético convencional.

Type: Estudios, phase EPA-SP.
HULP code: PI-3779.
Sponsored´s protocol code: PFI-INF-2019-01.
Sponsoredby: Pfizer S.L.U.
Signed date: 01/12/2020

Balsa Criado, Alejandro. Estudio observacional transversal, sobre la facilidad de uso del dispositivo de inyección errosa pen.

Type: Estudios, phase EPA-OD.
HULP code: PI-4167 .
Sponsored´s protocol code: GR-TE-01-2019.
Sponsoredby: Gedeon Ritcher Iberica S.A.U.
Signed date: 25/06/2020

Bonilla Hernán, Maria Gema. Evaluación del riesgo cardiovascular, y de sus determinantes, en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica. Proyecto Carma.

Type: Estudios, phase No EPA.
HULP code: Appendix 2 PI-011 .
Sponsored´s protocol code: CARMA.
Sponsoredby: Fundación Española de Reumatologia.
Signed date: 29/07/2020

Bonilla Hernán, Maria Gema. Evolución del lupus eritematoso sistémico en España.

Type: Estudios, phase No EPA.
HULP code: Appendix 1 PI-1909.
Sponsored´s protocol code: RELESSER-PROS.
Sponsoredby: Fundación Española de Reumatologia.
Signed date: 12/06/2020

Patents and trademarks

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D´Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.4 Innate Immune Response Group

Publications:	42
Impact Factor:	274.[376]
Q1:	31



Eduardo Manuel López-Collazo. Director Científico de IdiPAZ. Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Luis Augusto Aguirre Pérez. Investigador Senior. Director de Laboratorio. Hospital Universitario La Paz

Susana Alemany de la Peña. Investigadora Senior. Jefe de Laboratorio. IIB "Alberto Sols"

Jose Avendaño Ortiz. Investigador Junior. Hospital Universitario La Paz

Gloria Cristina Bonel Pérez. Investigador en Formación. Hospital Universitario La Paz

Lisardo Boscá Gomar. Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"

Ramón Cantero Cid. Facultativo Especialista de Área en Cirugía General y Aparato Digestivo. Hospital Universitario La Paz

Antonio Castrillo Viguera. Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"

Carlos del Fresno Sánchez. Investigador Postdoctoral (Contrato Miguel Servet - Tipo I). FIBHULP

Maria Fernández Velasco. Investigadora Senior (Contrato Miguel Servet - Tipo I). Hospital Universitario La Paz

Santiago Gómez Ruiz. Profesor Titular. Universidad Rey Juan Carlos

María Susana Guerra García. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Roberto Lozano Rodríguez. Investigador Predoctoral. Hospital Universitario La Paz

Charbel Antonio Maroun Eid. Facultativo Especialista de Área en Urgencias. Hospital del Norte

Paloma Martín Sanz. Investigadora Senior. Jefe de Laboratorio . IIB "Alberto Sols"

Karla Marina Montalbán Hernéndez. Investigadora Predoctoral. Hospital Universitario La Paz

Rebeca Pérez de Diego. Investigadora Senior (Contrato Ramón y Cajal). Hospital Universitario La Paz

Sanjiv Prashar. Profesor Titular. Universidad Rey Juan Carlos

Elisa Pulido Lucas. Técnico de laboratorio. Hospital Universitario La Paz

Alejandro Pascual Iglesias. Bioinformático. Hospital Universitario La Paz

Jaime Valentín Quiroga. Investigador Predoctoral. Hospital Universitario La Paz

Kilian Jesús Gutiérrez Viñas. Técnico de laboratorio. Hospital Universitario La Paz

José Carlos Casalvilla Dueñas. Técnico de laboratorio. Hospital Universitario La Paz

Laura Córdoba García. Investigador Junior. Hospital Universitario La Paz

Carolina Rubio Marín. Bioinformática. Hospital Universitario La Paz

Verónica Terrón Arcos. Técnico de Laboratorio. Hospital Universitario La Paz

Strategic Objective

This group focuses on the study of the reprogramming of the innate immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, acute coronary syndrome, lung cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages during refractory states.

The innate immune response is activated in various clinical contexts that can be modelled in vitro. The initial reaction of the Innate Immune System is marked by an inflammatory response that is similar in different contexts.

However, after the initial response, a "deviation" is produced towards an "alternative" response that may, in many cases, lead to refractory states such as endotoxin and tumour tolerance. These refractory states may have undesirable clinical consequences and their study is the objective of our research.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Molecular mechanisms of the innate immune system tolerance to tumours in several clinical contexts.
- Molecular mechanisms of endotoxin tolerance in several clinical contexts: respiratory diseases (OSA and cystic fibrosis), acute coronary syndrome, sepsis and septic shock and leukaemias.
- Role of the innate immune system in metastasis.
- Myeloid cell polarization and atherogenesis.
- Role of some mediators of the innate immune system in cardiovascular diseases.

Research Activity

Doctoral theses

Avendaño Ortiz J. Inmuno-checkpoints: PD-L1, una diana terapéutica más allá del cáncer[dissertation]. Madrid: UAM: 2020 (06/03/2020).

Director: López Collazo E

Publications

- Aguirre LA, Montalbán-Hernández K, Avendaño-Ortiz J, Marín E, Lozano R, Toledano V, Sánchez-Maroto L, Terrón V, Valentín J, Pulido E, Casalvilla JC, Rubio C, Diekhorst L, Laso-García F, del Fresno C, Collazo-Lorduy A, Jiménez-Munarriz B, Gómez-Campelo P, Llanos-González E, Fernández-Velasco M, Rodríguez-Antolín C, de Diego RP, Cantero-Cid R, Hernádez-Jiménez E, Álvarez E, Rosas R, López-Ayllon BD, de Castro J, Wculek SK, Cubillos-Zapata C, de Caceres II, Díaz-Agero P, Fernández MG, de Miguel MP, Sancho D, Schulte L, Perona R, Belda-Iniesta C, Bosca L, López-Collazo E. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. OncoImmunology. 2020; 9(1): 1773204. Article. IF: 8.11; Q1
- Andújar X, Loras C, González B, Socarras M, Sanchiz V, Bosca M, Domenech E, Calafat M, Rodríguez E, Sicilia B, Calvet X, Barrio J, Guardiola J, Iglesias E, Casanova MJ, Ber Y, Monfort D, López-Sanromán A, Rodríguez-Lago I, Bujanda L, Marquez L, Martín-Arranz MD, Zabana Y, Fernández-Banares F, Esteve M, Panes J, Mínguez M, Sánchez VG, Pérez-Gisbert J, Gomollón F, Piqueras M, Cabriada JL, Andreu M. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surg Endosc. 2020; 34(3): 1112-22. Article. IF: 4.584; Q1
- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Maroun-Eid C, Terrón V, Valentín J, Montalbán-Hernández K, de la Bastida FR, García-Garrido MA, Cubillos-Zapata C, del Balzo-Castillo A, Aguirre LA, López-Collazo E. Proteins from SARS-CoV-2 reduce T cell proliferation: A mirror image of sepsis. Heliyon. 2020; 6(12): e05635. Article. Not indexed
- Avendaño-Ortiz J, Rubio-Garrido M, Lozano-Rodríguez R, del Romero J, Rodríguez C, Moreno S, Aguirre LA, Holguin A, López-Collazo E. Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure. Medicine (Baltimore). 2020; 99(20): e20065. Article. IF: 1.889; Q3
- Calafat M, Manosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Calle JLP, Riestra S, Gomollón F, García-Planella E, Bermejo F, Hernández V, Martín-Arranz MD, Gutiérrez A, Torres P, Canete F, Domenech E. Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the ENEIDA registry. J Crohns Colitis. 2020; 14(9): 1290-8. Article. IF: 9.071; Q1
- Calderón-Sánchez EM, Ávila-Medina J, Callejo-García P, Fernández-Velasco M, Ordóñez A, Smani T. Role of Orai1 and L-type Ca(V)1.2 channels in Endothelin-1 mediated coronary contraction under ischemia and reperfusion. Cell Calcium. 2020; 86: 102157. Article. IF: 6.817; Q1
- Casanova MJ, Chaparro M, Minguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Roman A, Iglesias E, Beltran B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domenech E, Calvet X, Perez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Marquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Perez A, Martínez-Montiel P, Van Domselaar M, Alcain G, Dominguez-Cajal M, Munoz C, Gomollon F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutierrez A, Arguelles-Arias F, Rodríguez C, Rodríguez GE, Bujanda L, Llao J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad A, Ramirez-de la Piscina P, Lucendo AJ, Sese E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP. Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: Results from the Eneida registry. Inflamm Bowel Dis. 2020; 26(4): 606-16. Article. IF: 5.325; Q2
- Chaparro M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Hernández-Breijo B, Mesonero F, Sempere L, Gomollon F, Hinojosa J, Bermejo F, Beltrán B, Pescador AR, Banales JM, Olivares D, Aguilar-Melero P, Menchen L, Ferreiro-Iglesias R, Gómez IB, García BB, Guijarro LG, Marín A, Bernardo D, Gisbert JP. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2020; 32(5): 588-96. Article. IF: 2.566; Q4
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrián L, Cantero R, del Peso L, Burgos A, Barbachano A, Munoz A. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. Cancers. 2020; 12(8): 2302. Article. IF: 6.639; Q1
- Cubillos-Zapata C, Almendros I, Díaz-García E, Toledano V, Casitas R, Galera R, López-Collazo E, Farre R, Gozal D, García-Rio F. Differential effect of intermittent hypoxia and sleep fragmentation on PD-1/PD-L1 upregulation. Sleep. 2020; 43(5): zsz285. Article. IF: 5.849; Q1
- Cubillos-Zapata C, Martínez-García MA, Díaz-García E, Jauréguízar A, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Cano-Pumarega I, Corral-Penafiel J, Arias E, Mediano O, So-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

moza-González M, Dalmau-Arias J, Almendros I, Farre R, López-Collazo E, Gozal D, García-Rio F. Obesity attenuates the effect of sleep apnea on active TGF-ss 1 levels and tumor aggressiveness in patients with melanoma. Sci Rep. 2020; 10(1): 15528. Article. IF: 4.379; Q1

- Cubillos-Zapata C, Martínez-García MA, Díaz-García E, Toledano V, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Cano-Pumarega I, Corral-Penafiel J, Arias E, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Farre R, López-Collazo E, Gozal D, García-Rio F. Proangiogenic factor midkine is increased in melanoma patients with sleep apnea and induces tumor cell proliferation. Faseb J. 2020; 34(12): 16179-90. Article. IF: 5.191; Q1
- Díaz-García D, Montalbán-Hernández K, Mena-Palomo I, Achimas-Cadariu P, Rodríguez-Diéguez A, López-Collazo E, Prashar S, Paredes KO, Filice M, Fischer-Fodor E, Gómez-Ruiz S. Role of folic acid in the therapeutic action of nanostructured porous silica functionalized with organotin(IV) compounds against different cancer cell lines. Pharmaceutics. 2020; 12(6): 512. Article. IF: 6.321; Q1
- Díaz-García E, Jaureguízar A, Casitas R, García-Tovar S, Sánchez-Sánchez B, Zamarrón E, López-Collazo E, García-Rio F, Cubillos-Zapata C. SMAD4 overexpression in patients with sleep apnoea may be associated with cardiometabolic comorbidities. J Clin Med. 2020; 9(8): 2378. Article. IF: 4.241; Q1
- Falcón D, Galeano-Otero I, Martín-Bornez M, Fernández-Velasco M, Gallardo-Castillo I, Rosado JA, Ordóñez A, Smani T. TRPC Channels: Dysregulation and Ca2+ mishandling in ischemic heart disease. Cells. 2020; 9(1): 173. Review. IF: 6.6; Q2
- Fernández-García V, González-Ramos S, Martín-Sanz P, Castrillo A, Boscá L. Contribution of extramedullary hematopoiesis to atherosclerosis. The spleen as a neglected hub of inflammatory cells. Front Immunol. 2020; 11: 586527. Review. IF: 7.561; Q1
- Gil-Fernández M, Navarro-García JA, Val-Blasco A, González-Lafuente L, Martínez JC, Rueda A, Tamayo M, Morgado JL, Zaragoza C, Ruilope LM, Delgado C, Ruiz-Hurtado G, Fernández-Velasco M. Genetic deletion of NOD1 prevents cardiac Ca2+ mishandling induced by experimental chronic kidney disease. Int J Mol Sci. 2020; 21(22): 8868. Article. IF: 5.923; Q1
- González-Ramos S, Fernández-García V, Recalde M, Rodríguez C, Martínez-González J, Andrés V, Martín-Sanz P, Bosca L. Deletion or inhibition of NOD1 favors plaque stability and attenuates atherothrombosis in advanced atherogenesis. Cells. 2020; 9(9): 2067. Article. IF: 6.6; Q2
- González-Ramos S, Paz-García M, Fernández-García V, Portune KJ, Acosta-Medina EF, Sanz Y, Castrillo A, Martín-Sanz P, Obregon MJ, Bosca L. NOD1 deficiency promotes an imbalance of thyroid hormones and microbiota homeostasis in mice fed high fat diet. Sci Rep. 2020; 10(1): 12317. Article. IF: 4.379; Q1
- Guevara-Hoyer K, Ochoa-Grullón J, Fernández-Arquero M, Cardenas M, de Diego RP, Sánchez-Ramón S. Serum free immunoglobulins light chains: A common feature of common variable immunodeficiency? Front Immunol. 2020; 11: 2004. Article. IF: 7.561; Q1
- Guevara-Hoyer K, Saz-Leal P, Díez-Rivero CM, Ochoa-Grullón J, Fernández-Arquero M, de Diego RP, Sánchez-Ramon S. Trained immunity based-vaccines as a prophylactic strategy in common variable immunodeficiency. A proof of concept study. Biomedicines. 2020; 8(7): 203. Article. IF: 6.081; Q1
- Guevara-Hoyer K, Vasconcelos J, Marqués L, Fernandes AA, Ochoa-Grullón J, Marínho A, Sequeira T, Gil C, de la Pena AR, García IS, Recio MJ, Fernández-Arquero M, de Diego RP, Ramos JT, Neves E, Sánchez-Ramón S. Variable immunodeficiency study: Evaluation of two European cohorts within a variety of clinical phenotypes. Immunol Lett. 2020; 223: 78-88. Article. IF: 3.685; Q3
- Jaén RI, Fernández-Velasco M, Terrón V, Sánchez-García S, Zaragoza C, Canales-Bueno N, Val-Blasco A, Vallejo-Cremades MT, Bosca L, Prieto P. BML-111 treatment prevents cardiac apoptosis and oxidative stress in a mouse model of autoimmune myocarditis. Faseb J. 2020; 34(8): 10531-46. Article. IF: 5.191; Q1
- Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M. Innate immune receptors, key actors in cardiovascular diseases. JACC-Basic Transl Sci. 2020; 5(7): 735-49. Review. IF: 8.648; Q1
- Lloret J, Abos-Herrándiz R, Alemany S, Allue R, Bartra J, Basagana M, Berdalet E, Campas M, Carreno A, Demestre M, Diogene J, Fontdecaba E, Gascon M, Gómez S, Izquierdo A, Mas L, Marques M, Pedro-Botet J, Pery M, Peters F, Pinto X, Planas M, Sabates A, San J, Sánchez-Vidal A, Trepat M, Vendrell C, Fleming LE. The roses ocean and human health chair: A new way to engage the public in oceans and human health challenges. Int J Environ Res Public Health. 2020; 17(14): 5078. Article. IF: 3.39; Q1
- López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune response and COVID-19: A mirror image of Sepsis. Int J Biol Sci. 2020; 16(14): 2479-89. Review. IF: 6.58; Q1
- Mostazo MGC, Kurrle N, Casado M, Fuhrmann D, Alshamleh I, Haupl B, Martín-Sanz P, Brune B, Serve H, Schwalbe H, Schnutgen F, Marín S, Cascante M. Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Cancers. 2020; 12(11): 3443. Article. IF: 6.639; Q1
- Navarro-García JA, Rueda A, Romero-García T, Aceves-Ripoll J, Rodríguez-Sánchez E, González-Lafuente L, Zaragoza C, Fernández-Velasco M, Kuro-o M, Ruilope LM, Ruiz-Hurtado G. Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca(2+)handling. Br J Pharmacol. 2020; 177(20): 4701-19. Article. IF: 8.739; D1
- Nicolas-Ávila JA, Lechuga-Vieco AV, Esteban-Martínez L, Sánchez-Díaz M, Díaz-García E, Santiago DJ, Rubio-Ponce A, Li JL, Balachander A, Quintana JA, Martínez-de-Mena R, Castejon-Vega B, Pun-García A, Traves PG, Bonzon-Kulichenko E, García-Marqués F, Cusso L, A-González N, González-Guerra A, Roche-Molina M, Martín-Salamanca S, Crainiciuc G, Guzmán G, Larrazabal J, Herrero-Galán E, Alegre-Cebollada J, Lemke G, Rothlin CV, Jiménez-Borreguero LJ, Reyes G, Castrillo A, Desco M, Muñoz-Canoves P, Ibáñez B, Torres M, Ng LG, Priori SG, Bueno H, Vázquez J, Cordero MD, Bernal JA, Enríquez JA, Hidalgo A. A network of macrophages supports mitochondrial homeostasis in the heart. Cell. 2020; 183(1): 94-109. Article. IF: 41.582; D1
- Ocaña J, Cantero R, Abadia P, Ramos D, Pina JD, Pastor P, Ballestero A, Die J, García JC. Laparoscopic management of intra-operative iliac vein injury - a video vignette. Colorectal Dis. 2020; 22(9): 1201. Letter. IF: 3.788; Q1
- Ochoa-Grullón J, Cuesta CB, López CP, Cortijo AP, de la Pena AR, Carmona AA, Morales M, Llano-Hernández K, Williams LJ, de Frías ER, Guevara-Hoyer K, Torres GC, Orte C, Fernández-Arquero M, Fernández-Paredes L, Serrano-García I, Recio MJ, de Diego RP, Martínez R, Sánchez-Ramón S. Evaluation of polysaccharide typhim VI antibody response as a predictor of humoral immunodeficiency in haematological malignancies. Clin Immunol. 2020; 210: 108307. Article. IF: 3.969; Q3
- Pajares M, Rojo AI, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson's disease: Mechanisms and therapeutic implications. Cells. 2020; 9(7): 1687. Review. IF: 6.6; Q2
- Povo-Retana A, Mojena M, Stremtan AB, Fernández-García VB, Gómez-Saez A, Nuevo-Tapioles C, Molina-Guijarro JM, Avendaño-Ortiz J, Cuezva JM, López-Collazo E, Martínez-Leal JF, Boscá L. Specific effects of trabectedin and lurbinectedin on human macrophage function and fate-novel insights. Cancers. 2020; 12(10): 3060. Article. IF: 6.639; Q1
- Rodríguez-Sánchez E, Navarro-García JA, González-Lafuente L, Aceves-Ripoll J, Vázquez-Sánchez S, Poveda J, Mercado-García E, Corbacho-Alonso N, Calvo-Bonacho E, Fernández-Velasco M, Álvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Oxidized low-density lipoprotein associates with ventricular stress in young adults and triggers intracellular Ca2+ alterations in adult ventricular cardiomyocytes. Antioxidants. 2020; 9(12): 1213. Article. IF: 6.312; D1
- Ruiz-Hurtado G, Rueda A, Pereira L, Fernández-Velasco M. Editorial: Evolving picture of calcium handling in cardiac disease. Front Physiol. 2020; 11: 1013. Editorial Material. IF: 4.566; Q1
- Sánchez A, Contreras-Jurado C, Rodríguez D, Regadera J, Alemany S, Aranda A. Hematopoiesis in aged female mice devoid of thyroid

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

hormone receptors. J Endocrinol. 2020; 244(1): 83-94. Article. IF: 4.286; Q2

- Sánchez A, Orizaola MC, Rodríguez-Muñoz D, Aranda A, Castrillo A, Alemany S. Stress erythropoiesis in atherogenic mice. Sci Rep. 2020; 10(1): 18469. Article. IF: 4.379; Q1
- Stringa P, Toledano V, Papa-Gobbi R, Arreola M, Largo C, Machuca M, Aguirre LA, Rumbo M, López-Collazo E, Oliveros FH. Galactomannan as a potential modulator of intestinal ischemia-reperfusion injury. J Surg Res. 2020; 249: 232-40. Article. IF: 2.192; Q3
- Tamayo M, Fulgencio-Covián A, Navarro-García JA, Val-Blasco A, Ruiz-Hurtado G, Gil-Fernández M, Martín-Nunes L, López JA, Desviat LR, Delgado C, Richard E, Fernández-Velasco M. Intracellular calcium mishandling leads to cardiac dysfunction and ventricular arrhythmias in a mouse model of propionic acidemia. Biochim Biophys Acta-Mol Basis Dis. 2020; 1866(1): 165586. Article. IF: 5.187; Q1
- Tamayo M, Martín-Nunes L, Val-Blasco A, M-Piedras MJG, Navarro-García JA, Lage E, Prieto P, Ruiz-Hurtado G, Fernández-Velasco M, Delgado C. Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. Br J Pharmacol. 2020; 177(14): 3273-90. Article. IF: 8.739; D1
- Van Den Rym A, Taur P, Martínez-Barricarte R, Lorenzo L, Puel A, González-Navarro P, Pandrowala A, Gowri V, Safa A, Toledano V, Cubillos-Zapata C, López-Collazo E, Vela M, Perez-Martínez A, Sánchez-Ramon S, Recio MJ, Casanova JL, Desai MM, de Diego RP. Human BCL10 deficiency due to homozygosity for a rare allele. J Clin Immunol. 2020; 40(2): 388-98. Article. IF: 8.317; Q1
- Vila-Bedmar R, Cruces-Sande M, Arcones AC, Willemen HLDM, Prieto P, Moreno-Indias I, Díaz-Rodríguez D, Francisco S, Jaen RI, Gutierrez-Repiso C, Heijnen CJ, Bosca L, Fresno M, Kavelaars A, Mayor F, Murga C. GRK2 levels in myeloid cells modulate adipose-liver crosstalk in high fat diet-induced obesity. Cell Mol Life Sci. 2020; 77(23): 4957-76. Article. IF: 9.261; Q1

Research projects

López Collazo EM. Estudio del sistema inmune infiltrado en el cáncer de pulmón y búsqueda de marcadores pronósticos en células circulantes de pacientes que sufren esta enfermedad. Immunostep S. L. 2014-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Fallo en trasplante renal infantil: un abordaje inmunológico para los efectos secundarios y el rechazo. Fundación Familia Alonso. 2020-Ongoing.

Managment centre: FIBHULP



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

López Collazo EM. Formación del personal investigador en colaboración con instituciones publicas y privadas que dirigen sus actividades a este campo. Syf Galenus Center S. L. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Inmune checkpoint en pacientes con COVID-19: una propuesta para la estratificación y la terapia dirigida al huésped. Encinar Rodriguez, Jesus. 2020-Ongoing.

Managment centre: FIBHULP

López Collazo EM. La metástasis tumoral infantil: una propuesta para eliminarla. Fundación Familia Alonso. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Los inmune-checkpoints en la sepsis: un abordaje para el diagnóstico y la terapia (PI18/00148). ISCIII. 2019-2021.

Managment centre: FIBHULP

López Collazo EM. The risk of infections in severalpathologies: a thorough study with clinical tools development for personalised medicine (PIE15/00065). ISCIII. 2016-2021.

Managment centre: FIBHULP

López Collazo EM. Transplantation (SOT & HSCT) in children transchild. Comunidad de Madrid. 2016-Ongoing.

Managment centre: FIBHULP

Lozano Rodríguez R. Contrato predoctoral (FI19/00334). ISCIII. 2020-2023.

Managment centre: FIBHULP

Martín Arranz MD. Programa de actualización en el conocimiento de la enfermedad inflamatoria intestinal. Abbvie Spain S. L. U. 2020-Ongoing.

Managment centre: FIBHULP

Montalbán Hernández KM. INPHINIT_The risk of infection in several pathologies: a thorough study with clinical tools for personalised medicine (INPhINIT_Montalban). Fundación La Caixa. 2018-2021.

Managment centre: FIBHULP

Pérez de Diego R. Contrato predoctoral (PEJD2019_PRE/BMD_16556). CM. 2020-2021.

Managment centre: FIBHULP

Pérez de Diego R. Errores congénitos de la inmunidad y predisposición a la infección por Sars-Cov-2 y a la gravedad del COVID-19. Ácción coordinada internacional de secuenciación exómica completa (COV20/01333). ISCIII. 2020-2021.

Managment centre: FIBHULP

Pérez de Diego R. Medicina de precisión en inmunodeficiencias primarias: desde la identificación y caracterización de nuevas etiologías genéticas hasta la edición génica (PI17/00543). ISCIII. 2018-2022.

Managment centre: FIBHULP

Clinical trials

Guerra García, MS. Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.

Type: EECC, phase I.
HULP code: 5624.
Sponsored´s protocol code: 213406.
Sponsored by: Glaxosmithkline Research And Development Limited.
Signed date: 14/09/2020

Martín Arranz, MD. Estudio multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de ABT-494 para el tratamiento de inducción y mantenimiento en pacientes con colitis ulcerosa de moderada a grave.

Type: EECC, phase II.
HULP code: 5450.
Sponsored´s protocol code: M14-234.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 14/01/2020

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de upadacitinib (ABT 494) en pacientes con colitis ulcerosa de moderada a grave.

Type: EECC, phase III.
HULP code: 5452.
Sponsored´s protocol code: M14-675.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 14/01/2020

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave.

Type: EECC, phase III.
HULP code: Appendix 2 4937.
Sponsored´s protocol code: M16-006.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 21/05/2020

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave sin respuesta al tratamiento biológico previo.

Type: EECC, phase III.
HULP code: Appendix 2 4935.
Sponsored´s protocol code: M15-991.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 21/05/2020

Martín Arranz, MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de crohn que respondan al tratamiento de inducción en los estudios M16-006 o M15-991.

Type: EECC, phase III.
HULP code: Appendix 2 4936.
Sponsored´s protocol code: M16-000.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 21/05/2020

Martín Arranz, MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con colitis ulcerosa que respondan al tratamiento de inducción en los estudios M16-067 o M16-065.

Type: EECC, phase III.
HULP code: Appendix 1 5057.
Sponsored´s protocol code: M16-066.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 21/05/2020

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta al tratamiento biológico previo.

Type: EECC, phase III.
HULP code: Appendix 1 5058.
Sponsored´s protocol code: M16-067.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 21/05/2020

Martín Arranz, MD. Estudio de seguridad posautorización para evaluar la seguridad y la eficacia a largo plazo de la administración repetida de darvadstrocel en pacientes con enfermedad de Crohn y fístulas perianales complejas.

Type: EECC, phase IV.
HULP code: 5465.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Sponsored´s protocol code: Alofisel-4001.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 28/09/2020

Martín Arranz, MD. Estudio de extensión abierto para evaluar etrasimod cuando se administra a sujetos con colitis ulcerosa activa moderada o grave.

Type: EECC, phase III.
HULP code: Appendix 1 5368.
Sponsored´s protocol code: APD-334-303.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 25/06/2020

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ABBV-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: EECC, phase II.
HULP code: Appendix 2 5246.
Sponsored´s protocol code: M15-722.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 29/10/2020

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ABBV-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: EECC, phase II.
HULP code: Appendix 1 5246.
Sponsored´s protocol code: M15-722.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 28/05/2020

Martín Arranz, MD. Estudio fase 3b, aleatorizado, doble ciego, multicéntrico para evaluar la seguridad y la eficacia de la terapia de reinducción intravenosa con ustekinumab en pacientes con enfermedad de Crohn activa moderada a grave.

Type: EECC, phase III.
HULP code: Appendix 1 5427.
Sponsored´s protocol code: CNTO-1275CRD3008 (POWER).
Sponsored by: Janssen Cilag International N.V.
Signed date: 15/09/2020

Martín Arranz, MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.

Type: EECC, phase III.
HULP code: Appendix 1 5366.
Sponsored´s protocol code: APD334-301.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 02/07/2020

Martín Arranz, MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.

Type: EECC, phase III.
HULP code: Appendix 1 5367.
Sponsored´s protocol code: APD334-302.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 26/06/2020

Martín Arranz, MD. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa activa de moderada a grave.

Type: EECC, phase III.
HULP code: 5367.
Sponsored´s protocol code: APD334-302.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 22/01/2020

Martín Arranz, MD. Estudio fase 2b/3 aleatorizado, doble-ciego, controlado con placebo, grupo paralelo, multicéntrico, para evaluar la eficacia y seguridad de guselkumab en pacientes con colitis ulcerosa activa de moderada a severa.

Type: EECC, phase II.
HULP code: Appendix 1 5393.
Sponsored´s protocol code: CNT01959U-C03001 (QUASAR).
Sponsored by: Janssen Cilag International N.V.
Signed date: 06/07/2020

Martín Arranz, MD. Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de varias dosis para evaluar la eficacia, seguridad y farmacocinética de PF06480605 en participantes adultos con colitis ulcerosa de moderada a severa.

Type: EECC, phase II.
HULP code: 5507.
Sponsored´s protocol code: B7541007.
Sponsored by: Pfizer Inc.
Signed date: 14/04/2020

Martín Arranz, MD. Ensayo clínico multicéntrico de fase IB/IIA (prueba de concepto)aleatorizado, con doble ciego y controlado con placebo para evaluar la seguridad,farmacocinética y eficacia del tratamiento oral con OST-122 en pacientes con colitis ulcerosa de moderada a severa.

Type: EECC, phase I.
HULP code: 5473.
Sponsored´s protocol code: CT– OST – 122 – 02.
Sponsored by: Oncostellae S.L.
Signed date: 04/03/2020

Martín Arranz, MD. Estudio fase 3, multicéntrico, aleatorizado, con enmascaramiento para los evaluadores de la eficacia de risankizumab en comparación con ustekinumab para el tratamiento de sujetos adultos con enfermedad de Crohn de moderada a grave sin respuesta al tratamiento con terapia antiTNF.

Type: EECC, phase III.
HULP code: 5658.
Sponsored´s protocol code: M20-259.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 02/10/2020

Patents and trademarks

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.5 Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

Publications:	18
Impact Factor:	79.[62]
Q1:	7



Margarita López Trascasa.
Investigadora"ad honorem" IdiPAZ. Hospital Universitario La Paz. Profesora Asociada UAM. Universidad Autónoma de Madrid

Pilar Sánchez Corral Gómez.
Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Fernando Corvillo Rodríguez. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Laura Espinosa Román. Jefa de Servicio Nefrología Pediátrica. Hospital Universitario La Paz

Irene Gómez Delgado. Investigadora predoctoral. Hospital Universitario La Paz

Laura González Sánchez. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Alberto López Lera. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Marta Melgosa Hijosa. Facultativo Especialista de Área en Nefrología Infantil. Hospital Universitario La Paz

Pilar Nozal Aranda. Facultativo Especialista de Área en Inmunología. Investigadora postdoctoral. Hospital Universitario La Paz

Strategic Objective

This is a national reference group for the study of primary or acquired defects in the complement system.

The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in several human diseases, the majority of which are classified as rare diseases.

In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement components. By following a clearly translational approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up.

The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III), study of pathogenic mechanisms in acquired lipodystrophies (IV).

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Molecular mechanisms of the innate immune system tolerance to tumours in several clinical contexts.
- Molecular mechanisms of endotoxin tolerance in several clinical contexts: respiratory diseases (OSA and cystic fibrosis), acute coronary syndrome, sepsis and septic shock and leukaemias.
- Role of the innate immune system in metastasis.
- Myeloid cell polarization and atherogenesis.
- Role of some mediators of the innate immune system in cardiovascular diseases.

Research Activity

Publications

- Amesty MV, Fernández C, Espinosa L, Rivas-Vila S, Lobato R, Monsalve S, López-Pereira PC, Martínez-Urrutia MJ. Long-term outcomes of adult-size and size-matched kidney transplants in small pediatric recipients. J Pediatr Urol. 2020; 16(4): 481.e1-8. Article. IF: 1,83; Q3
- Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juarez G, Rodríguez A, de José AP, Rabasco C, Rodado R, Fernández L, Gómez VP, Ávila AI, Bravo L, Lumbreras J, Allende N, de la Nieta MDS, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megias M, González F, Shabaka A, López-Rubio ME, Fenollosa MA, Martín-Penagos L, Da Silva I, Titos JA, de Cordoba SR, de Jorge EG, Praga M. Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. Clin J Am Soc Nephrol. 2020; 15(9): 1287-98. Article. IF: 8.237; D1
- Corvillo F, Ceccarini G, Nozal P, Magno S, Pelosini C, Garrido S, López-Lera A, Moraru M, Vilches C, Fornaciari S, Gabbriellini S, Santini F, Araujo-Vilar D, López-Trascasa M. Immunological features of patients affected by Barraquer-Simons syndrome. Orphanet J Rare Dis. 2020; 15(1): 9. Article. IF: 4.123; Q2
- Corvillo F, de la Morena-Barrio ME, Marcos-Bravo C, López-Trascasa M, Vicente V, Emsley J, Caballero T, Corral J, López-Lera A. The FXII c.-4T > C polymorphism as a disease modifier in patients with hereditary angioedema due to the FXII p.Thr328Lys variant. Front Genet. 2020; 11: 1033. Article. IF: 4.599; Q2
- Corvillo F, Nozal P, López-Lera A, de Miguel MP, Pinero-Fernández JA, de Lucas R, García-Concepción MD, Beato MJ, Araujo-Vilar D, López-Trascasa M. Evidence of ongoing complement activation on adipose tissue from an 11-year-old girl with Barraquer-Simons syndrome. J Dermatol. 2020; 47(12): 1439-44. Article. IF: 4.005; Q2
- Dezfouli M, Bergstrom S, Skattum L, Abolhassani H, Neiman M, Torabi-Rahvar M, Jarava CF, Martín-Nalda A, Balaguer JMF, Slade CA, Roos A, Pereira LMF, López-Trascasa M, González-Granado LI, Allende-Martínez LM, Mizuno Y, Yoshida Y, Friman V, Lundgren A, Aghamohammadi A, Rezaei N, Hernández-González M, von Dobeln U, Truedsson L, Hara T, Nonoyama S, Schwenk JM, Nilsson P, Hammarstrom L. Newborn screening for presymptomatic diagnosis of complement and phagocyte deficiencies. Front Immunol. 2020; 11: 455. Article. IF: 7.561; Q1
- Doménech N, Sánchez-Corral P. Xenoantibodies and complement activity determinations by flow cytometry in pig-to-primate xenotransplantation. Methods Mol Biol. 2020; 2110: 73-81. Article. Not Indexed
- Dona D, Canizales JT, Benetti E, Cananzi M, De Corti F, Calore E, Hierro L, Boluda ER, Hijosa MM, Guereta LG, Martínez AP, Barrios M, Reis PC, Teixeira A, Lopes MF, Kalicinski P, Branchereau S, Boyer O, Debray D, Sciveres M, Wennberg L, Fischler B, Barany P, Baker A, Baumann U, Schwerk N, Nicastro E, Candusso M, Toporski J, Sokal E, Stephenne X, Lindemans C, Miglinas M, Rascon J, Jara P. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. Clin Transplant. 2020; 34(10): e14063. Article. IF: 2.863; Q2
- Germenis AE, Margaglione M, Pesquero JB, Farkas H, Cichon S, Csuka D, Lera AL, Rijavec M, Jolles S, Szilagyi A, Trascasa ML, Veronez CL, Drouet C, Zamanakou M. International consensus on the use of genetics in the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2020; 8(3): 901-11. Article. IF: 8.861; Q1
- Gokmen NM, Rodríguez-Alcalde C, Gulbahar O, López-Trascasa M, Onay H, López-Lera A. Novel homozygous variants in the SERPING1 gene in two Turkish families with hereditary angioedema of recessive inheritance. Immunol Cell Biol. 2020; 98(8): 693-9. Article. IF: 5.126; Q2
- López-Gálvez R, de la Morena-Barrio ME, López-Lera A, Pathak M, Minano A, Serrano M, Borgel D, Roldan V, Vicente V, Emsley J, Corral J. Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. Orphanet J Rare Dis. 2020; 15(1): 280. Article. IF: 4.123; Q2
- Martínez Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, Nozal P, Angeles Gonzalez M, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A. Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. Semin Arthritis Rheum. 2020; 50(1):E1-2. Letter. IF: 5.532; Q1
- Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Díez J, García-Ramirez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín- Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Sci Rep. 2020; 10(1): 17099. Article. IF: 4.379; Q1
- Medina PG, Román LE. Importance of assessing compliance with conservative treatment of primary hyperoxaluria type 1: A case report of a patient with I244T/c.969-3C>G Mutation. Perm J. 2020; 24(19): 136. Article. Not Indexed
- Melgosa M, Madrid A, Álvarez O, Lumbreras J, Nieto F, Parada E, Pérez-Beltran V. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. Pediatr Nephrol. 2020; 35(8): 1521-4. Article. IF: 3.714; Q1
- Ponard D, Gaboriaud C, Charignon D, Ghannam A, Wagenaar-Bos IGA, Roem D, López-Lera A, López-Trascasa M, Tosi M, Drouet C. SERPING1 mutation update: Mutation spectrum and C1

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Inhibitor phenotypes. Hum Mutat. 2020; 41(1): 38-57. Article. IF: 4.878; Q2

- Rodríguez-Martín E, Nieto-Ganan I, Hernández-Breijo B, Sobrino C, García-Hoz C, Bachiller J, Martínez-Feito A, Navarro-Compán V, Lapuente-Suanzes P, Bonilla G, Pascual-Salcedo D, Roy G, Jurado T, Nozal P, Vázquez-Díaz M, Balsa A, Villar LM, Plasencia-Rodríguez C. Blood lymphocyte subsets for early identification of non-remission to TNF inhibitors in rheumatoid arthritis. Front Immunol. 2020; 11: 1913. Article. IF: 7.561; Q1
- Urban JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martin CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutierrez RS, Santovena AZ, Hijosa MM, Camblor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frias J, Ramirez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? Transpl Infect Dis. 2020; 22(6): e13432. Article. IF: 2.228; Q4

Research projects

García-Giménez JL, Sánchez-Corral Gómez P. Validación de biomarcadores para el diagnóstico y el pronóstico de la sepsis neonatal (ACCI2018-09). ISCIII. 2019-2021.

Managment centre: CIBERER

López Lera A. Angioedema hereditario sin deficiencia de C1-Inhibidor: nuevas aproximaciones diagnósticas y pronósticas. Modelo para el estudio de FXII, una molécula pleiotrópica (ACCI2018-04). ISCIII. 2019-2021.

Managment centre: CIBERER

López Trascasa M. Complementest. Déficits y alteraciones del sistema del complemento en patología humana. Secugen S. L. 2011-Ongoing.

Managment centre: FIBHULP

Nozal Aranda P, Corvillo Rodríguez F. Detección y caracterización de autoanticuerpos en pacientes con lipodistrofia generalizada adquirida (síndrome de Lawrence). Asociación de Familiares y Afectados de Lipodistrofia (AELIP). 2019-2021.

Managment centre: CIBERER

Sánchez-Corral Gómez P. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-6873). CM. 2018-2020.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Contrato Miguel Servet Categoria A (CES07/030). CM. 2008-2025.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Contribución de variantes de las proteínas FHRS (factor H-Retaled) del complemeto en patología renal. Fundación SENEFRO. 2018-Ongoing.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. El sistema del complemento en salud y enfermedad (Complemento II-CM) (S2017/BMD-3673). CM. 2018-2021.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Nefropatías asociadas con desregulación del complemento: estudio de factores de riesgo y evolución mediante proteómica traslacional (PI16/00723). ISCIII. 2017-2020.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Perfiles cuantitativos de las proteínas FH/FHRS del complemento como biomarcadores de predisposición y pronóstico en el síndrome hemolítico-urémico primario y secundario (PI19/00970). ISCIII. 2020-2022.

Managment centre: FIBHULP

Cibers and Retics

Sánchez-Corral Gómez P. Networked Biomedical Research Center for Rare Diseases (CB06/07/1033). ISCIII. (31/12/2021)

Patents and trademarks

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.



Introduction


Executive summary

Information Groups by Area

Associated Clinicians

3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies Group

Publications:	10
Impact Factor:	43.042
Q1:	2



Eduardo López Granados. Coordinador de Inmunología. Hospital Universitario La Paz

Luz Yadira Bravo Gallego. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Bravo García-Morato. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Carmen Cámara Hijón. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Coronel Díaz. Técnico de Laboratorio. Hospital Universitario La Paz

Lucía del Pino Molina. Investigadora Postdoctoral. Hospital Universitario La Paz

Carla Cecilia Gianelli. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Diego Plaza López de Sabando. Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz

Ángel Julián Robles Marhuenda. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Rebeca Rodríguez Pena. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Carmen Salcedo Moreno. Técnico de Laboratorio. Hospital Universitario La Paz

Elena Sánchez Zapardiel. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Ana Sastre Urguelles. Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz

Juan Manuel Torres Canizales. Médico Inmunólogo. Hospital Universitario La Paz

Yolanda Soto Serrano. Investigadora Predoctoral. Hospital Universitario La Paz

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

Our group attempts to unravel the molecular bases of primary immunodeficiencies (PIDs), a large group of rare conditions (more that 400 types described so far) that virtually affect any cell type of the immune system and increase the risk of infections, autoimmunity and cancer in patients. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach.

By correlating clinical and experimental data, we aim to achieve a better understanding of these rare diseases and lay the grounds for, repurposed or new, more effective treatments.

Taking advantage of the knowledge and resources developed to dissect the immune system in PIDs, we are developing new schemes for immune monitoring of transplanted patients, to better estimate immunosupresion and tolerance, and early detection of severe complications as infections and rejection.

Finally, we explore novel approaches for monitoring, and fine tuning of immunotherapies.

Research lines

- To define the anatomical, cellular, molecular and (epi)genetic bases of immunological dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
- The maturation and functional specialization of human B lymphocytes, and its pathophysiology in primary and secondary antibody immunodeficiencies.
- The analysis of the immunological reconstitution after haemopoietic stem cell transplantation, and the discovery and clinical validation of immunological biomarkers for immunosuppression and tolerance in solid organ transplantation.
- The development and clinical implementation of patient-tailored monitoring schemes of immunotherapies in wide clinical use.

Research Activity

Publications

- Anderton J, Moroz V, Marec-Berard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Kaiser S, Fernández-Pinto M, Fenwick N, Evans A, Strauss S, Whelan J, Wheatley K, Brennan B. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Trials. 2020; 21(1): 96. Article. IF: 2.279; Q4
- Cordero E, Goycochea-Valdivia W, Méndez-Echevarría A, Allende LM, Alsina L, García-Morato MB, Gil-Herrera J, Gudiol C, Len-Abad O, López-Medrano F, Moreno-Pérez D, Muñoz P, Olbrich P, Sánchez-Ramon S, Soler-Palacín P, Cros CA, Arostegui JI, Serra IB, Carbone J, Fortún J, González-Granado LI, López-Granados E, Lucena JM, Parody R, Ramakers J, Regueiro JR, Riviere JG, Roca-Oporto C, Pena RR, Santos-Pérez JL, Rodríguez-Gallego C, Neth O. Executive summary of the consensus document on the diagnosis and management of patients with primary immunodeficiencies. J Allergy Clin Immunol-Pract. 2020; 8(10): 3342-7. Article. IF: 8.861; Q1
- Cordero E, Goycochea-Valdivia W, Méndez-Echevarría A, Allende LM, Alsina L, García-Morato MB, Gil-Herrera J, Gudiol C, Len-Abad O, López-Medrano F, Moreno-Pérez D, Muñoz P, Olbrich P, Sánchez-Ramón S, Soler-Palacin P, Cros CA, Arostegui JI, Serra IB, Carbone J, Fortun J, González-Granado LI, López-Granados E, Lucena JM, Parody R, Ramakers J, Regueiro JR, Riviere JG, Roca-Oporto C, Pena RR, Santos-Pérez JL, Rodriguez-Gallego C, Neth O. Executive summary of the consensus document on the diagnosis and management of patients with primary immunodeficiencies. Enferm Infec Microbiol Clin. 2020; 38(9): 438-43. Article. IF: 1.731; Q4
- García-Morato MB, Molina LD, Cañizales JMT, Rabes TD, Echevarría AM, Martínez BG, López-Granados E, Pena RR. A mutation in the promoter region of BTK causes atypical XLA. Heliyon. 2020; 6(9): e04914. Article. Not Indexed
- Jara P, Baker A, Baumann U, Borobia AM, Branchereu S, Candusso M, Carcas AJ, Chardot C, Cobas J, D'Antiga L, Ferreras C, Fitzpatrick E, Frauca E, Hernández-Oliveros F, Kalicinski P, Lindemans C, Lopes MF, López-Granados E, de Magnee C, Mota C, Muñoz JM, Ojeda JJ, Pérez-Martínez A, Perilongo G, Rascon J, Sciveres M, Stone R, Tarutis V, Toporski J, Torres JM, Wennberg L. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild. Orphanet J Rare Dis. 2020; 15(1): 16. Article. IF: 4.123; Q2
- Martínez-Fleta P, Alfranca A, González-Álvaro I, Casasnovas JM, Fernández-Soto D, Esteso G, Cáceres-Martell Y, Gardeta S, López-Sanz C, Prat S, Mateu-Albero T, Gabrie L, López-Granados E, Sánchez-Madrid F, Reyburn HT, Frade JMR, Vales-Gomez M. SARS-CoV-2 Cysteine-like protease antibodies can be detected in serum and saliva of COVID-19-seropositive individuals. J Immunol. 2020; 205(11): 3130-40. Article. IF: 5.422; Q2
- Pérez-Portilla A, Moraru M, Blázquez-Moreno A, Kolb P, García-Morato MB, Ranganath T, Esteso G, Gianelli C, Rodríguez-Pena R, Lozano-Rodriguez R, Torres-Canizales JM, Blish CA, Vales-Gómez M, Hengel H, Vilches C, López-Granados E, Reyburn HT. Identification of the first cases of complete CD16A deficiency: Association with persistent EBV infection. J Allergy Clin Immunol. 2020; 145(4): 1288-92. Article. IF: 10.793; D1
- Robles-Marhuenda A, Álvarez-Troncoso J, Rodríguez-Pena R, Busca-Arenzana C, López-Granados E, Arnalich-Fernández F. Chronic granulomatous disease: Single-center Spanish experience. Clin Immunol. 2020; 211(): 108323. Article. IF: 3.969; Q3
- Rodríguez-Martín C, Robledo C, Gómez-Mariano

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

G, Monzón S, Sastre A, Abelairas J, Sábado C, Martín-Begue N, Ferreres JC, Fernández-Teijeiro A, González-Campora R, Rios-Moreno MJ, Zaballos A, Cuesta I, Martínez-Delgado B, Posada M, Alonso J. Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotype-phenotype relationships. J Hum Genet. 2020; 65(2): 165-74. Article. IF: 3.172; Q3

- Saborido CM, Borobia AM, Cobas J, D'Antiga L, Frauca E, Hernández-Oliveros F, Jara P, López-Granados E, Muñoz JM, Nicastro E, Ojeda JJ, Pérez-Martínez A, Torres JM, Carcas A. Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis. BMJ Open. 2020; 10(12): e037721. Review. IF: 2.692; Q2

Research projects

López Granados E. Contrato predoctoral (PEJD2019_PRE/BMD_15188). CM. 2020-2021.

Managment centre: FIBHULP

López Granados E. Desregulación de la expresión génica del linfocito B en la inmunodeficiencia común variable: papel de la epigénetica y los microRNAs (PI16/01605). ISCIII. 2017-2020.

Managment centre: FIBHULP

López Granados E. European Rare Disease Coordination and support action (ERICA). UE. 2020-2024.

Managment centre: FIBHULP

Sánchez Zapardiel E. Validación de nuevas técnicas de estimación de la inmunosupresión y detección del rechazo en trasplante hepático pediátrico (PI19/01311). ISCIII. 2020-2022.

Managment centre: FIBHULP

Cibers and Retics

López Granados E. Centro de Investigación Biomédica en Red de Enfermedades Raras - CIBERer (CB19/07/00042). ISCIII. (31/12/2021)

Clinical trials

Robles Marhuenda, ÁJ. Estudio piloto multicéntrico, aleatorizado, abierto y con grupos paralelos para evaluar la seguridad y eficacia de la inmunoglobulina intravenosa (IGIV) a altas dosis junto con tratamiento médico estándar (TME) en comparación con el TME solo en sujetos hospitalizados con covid-19.

Type: EECC, phase II.
HULP code: 5722.
Sponsored´s protocol code: GC2004.
Sponsored by: Grifols Worldwide Operations, Ltd.
Signed date: 06/11/2020

Sastre Urguelles, A. Ensayo clínico fase 1/2 de un brazo para evaluar la seguridad y la eficacia del mesilato de eribulina en combinación con irinotecán en niños con tumores sólidos refractarios o recurrentes.

Type: EECC, phase I.
HULP code: Appendix 2 5125.
Sponsored´s protocol code: E7389-G000-213.
Sponsored by: Eisai Europe Limited.
Signed date: 26/11/2020

Sastre Urguelles, A. Estudio en fase 2, multicéntrico, abierto y aleatorizado para comparar la eficacia y la seguridad de lenvatinib en combinación con ifosfamida y etopósido frente a ifosfamida y etopósido en niños, adolescentes y adultos jóvenes con osteosarcoma recidivante o resistente (OLIE).

Type: EECC, phase II.
HULP code: 5500.
Sponsored´s protocol code: E7080-G000-230.
Sponsored by: Eisai Europe Limited.
Signed date: 25/02/2020

Patents and trademarks

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

PEDIAMÉCUM

3.3.7 Drug Hypersensibility and Innate Immune Response Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	12
Impact Factor:	55.[385]
Q1:	4



Teresa Bellón Heredia. Investigadora Senior (Contrato Miguel Servet -I2). Jefa de laboratorio. Hospital Universitario La Paz

María del Rosario Cabañas Moreno. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Jessica González Ramos. Médico Interno Residente en Dermatología. Hospital Universitario La Paz

Celia Martínez Prieto. Técnico de Grado Superior. Hospital Universitario La Paz

Aranzazú Isabel Rodríguez Sanz. Investigadora Postdoctoral. Hospital Universitario La Paz

Gaston Roustan Gullón. Facultativo Especialista de Área en Dermatología. Profesor Asociado. Facultad de Medicina. Hospital Universitario Puerta de Hierro. Universidad Autónoma de Madrid

Beatriz Sanz Minguela. Técnico de Grado Superior. Hospital Universitario La Paz

Strategic Objective

Cutaneous adverse drug reactions are unpredictable and represent a plethora of skin diseases with various degrees of severity. The spectrum ranges from mild to potentially fatal multisystem maladies. Those of most concern are usually referred to as severe cutaneous adverse reactions (SCARs), and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug induced hypersensitivity syndrome or hypersensitivity síndrome (DIHS/HSS), Stevens-Johnson's syndrome (SJS), and toxic epidermal necrolysis (TEN). Among them, SJS and TEN are the most severe clinical entities and are nowadays considered as variants of the same disease characterized by keratinocyte necrosis and epidermal detachment with the formation of subepidermal bullae. From the immunopatohogenic point of view, SCARs are T-cell mediated type IV hypersensitivity reactions. However, T cells can orchestrate different types of immune responses and this functional heterogeneity has led to a further sub-classification into type IVa-IVd hypersensitivity that considers the distinct cytokine production pattern by T cell subpopulations, and emphasizes the participation of different effector cells causing inflammation and tissue damage. Current knowledge supports the active participation of cytotoxic lymphocytes in different clinical entities.

Our project aims to a better understanding of the immune mechanisms underlying the etiopathogenesis of these diseases. The study is performed in the framework of the consortium PIELenRed (Plataforma interdisciplinar para el estudio de reacciones cutáneas graves en red) integrated by researchers belonging to different hospitals in Madrid.

Reactivation of latent herpesvirus has been described during the development of some of the previously mentioned clinical entities. In order to improve our understanding of

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

the behaviour of the immune system during viral replication, collaboration has been established with the Kidney Transplant Unit (Nephrology Service, HULP). Kidney transplant recipients are being followed immediately before and after transplant in order to identify patients with active CMV replication.

General objectives for the next 5 years

The main objectives are:

I) Biobanking of samples of severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN) associated to the registry PIELenRed, and integrated in the international registry RegiSCAR.

II) To investigate in vitro test for drug causality assessement.

III) To explore the involvement of the innate immune response (in particular natural cytotoxic activity) during the development of SCARs.

IV) Identification of biomarkers of susceptibility.

V) To find biomarkers for disease and response to treatments.

VI) To explore the potential of microRNAs in SJS/TEN as biomarkers of disease and of response to treatments, as well as their relationship with pathogenic mechanisms.

VII) To analyze the evolution of the cytotoxic response in patients with CMV replication.

VIII) Compare the innate immune response in patients with CMV replication after kidney transplant and in patients with SCARs.

Research lines

- Biobanking of biological samples from patients with severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN).
- Development and evaluation of in vtro tests for drug causality assessment.
- Identification of biomarkers of susceptibility.
- Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome /Toxic epidermal necrolysis (SJS/TEN).
- Differential analysis of the cytokine pattern involved in different SCARs (AGEP, DRESS and SJS/TEN).
- Analysis of miRNAs as biomarkers of disease and response to treatments.
- Identification of biomarkers of response to immunomodulatory treatments



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research Activity

Publications

- Balas A, Ramírez E, Trigo E, Cabañas R, Fiandor A, Arsuaga M, Lerma V, Sanz B, LuisVicario J, Herranz P, de Abajo F, Bellón T. HLA-A*68, -A*11:01, and -A*29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS. J Allergy Clin Immunol-Pract. 2020;8(9):3198-200. Letter. IF: 8.861; Q1
- Bellón T, Kardaun SH. CXCL10/IP-10, an early biomarker for late sequelae in DRESS?. Br J Dermatol. 2020; 183(5): 804-5. Editorial Material. IF: 9.302; D1
- Bellón T, Rodríguez-Martin S, Cabañas R, Ramírez E, Lerma V, González-Herrada C, González O, Sendagorta E, Fiandor A, de Abajo FJ. Assessment of drug causality in SJS/TEN: Concordance between lymphocyte transformation test and ALDEN. Allergy. 2020; 75(4): 956-9. Article. IF: 13.146; D1
- Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Dona I, Fernández J, García-Núñez I, García-Samaniego J, López-Rico R, Marín-Serrano E, Merida C, Moya M, Ortega-Rodríguez NR, Becerra BR, Rojas-Pérez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellón T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS Syndrome. J Invest Allergol Clin Immunol. 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Chang WC, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes JH, Hope EA, Hung SI, Hsieh CL, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou SY, Ueta M, Volpi S, Wan C, Wang H, Wang ZQ, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung WH, Phillips EJ, Carleton BC. SJS/TEN 2019: From science to translation. J Dermatol Sci. 2020; 98(1): 2-12. Review. IF: 4.563; Q1
- González-Ramos J, Lamas C, Bellón T, Ruiz-Bravo E, Ramírez E, Lerma V, Lecumberri B. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. Indian J Dermatol Venereol Leprol. 2020; 86(5): 515-8. Article. IF: 2.545; Q3
- Lazzarato I, González-MuÑoz M, Heredia R, Castellar FR, de la Guía AL, Cabañas R, Fiandor A, Domínguez-Ortega J. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. Eur Ann Allergy Clin Immunol. 2020; 52(5): 235-7. Letter. Not Indexed
- Loli-Ausejo D, Hernández-Martin I, Cabañas R, Entrala A, Gutiérrez-Alvarino M, Martínez-Sánchez N, Caballero T. Tranexamic acid plus bemiparin sodium as long-term prophylaxis in a patient With FXII-HAE during pregnancy: A case report. J Invest Allergol Clin Immunol. 2020; 30(6): 464-5. Editorial Material. IF: 4.333; Q2
- López-Oliva MO, Martínez V, Rodríguez-Sanz A, Álvarez L, Santana MJ, Selgas R, Jiménez C, Bellón T. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection. Clin Immunol. 2020; 211: 108329. Article. IF: 3.969; Q3
- Sánchez-González MJ, Barbarroja-Escudero J, Antolín-Amerigo D, Rodríguez-Rodríguez M, Fernández LP, Medina I, Bellón-Heredia T, Álvarez-Mon M. Erythema multiforme induced by tramadol: An allergy assessment. J Invest Allergol Clin Immunol. 2020; 30(4): 290-1. Editorial Material. IF: 4.333; Q2
- Turrión-Merino L, Alfageme-Roldán F, Salguero-Fernández I, Martínez-Mera C, Roustan-Gullon G. Pseudoflow in adnexal skin tumors. Actas Dermo-Sifilogr. 2020; 111(7): 621-2. Letter. Not Indexed
- Vian CD, Fernández IS, Roldan FA, Gullón GR. Subcutaneous neck lesion after chiropractic manipulation: The role of ultrasound skin imaging. Actas Dermo-Sifilogr. 2020; 111(2): 183-5. Letter. Not Indexed

Research projects

Bellón Heredia T. Contrato Miguel Servet Categoria B (CES06/016). ISCIII. 2007-2025.
Managment centre: FIBHULP

Bellón Heredia T. Convocatoria de retorno de overhead 2019 (Overhead_2019 TBH). FIBHULP. 2020-2022.
Managment centre: FIBHULP

Bellón Heredia T. Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodiálisis basadas en polysulfona (PI-3009). Nipro Euope NV. 2017-Ongoing.
Managment centre: FIBHULP

Bellón Heredia T. Enfermedad por CMV después del transplante renal. Importancia de la monitorización inmunológica: respuesta específica T CD8 y expresi´n de CD94/NKG2C en relación con el rechazo (PI-930-Roche). Roche Farma S. A. 2010-Ongoing.
Managment centre: FIBHULP

Bellón Heredia T. Impacto de los inhibidores de calcineurina sobre linfocitos efectores citotóxicos en síndrome de Stevens-Johnson/ necrolisis epidérmica tóxica de análisis de il-15 como biomarcador (PI18/00718). ISCIII. 2019-2021.
Managment centre: FIBHULP

Sanz Minguela B. Contrato técnico de apoyo estabilizado (ECA07/008). ISCIII. 2008-2025.
Managment centre: FIBHULP

Patents and trademarks

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b] indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceuticalcomposition and its use in the manufacture of a medicament for treating chronic kidney disease and method for screening compounds. 2014 January 27.P201430081, PCT/ES2015/070039;

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.8 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group

Publications:	35
Impact Factor:	134.^{622}
Q1:	10



Cristina Calvo Rey. Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

María Rosa Albañil Ballesteros. Pediatra Titular. Centro de Salud de Cuzco. Atención Primaria

Sonia Alcolea Ruiz. Investigadora Predoctoral. Hospital Universitario La Paz

María Mercedes Bueno Campaña. Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorclón

María Cabrerizo Sanz. Investigador titular. Instituto de Salud Carlos III

Inmaculada Casas Flechas. Cientifico Titular de OPIs. Instituto de Salud Carlos III

Teresa del Rosal Rabes. Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

María Luz García García. Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa

Carlos Daniel Grasa Lozano. Contrato Rio Hortega. Hospital Universitario La Paz

Mónica González Esguevillas. Ayudante de Investigación. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Ana María Méndez Echevarría. Facultativo Especialista de Área en Pediatría General. Hospital Universitario La Paz

Mar Molinero Calamita. Colaboradora I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III

María de la Montaña Iglesias Caballero. Titulado Superior ATP. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Almudena Otero Sánchez. Ayudante de Investigación I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Juan Francisco Pozo Sánchez. Investigador Titular de OPIs. Unidad de Virus Respiratorios y Gripe. Instituto de Salud Carlos III

Clara Udaondo Gascón. Facultativo Especialista en Reumatologa Pediátrica. Hospital Universitario La Paz

Strategic Objective

Infectious diseases are the most frequent pathology in childhood. Our group is focused in the study of paediatric infections with special attention to those associated to viruses.

The acute respiratory infections (ARIs) of lower respiratory tract are the most frequent infectious diseases in humans and these suppose at least 4 million of deaths yearly in the world. A high proportion of these infections are related with viral aetiology and particularly in children. In our country, the viral ARIs are one of the most frequent causes of hospitalization in children less than 2 years old. Using the metagenomics and applying

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

an adapted method designed and developed for ARIs study, we will have achieve an increased knowledge of viral infections in hospitalized children of all ages, as well as in outpatients. Metagenomics could allow recognizing new viruses and also permits a deeper knowledge of traditional respiratory virus groups. Any new technological tool and its application to respiratory infection will mean an improvement in the diagnosis and monitoring of these types of infections and their immediate use is specified for resolving alerts in public health associated with respiratory viral infections is like the case of MERS-CoV, avian flu, or other influenza pandemics. The pandemic caused by SARS-CoV-2 and the COVID-19 disease in childhood has occupied a large part of the research of our group since its appearance. We are also interested in the study of the immunological response of the infants to the viral infections, and the mechanisms that allow develop recurrent wheezing, or asthma (the most frequent chronic disease in children).

Emerging viral infections have also an important role in the pathology in childhood. Recently picornaviruses, mainly human parechovirus and enterovirus are causing outbreaks and several neurological infections, morbidity and mortality. They were associated with a wide range of pathologies, from febrile syndrome to respiratory, neurological or systemic diseases. In newborns, these infections can be severe, even fatal. Surveillance of these polio-like diseases is a public health concern and it is one of our group objectives.

Finally, to study viral infections in high risk group of children (newborn, chronic lung diseases, immunodefiencies, oncologic patients, rheumatic deseases...) is also a priority in our group.

Research lines

- Respiratory viral infections in hospitalized children. Viral metagenomic methods applied to the severe infections of the lower respiratory tract. SARS-CoV-2 infections in children.
- Respiratory viral infections in children in Primary Care. Diagnosis and treatment of infectious diseases in Primary Care.
- Respiratory viral infections in high risk group of children (newborn, chronic lung diseases, immunodefiencies, oncologic patients...). Torquteno virus in immunocompromised children.
- Applying of new technologies as echography to value risk conditions in viral infections.
- Immune response of the children and interleukins profile in infants with respiratory viral infections and correlation with the development of recurrent wheezing in the first years of life. Role of microbiome.
- Detection and characterization of enterovirus (EV) and parechovirus (PeV) systemic and neurological infections in children.
- Neurological development in children with EV and PeV infections.
- Kawasaki disease
- Osteoarticular infections
- Infections in children with rheumatic diseases.

Research Activity

Publications

- de Villalta MGF, Mellado-Peña MJ, Delgado-Hierro A, Limia-Sánchez A, Climent-Alcala FJ, Escosa-García L, Rodríguez-Alonso A, Calvo C, Méndez-Echevarría A. Greater efforts are needed to ensure that children with complex medical conditions are properly vaccinated. Acta Paediatr. 2020; 109(2): 422-3. Editorial Material. IF: 2.299; Q2
- Pérez RP, González FA, Baquero-Artigao F, Canete MC, Bru JDI, Landaluce AF, Vera CG, Bandera FH, Canovas CP, Rico JCS. Diagnosis and treatment of acute tonsillopharyngitis. Consensus document update. An. Pediatr. 2020;93(3): 206.e1-8. Article. IF: 1.5; Q4
- Calvo C, Tagarro A, Otheo E, Epalza C. Epidemiological update on SARS-CoV-2 infection in Spain. Comments on the management of infection in pediatrics. An Pediatr. 2020;92(4):239-40. Letter. IF: 1,5; Q4
- Cuadros EN, Rey CC, Saavedra-Lozano J. Evaluation of the impact of the Spanish consensus document on the approach to osteoarticular infections in Spain through the Paediatrics Osteoarticular Infections Network (RIOPED). An Pediatr. 2020; 93(5): 289-96. Article. IF: 1.5; Q4
- Garrido CF, Criado MD, Arboleya CG, Rey CC. Is the vertical transmission of Chlamydia trachomatis a problem in Spain? An Pediatr. 2020; 92(2): 119. Letter. IF: 1.5; Q4
- Rodríguez EM, Lorenzino L, Baquero-Artigao F, Calvo C. Need for surgery in paediatric deep abscesses of the neck. An Pediatr. 2020; 92(6): 389-90. Letter. IF: 1.5; Q4
- Calvo C, López-Hortelano MG, Vicente JC, Martínez JLV. Recommendations on the clinical management of the COVID-19 infection by the new coronavirus SARS-CoV2. Spanish Paediatric Association working group. An Pediatr (Engl Ed). 2020; 92(4): 241.e1-11. Article. IF: 1.5; Q4
- Pérez RP, Campos LM, Ortega MJC. Recommendations on the diagnosis and treatment of urinary infection. Response by the authors. An Pediatr. 2020; 92(3): 184-6. Letter. IF: 1.5; Q4
- Alonso-Arroyo A, de Dios JG, Calvo C, Calduch-Losa A, Aleixandre-Benavent R. Scientific impact and bibliometric contextualisation of Paediatrics compared to other specialities. An Pediatr. 2020; 92(3): 172.e1-12. . Article. IF: 1.5; Q4
- de Ceano-Vivas M, Martín-Espín I, del Rosal T, Bueno-Barriocanal M, Plata-Gallardo M, Ruiz-Domínguez JA, López-López R, Molina-Gutiérrez MA, Bote-Gascon P, González-Bertolín I, García-Sánchez P, Martín-Sánchez J, de Miguel-Lavisier B, Sainz T, Baquero-Artigao F, Méndez-Echevarría A, Calvo C. SARS-CoV-2 infection in ambulatory and hospitalised Spanish children. Arch Dis Child. 2020; 105(8):808-9. Letter. IF: 3.791; Q1
- Andrés-Martín A, Montaner AE, Mulet JF, García MLG, Murua JK, Moreno-Pérez D, De Liria CRG, Galdo AM. Consensus document on community-acquired pneumonia in children. SENP-SEPAR-SEIP. Arch Bronconeumol. 2020; 56(11): 725-41. Article. IF: 4.872; Q2

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Sánchez García L, Calvo C, Casas I, Pozo F, Pellicer A. Viral respiratory infections in very low birthweight infants at neonatal intensive care unit: prospective observational study. BMJ Paediatr Open. 2020; 4(1): e000661. Article. Not Indexed
- Rodríguez-Molino P, de la Calle M, del Rosal T, Baquero-Artigao F. Gestational and congenital tuberculosis: An ongoing problem. Enferm Infec Microbiol Clin. 2020; 38(10): 505-6. Letter. IF: 1.731; Q4
- Serrano CO, Alonso E, Andrés M, Buitrago NM, Vigara AP, Pajares MP, López EC, Moll GG, Espín IM, Barriocanal MB, la Calle MDV, Rey CC, Bretzurita M. Pediatric chest x-ray in covid-19 infection. Eur J Radiol. 2020; 131: 109236. Article. IF: 3.528; Q2
- Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, Bella A, Sognamiglios P, Moros MJS, Riutort AN, Demina YV, Mahieu R, Broas M, Bengner M, Buda S, Schilling J, Filleul L, Lepoutre A, Saura C, Mailles A, Levy-Bruhl D, Coignard B, Bernard-Stoecklin S, Behillil S, van der Werf S, Valette M, Lina B, Riccardo F, Nicastri E, Casas I, Larrauri A, Castell MS, Pozo F, Maksyutov RA, Martín C, Van Ranst M, Bossuyt N, Siira L, Sane J, Tegmark-Wisell K, Palmerus M, Broberg EK, Beaute J, Jorgensen P, Bundle N, Pereyaslov D, Adlhoch C, Pukkila J, Pebody R, Olsen S, Ciancio BC. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Eurosurveillance. 2020; 25(9): 2-7. Article. IF: 6.307; D1
- Redondo-Bravo L, Moros MJS, Sánchez EVM, Lorusso N, Ubago AC, García VG, Villanueva PS, Azón AP, Bescos JG, Boone ALD, Ibáñez AF, Fernández BA, Riutort AN, Castell MS, Duran JG, Gallo DN, Moreno MLR, de la Fuente AB, Raymundo LJV, Perena MH, Mena MC, Aparicio SH, Fernández MSI, Arribas SF, Rodríguez MDM, Martínez-Pino I, Jan M, Martínez A, Ciruela P, Bongiorno KV, Yague AM, Panades JP, Torvisco MDLT, Romero CG, Olivas BC, García SD, Deorador EC, Montalbán EG, Arrojo MD, García LA, Cortés AB, García-Fulgueiras A, Chirlaque MD, Barranco MI, Casado I, Castilla J, García-Cenoz M, Carril FG, Olaneta AS, de la Fuente MJLC, Ochoa EM, Pérez ACI, Martínez AB, Pérez AIR, Marín VR, Vinuesa MM, Pérez DC, Anes AAG, Pozo F, Casas I, Penalver-Argueso B, Pampaka D, Dominguez JAO, García MS, Larrauri A. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Eurosurveillance. 2020; 25(50): 15-27. Article. IF: 6.307; D1
- del Rosal T, Caminoa MB, González-Guerrero A, Falces-Romero I, Romero-Gómez MP, Baquero-Artigao F, Sainz T, Méndez-Echevarría A, Escosa-García L, Aracil FJ, Calvo C. Outcome of severe bacterial pneumonia in the era of pneumococcal vaccination. Front Pediatr. 2020; 8: 576519. Article. IF: 3.418; Q1
- del Rosal T, Méndez-Echevarría A, García-Vera C, Escosa-García L, Agud M, Chaves F, Roman F, Gutiérrez-Fernández J, de Gopegui ER, Ruiz-Carrascoso G, Ruiz-Gallego MD, Bernet A, Quevedo SM, Fernández-Verdugo AM, Díez-Sebastián J, Calvo C. Staphylococcus aureus nasal colonization in Spanish children. The COSACO Nationwide Surveillance Study. Infect. Drug Resistance. 2020; 13: 4643-51. Article. IF: 4.003; Q2
- García-García ML, González-Carrasco E, Bracamonte T, Molinero M, Pozo F, Casas I, Calvo C. Impact of prematurity and severe viral bronchiolitis on asthma development at 6-9 Years. J Asthma Allergy. 2020; 13: 343-53. Article. IF: 4.258; Q2
- González-Serrano L, Muñoz-Algarra M, González-Sanz R, Portero-Azorín MF, Amaro MJ, Higueras P, Cabrerizo M. Viral gastroenteritis in hospitalized patients: Evaluation of immunochromatographic methods for rapid detection in stool samples. J Clin Virol. 2020; 128: 104420. Article. IF: 3.168; Q3
- Soler-García A, Gamell A, Santiago B, Monsonis M, Calvo C, Cobo E, Colino E, Espiau M, Guerrero-Laleona C, Lobato Z, Martín-Nalda A, Pérez-Gorricho B, Pérez-Porcuna TM, Piqueras AI, Rodríguez-Molino P, Ruiz M, Soriano-Arandes A, Valmanya T, Tebruegge M, Noguera-Julian A. Diagnostic accuracy of QuantiFERON-TB gold plus assays in children and adolescents with tuberculosis disease. J Pediatr. 2020; 223: 212-5. Editorial Material. IF: 4.406; D1
- Bubba L, Broberg EK, Jasir A, Simmonds P, Harvala H. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect Dis. 2020; 20(3): 350-61. Article. IF: 25.071; D1
- Leon KE, Schubert RD, Casas-Alba D, Hawes IA, Ramachandran PS, Ramesh A, Pak JE, Wu W, Cheung CK, Crawford ED, Khan LM, Launes C, Sample HA, Zorn KC, Cabrerizo M, Valero-Rello A, Langelier C, Muñoz-Almagro C, DeRisi JL, Wilson MR. Genomic and serologic characterization of enterovirus A71 brainstem encephalitis. Neurol Neuroimmunol Neuroinflammation. 2020; 7(3): e703. Article. IF: 8.485; D1
- Mesa MD, Loureiro B, Iglesia I, González SF, Olive EL, Algar OG, Solana MJ, Pérez MJC, Sainz T, Martínez L, Escuder-Vieco D, Parra-Llorca A, Sánchez-Campillo M, Martínez GR, Roig DG, Gruz MP, Andréu-Fernández V, Clotet J, Sailer S, Iglesias-Platas I, López-Herce J, Aras R, Pallas-Alonso C, de Pipaón MS, Vento M, Gormaz M, Daza EL, Calvo C, Cabañas F. The evolving microbiome from pregnancy to early infancy: A comprehensive review. Nutrients. 2020; 12(1): 133. Review. IF: 5.717; Q1
- Calvo C, Alcolea S, Casas I, Pozo F, Iglesias M, González-Esguevillas M, García-García ML. A 14-year prospective study of human coronavirus infections in hospitalized children comparison with other respiratory viruses. Pediatr Infect Dis J. 2020; 39(8): 653-7. Article. IF: 2.129; Q3
- Hernandez PV, Rivas YB, Sánchez EO, Cabrero AM, Mateo LR, Roig PS, Quintanar AI, Penas RDD, Escudero VS, García-García ML. Autoimmune hemolytic anemia in a pediatric patient with severe acute respiratory syndrome coronavirus 2 lifection. Pediatr Infect Dis J. 2020; 39(9): E288. Letter. IF: 2.129; Q3
- Barreiro NC, Santiago-García B, Casas I, Pozo F, Sebastián MS, Navarro M, Mata C, Garrido-Colino C, Catalán P, Hernández-Rupérez B, Huerta J, Rincón-López E, Beléndez C, García-Morin M, Cela E, Hernández-Sampelayo T, Saavedra-Lozano J. Detection of respiratory viruses in the clinical outcome of children with fever and neutropenia. Pediatr Infect Dis J. 2020; 39(6): 533-8. Article. IF: 2.129; Q3
- Quintana-Ortega C, Méndez-Echevarría A, del Rosal T, González-Muñoz M, Baquero-Artigao F. False-positive results of quantiferon-Tb-gold assay in children. Pediatr Infect Dis J. 2020; 39(7): 620-3. Article. IF: 2.129; Q3
- Alcobendas RM, Loza SM, Camba AR, Gascón CU, Rey CC. Sacroilitis in preschool children: A case series and review of the literature. Pediatr Infect Dis J. 2020; 39(9): E272-4. Review. IF: 2.129; Q3
- Escosa-García L, Aguilera-Alonso D, Calvo C, Mellado MJ, Baquero-Artigao F. Ten key points about COVID-19 in children: The shadows on the wall. Pediatr Pulmonol. 2020; 55(10): 2576-86. Review. IF: 3.039; Q2
- Sastre B, García-García ML, Calvo C, Casas I, Rodrigo-Muñoz JM, Canas JA, Mora I, del Pozo V. Immune recovery following bronchiolitis is linked to a drop in cytokine and LTC4 levels. Pediatr Res. 2020; 87(3): 581-7. Article. IF: 3.756; Q1
- Climent FJ, Calvo C, García-Guereta L, Rodríguez-Álvarez D, Buitrago NM, Pérez-Martínez A. Fatal outcome of COVID-19 disease in a 5-month infant with comorbidities. Rev Esp Cardiol. 2020; 73(8): 667-9. Letter. IF: 4.753; Q2
- Arroyas M, Calvo C, Rueda S, Esquivias M, González-Menchen C, González-Carrasco E, García-García ML. Asthma prevalence, lung and cardiovascular function in adolescents born preterm. Sci Rep. 2020; 10(1): 19616. Article. IF: 4.379; Q1
- Melidou A, Hungnes O, Pereyaslov D, Adlhoch C, Segaloff H, Robesyn E, Penttinen P, Olsen SJ. Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 68.1A5A genetic subclades in the WHO European Region, 2018-2019. Vaccine. 2020; 38(35): 5707-17. Article. IF: 3.641; Q3
- Vidana B, Martínez-Orellana P, Martorell JM, Baratelli M, Martínez J, Migura-García L, Córdoba L, Pérez M, Casas I, Pozo F, Fraile L, Majo N, Montoya M. Differential viral-host immune interactions associated with oseltamivir-resistant H275Y and wild-type H1N1 A(pdm09) influenza virus pathogenicity. Viruses-Basel. 2020; 12(8): 794. Article. IF: 5.048; Q2

Research projects

Albañil Ballesteros R. Manejo diagnóstico y terapéutico de la infección del tracto urinario (ITU) en atención primaria (AP) pediátrica. (Financiación Privada). A. Española de Pediatría de Atención Primaria. 2019-2021.

Managment centre: Fundación Pediatría y Salud

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Cabrerizo Sanz M. Investigación de las infecciones neurológicas graves en niños causadas por enterovirus emergentes en España: EV-A71 y EV-D68 (PI18CIII/00017). ISCIII-AESI. 2019-2021.

Managment centre: ISCIII/CNM Virología

Calvo Rey C, Alcamí A. Transmisión de SARAS.CoV2 por el aire: detección en hospitales y tecnologías innovadoras. (COV20/00144). ISCIII. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato de intensificación (INT19/00009). ISCIII. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12351). CM. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato predoctoral (PEJD-2018-PRE/BMD-9430). CM. 2019-2020.

Managment centre: FIBHULP

Calvo Rey C. Contrato Rio Hortega (CM19/00015). ISCIII. 2020-2022.

Managment centre: FIBHULP

Calvo Rey C. Infecciones en niños con artritis idiopática juvenil (Financiación Privada). Fundación SEIP. 2017-Ongoing.

Managment centre: FIBHULP

Calvo Rey C. Infecciones osteoarticulares en pediatría. Estudio prospectivo multicéntrico. Fundación de la Asociación Española de Pediatría. 2017-Ongoing.

Managment centre: FIBHULP

Calvo Rey C. Infecciones respiratorias virales en recién nacidos de muy bajo peso. Fundación Neumomadrid. 2017-Ongoing.

Managment centre: FIBHULP

Calvo Rey C. Infecciones virales respiratorias en recién nacidos de muy bajo peso, respuesta inmunológica e implantaciones pronósticas (PI18/00167). ISCIII. 2019-2021.

Managment centre: FIBHULP

Casas Flecha I. Los virus respiratorios en las IRAs de recién nacidos y pacientes pediátricos: asociación con la aparición de sibilancias recurrentes. (PI18CIII/00009). ISCIII. 2019-2021.

Managment centre: CNM Virología

del Rosal Rabés T. Aplicación de las técnicas moleculares al estudio etiológico de la neumonía atípica o indeterminada en niños hospitalizados. Asociación Española de Pediatria. 2019-Ongoing.

Managment centre: FIBHULP

del Rosal Rabés T. Infecciones por virus respiratorios y células NK en vías respiratorias en niños receptores de trasplante de progenitores hematopoyéticos. Estudio prospectivo. European Society of Pediatric Infectious Diseases. 2017-Ongoing.

Managment centre: FIBHULP

García García ML. Asociación de los distintos perfiles del viroma, la microbiota y la respuesta inmune con la gravedad de la bronquiolitis viral aguda y con el desarrollo de sibilancias recurrentes (HULP-3546). UAX. 2019-Ongoing.

Managment centre: Fundación UAX

Méndez Echevarría AM; Calvo Rey C. Colonización por s.aureus resistente a meticilina en niños sanos de la comunidad (estudio Cosaco): estudio multicéntrico nacional (PI18/00372). ISCIII. 2019-2021.

Managment centre: FIBHULP

Méndez Echevarría AM; Calvo Rey C. Explorando la epidemiología del Sars-Cov-2 en un entorno de alto riesgo para caracterizar la dinámica de transmisión entre los contactos del hogar, centrándose en el papel de los niños y las mascotas. Estudio Sanicov: un estudio de cohorte prospectivo. Merck Sharp and Dohme de España S. A. 2020-Ongoing.

Managment centre: FIBHULP

Méndez Echevarría AM; Calvo Rey C; Escosa García L. Colonización por Staphylococcus Aureus resistente a meticilina en niños sanos de la comunidad. Estudio Cosaco. Estudio multicéntrico de ambito nacional. Fundación de la Asociación Española de Pediatría. 2018-Ongoing.

Managment centre: FIBHULP

Udaondo Gascón, Clara. Banco de imagenes de capilaroscopias en población pediátrica (Financiación Privada). Sociedad Española de Reumatología Pediatrica. 2019-Ongoing.

Managment centre: FIBHULP

Clinical trials

Calvo Rey, C. Estudio abierto, de un solo brazo para evaluar la farmacocinética, seguridad y tolerabilidad, y para explorar los resultados clínicos del tratamiento con dosis única o múltiple de zanamivir IV en neonatos e infantes menores de 6 meses con infección por gripe confirmada complicada.

Type: EECC, phase II.
HULP code: 5641.
Sponsored´s protocol code: 200925.
Sponsoredby: Glaxosmithkline S.A.
Signed date: 23/10/2020

Calvo Rey, C. Estudio en fase IIB abierto para evaluar la seguridad, tolerabilidad e inmunogenicidad de Menabcwy en lactantes sanos de 2 y 6 meses.

Type: EECC, phase IIb.
HULP code: 5716.
Sponsored´s protocol code: C3511002.
Sponsoredby: Pfizer S.L.U.
Signed date: 27/08/2020

Calvo Rey, C. Estudio fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de rilematovir en lactantes y niños (≥28 días a ≤5 años de edad) y posteriormente en recién nacidos (<28 días de edad), hospitalizados con infección aguda respiratoria por virus sincitial respiratorio.

Type: EECC, phase III.
HULP code: 5679.
Sponsored´s protocol code: 53718678RSV3001 DAISY.
Sponsoredby: Janssen Cilag International N.V.
Signed date: 20/10/2020

Calvo Rey, C. Estudio aleatorizado, controlado y doble ciego con grupo paralelo, en múltiples países para investigar la equivalencia de crecimiento y evaluar la seguridad y la tolerancia de la fórmula infantil con prebióticos y posbióticos derivados del proceso de fermentación de lactofidus TM en bebés a término sanos.

Type: Estudios, phase No EPA.
HULP code: PI-3988 .
Sponsored´s protocol code: EBB-18FI23464.
Sponsoredby: Nutricia Research B.V.
Signed date: 07/08/2020

Mendez Echevarria, AM. Estudio de fase 2/3 abierto y de un solo brazo que evalúa la seguridad, tolerabilidad, farmacocinética y eficacia de remdesivir (GS-5734TM)en participantes con covid-19 de 0 a <18 años de edad.

Type: EECC, phase III.
HULP code: 5615.
Sponsored´s protocol code: GS-US-540-5823.
Sponsoredby: Gilead Sciences S.L.
Signed date: 16/09/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.9 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases Group

Publications:	32
Impact Factor:	114.027
Q1:	12



María José Mellado Peña. Jefe de Servicio. Hospital Universitario La Paz

Fernando Baquero Artigao. Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz. Profesor asociado. Univesidad Autónoma de Madrid

Jorge Bustamante Amador. Investigador Predoctoral. Hospital Universitario La Paz

Francisco José Climent Alcalá. Facultativo Especialista de Área de Pediatría. Unidad de Patología Compleja. Hospital Universitario La Paz. Colaborador docente. Universidad Autónoma de Madrid

Luis Escosa García. Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz

Jaime Delgado Pérez. Investigador Predoctoral. Hospital Universitario La Paz

Miguel García Boyano. Médico Adjunto de Atención Primaria. Servicio Madrileño de Salud - Centro de Salud Bustarviejo

Marta García Fernández de Villalta. Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz. Colaborador Clínico Docente. Universidad Autónoma de Madrid

María Milagros García López de Hortelano. Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

Roi Piñeiro Pérez. Jefe Asociado del Servicio de Pediatría. Hospital General de Villalba

Paula Rodríguez Molino. Médico Interno Residente en Pediatría. Hospital Universitario La Paz

Talía Sainz Costa. Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz. Profesor colaborador clinico docente UAM. Universidad Complutense de Madrid

Strategic Objective

1. Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches.
2. Epidemiology of Paediatric Tuberculosis is Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.
3. Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response.
4. Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management. Covid-19 in children
5. Immunization strategies in children: immune response in high risk patient's vaccine effectiveness and barriers.
6. Social Determinants of Health in Pediatrics
7. Infection and immunity: microbiome ate the corssroad of immunity and allergy

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

Vertically acquired HIV infection in children

- Immuno-pathogenesis: Immune-activation, inflammation and biomarkers
- Epidemiology, immuno-virological factors
- Comorbidities, long term follow-up, cardioascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction.
- Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies.
- HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control.
- Gut Microbiota and bacterial traslocation intestinal as modulating factors for inflammation and Immune-activation in HIV-infected children.
- Transition to adult care: barriers, strategies to maintain adherence to care.

Epidemiology of paediatric Tuberculosis (TB).

- Epidemiology of paediatric TB. paediatric cases as as a sentinel for burden of diseases.
- Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients
- Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.
- Molecular Epidemiology of paediatric TB: resistant strains.

Omics for the diagnostis of pediatric TB

- New fixed-dosed combinations. Off label drugs in children. Pharmacodinamic and pharmacokinetic.

Congenital infectious diseases

- Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.
- CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.

Epidemiology of imported and emergent diseases in children

- Paediatric International Outbreaks: Epidemiology and public health impact: Zika. Rabies. Dengue. Chikungunya. Haemorragic fevers, Mers-co.
- Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children. Tropical and parasitic infections in children.
- COVID-19 disease in children: epidemiology, diagnostic markers, treatment.

Immunization strategies in children, including high risk patients

- Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.
- Vaccine immunogenicity: barriers in paediatric populations.
- New challengies in vaccinology

Microbiome in pediatric infectious diseases

- Microbiome-related biomarkers in food allergy and intolerances
- Microbiome-related biomarkers in childhood TB and other respiratory infections

Social Determinants of Health in Pediatrics

The burden of chronic disease in childhood

Social Determinants of Health in Pediatrics

Research Activity

Publications

- Aguilera-Alonso D, Escosa-García L, Saavedra-Lozano J, Cercenado E, Baquero-Artigao F. Carbapenem-resistant gram-negative bacterial infections in children. Antimicrob Agents Chemother. 2020; 64(3): e02183-19. Review. IF: 5.191; Q1
- Alejos B, Suarez-García I, Rava M, Bautista-Hernández A, GutiÉrrez F, Dalmau D, Sagastagoitia I, Rivero A, Moreno S, Jarrin I. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. J Antimicrob Chemother. 2020; 75(10): 3004-14. Article. IF: 5.79; Q1
- Calvo C, López-Hortelano MG, Vicente JCD, Martínez JLV. Recommendations on the clinical management of the COVID-19 infection by the new coronavirus SARS-CoV2. Spanish Paediatric Association working group. An Pediatr. 2020; 92(4): 241.e1-11. Article. IF: 1.5; Q4
- Carrasco I, Sainz T, Frick MA, de Ory SJ, Fortuny C, Burgos J, Montero M, Gavilán C, Falcón MD, Couceiro JA, Bernardino JI, Bisbal O, Guerrero C, Aldamiz-Echevarría MT, Berenguer J, Navarro ML. Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV coinfected patients. J Viral Hepatitis. 2020; 27(9): 955-8. Article. IF: 3.728; Q2
- Climent FJ, Calvo C, García-Guereta L, Rodríguez-Álvarez D, Buitrago NM, Pérez-Martínez A. Fatal outcome of COVID-19 disease in a 5-month infant with comorbidities. Rev Esp Cardiol. 2020; 73(8): 667-9. Letter. IF: 4.753; Q2
- Cuadros EN, Rey CC, Saavedra-Lozano J. Evaluation of the impact of the Spanish consensus document on the approach to osteoarticular infections in Spain through the Paediatrics Osteoarticular Infections Network (RIOPED). An Pediatr. 2020; 93(5): 289-96. Article. IF: 1.5; Q4
- de Ceano-Vivas M, Martín-Espin I, del Rosal T, Bueno-Barriocanal M, Plata-Gallardo M, Ruiz-Domínguez JA, López-López R, Molina-Gutierrez MA, Bote-Gascón P, González-Bertolín I, García-Sanchez P, Martín-Sanchez J, de Miguel-Lavisier B, Sainz T, Baquero-Artigao F, Méndez-Echevarría A, Calvo C. SARS-CoV-2 infection in ambulatory and hospitalised Spanish children. Arch Dis Child. 2020; 105(8):808-9. Letter. IF: 3.791; Q1
- del Rosal T, Caminoa MB, González-Guerrero A, Falces-Romero I, Romero-Gómez MP, Baquero-Artigao F, Sainz T, Méndez-Echevarría A, Escosa-García L, Aracil FJ, Calvo C. Outcome of severe bacterial pneumonia in the era of pneumococcal vaccination. Front Pediatr. 2020; 8: 576519. Article. IF: 3.418; Q1
- del Rosal T, Méndez-Echaevarría A, García-Vera C, Escosa-García L, Agud M, Chaves F, Román F, Gutiérrez-Fernández J, de Gopegui ER, Ruiz-Carrascoso G, Ruiz-Gallego MD, Bernet A, Quevedo SM, Fernández-Verdugo AM, Díez-Sebastián J,

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Calvo C. Staphylococcus aureus nasal colonization in spanish Children. The COSACO nationwide surveillance study. Infect Drug Resistance. 2020; 13: 4643-51. Article. IF: 4.003; Q2

- Domínguez-Rodríguez S, Prieto L, McPhee CF, Illaan-Ramos M, Beceiro J, Escosa L, Muñoz E, Olabarrieta I, Regidor FJ, Roa MA, Beneítez MDV, Guillén S, Navarro-Gómez ML, Amador JTR. Perinatal HCV transmission rate in HIV/HCV coinfected women with access to ART in Madrid, Spain. PLoS One. 2020; 15(4): e0230109. Article. IF: 3.24; Q2
- Escosa-García L, Aguilera-Alonso D, Calvo C, Mellado MJ, Baquero-Artigao F. Ten key points about COVID-19 in children: The shadows on the wall. Pediatr Pulmonol. 2020; 55(10): 2576-86. Review. IF: 3.039; Q2
- Fernández-McPhee C, Sainz T, Mellado MJ, Noguera-Julián A, Otero C, Fortuny C, Soler-Palacín P, Falcon MD, Amador JTR, Gavilán C, González-Tome MI, Navarro ML. Effect of hepatitis C virus coinfection on the progression of vertically acquired human immunodeficiency virus infection during childhood and adolescence. J Pediatr Infect Dis Soc. 2020; 9(2): 232-5. Article. IF: 3.164; Q1
- García-Boyano M, Caballero-Caballero JM, Alguacil-Guillén M, Baquero-Artigao F. Acute encephalopathy with biphasic seizures and late reduced diffusion in a Spanish girl. Brain Dev. 2020; 42(3): 307-10. Article. IF: 1.961; Q3
- García-Boyano M, Caballero-Caballero JM, Fernández-Menéndez A, Baquero-Artigao F. Title of the manuscript: Chylothorax in a 4-year-old boy with trisomy 21. Pediatr Pulmonol. 2020; 55(9): 2187-88. Letter. IF: 3.039; Q2
- García-Clemente P, Menéndez-Suso JJ, Falces-Romero I, Escosa-García L, Schuffelmann C, Cendejas-Bueno E. Utility of FilmArray (R) ME panel for prompt Neisseria meningitidis detection in non-cerebrospinal fluid samples- A case report. J Infect. 2020; 80(1): 140-2. Letter. IF: 6.072; Q1
- García-Navarro C, de Ory SJ, Higueras CV, Zamora B, Prieto L, Ramos JT, Navarro ML, Escosa-García L, Jurado-Barba R, Falcon D, Moreno D, González-Tome MI. Significant differences between verbal and non-verbal intellectual scales on a perinatally HIV-infected cohort: from pediatrics to young adults. Heliyon. 2020; 6(4): e03600. Article. Not indexed
- García-Navarro C, Martín-Bejarano M, de Ory SJ, Zamora B, Ruiz-Saez B, Velo C, Cuellar-Flores I, López-Hortelano MG, Guillén-Martín S, Navarro-Gómez ML, Ramos JT, González-Tome MI. Neurocognitive and quality of life study in perinatally HIV-infected young people and their peers. NeuroCoRISpeS study. Enferm Infec Microbiol Clin. 2020; 38(9): 417-24. Article. IF: 1.731; Q4
- Herrera S, Fernández-Felix BM, Hunt PW, Deeks SG, Sainz T, Heath SL, Achenbach CJ, Rodríguez B, Mathews C, Christopoulos K, Mayer K, Napravnik S, Moreno S, Serrano-Villar S. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. J Antimicrob Chemother. 2020; 75(6): 1604-10. Article. IF: 5.79; Q1
- López-Medina EM, Sainz T, de Ory SJ, Mellado-Pena MJ, González-Tome MI, Gil EC, Cucurull TV, Neyra F, Frick MA, Martínez-Pérez J, Andres AGA, Alonso MB, Laleona CG, Hernández MM, Hernández PC, Amador JTR, Gómez MLN, Santiago-García B. Tuberculosis in a Spanish cohort of children living with HIV: the CHOTIS study (Childhood HIV & TB study). Int J Tuberc Lung Dis. 2020;24(3):303-9. Article. IF: 2.373; Q4
- Mesa MD, Loureiro B, Iglesia I, González SF, Olive EL, Algar OG, Solana MJ, Pérez MJC, Sainz T, Martínez L, Escuder-Vieco D, Parra-Llorca A, Sánchez-Campillo M, Martínez GR, Roig DG, Gruz MP, Andreu-Fernández V, Clotet J, Sailer S, Iglesias-Platas I, López-Herce J, Aras R, Pallas-Alonso C, de Pipaon MS, Vento M, Gormaz M, Daza EL, Calvo C, Cabanas F. The evolving microbiome from pregnancy to early infancy: A comprehensive review. Nutrients. 2020; 12(1): 133. Review. IF: 5.717; Q1
- Minagorre PJA, Pinto EV, Fernández JMR, Rodríguez-Fernández R, Ronco MV, Escosa-García L, Jorge JIM, García JJG. Changes from COVID-19. A perspective from internal pediatric medicine. An Pediatr. 2020; 93(5): 343. e1-8. Article. IF: 1.5; Q4
- Pérez RP, Campos LM, Ortega MJC. Recommendations on the diagnosis and treatment of urinary infection. Response by the authors. An Pediatr. 2020; 92(3): 184-6. Letter. IF: 1.5; Q4
- Pérez RP, González FA, Baquero-Artigao F, Canete MC, Bru JDI, Landaluce AF, Vera CG, Bandera FH, Canovas CP, Rico JCS. Diagnosis and treatment of acute tonsillopharyngitis. Consensus document update. An Pediatr. 2020; 93(3): 206.e1-8. Article. IF: 1.5; Q4
- Quintana-Ortega C, Méndez-Echaevarría A, del Rosal T, González-Muñoz M, Baquero-Artigao F. False-positive results of quantiferon-Tb-gold assay in children. Pediatr Infect Dis J. 2020; 39(7): 620-3. Article. IF: 2.129; Q3
- Rodríguez EM, Lorenzino L, Baquero-Artigao F, Calvo C. Need for surgery in paediatric deep abcesses of the neck. An Pediatr. 2020; 92(6): 389-90. Letter. IF: 1.5; Q4
- Rodríguez-Molino P, de la Calle M, del Rosal T, Baquero-Artigao F. Gestational and congenital tuberculosis: An ongoing problem. Enferm Infec Microbiol Clin. 2020; 38(10): 505-6. Letter. IF: 1.731; Q4
- Sainz T, Gosalbes MJ, Talavera A, Jimenez-Hernández N, Prieto L, Escosa L, Guillén S, Ramos JT, Muñoz-Fernández MA, Moya A, Navarro ML, Mellado MJ, Serrano-Villar S. Effect of a nutritional intervention on the intestinal microbiota of vertically HIV-infected children: The pediabiota study. Nutrients. 2020; 12(7): 2112. Article. IF: 5.717; Q1
- Salvador F, Calabuig E, López-Velez R, Pardo-Lledias J, Torrus D, Penaranda M, Rodríguez-Guardado A, López-Hortelano MG, Belhassen-García M. Heterogeneity in cystic echinococcosis management among spanish centers: Results from a national survey. Am J Trop Med Hyg. 2020; 103(1): 303-7. Article. IF: 2.345; Q2
- Saralegui C, Ponce-Alonso M, Pérez-Viso B, Alegre LM, Escribano E, Lázaro-Perona F, Lanza VF, de Pipaón MS, Rodríguez JM, Baquero F, del Campo R. Genomics of serratia marcescens isolates causing outbreaks in the same pediatric unit 47 years apart: Position in an updated phylogeny of the species. Front Microbiol. 2020; 11: 451. Article. IF: 5.64; Q1
- Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zarraga MA, Vivancos MJ, Moreno S. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV. 2020; 7(8): E565-73. Article. IF: 12.767; D1
- Soler-García A, Gamell A, Santiago B, Monsonis M, Calvo C, Cobo E, Colino E, Espiau M, Guerrero-Laleona C, Lobato Z, Martín-Nalda A, Pérez-Gorricho B, Pérez-Porcuna TM, Piqueras AI, Rodríguez-Molino P, Ruiz M, Soriano-Arandes A, Valmanya T, Tebruegge M, Noguera-Julián A. Diagnostic accuracy of quantiFERON-TB gold plus assays in children and adolescents with tuberculosis disease. J Pediatr. 2020; 223: 212-5. Editorial Material. IF: 4.406; D1
- Soriano-Arandes A, Frick MA, López-Hortelano MG, Sulleiro E, Rodo C, Sanchez-Seco MP, Cabrera-Lafuente M, Suy A, De la Calle M, Santos M, Antolín E, Vinuela MD, Espiau M, Salazar A, Guarch-Ibáñez B, Vázquez A, Navarro-Morón J, Ramos-Amador JT, Martín-Nalda A, Dueñas E, Blazquez-Gamero D, Reques-Cosme R, Olabarrieta I, Prieto L, De Ory F, Thorne C, Byrne T, Ades AE, Ruiz-Burga E, Giaquinto C, Mellado-Pena MJ, García-Alix A, Carreras E, Soler-Palacín P. Clinical outcomes of a zika virus mother-child pair cohort in Spain. Pathogens. 2020; 9(5): 352. Article. IF: 3.492; Q2

Research projects

Mellado Peña MJ. Efecto de una intervención nutricional inmunomoduladora sobre la microbiota, translocación bacteriana, inflamación/activación inmune y respuesta a vacunas en la infección por el VIH en niños. Estudio piloto Pediabiota. European Society of Pediatric Infectious Diseases. 2014-Ongoing.

Managment centre: FIBHULP

Mellado Peña MJ. INFRADEV - European Paediatric Translational Research Infrastructure (H2020-ID-EPTRI). UE. 2017-2020.

Managment centre: FIBHULP

Mellado Peña MJ. Respuesta a vacunas en niños y adolescentes infectados por el VIH

en tratamiento antirretroviral: el cociente CD4/CD8 como predictor de respuesta. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2017-Ongoing.

Managment centre: FIBHULP

Mellado Peña MJ. Valoración de riesgo cardiovascular en niños y adolescentes infectados por el VIH. Asociación para el Estudio de las Enfermedades Infecciosas. 2014-Ongoing.

Managment centre: FIBHULP

Sainz Costa T. Capacitacion de personal sanitario en VIH y ETS en adolescentes (GLD17/0135.). Gilead SA. 2017-ongoing.

Managment centre: SEIMC-Gesida

Sainz Costa T. Hígado graso no alcohólico y esteatohepatitis en niños y adolescentes infectados por el VIH (PI17/01283). ISCIII. 2018-2021.

Managment centre: FIBHULP

Sainz Costa T. Microbioma intestinal y respuesta inmune: implicación en la alergia a proteínas de la leche de vaca no IgE mediada (HULP: PI-3699). Asociacion española de pediatria. 2015-2022.

Managment centre: SEIMC-Gesida

Sainz Costa T. Red de investigación traslacional en infectología pediátrica (PEJ2018-003755-A). MINECO. 2019-2021.

Managment centre: FIBHULP

Sainz Costa T. Utilidad de la ecografía torácica en la indicación de ventilación no invasiva en la bronquiolitis aguda del lactante hospitalizado. Estudio de cohorte. European Society of Pediatric Infectious Diseases. 2017-Ongoing.

Managment centre: FIBHULP

Clinical trials

Climent Alcalá, FJ. Estudio abierto y comparativo con tratamiento activo, de la seguridad y la eficacia extrapolada en pacientes pediátricos que requieren anticoagulación para el tratamiento de un acontecimiento tromboembólico venoso.

Type: EECC, phase III.
HULP code: Appendix 2 4852.
Sponsored´s protocol code: v B0661037.
Sponsored by: Pfizer S.L.U.
Signed date: 13/11/2020

Climent Alcalá, FJ. Ensayo de fase III, abierto, aleatorizado, multicéntrico y controlado para evaluar la farmacocinética y farmacodinámica de edoxabán y comparar la eficacia y seguridad de edoxabán con un tratamiento estándar anticoagulante en sujetos pediátricos desde el nacimiento hasta antes de los 18 años con tromboembolismo venoso confirmado.

Type: EECC, phase III.
HULP code: Appendix 2 4855.
Sponsored´s protocol code: DU176b-D-U312.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 17/02/2020

Mellado Peña, MJ. Ensayo en fase III, aleatorizado, doble ciego para evaluar la seguridad de una vacuna conjugada antineumocócica 20-valente en lactantes sanos.

Type: EECC, phase III.
HULP code: 5557.
Sponsored´s protocol code: B7471013.
Sponsored by: Pfizer S.L.U.
Signed date: 27/08/2020

Mellado Peña, MJ. Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al virus respiratorio sincitial, administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la enfermedad vías respiratorias bajas asociada al VRS en sus hijos hasta los 6 meses de edad.

Type: EECC, phase III.
HULP code: 5728.
Sponsored´s protocol code: 212171 (RSV MAT-009).
Sponsored by: Glaxosmithkline S.A.
Signed date: 18/11/2020

Sainz Costa, Talía. Estudio de ampliación abierto con rilpivirina en combinación con una pauta de base que contiene otros antirretrovirales en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 que participaron en estudios pediátricos con rilpivirina.

Type: EECC, phase II.
HULP code: 5611.
Sponsored´s protocol code: TMC278I-FD3004.
Sponsored by: Janssen Sciences Ireland U.C.
Signed date: 29/09/2020

Patents and trademarks

Mellado MJ, Piñeiro R, authors; ASOCIACION ESPAÑOLA DE PEDIATRIA (AEPED), assignee. Brand name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.10 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group

Publications:	15
Impact Factor:	75.272
Q1:	6



Antonio Pérez Martínez. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

David Bueno Sánchez. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Berta González Martínez. Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz

Eva Couto Serrano. Asistente Ejecutiva. Hospital Universitario La Paz

Adela Escudero López. Investigadora Postdoctoral. Hospital Universitario La Paz

Cristina Ferreras Puente. Investigadora Postdoctoral. Hospital Universitario La Paz

Pilar Guerra García. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Alfonso Navarro Zapata. Investigador Predoctoral. Hospital Universitario La Paz

Pedro María Rubio Aparicio. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Beatriz Ruz Caracuel. Investigadora Bioinformática. Hospital Universitario La Paz

Carla Martín Cortázar. Investigadora Postdoctoral. FIBHULP

Sonsoles San Román Pacheco. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Nerea Matamala Zamarro. Investigadora Postdoctoral. FIBHULP

Strategic Objective

Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells transplantation.

Research lines

- Analysis of solid/hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level.
- Cell therapy with activated NK cells in childhood cancer.
- Hematopoietic progenitor transplantation as a platform for cell therapy.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.
- Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2DCAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
- Optimization of NK cell therapy using nanotechnology and antigenic chimeric receptors (CAR).
- Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy.
- Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.
- Cell therapy with memory T lymphocytes from COVID-19 convalescent donors as an innovative therapy for COVID-19.

Research Activity

Publications

- de la Fuente J, Gluckman E, Makani J, Telfer P, Faulkner L, Corbacioglu S. The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematol. 2020;7(12):902-911. Article. IF: 18,959; Q1
- Grunewald TGP, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, Di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, Morales-Molina A, Musa J, Ohmura S, Ory B, Pereira-Silva M, Perut F, Rodríguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-Jonkers YMH, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12(11):-e11131. Review. IF: 12,137; Q1.SI
- Dona D, Canizales JT, Benetti E, Cananzi M, De Corti F, Calore E, Hierro L, Boluda ER, Hijosa MM, Guereta LG, Martínez AP, Barrios M, Reis PC, Teixeira A, Lopes MF, Kalicinski P, Branchereau S, Boyer O, Debray D, Sciveres M, Wennberg L, Fischler B, Barany P, Baker A, Baumann U, Schwerk N, Nicastro E, Candusso M, Toporski J, Sokal E, Stephenne X, Lindemans C, Miglinas M, Rascon J, Jara P. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. Clin Transplant. 2020;34(10):-e14063. Article. IF: 2,863; Q2
- Urban JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gomez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernandez EG, Martin CJ, Oliva MOL, Garcia EG, Sánchez GL, Cornejo GC, Gutierrez RS, Santovena AZ, Hijosa MM, Camblor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frias J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand?. Transpl Infect Dis. 2020;22(6):-e13432. Article. IF: 2,228; Q4
- Climent FJ, Calvo C, Garcia-Guereta L, Rodríguez-Álvarez D, Buitrago NM, Pérez-Martínez A. Fatal outcome of COVID-19 disease in a 5-month infant with comorbidities. Rev Esp Cardiol. 2020;73(8):667-669. Letter. IF: 4,753; Q2
- Faura A, Rives S, Lassaletta A, Sebastián E, Madero L, Huerta J, Garcia-Morin M, Martínez AP, Sisinni L, Astigarraga I, Velasco P, Gros L, Moreno L, Carbone A, Rodríguez-Vigil C, Riesco S, Mendoza MD, Macias EG, Trabazo M, Torrent M, Badell I, Fuster JL, Dominguez-Pinilla N, Ribelles AJ, Pérez-Alonso V, Sanmartin MF, Baragano M, Gorostegui M, Pérez-Jaume S, Fernandez-Teijeiro A, La Madrid AM, Dapena JL. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020;67(9):-e28557. Letter. IF: 3,167; Q1
- Vela M, Stringa P, González-Navarro P, Machuca M, Pascual-Miguel B, Mestre C, Arreola NM, Papa-Gobbi R, Navarro-Zapata A, Pires-Lobo SC, Andres AM, Hernández-Oliveros F, Pérez-Martínez A. Donor's graftex vivoT-cell depletion with fludarabine reduces graft-versus-host disease signs and improves survival after intestinal transplantation - an experimental study. Transpl Int. 2020;33(10):1302-1311. Article. IF: 3,782; Q2
- Mirones I, Moreno L, Patino-Garcia A, Lizeaga G, Moraleda JM, Toribio ML, Pérez-Martínez A. Immunotherapy with CAR-T cells in paediatric haematology-oncology. An Pediatr. 2020;93(1):-. Article. IF: 1,5; Q4
- Vicent MG, Martínez AP, del Castillo MT, Molina B, Sisini L, Morón G, Diaz MA. COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH). Pediatr Blood Cancer. 2020;67(9):-e28514. Letter. IF: 3,167; Q1
- de Rojas T, Pérez-Martínez A, Cela E, Baragano M, Gálan V, Mata C, Pereto A, Madero L. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer. 2020;67(7):-e28397. Letter. IF: 3,167; Q10
- Sánchez MDC, Casanova LF, Pérez-Martínez A. Beyond CAR-T cells: Natural killer cells immunotherapy. Med Clin. 2020;154(4):134-141. Review. IF: 1,725; Q3
- Van Den Rym A, Taur P, Martínez-Barricarte R, Lorenzo L, Puel A, González-Navarro P, Pandrowala A, Gowri V, Safa A, Toledano V, Cubillos-Zapata C, López-Collazo E, Vela M, Pérez-Martínez A, Sánchez-Ramón S, Recio MJ, Casanova JL, Desai MM, de Diego RP. Human BCL10 Deficiency due to Homozygosity for a Rare Allele. J Clin Immunol. 2020;40(2):388-398. Article. IF: 8,317; Q1
- Jara P, Baker A, Baumann U, Borobia AM, Branchereu S, Candusso M, Carcas AJ, Chardot C, Cobas J, D'Antiga L, Ferreras C, Fitzpatrick E, Frauca E, Hernández-Oliveros F, Kalicinski P, Lindemans C, Lopes MF, López-Granados E, de Magnee C, Mota C, Munoz JM, Ojeda JJ, Pérez-Martínez A, Perilongo G, Rascon J, Sciveres M, Stone R, Tarutis V, Toporski J, Torres JM, Wennberg L. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild. Orphanet J Rare Dis. 2020;15(1):-16. Article. IF: 4,123; Q2
- Saborido CM, Borobia AM, Cobas J, D'Antiga L, Frauca E, Hernández-Oliveros F, Jara P, López-Granados E, Munoz JM, Nicastro E, Ojeda JJ, Pérez-Martínez A, Torres JM, Carcas A. Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis. BMJ Open. 2020;10(12):-e037721. Review. IF: 2,692; Q2
- Builes MM, Cuenca MV, Soler JLF, Astigarraga I, Martínez AP, Valero JMV, Tong HY, Quiroga JV, Casanova LF, López AE, Sisinni L, Blanquer M, Aguilar IM, Martínez BG, Borobia AM, Pérez-Martínez A. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infu-

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

sing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020;10(1):-e029642. Article. IF: 2,692; Q2

Research projects

Escudero Lópeza A. Identificación de biomarcadores genéticos que ayuden a predecir la evolución del trasplante de progenitores hematopoyéticos en edad pediátrica (PI17/01921). ISCIII. 2018-2021.

Managment centre: FIBHULP

Pérez Martínez A, de la Oliva Senovilla P. Implementación de una escala pediátrica de valoración de alerta temprana en pacientes pediátricos hospitalizados con patología hemato-oncológica y trasplante de progenitores hematopoyéticos como plan de mejora de la calidad y seguridad asistencial. Fundación Aladina. 2020-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. A phase I trial of memory t cells expressing an anti-NKG2D chimeric antigen receptor in children, adolescents and young adults with advanced sarcoma. Fundación Asociación Española Contra el Cáncer. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. A phase I/II dose-escalation multi center study to evaluate the safety of infusion of natural killer cells os memory T cells as adoptive therapy in complicated coronavirus preumonia (Release). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2020-2020.

Managment centre: FIBHULP

Pérez Martínez A. Contrato predoctoral (PE-JD-2018-PRE/BMD-9122). CM. 2019-2021.

Managment centre: FIBHULP

Pérez Martínez A. Diseño del receptor antigenico quimerico NKG2D (CAR-NKG2D) como terapia celular en los sarcomas infantiles. Ong Otromundoesposible. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Ensayo clínica fase I/II, multicéntrico abierto, de infusión de celulas NK activadas para el tratamiento de niños, adolescentes y adultos jóvenes con sarcomas. Fundación la Sonrisa de Alex. 2017-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Ensayo clínico fase II de infusión intratumoral/intraventricular de células CART-NKG2D o NKIL15 en niños, adolescentes y adultos jóvenes con tumores de alto grado recurrentes/refractarios del sistema nervioso central (CINK-CAR) (ICI19/00052). ISCIII. 2020-2023.

Managment centre: FIBHULP

Clinical trials

González Martínez, B. Estudio fase II, abierto, multicéntrico, de un brazo único, para determinar la seguridad y la eficacia de tisagenlecleucel en pacientes pediátricos diagnosticados de linfoma no Hodgkin de células B maduras en recaída/refractario (Bianca).

Type: EECC, phase II.
HULP code: Appendix 2 5138.
Sponsored´s protocol code: CCTL019C2202.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 07/09/2020

Pérez Martínez, A. Infusion de células natural killer aloreactivas o estimuladaas con IL-15 ex vivo tras trasplante haploidéntico de progenitores hematopoyéticos en pacientes pediátricos con neoplasias hematológicas.

Type: EECC, phase I.
HULP code: 5521.
Sponsored´s protocol code: PHINK-01/2019.
Sponsored by: FIBHULP.
Signed date: 28/09/2020

Pérez Martínez, A. A phase I/II dose-escalation multi center study to evaluate the safety of infusion of natural killer cells or memory t cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia.

Type: EECC, phase I.
HULP code: 5579.
Sponsored´s protocol code: RELEASE.
Sponsored by: Pérez Martínez, Antonio.
Signed date: 29/09/2020

Rubio Aparicio, PM. An international multicenter phase II randomised trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemotherapy a siopen study.

Type: EECC, phase II.
HULP code: 5096.
Sponsored´s protocol code: VERITAS.
Sponsored by: Instituto Investigacion Sanitaria Hospital La Fe.
Signed date: 12/02/2020

Rubio Aparicio, PM. Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.

Type: EECC, phase II.
HULP code: Appendix 1 4854.
Sponsored´s protocol code: GEIS-52.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 06/05/2020

Patents and trademarks

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

Antonio Pérez-Martínez; Bernat Soria; Cristina Ferreras. Memory T cells as Adoptive Cell Therapy for Viral Infections. Universidad Autónoma de Madrid (UAM), Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP), Universidad Miguel Hernández de Elche, Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica deAlicante (ISABIAL). EP20382850. Deposited on 25/09/2020.


Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.3.11 Immunomediate Gastrointestinal Diseases and other Digestive Pathologies Group*



María Dolores Martín Arranz. Jefa de Sección de Aparato Digestivo. Hospital Universitario La Paz. Profesora Asociada. Unidad Autónoma de Madrid

Eduardo Martin Arranz. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Laura García Ramírez. Investigadora Predoctoral. FIBHULP

Jesús Noci Belda. Enfermero. Hospital Universitario La Paz

Joaquín Poza Cordón. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

José Luis Rueda García. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

María Sánchez Azofra. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Cristina Julia Suárez Ferrer. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Tamara Verges Martínez-Meco. Investigadora Predoctoral. FIBHULP

Strategic Objective

Clinical research on cardiotoxicity in oncohematological treatments, bioethical aspects of the management of defibrillators at the end of lifeOur work focuses on diseases of the Digestive System with special dedication to Inflammatory Bowel Disease (IBD) and other immune-mediated diseases. The group is formed by gastroenterologists, biologists, pharmacists and nurses; all of them are part of a multidisciplinary working group.

In addition to promoting our own research projects in our area, we participate in numerous clinical trials of molecules in development.

Our objectives are to optimize existing treatments, promote measures to improve the quality of life and translational research in search of precision medicine, incorporating new technologies to the management of our patients.

Research lines

- Optimization of biological treatments by means of the use of levels
- Intestinal ultrasound
- Validation of virtual chromoendoscopy techniques in CRC screening.
- Drugs in pregnancy in the setting of IBD
- Hypercoagulability profiles detected by rotaconal thromboelastometry
- Identification of cellular profiles in Intestinal biopsies

* Group recently created, december 2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.4 Large System Pathologies Area

Francisco García Río

Documents:	451	IF:	2390.844
Originals:	310	IF:	1700.748
D1:	74	Q1:	174

3.4.1 Internal Medicine and Systemic Diseases Group
3.4.2 Organic Dysfunction and Failure in the Aggression Group
3.4.3 Respiratory Diseases Group
3.4.4 Regulation of Gene Expression and by Hypoxia Group
3.4.5 Nephrology Group
3.4.6 Neonatology Group
3.4.7 Aging and Fragility in the Elderly Group
3.4.8 Molecular Hepatology Group
3.4.9 Diagnosis and Treatment of Allergic Diseases Group
3.4.10 Gynecologic Oncology Group
3.4.11 Patient Blood Management Group
3.4.12 Urology Group
3.4.13 Health Care Nurses Research Group
3.4.14 Maternal and Fetal Medicine Group
3.4.15 Emergency and Critical Pathology Group
3.4.16 Hospital Pharmacy Group



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.4 Large System Pathologies Area



Strategic Objectives	Development forecast for the coming years	Actions
Includes 16 research groups that focus their interest on the study of pathogenic mechanisms and therapeutic options in some of the most prevalent diseases in our environment: respiratory, allergological, renal, digestive, gynaecological, and ophthalmological and paediatric, both in stable phase and at different levels of severity. In addition, we maintain interest in their involvement in the different phases of development, analyzing both the neonatal phase and old age.	Redefinition of the area with a more transversal character. Although this proposal requires a greater elaboration and consensus of all the groups in the area, the reformulation of the area is proposed as a new one focused, for example, on inflammation and hypoxia.	**Conduct seminars and coordination meetings among groups of different areas.**
	Incorporation of related groups from other areas (immunorheumatology, hepatology, among others) and consolidation of some emerging groups.	**Promote work and synergies with other research groups of the institute with a deeper trajectory.**
	To ensure that 50% of the publications are in the first quartile of each thematic area.	**Improve the annual number of publications in the first quartile.**
	To promote intramural collaborations between groups.	**Promote work and synergies with other research groups of the institute with a deeper trajectory.**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.1 Internal Medicine and Systemic Diseases Group

Publications:	9
Impact Factor:	43.^{072}
Q1:	3



Francisco Arnalich Fernández. Jefe Servicio de Medicina Interna. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

José Luis Cedillo Mireles. Investigador Predoctoral (contrato FPU). Universidad Autónoma de Madrid

Carmen Montiel López. Catedrática. Facultad de Medicina. Universidad Autónoma de Madrid

María del Carmen Fernández Capitán. Jefa de Sección de Medicina Interna. Hospital Universitario La Paz

Juan José Ríos Blanco. Subdirector Médico. Hospital Universitario La Paz

María Angustias Quesada Simón. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz. Profesora Honoraria. Universidad Autónoma de Madrid

Strategic Objective

In the setting of the systemic response frequently found in patients attended in Internal Medicine wards, our group has studied some regulatory mechanisms of the innate immune response in patients with sepsis and other inflammatory states such as acute coronary syndromes (ACS), cystic fibrosisand cancer.

The first line of our research is the link between the parasympathetic and innate immune systems, that is the molecular mechanisms by which acetylcholine can influence the immune system via the "cholinergic anti-inflammatory pathway".

This pathway is mediated by the vagus nerve whichreleases acetylcholine to interact with the α7 subunit of the nicotinic acetylcholine receptor (α7nAChR).

We firstly reported that the neuronal α7 nicotinic receptor subunit gene (CHRNA7) is partially duplicated in the human genome forming a hybrid gene (CHRFAM7A) with the novel FAM7A gene, and provided experimental data showing that dupα7 could modulate Symbol 7 receptor-mediated synaptic transmission and cholinergic anti-inflammatory response (J Biol Chem 2011). The Toll-like receptor (TLR) plays an important role in the induction of the hyperinflammatory response and tissue injury in sepsis. We found that the Symbol 7 gene expression level in septic patients' peripheral blood mononuclear cells (PBMC) is a clinically relevant marker to assess the magnitude of the patient's inflammatory state, disease severity, and clinical outcome (J Infect Dis 2015).

Another exciting line of our research is the involvement of the Symbol 7-nicotinic receptor and its endogenous modulator dupSymbol 7 in human smoking- related tumors, and particularly their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistence. This topic has attracted a grant from the Ministerio de Economia y Competitividad from 2014-2017. Besides, professor Jaime Renart who works in our team group, is doing new research on the molecular mechanisms of podoplanin, a type I transmembrane mucin widely known as a marker for lymphatic endothelial cells that has a critical role during development of the heart, lungs and lymphatic endothelial system. The expression of podoplanin is significantly enhanced during tissueremodelling processes and in several types of human cancer, including squamous cell carcinomas.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Molecular mechanisms involved in the innate immune response.
- Link between the parasympathetic and innate immune systems.

Collaborative research line:

- Adaptative imnune response in human immunodeficiency virus (HIV) infection.
- Multicentric group: RIETE group (Registro Español de Enfermedad Trombo-Embólica).
- Molecular mechanisms of podoplanin during tissuere modelling processes and in several types of human cancer.
- Mechanisms and clinical features of systemic autoimmne diseases.

Lines of study framed in basic research projects:

- Study of the pathophysiological role of nicotinica7 and dup-a7 receptors expressed in human macrophages, neurons and lung carcinoma cells.
- Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLRmediated inflammation in human macrophages.

Research Activity

Publications

- Arenzana CB, Marhuenda AR, Mozo AN, Abanades CS, Robles EM, Blanco JJR. Macitentan for the treatment of severe digital ulcers in a patient with mixed connective tissue disease: avoiding drug interactions. Clin Exp Rheumatol. 2020; 38(1): 171. Letter. IF: 4.473; Q2
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A Cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Casas-Rojo JM, Anton-Santos JM, Millan-Núñez-Cortes J, Lumbreras-Bermejo C, Ramos-Rincon JM, Roy-Vallejo E, Artero-Mora A, Arnalich-Fernández F, García-Brunen JM, Vargas-Núñez JA, Freire-Castro S, Manzano-Espinosa L, Perales-Fraile I, Crestelo-Viéitez A, Puchades-Gimeno F, Rodilla-Sala E, Solis-Marquínez MN, Bonet-Tur D, Fidalgo-Moreno MP, Fonseca-Aizpuru EM, Carrasco-Sánchez FJ, Rabadan-Pejenaute E, Rubio-Rivas M, Torres-Pena JD, Gómez-Huelgas R. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev Clin Esp. 2020; 220(8):480-94. Article. IF: 1.556; Q3
- de la Fuente M, Sánchez C, Vallejo C, Díaz-del Cerro E, Arnalich F, Hernanz A. Vitamin C and vitamin C plus E improve the immune function in the elderly. Exp Gerontol. 2020; 142: 111118. Article. IF: 4.032; Q2
- García-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, González-García J, Jiménez-Sousa A, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Resino S, Carrero A, Miralles P, López JC, Parras F, Padilla B, Aldámiz-Echevarría T, Tejerina F, Díez C, Pérez-Latorre L, Fanciulli C, Gutiérrez I, Ramírez M, Carretero S, Bellon JM, Bermejo J, Berenguer J, Hontañón V, Arribas JR, Montes ML, Bernardino I, Pascual JF, Zamora F, Pena JM, Arnalich F, Díaz M, González-García J, Domingo P, Guardiola JM, Van den Eynde E, Pérez M, Ribera E, Crespo M, Casado JL, Dronda F, Moreno A, Pérez-Elias MJ, Sanfrutos MA, Moreno S, Quereda C, Arranz A, Casas E, de Miguel J, Schroeder S, Sanz J, Santos I, Bustinduy MJ, Iribarren JA, Rodríguez-Arrondo F, Von-Wichmann MA, Vergas J, Téllez MJ, Vinuesa D, Muñoz L, Hernández-Quero J, Ferrer A, Galindo MJ, Ortiz L, Ortega E, Montero M, Blanes M, Cuellar S, Lacniz J, Salavert M, López-Aldeguer J, Pérez G, Gaspar G, Yllescas M, Crespo P, Aznar E, Esteban H. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. J Infect. 2020; 80(1): 99-110. Article. IF: 6.072; Q1
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Pano-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae. Gut Pathogens. 2020; 12(1): 15. Article. IF: 4.181; Q2
- Robles-Marhuenda A, Álvarez-Troncoso J, Rodríguez-Pena R, Busca-Arenzana C, López-Granados E, Arnalich-Fernández F. Chronic granulomatous disease: Single-center Spanish experience. Clin Immunol. 2020; 211: 108323. Article. IF: 3.969; Q3
- Rubio-Rivas M, Corbella X, Guillén-del-Castillo A, Vilella CT, Arguelles DC, Argibay A, Hitos JAV, Parra JAT, González-Echavarri C, Ortego-Centeno N, Martínez LT, Carballeira MR, Ballve AM, Salas XP, Fraile IP, Chamorro AJ, Vuelta ABM, Freire M, Muñoz MR, García AG, del Campo IPM, García MES, Bello DB, Espinosa G, Hernández FJG, Comet LS, Blanco JJR, Giménez RAFD, Trigo SS, Pla VF, Aznar CPS. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. Autoimmun Rev. 2020; 19(5): 102507. Review. IF: 9.754; D1
- Solans-Laque R, Rodríguez-Carballeira M, Ríos-Blanco JJ, Fraile G, Saez-Comet L, Martínez-Zapico A, Frutos B, Solanich X, Fonseca-Aizpuru E, Pasquau-Liano F, Zamora M, Oristrell J, Fanlo P, López-Dupla M, Abdilla M, García-Sánchez I, Sopena B, Castillo MJ, Perales I, Callejas JL. Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: A study of 550 patients from Spain (REVAS Registry). Arthritis Care Res. 2020; 72(7): 1001-10. Article. IF: 4.794; Q2

Research projects

Montiel López C, Arnalich Fernández F. Resistance to chemotherapy and EGFR-targeted therapy induced by tobacco use through nicotinic receptors in non-small cell lung cancer: in vitro, in vivo and patient studies (SAF2017-82689-R). Ministerio de Economía, Industria y Competitividad. 2018-2020.

Managment centre: UAM

Ríos Blanco JJ. Estudio de la relación entre la rigidez arterial y la función endotelial en pacientes con hipertensión de bata blanca. Menarini Diagnósticos S. A. 2009-Ongoing.

Managment centre: FIBHULP

Clinical trials

Arnalich Fernández, F. Ensayo clínico del uso de anakinra (Anti il-1) en el síndrome de tormenta de citoquinas secundario a covid-19.

Type: EECC, phase II.
HULP code: 5589.
Sponsored´s protocol code: ANA-COVID-GEAS.
Sponsored by: Fundación Miguel Servet-Instituto de Investigaciones Biomédicas.
Signed date: 01/05/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.2 Organic Dysfunction and Failure in the Aggression Group

Publications:	30
Impact Factor:	271.[264]
Q1:	11



Abelardo García de Lorenzo y Mateos. Jefe de Servicio de Medicina Intensiva. Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

Alejandro Agrifoglio Rotaeche. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Jose Manuel Añon Elizalde. Jefe de Sección en Medicina Intensiva. Hospital Universitario La Paz

Maria Antonia Arce Mendiburu. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

María José Asensio Martín. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Lucía Cachafeiro Fuciños. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Belén Civantos Martín. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

María Belén Estebánez Montiel. Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Trasplante. Hospital Universitario La Paz

Juan Carlos Figueira Iglesias. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Eva Mercedes Flores Cabeza. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Ricardo García Hernández. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Mónica Hernández Bernal. Médico Adjunto Especialista en Unidad de Cuidados Intensivos. Hospital Universitario La Paz

Eva Herrero de Lucas. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Jesús Javier Manzanares Gómez. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Eva Perales Ferrera. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Itziar Pozuelo Echegaray. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Montserrat Aránzazu Rodríguez Aguirregaviria. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario Infanta Leonor

Santos Manuel Sánchez Sánchez. Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz

Santiago Yus Teruel. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Strategic Objective

The global objective of the investigation team on DYSFUNCTION AND ORGAN FAILURE IN AGGRESSION is the optimization of the patient management in the really critical ill patients who can develop Organ Dysfunction or Organ Failure. Multiorgan Dysfuntion & Multiorgan Failure Syndrome (MOF-MOD Syndrome) are correlated with bad prognostic and high mortality rates

D-FMO Syndrome is correlated both with the disease severity and the therapeutic

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

efforts. The therapeutic management of the patient must be early and directed to specific objectives

Otherwise, the support measures must be directed to the specific situations (like sepsis, trauma ...) and to the Organs or Systems in Dysfunction or Failure (coagulation, haemodynamic, respiratory or renal ..) Finally, the detection or D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers ...) can bring a higher efficacy and better results

Finally, the detection or D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers ...) can bring a higher efficacy and better results

Research lines

- Biomarkers
- Resuscitation income
- Therapeutic support

Research Activity

Doctoral theses

Núñez Villaveira T. Considerations fore a full facial allotransplantation including the temporo-mandibular joints: a radiological and anatomical cadaveric study[dissertation]. Madrid: UAM: 2020(16/09/20).

Director: García de Loreanzo y Mateos A.

Publications

- Acuña-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña-Fernández C. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020; 69(3): e12683. Editorial Material. IF: 13.007; D1
- Agrifoglio A, Cachafeiro L, Figueira JC, Anon JM, de Lorenzo AG. Critically ill patients with COVID-19 and candidaemia: We must keep this in mind. J Mycol Med. 2020; 30(4): 101012. Letter. IF: 2.391; Q4
- Añón JM, Curto J, del Rosario Urbez M, Burnham PM, Testillano ML, de la Cerda G, Álvarez-Rojas E, García de Lorenzo A. Postintensive care syndrome and follow-up clinics: results after a two-year pilot. Minerva Anestesiol. 2020; 86(11): 1246-8. Letter. IF: 3.051; Q3
- Añon JM, Gutiérrez CE, Escuela MP, Arevalo C, García-de-Lorenzo A. Tracheostomy: what is known and what remains to be determined. Intens Care Med. 2020; 46(5): 1070-1. Letter. IF: 17.44; D1
- Balibrea JM, Badía JM, Pérez IR, Antona EM, Pena EA, Botella SG, Gallego MA, Pérez EM, Cortijo SM, Miguelanez IP, Díaz LP, Rodríguez JLR, Basany EE, Santos RS, Aledo VS, Barrachina RL, Morales-Conde S. Surgical Management of patients with COVID-19 infection. recommendations of the spanish association of surgeons. Cir Espan. 2020; 98(5): 251-9. Article. IF: 1.653; Q3
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buno A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Rios JJ, Hernan MA, Frias J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Cabeza EF, Sánchez-Sánchez M, Fuciños LC, de Lorenzo AG. Early acute kidney injury in severe burns. Burns. 2020; 46(6): 1472-3. Letter. IF: 2.744; Q3
- Culebras JM, de Lorenzo AG. Eduard Jaurrieta Mas (1948-2020) In memoriam. Nutr Hosp. 2020; 37(5): 1091-2. Article. IF: 1.057; Q4
- de Lucas EH, Manuel SS, Fucinos LC, Rotaeche AA, Mendez JRM, Cabeza EF, Estan PM, García-de-Lorenzo A. Lactate and lactate clearance in critically burned patients: usefulness and limitations as a resuscitation guide and as a prognostic factor. Burns. 2020; 46(8): 1839-47. Article. IF: 2.744; Q3
- del Castillo Pardo de Vera JL, Cebrián Carretero JL, Guiñales Díaz de Cevallos J, Garrido Ortega P, Noguera Tomás J, Manuel Muñoz Caro J, González Otero T, Morán Soto MJ, Malet Contreras A, Sánchez Gallego-Albertos C, Figueira Iglesias JC, Asensio Martín MJ, Añón Elizalde JM, Burgueño García M. Traqueotomías en pacientes críticos durante la pandemia por COVID-19. Estudio preliminar de nuestra experiencia en el Hospital Universitario La Paz de Madrid. Rev Esp Cir Oral Maxilofa. 2020; 42(2): 60-8. Article. Not Indexed
- Fuciños LC, Sánchez MS, Mateos AGDY. Mechanical ventilation in critically ill burn patient with inhalation injury: Can we avoid it? Med Intensiva. 2020; 44(1): 54-6. Editorial Material. IF: 2.491; Q3
- García-Martínez MA, González JCM, Mateos AGDLY, Teijeira S. Muscle weakness: Understanding the principles of myopathy and neuropathy in the critically ill patient and the management options. Clin Nutr. 2020; 39(5): 1331-44. Review. IF: 7.324; D1
- González-Castro A, de Lorenzo AG, Escudero-Acha P, Rodríguez-Borregán JC. Post-intensive care syndrome after SARS-CoV-2 pandemic. Med Intensiva. 2020; 44(8): 522-3. Letter. IF: 2.491; Q3
- González-Castro A, Escudero-Acha P, Penasco Y, Leizaola O, Sánchez VMD, de Lorenzo AG. Intensive care during the 2019-coronavirus epidemic. Med Intensiva. 2020; 44(6): 351-62. Article. IF: 2.491; Q3
- González-Fernández O, de Antonio IP, Rodríguez SOR, Cantador JR, Iglesias JCF, Hentschel JLLS. D-dimer and right ventricular abnormalities as prognostic factors in critically ill COVID-19 patients. Rev Esp Cardiol. 2020; 73(11): 966-8. Letter. IF: 4.753; Q2
- Guillen-Guio B, Lorenzo-Salazar JM, Ma SF, Hou PC, Hernández-Beeftink T, Corrales A, García-Laorden MI, Jou J, Espinosa E, Muriel A, Domínguez D, Lorente L, Martín MM, Rodríguez-Gallego C, Sole-Violán J, Ambros A, Carriedo D, Blanco J, Añón JM, Reilly JP, Jones TK, Ittner CAG, Feng R, Schoneweck F, Kiehntopf M, Noth I, Scholz M, Brunkhorst FM, Scherag A, Meyer NJ, Villar J, Flores C. Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study. Lancet Respir Med. 2020; 8(3): 258-66. Article. IF: 30.7; D1
- Kacmarek RM, Villar J, Parrilla D, Alba F, Solano R, Liu SQ, Montiel R, Rico-Feijoo J, Vidal A, Ferrando C, Murcia I, Corpas R, González-Higueras E, Sun Q, Pinedo CE, Pestana D, Martínez D, Aldecoa C, Añón JM, Soro M, González-Martín JM, Fernández C, Fernández RL. Neurally adjusted ventilatory assist in acute respiratory failure:

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

a randomized controlled trial. Intens Care Med. 2020; 46(12): 2327-37. Article. IF: 17.44; D1

- Lázaro-Perona F, Dandouh E, Román-Soto S, Jiménez-Rodríguez S, Rodríguez-Antolín C, de la Calle F, Agrifoglio A, Membrillo FJ, García-Rodríguez J, Mingorance J. Metagenomic detection of two vientoviruses in a human sputum sample. Viruses-Basel. 2020; 12(3): 327. Article. IF: 5.048; Q2
- Martíndale RG, Berlana D, Boullata JI, Cai W, Calder PC, Deshpande GH, Evans D, García-de-Lorenzo A, Goulet OJ, Li A, Mayer K, Mundi MS, Muscaritoli M, Pradelli L, Rosenthal M, Seo JM, Waitzberg DL, Klek S. Summary of proceedings and expert consensus statements from the international summit lipids in parenteral nutrition. JPEN-Parenter Enter. 2020; 44: S7-20. Review. IF: 4.016; Q2
- Martínez MAG, Zurbano IMD, Mateos AGDY. Recommendations for specialized nutritional-metabolic treatment of the critical patient: Metabolic response to stress. Metabolism and Nutrition Working Group of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC). Med Intensiva. 2020; 44: 15-8. Article. IF: 2.491; Q3
- Mayer K, Klek S, García-de-Lorenzo A, Rosenthal MD, Li A, Evans DC, Muscaritoli M, Martíndale RG. Lipid use in hospitalized adults requiring parenteral nutrition. JPEN-Parenter Enter. 2020; 44: S28-38. Review. IF: 4.016; Q2
- McGrath BA, Brenner MJ, Warrillow SJ, Pandián V, Arora A, Cameron TS, Añón JM, Martínez GH, Truog RD, Block SD, Lui GCY, McDonald C, Rassekh CH, Atkins J, Qiang L, Vergez S, Dulguerov P, Zenk J, Antonelli M, Pelosi P, Walsh BK, Ward E, Shang Y, Gasparini S, Donati A, Singer M, Openshaw PJM, Tolley N, Markel H, Feller-Kopman DJ. Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. Lancet Respir Med. 2020; 8(7): 717-25. Article. IF: 30.7; D1
- Núñez-Villaveiran T, Fahradyan V, Dalla Pozza E, Rezaei M, Drake RL, Jellema LM, García-de-Lorenzo A, Papay FA, Gharb BB, Rampazzo A. Full facial allotransplantation including the temporomandibular joints: A radiologic and anatomical cadaveric study. Plast Reconstr Surg. 2020; 146(3): 621-34. Article. IF: 4.73; Q1
- Núñez-Villaveiran T, González-Castro A, Nevado-Losada E, García-de-Lorenzo A, Garro P. All for one and one for all: Voluntary physicians in the intensive medicine units during the COVID-19 outbreak in Spain. Disaster Med Public Health Prep. 2020: 1-7. Article. IF: 1.385; Q4
- Pozuelo-Carrascosa DP, Herraiz-Adillo A, Álvarez-Bueno C, Añón JM, Martínez-Vizcaino V, Cavero-Redondo I. Subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis. Eur Respir Rev. 2020; 29(155): 190107. Review. IF: 8.839; Q1
- Rodríguez-Rubio M, Figueira JC, Acuñaa-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21(1): 699. Letter. IF: 2.279; Q4
- Sánchez-Sánchez M, Martínez JR, Civantos B, Millan P. Perioperative in intensive medicine of reconstructive surgery and burned patients. Med Intensiva. 2020; 44(2): 113-21. Article. IF: 2.491; Q3
- Sterne JAC, Murthy S, Díaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Juni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Moller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 a meta-analysis. JAMA-J Am Med Assoc. 2020; 324(13): 1330-41. Article. IF: 56.272; D1
- Villar J, Añón JM, Ferrando C, Aguilar G, Muñoz T, Ferreres J, Ambros A, Aldecoa C, Suárez-Sipmann F, Thorpe KE, Juni P, Slutsky AS. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. Trials. 2020; 21(1): 717. Article. IF: 2.279; Q4
- Villar J, Ferrando C, Martínez D, Ambros A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, Martín-Rodríguez C, Díaz-Domínguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernández RL, González-Martín JM. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8(3): 267-76. Article. IF: 30.7; D1

Clinical trials

Agrifoglio Rotaeche, Alexander. Estudio observacional de cohortes para caracterizar el uso actual de la nutrición parenteral y los resultados clínicos en pacientes adultos en estado crítico hospitalizados en unidades de cuidados intensivos en Europa.

Type: Study, phase EPA-SP.
HULP code: PI-3777 .
Sponsored´s protocol code: NScr-003-CNI.
Sponsored by: Fresenius Kabi Deutschland Gmbh.
Signed date: 06/02/2020

Figueira Iglesias, Juan Carlos. Ensayo clínico de fase II, unicéntrico, doble ciego, aleatorizado, controlado con placebo para explorar la eficacia y seguridad de melatonina i.v. en pacientes con covid-19 ingresados en UCI (Estudio Melcovid).

Type: Clinical Trial, phase II.
HULP code: 5609.
Sponsored´s protocol code: PHM-2020-001.
Sponsored by: Pharmamel S.L.
Signed date: 06/06/2020

Patents and trademarks

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.3 Respiratory Diseases Group

Publications:	24
Impact Factor:	130.[453]
Q1:	12



Francisco José García Río. Jefe de Sección de Neumología (Contrato de Intensificación). Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

Sergio Alcolea Batres. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Rodolfo Álvarez-Sala Walther. Jefe de Servicio de Neumología. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Juan José Cabanillas Martín. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carlos Javier Carpio Segura. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Raquel Casitas Mateo. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carolina Cubillos Zapata. Investigadora Postdoctoral. Contrtato Miguel Servet tipo I. Hospital Universitario La Paz

Elena Díaz García. Investigador Predoctoral. CIBERER

Raúl Galera Martínez. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Luis Gómez Carrera. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

María Antonia Gómez Mendieta. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Ana Jaureguizar Oriol. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Elisabet Martínez Cerón. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Concepción Prados Sánchez. Jefe de Sección de Neumología. Hospital Universitario La Paz

David Romero Ribate. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Ana Santiago Recuerda. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carlos Villasante Fernández-Montes. Jefe de Sección de Neumología. Hospital Universitario La Paz

Ester Zamarrón de Lucas. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Strategic Objective

Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome(SAHS).

We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mechanisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders.

In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS.

Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define the methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

Research lines

- Morbidity of sleep-disordered breathing
- Pathogenesis of airflow limitation
- Systematization of lung function testing

Research Activity

Doctoral theses

Galera Martínez R. Efecto de la hiperinsuflación dinámica sobre la respuesta cardiovascular al ejercicio en pacientes con enfermedad pulmonar obstructiva crónica[dissertation]. Madrid: UAM: 2020(16/12/2020).

Directors: García Río F, Álvarez-Sala R.

Polo Bibian B. Exacerbaciones de asma en el servicio de urgencias del Hospital Universitario La Paz[dissertation]. Madrid: UAM: 2020(07/02/2020).

Director: Alvarez-Sala R.

Publications

- Aguilar PM, de Lucas EZ, Walther RAS. Lung cysts in a patient with SARS-CoV-2. Med Clin. 2020; 155(7): 325. Editorial Material. IF: 1.725; Q3
- Alonso-Fernández A, Toledo-Pons N, García-Rio F. Obstructive sleep apnea and venous thromboembolism: Overview of an emerging relationship. Sleep Med Rev. 2020; 50: 101233. Review. IF: 11.609; D1
- Bastir M, García-Martínez D, Torres-Tamayo N, Palancar CA, Beyer B, Barash A, Villa C, Sanchís-Gimeno JA, Riesco-López A, Nalla S, Torres-Sánchez I, García-Río F, Been E, Gómez-Olivencia A, Haeusler M, Williams SA, Spoor F. Rib cage anatomy inHomo erectussuggests a recent evolutionary origin of modern human body shape. Nat Ecol Evol. 2020; 4(9): 1178-87. Article. IF: 15.46; D1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020 ;9(6): 1733. Article. IF: 4.241; Q1
- Cubillos-Zapata C, Almendros I, Díaz-García E, Toledano V, Casitas R, Galera R, López-Collazo E, Farre R, Gozal D, García-Río F. Differential effect of intermittent hypoxia and sleep fragmentation on PD-1/PD-L1 upregulation. Sleep. 2020; 43(5): zsz285. Article. IF: 5.849; Q1
- Cubillos-Zapata C, Angulo I, Almanza H, Borrego B, Zamora-Ceballos M, Castón JR, Mena I, Blanco E, Barcena J. Precise location of linear epitopes on the capsid surface of feline calicivirus recognized by neutralizing and non-neutralizing monoclonal antibodies. Vet Res. 2020; 51(1): 59. Article. IF: 3.683; D1
- Cubillos-Zapata C, Martínez-García MA, Díaz-García E, Jaureguízar A, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuno V, Cano-Pumarega I, Corral-Penafiel J, Arias E, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Farre R, López-Collazo E, Gozal D, García-Rio F. Obesity attenuates the effect of sleep apnea on active TGF-ss 1 levels and tumor aggressiveness in patients with melanoma. Sci Rep. 2020; 10(1): 15528. Article. IF: 4.379; Q1
- Cubillos-Zapata C, Martínez-García MA, Díaz-García E, Toledano V, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Cano-Pumarega I, Corral-Penafiel J, Arias E, Mediano O, Somoza-González M, Dalmáu-Arias J, Almendros I, Farre R, López-Collazo E, Gozal D, García-Río F. Proangiogenic factor midkine is increased in melanoma patients with sleep apnea and induces tumor cell proliferation. Faseb J. 2020; 34(12): 16179-90. Article. IF: 5.191; Q1
- Díaz-García E, Jaureguízar A, Casitas R, García-Tovar S, Sánchez-Sánchez B, Zamarrón E, López-Collazo E, García-Rio F, Cubillos-Zapata C. SMAD4 overexpression in patients with sleep apnoea may be associated with cardiometabolic comorbidities. J Clin Med. 2020; 9(8): 2378. Article. IF: 4.241; Q1
- García-Martínez D, Bastir M, Villa C, García-Río F, Torres-Sánchez I, Recheis W, Barash A, Khonsari RH, O'Higgins P, Meyer MR, Heuze Y. Late subadult ontogeny and adult aging of the human thorax reveals divergent growth trajectories between sexes. Sci Rep. 2020; 10(1): 10737. Article. IF: 4.379; Q1
- García-Quero C, Carreras J, Martínez-Cerón E, Casitas R, Galera R, Utrilla C, Torres I, García-Rio F. Small airway dysfunction impairs quality of life among smokers with no airflow limitation. Arch Bronconeumol. 2020; 56(1): 9-17. Article. IF: 4.872; Q2
- Horcajada JP, Salata RA, Álvarez-Sala R, Nitu FM, Lawrence L, Quintas M, Cheng CY, Cammarata S. A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2020; 7(1): ofz514. Article. IF: 3.835; Q3
- Ioachimescu OC, Stoller JK, García-Río F. Area under the expiratory flow-volume curve: predicted values by artificial neural networks. Sci Rep. 2020; 10(1): 16624. Article. IF: 4.379; Q1
- López-Padilla D, García-Rio F, Alonso-Arroyo A, Gallán MP, Maestu LP, Segrelles-Calvo G, de Granda-Orive JI. Altmetrics analysis of archivos de bronconeumología From 2014 to 2018. Arch Bronconeumol. 2020; 56(5): 298-305. Article. IF: 4.872; Q2
- Mediano O, Cano-Pumarega I, Sánchez-de-la-Torre M, Alonso-Álvarez ML, Troncoso MF, García-Rio F, Egea C. Upcoming scenarios for the comprehensive management of obstructive sleep apnea: An overview of the Spanish sleep network. Arch Bronconeumol. 2020; 56(1): 35-41. Article. IF: 4.872; Q2
- Prados C, Zamarrón E, Girón R. What Spanish consensus meant for the treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis in the initial lung infection? Med Clin. 2020; 154(6): 232-5. Article. IF: 1.725; Q3
- Puente-Maestu L, Ortega F, de Pedro JG, Rodríguez-Nieto MJ, Gómez-Seco J, Galdiz B, Ojanguren I, Muñoz X, Blanco I, Burgos F, Rodríguez-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Chiaradia DA, Gea J, García-Rio F. Prediction equations for maximal aerobic capacity on cycle ergometer for the Spanish adult population. Arch Bronconeumol. 2020; 57(7): 471-8. Article. IF: 4.872; Q2

- Rosas-Alonso R, Galera R, Sánchez-Pascual JJ, Casitas R, Burdiel M, Martínez-Cerón E, Vera O, Rodríguez-Antolín C, Pernía O, de Castro J, García-Río F, Ibáñez-de-Cáceres I. Hypermethylation of anti-oncogenic MicroRNA 7 is increased in emphysema patients. Arch Bronconeumol. 2020; 56(8): 506-13. Article. IF: 4.872; Q2
- Sánchez CP, Carro LM, de Lucas EZ, Walther RAS. Are inhalation devices important in antibiotic treatment? Arch Bronconeumol. 2020; 56(12): 771-2. Editorial Material. IF: 4.872; Q2
- Sanchís-Gimeno JA, Lois-Zlolniski S, González-Ruiz JM, Palancar CA, Torres-Tamayo N, García-Martínez D, Aparicio L, Pérez-Bermejo M, Blanco-Pérez E, Mata-Escolano F, Llido S, Torres-Sánchez I, García-Rio F, Bastir M. Association between ribs shape and pulmonary function in patients with Osteogenesis Imperfecta. J Adv Res. 2020; 21: 177-85. Article. IF: 10.479; Q1
- Toledo-Pons N, Alonso-Fernández A, de la Pena M, Pierola J, Barcelo A, Fernández-Capitan C, Lorenzo A, Núñez JAM, Carrera M, Soriano JB, Calvo N, Pinilla I, García-Rio F. Obstructive sleep apnea is associated with worse clinical-radiological risk scores of pulmonary embolism. J Sleep Res. 2020; 29(2): e12871. Article. IF: 3.981; Q2
- Van Den Rym A, Taur P, Martínez-Barricarte R, Lorenzo L, Puel A, González-Navarro P, Pandrowala A, Gowri V, Safa A, Toledano V, Cubillos-Zapata C, López-Collazo E, Vela M, Pérez-Martínez A, Sánchez-Ramón S, Recio MJ, Casanova JL, Desai MM, de Diego RP. Human BCL10 deficiency due to homozygosity for a rare allele. J Clin Immunol. 2020; 40(2): 388-98. Article. IF: 8.317; Q1
- Villamañán E, Herrero A, Álvarez-Sala R, Quirce S. Multidisciplinary severe asthma management: The role of hospital pharmacists in accredited specialized adult asthma units in Spain. J Invest Allergol Clin Immunol. 2020; 30(4): 305-6. Letter. IF: 4.333; Q2
- Zamarrón E, Romero D, Fernández-Lahera J, Villasante C, Pinilla I, Barranco P, Domínguez-Ortega J, Walther RAS. Should we consider paranasal and chest computed tomography in severe asthma patients? Respir Med. 2020; 169: 106013. Article. IF: 3.415; Q2

Research projects

Cubillos Zapata C. El papel del inflammasoma en el progreso de las comorbilidades en pacientes con apnea obstructiva del sueño (CP18/00028). ISCIII. 2019-2022.

Managment centre: FIBHULP

Cubillos Zapata C. Estudio de la respuesta inmune en casos anidados en una cohorte para evaluar el efecto de los antiretrovirales en la evolución de la infección por el coronavirus Sars-Cov-2 (COV20/00207). ISCIII. 2020-2021.

Managment centre: FIBHULP

Cubillos Zapata C. Identificación del riesgo de cáncer en pacientes con apnea obstructiva del sueño con la detección de inmunocheckpoints (PI19/01363). ISCIII. 2020-2022.

Managment centre: FIBHULP


García Río FJ. Análisis de la actividad del sistema inmune innato en pacientes con síndrome de apneas-hipopneas del sueño grave. Roche Farma S. A. 2014-Ongoing.

Managment centre: FIBHULP

García Río FJ. Contribución de las alteraciones de la percepción de la disnea al diagnóstico de asma ficticio en obesos. Astrazeneca Farmacéutica Spain S. A. 2009-Ongoing.

Managment centre: FIBHULP

García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstruc-



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

tiva del sueño (PI16/00201). ISCIII. 2017-2021.

Managment centre: FIBHULP

García Río FJ. Relación entre la actividad física cotidiana de pacientes con EPOC y la actividad de su sistema inmune innato y adaptativo. Identificación de biomarcadores pronósticos (PI19/01612). ISCIII. 2020-2022.

Managment centre: FIBHULP

Gómez Carrera L. Auditoría clínica sobre manejo de fibrosis pulmonar idiopática en el area sanitaria del Hospital La Paz. Boehringer Ingelheim España S. A. 2016-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

García Río F. CIBER de Enfermedades Respiratorias - CIBERes (CB15/00037). ISCIII. (31/12/2021)

Clinical trials

Alcolea Batres, S. Estudio en fase III, prospectivo, multicéntrico, doble ciego, con doble simulación, aleatorizado, controlado con fármaco activo, de grupos paralelos, de grupos secuenciales, adaptativo y basado en acontecimientos para comparar la eficacia, la seguridad y la tolerabilidad de macitentán 75 mg frente a macitentán 10 mg en pacientes con hipertensión arterial pulmonar, seguido de un periodo de tratamiento abierto con macitentán 75 mg.

Type: Clinical Trial, phase III.
HULP code: 5546.
Sponsored´s protocol code: AC-055-315 UNISUS.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 25/05/2020

Alvarez-Sala Walther, R. Estudio fundamental de 52 semanas de duración, aleatorizado, doble ciego, controlado con placebo en grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de dupilumab en pacientes con enfermedad pulmonar obstructiva crónica de moderada grave con inflamación tipo2.

Type: EECC, phase III.
HULP code: 5539.
Sponsored´s protocol code: EFC15805.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 15/05/2020

García Río, FJ. Ensayo clínico fase II aleatorizado para explorar la eficacia del uso de células mesenquimales alogénicas de tejido de cordón umbilical en pacientes con afectación pulmonar grave por covid-19.

Type: Clinical Trial, phase II.
HULP code: 5586.
Sponsored´s protocol code: MESCEL-COVID19.
Sponsored by: Fundación Investigación Biomédica del Hospital Niño Jesús.
Signed date: 29/04/2020

Prados Sánchez, C. Ensayo clínico con enmascaramiento doble, multicéntrico y controlado con placebo para investigar la eficacia y seguridad de 12 meses de terapia con Promixin® inhalado (colistimetato de sodio) para el tratamiento de pacientes con bronquiectasia no debida a fibrosis quística con infección crónica por pseudomonas aeruginosa.

Type: Clinical Trial, phase III.
HULP code: Appendix 1 4779.
Sponsored´s protocol code: Z7224L01.
Sponsored by: Zambon, S.A..
Signed date: 05/10/2020

Prados Sánchez, C. Estudio en fase III y abierto para evaluar la seguridad a largo plazo del tratamiento combinado VX-445 en sujetos con fibrosis quística.

Type: Clinical trial, phase III.
HULP code: 5383.
Sponsored´s protocol code: VX18-445-113.
Sponsored by: Vertex Pharmaceuticals Incorporated.
Signed date: 24/01/2020

Romero Ribate, D. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar el efecto de dupilumab en la inflamación de las vías respiratorias a través de evaluaciones de la función pulmonar, taponamiento mucoso y otros parámetros de imagen pulmonar en pacientes con asma.

Type: clinical Trial, phase IV.
HULP code: 5536.
Sponsored´s protocol code: LPS15834.
Sponsored by: Sanofi Aventis S.A.
Signed date: 03/07/2020

Romero Ribate, D. Estudio sobre la carga que supone para el sistema sanitario y los pacientes la tos crónica refractaria o inexplicada.

Type: Study, phase EPA-OD.
HULP code: PI-4393 .
Sponsored´s protocol code: BURDEN/ID VEAP: 8614.
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 06/11/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.4 Regulation of Gene Expression and by Hypoxia Group

Publications:	4
Impact Factor:	22.[314]
Q1:	3

Luis del Peso Ovalle. Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

Benilde Jiménez Cuenca. Profesor Titular. Departamento de Bioquímica Facultad de Medicina. Universidad Autónoma de Madrid



Strategic Objective

The elucidation of the cellular and molecular responses to changes in oxygen tension constitutes an exciting research topic given the dependence of virtually all human tissues on appropriate oxygen supply and the involvement of hypoxia in high-incidence pathologies such as cardiopulmonary diseases and cancer. The Hypoxia Inducible transcription Factor (HIF) plays a pivotal role in this response by controlling the expression of most of the genes involved in the adaptation to hypoxia. Our research group aims to provide novel insight into transcriptional response to hypoxia and to exploit this knowledge to improve clinical management of pathologies in which hipoxia is a common feature. To this end we are currently involved in the following.

Research lines

- Identification of network motifs within the gene regulatory network regulated by HIF and study of their role in the adaptation to hypoxia.
- Characterization of the effect of hypoxia/HIF on endothelial cell proliferation and integration of this response in the induction of angiogenesis.
- Analysis of the functional effect of polymorphisms affecting HIF binding and investigation of their correlation with the different phenotypes in chronic respiratory diseases and cancer

Research Activity

Publications

- Acosta-Iborra B, Tiana M, Maeso-Alonso L, Hernández-Sierra R, Herranz G, Santamaría A, Rey C, Luna R, Puente-Santamaría L, Marqués MM, Marín MC, del Peso L, Jiménez B. Hypoxia compensates cell cycle arrest with progenitor differentiation during angiogenesis. Faseb J. 2020; 34(5): 6654-74. Article. IF: 5.191; Q1
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrián L, Cantero R, del Peso L, Burgos A, Barbachano A, Muñoz A. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. Cancers. 2020; 12(8): 2302. Article. IF: 6.639; Q1
- Fernández-Barral A, Costales-Carrer A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrián L, Lafarga M, García-Olmo D, Cantero R, del Peso L, Batlle E, Rojo F, Muñoz A, Barbachan A. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. FEBS J. 2020; 287(1): 53-72. Article. IF: 5.542; Q1
- Tiana M, Acosta-Iborra B, Hernández R, Galiana C, Fernández-Moreno MA, Jiménez B, del Peso L. Metabolic labeling of RNA uncovers the contribution of transcription and decay rates on hypoxia-induced changes in RNA levels. RNA. 2020; 26(8): 1006-22. Article. IF: 4.942; Q2

Research projects

del Peso Ovalle L. Hipoxia y angiogenesis: mecanismos básicos en fisiología y enfermedad (SAF2017-88771-R). Ministerio de Ciencia, Innovación y Universidades. 2018-2020.

Managment centre: UAM

del Peso Ovalle L. Implementación de procedimientos para análisis de datos derivados de técnicas de secuenciación de alto rendimiento (IND2019/BMD-17134). CM. 2020-2022.

Managment centre: UAM

3.4.5 Nephrology Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	27
Impact Factor:	118.[56]
Q1:	13

María Auxiliadora Bajo Rubio. Jefe de Sección de Nefrología. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Olga Costero Fernández. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Gloria del Peso Gilsanz. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

María José Castro Notario. Enfermera. Hospital Universitario La Paz

María José Fernández Reyes. Facultativo Especialista de Área en Nefrología. Hospital de Segovia

Helena García LLana. Psicóloga Investigadora. Hospital Universitario La Paz

María Elena González García. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Guadalupe González Mateo. Investigadora Postdoctoral. Hospital Universitario La Paz

Carlos Jiménez Martín. Jefe de Sección de Nefrología. Hospital Universitario La Paz

María Ovidia López Oliva. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz


Teresa Olea Tejero. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Almudena Pérez Torres. Dietista-Nutricionista. Hospital Universitario Santa Cristina

Begoña Rivas Becerra. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Rafael Jesús Sánchez Villanueva. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Rafael Selgas Gutiérrez. Jefe de Servicio de Nefrología. Hospital Universitario La Paz



Strategic Objective

The strategic objective of this care-research group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for overall nephrology

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.

A) Incipient nephropathies and kidney disease progression:

- Glomerular and tubular nephropathies. New diagnostic markers and interventions.
- Organisational Research (computerisation, organisation of generational change in the department and network).
- Morbidity, mortality and progression of Diabetic Nephropathy and other glomerular nephropathies.
- Autosomal Dominant Polycystic Kidney Disease. Family Studies and treatment approaches with Tolvaptan.
- Association of cardiovascular disease with the progress of nephropathies (NEFRONA multicenter study, REDinREN).
- Incorporation of a psychologist into the department of nephrology: criteria and process. Issues on monitoring therapeutic adherence, inparticular among transplanted patients
- Occult Hepatits C virus in different kidney disease situations.

B) Complications of dialysis

- Establishment of normal peritoneal functional in humans. Implications for patient survival and long-term treatment. New dialysis fluids. Aquaporin 1 (AQP1) and its genetic polymorphisms: relationship with peritoneal transport of water. Multicentre European study.
- The alternatively activated macrophage in peritoneal effluent (AAM): its relationship with defence and peritoneal fibrosis. CCL18 as a chemokine of AAM and a mediator of peritoneal fibrosis.
- Peritoneal biopsy for the complete evaluation of the peritoneal membrane. A correspondence study with cell and components findings in peritoneal effluent during kidney transplantation is ongoing (Multicenter).
- Cardiovascular risk in patients with advanced kidney disease and on dialysis. Endocrine aspects. The abdominal adipocyte and adipocytokines. FABP antagonists as blockers of the adipocyte-macrophage response. Nonthyroidal diseases, influence on CKD patients. FGF 21 role in uremic insulin resistance.
- Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
- Allergic reactions to hemodialysis membranes: mechanisms and alternatives.

C) Complications of kidney transplantation:

- Toxicity due to immunosuppressants. Ultrasound contrast in the analysis of renal microvasculature in kidney transplantation and complications.
- The involvement of CMV in the renal graft response: anticipated diagnosis.

Research Activity

Doctoral theses

Olea Tejero T. Infección por el virus de la hepatitis C oculto en varias situaciones de enfermedad renal crónica[dissertation]. Madrid: UAM: 2020(13/01/2020).

Director: Selgas Gutierrez R.

Publications

- Alonso CS, da Silva AC, González MO, Gilsanz GD, Martín MM, González PR, Gutiérrez RS, Rubio MAB. Morgagni hernia in incremental peritoneal dialysis: Is it possible to continue with the technique? Nefrología. 2020; 40(6): 685-6. Letter. IF: 2.033; Q3
- Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Dona I, Fernández J, García-Núñez I, García-Samaniego J, López-Rico R, Marín-Serrano E, Mérida C, Moya M, Ortega-Rodríguez NR, Becerra BR, Rojas-Pérez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellón T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Invest Allerg Clin. 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juarez G, Rodríguez A, de Jose AP, Rabasco C, Rodado R, Fernández L, Gómez VP, Ávila AI, Bravo L, Lumbreras J, Allende N, de la Nieta MDS, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MA, Martín-Penagos L, Da Silva I, Titos JA, de Córdoba SR, de Jorge EG, Praga M. Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. Clin J Am Soc Nephro. 2020; 15(9): 1287-98. Article. IF: 8.237; D1
- Carriazo S, Ramos AM, Sanz AB, Sánchez-Niño MD, Kanbay M, Ortiz A. Chronodisruption: A poorly recognized Feature of CKD. Toxins. 2020; 12(3): 151. Review. IF: 4.546; Q1
- Cuarental L, Valino-Rivas L, Mendonca L, Saleem M, Mezzano S, Sanz AB, Ortiz A, Sánchez-Nino MD. Tacrolimus prevents TWEAK-induced PLA2R expression in cultured human podocytes. J Clin Med. 2020; 9(7): 2178. Article. IF: 4.241; Q1
- Díaz R, Sandoval P, Rodrigues-Díez RR, del Peso G, Jiménez-Heffernan JA, Ramos-Ruiz R, Llorens C, Laham G, Álvarez-Quiroga M, López-Cabrera M, Ruiz-Ortega M, Bajo MA, Selgas R. Increased miR-7641 levels in peritoneal hyalinizing vasculopathy in long-term peritoneal dialysis patients. Int J Mol Sci. 2020; 21(16): 5824. Article. IF: 5.923; Q1
- Fernández-Fernández B, Valino-Rivas L, Sánchez-Nino MD, Ortiz A. Albuminuria downregulation of the anti-aging factor Klotho: The missing

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

link potentially explaining the association of pathological albuminuria with premature death. Adv Ther. 2020; 37(SUPPL 2): 62-72. Review. IF: 3.845; Q2

- Fontana F, Torelli C, Giovanella S, Ligabue G, Alfano G, Gerritsen K, Selgas R, Cappelli G. Influence of dialysate temperature on creatinine peritoneal clearance in peritoneal dialysis patients: a randomized trial. BMC Nephrol. 2020; 21(1): 448. Article. IF: 2.388; Q3
- Fontecha-Barriuso M, Martín-Sánchez D, Martínez-Moreno JM, Monsalve M, Ramos AM, Sánchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. The role of PGC-1 alpha and mitochondrial biogenesis in kidney diseases. Biomolecules. 2020; 10(2): 347. Review. IF: 4.879; Q2
- Granado-Martínez P, García-Ortega S, González-Sánchez E, McGrail K, Selgas R, Grueso J, Gil R, Naldaiz-Gastesi N, Rhodes AC, Hernández-Losa J, Ferrer B, Canals F, Villanueva J, Mendez O, Espinosa-Gil S, Lizcano JM, Muñoz-Couselo E, García-Patos V, Recio JA. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Commun Biol. 2020 ;3(1): 366. Article. IF: 6.268; D1
- Jiménez-Heffernan JA, Rodríguez-García AM, González-Peramato P, López-Ferrer P, Muñoz-Hernández P, Gordillo CH, Viguer JM, Vicandi B. Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature. Diagn Cytopathol. 2020; 48(11): 1013-20. Review. IF: 1.582; Q4
- López V, Vázquez T, Alonso-Titos J, Cabello M, Alonso A, Beneyto I, Crespo M, Díaz-Corte C, Franco A, González-Roncero F, Gutiérrez E, Guirado L, Jiménez C, Jironda C, Lauzurica R, Llorente S, Mazuecos A, Paul J, Rodríguez-Benot A, Ruiz JC, Sánchez-Fructuoso A, Sola E, Torregrosa V, Zarraga S, Hernández D. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. Nefrología. 2020; 40(3): 265-71. Article. IF: 2.033; Q3
- López-Medrano F, Silva JT, Fernández-Ruiz M, Vidal E, Origuen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jironda-Gallegos C, Escudero R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Arminanzas C, González-Rico C, Farinas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andrés A, Aguado JM. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort. Am J Transplant. 2020; 20(2): 451-62. Article. IF: 8.086; D1
- López-Oliva MO, Martínez V, Rodríguez-Sanz A, Álvarez L, Santana MJ, Selgas R, Jiménez C, Bellón T. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection. Clin Immunol. 2020; 211: 108329. Article. IF: 3.969; Q3
- Marchant V, Tejera-Muñoz A, Márquez-Expósito L, Rayego-Mateos S, Rodrigues-Díez RR, Tejedor L, Santos-Sánchez L, Egido J, Ortiz A, Valdivielso JM, Fraser DJ, López-Cabrera M, Selgas R, Ruiz-Ortega M. IL-17A as a potential therapeutic target for patients on peritoneal dialysis. Biomolecules. 2020; 10(10): 1361. Review. IF: 4.879; Q2
- Moreno ALQ, Saez PO, Calle PF, Gilsanz GD, Ramos SA, Almiron MD, Soto AB. Clinical, operative, and economic outcomes of the point-of-care blood gases in the nephrology department of a third-level Hospital. Arch Pathol Lab Med. 2020; 144(10): 1209-16. Article. IF: 5.534; Q1
- Orejudo M, García-Redondo AB, Rodrigues-Díez RR, Rodrigues-Díez R, Santos-Sánchez L, Muñoz AT, Egido J, Selgas R, Salaices M, Briones AM, Ruiz-Ortega M. Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation. Clin Sci. 2020; 134(5): 513-27. Article. IF: 6.124; Q1
- Peces R, Mena R, Martín Y, Hernández C, Peces C, Telleria D, Cuesta E, Selgas R, Lapunzina P, Nevado J. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2. Mol Genet Genomic Med. 2020; 8(8): e1321. Article. IF: 2.183; Q3
- Peces R, Mena R, Peces C, Cuesta E, Selgas R, Barruz P, Lapunzina P, Nevado J. Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression. Clin Genet. 2020; 97(6): 857-68. Article. IF: 4.438; Q2
- Pérez-Saez MJ, Blasco M, Redondo-Pachón D, Ventura-Aguiar P, Bada-Bosch T, Pérez-Flores I, Melilli E, Sánchez-Cámara LA, López-Oliva MO, Canal C, Shabaka A, Garra-Moncau N, Martín-Moreno PL, López V, Hernández-Gallego R, Siverio O, Galeano C, Espi-Reig J, Cabezas CJ, Rodrigo MT, Llinas-Mallol L, Fernández-Reyes MJ, Cruzado-Vega L, Pérez-Tamajón L, Santana-Estupinan R, Ruiz-Fuentes MC, Tabernero G, Zarraga S, Ruiz JC, Gutiérrez-Dalmau A, Mazuecos A, Sánchez-Álvarez E, Crespo M, Pascual J. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant. 2020; 20(11): 3182-90. Article. IF: 8.086; D1
- Roblero MFS, Borman N, Rubio MAB. Integrated care: enhancing transition from renal replacement therapy options to home haemodialysis. Clin Kidney J. 2020; 13(1): 105-10. Review. IF: 4.452; Q1
- Sánchez-Niño MD, Fernández-Fernández B, Ortiz A. Klotho, the elusive kidney-derived antiageing factor. Clin Kidney J. 2020; 13(2): 125-7. Editorial Material. IF: 4.452; Q1
- Urban JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martín CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutiérrez RS, Santovena AZ, Hijosa MM, Camblor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frias J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? Transpl Infect Dis. 2020; 22(6): e13432. Article. IF: 2.228; Q4
- Valino-Rivas L, Cuarental L, Núñez G, Sanz AB, Ortiz A, Sánchez-Niño MD. Loss of NLRP6 expression increases the severity of acute kidney injury. Nephrol Dial Transpl. 2020; 35(4): 587-98. Article. IF: 5.992; Q1
- van Gelder MK, de Vries JC, Simónis F, Monninkhof AS, Hazenbrink DHM, Ligabue G, Giovanella S, Joles JA, Verhaar MC, Rubio MAB, Selgas R, Cappelli G, Gerritsen KGF. Evaluation of a system for sorbent-assisted peritoneal dialysis in a uremic pig model. Physiol Rep. 2020; 8(23): 14593. Article. Not Indexed
- van Gelder MK, Ligabue G, Giovanella S, Bianchini E, Simónis F, Hazenbrink DHM, Joles JA, Rubio MAB, Selgas R, Cappelli G, Gerritsen KGF. In vitro efficacy and safety of a system for sorbent-assisted peritoneal dialysis. Am J Physiol-Renal. 2020; 319(2): F162-70. Article. IF: 3.377; Q2
- Vega A, Sánchez-Niño MD, Ortiz A, Abad S, Macias N, Aragoncillo I, Santos A, García-Prieto A, Torres E, Hernández A, Sánchez-Camara L, Hurtado E, Valino-Rivas L, Luno J. The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients. Clin Kidney J. 2020; 13(2): 172-78. Article. IF: 4.452; Q1

Research projects

Bajo Rubio MA. Biopsia líquida en diálisis peritoneal: correlación biopsia /efluente periotenal (PI18/00882). ISCIII. 2019-2021.

Managment centre: FIBHULP

Bajo Rubio MA. Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (CORDIAL). UE. 2020-2024.

Managment centre: FIBHULP

Jiménez Martín C. Evaluación de la microcirculación cortical del trasplante renal a largo plazo medida por ecografía con contraste y su correlación histopatológica por biopsia renal. Sociedad Madrileña de Trasplantes. 2019-Ongoing.

Managment centre: FIBHULP

Selgas Gutiérrez R, Bajo Rubio MA. Actualización y renovación de la actividad investigadora en nefrología clínica hospitalaria. Hospital Universitario La Paz. 2009-Ongoing.

Managment centre: FIBHULP

Selgas Gutiérrez R, Bajo Rubio MA. Las células mesoteliales del efluente crecidas ex

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

vivo reflejan las alteraciones peritoneales encontradas en la biopsia peritoneal. Oportunidades adicionales para biomarcadores en el efluente. Fundación SENEFRO. 2016-Ongoing.

Managment centre: FIBHULP

Selgas Gutiérrez R, Jiménez Martín C. Desarrollo y aplicación de un programa grupal de atención psicológica basada en las preferencias y valores con el objetivo de mejora de resultados en salud en el paciente con trasplante renal. Astellas Pharma S. A. 2018-Ongoing.

Managment centre: FIBHULP

Selgas Gutiérrez R. Evaluación e intervención en el bienestar emocional del personal y pacientes nefrológicos. Wyeth Farma S. A. 2007-2020.

Managment centre: FIBHULP

Selgas Gutiérrez R. Vasculopía hialinizante en diálisis peritoneal. Relación con la transición endotelio-mesenquimal y la disfunción del endotelio y del músculo liso vascular (PI15/00120). ISCIII. 2016-2020.

Managment centre: FIBHULP

Selgas Gutiérrez R; Bellón Heredia T; Sánchez Villanueva RJ. Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodiálisis basadas en polysulfona. Chiesi España S. A. 2017-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Selgas Gutiérrez R. Red de Investigación Renal (RD16/0009/0008). ISCIII. (31/12/2021)

Clinical trials

Jiménez Martín, C. Caracterización de las curvas dosis-respuesta y del funcionamiento clínico del inmunobiograma, un nuevo método de diagnóstico in vitro para evaluar el perfil de resistencia a inmunosupresores en una muestra representativa de pacientes con trasplante renal.

Type: Study, phase No EPA.
HULP code: PI-4366 .
Sponsored´s protocol code: BH-IMBG-TR-2020-002.
Sponsored by: Biohope Scientific Solutions For Human Health S.L.
Signed date: 21/09/2020

Rivas Becerra, B. Estudio posautorizacion de seguridad multicentrico y no intervencionista de 6 anos de duracion realizado en pacientes a los que se ha recetado Jinarc® debido a poliquistosis renal autosomica dominante.

Type: Study, phase EPA-LA.
HULP code: Appendix 1 PI-2881.
Sponsored´s protocol code: 156-12-299.
Sponsored by: Otsuka Pharmaceutical Development & Commercializacion Inc.
Signed date: 27/08/2020

Patents and trademarks

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b] indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. PCT/EP2015/074955, EP3212199, US2017304335, CN107073022; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). WO2017042253, DE102015115158; 2015 September 09.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.6 Neonatology Group

Publications:	35
Impact Factor:	149.944
Q1:	18



Adelina Pellicer Martínez. Jefe de Sección de Neonatología. Hospital Universitario La Paz

Susana Ares Segura. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz

Maria Carmen Bravo Laguna. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz

Antonio Buño Soto. Jefe de Servicio de Laboratorio de Urgencias. Hospital Universitario La Paz

Fernando Cabañas González. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Departamento de Pediatría y Neonatología. Universidad Autónoma de Madrid

María Dolores Elorza Fernández. Jefe de Sección de Neonatología. Hospital Universitario La Paz

Miriam Martínez Biarge. Facultativo Especialista de Área en Neonatología. Hospital Hammer Smith Londres

María Teresa Montes Bueno. Enfermera. Hospital Universitario La Paz

María Jesús del Olmo Barros. Profesora Contratada. Universidad Autónoma de Madrid

Laura Sánchez García. Médico Adjunto en Neonatología. Hospital Universitario La Paz

Belén Sáenz-Rico de Santiago. Profesor Contratado Doctor. Universidad Complutense de Madrid

Miguel Sáenz de Pipaón Marcos. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Eva Valverde Núñez. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Strategic Objective

Prevent structural damage to organs and systems in the high risk newborn.

Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.

Research lines

- Developmental Neurobiology.
- Neonatal pulmonary and cardiovascular pathology.
- Nutrition. Breast feeding. Mycrobiota.
- Perinatal and neonatal infectology. Inmunology and vaccines.
- Neurodevelopmental. Follow-up.
- Quality improvement.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Doctoral theses

de León Barrios YJ. La influencia de la musicoterapia en procesos neurobioquímicos del desarrollo temprano.[dissertation]. Madrid: UAM: 2020(18/06/2020).

Directors: Pellicer Martínez A, del Olmo Barros MJ

Rodríguez Fraga O. Utilidad de la medición de biomarcadores cardíacos en pacientes adultos con cardiotoxicidad por terapia antineoplásica[dissertation]. Madrid: UAM: 2020(26/06/2020).

Director: Buño Soto A

Publications

- Agut T, Alarcón A, Cabañas F, Bartocci M, Martínez-Biarge M, Horsch S. Preterm white matter injury: ultrasound diagnosis and classification. Pediatr Res. 2020; 87(SUPPL 1): 37-49. Review. IF: 3.756; Q1
- Barrio BC, Laguna MCB, Fernández MD, Martínez AP. Consumption of paracetamol during pregnancy. An Pediatr. 2020; 93(3): 196-7. Letter. IF: 1.5; Q4
- Bognar Z, De Luca D, Domellof M, Hadjipanayis A, Haffner D, Johnson M, Kolacek S, Koletzko B, de Pipaón MS, Shingadia D, Tissieres P, Titomanlio L, Topaloglu R, Truck J. Promoting breastfeeding and interaction of pediatric associations with providers of nutritional products. Front Pediatr. 2020; 8: 562870. Article. IF: 3.418; Q1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buno A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernán MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Camfferman FA, de Goederen R, Govaert P, Dudink J, van Bel F, Pellicer A, Cools F. Diagnostic and predictive value of Doppler ultrasound for evaluation of the brain circulation in preterm infants: a systematic review. Pediatr Res. 2020; 87(SUPPL 1): 50-8. Review. IF: 3.756; Q1
- Colomer BF, Sánchez-Luna M, Romero CD, Alarcón A, Souto AB, Longueira FC, Cernada M, Pradell ZG, López MG, Herrera MCL, Bautista CR, García LS, Flores EZ, Pellicer A, Díaz CA, Perea CH, Ramírez DSR, Teran ID, Chamorro IP, Trisac JLF, Gómez LA, Fernández LMC, García MJG, López MN, López MH, Gómez MR, González NH, Sánchez RG, Sert SZ, Capaces SL, del Pozo VM. Neonatal infection due to SARS-CoV-2: An epidemiological study in Spain. Front Pediatr. 2020; 8: 580584. Article. IF: 3.418; Q1
- de Pipaón MS, Flores-Rojas K, Gil A, Gil-Campos M. Commentary: Consumer reports of Keto flu associated with the ketogenic diet. Front Nutr. 2020; 7: 113. Editorial Material. IF: 6.576; Q1
- Díaz-Garzón J, Fernández-Calle P, Aarsand AK, Sandberg S, Buño A. Increases in high-sensitivity cardiac troponin I in athletes during a long-term period of routine training out of competition. Clin Chem. 2020; 66(8): 1109-11. Letter. IF: 8.327; D1
- Díaz-Garzón J, Oliver P, Crespo G, Duque M, Fernández-Calle P, Gómez M, Mora R, Moreno I, Pascual L, Qasem AL, Rodríguez-Fraga O, Simón M, Buno A. Experience on how to implement a preanalytical and POCT unit in Madrid's IFEMA field hospital during this unprecedented COVID-19 emergency. Biochem Medica. 2020; 30(3): 30403. Letter. IF: 2.313; Q3
- Dudink J, Steggerda SJ, Horsch S, (Barvo MC, Cabañas F, Pellicer A). State-of-the-art neonatal cerebral ultrasound: technique and reporting. Pediatr Res. 2020; 87(SUPPL 1): 3-12. Review. IF: 3.756; Q1
- Ferreiro SR, López AM, Villares JMM, (Sáenz de Pipaón M). Position paper on vegetarian diets in infants and children. Committee on nutrition and breastfeeding of the Spanish paediatric association. An Pediatr. 2020; 92(5): 306.e1-6. Article. IF: 1.5; Q4
- Fumagalli M, Parodi A, Ramenghi L, Limperopoulos C, Steggerda S, (Barvo MC, Cabañas F, Pellicer A). Ultrasound of acquired posterior fossa abnormalities in the newborn. Pediatr Res. 2020; 87(SUPPL 1): 25-36. Review. IF: 3.756; Q1
- Gabriel MMA, Cuadrado I, Fernández BA, Carrasco EG, Díaz CA, Martín IL, Sánchez L, Olivas C, de las Heras S, Criado E. Multicentre Spanish study found no incidences of viral transmission in infants born to mothers with COVID-19. Acta Paediatr. 2020; 109(11): 2302-8. Article. IF: 2.299; Q2
- García LS, Calvo C, Casas I, Pozo F, Pellicer A. Viral respiratory infections in very low birthweight infants at neonatal intensive care unit: prospective observational study. BMJ Paediatr Open. 2020; 4(1): e000661. Article. Not Indexed
- Gila-Díaz A, Carrillo GH, Canas S, de Pipaón MS, Martínez-Orgado JA, Rodríguez-Rodríguez P, de Pablo ALL, Martín-Cabrejas MA, Ramiro-Cortijo D, Arribas SM. Influence of maternal age and gestational age on breast milk antioxidants during the first month of lactation. Nutrients. 2020; 12(9): 2569. Article. IF: 5.717; Q1
- Hansen ML, Rasmussen MI, Rubin S, Pellicer A, Cheng GQ, Xu X, Yin ZQ, Zoffmann V, Greisen G. Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III. Trials. 2020; 21(1): 356. Article. IF: 2.279; Q4
- Jiménez BC, Lafuente MC, Couce ML, Madero R, Vento M, Marín AV, de Pipaón MS. The influence of donor milk supplementation on duration of parenteral nutrition in preterm infants. J Hum Lact. 2020; 36(2): 245-53. Article. IF: 2.219; Q2
- López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Albendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, González-Juanatey JR, Monzonis AM, Prieto PG, González-Costello J, Antolín JMS, Chamorro RC, Fernández TL. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-9. Article. IF: 29.983; D1
- Martínez-Losas P, de Sa EL, Armada E, Rosillo S, Monedero MC, Rey JR, Caro-Codon J, Soto AB, Sendón JPLL. Neuron-specific enolase kinetics: an additional tool for neurological prognostication after cardiac arrest. Rev Esp Cardiol. 2020; 73(2): 123-30. Article. IF: 4.753; Q2
- Mesa MD, Loureiro B, Iglesia I, González SF, Olive EL, Algar OG, Solana MJ, Pérez MJC, Sainz T, Martínez L, Escuder-Vieco D, Parra-Llorca A, Sánchez-Campillo M, Martínez GR, Roig DG, Gruz MP, Andréu-Fernández V, Clotet J, Sailer S, Iglesias-Platas I, López-Herce J, Aras R, Pallas-Alonso C, de Pipaón MS, Vento M, Gormaz M, Daza EL, Calvo C, Cabañas F. The evolving microbiome from pregnancy to early infancy: A comprehensive review. Nutrients. 2020; 12(1): 133. Review. IF: 5.717; Q1
- Montes MT, Herranz-Rubia N. Neonatal nursing in the COVID-19 pandemic: can we improve the future? J Neonatal Nurs. 2020; 26(5): 247-51. Article. Not Indexed
- Oliver P, Fernández-Calle P, Mora R, Díaz-Garzon J, Prieto D, Manzano M, Domínguez I, Buno A. Real-world use of key performance indicators for point-of-Care Testing network accredited by ISO 22870. Pract Lab Med. 2020; 22: e00188. Article. Not Indexed
- Parodi A, Govaert P, Horsch S, Bravo MC, Ramenghi LA. Cranial ultrasound findings in preterm germinal matrix haemorrhage, sequelae and outcome. Pediatr Res. 2020; 87(SUPPL 1): 13-24. Review. IF: 3.756; Q1
- Ramiro-Cortijo D, de Pablo ALL, López-Giménez MR, Martín CR, Brown J, de Pipaón MS, Arribas SM. Plasma oxidative status in preterm infants receiving LCPUFA supplementation: A pilot study. Nutrients. 2020; 12(1): 122. Article. IF: 5.717; Q1

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Rey JR, Caro-Codon J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I, Martín-Polo L, Merino-Argos C, Rodríguez-Sotelo L, García-Veas JM, Martínez-Marín LA, Martínez-Cossiani M, Buño A, González-Valle L, Herrero A, López-Sendón JL, Merino JL. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12): 2205-15. Article. IF: 15.534; D1
- Ros IM, García LS, Torres AS, Pena RM, Grande MDP, Castano MJR, Fernández MDE, Luna MS. Evaluation of specific quality metrics to assess the performance of a specialised newborn transport programme. Eur J Pediatr. 2020; 179(6): 919-28. Article. IF: 3.183; Q1
- Ruiz-Extremera A, Díaz-Alcazar MDM, Muñoz-Gámez JA, Cabrera-Lafuente M, Martín E, Arias-Llorente RP, Carretero P, Gallo-Vallejo JL, Romero-Narbona F, Salmerón-Ruiz MA, Alonso-Díaz C, Maese-Heredia R, Cerrillos L, Fernández-Alonso AM, Camarena C, Aguayo J, Sánchez-Forte M, Rodríguez-Maresca M, Pérez-Rivilla A, Quilés-Pérez R, de Rueda PM, Exposito-Ruiz M, García F, García F, Salmerón J. Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission. Plos One. 2020; 15(5): e0233528. Article. IF: 3.24; Q2
- Salas-Salvado J, Maraver F, Rodríguez-Mañas L, de Pipaón MS, Vitoria I, Moreno LA. The importance of water consumption in health and disease prevention: the current situation. Nutr Hosp. 2020; 37(5): 1072-86. Article. IF: 1.057; Q4
- Sánchez CP, Sáez PO, Fernández-Calle P, Giménez MS, Díaz RMA, Zafra EP, Capell NE, Soto AB. Analytical evaluation of ABL90 flex plus blood gas analyzer for urea and creatinine multicenter method comparison. Point Care. 2020; 19(2): 37-42. Article. Not Indexed
- Sánchez García L, Calvo C, Casas I, Pozo F, Pellicer A. Viral respiratory infections in very low birthweight infants at neonatal intensive care unit: prospective observational study. BMJ Paediatr Open. 2020; 4(1): e000661. Article. Not Indexed
- Saralegui C, Ponce-Alonso M, Pérez-Viso B, Alegre LM, Escribano E, Lázaro-Perona F, Lanza VF, de Pipaón MS, Rodríguez JM, Baquero F, del Campo R. Genomics of serratia marcescens Isolates causing outbreaks in the same pediatric unit 47 years apart: Position in an updated phylogeny of the species. Front Microbiol. 2020; 11: 451. Article. IF: 5.64; Q1
- Soriano-Arandes A, Frick MA, López-Hortelano MG, Sulleiro E, Rodo C, Sánchez-Seco MP, Cabrera-Lafuente M, Suy A, de la Calle M, Santos M, Antolin E, Vinuela MD, Espiau M, Salazar A, Guarch-Ibanez B, Vázquez A, Navarro-Moron J, Ramos-Amador JT, Martín-Nalda A, Dueñas E, Blázquez-Gamero D, Reques-Cosme R, Olabarrieta I, Prieto L, De Ory F, Thorne C, Byrne T, Ades AE, Ruiz-Burga E, Giaquinto C, Mellado-Pena MJ, García-Alix A, Carreras E, Soler-Palacin P. Clinical outcomes of a zika virus mother-child pair cohort in Spain. Pathogens. 2020; 9(5): 352. Article. IF: 3.492; Q2
- Tornero C, Navarro-Compán V, Tenorio JA, García-Carazo S, Buño A, Monjo I, Plasencia-Rodríguez C, Iturzaeta JM, Lapunzina P, Heath KE, Balsa A, Aguado P. Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia? Orphanet J Rare Dis. 2020; 15(1): 51. Article. IF: 4.123; Q2
- Zozaya C, Avila-Álvarez A, Argibay IS, Rodrigo FGM, Oikonomopoulou N, Encinas JL, de Pipaón MS, Couce ML. Prevention, diagnosis and treatment of necrotising enterocolitis in newborns less than 32 weeks at birth in Spain. An Pediatr. 2020; 93(3): 161-9. Article. IF: 1.5; Q4
- Zozaya C, González IG, Avila-Álvarez A, Oikonomopoulou N, Tamayo TS, Salguero E, de Pipaón MS, Rodrigo FGM, Couce ML. Incidence, treatment, and outcome trends of necrotizing enterocolitis in preterm infants: A multicenter cohort study. Front Pediatr. 2020; 8: 188. Article. IF: 3.418; Q1

Research projects

Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiográficamente guiado en el recién nacido prematuro con ibuprofeno con perfusion continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestinal. Fundación Mutua Madrileña. 2016-2021.

Managment centre: FIBHULP

Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiográficamente guiado en el recien nacido prematuro con ibuprofeno en perfusión continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestinal (PI16/00644). ISCIII. 2017-2021.

Managment centre: FIBHULP

Bravo Laguna MC. Valoración cuantitativa de la repercusión hemodinámica del ductus arterioso persistente y su tratamiento en el recién nacido de bajo peso. Neonatcare S. L. 2018-Ongoing.

Managment centre: FIBHULP

Buño Soto A. Estudio en población cognitivamente sana (sin demencia) para la determinacion de valores de referencia de una nueva técnica diagnóstica basada en espectroscopia Raman. Raman Health Technologies S. L. 2016-Ongoing.

Managment centre: FIBHULP

Buño Soto A. Evaluación de un nuevo sistema analítico de inmunoensayo atellica solutions en el laboratorio core del Servicio de Análisis Clínicos. Siemens Heatlhcare S. L. 2017-Ongoing.

Managment centre: FIBHULP

Buño Soto A. Recogida de muestras en deportistas de alto rendimiento para la evaluación de su variación biológica. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2016-Ongoing.

Managment centre: FIBHULP

Buño Soto A. Validación de un nuevo método para la detección de anticuerpos IGG e IGM anti Sars-Cov-2 en el analizador atellica solution. Siemens Heatlhcare S. L. 2020-Ongoing.

Managment centre: FIBHULP

Elorza Fernández MD. Actuación ante situaciones de crisis (CRM) en neonatología. Formación e Investigación. Varios. 2019-Ongoing.

Managment centre: FIBHULP

Elorza Fernández MD. Actuación en situación de crisis en neonatología. Varios. 2020-2020.

Managment centre: FIBHULP

Pellicer Martínez A. Alliance for Family Integrated Care (FICare) Implementation in Neonatal Intensive Care Units (RISEinFAMILY). UE. 2020-2025.

Managment centre: FIBHULP

Pellicer Martínez A. Desarrollo de un equipo de ultrasonidos para la ayuda al diagnóstico de meningitis. Neos New Born Solutions S. L. 2018-Ongoing.

Managment centre: FIBHULP

Pellicer Martínez A. Estudio aleatorizado, doble ciego, de tres brazos controlado con placebo, sobre el tratamiento con dobutamina de la insuficiencia hemodinámica en el periodo postnatal inmediato (PI18/01551). ISCIII. 2019-2021.

Managment centre: FIBHULP

Pellicer Martínez A. Estudio retrospectivo de pacientes con sospecha de meningitis para identificar meningitis que requieran o no tratamiento mediante un moelo de IA. Neos New Born Solutions S. L. 2020-Ongoing.

Managment centre: FIBHULP

Pellicer Martínez A. Online cerebral pressure autoregulation continuous monitorin as a neurobiomarker to guide assessment and intervention to prevent or minimise brain

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

injury in the high-risk preterm infant. Abbvie Spain S. L. U. 2017-Ongoing.

Managment centre: FIBHULP

Pellicer Martínez A. Salvaguardando el cerebro de nuestros niños más pequeños– ensayo clínico por iniciativa del investigador, pragmático, abierto, multinacional, aleatorizado fase III que evalúa el tratamiento basado en la monitorización con espectrometría cercana al infrarrojo versus tratamiento estándar en el niño prematuro. Fundación Mutua Madrileña. 2019-Ongoing.

Managment centre: FIBHULP

Pellicer Martínez A. Seguridad de la lactancia materna en la infección confirmada por Sars-Cov-2 (COVID-19) (COV20/01046). ISCIII. 2020-2021.

Managment centre: FIBHULP

Sáenz de Pipaón Marcos M. Análisis del perfil metabolómico en orina de neonatos pretérmino y a término al nacimiento, a los 6 y 12 meses de edad mediante espectroscopia de resonancia magnética de protón de alto rendimiento 1h NMR y su potencial relación con el estado nutricional. Sociedad de Pediatría de Galicia. 2017-Ongoing.

Managment centre: FIBHULP

Sáenz de Pipaón Marcos M. Efecto de la suplementacion precoz con ácido araquidónico y acido docosahexanoico en la evolución de las concentraciones plasmáticas y eritrocitarias de DHA en recién nacidos prematuros: ensayo controlado aleatorizado. Nestle España S. A. 2016-Ongoing.

Managment centre: FIBHULP

Sáenz de Pipaón Marcos M. Efecto de la suplementación temprana con ácido docosahexanoico y ácido araquidónico sobre la incidencia de displasia broncopulmonar en niños extremadamente prematuros. European Society For Paediatric Gastroenterology, Hepatology and Nutrition. 2020-Ongoing.

Managment centre: FIBHULP

Sánchez García L, Sáenz de Pipaón Marcos M. Colonización de gestantes por bacterias multirresistentes y transmision perinatal en <32 semanas: prevalencia y morbilidad. Fundación de la Sociedad Española de Neonatología. 2019-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Cabañas González F. Research Network for Maternal and Child Health and Development - SAMID (RD16/0022/0004). (31/12/2021)

Clinical trials

Pellicer Martínez, A. An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic insufficiency in the immediate postnatal period.

Type: Clinical Trial, phase .
HULP code: 5533.
Sponsored´s protocol code: NeoCirc-003 TRIAL.
Sponsored by: FIBHULP.
Signed date: 05/06/2020

Saenz De Pipaon Marcos, M Comparación entre nutrición parenteral individualizada y estándar en recién nacidos prematuros, con edad gestacional de menos de 37+0 semanas, y un peso al nacimiento superior a 1250 gramos: ensayo clínico aleatorizado.

Type: Clinical Trial, phase IV.
HULP code: 5381.
Sponsored´s protocol code: SP-PP18.
Sponsored by: Virgilio P. Carnielli.
Signed date: 23/10/2020

Saenz De Pipaon Marcos, M. Efecto de la suplementación temprana con ácido docosahexanoico y ácido araquidónico sobre la incidencia de displasia broncopulmonar en niños extremadamente prematuros.

Type: Study, phase Medical Devices.
HULP code: 4840.
Sponsored´s protocol code: Estudio DHA.
Sponsored by: Sáenz de Pipaon Marcos, Miguel.
Signed date: 30/11/2020

Patents and trademarks

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.7 Aging and Fragility in the Elderly Group

Publications:	11
Impact Factor:	26.^{864}
Q1:	4



Juan Ignacio González Montalvo. Jefe de Servicio de Geriatría. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Juan Carlos Abánades Herranz. Subdirector Médico. Responsable de la Unidad de Formación e Investigación. Atención Primaria

María Teresa Alarcón Alarcón. Jefe de Sección de Geriatría. Hospital Universitario La Paz

Juan Cárdenas Valladolid. Técnico de la Gerencia Adjunta de Planificación y Calidad de Atención Primaria. Atención Primaria

María Victoria Castell Alcalá. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Patricia Ysabel Condorhuamán Alvarado. Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz

Carmen de Burgos Lunar. Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz

Macarena Díaz de Bustamante de Ussía. Médico Interno Residente. Hospital Universitario La Paz

Araceli Garrido Barral. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Paloma Gómez Campelo. Subdirectora Científica de IdiPAZ. Investigadora Postdoctoral. FIBHULP

Pilar Gotor Pérez. Enfermera. Unidad de Valoración Geriátrica y Ortogeriatría. Hospital Universitario La Paz

Alicia Gutierrez Misis. Profesor ayudante Doctor. Universidad Autónoma de Madrid

Rosa Julián Viñals. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Centro de Salud "Raúl de Castroviejo. Atención Primaria

Rocío Menéndez Colino. Facultativo Especialista de Área en Geriatría. Hospital de Cantoblanco - Hospital Universitario La Paz

Débora Moral Cuesta. Médico Interno Residente en Geriatría. Hospital Universitario La Paz

Ángel Otero Puime. Profesor Emérito de Medicina Preventiva y Salud Pública. Universidad Autónoma de Madrid

Rocío Queipo Matas. Investigadora Predoctoral. Universidad Autónoma de Madrid

Raquel Ramírez Martín. Médico Interno Residente. Hospital Universitario La Paz

Peggy Paola Ríos Germán. Médico Interno Residente en Geriatría. Hospital Universitario La Paz

Ana María Rosas Hernández. Investigadora Predoctoral. Universidad Autónoma de Madrid

María del Pilar Sáez López. Facultativo Especialista de Área en Geriatría. Complejo Asistencial de Ávila

Miguel Ángel Salinero Fort. Gerente Adjunto de Planificación y Calidad. Atención Primaria

Mercedes Sánchez Martínez. Profesor Asociado. Universidad Autónoma de Madrid

Strategic Objective

- To promote and improve the quality of research in the field of Primary Health Care and Geriatrics in the area of influence of IdiPAZ.
- To continue the follow-up of the Cohorts of the Group: elderly people with population-based (Peñagrande Study), patients with frailty síndrome (FONDA) and patients with Type 2 Diabetes Mellitus (MADiabetes).
- Progress in the epidemiological study of frailty in the elderly.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- To consolidate clinical studies related to hip fracture and chronic diseases in the elderly, specially the Diabetes Mellitus.

Research lines

- Frailty syndrome in the elderly. To promote the detection of frailty syndrome in elderly people above 75 years that consults at the Primary Heatlh Care Center of the Hospital La Paz Setting and create a new cohort of those patients with functional impairment.

  Additionally, to develop and evaluate an intervention program with these patients, focused on the physical exercise, the geriatric evaluation, management of comorbidity, in the medication adjustment in nutritional supplementation when necessary.
- Follow-up of patients with Type 2 Diabetes Mellitus (MADiabetes Cohort, more than 3.500 patients) and prediabetes patients (SPREDIA Cohort, n=600) of Madrid, to analyze clinical and psychosocial factors related to clinical outcomes (cardiovascular events, chronic kidney disease, retinopathy, and mortality), we are developing predictive models for main outcomes (chronic kidney disease, all-cause mortality and cardiovascular mortality).
- Coordination of the National Registry of Hip Fractures: a multicenter observational study including patients from 75 Spanish hospitals with an acute fargility hip fracture. The registry collects data from the acute hospital phase and a one-month follow-up.

Research Activity

Publications

- Alarcón T, Ojeda-Thíes C, Saez-López P, Gómez-Campelo P, Navarro-Castellanos L, Otero-Puime A, González-Montalvo J. Usefulness of a national hip fracture registry to evaluate the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. Osteoporosis Int. 2020; 31(7): 1369-75. Article. IF: 4.507; Q2
- Fernández-Caso B, Vázquez R, Alarcón T, Girón R, López-Giménez MR, Domingo D. Prevalence and importance of non-tuberculous mycobacteria in adult patients with cystic fibrosis in a hospital in Madrid. Enferm Infec Micr Cl. 2020; 38(7): 323-6. Article. IF: 1.731; Q4
- García-Gollarte F, Ríos German PP, Alarcón T, Paz Francisco J, Cuenllas-Díaz A, González-Montalvo JI. Functional and clinical outcomes in patients admitted to nursing homes after hip fractures. Implementation of a multi-level intervention program. Rev Esp Geriatr Gerontol. 2020; 55(1): 11-7. Article. Not Indexed
- González-Guerrero JL, Paredes-Galán E, Ferrero-Martínez AI, Galán Maria C, Hornillos-Calvo M, Menéndez-Colino R, Torres-Torres I, Rodríguez-Artalejo F, Rodríguez-Pascual C. Characteristics and one-year outcomes in elderly patients hospitalised with heart failure and preserved, mid-range and reduced ejection fraction. Rev Esp Geriatr Gerontol. 2020; 55(4): 195-200. Article. Not Indexed
- González-Montalvo JI, Ramírez-Martín R, Menéndez Colino R, Alarcón T, Tarazona-Santabalbina FJ, Martínez-Velilla N, Vidan Maria T, Pi-Figueras Valls M, Formiga F, Rodríguez Couso M, Hormigo Sánchez AI, Vilches-Moraga A, Rodríguez-Pascual C, Gutiérrez Rodríguez J, Gómez-Pavon J, Saez López P, Bermejo Boixareu C, Serra Rexach JA, Martínez Peromingo J, Sánchez Castellano C, González Guerrero JL, Martín-Sánchez FJ. Cross-speciality geriatrics: A health-care challenge for the 21st century. Rev Esp Geriatr Gerontol. 2020; 55(2): 84-97. Article. Not Indexed
- Hernández AMR, Alarcón T, Menéndez-Colino R, Maestre IM, González-Montalvo JI, Puime AO. Factors affecting exercise program adherence in patients with acute hip fracture and impact on one-year survival. Braz J Phys Ther. 2020; 24(6): 479-87. Article. IF: 3.377; Q1
- McNicholl AG, Garre A, Llorca L, Bujanda L, Molina-Infante J, Barenys M, Pérez J, Guerrero-Torres MD, Tamayo E, Montes M, Prados-Manzano R, Sánchez-García A, Ramas M, Blanco VBV, Montoro M, Calvet X, Figuerola A, Lario S, Quílez E, Lanas A, Silva-PoMaríno P, Pérez-Aisa A, Donday MG, Belloc B, Montserrat-Torres A, Fernández-Moreno N, Ramírez MJ, Alarcón T, Gisbert JP. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STATI rapid test) for the diagnosis of Helicobacter pylori infection. Gastroent Hepat-Barc. 2020; 43(3): 117-25. Article. IF: 2.102; Q4
- Ortega-Hernández A, Martínez-Martínez E, Gómez-Gordo R, López-Andrés N, Fernández-Celis A, Gutiérrez-Miranda B, Nieto ML, Alarcón T, Alba C, Gómez-Garre D, Cachofeiro V. The interaction between mitochondrial oxidative stress and gut microbiota in the cardiometabolic consequences in diet-induced obese rats. Antioxidants. 2020; 9(7): 640. Article. IF: 6.312; D1
- Pérez-Rodríguez P, Rabes-Rodríguez L, Sáez-Nieto C, Alarcón TA, Queipo R, Otero-Puime A, Montalvo JIG. Handgrip strength predicts 1-year functional recovery and mortality in hip fracture patients. Maturitas. 2020; 141: 20-5. Article. IF: 4.342; Q1
- Portegijs E, Timmermans EJ, Castell MV, Dennison EM, Herbolsheimer F, Limongi F, van der Pas S, Schaap LA, van Schoor N, Deeg DJH. Neighborhood resources associated with active travel in older adults-a cohort study in six European countries. J Aging Phys Activ. 2020; 28(6): 920-33. Article. IF: 1.961; Q3
- van Schoor NM, Dennison E, Castell MV, Cooper C, Edwards MH, Maggi S, Pedersen NL, van der Pas S, Rijnhart JJM, Lips P, Deeg DJH. Clinical osteoarthritis of the hip and knee and fall risk: The role of low physical functioning and pain medication. Semin Arthritis Rheu. 2020; 50(3): 380-6. Article. IF: 5.532; Q1

Research projects

González Montalvo JI, Gómez Campelo P. Registro nacional de fracturas de cadera estudio RNFC. Fundación Mutua Madrileña. 2018-Ongoing.

Managment centre: FIBHULP

González Montalvo JI, Gómez Candela C. Herranmienta gratuita, destinada a los profesionales de la salud, con el objetivo de ayudar a éstos en la planificación y elaboración de dietas terapéuticas personalizdas para sus pacientes en riesgo nutricional y aptas para cubrir las necesidades nutricionales de estos últimos, creando, al efecto, una sede, sitio o potal web en la red internet. Nestle España S. A. 2017-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Geriatría transversal: detección y manejo de la fragilidad en pa-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

cientes adultos mayores con patología quirúrgica. Varios. 2019-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Prevención secundaria de fracturas por fragilidad: descripción del tipo de pacientes y del funcionamiento de una fracture liaison service en pacientes con fractura de cadera tratados en un Servicios de Ortogeriatría. Amgen S. A. 2018-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Proyecto de actualización bibliográfica básica de temas de investigación, documentación, actualización y transmisión bibliográfica en sesiones conjuntas de servicio. Lundbeck España S. A. 2008-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Proyecto del registro nacional de fracturas de cadera por fragilidad en el anciano. Amgen S. A. 2017-Ongoing.

Managment centre: FIBHULP

Menéndez Colino R. Impacto de una intervención multidisciplinaria en el pronóstico de pacientes frágiles con estenosis aórtica severa sintomática: ensayo randomizado. (PI19/01010). ISCIII. 2020-2022.

Managment centre: FIBHULP

Cibers and Retics

Gómez Campelo P. Plataforma Red de Biobancos (PT17/0015/0025). ISCIII. (28/02/2021)

Clinical trials

Condorhuamán Alvarado, PY. Estudio observacional, prospectivo, del efecto de un suplemento nutricional hipercalórico e hiperproteico con HMB, de administración oral, en una población de edad avanzada desnutrida o en riesgo de desnutrición que ha sufrido una fractura de cadera.

Type: Study, phase No EPA.
HULP code: PI-3505.
Sponsored´s protocol code: DA20.
Sponsored by: Abbott Laboratories S.A.
Signed date: 14/09/2020



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.8 Molecular Hepatology Group

Publications:	11
Impact Factor:	83.[158]
Q1:	5



Paloma Jara Vega. Emérito Asistencial. Hospital Universitario La Paz

Carmen Camarena Grande. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

Ángela de la Vega Bueno. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

María Carmen Díaz Fernández. Jefe de Servicio de Hepatología Pediátrica. Hospital Universitario La Paz

Esteban Frauca Remacha. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

Loreto Hierro Llanillo. Jefe de Sección Hepatología Pediátrica. Hospital Universitario La Paz

Gema Muñoz Bartolo. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

María Ángeles Pajares Tarancón. Investigador Cientifico. CSIC

Luiz Stark Aroeira. Investigador Postdoctoral. Hospital Universitario La Paz

David Vicent López. Investigador Senior (Contrato Miguel Servet - I2). Hospital Universitario La Paz

Strategic Objective

Our research interest is focused on the study of the molecular mechanisms underlying the most severe paediatric liver disorders, namely cholestasis, which results from the impaired secretion of bile from the liver to the intestine.

As such, it represents a clinical and biochemical syndrome that is produced by a wide variety of disease processes that affect the liver. Individuals with cholestasis manifest jaundice, severe itching, malabsorption of fats and lipidsoluble vitamins and, in many cases, progressive liver damage. These clinical manifestations are due to the accumulation in blood and tissues of substances normally secreted in the bile, such as bilirubin, bile acids, and cholesterol and to the absence of bile from the intestine.

When manifested in early infancy, cholestasis is often life threatening and usually requires liver transplantation. Extrahepatic biliary atresia (EHBA), Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) constitute the main paediatric cholestatic disorders. EHBA is an enigmatic disease of unknown aetiology, characterised by a precocious and accelerated obstruction of the biliary tree. Alagille syndrome is

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

associated with mutations in the Jag1 gene and is characterised by a paucity or absence of intrahepatic bile ducts. PFIC encompasses a heterogeneous group of autosomal recessive diseases that exhibit similar clinical features. These diseases are caused by mutations in proteins located in the canalicular membrane of the hepatocyte and in proteins involved in bile secretion, such as the bile salt export pump (BSEP; ABCB11), the phospholipid transport protein MDR3 (ABCB4) and the aminophospholipid translocase FIC1 (ATP8B1). These cholestatic disorders constitute the most common indication for liver transplantation in childhood.

Research lines

- Molecular basis of paediatric liver diseases
- Liver Pathobiology

Research Activity

Publications

- de Frutos LL, Cebolla JJ, Aldámiz-Echevarría L, de la Vega A, Stanescu S, Lahoz C, Irún P, Giraldo P. New variants in Spanish Niemann-Pick type c disease patients. Mol Biol Rep. 2020; 47(3): 2085-95. Article. IF: 2.316; Q4
- Dona D, Canizales JT, Benetti E, Cananzi M, De Corti F, Calore E, Hierro L, Boluda ER, Hijosa MM, Guereta LG, Martínez AP, Barrios M, Reis PC, Teixeira A, Lopes MF, Kalicinski P, Branchereau S, Boyer O, Debray D, Sciveres M, Wennberg L, Fischler B, Barany P, Baker A, Baumann U, Schwerk N, Nicastro E, Candusso M, Toporski J, Sokal E, Stephenne X, Lindemans C, Miglinas M, Rascon J, Jara P. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. Clin Transplant. 2020; 34(10): e14063. Article. IF: 2.863; Q2
- Jara P, Baker A, Baumann U, Borobia AM, Branchereau S, Candusso M, Carcas AJ, Chardot C, Cobas J, D'Antiga L, Ferreras C, Fitzpatrick E, Frauca E, Hernández-Oliveros F, Kalicinski P, Lindemans C, Lopes MF, López-Granados E, de Magnee C, Mota C, Muñoz JM, Ojeda JJ, Pérez-Martínez A, Perilongo G, Rascon J, Sciveres M, Stone R, Tarutis V, Toporski J, Torres JM, Wennberg L. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild. Orphanet J Rare Dis. 2020; 15(1): 16. Article. IF: 4.123; Q2
- Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, Hierro L, Kelly D, Ling SC, Strokova T, del Valle-Segarra A, Lovell S, Liu W, Ng TI, Porcalla A, González YS, Burroughs M, Sokal E. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA Study. Hepatology. 2020; 71(2): 456-62. Article. IF: 17. 425; D1
- Koot BGP, Kelly DA, Hadzic N, Gonzales E, Hierro L, Davenport M, Keil R, Fockens P, Baumann U. Endoscopic retrograde cholangiopancreatography in infants: Availability under threat: A survey on availability, need, and clinical practice in Europe and israel. J Pediatr Gastroenterol Nutr. 2020; 71(2): E54-8. Article. IF: 2.839; Q2
- Meneses D, Olveira A, Corripio R, Méndez MD, Romero M, Calvo-Vinuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of noninvasive liver fibrosis scores in the morbid obese patient, same scores but different thresholds. Obes Surg. 2020; 30(7): 2538-46. Article. IF: 4.129; Q1
- Pajares MA, Zimmermann T, Sánchez-Gómez FJ, Ariza A, Torres MJ, Blanca M, Canada FJ, Montanez MI, Pérez-Sala D. Amoxicillin inactivation by thiol-catalyzed cyclization reduces protein haptenation and antibacterial potency. Front Pharmacol. 2020; 11: 189. Article. IF: 5.81; Q1
- Portillo F, Vázquez J, Pajares MA. Protein-protein interactions involving enzymes of the mammalian methionine and homocysteine metabolism. Biochimie. 2020; 173: 33-47. Review. IF: 4.079; Q2
- Saborido CM, Borobia AM, Cobás J, D'Antiga L, Frauca E, Hernández-Oliveros F, Jara P, López-Granados E, Muñoz JM, Nicastro E, Ojeda JJ, Pérez-Martínez A, Torres JM, Carcas A. Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis. BMJ Open. 2020; 10(12): e037721. Review. IF: 2.692; Q2
- van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipinski P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly DA, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikan C, Polat E, Debray D, Lacaille F, Goncalves C, Hierro L, Bartolo GM, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsofi A, Calvo PL, Grabhorn E, Sturm E, van der Woerd WJ, Kamath BM, Wang JS, Li LT, Durmaz O, Onal Z, Bunt TMG, Hansen BE, Verkade HJ. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020; 73(1): 84-93. Article. IF: 25.083; D1
- Viedma-Poyatos A, Pajares MA, Pérez-Sala D. Type III intermediate filaments as targets and effectors of electrophiles and oxidants. Redox Biol. 2020; 36: 101582. Review. IF: 11.799; D1

Research projects

Hierro Llanillo L. Desarrollo de métodos de diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario6. Fundación Pfizer. 2005-Ongoing.

Managment centre: FIBHULP

Hierro Llanillo L. Diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación ACS. 2012-Ongoing.

Managment centre: FIBHULP

Hierro Llanillo L. Estableciendo una base de datos como parte de la red europea de referencia en enfermedades rara hepáticas. R-liver. Asociación Nacional para la Defensa y Ayuda de Afectados por Hepatitis C. 2019-Ongoing.

Managment centre: FIBHULP

Hierro Llanillo L. Identificación de causas genéticas y epigenéticas en enfermedades colestásicas infantiles idiopáticas (PI15/01127). ISCIII. 2016-2020.

Managment centre: FIBHULP

Hierro Llanillo L. Identificación de nuevos genes responsables de enfermedades hepáticas infantiles. Fundación ACS. 2015-Ongoing.

Managment centre: FIBHULP

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Hierro Llanillo L. Tomoxliver: estudio de la disfunción del hepatocito desde un abordaje multidisciplinar (S2017/BMD-3817). CM. 2018-2021.

Managment centre: FIBHULP

Jara Vega P. Estudio epidemiológico, observacional sobre el riesgo de desarrollo de síndrome linfoproliferativo en pacientes pediátricos trasplantados hepáticos, en el HULP. Roche Farma S. A. 2008-Ongoing.

Managment centre: FIBHULP

Jara Vega P. Integration systems for specific dataset, e-learning and support of ERN Core Services in the ERN TransplantChild (ICT 1816948). UE. 2019-2021.

Managment centre: FIBHULP

Jara Vega P. Novel strategies in paediatric transplantation. Varios Financiadores. 2020-Ongoing.

Managment centre: FIBHULP

Jara Vega P. PaEdiatric Transplantation European Registry (PETER). UE. 2019-2023.

Managment centre: FIBHULP

Vicent López D. Caracterización clínica del nuevo factor de riesgo cardiovascular trimetilamina-D-óxido en pacientes diabéticos obesos. Sección de Endocrinología y Nutrición Severo Ochoa. 2015-Ongoing.

Managment centre: FIBHULP

Vicent López D. Contrato Miguel Servet Categoria C (CES06/007). ISCIII. 2008-2025.

Managment centre: FIBHULP

Cibers and Retics

Hiero Llanillo L. European reference networkon hepatological dieases. UE. 2016-2020.Managment Centre: FIBHULP

Jara Vega P. European references network on transplantation in children. UE. 2019-2021.Managment Centre: FIBHULP

Clinical trials

Hierro Llanillo, L. Estudio abierto de extensión para evaluar la eficacia y la seguridad a largo plazo de A4250 en niños con colestasis intrahepática familiar progresiva de tipo 1 y 2. Type: EECC, phase III. HULP code: Anexo 2 4790. Sponsored´s protocol code: 64294178HPC3001. Sponsored by: Albireo Ab. Signed date: 03/11/2020. Hierro Llanillo, Loreto.

Type: , phase Estudio abierto de extensión para evaluar la eficacia y la seguridad a largo plazo de A4250 en niños con colestasis intrahepática familiar progresiva de tipo 1 y 2.

HULP code: 4790 .
Sponsored´s protocol code: Anexo 2.
Sponsored by: Albireo Ab.
Signed date: 12/07/2020

Hierro Llanillo, L. Estudio de seguridad a largo plazo sobre el maralixibat, un inhibidor del transportador apical de ácidos biliares dependiente de sodio (ASBTI), para el tratamiento de pacientes con colestasis hepática que participaron previamente en un estudio sobre el aralixibat.

Type: Clinical Trial, phase II.
HULP code: 5472.
Sponsored´s protocol code: MRX-800.
Sponsored by: Mirum Pharaceutical Inc.
Signed date: 08/01/2020



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.9 Diagnosis and Treatment of Allergic Diseases Group

Publications:	49
Impact Factor:	298.[392]
Q1:	20



Santiago Eugenio Quirce Gancedo.
Jefe de Servicio de Alergología. Hospital Universitario La Paz

María Pilar Encarnación Barranco Sanz. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Teresa Caballero Molina. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Luisa Caballero Soto. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Francisco Javier Contreras Porta. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Francisco Javier Domínguez Ortega. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Ana María del Carmen Fiandor Román. Jefe de Sección de Alergologia. Hospital Universitario La Paz

Carmen Gómez Traseira. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Juan Alberto Luna Porta. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Magdalena Lluch Bernal. Facultativo Especialista de Área en Alergología . Hospital Universitario La Paz

María Pedrosa Delgado. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Rosa Rodríguez Pérez. Investigadora Senior (Contrato Miguel Servet- Tipo 2). Hospital Universitario La Paz

Margarita Tomás Pérez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Ana María Umpiérrez Rodríguez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Strategic Objective

These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angiooedema and drug allergies).

The group's strategic research objectives include:

- The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile
- The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- The study of the pathogenesis and treatment of eosinophilic diseases of the airways (eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis)
- The characterisation of various types of angiooedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment
- Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs

Research lines

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult to control asthma: study on the influence of common and occupational allergens, comorbidities and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved.
- Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.
- Study of hypersensitivity reactions due to excipients present in the formulation of drugs, vaccines and cosmetics

Research Activity

Doctoral theses

Pola Pola B. Exacerbaciones de asma en el servicio de urgencias del Hospital Universitario La Paz[dissertation]. Madrid: UAM: 2020(43868).

Directors: Quirce Gancedo S, Álvarez-Sala Walther R.

Publications

- Agache I, Beltrán J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy. 2020; 75(5): 1023-42. Article. IF: 13.146; D1
- Agache I, Rocha C, Beltrán J, Song Y, Posso M, Sola I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75(5): 1043-57. Article. IF: 13.146; D1
- Agache I, Song Y, Rocha C, Beltrán J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75(5): 1058-68. Review. IF: 13.146; D1
- Balas A, Ramírez E, Trigo E, Cabañas R, Fiandor A, Arsuaga M, Lerma V, Sanz B, LuisVicario J, Herranz P, de Abajo F, Bellón T. HLA-A*68, -A*11:01, and -A*29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS. J Allergy Clin Immunol-Pract. 2020; 8(9): 3198-200. Letter. IF: 8.861; Q1
- Busse WW, Maspero JF, Lu YF, Corren J, Hanania NA, Chipps BE, Katelaris CH, FitzGerald JM, Quirce S, Ford LB, Rice MS, Kamat S, Khan AH, Jagerschmidt A, Harel S, Rowe P, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020; 125(5):565-576. Article. IF: 6.347; Q1
- Caballero ML, Quirce S. Delayed hypersensitivity reactions caused by drug excipients: A literature review. J Invest Allergol Clin Immunol. 2020; 30(6): 400-8. Review. IF: 4.333; Q2
- Caballero ML, Quirce S. Immediate hypersensitivity reactions caused by drug excipients: A literature review. J Invest Allergol Clin Immunol. 2020; 30(2): 86-100. Review. IF: 4.333; Q2
- Cabrejos S, Moreira A, Ramírez A, Quirce S, Campos GS, Davila I, Campo P. FENOMA study: Achieving full control in patients with severe allergic asthma. J ASTHMA ALLERGY. 2020; 13: 159-66. Article. IF: 4.258; Q2
- Cordón JP, Pallares PD, Molina TC. Ultrasound findings in an abdominal crisis of a patient with hereditary angioedema. Rev Esp Enferm Dig. 2020; 112(5): 418. Letter. IF: 2.086; Q4
- Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu YF, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol-Pract. 2020; 8(2): 516-26. Article. IF: 8.861; Q1
- Corvillo F, de la Morena-Barrio ME, Marcos-Bravo C, López-Trascasa M, Vicente V, Emsley J, Caba-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

llero T, Corral J, López-Lera A. The FXII c.-4T > C Polymorphism as a disease modifier in patients with hereditary angioedema due to the FXII p.Thr328Lys variant. Front Genet. 2020; 11: 1033. Article. IF: 4.599; Q2

- Domínguez-Ortega J, López-Carrasco V, Barranco P, Ifim M, Luna JA, Romero D, Quirce S. Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy. J Allergy Clin Immunol-Pract. 2020; 8(8): 2784-6. Letter. IF: 8.861; Q1
- Domínguez-Ortega J, Navarro A, Romero JD, Dordal T, Habernau A, Rodríguez M, Mur-Gimeno P, Gutiérrez MLG, Pérez-Frances C, Miravalles MJP, Colas C, Davila I, Fernández FR, Hernández MCS, Valero A. Pollen-induced allergic asthma and rhinoconjunctivitis: Differences in outcome between seasonal and nonseasonal exposure to allergens under real-life conditions (The LANDSCAPE Study). J Invest Allergol Clin Immunol. 2020; 30(6): 454-6. Editorial Material. IF: 4.333; Q2
- Domínguez-Ortega J, Sáez-Martínez FJ, Gómez-Saenz JT, Molina-Paris J, Álvarez-Gutiérrez FJ. The management of asthma as a chronic inflammatory disease and global health problem: A position paper from the scientific societies. Med Fam-SEMERGEN. 2020; 46(5): 347-54. Article. Not Indexed
- García-Boyano M, Gómez-Traseira C, Umpiérrez AM, Quirce S, Boyano-Martínez T. Drug provocation tests for assessing antibiotic hypersensitivity is shorter also better? Pediatr Infect Dis J. 2020; 39(9): 835-9. Article. IF: 2.129; Q3
- Germenis AE, Margaglione M, Pesquero JB, Farkas H, Cichon S, Csuka D, Lera AL, Rijavec M, Jolles S, Szilagyi A, Trascasa ML, Veronez CL, Drouet C, Zamanakou M. International consensus on the use of genetics in the management of hereditary angioedema. J Allergy Clin Immunol-Pract. 2020; 8(3): 901-11. Article. IF: 8.861; Q1
- Grabenhenrich L, Trendelenburg V, Bellach J, Yurek S, Reich A, Fiandor A, Rivero D, Sigurdardottir S, Clausen M, Papadopoulos NG, Xepapadaki P, Sprikkelman AB, Dontje B, Roberts G, Grimshaw K, Kowalski ML, Kurowski M, Dubakiene R, Rudzeviciene O, Fernández-Rivas M, Couch P, Versteeg SA, van Ree R, Mills C, Keil T, Beyer K. Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort. Allergy. 2020; 75(9): 2294-308. Article. IF: 13.146; D1
- Grimshaw KEC, Roberts G, Selby A, Reich A, Butiene I, Clausen M, Dubakiene R, Fiandor A, Fiocchi A, Grabenhenrich LB, Larco JI, Kowalski ML, Rudzeviciene O, Papadopoulos NG, Rosenfeld L, Sigurdardottir ST, Sprikkelman AB, Schoemaker AA, Xepapadaki P, Mills ENC, Keil T, Beyer K. Risk factors for Hen's egg allergy in Europe: EuroPrevall Birth Cohort. J Allergy Clin Immunol-Pract. 2020; 8(4): 1341-8. Article. IF: 8.861; Q1
- Howarth P, Quirce S, Papi A, Israel E, Mallett S, Bates S, Yancey S, Albers FC, Kwon N. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. Allergy. 2020; 75(8): 2085-8. Letter. IF: 13.146; D1
- Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, Quirce S, Vogelmeier CF. SABINA: An overview of short-acting beta(2)-agonist use in asthma in European countries. Adv Ther. 2020; 37(3): 1124-35. Article. IF: 3.845; Q2
- Klug C, Hemmer W, Román-Carrasco P, Focke-Tejkl M, Quirce S, Boyano-Martínez T, Gaubitzer E, Wank H, Swoboda I. Gal d 7-a major allergen in primary chicken meat allergy. J Allergy Clin Immunol. 2020; 146(1): 169-79. Article. IF: 10.793; D1
- Lazzarato I, González-Muñoz M, Heredia R, Castellar FR, de la Guía AL, Cabañas R, Fiandor A, Domínguez-Ortega J. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. Eur Ann Allergy Clin Immunol. 2020; 52(5): 235-7. Letter. Not Indexed
- Levy D, Caballero T, Hussain I, Reshef A, Anderson J, Baker J, Schwartz LB, Cicardi M, Prusty S, Feuersenger H, Pragst I, Manning ME. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2020; 33(3): 136-41. Article. IF: 1.349; Q4
- Loli-Ausejo D, Hernández-Martín I, Cabañas R, Entrala A, Gutiérrez-Alvarino M, Martínez-Sánchez N, Caballero T. Tranexamic acid plus bemiparin sodium as long-term prophylaxis in a patient with FXII-HAE during pregnancy: A case report. J Invest Allergol Clin Immunol. 2020; 30(6): 464-5. Editorial Material. IF: 4.333; Q2
- Loli-Ausejo D, Vílchez-Sánchez F, Gómez-Traseira C, Tomás-Pérez M, González-Muñoz M. Fixed food eruption caused by peanut confirmed by open oral food challenge and in vitro cellular testing. Contact Dermatitis. 2020; 83(3): 227-9. Editorial Material. IF: 6.6; D1
- Marqués-Mejías MA, Tomás-Pérez M, Vila-Nadal G, Quirce S. Acute urticaria in the pediatric emergency department Management and possible triggers. Ann Allergy Asthma Immunol. 2020; 124(4): 396-7. Letter. IF: 6.347; Q1
- Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, Arnaout R, Arruda LK, Asero R, Aygoren-Pursu E, Banerji A, Bauer A, Ben-Shoshan M, Berardi A, Bernstein JA, Betschel S, Bindslev-Jensen C, Bizjak M, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Broesby-Olsen S, Busse P, Buttgereit T, Bygum A, Caballero T, Campos RA, Cancian M, Cherrez-Ojeda I, Cohn DM, Costa C, Craig T, Criado PR, Criado RF, Csuka D, Dissemond J, Du-Thanh A, Ensina LF, Ertas R, Fabiani JE, Fantini C, Farkas H, Ferrucci SM, Figueras-Nart I, Fili NL, Fomina D, Fukunaga A, Gelincik A, Giménez-Arnau A, Godse K, Gompels M, Goncalo M, Gotua M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Ilina N, Inomata N, Jakob T, Josviack DO, Kang HR, Kaplan A, Kasperska-Zajac A, Katelaris C, Kessel A, Kleinheinz A, Kocaturk E, Kosnik M, Krasowska D, Kulthanan K, Kumaran MS, Sousa JIL, Longhurst HJ, Lumry W, MacGinnitie A, Magerl M, Makris MP, Malbran A, Marsland A, Martínez-Saguer I, Medina IV, Meshkova R, Metz M, Nasr I, Nicolay J, Nishigori C, Ohsawa I, Ozyurt K, Papadopoulos NG, Parisi CAS, Peter JG, Pfutzner W, Popov T, Prior N, Ramon GD, Reich A, Reshef A, Riedl MA, Ritchie B, Rockmann-Helmbach H, Rudenko M, Salman A, Sánchez-Borges M, Schmid-Grendelmeier P, Serpa FS, Serra-Baldrich E, Sheikh FR, Smith W, Soria A, Staubach P, Steiner UC, Stobiecki M, Sussman G, Tagka A, Thomsen SF, Treudler R, Valle S, van Doorn M, Varga L, Vázquez DO, Wagner N, Wang LC, Weber-Chrysochoou C, Ye YM, Zalewska-Janowska A, Zanichelli A, Zhao ZT, Zhi YX, Zuberbier T, Zwiener RD, Castaldo A. Definition, aims, and implementation of GA(2)LEN/HAEi angioedema centers of reference and excellence. Allergy. 2020; 75(8): 2115-23. Letter. IF: 13.146; D1
- Moral VP, Gómez-Outes A, Gancedo SQ, Alobid I, Rodríguez CA, Aparicio MB, García G, Ruiz FG, Requena AH, Murua JK, París JM, Belinchon FJP, Encinas MP, Zamora JP, Crespo MP, Pina CS, Ortega JS. Discrepancies between GEMA and GINA in the classification of inhaled corticosteroids. Arch Bronconeumol. 2020; 56(7): 472-3. Letter. IF: 4.872; Q2
- Moscato G, Apfelbacher C, Brockow K, Eberle C, Genuneit J, Mortz CG, Quecchia C, Quirce S, Siracusa A, Tarlo SM, van Kampen V, Walusiak-Skorupa J, Raulf M. Gender and occupational allergy: Report from the task force of the EAACI Environmental and Occupational Allergy Interest Group. Allergy. 2020; 75(11): 2753-63. Article. IF: 13.146; D1
- Pedrosa M, Guerrero-Sánchez VM, Canales-Bueno N, Loli-Ausejo D, Castillejo MA, Quirce S, Jorrin-Novo JV, Rodríguez-Pérez R. Quercus ilexpollen allergen, Que i 1, responsible for pollen food allergy syndrome caused by fruits in Spanish allergic patients. Clin Exp Allergy. 2020; 50(7): 815-23. Article. IF: 5.018; Q2
- Pinera-Salmerón P, Álvarez-Gutiérrez FJ, Domínguez-Ortega J, Álvarez C, Blanco-Aparicio M, Dávila I, López-Vina A, Miguens I, Soto-Retes L. Referral recommendations for adult emergency department patients with exacerbated asthma. Emergencias. 2020; 32(4): 258-68. Article. IF: 3.881; Q1
- Plaza V, del Cuvillo A, Soto-Retes L, Gras JR, Cisneros C, Sánchez-Cuellar S, Gómez-Bastero A, Martínez-Moragón E, Sabadell C, Quirce S, Álvarez F, Rosado A, Lluch I, Soto G. Functional endoscopic sinus surgery for nasal polyposis in asthma patients: Impact on bronchial inflammation. Arch Bronconeumol. 2020; 56(6): 403-5. Letter. IF: 4.872; Q2
- Quirce S, Heffler E, Nenasheva N, Demoly P, Menzies-Gow A, Moreira-Jorge A, Nissen F, Hanania NA. Revisiting late-onset asthma: Clinical characteristics and association with allergy. J

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Asthma Allergy. 2020; 13: 743-52. Review. IF: 4.258; Q2

- Román-Carrasco P, Hemmer W, Klug C, Friedrich A, Stoll P, Focke-Tejkl M, Altmann F, Quirce S, Swoboda I. Individuals with IgE antibodies to alpha-Gal and CCD show specific IgG subclass responses different from subjects non-sensitized to oligosaccharides. Clin Exp Allergy. 2020; 50(9): 1107-10. Letter. IF: 5.018; Q2
- Ruiz-Hornillos J, Jiménez BR, Vila AF, Fernández AM, García MJH, Domínguez-Ortega J. Omalizumab as a therapeutic option for nasal polyposis in moderate-to-severe persistent allergic asthma: Evidence from a prospective study in a real-world setting. J Invest Allergol Clin Immunol. 2020; 30(6): 470-2. Editorial Material. IF: 4.333; Q2
- Sánchez-García S, Rial MJ, Domínguez-Ortega J. Long and winding road: from infant wheeze to adult asthma. Curr Opin Pulm Med. 2020; 26(1): 3-9. Review. IF: 3.155; Q3
- Sigsgaard T, Basinas I, Doekes G, de Blay F, Folletti I, Heederik D, Lipinska-Ojrzanowska A, Nowak D, Olivieri M, Quirce S, Raulf M, Sastre J, Schlunssen V, Walusiak-Skorupa J, Siracusa A. Respiratory diseases and allergy in farmers working with livestock: a EAACI position paper. Clin Transl Allergy. 2020; 10(1): 29. Review. IF: 5.871; Q2
- Suojalehto H, Suuronen K, Cullinan P, Lindstrom I, Sastre J, Walusiak-Skorupa J, Muñoz X, Talini D, Klusackova P, Moore V, Merget R, Svanes C, Mason P, Dell'Omo M, Moscato G, Quirce S, Hoyle J, Sherson D, Preisser A, Seed M, Rifflart C, Godet J, de Blay F, Vandenplas O. Phenotyping occupational asthma caused by acrylates in a multicenter cohort study. J Allergy Clin Immunol-Pract. 2020 ;8(3): 971-9. Article. IF: 8.861; Q1
- Tarlo SM, Quirce S. Impact of identification of clinical phenotypes in occupational asthma. J Allergy Clin Immunol-Pract. 2020; 8(10): 3277-82. Review. IF: 8.861; Q1
- Tomás-Pérez M, Gómez-Traseira C, González-Muñoz M, Quirce S. Adverse reaction with hexavalent vaccine: An unusual case. Allergol Immunopath. 2020; 48(6): 801-3. Article. IF: 1.667; Q4
- Tomás-Pérez M, Domínguez-Ortega J. Pemphigoid reaction by specific allergen immunotherapy: An unusual adverse reaction. J Invest Allergol Clin Immunol. 2020; 67(1): 83-6. Article. Not Indexed
- Urrutia I, Delgado J, Domínguez-Ortega J, Mascaros E, Pérez M, Resler G, Plaza V, Flor X, Vega JM, Martínez GL, Fernández JP, Muñoz X, Roger A, Navarro EM, Gómez E, Adrados ACG, Pérez RG, Pérez JMH, Barcala FJG, Rey JG, Bobolea ID, García SS, Saenz JTG, Cebollera P, Vina AL, Moragon EM, Valero A, Campos RD, Talavera IG, Viteri SA, Robaina JCG, Arrondo AP. Clinical factors associated with overuse of asthma reliever medication. J Invest Allergol Clin Immunol. 2020; 30(1): 42-8. Article. IF: 4.333; Q2
- Vicente F, Sanchiz A, Rodríguez-Pérez R, Pedrosa M, Quirce S, Haddad J, Besombes C, Linacero R, Allaf K, Cuadrado C. Influence of instant controlled pressure drop (DIC) on allergenic potential of tree nuts. Molecules. 2020; 25(7): 1742. Article. IF: 4.411; Q2
- Vílchez-Sánchez F, Domínguez-Ortega J, Muñoz MG, Loli-Ausejo D, Heredia-Revuelto R, Román AF, Quirce S. Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test. Eur Ann Allergy Clin Immunol. 2020; 52(2): 91-3. Article. Not Indexed
- Vílchez-Sánchez F, Loli-Ausejo D, Rodríguez-Mariblanca A, Montserrat-Villatoro J, Ramírez E, Domínguez-Ortega J, González-Muñoz M. Lymphocyte transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. Allergy. 2020; 75(12): 3267-72. Letter. IF: 13.146; D1
- Villamañán E, Herrero A, Álvarez-Sala R, Quirce S. Multidisciplinary severe asthma management: The role of hospital pharmacists in accredited specialized adult asthma units in Spain. J Invest Allergol Clin Immunol. 2020; 30(4): 305-6. Letter. IF: 4.333; Q2
- Wanden-Berghe C, Compes CC, Jiménez MIM, Cunill JLP, Boluda ER, Candela CG, Casas NV, Pelaez RB, Román DAD, Lázaro MAP, Martos EAS, Faedo CM, Guardiola PD, Hernández JA, Murillo AZ, Martín CC, Paris AS, Fontalba MDM, Lobo G, Martín PM, Pérez FC, Folgueras TM, Palmero MAM, Pérez LML, Burdiel OSV, Costa CM, Pérez CT, Ramírez MJM, Delgado YG, González MAP, Roca SM, Zafra MVG, Díaz MG, Gabino VR, Baeza BM, Marín MG, Rocamora JAI, Sánchez RS, Celaya AA, Ortiz CJ, Llanos JPS, de la Maza BP, García PL, Martínez MCG, Santaliestra MJC. Home and ambulatory artificial nutrition (NADYA) group report. Home parenteral nutrition in Spain, 2018. Nutr Hosp. 2020; 37(2): 403-7. Article. IF: 1.057; Q4
- Wardlaw A, Howarth PH, Israel E, Taille C, Quirce S, Mallett S, Bates S, Albers FC, Kwon N. Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma. Clin Exp Allergy. 2020; 50(7): 869-72. Letter. IF: 5.018; Q2
- Zamarrón E, Romero D, Fernández-Lahera J, Villasante C, Pinilla I, Barranco P, Domínguez-Ortega J, Walther RAS. Should we consider paranasal and chest computed tomography in severe asthma patients? Respir Med. 2020; 169: 106013. Article. IF: 3.415; Q2

Research projects

Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DTV-IHAE-QOL) (PI-281). AEDAF. 2009-Ongoing.

Managment centre: FIBHULP

Caballero Molina MT. Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). ISCIII. 2020-2022.

Managment centre: FIBHULP

Caballero Molina MT. Humanistic and economic burden of hereditary angioedema in Spain (Carga económica y humanística del angioedema hereditario en España). Shire-Takeda. 263.480€. PI: 4674. (IIR-ESP-002527. PI: 4674). Shire-Takeda. 2019-Ongoing.

Managment centre: FIBHULP

Caballero Molina MT. Nuevos biomarcadores en enfermedades mediadas por el sistema del complemento (PI15/00255). ISCIII. 2016-2020.

Managment centre: FIBHULP

Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen gramíneas. Inmunotek. 2015-Ongoing.

Managment centre: FIBHULP

Domínguez Ortega FJ. Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. Glaxosmithkline S. A. 2021-Ongoing.

Managment centre: FIBHULP

Quirce Gancedo S. Programa de la unidad multidisciplinar de asma grave de La Paz: de la investigación a la práctica clínica. Astrazeneca Farmacéutica Spain S. A. 2019-Ongoing.

Managment centre: FIBHULP

Quirce Gancedo S. Relación entre asma y obesidad en la población española mayor o igual a 18 años. Novartis Farmacéutica S. A. 2009-Ongoing.

Managment centre: FIBHULP

Quirce Gancedo S. Sesiones en investigación del diagnóstico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alérgica y alergia a alimentos. Thermo Fisher Diagnostics S. L. U. 2017-Ongoing.

Managment centre: FIBHULP

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Quirce Gancedo SE, Fiandor Román AMC. Plan de formación de la unidad de asma grave del Hosptial Universitario La Paz: de la investigación a la práctica clínica. Astrazeneca Farmacéutica Spain S. A. 2020-2021.
Managment centre: FIBHULP

Quirce Gancedo SE, Herranz Pinto P. New findings in asthma, allergy and atopic dermatitis. Omnix Pharma S. L. 2018-Ongoing.
Managment centre: FIBHULP

Rodríguez Pérez MR. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12199). CM. 2020-2021.
Managment centre: FIBHULP

Rodríguez Pérez MR. Desarrollo de un programa formativo de formación en investigación en centros de trabajo. Colegio Valle del Miro. 2016-Ongoing.
Managment centre: FIBHULP

Rodríguez Pérez MR. Evaluación de la capacidad alergénica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. Angulas Aguinaga S. A. U. 2018-Ongoing.
Managment centre: FIBHULP

Cibers and Retics

Caballero Molina MT. Centro de Investigación Biomédica en Red de Enfermedades Raras - CIBERER (CB06/07/1033). ISCIII. (31/12/2020):
Managment centre: FIBHULP

Clinical trials

Caballero Molina, MT. BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCX7353 como tratamiento oral para la prevención de ataques en pacientes con angioedema hereditario.
Type: Clinical Trial, phase III.
HULP code: Appendix 2 4984.
Sponsored´s protocol code: BCX7353-302.
Sponsored by: Biocryst Pharmaceuticals Inc.
Signed date: 19/02/2020

Caballero Molina, MT. Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la eficacia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de C1 (C1-INH) normal y angioedema adquirido debido a déficit de C1-INH.
Type: Clinical Trial, phase III.
HULP code: 5550.
Sponsored´s protocol code: SHP643-303.
Sponsored by: Dyax Corp.
Signed date: 18/11/2020

Lluch Bernal, MM. Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia al polen de gramíneas.
Type: Clinical Trial, phase II.
HULP code: 5553.
Sponsored´s protocol code: SL-51A.
Sponsored by: Roxall Medicina España S.A (Bial Industrial Farmacéutica S.A.).
Signed date: 10/09/2020

Quirce Gancedo, SE. Real world effectiveness study of mepolizumab in severe eosinophilic asthma in spain. Redes study.
Type: Study, phase EPA-OD.
HULP code: PI-3885 .
Sponsored´s protocol code: GLA-MEP-2019-01.
Sponsored by: Glaxosmithkline S.A.
Signed date: 09/01/2020

Patents and trademarks

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIIS-FJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.10 Gynecologic Oncology Group

Publications:	15
Impact Factor:	58.^{833}
Q1:	5



Ignacio Zapardiel Gutiérrez. Subdirector Científico de IdiPAZ. Hospital Universitario La Paz. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

Diana Alecsandru Danceanu . Médico Especialista en Inmunología. IVI Madrid

Covadonga Álvarez López. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Cerrillo Martínez. Ginecóloga Especialista en Reproducción Humana. IVI Madrid

Ónica María Armijo Suárez. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. Hospital Universitario La Paz

María Dolores Diestro Tejada. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz

Juan Antonio García Velasco. Profesor Titular. Universidad Rey Juan Carlos

Cristina González Benítez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Alicia Hernández Gutiérrez. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María Josefa Herrera de la Muela . Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Patología Mamaria. Hospital Universitario La Paz

Ana López Carrasco. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Israel Ortega Sánchez. Coordinador del Departamento Internacional. IVI Madrid

Margarita Sánchez-Pastor Ruiz. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María Serrano Velasco. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Elisa Varela Sanz. Investigadora Postdoctoral. Centro Nacional de Investigaciones Oncológicas

Strategic Objective

The main objective of our group is to study all aspects related to gynaecologic malignancies. It includes from diagnosis to treatment and follow-up. For the next years we will focus our research on the malignancies affecting female uterus, including cervical and endometrial cancer as well as uterine sarcomas.

We will develop at least two stable and comprehensive specific research lines trying to pay attention to molecular aspects as well as clinical features of the Gynaecological cancers. But we will support the rest of aspects of the subspecialty.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Evaluation, treatment and surgery of oncologic diseases in gynecology.
- Pelvic floor reconstructive surgery.
- Molecular disorders in preeclamsia, placenta and other obstetrical diseases.

Research Activity

Publications

- Ángeles MA, Rychlik A, Cabarrou B, Spagnolo E, Guyon F, Pérez-Benavente A, Gil-Moreno A, Siegrist J, Querleu D, Mery E, Gladieff L, Hernández A, Ferron G, Martínez A. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2020; 158(3): 614-21. Article. IF: 5.482; D1
- Cabanes M, Boria F, Gutiérrez AH, Zapardiel I. Intra-operative identification of ureters using indocyanine green for gynecological oncology procedures. Int J Gynecol Cancer. 2020; 30(2): 278. Editorial Material. IF: 3.437; Q2
- Calaf J, Palacios S, Cristóbal I, Canete ML, Monleón J, Fernández J, Hernández A, Vázquez F. Validation of the Spanish version of the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire in women with uterine myomatosis. Med Clin. 2020; 154(6): 207-13. Article. IF: 1.725; Q3
- Cibula D, Kocian R, Plaikner A, Jarkovsky J, Klat J, Zapardiel I, Pilka R, Torne A, Sehnal B, Ostojich M, Petiz A, Sánchez OA, Presl J, Buda A, Raspagliesi F, Kascak P, van Lonkhuijzen L, Barahona M, Minar L, Blecharz P, Pakiz M, Wydra D, Snyman LC, Zalewski K, Zorrero C, Havelka P, Redecha M, Vinnytska A, Vergote I, Tingulstad S, Michal M, Kipp B, Slama J, Marnitz S, Bajsova S, Hernández A, Fischerova D, Nemejcova K, Kohler C. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. Eur J Cancer. 2020; 137: 69-80. Article. IF: 9.162; Q1
- Díaz-Feijoo B, Franco S, Torne A, Benito V, Hernández A, Lago V, Rovira R, Acosta U, Agusti N, Gil-Moreno A, Gil-Ibáñez B, Bebia V, Tejerizo A, Pérez-Regadera JF, Lubrano A, González C, Domingo S, Ruiz R, Cobos P, Luna-Guibourg R, Gilabert-Estelles J, Chipiriliu D, Llueca A, Piquer L, Coronado P, Gracia M. Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study. Gynecol Oncol. 2020; 158(2): 287-93. Article. IF: 5.482; D1
- Díaz-Feijoo B, Torne A, Tejerizo A, Benito V, Hernández A, Ruiz R, Domingo S, Luna-Guibourg R, Llueca A, Coronado P, Gilabert-Estelles J, Bebia V, Gil-Ibáñez B, Gil-Moreno A. Prognostic value and therapeutic implication of laparoscopic extraperitoneal paraaortic staging in locally advanced cervical cancer: A spanish multicenter study. Ann Surg Oncol. 2020; 27(8): 2829-39. Article. IF: 5.344; Q2
- García JC, Caraballo AJ, Vallejo MDR, Zapardiel I. Retrospective cohort study on the symptomatic recurrence pattern after hysteroscopic polypectomy. Gynecol Minim Invasive Ther-GMIT. 2020; 9(4): 209-14. Article. Not Indexed
- Gorostidi M, Gil-Ibáñez B, Alonso S, Gil-Moreno A, Hernández A, Torne A, Zapardiel I. Fertility preservation treatment of gynecological cancer patients in Spain: a national survey (GOFER study). Arch Gynecol Obstet. 2020; 301(3): 793-800. Article. IF: 2.344; Q3
- Halaska MJ, Gracia M, Laky R, Zapardiel I. Morcellation of the Uterus: Is there any place? Curr Oncol Rep. 2020; 22(7): 68. Review. IF: 5.075; Q2
- Peiretti M, Candotti G, Buda A, Zapardiel I, Fanni D, Proto A, Fais ML, Mais V. Feasibility of hand-assisted laparoscopic sentinel node biopsy in open endometrial cancer surgery. Minim Invasive Ther Allied Technol. 2020; 29(5): 299-303. Article. IF: 2.442; Q2
- Pineda VG, Gutiérrez AH, Segovia MG, Ridruejo JS, Tejeda MDD, Zapardiel I. Low-volume nodal metastasis in endometrial cancer: Risk factors and prognostic significance. J Clin Med. 2020; 9(6): 1999. Article. IF: 4.241; Q1
- Pineda VG, Hernández A, Cabanes M, Siegrist J, Gracia M, Zapardiel I. Tertiary cytoreductive surgery by laparoscopy in granulosa cell tumor recurrence. Int J Gynecol Cancer. 2020; 30(11): 1844-5. Editorial Material. IF: 3.437; Q2
- Rychlik A, Zapardiel I, Baquedano L, Maestre MAM, Querleu D, Martín PJC. Clinical relevance of high-intermediate risk endometrial cancer according to European risk classification. Int J Gynecol Cancer. 2020; 30(10): 1528-34. Article. IF: 3.437; Q2
- Spagnolo E, Hernández A, Pascual I, Cabanes M, López A, Zapardiel I. Bowel and ureteral assessment by indocyanine green real-time visualization during deep infiltrating endometriosis surgery. Colorectal Dis. 2020; 22(10): 1464-5. Letter. IF: 3.788; Q1
- Zapardiel I, Iacoponi S, Coronado PJ, Zalewski K, Chen F, Fotopoulou C, Dursun P, Kotsopoulos IC, Jach R, Buda A, Martínez-Serrano MJ, Grimm C, Fruscio R, García E, Sznurkowski JJ, Ruiz C, Noya MC, Barazi D, Díez J, de la Noval BD, Bartusevicius A, De Iaco P, Otero M, Díaz M, Haidopoulos D, Franco S, Blecharz P, Zuniga MA, Rubio P, Gardella B, Papatheodorou DC, Yildirim Y, Fargas F, Macuks R. Prognostic factors in patients with vulvar cancer: the VULCAN study. Int J Gynecol Cancer. 2020; 30(9): 1285-91. Article. IF: 3.437; Q2

Research projects

Hernández Gutiérrez A. Convocatoria interna Jesús Antolín Garciarena 2018. Contrato Emanuela Spagnolo. FIBHULP. 2018-Ongoing.

Managment centre: FIBHULP

Hernández Gutiérrez A. Factores inmunológicos en la transformación maligna de la endometriosis. FIBHULP. 2018-Ongoing.

Managment centre: FIBHULP

Herrera de la Muela MJ. Calidad de vida y satisfacción con la cirugía en mujeres con cáncer de mama con reconstrucción postmastectomia: Estudio BRECAR (Breast Cancer Reconstruction Study). FIBHULP. 2015-Ongoing.

Managment centre: FIBHULP

Zapardiel Gutiérrez I. Evaluación del antígeno epididimal humano -HE4 - en el diagnóstico diferencial y seguimiento de la endometriosis superficial y profunda. Abbott Laboratories S.A. 2012-Ongoing.

Managment centre: FIBHULP

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Zapardiel Gutiérrez I. Ultraestadificación molecular ganblio centinela en cáncer de cérvix: mRNA e6/e7 HPV. Secuvita S. L. 2013-Ongoing.

Managment centre: FIBHULP

Clinical trials

Diestro Tejeda, MD. Evaluación del método Osna para la detección rápida de metástasis en ganglios linfáticos en mujeres con cáncer endometrial.

Type: Study, phase No EPA.
HULP code: PI-4275B .
Sponsored´s protocol code: CP-OSNA-EC-210.
Sponsored by: Sysmexeurope GMBH.
Signed date: 02/10/2020

Hernández Gutiérrez, A. Randomized, double-blind and placebo-controlled trial to evaluate the effect of a probiotic mix on bacterial vaginosis in adult women.

Type: Study, phase Medical Devices.
HULP code: 5502.
Sponsored´s protocol code: VAG/001/19 REProVag.
Sponsored by: Otcem Pharmaceuticals S.L.
Signed date: 27/01/2020

López Carrasco, A. Estudio de extensión, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de linzagolix a largo plazo en pacientes con dolor de moderado a intenso asociado a endometriosis.

Type: Clinical Trial, phase III.
HULP code: 5522.
Sponsored´s protocol code: 19OBE2109-006.
Sponsored by: Obseva S.A.
Signed date: 08/06/2020

Zapardiel Gutiérrez, I. Follow-up in gynecological cancer survivors: an eortc qlg-gcg survivorship study.

Type: Study, phase No EPA.
HULP code: PI-3676 .
Sponsored´s protocol code: 1514-QLQ-GCG.
Sponsored by: Eortc Accounting Department.
Signed date: 23/04/2020

Patents and trademarks

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.

3.4.11 Patient Blood Management Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	17
Impact Factor:	57.595
Q1:	8



Manuel Quintana Díaz. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María José Alcaide Martín. Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz

Eva María Andrés Esteban. Epidemióloga. Hospital Universitario La Paz

Sara Fabra Cadenas. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz

Pilar Fernández Calle. Facultativo Especialista de Área en Análisis Clínicos. Coordinadora de Calidad de Análisis Clínicos. Hospital Universitario La Paz

Milagros Martí de Gracia. Facultativo Especialista de Área en Radiodiagnóstico. Jefe de Sección de Radiología de Urgencias. Hospital Universitario La Paz

José Antonio García Erce. Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca

Raúl Juárez Vela. Profesor Titular de Universidad. Universidad de La Rioja

Ana María Martínez Virto. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. Hospital Universitario La Paz

Paloma Oliver Sáez. Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz

María Inmaculada Pinilla Fernández. Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz

María Angélica Rivera Núñez. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Marcelino Sánchez Casado. Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

Stratifying risk in the critically ill patient

- Stratify pulmonary thromboembolis risk
- Try to diagnose the potentially ill politraumatized patient at the emergency room Enhance the use of blood products
- Critically ill patient coagulopathy
- Early diagnose of anemia at the emergency room
- Intravenous iron usage

Anticoagulation Reserval

Patient Blood Mangement Implementation

Research lines

- Critical Bleeding
- Anticoagulation reversal
- Fraility
- COVID19

Interrelation in Cardiovascular Diseases and Cares

Research Activity

Doctoral theses

Suárez Rovira NA. Protocolos de Transfusión Masiva con esquemas predeterminados vs guiados por tests viscoelásticos: estudio comparativo y análisis de coste efectividad en pacientes con trauma grave.[dissertation]. Madrid (virtual): UAM: 2020(03/09/2020).

Directors: Quintana Díaz M, García-Erce JA.

Mesa Galán LA. Utilidad clínica de la ecografía ocular en el diagnóstico de Síndrome de Terson en pacientes neurocríticos[dissertation]. Madrid: UAM: 2020(15/12/2020).

Director: Quintana-Díaz M.

Publications

- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buno A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martide-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Borobia AM, Collado SG, Cardona CC, Pueyo RC, Alonso CF, Torres IP, González MC, Codesido JRC, Betegon MA, Barcela LA, Andicoechea AO, Testa AF, Colina JT, Dorribo AC, Galán CD, Ávila JCM, Lugilde ST, Sansuán AJC. Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma Pain: InMEDIATE: A randomized controlled trial in emergency departments. Ann Emerg Med. 2020; 75(3): 315-28. Article. IF: 5.721; D1
- Chico-Fernández M, Sánchez-Casado M, Barea-Mendoza JA, García-Saez I, Ballesteros-Sanz MA, Guerrero-López F, Quintana-Díaz M, Molina-Díaz I, Martín-Iglesias L, Toboso-Casado JM, Pérez-Barcena J, Llompart-Pou JA. Outcomes of very elderly trauma ICU patients. Results from the Spanish trauma ICU registry. Med Intensiv. 2020; 44(4): 210-5. Article. IF: 2.491; Q3
- Czapla M, Karniej P, Juarez-Vela R, Lokiec K. The association between nutritional status and in-hospital mortality among patients with acute coronary syndrome-a result of the retrospective nutritional status heart study (NSHS). Nutrients. 2020; 12(10): 3091. Article. IF: 5.717; Q1
- del Moral-Barbudo B, Blancas R, Ballesteros-Ortega D, Quintana-Díaz M, Martínez-González O. Current and research therapies for the prevention and treatment of delayed neurological syndrome associated with carbon monoxide poisoning: A narrative review. Hum Exp Toxicol. 2020; 39(6): 765-72. Review. IF: 2.903; Q3
- Doménech-Briz V, Romero RG, de Miguel-Montoya I, Juárez-Vela R, Martínez-Riera JR, Marmol-López MI, Verdeguer-Gómez MV, Sánchez-Rodríguez A, Gea-Caballero V. Results of nurse case management in primary heath care: Bibliographic review. Int J Environ Res Public Health. 2020; 17(24): 9541. Review. IF: 3.39; Q1
- Jérico C, Beverina I, Quintana-Díaz M, Salvadori U, Melli C, Rondinelli MB, Recasens V, Brando B, García-Erce JA. Efficacy and safety of high-dose intravenous iron as the first-choice therapy in outpatients with severe iron deficiency anemia. Transfusion. 2020; 60(7): 1443-9. Article. IF: 3.157; Q3
- López-Fernández A, Quintana-Díaz M, Sánchez-Sánchez M. Diffuse axonal injury associated with COVID-19 infection. Med Clin. 2020; 155(6): 274-5. Letter. IF: 1.725; Q3
- Martínez-Riera JR, Juárez-Vela R, Díaz-Herrera MA, Montejano-Lozoya R, Doménech-Briz V, Benavent-Cervera JV, Cabellos-García AC, Melo P, Nguyen TH, Gea-Caballero V. Qualitative analysis by experts of the essential elements of the nursing practice environments proposed by the TOP10 questionnaire of assessment of environments in primary health care. Int J Environ Res Public Health. 2020; 17(20): 7520. Article. IF: 3.39; Q1
- Muñoz-Lucas MA, Jareno-Esteban J, Gutiérrez-Ortega C, López-Guijarro P, Collado-Yurrita L, Quintana-Díaz M, Callol-Sánchez L. Influence of chronic obstructive pulmonary disease on volatile organic compounds in patients with non-small cell lung cancer. Arch Bronconeumol. 2020; 56(12): 801-5. Article. IF: 4.872; Q2
- Quintana-Díaz M, Andrés-Esteban EM, Ramírez-Cervantes KL, Oliván-Blázquez B, Juárez-Vela R, Gea-Caballero V. Coagulation parameters: An efficient measure for predicting the prognosis and clinical management of patients with COVID-19. J Clin Med. 2020; 9(11): 3482. Article. IF: 4.241; Q1

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

- Quintana-Díaz M, Andrés-Esteban EM, Sánchez-Serrano J, Martínez-Virto A, Juárez-Vela R, García-Erce JA. Transfusions in the Emergency department: More than a blood transfusion. Rev Clin Esp. 2020; 220(7): 393-9. Article. IF: 1.556; Q3
- Quintana-Díaz M, Jerico-Alba C, Zalba-Marcos S, García-Erce JA. Reply to transfusions in the emergency department: Are there other care alternatives? Rev Clin Esp. 2020; 220(7): 456. Letter. IF: 1.556; Q3
- Silva-Obregón JA, Quintana-Díaz M, Saboya-Sánchez S, Marián-Crespo C, Romera-Ortega MA, Chamorro-Jambrina C, Estrella-Alonso A, Andrés-Esteban EM. Frailty as a predictor of short- and long-term mortality in critically ill older medical patients. J Crit Care. 2020; 55: 79-85. Article. IF: 3.425; Q2
- Tung-Chen Y, de Gracia MM, Díez-Tascón A, Alonso-González R, Agudo-Fernández S, Parra-Gordo ML, Ossaba-Vélez S, Rodríguez-Fuertes P, Llamas-Fuentes R. Correlation between chest computed tomography and lung ultrasonography in patients with coronavirus disease 2019 (COVID-19). Ultrasound Med Biol. 2020; 46(11): 2918-26. Article. IF: 2.998; Q1
- Tung-Chen Y, Rivera-Núñez MA, Martínez-Virto AM. Lung ultrasound in the frontline diagnosis of COVID-19 infection. Med Clin. 2020; 155(5): 232. Editorial Material. IF: 1.725; Q3
- Viejo-Moreno R, Cabrejas-Aparicio A, Arriero-Fernández N, Quintana-Díaz M, Galvan-Roncero E, Gálvez-Marco MD, Carriedo-Scher C, Balaguer-Recena J, Marián-Crespo C. Mobile intensive care unit versus hospital walk-in patients, in the treatment of first episode ST- elevation myocardial infarction. Eur J Intern Med. 2020; 73: 83-9. Article. IF: 4.487; Q1

Research projects

Andrés Esteban EA. Variables pronósticos. recuros consumidos y coste hospitalario de pacientes ingresados por infección Sars-Cov-2 según su fragilidad (COV20/00519). ISCIII. 2020-2021.

Managment centre: FIBHULP

Martí de Gracia M. Mejora de la adecuación en la solicitud de pruebas de imagen con radiación ionizante (TC y RX) en los servicios de urgencias hospitalarios. proyecto MAPAC-IMAGEN II (PI16/01828). ISCIII. 2017-2021.

Managment centre: FIBHULP

Martínez Virto AM. Epidemiología del angioedema en los Servicios de Urgencias. Shire International GMBH. 2020-Ongoing.

Managment centre: FIBHULP

Oliver Sáez P. Estudio de gasometría en el lugar de asistencia. Beneficio para el paciente. Asociación Española de Farmaceúticos Analistas. 2012-Ongoing.

Managment centre: FIBHULP

Quintana Díaz M, Cobas Gamallo J, Pérez Blanco JJ. Implantación de un programa de cursos de formacion de la mas alta calidad destinado a veterinarios en España. Improve Formación Veterinaria S. L. 2016-Ongoing.

Managment centre: FIBHULP

Quintana Díaz M. Estudio de la coagulopatía y de los perfiles de inflamación sistémica asociados a la hemorragia subaracnoidea aneurismática. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2020-Ongoing.

Managment centre: FIBHULP

Quintana Díaz M. Estudio de monitorización de heparinas de bajo peso molecular como profilaxis en un Servicio de Urgencias. Bayer Hispania S. L. 2011-Ongoing.

Managment centre: FIBHULP

Quintana Díaz M. Identificaión de factores de gravedad en el paciente con traumatismo potencialmente grave. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2013-Ongoing.

Managment centre: FIBHULP

Quintana Díaz M. Traumatismo y transfusión ¿una asociación necesaria? Fundación Mutua Madrileña. 2019-Ongoing.

Managment centre: FIBHULP

Clinical trials

Quintana Diaz, M. A multicenter, randomized, open-label, parallel group pilot study to evaluate safety and efficacy of convalescent methylene blue treated (mbt) plasma from donors recovered from coronavirus disease 2019 (covid-19) with standard medical treatment (smt) versus smt alone in subjects with covid-19 requiring admission to the intensive care unit (icu).

Type: Study, phase No EPA.
HULP code: 5581.
Sponsored´s protocol code: GC2003.
Sponsored by: Grifols Worldwide Operations, Ltd.
Signed date: 17/04/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.12 Urology Group

Publications:	63
Impact Factor:	336.[465]
Q1:	25



Luis Martínez-Piñeiro Lorenzo. Jefe de Servicio en Urología. Hospital Universitario La Paz

Alfredo Aguilera Bazán. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

José María Alonso Dorrego. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Mario Álvarez Maestro. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Luisa María Botella Cubells. Investigadora Científica. Centro de Investigaciones Biológicas - CSIC

José Ramón Cansino Alcaide. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Cristina de Castro Guerin. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Esaú Fernández Pascual. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Mercedes Ferrer Parra. Profesor Titular. Departamento de Fisiología. Universidad Autónoma de Madrid

Eugenia García Fernández. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

María Justa García Matres y Cortés. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

José Miguel Gómez de Vicente. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Asier Leivar Tamayo. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Estefanía Esperanza Linares Espinos. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Pedro López Pereira. Jefe de Servicio de Urología Pediátrica. Hospital Universitario La Paz

Nuria Malats Riera. Investigadora Senior. Centro Nacional de Investigaciones Oncológicas

Jose Antonio Moreno Valle. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

José Ramón Pérez-Carral García. Médico Adjunto en Urología. Hospital Universitario La Paz

Francisco Xavier Real Arribas. Investigador Senior. Centro Nacional de Investigaciones Oncológicas

Emilio Ríos González. Médico Adjunto en Urología. Hospital Univiversitario Infanta Sofía

Maria del Mar Valés Gómez. Científico Titular. Centro Nacional de Biotecnología-CSIC

Strategic Objective

We aim to consolidate a strong research group into:

- Urologic Oncology
- Reconstructive surgery
- Endurologic and minimally invasive surgery
- Lithiasis
- Incontinence / Neuro-urology

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Andrology / Reproduction

Through basic and experimental research, clinical research, translational research and clinical trials.

The results of this projects should be translated into doctoral theses, publications in high impact journals and visibility factor, as to finally achieve patents and trademarks.

Research lines

Urological Oncology

The group's efforts will focus on the following fields of research:

BLADDER CANCER

- Immunological response in patients with bladder cancer treated with BCG.
- Urinary markers in diagnosis and prediction of response in patients with bladder cancer.
- New immunomodulatory treatments in bladder cancer.
- New imaging methods for the diagnosis of bladder cancer.
- Efficacy of combined chemo and immunotherapy hyperthermia in bladder cancer.

PROSTATE CANCER

- Castration resistant prostate carcinoma, immune response, and evaluation of predictive markers of therapeutic response.
- Medical treatment of locally advanced and metastatic prostate cancer.
- Development of new surgical minimally invasive techniques for localized prostate cancer.

KIDNEY CANCER

- Development of new surgical minimally invasive techniques for localized kidney cancer.
- Research of new therapeutic lines in hereditary renal cancer.
- Medical treatment

Reconstructive surgery

- Development and improvement of new reconstructive surgery techniques for complex urethral strictures, genitourinary congenital malformations and genitourinary fistulas.
- Development of a Regenerative Medicine Unit and Tissue Bioengineering applied to reconstructive urologic surgery.

Endurologic and minimally invasive surgery

- Development of new endourological surgery techniques for minimally invasive treatment of benign prostatic hyperplasia and urinary lithiasis.
- Development of a learning program in laparoscopy and other minimally invasive surgeries.

Lithiasis

- Study of new inhibitors of crystallization of urine solutes as prevention of lithogenesis.
- Metabolic study of renal lithiasis.

Incontinence and Neuro-urology

- Study and treatment of chronic pelvic pain.
- Development and improvement of new systems for

Research Activity

Publications

- Aguilera A, Rivas JG, Álvarez-Maestro M, Martínez-Piñeiro L. How to deal with major complications during laparoscopic surgery? New training model for vascular lesions. Actas Urol Esp. 2020; 44(7): 447-9. Editorial Material. IF: 0.994; Q4
- Albinana V, Gallardo-Vara E, de Rojas I, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, González-Peramato P, Martínez-Piñeiro L, Cuesta AM, Botella LM. Targeting beta 2-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from Von Hippel-Lindau disease. J Clin Med. 2020; 9(9): 2740. Article. IF: 4.241; Q1
- Álvarez-Maestro M, Rivas JG, Olarte JQ, Monsalve DC, Guzman CT, Ballesteros C, Quintana LM, Bazán AA, Martínez-Piñeiro L, Liatsikos E, Barret E. Magnetic resonance as imaging diagnostic tool in prostate cancer: New evidences-The EAU Section of Uro-Technology position. Actas Urol Esp. 2020; 44(3): 148-55. Review. IF: 0.994; Q4
- Amesty MV, Fernández C, Espinósa L, Rivas-Vila S, Lobato R, Monsalve S, López-Pereira PC, Martínez-Urrutia MJ. Long-term outcomes of adult-size and size-matched kidney transplants in small pediatric recipients. J Pediatr Urol. 2020; 16(4): 481.e1-8. Article. IF: 1.83; Q3
- Bonillo-García MA, Moran-Pascual E, Puche-Sanz I, Campos-Juanatey F, Martínez-Piñeiro L, de Leon-Roca JP. Reconstructive surgery protocol recommendations during COVID-19 pandemia. Arch Esp Urol. 2020; 73(5): 413-9. Article. IF: 0.436; Q4
- Bruins HM, Veskimae E, Hernández V, Neuzillet Y, Cathomas R, Comperat EM, Cowan NC, Gakis G, Espinós EL, Lorch A, Ribal MJ, Rouanne M, Thalmann GN, Yuan YH, van der Heijden AG, Witjes JA. The Importance of hospital and surgeon volume as major determinants of morbidity and mortality after radical cystectomy for bladder cancer: A systematic review and recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. Eur Urol Oncol. 2020; 3(2): 131-44. Review. IF: 7.479; D1
- Bueno-Jiménez A, Serradilla J, Nava B, Rivas S, Lobato R, Amesty V, López-Pereira P, Castillo S, Martínez-Urrutia M J. Preliminary results of complete delayed primary bladder exstrophy reconstruction in male patients. Cir Pediatr. 2020; 33(2): 75-8. Article. Not Indexed

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Campos-Juanatey F, Martín JAP, Lorenzo LMP. Management of male anterior urethral strictures in adults. Results from a national survey among urologists in Spain. Actas Urol Esp. 2020; 44(2): 71-7. Article. IF: 0.994; Q4
- Carando R, Pradere B, Afferi L, Marra G, Aziz A, Roghmann F, Krajewski W, Di Bona C, Álvarez-Maestro M, Pagliarulo V, Xylinas E, Moschini M. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. Prog Urol. 2020; 30(6): 322-31. Review. IF: 0.915; Q4
- Carrión DM, Bazán AA, Martínez-Piñeiro L. Re: Do patients with stage 3-5 chronic kidney disease benefit from ischaemia-sparing techniques during partial nephrectomy? Eur Urol. 2020; 78(4): 629-30. Editorial Material. IF: 20.096; D1
- Carrión DM, Linares-Espinós E, González ER, Bazán AA, Álvarez-Maestro M, Martínez-Piñeiro L. Invasive management of renal cell carcinoma in von Hippel-Lindau disease. Cent Eur J Urol. 2020; 73(2): 167-72. Article. Not Indexed
- Carrión DM, Mantica G, Antón-Juanilla M, Pang KH, Tappero S, Rodríguez-Serrano A, Parodi S, Crespo-Atín V, Cansino R, Terrone C, Nikles S, Rivas JG, Esperto F. Assessment of trends and clinical presentation in the emergency department of patients with renal colic during the COVID-19 pandemic era. Actas Urol Esp. 2020; 44(10): 653-8. Article. IF: 0.994; Q4
- Carrión DM, Rivas JG, Rodríguez-Socarras ME, Mantica G, Esperto F, Álvarez-Maestro M, Cansino R, Bazán AA, Martínez-Piñeiro L. Implementation of remote clinics in urology practice during the COVID-19 era: What have we learned? Arch Esp Urol. 2020; 73(5): 345-52. Article. IF: 0.436; Q4
- Carrión DM, Rivas JG, Ruiz CB, Álvarez-Maestro M, Bazán AA, Martínez-Piñeiro L. Precave: Immediate neoadjuvant instillation of chemotherapy for the prevention of non-muscle invasive bladder carcinoma recurrence: A prospective randomized clinical trial protocol. Int J Surg Protocol. 2020; 24: 21-6. Article. Not Indexed
- Carrión DM, Rodríguez-Socarras ME, Mantica G, Pang KH, Esperto F, Mattigk A, Duijvesz D, Vasquez JL, Díez Sebastian J, Scarpa RM, Papalia R, Palou J, Gómez Rivas J. Interest and involvement of European urology residents in academic and research activities An ESRU-ESU-ESUT collaborative study. Minerva Urol Nefrol. 2020; 72(3): 384-7. Letter. IF: 3.72; Q2
- de la Rosette J, Laguna P, Álvarez-Maestro M, Eto M, Mochtar CA, Albayrak S, Mendoza-Valdés A, Ong TA, Khadgi S, Al-Terki A, Bolton D, Gómez R, Klotz L, Kulkarni S, Tanguay S, Gravas S. Cross-continental comparison of safety and protection measures amongst urologists during COVID-19. Int J Urol. 2020; 27(11): 981-9. Article. IF: 3.369; Q2
- Dubin JM, Greer AB, Patel P, Carrión DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Gómez AMA, Rivas JG, Ramasamy R, Loeb S. Global survey evaluating drawbacks of social media usage for practising urologists. BJU Int. 2020; 126(1): 7-8. Letter. IF: 5.588; Q1
- Earl J, Galindo-PuMarino C, Encinas J, Barreto E, Castillo ME, Pachon V, Ferreiro R, Rodríguez-Garrote M, González-Martínez S, Cajal TRY, Díaz LR, Chirivella-González I, Rodríguez M, de Castro EM, García-Seisdedos D, Muñoz G, Rosa JMR, Márquez M, Malats N, Carrato A. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. EBioMedicine. 2020; 53: 102675. Article. IF: 8.143; Q1
- Eguibar A, Martínez-Piñeiro L. Re: External validation of the European Association of Urology biochemical recurrence risk group to predict metastasis and mortality after radical prostatectomy in a european cohort. Eur Urol. 2020; 78(3): 471-2. Editorial Material. IF: 20.096; D1
- Enikeev D, Morozov A, Taratkin M, Barret E, Kozlov V, Singla N, Rivas JG, Podoinitsin A, Margulis V, Glybochko P. Active surveillance for intermediate-risk prostate cancer: Systematic review and meta-analysis of current protocols and outcomes. Clin Genitourin Cancer. 2020; 18(6): E739-53. Review. IF: 2.872; Q3
- Enikeev D, Taratkin M, Morozov A, Shpikina A, Singla N, Gómez Rivas J, Barret E, Glybochko P. Focal irreversible electroporation for localized prostate cancer management: prospective assessment of efficacy and safety. Minerva Urol Nefrol. 2020; 72(5): 644-5. Editorial Material. IF: 3.72; Q2
- Escosa-García L, Aguilera-Alonso D, Calvo C, Mellado MJ, Baquero-Artigao F. Ten key points about COVID-19 in children: The shadows on the wall. Pediatr Pulmonol. 2020; 55(10): 2576-86. Review. IF: 3.039; Q2
- Gakis G, Bruins HM, Cathomas R, Comperat EM, Cowan NC, van der Heijden AG, Hernández V, Espinós EEL, Lorch A, Neuzillet Y, Ribal MJ, Rouanne M, Thalmann GN, Veskimae E, Witjes AJ. European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update. Eur Urol Oncol. 2020; 3(4): 424-32. Article. IF: 7.479; D1
- Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirady P, Varga J, Ditonno P, Boccasile S, Primiceri G, De Nunzio C, Tema G, Tubaro A, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Puliatti S, Micali S, Álvarez-Maestro M, Olarte JQ, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Sosnowski R, Schips L, Cindolo L. Radical penectomy, a compromise for life: results from the PECAD study. Transl Androl Urol. 2020; 9(3): 1306-13. Article. IF: 3.15; Q2
- Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Turkeri LN, Palou J, Patel A, Bjartell AS, Caris C, Schipper RG, Witjes WPJ, Horstmann J, Machtens S, Mumperow E, Al Ghazal A, Pulte T, Stephan-Odenthal M, Gakis G, Kramer M, Zaak D, Schmitz-Drager B, Schreier H, Lehmann J, Werner T, Klier J, Marín J, Rulf W, Hellmis E, Schneider A, Spiegelhalder, Wirth M, Klotz T, Suttmann H, Siebels M, Rodemer G, Rudolph R, Zillmann R, de Bruin M, Bos S, van Moorselaar R, de Reijke T, Boormans J, Wijsman B, van Melick HHE, van Boven E, Meijer RP, van der Heijden AG, Vergunst H, te Slaa E, Leliveld-Kors AM, Ruffion A, Pfister C, Roupret M, Irani J, Stoica G, Van Bruwaene S, Ameye F, Arentsen H, Joniau S, Beardo P. Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: Results of the European Association of Urology Research foundation randomised phase III clinical trial NIMBUS. Eur Urol. 2020; 78(5): 690-8. Article. IF: 20.096; D1
- Herrero IG, Fentes DP, Ríos E, Martínez-Piñeiro L, Palou J, Breda A, Romo MIG. Current status for urpper tract transitional cell carcinoma during COVID-19 pandemia. Arch Esp Urol. 2020; 73(5): 384-9. Article. IF: 0.436; Q4
- Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjot L, Hoglund M, Lerner SP, Real FX, Radvanyi F. A Consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020; 77(4): 420-33. Article. IF: 20.096; D1
- Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo QX, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjot L, Hoglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus genomic subtypes of muscle-invasive bladder cancer: A step in the right direction but still a long way to go. Eur Urol 2020; 77: 434-5. Editorial Material. IF: 20.096; D1
- Koutros S, Kogevinas M, Friesen MC, Stewart PA, Baris D, Karagas MR, Schwenn M, Johnson A, Hosain GMM, Serra C, Tardon A, Carrato A, García-Closas R, Moore LE, Nickerson ML, Hewitt SM, Lenz P, Schned AR, Lloreta J, Allory Y, Zhang HY, Chatterjee N, García-Closas M, Rothman N, Malats N, Silverman DT. Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. Environ Int. 2020; 135: 105346. Article. IF: 9.621; D1
- Krajewski W, Moschini M, Nowak L, Poletajew S, Tukiendorf A, Afferi L, Teoh J, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Gozzo A, Mari A, Di Trapani E, Hendricksen K, Álvarez-Maestro M, Serrano AR, Simóne G, Zamboni S, Simeone C, Marconi MC, Mastroianni R, Ploussard G, Rajwa

Introduction


Executive summary

Information Groups by Area

Associated Clinicians

P, Laukhtina E, Zdrojowy-Welna A, Kolodziej A, Paradysz A, Tully K, Krajewska J, Piszczek R, Xylinas E, Zdrojowy R. Restaging transurethral resection of bladder tumours after BCG immunotherapy induction in patients with T1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit. J Clin Med. 2020; 9(10): 3306. Article. IF: 4.241; Q1

- López-Campos F, Linares-Espinós E, Pijoan XM, Pardo GS, Morgan TM, Martínez-Ballesteros C, Martínez-Salamanca J, Counago F. Genetic testing for the clinician in prostate cancer. Expert Rev Mol Diagn. 2020; 20(9): 933-46. Review. IF: 5.225; Q1
- Marchioni M, de Francesco P, Castellucci R, Papalia R, Sarikaya S, Gómez Rivas J, Schips L, Scarpa RM, Esperto F. Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. Minerva Urol Nefrol. 2020; 72(5): 543-4. Review. IF: 3.72; Q2
- Marqués M, Tranchant R, Risa-Ebri B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, del Pozo N, de Villarreal JM, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX. Combined MEK and PI3K/p110 beta Inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 2020; 80(4): 843-56. Article. IF: 12.701; D1
- Martínez-Fleta P, Alfranca A, González-Álvaro I, Casasnovas JM, Fernández-Soto D, Esteso G, Cáceres-Martell Y, Gardeta S, López-Sanz C, Prat S, Mateu-Albero T, Gabrie L, López-Granados E, Sánchez-Madrid F, Reyburn HT, Frade JMR, Vales-Gómez M. SARS-CoV-2 cysteine-like protease antibodies can be detected in serum and saliva of COVID-19-seropositive individuals. J Immunol. 2020; 205(11): 3130-40. Article. IF: 5.422; Q2
- Mayor J, Álvarez-Maestro M, Arranz JA, Laguna MP. De-escalation: Testicular cancer. Arch Esp Urol. 2020; 73(5): 390-4. Article. IF: 0.436; Q4
- Mir MC, Pavan N, Capitanio U, Antonelli A, Derweesh I, Rodríguez-Faba O, Linares E, Takagi T, Rha KH, Fiori C, Maurer T, Zang C, Mottrie A, Umari P, Long JA, Fiard G, De Nunzio C, Tubaro A, Tracey AT, Ferro M, De Cobelli O, Micali S, Bevilacqua L, Torres J, Schips L, Castellucci R, Dobbs R, Quarto G, Bove P, Celia A, De Concilio B, Trombetta C, Silvestri T, Larcher A, Montorsi F, Palumbo C, Furlan M, Bindayi A, Hamilton Z, Breda A, Palou J, Aguilera A, Tanabe K, Raheem A, Amiel T, Yang B, Lima E, Crivellaro S, Perdona S, Gregorio C, Barbati G, Porpiglia F, Autorino R. Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World J Urol. 2020; 38(1): 151-8. Article. IF: 4.226; Q1
- Morozov A, Taratkin M, Barret E, Singla N, Bezrukov E, Chinenov D, Enikeev M, Rivas JG, Shpikina A, Enikeev D. A systematic review of irreversible electroporation in localised prostate cancer treatment. Andrologia. 2020; 52(10): e13789. Review. IF: 2.775; Q3
- Pang KH, Carrión DM, Rivas JG, Mantica G, Mattigk A, Pradere B, Esperto F. The impact of COVID-19 on European health care and urology trainees. Eur Urol. 2020; 78(1): 6-8. Editorial Material. IF: 20.096; D1
- Pérez-Carral JR, Cansino R, Trelles C, Quintana LM, Mainez JA, Martínez-Piñeiro L. Holmium laser prostate enucleation. All we should aim for. Arch Esp Urol. 2020; 73(8): 699-708. Article. IF: 0.436; Q4
- Pérez-Portilla A, Moraru M, Blázquez-Moreno A, Kolb P, García-Morato MB, Ranganath T, Esteso G, Gianelli C, Rodríguez-Pena R, Lozano-Rodríguez R, Torres-Canizales JM, Blish CA, Vales-Gómez M, Hengel H, Vilches C, López-Granados E, Reyburn HT. Identification of the first cases of complete CD16A deficiency: Association with persistent EBV infection. J Allergy Clin Immunol. 2020; 145(4): 1288-92. Article. IF: 10.793; D1
- Puche-Sanz I, Sabio-Bonilla A, Sánchez-Conde V, Jiménez-Domínguez AC, Tamayo-Gómez A, Vila-Brana P, Vázquez-Alonso F, Rivas JG, Gó-



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

mez-Gómez E, Campos-Juanatey F, Rodríguez JGO, Flores-Martín J, Moreno-Jiménez J, Cozar-Olmo JM. Emergency surgery during COVID-19 pandemia. Arch Esp Urol. 2020; 73(5): 353-9. Article. IF: 0.436; Q4

- Quesada-Olarte J, Álvarez-Maestro M, Gómez-Rivas J, Toribio-Vázquez C, Bazán AA, Martínez-Piñeiro L. Organ-sparing cystectomy techniques: functional and oncological outcomes, review and current recommendations. Arch Esp Urol. 2020; 73(10): 961-70. Review. IF: 0.436; Q4
- Quesada-Olarte JM, Allaf ME, Álvarez-Maestro M, Martínez-Piñeiro L. Molecular imaging of prostate cancer: Review of imaging agents, modalities, and current status. Actas Urol Esp. 2020; 44(6): 386-99. Review. IF: 0.994; Q4
- Quintana LM, Pascual EF, Espinós EL, Martínez-Ballesteros C, Martín-Vivas C, Abbad DR, Caruso ND, Allona A, Martínez-Salamanca JI. Initial experience with SelectMDx (R) in the diagnosis of prostate cancer in a real-world evidence clinical practice setting. Actas Urol Esp. 2020; 44(6): 400-7. Article. IF: 0.994; Q4
- Rivas JG, Domínguez M, Gaya JM, Ramírez-Backhaus M, Puche-Sanz I, de Luna F, Juárez A. Prostate cancer and COVID-19 pandemia: Current recommendations. Arch Esp Urol. 2020; 73(5): 367-73. Article. IF: 0.436; Q4
- Rivas JG, Enikeev D. There is a need of novel risk classifications in prostate cancer. An invited commentary on 'Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study'. Int J Surg. 2020; 77: 61-2. Editorial Material. IF: 6.071; D1
- Rivas JG, Quintana LM, Álvarez-Maestro A, Aguilera A, Piñeiro LM, Sarikaya S. Retroperitoneal fibrosis: a literature review. Arch Esp Urol. 2020; 73(1): 60-7. Review. IF: 0.436; Q4
- Rivas JG, Rodríguez-Serrano A, Loeb S, Teoh JYC, Ribal MJ, Bloemberg J, Catto J, NDow J, van Poppel H, González J, Esteban M, Socarras MR. Telemedicine and smart working: Spanish adaptation of the European Association of Urology recommendations. Actas Urol Esp. 2020; 44(10): 644-52. Review. IF: 0.994; Q4
- Rivas JG. Last minute cancelations in elective surgery are inevitable. Can we reduce them? An invited commentary on reduction of last-minute cancellations in elective urology surgery: A quality improvement study. Int J Surg. 2020; 74: 109-10. Editorial Material. IF: 6.071; D1
- Rodríguez-Seguel E, Villamayor L, Arroyo N, de Andrés MP, Real FX, Martín F, Cano DA, Rojas A. Loss of GATA4 causes ectopic pancreas in the stomach. J Pathol. 2020; 250(4): 362-73. Article. IF: 7.996; D1
- Rodríguez-Socarrás M, Kingo PS, Uvin P, Ostergren P, Patruno G, Edison E, Kasivisvanathan V, Vásquez JL, Esperto F, Rivas JG. Lifestyle among urology trainees and young urologist in the context of burn-out syndrome. Actas Urol Esp. 2020; 44(1): 19-26. Article. IF: 0.994; Q4
- Rojas MM, Villalpando DM, Ferrer M, Alexander-Aguilera A, García HS. Conjugated linoleic acid supplemented diet influences serum markers in orchidectomized sprague-dawley rats. Eur J Lipid Sci Technol. 2020; 122(3): 1900098. Article. IF: 2.679; Q3
- Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher MF, Heck M, Amiel T, Kriegmair MC, Rubio J, Musquera M, D'Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinós E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir MC, Albersen M. Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma. Eur Urol Oncol. 2020; 3(4): 523-9. Article. IF: 7.479; D1
- Segui-Moya E, González-Padilla DA, Ortega-Polledo LE, Sánchez-García M, López-González JA, Antón-Juanilla M, Mercader-Barrull C, Carrión DM, Rivas JG, Álvarez-Ossorio JL. Impact of COVID-19 in spanish urology residents: Recommendations and perspective. Arch Esp Urol. 2020; 73(5): 471-8. Article. IF: 0.436; Q4
- Socarrás MER, Rivas JG, Rivera VC, Elbers JR, González LL, Mercado IM, del Alamo JF, del Dago PJ, Sancha FG. Prostate mapping for cancer diagnosis: The madrid protocol. transperineal prostate biopsies using multiparametric magnetic resonance imaging fusion and micro-ultrasound guided biopsies. J Urol. 2020; 204(4): 726-32. Article. IF: 7.45; Q1
- Socarrás MR, Loeb S, Teoh JYC, Ribal MJ, Bloemberg J, Catto J, N'Dow J, Van Poppel H, Rivas JG. Telemedicine and smart working: Recommendations of the European Association of Urology. Eur Urol. 2020; 78(6): 812-9. Review. IF: 20.096; D1
- Tamayo AL, Espinós EL, González ER, Guzmán CT, Álvarez-Maestro M, Guerín CD, Fernández-Pascual E, de Francisco MG, de Vicente JMG, Rivas JG, Rodríguez JAM, Pérez-Carral JR, García-Matres MJ, Martínez-Piñeiro L. Evaluation of teleconsultation system in the urological patient during the COVID-19 pandemic. Actas Urol Esp. 2020;44(9):617-22. Article. IF: 0.994; Q4
- Teoh JYC, Mackenzie G, Tortolero L, Rivas JG. Social media analytics: What you need to know as a urologist. Eur Urol Focus. 2020; 6(3): 434-6. Review. IF: 5.996; Q1
- Toribio-Vázquez C, Rivas JG, Yebes A, Carrión DM, Quesada-Olarte J, Trelles CR, Álvarez-Maestro M, van der Poel H, Martínez-Piñeiro L. Immunotherapy toxicity. diagnosis and treatment. Arch Esp Urol. 2020; 73(10): 906-17. Article. IF: 0.436; Q4
- Valés-Gómez M, Esteso G, Felgueres MJ, Huete-Carrasco J. Bladder cancer immunological background and biomarkers. Arch Esp Urol. 2020; 73(10): 895-905. Article. IF: 0.436; Q4
- Villalpando DM, Rivas JG, Flynn D, de Bethencourt FR, Ferrer M. Gonadal function protects against organ culture-induced vascular damage. Involvement of prostanoids. Prostaglandins Other Lipid Mediat. 2020; 148: 106406. Article. IF: 3.072; Q3
- Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Domínguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernández V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020; 77(2): 223-50. Article. IF: 20.096; D1
- Yebes A, Rivas JG, Toribio C, Álvarez-Maestro M, Cansino R, Aguilera A, Martínez-Piñeiro L. Laser-in-prostate.cancer. Applicability. Arch Esp Urol. 2020; 73(8): 724-34. Article. IF: 0,436; Q4

Research projects

Ferrer Parra M. Acción no genómica de 5β-dihidrotestosterona. Utilización terapéutica en el tratamiento de las alteraciones vasculares asociadas a déficit androgénico. (PI19/01282). Instituto de Salud Carlos III. 2020-2022.

Managment centre: UAM

López Pereira P. Estudio del desarrollo vesical en un modelo de mielomeningocele corregido prenatalmente. Coloplast Productos Medicos S. A. 2009-Ongoing.

Managment centre: FIBHULP

López Pereira P. Utilización de constructos

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

de mucosa urotelial autóloga obtenidos mediante ingeniería tisular para la realización uretroplastias reconstructivas en un modelo experimental de hipospadias proximal en conejos. Fundación para la Investigación en Urología. 2016-Ongoing.

Managment centre: FIBHULP

Martínez-Piñeiro Lorenzo L. Inmunothercan-CM: Inmunidad tumoral e inmunoterapia del cáncer (S2017/BMD-3733). CM. 2018-2021.

Managment centre: FIBHULP

Valés Gomez MM. Inmunothercan-CM: Inmunidad tumoral e inmunoterapia del cáncer (S2017/BMD-3733). CM. 2018-2022.

Managment centre: CNB

Valés Gomez MM. Mejora del tratamiento del cáncer de vejiga por Baciloterapia (RTC-2017-6379-1). MINECO . 2018-2022.

Managment centre: CNB

Valés Gomez MM. Modulación de la respuesta Natural Killer en el reconocimiento y evasión tumoral (MoNKTuRE) (RTI2018-093569-B-I00). MINECO . 2019-2021.

Managment centre: CNB

Valés Gomez MM. Red traslacional para la aplicación clínica de vesículas extracelulares (RED2018-102411-T). MINECO . 2020-2021.

Managment centre: UAM

Cibers and Retics

Botella Cubells LM. Centro de Investigación Biomédica en Red de Enfermedades Raras - CIBERer (CB06/07/0038). (31/12/2021).

Managment Centre: CISC

López Pereira P. Red Europea de enfermedades urologicas raras (e UROGEN). UE. 2016-2021. Associated National Centre

Clinical trials

Álvarez Maestro, M. Quimioterapia neoadyuvante versus adyuvante en carcinoma urotelial del tracto urinario superior. Ensayo clínico randomizado de viabilidad fase II. URANOS.

Type: Clinical Trial, phase II.
HULP code: 5582 .
Sponsored´s protocol code: EUOG-2016-003.
Sponsored by: European Uro-Oncology Group.
Signed date: 28/09/2020

Álvarez Maestro, M. Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma urotelial de tracto urinario resecable.

Type: Clinical Trial, phase IV.
HULP code: 5053.
Sponsored´s protocol code: VitDURO-AECC17-01.
Sponsored by: CEIC Hospital Universitari Germans Trias I Pujol.
Signed date: 07/02/2020

Álvarez Maestro, M. Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de durvalumab y el bacilo de Calmette-Guerin administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG .

Type: Clinical Trial, phase III.
HULP code: Appendix 1 5344.
Sponsored´s protocol code: D419JC00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 20/04/2020

Álvarez Maestro, M. Ensayo clínico de fase 3, aleatorizado y controlado con un comparador para estudiar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con el bacilo de calmette-guérin (BCG) en participantes con cáncer de vejiga no músculo invasivo de alto riesgo que es persistente o recurrente tras un tratamiento de inducción con BCG (keynote-676).

Type: Clinical Trial, phase III.
HULP code: 5493.
Sponsored´s protocol code: MK-3475-676.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 22/01/2020

Ríos González, E. Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical.

Type: Clinical Trial, phase III.
HULP code: Appendix 2 5226.
Sponsored´s protocol code: 56021927pcr3011.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 16/11/2020

Ríos González, E. Estudio aleatorizado, doble ciego, controlado con placebo de fase III de niraparib en combinación con acetato de abiraterona y prednisona frente a acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico sensible a la castración con mutaciones deletéreas en la línea germinal o somáticas en los genes de reparación por recombinación homóloga.

Type: Clinical Trial, phase III.
HULP code: 5654.
Sponsored´s protocol code: 676520000PCR3002.
Sponsored by: Janssen Cilag International N.V.
Signed date: 27/08/2020

Patents and trademarks

Botella Cubells LM, Albiñana Díaz V, Villar Gómez de las Heras K, inventors; CSIC, Alianza Española de Familias de Von Hippel-Lindau-VHL, assignee; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/ES2018/071220; 2018 August 18

Botella Cubells LM, inventor; CSIC, assignee; Inhibidores de TGF-ß1 y productores de endoglina para su uso en el tratamiento de epidermólisis bullosa. P201831072; 2018 November 07

Botella Cubells LM, inventor; CSIC, assignee; Treatment and prevention of glioblastoma. EP18382917; 2018 December 12

Reyburn HT, Valés-Gómez M, inventors; assignees; Assay for the detection of the Cys-like protease (Mpro) of SARS-CoV-2. EP20382495.8; 2020 August.

Valés-Gómez M, inventors; assignees; Method for the detection and/or quantification of extracellular vesicles in fluid biological samples. EP16411562; 2020 August

Sánchez-Puelles González-Carvajal JM, Botella Cubells LM, Aguado Sánchez T, Del Río Nechaevsky M, García Martín A, García Díez M, Larcher Laguzzi F, Carretero Trillo M, inventors; CSIC, UC3M, CIEMAT, assignees; Inhibitors of TGF-β1 and endoglin producers for use in the treatment of epidermolysis bullosa. P201831072, PCT/ES2019/070757; 2018 November 07.

Aguado Sánchez T, Albiñana Díaz V, Botella Cubells LM, Cuesta Martínez A, Sánchez-Puelles González-Carvajal JM, Villar Gómez-de las Heras K, inventors; Alianza Española De Familias De Von Hippel-Lindau–VHL, CSIC, Consorcio Centro de Investigación Biomédica en Red M.P., assignees; Treatment and prevention of glioblastoma. EP18382917A, PCT/EP2019/084822, CA3122640A1; 2018 December 12.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.13 Health Care Nurses Research Group

Publications:	1
Impact Factor:	1.5
Q1:	0



Jesús Castro Toro. Supervisor de Área Funcional. Hospital Universitario La Paz

Laura Alonso Recio. Profesora Contratada. Universidad a Distancia de Madrid

Víctor Manuel Cornejo del Río. Supervisor de Unidad Quirúrgica. Hospital Universitario La Paz

María Luisa Díaz Martínez. Profesora Contratada. Universidad Autónoma de Madrid

María Ricardina Delgado Sandoval. Enfermera en Servicio de Consultas Externas. Hospital Universitario La Paz

María Durán Agüí. Enfermera en Servicio de Medicina Interna. Hospital Universitario La Paz

Salomé Herrero Cereceda. Enfermera Unidad Quirúrgica. Hospital Cantoblanco-Hospital Universitario La Paz

Patricia Luna Castaño. Supervisora Unidad Apoyo de Investigación en Cuidados. Hospital Universitario La Paz

Pedro Piqueras Rodríguez. Supervisor de Enfermería de Intensivos Pediatricos. Hospital Universitario La Paz

Ana Ramos Cruz. Supervisora de Urgencias Pediátricas. Hospital Universitario La Paz.

Profesora Asociada de Grado de Enfermería. Centro Universitario de Ciencias de la Salud San Rafael-Nebrija

María del Carmen Sellán Soto. Profesora Contratada. Universidad Autónoma de Madrid

Gema Tapia Serrano. Enfermera de Cuidados Intensivos Neonatales. Hospital Universitario La Paz

Strategic Objective

Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live.

This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful. Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowledge and use of research results in clinical practice will contribute to improving the health of the population. Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes.

In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients.

Finally, it should be noted that using evidence in daily practice can achieve health goals at a minimum cost.

Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

At the same time, society is facing new economic, political, demographic, social and cultural challenges that require health services capable of meeting the growing health needs of the population.

It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.



Research lines

- Vital Processes and complex care
- Technological innovation and its application in health care
- Management of care and results of professional practice

Research Activity

Publications

- Bosch-Alcaraz A, Luna-Castano P, García-Soler P, Tamame-San Antonio M, Falco-Pegueroles A, Alcolea-Monge S, Fernández Lorenzo R, Piqueras-Rodríguez P, Molina-Gallego I, Potes-Rojas C, Gesti-Senar S, Orozco-Gámez R, Tercero-Cano MC, Saz-Roy MA, Jordan I, Belda-Hofheinz S. Level of discomfort in critically ill paediatric patients and its correlation with sociodemographic and clinical variables, analgosedation and withdrawal syndrome. COSAIP multicentre study (Phase 2). An Pediatr (Engl Ed). 2020; S1695-4033(20):30475-6. Article. IF: 1.5; Q4

Research projects

CODEM. Efectividad del masaje terapéutico para aliviar el malestar de niños y niñas con bronquiolitis. CODEM. 2019-ongoing.

Managment centre: Red Internacional de Enfermería en Salud infantil

3.4.14 Maternal and Fetal Medicine Group

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	13
Impact Factor:	47.08
Q1:	3



José Luis Bartha Rasero. Jefe de Servicio de Obstetricia y Ginecología. Hospital Universitario La Paz. Catedrático de Obstetricia y Ginecología. Universidad Autónoma de Madrid

Blanca Amador Sastre. Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz

Eugenia Antolín Alvarado. Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid

Marta Cortés León. Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz

Marcos Javier Cuerva González. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Inmaculada Duyos Mateo. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Amparo Gimeno Sanmartín. Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz

María del Mar González Arlazón. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María de la Calle Fernández-Miranda. Jefa de Sección de Tocología de Alto Riesgo y Obstetricia Médica. Hospital Universitario La Paz. Profesora asociada. Universidad Autónoma de Madrid

María de la Cruz González Álvarez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Beatriz Herrero Ruiz. Médico Adjunto de la Sección de Ecografía y Medicina Fetal. Hospital Universitario La Paz

Sara López Magallón. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Francisco López Sánchez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Elena Martín Boado. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Fernando Magdaleno Dans. Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid

Nuría Martínez Sánchez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Inmaculada Orensanz Fernández. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Roberto Rodríguez González. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Laura Sotillo Mallo. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Strategic Objective

1. To evaluate the involvement of placental energy metabolism in obstetric disorders
2. To find new biomarkers in gestational diabetes mellitus and macrosomia
3. To find new biomarkers of fetal and perinatal neurological damage establishing new prevention strategies
4. To improve our understanding of the pathophysiology fetal heart damage in Anti-Ro positivewomen and to find new lines of treatment in these cases

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research lines

- Diabetes mellitus, obesity and metabolic syndrome during pregnancy
- Energy metabolism during pregnancy
- Fetal neurodevelopment
- Inflammation, autoimmunity and pregnancy

Research Activity

Publications

- Ramiro-Cortijo D, de la Calle M, Boger R, Hannemann J, Luneburg N, López-Giménez MR, Rodríguez-Rodríguez P, Martín-Cabrejas MA, Benitez V, de Pablo ALL, González MD, Arribas SM. Male fetal sex is associated with low maternal plasma anti-inflammatory cytokine profile in the first trimester of healthy pregnancies. Cytokine. 2020;136:-155290. Article. IF: 3,861; Q3
- Rodríguez-Molino P, de la Calle M, del Rosal T, Baquero-Artigao F. Gestational and congenital tuberculosis: An ongoing problem. Enferm Infec Microbiol Clin. 2020;38(10):505-506. Letter. IF: 1,731; Q4
- Codina M, Corcoy R, Goya MM. Update of the hyperglycemia Gestational diagnosis during the COVID-19 pandemic. Endocrinol Diabetes Nutr. 2020;67(8):545-552. Article. IF: 1,417; Q4
- Ramiro-Cortijo D, de la Calle M, Rodríguez-Rodríguez P, Phuthong S, de Pablo ALL, Martín-Cabrejas MA, Arribas SM. First trimester elevations of hematocrit, lipid peroxidation and nitrates in women with twin pregnancies who develop preeclampsia. Pregnancy Hypertens. 2020;22:132-135. Article. IF: 2,899; Q2
- Illescas T, Mansilla E, Herrero B, Rodríguez R, López F, Aza-Carmona M, Regojo RM, Santos-Simarro F, Heath KE, Bartha JL, Antolin E. Prenatal diagnosis of fetal skeletal dysplasias in a tertiary Hospital in Spain. Eur J Obstet Gynecol Reprod Biol. 2020;250:209-215. Article. IF: 2,435; Q3
- Boria F, de la Calle M, Cuerva M, Sainz A, Bartha JL. Impact of oocyte donation on obstetric and perinatal complications in twin pregnancies. J Matern-Fetal Neonatal Med. 2020;33(11):1960-1963. Article. IF: 2,398; Q3
- Díaz SD, de la Calle M, Valbuena-López SC, López NM, Colunga PM, Bartha JL, Guzman-Martínez G. Does the right ventricle experiment morphologic and functional changes similarly to the left ventricle during pregnancy?. Echocardiography-J Cardiovasc Ultrasound Allied Tech. 2020;37(6):850-857. Article. IF: 1,724; Q4
- Soriano-Arandes A, Frick MA, López-Hortelano MG, Sulleiro E, Rodo C, Sánchez-Seco MP, Cabrera-Lafuente M, Suy A, De la Calle M, Santos M, Antolin E, Vinuela MD, Espiau M, Salazar A, Guarch-Ibanez B, Vázquez A, Navarro-Moron J, Ramos-Amador JT, Martín-Nalda A, Duenas E, Blazquez-Gamero D, Reques-Cosme R, Olabarrieta I, Prieto L, De Ory F, Thorne C, Byrne T, Ades AE, Ruiz-Burga E, Giaquinto C, Mellado-Pena MJ, García-Alix A, Carreras E, Soler-Palacin P. Clinical Outcomes of a Zika Virus Mother-Child Pair Cohort in Spain. Pathogens. 2020;9(5):-352. Article. IF: 3,492; Q2
- Gallardo-Vara E, Gamella-Pozuelo L, Pérez-Roque L, Bartha JL, García-Palmero I, Casal JI, López-Novoa JM, Pericacho M, Bernabeu C. Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4. Cells. 2020;9(4):-988. Article. IF: 6,6; Q2
- Ramiro-Cortijo D, de la Calle M, Rodríguez-Rodríguez P, de Pablo ALL, López-Giménez MR, Aguilera Y, Martín-Cabrejas MA, González MD, Arribas SM. Maternal Antioxidant Status in Early Pregnancy and Development of Fetal Complications in Twin Pregnancies: A Pilot Study. Antioxidants. 2020;9(4):-269. Article. IF: 6,312; D1
- Sotillo L, De la Calle M, Magdaleno F, Bartha JL. Efficacy of carbetocin for preventing postpartum bleeding after cesarean section in twin pregnancy. J Matern-Fetal Neonatal Med. 2020;33(2):267-271. Article. IF: 2,398; Q3
- Barquiel B, Herranz L, Martínez-Sánchez N, Mantes C, Hillman N, Bartha JL. Increased risk of neonatal complications or death among neonates born small for gestational age to mothers with gestational diabetes. Diabetes Res Clin Pract. 2020;159:-107971. Article. IF: 5,602; Q1
- Crespillo-Andujar C, Díaz-Menéndez M, Trigo E, Arsuaga M, De la Calle F, Lago M, de Guevara MCL, Barreiro P, Montero D, García-Bujalance S, Alvarado EA, de la Calle M, Sánchez-Seco MP, de Ory F, Vázquez A, Arribas JR, La Paz-Carlos III, García J, Martín-Boado E, Martínez-Sánchez N, Rodríguez R, Herrero B, López F, Bartha JL, Elorza MD, Lafuente MC, Hortelano MG. Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. Travel Med Infect Dis. 2020;33:-101543. Article. IF: 6,211; D1

Research projects

Antolín Alvarado E. Modelos predictivos de daño neurológico y riesgo cardiovascular mediante la integración de técnicas de imagen y biomarcadores en la gestación monocorial. Biologia de sistemas (PI19/00904). ISCIII. 2020-2022.

Managment centre: FIBHULP

Bartha Rasero JL. Aplicación de la biología de sistemas al conocimiento de la fisiopatología e identificación de nuevos biomarcadores de la diabetes gestacional (PI15/01563). ISCIII. 2016-2020.

Managment centre: FIBHULP

Bartha Rasero JL. Biologia de sistemas para la búsqueda de marcadores precoces de placentacion deficiente (PI19/00915). ISCIII. 2020-2022.

Managment centre: FIBHULP

Bartha Rasero JL. Implicación de la oxidación mitocondrial de ácidos grasos placentaria en la patogenesis y clínica de la preeclampsia. Laboratorios Farmaceúticos Rovi S. A. 2016-Ongoing.

Managment centre: FIBHULP

Clinical trials

Bartha Rasero, JL. Ensayo en fase III, aleatorizado, doble ciego o con enmascaramiento para el observador, controlado con placebo, para evaluar la eficacia y seguridad de una vacuna de subunidad F prefusión contra el virus respiratorio sincitial (VRS) en lactantes nacidos de mujeres vacunadas durante el embarazo.

Type: Clinical Trial, phase III.
HULP code: 5526.
Sponsored´s protocol code: C3671008.
Sponsored by: Pfizer S.L.U.
Signed date: 04/06/2020

De La Calle Fernandez-Miranda, M. Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al virus respiratorio sincitial, administrada por vía im a gestantes de 18 a 49 años de edad, para la prevención de la enfermedad vías respiratorias bajas asociada al VRS en sus hijos hasta los 6 meses de edad.

Type: Clinical Trial, phase III.
HULP code: 5728B .
Sponsored´s protocol code: 212171 RSV MAT-009.
Sponsored by: Glaxosmithkline S.A.
Signed date: 18/11/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.4.15 Emergency and Critical Pathology Group

Publications:	21
Impact Factor:	64.941
Q1:	6



Alejandro Martín Quiros. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Gillermina Bejarano Redondo. Médico Adjunto en Urgencias. Hospital Universitario La Paz

Lubna Dani Ben Abdel-Iah. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Julio Cobo Mora. Jefe de la Unidad de Urgencias. Hospital Universitario La Paz

María Elena Calvín García. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

María de los Ángeles García Martín. Facultativo Especialista de Área especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

Olga González Peña. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz

Manuel Jesús González Viñolis. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Macarena Lerín Baratas. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Maria Lorena López Corcuera. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Mikel Rico Briñas. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Paloma Isabel Romero Gallego-Acho. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

María José Simón Merlo. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Yaletung Chen. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Strategic Objective

We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.

We develop a new and pioneering line of imagingdiagnostic, with the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise.

We will investigate the possibility of supporting us in new technologies that help the clinician in the decisión making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level.

Research lines

- Integral management of the treatment and follow-up of the diabetic patient.
- Emergency ultrasound.
- Sepsis
- SARS-CoV-2 and COVID19 acute management
- Care of infectious diseases in the emergency room.
- Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes.
- Attention to cardiovascular pathology of emergencies.
- Attention to respiratory pathology.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Publications

- Arenas-Berenguer I, Tung-Chen Y, González BA. Usefulness of point-of-care ultrasonography in the diagnosis and follow-up of acute sinusitis. Enferm Infec Microbiol Clin. 2020;38(10):508-9. Letter. IF: 1.731; Q4
- Avendano-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Maroun-Eid C, Terron V, Valentin J, Montalban-Hernández K, de la Bastida FR, García-Garrido MA, Cubillos-Zapata C, Del Balzo-Castillo A, Aguirre LA, López-Collazo E. Proteins from SARS-CoV-2 reduce T cell proliferation: A mirror image of sepsis. Heliyon. 2020; 6(12): e05635. Article. Not Indexed
- Shokoohi H, Duggan NM, Sánchez GGD, Torres-Arrese M, Tung-Chen Y. Lung ultrasound monitoring in patients with COVID-19 on home isolation. Am J Emerg Med. 2020; 38(12): 2759.e5. Article. IF: 2.469; Q2
- Gil-Borrelli CC, Ríos MDM, Zamalloa PL, López-Corcuera L, Ben-Abdellah LD, Arenas MAR. Hate violence in the emergency rooms of third level hospitals. First data in Spain. Gac Sanit. 2020; 34(6): 561-6. Article. IF: 2.139; Q3
- Tung-Chen Y, de Gracia MM, Díez-Tascón A, Alonso-González R, Agudo-Fernández S, Parra-Gordo ML, Ossaba-Vélez S, Rodríguez-Fuertes P, Llamas-Fuentes R. Correlation between chest computed tomography and lung ultrasonography in patients with coronavirus disease 2019 (COVID-19). Ultrasound Med Biol. 2020; 46(11): 2918-26. Article. IF: 2.998; Q1
- Yale TC, Martín AA, Gallego-Acho PR. Usefulness ofpoint-of-care ultrasonography in the suspicion of necrotizingfasciitis. Enferm Infec Microbiol Clin. 2020; 38(9): 457-8. Letter. IF: 1.731; Q4
- Tung-Chen Y, Rivera-Núñez MA, Martínez-Virto AM. Lung ultrasound in the frontline diagnosis of COVID-19 infection. Med Clin. 2020; 155(5): 232. Editorial Material. IF: 1.725; Q3
- Rivera-Núñez MA, Tung-Chen Y, Álvarez MCH, Díaz MQ, Virto AMM, Santos-Olmo RT. A prospective study of the adequacy in the tromboprofilaxis in patients admitted in a short-stay unit. Angiologia. 2020; 72(5): 219-28. Article. Not Indexed
- Moreno RG, Martos RN, Tung-Chen Y, Villega TV. Unmasking congestive jaundice with point-of-care ultrasound. Med Fam-SEMERGEN. 2020; 46(6): 434-6. Editorial Material. Not Indexed
- Soriano IA, Tung-Chen Y, Palacios RD. Point-of-care ultrasound in the evaluation of acute pericarditis. Med Fam-SEMERGEN. 2020;46(6):426-427. Letter. Not Indexed
- Gil-Rodrigo A, Miro O, Pinera P, Burillo-Putze G, Jiménez S, Martín A, Martín-Sánchez FJ, Jacob J, Guardiola JM, García-Lamberechts EJ, Espinosa B, Mojarro EM, Tejera MG, Serrano L, Aguera C, Soy E, Llauger L, Juan MA, Palau A, del Arco C, Miranda BR, Vera MTM, Quirós AM, de los Santos LT, de Lobera NR, Vela MI, Garate RT, Alquezar-Arbe A, del Castillo JG, Llorens P. Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments. Emergencias. 2020; 32(4): 233-41. Article. IF: 3.881; Q1
- Tung-Chen Y, Blanco-Alonso S, Anton-Huguet B, Figueras-López C, Ugueto-Rodrigo C. Persistent chest pain after resolution of coronavirus 2019 disease (COVID-19). Med Fam-SEMERGEN. 2020; 46: 95-7. Editorial Material. Not Indexed
- Menchón CS, Paoli S, Tung-Chen Y. Point-of-care ultrasound in the assessment of community acquired pneumonia in pregnant women. Med Clin. 2020; 155(1): 46-7. Letter. IF: 1.725; Q3
- Tung-Chen Y. Lung ultrasound in the monitoring of COVID-19 infection. Clin Med. 2020; 20(4): E62-5. Article. IF: 2.659; Q2
- Liu RHB, Tayal VS, Panebianco NL, Tung-Chen Y, Nagdev A, Shah SH, Pivetta E, Henwood PC, Nelson MJ, Moore CL. Ultrasound on the Frontlines of COVID-19: Report From an International Webinar. Acad Emerg Med. 2020; 27(6): 523-6. Editorial Material. IF: 3.451; Q1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Marti-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Rios JJ, Hernan MA, Frias J, Arribas JR. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Rubio-Pérez I, Badía JM, Mora-Rillo M, Quirós AM, Rodríguez JG, Balibrea JM. COVID-19: Key concepts for the surgeon. Cir Espan. 2020; 98(6): 310-9. Article. IF: 1.653; Q3
- Rueda MDA, Troncoso JA, Chen YT, Villegas TV. Point-of-care ultrasound in early detection of superior vena cava syndrome. Med Clin. 2020; 154(10): 433. Editorial Material. IF: 1.725; Q3
- Gil-Borrelli CC, Martín-Ríos MD, Corcuera LL, Martínez BR, Santos-Olmo RT, Patino EM, Rodríguez-Arenas MA. Preparation of a questionnaire to detect cases of hate violence in emergency rooms. Gac Sanit. 2020; 34(2): 166-70. Article. IF: 2.139; Q3
- Pericas JM, Llopis J, Muñoz P, Galvez-Acebal J, Kestler M, Valerio M, Hernández-Meneses M, Goenaga MA, Cobo-Belaustegui M, Montejo M, Ojeda-Burgos G, Sousa-Regueiro MD, de Alarcón A, Ramos-Martínez A, Miro JM, (Martín Quirós A). A Contemporary picture of enterococcal endocarditis. J Am Coll Cardiol. 2020; 75(5) :482-94. Article. IF: 24.094; D1
- López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune Response and COVID-19: A mirror image of Sepsis. Int J Biol Sci. 2020; 16(14): 2479-89. Review. IF: 6.58; Q1

Research projects

Martín Quirós A. Inmunidad en Sars-Cov-2 y riesgo cardiovascular. Cohorte prospectiva (I-ScarPRO). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2020-Ongoing.

Managment centre: FIBHULP

Martín Quirós A. Development of robust and innovative vaccine effectiveness (DRIVE). EU. 2019-2020.

Managment centre: FIBHULP

Martín Quirós A. Strategic partnership of emergency medical service practitioners for coordination of innovation procurement (IPROCURESECURITY). EU. 2019-2020.

Managment centre: FIBHULP

Martín Quirós A. Development of robust and innovative vaccine effectiveness (DRIVE). EU. 2020-2021.

Managment centre: FIBHULP

Martín Quirós A. Evaluación de la probabilidad clínica pre-test de cardiopatía isquemica en pacientes con DTA en los Servicios de Urgencias. (MAPAC-cardioTC. PI16/01045). ISCIII. 2016-2020.

Managment centre: FIBHULP

Clinical trials

Martín Quirós, A. Estudio descriptivo de pacientes con síndrome gripal atendidos en un servicio de urgencias de un hospital terciario.

Type: Study, phase No EPA.
HULP code: PI-3889 .
Sponsored´s protocol code: GRIPE 19.
Sponsored by: Martín Quirós, Alejandro.
Signed date: 15/05/2020

3.4.16 Hospital Pharmacy Group*

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



Alejandro Martín Quirós. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Alicia Herrero Ambrosio. Jefa de Servicio de Farmacia Hospitalaría. Hospital Universitario La Paz. Profesora Asociada. Universidad Complutense de Madrid

Gillermina Bejarano Redondo. Médico Adjunto en Urgencias. Hospital Universitario La Paz

Susana Andrés Morera. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Cristina Bilbao Gómez-Martino. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Nuria Blázquez Ramos. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Cristina Cárdenas Serralde. Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP

María Gema Casado Abad. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

María del Río Durango. Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP

Luis González del Valle. Jefe de Sección de Farmacia Hsopitalaria. Hospital Universitario La Paz

María Ángeles González Fernández. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Inmaculada Jiménez Nacher. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Catalina Lara Cátedra. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Marta Moro Agud. Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

Tamara Pérez Robles. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Elena María Rodríguez Martín. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

José Antonio Romero Garrido. Farmacéutico Adjunto. Hospital Universitario La Paz

Margarita Ruano Encinar. Facultativo Especialista de Área en Farmacia Hospitalaria

Rosario Fátima Ros Catellar. Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

Luis Sánchez-Rubio Fernández. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Carmen Sobrino Jiménez. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

María Luisa Testillano Tarrero. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Elena Villamañán Bueno. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

* Group recently created, december 2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

The Hospital Pharmacy group aims to investigations on pharmacotherapy focused on both, researches on treatments and innovation technology related to the medication use process in order to optimize clinical practice.

Research lines

1. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:
   - Coagulopathies
   - Oncology
   - Biologic therapies
   - Infectious diseases
   - Rare diseases
   - Gene therapy
   - Link between the parasympathetic and innate immune systems.
2. Investigation on strategies for early detection and prevention of medication errors either in patients with critical illness and patients with complex chronic conditions.
3. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:
   - Telepharmacy programs including or not medications home delivery. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis, prostate cancer and asthma.
   - Development and evaluation of digital health tools applied to congenital coagulopathies and its impact in terms of adherence and treatment cost-effectiveness improvement.
   - Research on the effect of predictive analytics and big data on clinical decision making and pharmaceutical outcomes optimization.
   - Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLR-mediated inflammation in human macrophages.
4. Development of new drugs: Advanced therapies

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.5 Cancer and Human Molecular Genetics Area


Gema Moreno Bueno

Documents:	206	IF:	1454.[196]
Originals:	171	IF:	1139.[106]
D1:	55	Q1:	101



3.5.1 INGEMM- Institute of Medical and Molecular Genetics Group
3.5.2 Translational Oncology Group
3.5.3 Experimental Therapies and Biomarkers in Cancer Group
3.5.4 Oto-Neurosurgery Research Group
3.5.5 Cancer Molecular Pathology and Therapeutic Targets Group
3.5.6 Mechanisms of Tumour Progression Group
3.5.7 Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Group
3.5.8 Research and Diagnosis of Inherited Metabolic Diseases Group
3.5.9 Regulation of Ciliary Structure and Function by Phosphoinositides Group
3.5.10 Dyslipidemias of Genetic Origin and Metabolic Diseases

3.5 Cancer and Human Molecular Genetics Area



Strategic Objectives	Development forecast for the coming years	Actions
Cancer and Medical Genetics area is made up of 10 groups and its objective is to deepen its knowledge in all aspects related to neoplastic disease, including the biology of the tumour, identification of therapeutic targets, development of new treatments, analysis of the efficacy of available treatments, identification of biomarkers and carrying out studies aimed at prevention and early diagnosis. In relation to human and molecular genetics, the aim is to identify genetic alterations related to human diseases in order to make an early diagnosis and prevent the development of pathologies.	Research in the area of cancer and genetics is expanding, both in terms of basic and translational research and clinical research. It is foreseeable that collaboration between groups in the area will continue to increase but also the collaboration with external organisations.	**Facilitate the application request for European projects through the IdiPAZ Internalization Platform.**
	In order to facilitate its development, it will be necessary for the Institution to provide sufficient space and adequate common infrastructures.	**Support researchers to continue being a reference in the international area.**
	It is foreseeable that this expansion will lead to the possibility of applying for European projects and leading consortiums, where once again the support of the Foundation will be essential for their application and management.	**Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.**

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.1 INGEMM - Institute of Medical and Molecular Genetics (Instituto de Genetica Medica y Molecular) Group

Publications:	46
Impact Factor:	276.[532]
Q1:	19



Pablo Daniel Lapunzina Badía.
Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

Cinthia Amiñoso Carbonero. Técnico de Laboratorio. Hospital Universitario La Paz

Pedro Arias Lajara. Técnico de Laboratorio. Hospital Universitario La Paz

Sara Benito Sanz. Investigadora Postdoctoral. Hospital Universitario La Paz

Ángel Campos Barros. Investigador Senior (Contrato Miguel Servet- I2). Jefe de Laboratorio. Hospital Universitario La Paz

Ángela del Pozo Mate. Técnico Informático. Hospital Universitario La Paz

Begoña Ezquieta Zubicaray. Bioquímico Adjunto. Hospital Universitario La Paz

Luis Fernández García-Moya. Biólogo. Hospital Universitario La Paz

Blanca Nieves Fernández Martínez. Técnico de Laboratorio. Hospital Universitario La Paz

María Victoria Fernández Montaña. Técnico de Laboratorio. Hospital Universitario La Paz

Amparo García Cardenal. Técnico de Laboratorio. Hospital Universitario La Paz

Fe Amalia García Santiago. Bióloga. Hospital Universitario La Paz

Sixto García-Miñaur Rica. Genetista. Hospital Universitario La Paz

Isabel Gómez Nieto. Técnico de Laboratorio. Hospital Universitario La Paz

Karen Elise Heath. Investigadora Senior (Contrato Ramón y Cajal- I3). Jefe de Laboratorio. Hospital Universitario La Paz

Teresa López Timénez. Técnico de Laboratorio. Hospital Universitario La Paz

Alicia Llorente Alonso. Técnico de Laboratorio. Hospital Universitario La Paz

María Elena Mansilla Aparicio. Genetista. Hospital Universitario La Paz

Pilar Martínez González. Bióloga. Hospital Universitario La Paz

Víctor Manuel Martínez González. Investigador Postdoctoral. Hospital Universitario La Paz

María Cruz Martínez Martínez. Técnico de Laboratorio. Hospital Universitario La Paz

José Carlos Moreno Navarro. Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

María Ángeles Mori Álvarez. Bioquímico Adjunto. Hospital Universitario La Paz

Julián Nevado Blanco. Biólogo. Hospital Universitario La Paz

María Palomares Bralo. Bióloga. Hospital Universitario La Paz

María Sol Pérez Coto. Técnico de Laboratorio. Hospital Universitario La Paz

Víctor Luis Ruiz Pérez. Investigador Cientifico de OPIs. Jefe de laboratorio. IIB "Alberto Sols"

Carmen Sánchez Gómez. Técnico de Laboratorio. Hospital Universitario La Paz

Fernando Santos Simarro. Médico Adjunto de Pediatría. Hospital Universitario La Paz

Jesús Solera García. Facultativo Especialista de Área en Análisis Bioquímicos. Hospital Universitario La Paz

Elena Vallespín García. Jefa de Grupo de la Sección de Ofalmogenética Molecular. Hospital Universitario La Paz

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

This is a clinical and basic research team that conducts several lines of research into early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects.

It is a heterogeneous group consisting of physicians, pharmacists, molecular biologists, bioinformaticians, technicians and administrative officers.

Research lines

- Subtelomeric rearrangements in patients with idiopathic mental retardation.
- Genetic and functional analysis of the SHOX and SHOX2 genes in human growth.
- Overgrowth syndromes. Clinical and molecular analysis.
- Genetic determinants of syndromic and non-syndromic proportional short stature
- Genetic detrerminants of disglycaemia: hypoglycaemia, diabetes mellitus and hyperinsulinism
- Genetic determinants of congenital hypopitutarism
- SNPs arrays in pharmacogenetics, HIV patients and genetic associations.
- CGHarrays and genomic rearrangements in patients with congenital malformations, intelectual disability and tumores.
- Molecular genetics of hypertrophic myocardiopathy.
- Functional analysis of CLCN1 mutations in congenital myotonia.
- Molecular study of endothelial dysfunction in diabetes and ageing.
- Molecular characterization of the 22q11.2 región by MLPA, microsatélites and FISH.
- Pharmacogenetics and pharcogenomics.
- Autosomal recessive osteogénesis imperfecta.
- Genomic tools for diagnosis: oligos and SNP arrays.
- Macrocephaly-capillary malformations and syndromes with macrocephaly.
- Next generation sequencing as a new tool in the diagnosis of genetic diseases.
- Classification and Ontolgies of Diseases
- Primary Pulmonary hypertension
- Análisis genómico global en el Síndrome de invdup(15) [idic(15) syndrome]
- Molecular characterization of inv dup del (8p) by Karyotype, SNP arrays and FISH

Research Activity

Publications

- Baumann M, Beaver EM, Palomares-Bralo M, Santos-Simarro F, Holzer P, Povysil G, Muller T, Valovka T, Janecke AR. Further delineation of putative ACTB loss-of-function variants: A 4-patient series. Hum Mutat. 2020; 41(4): 753-8. Article. IF: 4.878; Q2
- Berrocoso S, Amayra I, Lazaro E, Martínez O, López-Paz JF, García M, Pérez M, Al-Rashaida M, Rodríguez AA, Luna PM, Pérez-Núñez P, Blanco R, Nevado J. Coping with Wolf-Hirschhorn syndrome: quality of life and psychosocial features of family carers. Orphanet J Rare Dis. 2020; 15(1): 293. Article. IF: 4.123; Q2
- Braslavsky D, Scaglia P, Sanguineti N, Aza-Carmona M, Blanco JN, Badia PDL, Fernández MD, Ruiz O, Carmona A, Szlago M, Arberas C, Cassinelli H, Heath K, Rey R, Bergada I. Osteoporosis-pseudoglioma Syndrome: a pediatric case of primary osteoporosis. Arch Argent Pediatr. 2020; 118(3): E300-4. Article. IF: 0.635; Q4
- Castanedo LQ, Orta AS, Pedrero RM, Simarro FS, Bralo MP, Rodríguez MF, Laguna RD. Skin and nails abnormalities in a patient with ZTTK syndrome and a de novo mutation inSON. Pediatr Dermatol. 2020; 37(3): 517-9. Article. IF: 1.588; Q3
- Castaño JAT, Hernández-González I, Gallego N, Pérez-Olivares C, Parra NO, Arias P, Granda E, Acebo GG, Lago-Docampo M, Palomino-Doza J, Meseguer ML, del Cerro MJ, Valverde D, Lapunzina P, Escribano-Subias P. Customized massive parallel sequencing panel for diagnosis of pulmonary arterial hypertension. Genes. 2020; 11(10): 1158. Article. IF: 4.096; Q2
- Davies RW, Fiksinski AM, Breetvelt EJ, Williams NM, Hooper SR, Monfeuga T, Bassett AS, Owen MJ, Gur RE, Morrow BE, McDonald-McGinn DM, Swillen A, Chow EWC, van den Bree M, Emanuel BS, Vermeesch JR, van Amelsvoort T, Arango C, Armando M, Campbell LE, Cubells JF, Eliez S, García-Miñaur S, Gothelf D, Kates WR, Murphy KC, Murphy CM, Murphy DG, Philip N, Repetto GM, Shashi V, Simon TJ, Suner DH, Vicari S, Scherer SW, Bearden CE, Vorstman JAS. Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nat Med. 2020; 26(12): 1912-8. Article. IF: 53.44; D1
- Davis EE, Balasubramanian R, Kupchinsky ZA, Keefe DL, Plummer L, Khan K, Meczekalski B, Heath KE, López-González V, Ballesta-Martínez MJ, Margabanthu G, Price S, Greening J, Brauner R, Valenzuela I, Cusco I, Fernández-Álvarez P, Wierman ME, Li TB, Lage K, Barroso PS, Chan YM, Crowley WF, Katsanis N. TCF12 haploinsufficiency causes autosomal dominant Kallmann syndrome and reveals network-level interactions between causal loci. Hum Mol Genet. 2020; 29(14): 2435-50. Article. IF: 6.15; Q1
- Díaz-González F, Parrón-Pajares M, Barcia-Ramírez A, Heath KE. First case of compound heterozygous BHLHA9 variants in mesoaxial synostotic syndactyly with phalangeal reduction. Am J Med Genet A. 2020; 182(4): 628-31. Article. IF: 2.802; Q3
- Espeche LD, Solari AP, Mori MA, Arenas RM, Palomares M, Pérez M, Martínez C, Lotersztein V, Segovia M, Armando R, Dain LB, Nevado J, Lapunzina P, Rozental S. Implementation of chromosomal microarrays in a cohort of patients with intellectual disability at the Argentinean public health system. Mol Biol Rep. 2020; 47(9): 6863-78. Article. IF: 2.316; Q4
- García-Mendiola T, Gutiérrez-Sanchez C, Gibaja C, Torres I, Buso-Rogero C, Pariente F, Solera J, Razavifar Z, Palacios JJ, Zamora F, Lorenzo E. Functionalization of a few-layer antimonene with oligonucleotides for DNA sensing. ACS Appl Nano Mater. 2020; 3(4): 3625-33. Article. IF: 5.097; Q2

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Hernández-González I, Tenorio J, Palomino-Doza J, Menaca AM, Ruiz RM, Lago-Docampo M, Gomez MV, Román JG, Valls ABE, Pérez-Olivares C, Valverde D, Carbonell JG, Rodríguez-Monte EGL, del Cerro MJ, Lapunzina P, Escribano-Subias P. Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. PLoS One. 2020; 15(4): e0232216. Article. IF: 3.24; Q2
- Illescas T, Mansilla E, Herrero B, Rodríguez R, López F, Aza-Carmona M, Regojo RM, Santos-Simarro F, Heath KE, Bartha JL, Antolin E. Prenatal diagnosis of fetal skeletal dysplasias in a tertiary Hospital in Spain. Eur J Obstet Gynecol Reprod Biol. 2020; 250: 209-15. Article. IF: 2.435; Q3
- Ivars M, Azana JM, Weibel L, Theiler M, Boixeda P, Norris DI, Martínez-Glez V, Agra N, Rodríguez-Laguna L, Colmenero I, Beato-Merino MJ, López-Gutiérrez JC. Capillary malformation with segmental distribution and central atrophy: A series of 7 cases. J Am Acad Dermatol. 2020; 83(1): 213-4. Letter. IF: 11.527; D1
- Ivars M, Boixeda P, Triana P, Martínez-Glez V, Rodríguez-Laguna L, Agra N, López-Gutiérrez JC. Clinical overlap between CLAPO syndrome and macrocephaly-capillary malformation syndrome. J Dtsch Dermatol Ges. 2020; 18(5): 479-82. Letter. IF: 5.584; D1
- Ivars M, Boixeda P, Triana P, Martínez-Glez V, Rodríguez-Laguna L, Agra N, López-Gutiérrez JC. Klinische Uberlappung zwischen CLAPO-Syndrom und Megalenzephalie-Kapillarfehlbildungen-Polymikrogyrie-Syndrom. J Dtsch Dermatol Ges. 2020;18(5): 480-4. Letter. IF: 5.584; D1
- Ivars M, López-Gutiérrez JC, Martínez-Glez V, Redondo P. Ein asymptomatischer Fleck auf der Stirn. J Dtsch Dermatol Ges. 2020; 18(12): 1511-4. Article. IF: 5.584; D1
- Lacamara N, Lecumberri B, Barquiel B, Escribano A, González-Casado I, Álvarez-Escola C, Aleixandre-Blanquer F, Morales F, Alfayate R, Bernal-Soriano MC, Miralles R, Simsir IY, Ozgen AG, Bernal J, Berbel P, Moreno JC. Identification of resistance to exogenous thyroxine in humans. Thyroid. 2020; 30(12): 1732-44. Article. IF: 6.568; Q1
- Lago-Docampo M, Tenorio J, Hernández-González I, Pérez-Olivares C, Escribano-Subias P, Pousada G, Baloira A, Arenas M, Lapunzina P, Valverde D. Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. Sci Rep. 2020; 10(1): 15135. Article. IF: 4.379; Q1
- Lamuedra A, Gratal P, Calatrava L, Ruiz-Pérez VL, Largo R, Herrero-Beaumont G. Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. Sci Rep. 2020; 10(1): 10745. Article. IF: 4.379; Q1
- Limeres J, Serrano C, de Nova JM, Silvestre-Rangil J, Machuca G, Maura I, Ruiz-Villandiego JC, Diz P, Blanco-Lago R, Nevado J, Diniz-Freitas M. Oral manifestations of Wolf-Hirschhorn syndrome: Genotype-phenotype correlation analysis. J Clin Med. 2020; 9(11): 3556. Article. IF: 4.241; Q1
- Lorente-Ros M, Andrés AM, Sánchez-Galán A, Aminoso C, García S, Lapunzina P, García JS. New mutations associated with Hirschsprung disease. An Pediatr. 2020; 93(4): 222-7. Article. IF: 1.5; Q4
- Meerschaut I, de Coninck S, Steyaert W, Barnicoat A, Bayat A, Benedicenti F, Berland S, Blair EM, Breckpot J, de Burca A, Destree A, García-Miñaur S, Green AJ, Hanna BC, Keymolen K, Koopmans M, Lederer D, Lees M, Longman C, Lynch SA, Male AM, McKenzie F, Migeotte I, Mihci E, Nur B, Petit F, Piard J, Plasschaert FS, Rauch A, Ribai P, Pacheco IS, Stanzial F, Stolte-Dijkstra I, Valenzuela I, Varghese V, Vasudevan PC, Wakeling E, Wallgren-Pettersson C, Coucke P, De Paepe A, De Wolf D, Symoens S, Callewaert B. A clinical scoring system for congenital contractural arachnodactyly. Genet Med. 2020; 22(1): 124-31. Article. IF: 8.822; D1
- Mejia RR, Aza-Carmona M, del Pino M, Heath KE, Fano V, Obregon MG. Clinical and radiologic evaluation of an individual with hypochondroplasia and a novel FGFR3 mutation. J Pediatr Genet. 2020; 9(1): 48-52. Article. Not Indexed
- Míguez MP, Santos-Simarro F, García-Miñaur S, Fragua RV, del Pozo A, Solis M, Rodríguez CJ, Rufo-Rabadan V, Fernández VE, Rueda I, del Pozo MVG, Gallego N, Lapunzina P, Palomares-Bralo M. Pathogenic variants in KPTN, a rare cause of macrocephaly and intellectual disability. Am J Med Genet A. 2020; 182(10): 2222-5. Letter. IF: 2.802; Q3
- Monteagudo-Sánchez A, Mora JRH, Simón C, Burtón A, Tenorio J, Lapunzina P, Clark S, Esteller M, Kelsey G, López-Siguero JP, de Nanclares GP, Torres-Padilla ME, Monk D. The role of ZFP57 and additional KRAB-zinc finger proteins in the maintenance of human imprinted methylation and multi-locus imprinting disturbances. Nucleic Acids Res. 2020; 48(20): 11394-407. Article. IF: 16.971; D1
- Mulder PA, van Balkom IDC, Landlust AM, Priolo M, Menke LA, Acero IH, Alkuraya FS, Arias P, Bernardini L, Bijlsma EK, Cole T, Coubes C, Dapia I, Davies S, Di Donato N, Elcioglu NH, Fahrner JA, Foster A, González NG, Huber I, Iascone M, Kaiser AS, Kamath A, Kooblall K, Lapunzina P, Liebelt J, Lynch SA, Maas SM, Mammi C, Mathijssen IB, McKee S, Mirzaa GM, Montgomery T, Neubauer D, Neumann TE, Pintomalli L, Pisanti MA, Plomp AS, Price S, Salter C, Santos-Simarro F, Sarda P, Schanze D, Segovia M, Shaw-Smith C, Smithson S, Suri M, Tatton-Brown K, Tenorio J, Thakker RV, Valdez RM, Van Haeringen A, Van Hagen JM, Zenker M, Zollino M, Dunn WW, Piening S, Hennekam RC. Development, behaviour and sensory processing in Marshall-Smith syndrome and Malan syndrome: phenotype comparison in two related syndromes. J Intell Disabil Res. 2020; 64(12): 956-69. Article. IF: 2.424; Q2
- Palencia-Campos A, Aoto PC, Machal EMF, Rivera-Barahona A, Soto-Bielicka P, Bertinetti D, Baker B, Vu L, Piceci-Sparascio F, Torrente I, Boudin E, Peeters S, Hul WV, Huber C, Bonneau D, Hildebrand MS, Coleman M, Bahlo M, Bennett MF, Schneider AL, Scheffer IE, Kibaek M, Kristiansen BS, Issa MY, Mehrez MI, Ismail S, Tenorio J, Li GY, Skalhegg BS, Otaify GA, Temtamy S, Aglan M, Jonch AE, De Luca A, Mortier G, Cormier-Daire V, Ziegler A, Wallis M, Lapunzina P, Herberg FW, Taylor SS, Ruiz-Pérez VL. Germline and Mosaic Variants in PRKACA and PRKACB Cause a Multiple Congenital Malformation Syndrome. Am J Hum Genet. 2020; 107(5): 977-88. Article. IF: 11.025; D1
- Pascual-Alonso A, Blasco L, Vidal S, Gean E, Rubio P, O'Callaghan M, Martínez-Monseny AF, Castells AA, Xiol C, Catala V, Brandi N, Pacheco P, Ros C, del Campo M, Guillen E, Ibanez S, Sanchez MJ, Lapunzina P, Nevado J, Santos F, Lloveras E, Ortigoza-Escobar JD, Tejada MI, Maortua H, Martínez F, Orellana C, Rosello M, Mesas MA, Obon M, Plaja A, Fernández-Ramos JA, Tizzano E, Marin R, Pena-Segura JL, Alcantara S, Armstrong J. Molecular characterization of Spanish patients with MECP2 duplication syndrome. Clin Genet. 2020; 97(4): 610-20. Article. IF: 4.438; Q2
- Peces R, Mena R, Martín Y, Hernández C, Peces C, Telleria D, Cuesta E, Selgas R, Lapunzina P, Nevado J. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2. Mol Genet Genom Med. 2020; 8(8): e1321. Article. IF: 2.183; Q3
- Peces R, Mena R, Peces C, Cuesta E, Selgas R, Barruz P, Lapunzina P, Nevado J. Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression. Clin Genet. 2020; 97(6): 857-68. Article. IF: 4.438; Q2
- Pernia O, Sastre-Perona A, Rodríguez-Antolín C, García-Guede A, Palomares-Bralo M, Rosas R, Sánchez-Cabrero D, Cruz P, Rodríguez C, Diestro M, Martín-Arenas R, Pulido V, Santisteban P, de Castro J, Vera O, de Cáceres II. A novel role for the tumor suppressor gene ITF2 in tumorigenesis and chemotherapy response. Cancers. 2020; 12(4): 786. Article. IF: 6.639; Q1
- Piceci-Sparascio F, Palencia-Campos A, Soto-Bielicka P, D'Anzi A, Guida V, Rosati J, Caparros-Martín JA, Torrente I, D'Asdia MC, Versacci P, Briuglia S, Lapunzina P, Tartaglia M, Marino B, Digilio MC, Ruiz-Pérez VL, de Luca A. Common atrium/atrioventricular canal defect and postaxial polydactyly: A mild clinical subtype of Ellis-van Creveld syndrome caused by hypomorphic mutations in theEVCgene. Hum Mutat. 2020; 41(12): 2087-93. Article. IF: 4.878; Q2
- Rodríguez-Jiménez P, Chicharro P, Llamas-Velasco M, Moyano B, Sánchez-Carpintero I, López-Gutiérrez JC, Martínez-Glez V, Rodríguez-Laguna L, Torrelo A. A case of naevus vascularis mixtus with hypotrophy and hypotrichosis due to mosaic GNA11 mutation. J Eur Acad Dermatol Venereol. 2020; 34(8): E420-2. Letter. IF: 6.166; Q1
- Rodríguez-Novoa S, Rodríguez-Jiménez C, Alonso C, Rodríguez-Laguna L, Gordo G, Martínez-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Glez V, Polo IG. Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR). Atherosclerosis. 2020; 311: 37-43. Article. IF: 5.162; Q2

- Sánchez-Rodríguez C, Peiro C, Rodríguez-Mañas L, Nevado J. Polyphenols attenuate highly-glycosylated haemoglobin-induced damage in human peritoneal mesothelial cells. Antioxidants. 2020; 9(7): 572. Article. IF: 6.312; D1
- Sentchordi-Montane L, Benito-Sanz S, Aza-Carmona M, Pereda A, Parrón-Pajares M, de la Torre C, Vasques GA, Funari MFA, Travessa AM, Dias P, Suárez-Ortega L, González-Buitrago J, Portillo-Najera NE, Llano-Rivas I, Martín-Frías M, Ramírez-Fernández J, del Pozo JS, Garzón-Lorenzo L, Martos-Moreno GA, Alfaro-Iznaola C, Mulero-Collantes I, Ruiz-Ocana P, Casano-Sancho P, Portela A, Ruiz-Pérez L, del Pozo A, Vallespin E, Solis M, Lerario AM, González-Casado I, Ros-Pérez P, de Nanclares GP, Jorge AAL, Heath KE. Clinical and molecular description of 16 families with heterozygous IHH variants. J Clin Endocrinol Metab. 2020; 105(8): 2654-66. Article. IF: 5.958; Q1
- Suter AA, Santos-Simarro F, Toerring PM, Pérez AA, Ramos-Mejia R, Heath KE, Huckstadt V, Parrón-Pajares M, Mensah MA, Hulsemann W, Holtgrewe M, Mundlos S, Kornak U, Bartsch O, Ehmke N. Variable pulmonary manifestations in Chitayat syndrome: Six additional affected individuals. Am J Med Genet A. 2020; 182(9): 2068-76. Article. IF: 2.802; Q3
- Taylor BG, Sancho MLM, Rieger ED, Juliá SC, Nevado J, Ferre FS. Prevalence of the Phelan-McDermid syndrome in Spain. Rev Esp Salud Publica. 2020; 94: e202012121. Article. IF: 0.756; Q4
- Tenorio J, Alarcón P, Arias P, Dapia I, García-Miñaur S, Bralo MP, Campistol J, Climent S, Valenzuela I, Ramos S, Monseny AM, Grondona FL, Botet J, Serrano M, Solis M, Santos-Simarro F, Álvarez S, Teixido-Tura G, Jaen AF, Gordo G, Rivera MBB, Nevado J, Hernández A, Cigudosa JC, Ruiz-Pérez VL, Tizzano EF, Lapunzina P. Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients. Eur J Hum Genet. 2020; 28(4): 469-79. Article. IF: 4.246; Q2
- Tenorio J, Nevado J, González-Meneses A, Arias P, Dapia I, Venegas-Vega CA, Calvente M, Hernández A, Landera L, Ramos S, Cigudosa JC, Pérez-Jurado LA, Lapunzina P. Further definition of the proximal 19p13.3 microdeletion/microduplication syndrome and implication of PIAS4 as the major contributor. Clin Genet. 2020; 97(3): 467-76. Article. IF: 4.438; Q2
- Tornero C, Navarro-Compán V, Tenorio JA, García-Carazo S, Buno A, Monjo I, Plasencia-Rodríguez C, Iturzaeta JM, Lapunzina P, Heath KE, Balsa A, Aguado P. Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia? Orphanet J Rare Dis. 2020; 15(1): 51. Article. IF: 4.123; Q2
- Travessa AM, Díaz-González F, Mirco T, Oliveira-Ramos F, Parrón-Pajares M, Heath KE, Sousa AB. Spondyloepiphyseal dysplasia type Stanescu: Expanding the clinical and molecular spectrum of a very rare typeIIcollagenopathy. Am J Med Genet A. 2020; 182(11): 2715-21. Article. IF: 2.802; Q3
- Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros A, Gámez-Pozo A, Feliú J, Vara JAF. Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma. Transl Oncol. 2020; 13(7): 100778. Article. IF: 4.243; Q2
- van Dijk FS, Semler O, Etich J, Kohler A, Jimenez-Estrada JA, Bravenboer N, Claeys L, Riesebos E, Gegic S, Piersma SR, Jimenez CR, Waisfisz Q, Flores CL, Nevado J, Harsevoort AJ, Janus GJM, Franken AAM, van der Sar AM, Meijers-Heijboer H, Heath KE, Lapunzina P, Nikkels PGJ, Santen GWE, Nuchel J, Plomann M, Wagener R, Rehberg M, Hoyer-Kuhn H, Eekhoff EMW, Pals G, Morgelin M, Newstead S, Wilson BT, Ruiz-Pérez VL, Maugeri A, Netzer C, Zaucke F, Micha D. Interaction between KDELR2 and HSP47 as a key determinant in osteogenesis imperfecta caused by Bi-allelic variants in KDELR2. Am J Hum Genet. 2020; 107(5): 989-99. Article. IF: 11.025; D1
- Zhao YJ, Diacou A, Johnston HR, Musfee FI, McDonald-McGinn DM, McGinn D, Crowley TB, Repetto GM, Swillen A, Breckpot J, Vermeesch JR, Kates WR, Digilio MC, Unolt M, Marino B, Pontillo M, Armando M, Di Fabio F, Vicari S, van den Bree M, Moss H, Owen MJ, Murphy KC, Murphy CM, Murphy D, Schoch K, Shashi V, Tassone F, Simon TJ, Shprintzen RJ, Campbell L, Philip N, Heine-Suner D, García-Miñaur S, Fernández L, Bearden CE, Vingerhoets C, van Amelsvoort T, Eliez S, Schneider M, Vorstman JAS, Gothelf D, Zackai E, Agopian AJ, Gur RE, Bassett AS, Emanuel BS, Goldmuntz E, Mitchell LE, Wang T, Morrow BE. Complete sequence of the 22q11.2 allele in 1,053 subjects with 22q11.2 deletion syndrome reveals modifiers of conotruncal heart defects. Am J Hum Genet. 2020; 106(1): 26-40. Article. IF: 11.025; D1
- Ziats CA, Jain L, McLarney B, Vandenboom E, DuPont BR, Rogers C, Sarasua S, Nevado J, Cordisco EL, Phelan K, Boccuto L. Neurofibromatosis type 2 in Phelan-McDermid syndrome: Institutional experience and review of the literature. Eur J Med Genet. 2020; 63(11): 104042. Review. IF: 2.708; Q3

Research projects

Campos Barros A. Contrato Miguel Servet Categoria B (CES06/019). ISCIII. 2008-2025.

Managment centre: FIBHULP

Campos Barros A. Descifrando la complejidad genética del hipopituitatismo congénito (PI18/00402). ISCIII. 2019-2021.

Managment centre: FIBHULP

García-Miñaur Rica S. Manejo clínico perinatal y evolución y pronóstico en el síndrome de selección 22q11. The International 22Q11.2 Foundation Inc. 2019-Ongoing.

Managment centre: FIBHULP

Heath KE. Contrato I3 Estabilizado (CESI308/003). ISCIII. 2009-2025.

Managment centre: FIBHULP

Heath KE. Estudio comprensivo de la genética de las displasias esqueléticas: 1) Caracterizacion de la regulación de SHOX en la placa de crecimiento humano, y 2) análisis genético de las displasias esqueléticas mediante ACGH y NGS. Acuña y Fombona S. A. 2012-Ongoing.

Managment centre: FIBHULP

Heath KE. Identificación y estudio funcional de nuevos defectos moleculares en displasias esqueléticas (SAF2017-84646-R). MINECO. 2018-2021.

Managment centre: FIBHULP

Lapunzina Badía PD, Feliú Batlle J, Hardisson Hernáez D. Determinación genómica de muestras del biomarcador del gen KRAS y NRAS. Amgen S. A. 2014-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genético y genómico en pacientes afectados por la enfermedad de Gorham-Stout y por anomalías generales. The Lymphatic Malformation Institute. 2012-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el síndrome de Invdup 15 syndrome: evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. Fundación Inversión Duplicación del Cromosoma 15. 2017-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el síndrome de invdupdel 8P: evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. La Asociación Síndrome Duplicidad Inversíon Delecion del Brazo Corto del Cromosoma 8. 2015-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis global de la hipofosfatasia: evaluación de la dosis genómica mediante MLPA y estudio del gen

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

ALPL en pacientes con sospecha clínica. Innovaciones Geneticas S. L. 2014-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Búsqueda de mutaciones en el gen Cripak y otros modificadores en pacientes con hipertension arterial pulmonar. Fundación contra la Hipertension Pulmonar. 2018-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Búsqueda de nuevos genes y nuevas patologías mediante la aplicación de secuenciación masiva en una cohorte de pacientes con síndromes de sobrecrecimiento bien caracterizados clínicamente (PI15/01481). ISCIII. 2016-2020.

Managment centre: FIBHULP

Lapunzina Badía PD. Contrato predoctoral (PEJD2019_PRE/BMD_15054). CM. 2020-2021.

Managment centre: FIBHULP

Lapunzina Badía PD. Craniofacial microsomia> genetic causes and pathway discovery. Seattle Children-S Hospital Research Foundation. 2017-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Desarrollo de las tareas de análisis de variantes y alteraciones genéticas en genes específicos necesarios para el desarrollo del estudio "ERC-Avatar" del Hospital Universitario de Fuenlabrada. Hospital Universitario de Fuenlabrada. 2019-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Estudio clínico molecular en pacientes con síndrome de sobrecrecimiento. Estudio de los genes NSD1, NIZP1, HRAS, CDKN1C, GLP, y de las regiones cromosómicas 5q35, xq26 y 11p en pacientes con SSC. Effice Servicios para la Investigación S. L. 2005-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Estudio genético-molecular de genes candidatos en pacientes con hipertensión pulmonar idiopática. Actelion Pharmaceuticals España. 2011-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Estudios citogenéticas y moleculares en población con enfermedades de base genética en el Hospital La Paz. Agilent Technologies Spain S. L. 2007-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Evaluación psicomética en pacientes con síndrome de Phelan-M Dermid Síndrome de microdelección 22q13. Oryzon Genomics S. A. 2020-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Exomas baleares y extremadura. Sanidad Pública de la Comunidad Autónoma de Extremadura. 2018-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Inteligencia artificial y machine learning en enfermedades humanas. Fundación Ramón Areces. 2019-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Proyecto piloto para la mejora del diagnóstico genético de personas y familias afectadas con enfermedades raras de base genética. MSCBS. 2018-2021.

Managment centre: FIBHULP

Lapunzina Badía PD. Screening of high-risk pediatric population using an epilepsy gene panel for early diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2) disease. Biomarin International Limited. 2017-Ongoing.

Managment centre: FIBHULP

Martínez González VM. En búsqueda del diagnóstico genético en pacientes con espectro Pros. Fundación Bancaria Caixa D'Estalvis I Pensions de Barcelona la Caixa. 2019-Ongoing.

Managment centre: FIBHULP

Martínez González VM. Estudio genético y funcional en pacientes con enfermedades de Gorham-Stout (GSD) y anomalías linfáticas generalizadas. Comunidad de Madrid. 2018-Ongoing.

Managment centre: FIBHULP

Moreno Navarro JC. Disección genética de la narcolepsia y otras hipersomnias centrales. Merino Andreu, Milagros. 2019-Ongoing.

Managment centre: FIBHULP

Moreno Navarro JC. Disrupción tiroidea gestacional por xenobióticos fenólicos halogenados: efectos tiroideos, cerebrales y hepáticos en el modelo murino dehal1(-/-) y en mujeres embarazadas (PI16/00830). ISCIII. 2017-2021.

Managment centre: FIBHULP

Moreno Navarro JC. Síndrome de restistencia a las hormonas tiroideas. Estudio genético-molecular en población española. Moreno Navarro, José Carlos. 2013-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J, Lapunzina Badía PD. Evaluación genómica en el síndrome de Wolf-Hirschhorn [Síndrome 4P]: microarrays personalizados de SNPS y estudio de genes candidatos. Asociación Española del Síndrome de Wolf Hirschhom. 2017-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J. Aproximación genómica en el síndrome de Phelanmc Dermid [Sindrome de microdeleción 22q13]: microarrays personalizados de SNPS y evaluación de los genes candidatos. La Asociación Síndrome Phelan-Mcdermid. 2017-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J. Evaluación genómica en el s. de Wolf-Hirschhorn; microarrays personalizados de SNPS y genes candidatos: aproximación a las alteraciones dentales y a una epilepsia compleja (PI18/01433). ISCIII. 2019-2021.

Managment centre: FIBHULP

Palomares Bralo M. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-6201). CM. 2018-2021.

Managment centre: FIBHULP

Palomares Bralo M. Red de recursos genómicos, funcionales, clínicos y terapéuticos para el estudio de las enfermedades raras neurológicas (S2017/BMD-3721). CM. 2018-2021.

Managment centre: FIBHULP

Palomares Bralo M. Secuenciación rápida del exoma, utilidad/aplicación en pacientes pediátricos ingresados en unidades de críticos o de alta complejidad (PI19/01681). ISCIII. 2020-2022.

Managment centre: FIBHULP

Solera García J. Estudio de microRNAs en pacientes con glucogenosis tipo II (enfermedad de Pompe) como marcadores de diagnóstico, progresión de la enfermedad y respuesta al tratamiento. Fundación Genzyme. 2013-Ongoing.

Managment centre: FIBHULP

Solís López M. Contrato de apoyo bioinformático (CA18/00033). ISCIII. 2019-2021.

Managment centre: FIBHULP

Vallespín García E. Desarrollo e implementación de un protocolo integral combinado con la búsqueda de nuevos genes de cataratas congénitas bilaterales no sindrómicas. Grupo Social ONCE. 2020-2021.

Managment centre: FIBHULP

Vallespín García E. Miopía magna de inicio precoz (<10 años) con o sin Nistagmo: estudio clínico y genético (PI18/01234). ISCIII. 2019-2021.

Managment centre: FIBHULP

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Cibers and Retics

Lapunzina Badía P. CIBER Enfermedades Raras (CB06/07/1033). ISCIII. (31/12/2021).

Clinical trials

Santos Simarro, F. Phase 2, open-label, dose-escalation and dose-expansion study of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in children with achondroplasia: Propel 2.

Type: EECC, phase II.
HULP code: 5596.
Sponsored´s protocol code: QBGJ398-201.
Sponsored by: Qed Therapeutics Inc.
Signed date: 01/10/2020

Santos Simarro, F. Achieve: estudio multicéntrico, longitudinal y observacional de niños con acondroplasia.

Type: Estudios, phase No EPA.
HULP code: PI-3832 .
Sponsored´s protocol code: TCC-NHS-01.
Sponsored by: Ascendis Pharma Growth Disorders.
Signed date: 04/02/2020

Santos Simarro, F. Estudio de evaluacion clínica prospectiva en niños con acondroplasia: el ensayo Propel.

Type: Estudios, phase No EPA.
HULP code: PI-4027 .
Sponsored´s protocol code: QBGJ398-001.
Sponsored by: Qed Therapeutics Inc.
Signed date: 25/02/2020

Patents and trademarks

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.

Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee. Brand name: Pharma Genfinder; CM18332183; 2020 November 05.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.2 Translational Oncology Group

Publications:	37
Impact Factor:	328.[404]
Q1:	17



Jaime Feliú Batlle. Jefe de Servicio de Oncología Médica. Hospital Universitario La Paz. Profesor Titular de Oncología. Universidad Autónoma de Madrid

Jorge Barriuso Feijoó. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Borja Belandía Gómez. Científico Titular. IIB "Alberto Sols"

Beatriz Castelo Fernández. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Paloma Cejas Guerrero. Investigadora Postdoctoral. Hospital Universitario La Paz

Roberto Crespo San Pedro. Técnico Superior en Anatomía Patológica. Hospital Universitario La Paz

Ana Belén Custodio Carretero. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Enrique Espinosa Arranz. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Juan Ángel Fresno Vara. Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Alejandro Gallego Martínez. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Ángelo Gámez Pozo. Investigador Postdoctoral (Contrato Técnico de Apoyo). Hospital Universitario La Paz

Laura García Acebedo. Médico Interno Residente. Coordinadora del Registro de Tumores. Hospital Universitario La Paz

Ismael Ghanem Cañete. Médico Adjunto en Oncología Médica. Hospital Universitario La Paz

Juan Carlos Lacal Sanjuán. Profesor de Investigación. IIB "Alberto Sols"

Victoria María Heredia Soto. Investigadora Postdoctoral. Hospital Universitario La Paz

Rocío López Vacas. Técnico de Laboratorio (Contrato Técnico de Apoyo). Hospital Universitario La Paz

Virginia Martínez Marín. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Ignacio Palmero Rodríguez. Científico Titular. IIB "Alberto Sols"

Álvaro Pinto Marín. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Andrés Redondo Sánchez. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Nuria Rodríguez Salas. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Lucía Trilla Fuertes. Investigadora Predoctoral. Biomedica Molecular Medicine SL

Pilar Zamora Auñón. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Strategic Objective

The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis.

The Translational Oncology group's objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians.

Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in healthcare takes too much

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.

The main lines of study are based on tumours with the greatest incidence and impact on survival, such as lung, colorectal, breast and ovarian cancer, although other types of neoplasms have been incorporated such as gastric and renal cancer. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour.

Research lines

- Identification of prognostic factors Clinical Genomic Proteomic.
- Identification of mechanisms of resistance to drugs.
- Efficacy and toxicity of antineoplastic therapies.
- Palliative care and supportive treatments.

Research Activity

Publications

- Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodríguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ. Genomic Predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer. Cancer Res. 2020;80(20): 4476-86. Article. IF: 12.701; Q1
- Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliú J, Munoz A, Ponz-Sarvise M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Haras AV, Von Hoff DD, Hidalgo M. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat. Med. 2020; 26(6): 878-85. Article. IF: 53.44; D1
- Cejas P, Long HW. Principles and methods of integrative chromatin analysis in primary tissues and tumors. Biochim. Biophys. Acta-Rev. Cancer. 2020; 1873(1): 188333. Review. IF: 10.68; D1
- Chin HG, Sun ZY, Vishnu US, Hao PY, Cejas P, Spracklin G, Esteve PO, Xu SY, Long HW, Pradhan S. Universal NicE-seq for high-resolution accessible chromatin profiling for formaldehyde-fixed and FFPE tissues. Clin. Epigenetics. 2020; 12(1): 143. Article. IF: 6.551; Q1
- Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song CY, Boulet T, Trask P, Geyer CE. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2020; 126(13): 3132-9. Article. IF: 6.86; Q1
- de Juan A, Redondo A, Rubio MJ, García Y, Cueva J, Gaba L, Yubero A, Alarcón J, Maximiano C, Oaknin A. SEOM clinical guidelines for cervical cancer (2019). Clin. Transl. Oncol. 2020; 22(2): 270-8. Article. IF: 3.405; Q3
- Feliú J, García-Carbonero R, Capdevila J, Guasch I, Alonso-Orduña V, López C, García-Alfonso P, Castañón C, Sevilla I, Cerezo L, Conill C, Quintana-Ángel B, Sánchez ME, Ghanem I, Martín-Richard M, López-Gómez M, Leon A, Caro M, Fernández T, Maurel J. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). Cancer Med. 2020; 9(3): 1008-16. Article. IF: 4.452; Q2.
- Feliú J, Heredia-Soto V, Girones R, Jiménez-Munarriz B, Saldana J, Guillen-Ponce C, Molina-Garrido MJ. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin. Transl. Oncol.. 2020;22(4):457-467. Review. IF: 3,405; Q3
- Feliú J, Jiménez-Muñárriz B, Basterretxea L, Paredero I, Llabres E, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Muñoz MD, Díaz-Almirón M, Gómez-Mediavilla J, Pinto A, Torregrosa MD, Soler G, Cruz P, Higuera O, Molina-Garrido MJ. Predicting chemotherapy toxicity in older patients with cancer: A multicenter prospective study. Oncologist. 2020; 25(10): E1516-24. Article. Not indexed
- Font-Tello A, Kesten N, Xie YT, Taing L, Vareslija D, Young LS, Hamid AA, Van Allen EM, Sweeney CJ, Gjini E, Lako A, Hodi FS, Bellmunt J, Brown M, Cejas P, Long HW. FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat. Protoc. 2020; 15(8): 2503-18. Article. IF: 13.491; D1
- Ghanem I, Castelo B, Jiménez-Fonseca P, Carmona-Bayonas A, Higuera O, Beato C, García T, Hernández R, Calderón C. Coping strategies and depressive symptoms in cancer patients. Clin. Transl. Oncol. 2020; 22(3): 330-6. Article. IF: 3.405; Q3
- Grande E, Teule A, Alonso-Gordoa T, Jiménez-Fonseca P, Benavent M, Capdevila J, Custodio A, Vera R, Munarriz J, La Casta A, Diez JJ, Gajate P, Molina-Cerrillo J, Matos I, Cristobal EM, Ruffinelli JC, Palacios J, García-Carbonero R. The PALBONET trial: A phase II study of palbociclib in metastatic grade 1 and 2 pancreatic neuroendocrine tumors (GETNE-1407). Oncologist. 2020; 25(9): 745-e1265. Article. Not Indexed
- Heredia-Soto V, López-Guerrero J A, Redondo A, Mendiola M. The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. EJC Suppl. 2020; 15: 49-55. Article. IF: 9.386; Q1.
- Heredia-Soto V, Redondo A, Kreilinger JJP, Martínez-Marín V, Berjón A, Mendiola M. 3D culture modelling: An emerging approach for translational cancer research in sarcomas. Curr Med Chem. 2020; 27(29): 4778-88. Review. IF: 4.53; Q2
- Lebbe C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, de Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dreno B. Pimasertib versus dacarbazine in patients with unresectableNRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover. Cancers. 2020; 12(7): 1727. Article. IF: 6.639; Q1
- López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Albendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, Gonzalez-Juanatey

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

JR, Monzonis AM, Prieto PG, González-Costello J, Antolín JMS, Chamorro RC, Fernández TL. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-9. Article. IF: 29.983; D1

- Martín-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, López-Guerrero JA, Dopazo J, Pena-Chilet M, Gutiérrez A, Collini P, Karanian M, Redondo A, López-Pousa A, Grignani G, Díaz-Martín J, Marcilla D, Fernández-Serra A, González-Aguilera C, Casali PG, Blay JY, Stacchiotti S. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(3): 456-66. Article. IF: 41.316; D1
- Martín-Broto J, Hindi N, Grignani G, Martínez-Trufero J, Redondo A, Valverde C, Stacchiotti S, López-Pousa A, D'Ambrosio L, Gutiérrez A, Pérez-Vega H, Encinas-Tobajas V, de Alava E, Collini P, Pena-Chilet M, Dopazo J, Carrasco-García I, López-Álvarez M, Moura DS, López-Martín JA. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020; 8(2): e001561. Article. IF: 13.751; Q1
- Martín-Broto J, Hindi N, López-Pousa A, Peinado-Serrano J, Álvarez R, Álvarez-González A, Italiano A, Sargos P, Cruz-Jurado J, Isern-Verdum J, Dolado MC, Rincón-Pérez I, Sánchez-Bustos P, Gutiérrez A, Romagosa C, Morosi C, Grignani G, Gatti M, Luna P, Alastuey I, Redondo A, Belinchón B, Martínez-Serra J, Sunyach MP, Coindre JM, Dei Tos AP, Romero J, Gronchi A, Blay JY, Moura DS. Assessment of safety and efficacy of combined trabectedin and low-dose radiotherapy for patients with metastatic soft-tissue sarcomas: A nonrandomized phase 1/2 clinical Trial. JAMA Oncol. 2020; 6(4): 535-41. Article. IF: 31.777; D1
- Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol. 2020; 22(2): 236-44. Article. IF: 3.405; Q3
- Povedano E, Montiel VRV, Gamella M, Pedrero M, Barderas R, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Yáñez-Sedeno P, Campuzano S, Pingarrón JM. Amperometric bioplatforms to detect regional DNA methylation with single-base sensitivity. Anal Chem. 2020; 92(7): 5604-12. Article. IF: 6.986; D1
- Ramírez SP, del Monte-Millán M, López-Tarruella S, Jánez NM, Márquez-Rodas I, Samper FL, Perón YI, Terres CR, Rodríguez DR, García-Saenz JA, Antón FM, Auñón PZ, Yustos MA, Álvarez MAL, Gil EMC, Sánchez LM, González MJE, Martínez JAG, Sánchez CJ, Muino CB, Adrián SG, Galindo JRC, Maganto VV, Martín M. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. Clin Transl Oncol. 2020; 22(5): 717-24. Article. IF: 3.405; Q3
- Redondo A, Colombo N, McCormack M, Dreosti L, Nogueira-Rodrigues A, Scambia G, Lorusso D, Joly F, Schenker M, Ruff P, Estévez-Diz M, Irahara N, Donica M, Gonzalez-Martín A. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020; 159(1): 142-9. Article. IF: 5.482; D1
- Rodríguez N, Vinal D, Rodríguez-Cobos J, de Castro J, Domínguez G. Genomic profiling in oncology clinical practice. Clin Transl Oncol. 2020; 22(9): 1430-9. Review. IF: 3.405; Q3
- Sanchís AC, Gallego J, Hernández R, Arrazubi V, Custodio A, Cano JM, Aguado G, Macías I, López C, López F, Visa L, Garrido M, Lago NM, Montes AF, Limón ML, Azkarate A, Pimentel P, Reguera P, Ramchandani A, Cacho JD, Carnicero AM, Granja M, Richard MM, Pérez CH, Hurtado A, Serra O, Buxo E, Tocino RV, Jiménez-Fonseca P, Carmona-Bayonas A. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS One. 2020; 15(7): e0235848. Article. IF: 3.24; Q2
- Santaballa A, Pinto A, Balanya RP, Merino NR, Martín IR, Grau SS, Fombella JPB, Cano JM, Gonzalez CH, Bayo J. SEOM clinical guideline for secondary prevention (2019). Clin Transl Oncol. 2020; 22(2): 187-92. Article. IF: 3.405; Q3
- Segui MA, Cruz JJ, Alba E, Feliú J, Jara C, Rivera F, Lescure AR, Lorenzo A, Martín M. Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. Clin Transl Oncol. 2020; 22(7): 1049-58. Review. IF: 3.405; Q3.
- Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, López-Vacas R, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Ferrer-Gómez M, Navarro H, Nanni P, Zamora P, Espinosa E, Main P, Vara JAF. Bayesian networks established functional differences between breast cancer subtypes. PLoS One. 2020; 15(6): e0234752. Article. IF: 3.24; Q2
- Trilla-Fuertes L, Gámez-Pozo A, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Arevalillo JM, Díaz-Almirón M, Navarro H, Main P, Espinosa E, Zamora P, Vara JAF. Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer. BMC Cancer. 2020; 20(1): 307. Article. IF: 4.43; Q2
- Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Vara JAF, Feliú J. Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification. Mol Cell Proteomics. 2020; 19(4): 690-700. Article. IF: 5.911; Q1
- Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros A, Gámez-Pozo A, Feliú J, Vara JAF. Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma. Transl Oncol. 2020; 13(7): 100778. Article. IF: 4.243; Q2
- Trilla-Fuertes L, Miranda N, Castellano D, López-Vacas R, Tello CAF, de Velasco G, Villacampa F, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, Espinosa E, Vara JAF, Pinto A, Gámez-Pozo A. miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma. PLoS One. 2020; 15(2): e0229075. Article. IF: 3.24; Q2
- Tuca A, Gallego R, Ghanem I, Gil-Raga M, Feliú J. Chemotherapy and targeted agents in the treatment of elderly patients with metastatic colorectal cancer. J Clin Med. 2020; 9(12): 4015. Review. IF: 4.241; Q1
- Vinal D, Martínez D, García-Cuesta JA, Gutiérrez-Sainz L, Martínez-Recio S, Villamayor J, Martínez-Marín V, Gallego A, Ortiz-Cruz E, Mendiola M, Pozo-Kreilinger JJ, Berjón A, Belinchón B, Bernabeu D, Espinosa E, Feliú J, Redondo A. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. Clin Transl Oncol. 2020; 22(10): 1849-56. Article. IF: 3.405; Q3
- Vinal D, Rodríguez-Salas N, Pérez-Wert P, Higuera O, Ghanem I, Feliú J. Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. Clin Transl Oncol. 2020; 22(8): 1288-94. Review. IF: 3.405; Q3
- Viúdez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernandez R, Cano JM, Macías I, Custodio A, de Castro EM, Sánchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sánchez-Canovas M, Mangas M, Limón ML, Martínez-Torron A, Asensio E, Ramchandani A, Martín-Carnicero A, Hurtado A, Cerda P, Garrido M, Sánchez-Bayonas R, Serrano R, Jiménez-Fonseca P. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol. 2020; 22(5): 734-50. Article. IF: 3.405; Q3
- Zimmerman T, Chasten V, Lacal JC, Ibrahim SA. Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae. Sci Rep. 2020; 10(1): 15418. Article. IF: 4.379; Q1

Research projects

Cejas Guerrero P. Análisis dinámico de la cromatina en el adenocarcinoma de páncreas mediante análisis fit-seq de la marca de histona H3K4ME2 (PI18/01604). ISCIII. 2019-2021.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Managment centre: FIBHULP

Custodio Carretero AB. Implicación de los cambios dinámicos de la cromatina en la progresión tumoral y la predicción de respuesta a quimioterapia neoadyuvante en adenocarcinoma gástrico localmente avanzado (PI16/01646). ISCIII. 2017-2021.

Managment centre: FIBHULP

Espinosa Arranz E. Antitumor effects o anti PD-LI immunotherapy atezolizumab plus metformin and chemotherapy in triple negative breast cáncer. Roche Farma S. A. 2021-Ongoing.

Managment centre: FIBHULP

Espinosa Arranz E. Desarrollo y validación de un predictor molecular con valor pronóstico en melanoma en estadios localizados para mejorar el seguimiento y el uso de terapia adyuvante (IND2017/BMD-7783). CM. 2018-2021.

Managment centre: FIBHULP

Feliú Batlle J, Barriuso Feijoó J. Puesta a punto de la técnica de PCR cuantitativa y determinación de grupos de genes que permitirán el desarrollo del conocimiento de los tumores nueroendcrinos pancreáticos. Pfizer S. L. U. 2012-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Development of a protocol to identify microbiota proteins in colorectal paraffin samples (EPIC-XS0000153). European EPIC-XS Consortium of Proteomics. 2020-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Estudio de biomarcadores pronósticos y predictivos en adenocarcinoma de páncreas. Varios. 2015-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Estudio de factores predictivos de toxicidad grave (grado 3-4) en anciano. Fundación Pfizer. 2012-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Identificación de una huella genética para el pronóstico en pacientes con cáncer de colon en estado II operados con intención curativa. Varios. 2013-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Proyecto desarrollo de consulta de psicooncología en el Hospital Universitario La Paz. Merck S. L. 2012-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Reanima-CM (S2017/BMD-3875). CM. 2018-2021.

Managment centre: FIBHULP

Feliú Batlle J. Sesiones clínicas en investigación y actualización en oncología médica del Hospital Universitario La Paz. Astrazeneca Farmacéutica Spain S. A. 2020-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Utilidad de la determinación del DNA circulante para monitorizar la respuesta al tratamiento neoadyuvante en los pacientes con cáncer de recto localmente avanzado. Fundación Seom. 2014-Ongoing.

Managment centre: FIBHULP

Feliú Batlle J. Validation of biomakers to predict response to anti-egfr therapy identified by shotgun proteomics. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2018-Ongoing.

Managment centre: FIBHULP

Fresno Vara JA. Caracterización molecular del cáncer de mama mediante TaqMan Low Density Arrays: Aplicación al diagnósitico. Fundación de la Universidad Autonoma de Madrid. 2014-Ongoing.

Managment centre: FIBHULP

Fresno Vara JA. Contrato Miguel Servet Categoria A (CES11/020). ISCIII. 2012-2025.

Managment centre: FIBHULP

Fresno Vara JA. Convocatoria interna Jesús Antolin Garciarena 2018. Contrato Andrea Zapater Moros. Comunidad de Madrid. 2018-Ongoing.

Managment centre: FIBHULP

Fresno Vara JA. Desarrollo de test moleculares predictivos, basados en el análisis del metaboloma, de la respuesta a neoadyuvancia en cáncer de mama (IND2018/BMD-9262). CM. 2019-2021.

Managment centre: FIBHULP

Fresno Vara JA. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente de cáncer de mama (PI15/01310). ISCIII. 2016-2020.

Managment centre: FIBHULP

Fresno Vara JA. Identification of therapeutic targets by the proteomics study of paired pancreatic adenocarcinoma samples (EPIC-XS000027). European EPIC-XS Consortium of Proteomics. 2020-Ongoing.

Managment centre: FIBHULP

Gámez Pozo A. Identification of new biomarkers and therapeutic targets by proteomics characterization of clear cell renal carcinoma (EPIC-XS000029). European EPIC-XS Consortium of Proteomics. 2020-Ongoing.

Managment centre: FIBHULP

Ghanem Cañete I. Alteraciones genómicas en carcinoma escamoso de ano. Secuenciación del exoma completo. Roche Farma S. A. 2019-Ongoing.

Managment centre: FIBHULP

Martinez Marín V. Estudio perfil mutacional e inmunohistoquímico en GIST: búsqueda de factores pronósticos y predictivos. Pfizer S. L. U. 2013-Ongoing.

Managment centre: FIBHULP

Pinto Marín A. Evaluación del metaboloma sanguineo como fuente de biomarcadores para el manejo del paciente con cáncer: el caso del cáncer de prostata metastásico. Varios. 2015-Ongoing.

Managment centre: FIBHULP

Pinto Marín A. Validación del test con valor pronóstico BIO-MIRCC. Biomédica Molecular Medicine S. L. 2020-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A, Mendiola Sabio M. Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de PARP en líneas celulares establecidas y organoides derivados de pacientes con cáncer de ovario. Grupo Español de Investigación Cáncer de Ovario. 2021-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Roche Farma S. A. 2014-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Cáncer de mama y angiogénesis: estudio de perfiles de expresión génica en muestras parafinadas. Roche Farma S. A. 2009-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización de la acción de trabectedina y análogos, lurbinectedina y análogos y PM60184 en modelos celulares en dos y tres dimensiones de carcinoma de ovario. Pharmamar S. A. 2016-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización in vitro del efecto antitumoral de eribulina (en monoterapia y en combinación con otros fármacos) en líneas celulares de liposarcoma

y leiomiosarcoma. Eisai Farmacéutica S. A. 2018-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización molecular y estudio de biomarcadores de inmunomodulación en el cáncer de endometrio. Subestudio: Estudio in vitro de modelos de cocultivo entre células tumorales de cáncer de ovario y fibroblastos. Grupo Español de Investigación Cáncer de Ovario. 2019-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Estudio in vitro de modelos en tres dimensiones de cáncer de ovario: interaccion entre las celulas tumorales y celulas del microambiente tumoral. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. International sarcoma scientifica meeting. Eisai Farmacéutica S. A. 2017-Ongoing.

Managment centre: FIBHULP

Zamora Auñón P. Metabolómica y modelización del matebolismo celular del cáncer para la deteccion de enfermadad mínima residual en pacientes con cáncer de mama. Roche Farma S. A. 2018-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Feliú Batlle J. Networked Biomedical Research Center for Cancer (CB16/12/00398). ISCIII. (31/12/2022)

Clinical trials

Castelo Fernandez, B. Estudio en fase 3, aleatorizado, doble ciego sobre avelumab combinado con la quimiorradioterapia de referencia (cisplatino más radioterapia definitiva) en comparación con la quimiorradioterapia de referencia en el tratamiento de primera línea de pacientes con carcinoma epidermoide localmente avanzado de cabeza y cuello.

Type: EECC, phase III.
HULP code: Appendix 3 4861.
Sponsored´s protocol code: B9991016.
Sponsored by: Pfizer S.L.U.
Signed date: 05/08/2020

Castelo Fernandez, B. Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101B en el tratamiento de sujetos con cáncer orofaríngeo VPH-16 positivo resistente al platino.

Type: EECC, phase II.
HULP code: Appendix 1 5124.
Sponsored´s protocol code: ISA101B-HN-01-17.
Sponsored by: Isa Therapeutics B.V.
Signed date: 11/11/2020

Castelo Fernandez, B. Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con ret mutante y sin tratamiento anterior con inhibidores de quinasa (libretto-531).

Type: EECC, phase III.
HULP code: 5441.
Sponsored´s protocol code: J2G-MC-JZJB.
Sponsored by: Lilly S.A.
Signed date: 05/02/2020

Castelo Fernandez, B. Estudio de fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metastásico con expresión de PD-L1.

Type: EECC, phase II.
HULP code: 5492.
Sponsored´s protocol code: 209229.
Sponsored by: Glaxosmithkline S.A.
Signed date: 03/03/2020

Castelo Fernandez, B. Estudio de fase II/III aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 en combinación con pembrolizumab y quimioterapia con 5FU-platino frente a placebo en combinación con pembrolizumab y quimioterapia con 5FU-platino para el tratamiento en primera línea de carcinoma de células escamosas de cabeza y cuello recurrente/metastásico.

Type: EECC, phase II.
HULP code: 5631.
Sponsored´s protocol code: 209227.
Sponsored by: Glaxosmithkline S.A.
Signed date: 06/08/2020

Castelo Fernandez, B. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimioradioterapia definitiva (Trilynx).

Type: EECC, phase III.
HULP code: 5602.
Sponsored´s protocol code: Debio 1143-SCCHN-301.
Sponsored by: Debiopharm S.A.
Signed date: 09/07/2020

Custodio Carretero, AB. Ensayo clínico exploratorio "Basket" de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino.

Type: EECC, phase II.
HULP code: 5399.
Sponsored´s protocol code: GETNE-T1914.
Sponsored by: Grupo Español de Tumores Neuroendocrinos.
Signed date: 04/09/2020

Custodio Carretero, AB.. Ensayo clínico en fase III, multicéntrico, doble ciego, aleatorizado para evaluar la eficacia y la seguridad de sintilimab frente a placebo, en combinación con quimioterapia, para el tratamiento de primera línea del carcinoma escamoso de esófago irresecable, localmente avanzado, recurrente o metastásico (Orient-15).

Type: EECC, phase III.
HULP code: 5595.
Sponsored´s protocol code: CIBI308A301.
Sponsored by: Innovent Biologics.
Signed date: 09/06/2020

Espinosa Arranz, E. Ensayo de fase 1b/3 multicéntrico de talimogene laherparepvec en combinación con pembrolizumab (MK-3475) para el tratamiento del melanoma en estadio IIIB a IVM1c no resecable.

Type: EECC, phase IIIb.
HULP code: Appendix 1 4636.
Sponsored´s protocol code: 20110265.
Sponsored by: Amgen S.A.
Signed date: 30/04/2020

Espinosa Arranz, E. Estudio de fase IB multicéntrico, sin enmascaramiento para evaluar la seguridad y la eficacia de ipatasertib en combinación con atezolizumab y paclitaxel o NAB-paclitaxel en pacientes con cáncer de mama triple negativo localmente avanzado o metastásico.

Type: EECC, phase I.
HULP code: Appendix 2 5012.
Sponsored´s protocol code: C040151.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 09/10/2020

Espinosa Arranz, E. Estudio en fase II, multicéntrico, abierto y aleatorizado para evaluar la eficacia y seguridad de RO7198457 en

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

combinación con pembrolizumab frente a pembrolizumab en pacientes con melanoma avanzado sin tratamiento previo.

Type: EECC, phase II.
HULP code: 5585.
Sponsored´s protocol code: GO40558.
Sponsored by: Genentech Inc.
Signed date: 26/06/2020

Espinosa Arranz, E. Describe-AD: Retrospective study of adjuvant dabrafenib and trametinib combination in patients with resected melanoma in Spain.

Type: Estudios, phase EPA-OD.
HULP code: PI-4166 .
Sponsored´s protocol code: GEM-1901.
Sponsored by: Grupo Español Multidisciplinar de Melanoma.
Signed date: 22/07/2020

Espinosa Arranz, E. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España.

Type: Estudios, phase EPA-SP.
HULP code: Appendix 1 PI-3208.
Sponsored´s protocol code: GEM-IPI-2018-01.
Sponsored by: Grupo Español Multidisciplinar de Melanoma.
Signed date: 05/11/2020.

Espinosa Arranz, E.. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España.

HULP code: PI-3208 .
Sponsored´s protocol code: Appendix 1.
Signed date: 12/07/2020


Feliú Batlle, J. Estudio en fase 1b/2 del tratamiento combinado con ibrutinib en tumores gastrointestinales y genitourinarios avanzados seleccionados.

Type: EECC, phase I.
HULP code: Appendix 1 4630.
Sponsored´s protocol code: PCYC-1128-CA.
Sponsored by: Pharmacyclics Llc.
Signed date: 16/09/2020

Feliú Batlle, J. Estudio en fase II, multicéntrico y abierto, para investigar la eficacia, la seguridad y la farmacocinética del anticuerpo monoclonal anti-PD-1, BGB-A317, en pacientes con carcinoma hepatocelular irresecable tratado anteriormente.

Type: EECC, phase II.
HULP code: Appendix 2 4996.
Sponsored´s protocol code: BGB-317-208.
Sponsored by: Beigene USA Inc.
Signed date: 14/05/2020

Feliú Batlle,J. Estudio de fase 3 aleatorizado para evaluar el uso de eryaspase en combinación con quimioterapia, comparada con quimioterapia sola como tratamiento de segunda línea en pa-



Introduction
Executive summary
Information Groups by Area
Associated Clinicians

cientes con adenocarcinoma pancreático.

Type: EECC, phase III.
HULP code: Appendix 1 5105.
Sponsored´s protocol code: GRASPANC 2018-01.
Sponsored by: Erytech Pharma S.A.
Signed date: 10/06/2020

Feliú Batlle, J. Estudio en fase I-II, primero en humanos, de CX-2029 en adultos con linfomas difusos de linfocitos B grandes o tumores sólidos no resecables localmente avanzados o metastásicos (Proclaim-CX-2029).

Type: EECC, phase I.
HULP code: Appendix 1 5153.
Sponsored´s protocol code: CTMX-M-2029-001.
Sponsored by: Cytomx Thereapeutics Inc.
Signed date: 03/11/2020

Feliú Batlle, J. Primer estudio en humanos de fase I/II de la seguridad y eficacia del IMC-C103C en monoterapia y en combinación con atezolizumab en pacientes con HLA-A*0201 positivo y cáncer positivo para Mage-A4 avanzado.

Type: EECC, phase I.
HULP code: Appendix 1 5423.
Sponsored´s protocol code: IMC-C103C-101.
Sponsored by: Immunocore Ltd.
Signed date: 14/09/2020

Feliú Batlle, J. Primer estudio en humanos de fase I/II de la seguridad y eficacia del IMC-c103c en monoterapia y en combinación con atezolizumab en pacientes con HLA-a*0201 positivo y cáncer positivo para mage-a4 avanzado.

Type: EECC, phase I.
HULP code: 5423.
Sponsored´s protocol code: IMC-C103C-101.
Sponsored by: Immunocore Ltd.
Signed date: 05/02/2020

Feliú Batlle, J. Estudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarcinoma de páncreas metastásico.

Type: EECC, phase III.
HULP code: 5490.
Sponsored´s protocol code: D-US-60010-001.
Sponsored by: Ipsen Bioscience Inc.
Signed date: 17/02/2020

Feliú Batlle, J. Estudio de fase 1 para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de AMG 404, un anticuerpo de la muerte celular programada 1 (PD-1), en pacientes con tumores sólidos avanzados.

Type: EECC, phase I.
HULP code: 5659.
Sponsored´s protocol code: 20180143.
Sponsored by: Amgen S.A.
Signed date: 09/09/2020

Feliú Batlle, J. Estudio clínico de fase III aleatorizado, abierto, internacional, multicéntrico, del anticuerpo PD-1 SHR-1210 más mesilato de apatinib (rivoceranib) en comparación con sorafenib como tratamiento de primera línea en pacientes con carcinoma hepatocelular avanzado que no han recibido previamente tratamiento sistémico.

Type: EECC, phase III.
HULP code: 5409.
Sponsored´s protocol code: SHR-1210-III-310.
Sponsored by: Jiangsu Heng Rui Medicine Co. Ltd.
Signed date: 11/05/2020

Feliú Batlle, J. Estudio aleatorizado global, multicéntrico, doble ciego de fase III de carboplatino paclitaxel con INCMGA00012 o placebo para participantes con carcinoma escamoso localmente recurrente o metastásico inoperable del canal anal no tratado previamente con quimioterapia sistémica (POD1UM-303/Interaact).

Type: EECC, phase III.
HULP code: 5627.
Sponsored´s protocol code: INCMGA0012-303.
Sponsored by: Incyte Corporation.
Signed date: 06/11/2020

Feliú Batlle, J. Estudio fase 2, abierto, de múltiples cohortes para evaluar la eficacia y la seguridad del SAR408701 en pacientes con tumores sólidos avanzados positivos a CEACAM5.

Type: EECC, phase II.
HULP code: 5720.
Sponsored´s protocol code: ACT16432.
Sponsored by: Sanofi Aventis S.A.
Signed date: 14/12/2020

Ghanem Cañete, I.. Estudio de fase 3, multicéntrico, abierto, aleatorizado y controlado de infigratinib oral frente a gemcitabina con cisplatino en sujetos con colangiocarcinoma avanzado/metastásico o inoperable con fusiones/translocaciones del gen FGFR2:

Type: EECC, phase III.
HULP code: 5347.
Sponsored´s protocol code: QBGJ398-301.
Sponsored by: Qed Therapeutics Inc.
Signed date: 31/03/2020

Ghanem Cañete, I. Estudio para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de TRK-750 en pacientes con cáncer colorrectal que padecen neuropatía periférica inducida por la quimioterapia después de recibir quimioterapia que contiene oxaliplatino en adyuvancia.

Type: EECC, phase II.
HULP code: 5497.
Sponsored´s protocol code: 750CNP01.
Sponsored by: Toray Industries Inc.
Signed date: 08/04/2020

Ghanem Cañete, I. Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos.

Type: Estudios, phase No EPA.
HULP code: PI-4330.
Sponsored´s protocol code: TTD-20-01.
Sponsored by: Grupo Tratamiento Tumores Digestivos.
Signed date: 28/08/2020

Ghanem Cañete, I. Un estudio retrospectivo no intervencional sobre el tratamiento de primera línea para pacientes con cáncer colectivo metástico mutante BRAVF600E (MCRC).

Type: Estudios, phase No EPA.
HULP code: PI-4371 .
Sponsored´s protocol code: PFA-CET-2020-01.
Sponsored by: SAS Pierre Fabre Medicament.
Signed date: 22/09/2020

Pinto Marín, Á. Estudio de fase III, estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico.

Type: EECC, phase III.
HULP code: Appendix 1 4699.
Sponsored´s protocol code: MO29983.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 24/02/2020

Pinto Marín, Á. Un ensayo multicéntrico, abierto, fase 1b/2 de lenvatinib (e7080) más pembrolizumab en sujetos con tumores sólidos seleccionados.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Type: EECC, phase I.
HULP code: Appendix 2 5046.
Sponsored´s protocol code: E7080-A001-111.
Sponsored by: Covance Inc.
Signed date: 18/03/2020

Pinto Marín, Á. Estudio de fase IB de aumento escalonado de la dosis de cabozantinib (XL184) en combinación con atezolizumab en pacientes con tumores sólidos localmente avanzados o metastásicos.

Type: EECC, phase I.
HULP code: 5583.
Sponsored´s protocol code: XL184-021.
Sponsored by: Exelixis Inc.
Signed date: 13/05/2020

Pinto Marín, Á. Estudio de fase 3 aleatorizado de cistectomía más pembrolizumab perioperatorio frente a cistectomía sola en participantes con cáncer de vejiga con invasión muscular que no son aptos para recibir cisplatino (KEYNOTE-905).

Type: EECC, phase III.
HULP code: Appendix 1 5304.
Sponsored´s protocol code: MK-3475-905.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 27/11/2020

Pinto Marín, Á. Estudio de fase II, abierto, aleatorizado y multicéntrico para evaluar la eficacia y la seguridad de pemigatinib más pembrolizumab en comparación con pemigatinib solo y con el tratamiento de referencia como tratamiento de primera línea para el carcinoma urotelial metastásico o no resecable en participantes no aptos para cisplatino, cuyos tumores expresan mutación o reordenamiento de FGFR3 (Fight-205).

Type: EECC, phase II.
HULP code: 5439.
Sponsored´s protocol code: INCB 54828-205.
Sponsored by: Incyte Corporation.
Signed date: 25/02/2020

Pinto Marín, Á. Ensayo de fase III, multicéntrico, doble ciego, aleatorizado y controlado con placebo de infigratinib para el tratamiento adyuvante de sujetos con carcinoma urotelial invasivo con alteraciones del gen FGFR3 sensibles .

Type: EECC, phase III.
HULP code: 5481.
Sponsored´s protocol code: QBGJ398-302.
Sponsored by: Qed Therapeutics Inc.
Signed date: 26/02/2020

Pinto Marín, Á. Estudio de fase III multicéntrico, aleatorizado, abierto para evaluar la eficacia y seguridad de atezolizumab administrado en combinación con cabozantinib frente a cabozantinib en monoterapia en pacientes con carcinoma de células renales localmente avanzado o metastásico inoperable que han presentado progresión tumoral radiológica durante o después del tratamiento con un inhibidor de puntos de control inmunitario.

Type: EECC, phase III.
HULP code: 5677.
Sponsored´s protocol code: WO41994.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

Pinto Marín, Á. Fase II, ensayo multicéntrico, no aleatorio, de un solo brazo, abierto, de atezolizumab en combinación de dosis divididas de gemcitabina más cisplatino en pacientes con carcinoma urotelial metastásico localmente avanzado. Phase II, multicenter, nonrandomized, single-arm, open-label trial of atezolizumab in combination of split-doses of gemcitabine plus cisplatin in patients with locally advanced or metastatic urothelial carcinoma.

Type: EECC, phase II.
HULP code: 5662.
Sponsored´s protocol code: SOGUG-2020-IEC(VEJ)-1.
Sponsored by: Grupo Sogug.
Signed date: 23/11/2020

Pinto Marín, Á. preferencias de pacientes y oncólogos por las características del tratamiento de carcinoma de células renales en España y Portugal. Código de protocolo CA209-9W6. Código de clasificación de la AEMPS BMS-INM2018-01.

Type: Estudios, phase EPA-OD.
HULP code: PI-4025 .
Sponsored´s protocol code: CA209-9W6.
Sponsored by: Bristol Myers Squibb S.A.U.
Signed date: 24/04/2020

Redondo Sánchez, A. Ensayo de fase II aleatorizado, doble ciego, controlado con placebo, de dicloruro de radio-223 en combinación con exemestano y everolimús frente a placebo en combinación con exemestano y everolimús, administrado a pacientes con cáncer de mama metastásico negativo para HER2 y positivo para los receptores hormonales, con metástasis óseas.

Type: EECC, phase II.
HULP code: Appendix 2 4263.
Sponsored´s protocol code: .
Sponsored by: Bayer Pharma Ag.
Signed date: 30/06/2020

Redondo Sánchez, A. Atezolizumab en combinación con bevacizumab y quimioterapia versus bevacizumab y quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de fase III.

Type: EECC, phase III.
HULP code: Appendix 1 5305.
Sponsored´s protocol code: 0 AGO-OVAR 2.29.
Sponsored by: Ago Research Gmbh.
Signed date: 28/04/2020

Redondo Sánchez, A. Atezolizumab en combinación con bevacizumab y quimioterapia versus bevacizumab y quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de fase III.

Type: EECC, phase III.
HULP code: 5305.
Sponsored´s protocol code: AGO-OVAR 2.29.
Sponsored by: Ago Research Gmbh.
Signed date: 03/02/2020

Redondo Sánchez, A. Estudio de fase 1/2, aleatorizado, sin enmascaramiento, en el que se evalúa ramucirumab en pacientes menores de edad y en adultos jóvenes con tumores desmoplásicos de células pequeñas y redondas recidivantes, recurrentes o resistentes al tratamiento.

Type: EECC, phase I.
HULP code: 5278.
Sponsored´s protocol code: J1S-MC-JV01.
Sponsored by: Lilly S.A.
Signed date: 20/02/2020

Redondo Sánchez, A. Estudio de fase 2, aleatorizado, sin enmascaramiento, en el que se evalúa ramucirumab en pacientes menores de edad y en adultos jóvenes con sarcoma sinovial recidivante, recurrente o resistente al tratamiento.

Type: EECC, phase I.
HULP code: 5279.
Sponsored´s protocol code: J1S-MC-JV02.
Sponsored by: Lilly S.A.
Signed date: 20/02/2020

Redondo Sánchez, A. Ensayo clínico aleatorizado fase I/II de selinexor más gemcitabina en determinados sarcomas de partes blandas y osteosarcomas avanzados.

Type: EECC, phase I.
HULP code: 5541.
Sponsored´s protocol code: GEIS-67.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 08/07/2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Redondo Sánchez, A. Estudio fase II para evaluar la seguridad y eficacia de tiragolumab más atezolizumab y de atezolizumab en monoterapia en pacientes con cáncer de cérvix metastásico y/o recurrente PD-L1 positivo.

Type: EECC, phase II.
HULP code: 5700.
Sponsored´s protocol code: WO42017.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 19/11/2020

Redondo Sánchez, A. Estudio en fase III de grupo único sobre mirvetuximab soravtansina en cáncer epitelial de ovario, peritoneal primario o de las trompas de falopio de alto grado avanzado con expresión elevada del receptor de folato a.

Type: EECC, phase III.
HULP code: 5564.
Sponsored´s protocol code: IMGN853-0417.
Sponsored by: Immunogen Inc.
Signed date: 05/06/2020

Rodríguez Salas, N. Estudio de fase II, multicéntrico y sin enmascaramiento para evaluar la seguridad y la eficacia de U3-1402 en sujetos con cáncer colorrectal avanzado o metastásico.

Type: EECC, phase II.
HULP code: 5613.
Sponsored´s protocol code: U31402-A-U202.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 25/11/2020

Rodríguez Salas, N. Ensayo en fase III global, multicéntrico, aleatorizado y controlado con placebo para comparar la eficacia y la seguridad de fruquintinib, más los mejores cuidados paliativos frente a placebo, más los mejores cuidados paliativos en pacientes con cáncer de colorrectal metastásico resistente (Fresco2).

Type: EECC, phase III.
HULP code: 5592.
Sponsored´s protocol code: 2019-013-GLOB1.
Sponsored by: Hutchison Medipharma Limited.
Signed date: 09/09/2020

Rodríguez Salas, N. Estudio de fase II de un solo grupo para investigar el tepotinib en combinación con cetuximab en pacientes con cáncer colorrectal metastásico del lado izquierdo sin mutaciones RAS/BRAF que han adquirido resistencia al tratamiento frente al anticuerpo anti-EGFR debido a la amplificación de MET.

Type: EECC, phase II.
HULP code: 5629.
Sponsored´s protocol code: MS202202-0002.
Sponsored by: Merck Healthcare KGAA.
Signed date: 03/11/2020

Rodríguez Salas, N. A multi-center observational retrospective study to evaluate the clinical management of patients diagnosed with colorectal metastatic tumors and to characterize the management of DMMR and MSI-H in Spain.

Type: Estudios, phase EPA-OD.
HULP code: PI-4315 .
Sponsored´s protocol code: 8621 (COMISH).
Sponsored by: Merck Sharp And Dohme de España S.A.
Signed date: 07/10/2020

Zamora Auñón, P. Estudio ventana de oportunidad con pelareorep en cáncer de mama en estadio temprano (Aware-1).

Type: EECC, phase I.
HULP code: 5256.
Sponsored´s protocol code: REO027.
Sponsored by: Oncolytics Biotech Inc.
Signed date: 13/02/2020

Zamora Auñón, P. Ensayo clínico de fase III, doble ciego y aleatorizado, para evaluar la eficacia y seguridad de capivasertib + paclitaxel en comparación con un placebo + paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo localmente avanzado (inoperable) o metastásico, confirmado histológicamente.

Type: EECC, phase III.
HULP code: 5549.
Sponsored´s protocol code: D3614C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 04/05/2020

Zamora Auñón, P. Estudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormonal positivo, receptor del factor de crecimiento epidérmico humano 2 negativo (hr+/her2–) después de la recurrencia o la progresión durante o después del tratamiento con un inhibidor de la aromatasa (capitello-291).

Type: EECC, phase III.
HULP code: 5516.
Sponsored´s protocol code: D3615C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 11/03/2020

Zamora Auñón, P.. Ensayo en fase 3, randomizado, multicéntrico con tratamiento abierto de trastuzumab deruxtecán (T-DXD; DS-8201A) frente a quimioterapia a elección del investigador en pacientes con cáncer de mama con expresión baja del receptor del factor de crecimiento epidérmico-2 (HER2-LOW) y receptores hormonales positivos, cuya enfermedad ha progresado durante el tratamiento endocrino en el contexto metastásico (Destiny-BREAST06).

Type: EECC, phase III.
HULP code: 5632.
Sponsored´s protocol code: D9670C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 14/10/2020

Zamora Auñón, P. Estudio fase II multicéntrico, aleatorizado, abierto, con dos brazos de tratamiento neoadyuvante, para evaluar la eficacia, seguridad y farmacocinética de GDC-9545 más palbociclib comparado con anastrozol más palbociclib en mujeres posmenopáusicas con cáncer de mama precoz no tratado, con receptor de estrógeno-positivo y HER2-negativo.

Type: EECC, phase II.
HULP code: 5656.
Sponsored´s protocol code: WO42133.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 02/12/2020

Zamora Auñón, P. Estudio fase 3, aleatorizado, multicéntrico, doble ciego de SAR439859 más palbociclib en comparación con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama RE(+), HER2(–) que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada.

Type: EECC, phase III.
HULP code: 5644.
Sponsored´s protocol code: EFC15935.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 08/10/2020

Zamora Auñón, P. Estudio observacional retrospectivo para evaluar el perfil demográfico y clinicopatológico y el manejo de pacientes con cáncer de mama precoz HER2-positivo y enfermedad residual tratados con trastuzumab emtansina en España: estudio Karma.

Type: Estudios, phase EPA-OD.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

HULP code: PI-4029 .
Sponsored´s protocol code: ML41735.
Sponsored by: Roche Farma S.A.
Signed date: 28/02/2020

Patents and trademarks

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH120, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP16774644.5, US20180346990, CN108174608; 2015 September 23.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Fernández Martos C.; Trilla Fuertes L.; Fresno Vara JÁ; Gámez Pozo A.; Ghanem Cañete I.; Feliu Battle J.. EP19382982.7. In vitro method for the prognosis of anal squamous cell carcinoma. 11/11/2019. Biomedica Molecular Medicine SL.

Gayá Moreno F.; Díaz Almirón M.; Trilla Fuertes L.; Fresno Vara J.A; Gámez Pozo A. Nuevo método de resolución de Gene-Protein-Reaction Associations. 30/08/2017. Biomedica Molecular Medicine SL.

Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.3 Experimental Therapies and Biomarkers in Cancer Group

Publications:	21
Impact Factor:	170.422
Q1:	10



María Inmaculada Ibáñez de Cáceres. Investigadora Senior (Contrato Miguel Servet-Tipo 2). Jefe de Laboratorio. Hospital Universitario La Paz

Javier de Castro Carpeño. Jefe de Sección de Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Miranda Burdiel Herencia. Investigadora Predoctoral. Hospital Universitario La Paz

Julián Colmenarejo Fernández. Investigador Predoctoral. Hospital Universitario La Paz

Patricia Cruz Castellanos. Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz

María Isabel Esteban Rodríguez. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Álvaro García Guede. Investigador Predoctoral. Hospital Universitario La Paz

Julia Jiménez Hernández. Investigadora Predoctoral. Universidad Autónoma de Madrid

Cristina Manguán García. Técnico de Laboratorio. IIB "Alberto Sols"

Olga Pernía Arias. Técnico de Laboratorio (Contrato PTA). Hospital Universitario La Paz

Garcilaso Riesco Eizaguirre. Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz

Carlos Rodríguez Antolín. Bioinformático Contratado. Hospital Universitario La Paz

Rocío Rosas Alonso. Farmacéutica Interna Residente. Hospital Universitario La Paz

Ana Sastre Perona. Investigadora Senior (Contrato Miguel Servet- Tipo I). Hospital Universitario La Paz

Strategic Objective

Our research is focused on two distinct areas:

1- Genetic and epigenetic mechanisms involved in the resistance to chemotherapeutic drugs. Drug resistance is a crucial problem in clinical practice. We have used various strategies to approach this problem, such as identifying new targets involved in drug responses and studying their alterations in human samples. In addition, we have identified genetic and epigenetic changes in tumour suppressor genes, miRNAs and lncRNAs with associated clinical use in diagnosis, prognosis and drug response prediction in solid tumors and in liquid biopsy. Some of these targets preset a strong potential role as therapeutic target in lung, ovarian and head and neck cancer treatment.

2- Strategies to reactivate telomerase activity in human cells with defects in telomerase and premature senescence. We have identified a genetic suppressor element (GSE) termed 24-2 that, once expressed in human cells, is able to recover telomerase activity and promote survival to cisplatin. This GSE corresponds to an internal

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

fragment of dyskerin, a protein that is part of the telomerase complex. Expression of this GSE reactivates telomerase activity in cells with X-linked dyskeratosis congenita, a disease that is characterised by bone marrow failure and several other defects associated with a decrease in telomerase activity.

Research lines

Translational research:

- Identification of predictive genetic and epigenetic biomarkers in the emergence of resistance in cancer and new therapeutic targets in NSCLC and ovarian cancer.
- Identification of novel microRNAs and lncRNAs involved in chemoradiotherapy response in lung and ovarian cancer as well as in rare diseases as biomarkers for clinical use.
- Study of the mechanisms of resistance to chemotherapy in cancer: the role of tumour stem cells in the response to chemotherapy in non-small cell lung cancer.
- Identification of mechanish responsible for therapy resistance in head and neck squamous cell carcinomas and development of human organoid models.

Approach to new strategies in the diagnosis, prognosis and follow-up by liquid biopsy in glioblastomas

- Development of new strategies for the treatment of telomerase defective diseases.

Research Activity

Publications

- Aguirre LA, Montalbán-Hernández K, Avendaño-Ortiz J, Marín E, Lozano R, Toledano V, Sánchez-Maroto L, Terrón V, Valentín J, Pulido E, Casalvilla JC, Rubio C, Diekhorst L, Laso-García F, del Fresno C, Collazo-Lorduy A, Jiménez-Muñárriz B, Gómez-Campelo P, Llanos-Gonzáles E, Fernández-Velasco M, Rodríguez-Antolín C, de Diego RP, Cantero-Cid R, Hernádez-Jiménez E, Álvarez E, Rosas R, López-Ayllón BD, de Castro J, Wculek SK, Cubillos-Zapata C, de Cáceres II, Díaz-Agero P, Fernández MG, de Miguel MP, Sancho D, Schulte L, Perona R, Belda-Iniesta C, Boscá L, López-Collazo E. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. OncoImmunology. 2020; 9(1): 1773204. Article. IF: 8.11; Q1
- Campos-Balea B, Carpeño JD, Massuti B, Vicente-Baz D, Parente DP, Ruiz-Gracia P, Crama L, Dols MC. Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. Thorac Cancer. 2020;11(11):3357-3364. Article. IF: 3,5; Q2
- Esteban-Rodríguez I, Ruiz Bravo-Burguillos E, Rosas R, Losantos I, Rodríguez-Antolín C, de Castro J. Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data]. Rev Esp Patol. 2020; 53(1): 10-8. Article. Not Indexed
- Estévez FV, Alarcon MDL, Babarro AA, Gayoso LO, de Castro J, Leria-Gelabert M, Melogno-Klinkas M. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription. Curr Med Res Opin. 2020;36(8): 1383-91. Article. IF: 2.58; Q2
- García-Guede A, Vera O, Ibáñez-de-Cáceres I. When oxidative stress meets epigenetics: implications in cancer development. Antioxidants. 2020; 9(6): 468. Review. IF: 6.312; D1
- Garrido P, Conde E, de Castro J, Gómez-Roman JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Rios F. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020; 22(7): 989-1003. Article. IF: 3.405; Q3
- Gonzáles-Cao M, Morán T, Dalmau J, García-Corbacho J, Bracht JWP, Bernabe R, Juan OS, de Castro J, Blanco R, Drozdowskyj A, Argilaguet J, Meyerhans A, Blanco J, Prado JG, Carrillo J, Clotet B, Massuti B, Provencio M, Molina-Vila MA, de las Casa CM, Garzon M, Cao P, Huang CY, Martinez-Picado J, Rosell R. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection the phase 2 DURVAST study. JAMA Oncol. 2020; 6(7): 1063-7. Article. IF: 31.777; D1
- Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol. 2020; 22(5): 759-71. Article. IF: 3.405; Q3
- Kim KJ, Kim SG, Tan J, Shen XP, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sykorova V, Xing MZ. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer. 2020; 124: 161-9. Article. IF: 9.162; Q1
- López-Ríos F, Paz-Ares L, Sanz J, Isla D, Pijuán L, Felip E, Gómez-Román JJ, de Castro J, Conde E, Garrido P. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Rev Esp Patol. 2020; 53(3): 167-81. Article. Not indexed
- Mielgo-Rubio X, Calvo V, Luna J, Remón J, Martin M, Berraondo P, Jarabo JR, Higuera O, Conde E, de Castro J, Provencio M, Trancho FH, López-Rios F, Counago F. Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers. Cancers. 2020; 12(11): 3459. Review. IF: 6.639; Q1
- Pernía O, Sastre-Perona A, Rodríguez-Antolín C, García-Guede A, Palomares-Bralo M, Rosas R, Sánchez-Cabrero D, Cruz P, Rodríguez C, Diestro M, Martín-Arenas R, Pulido V, Santisteban P, de Castro J, Vera O, de Cáceres II. A novel role for the tumor suppressor gene ITF2 in tumorigenesis and chemotherapy response. Cancers. 2020; 12(4): 786. Article. IF: 6.639; Q1
- Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Domine M, Majem M, Rodríguez-Abreu D, Martínez-Marti A, Carpeño JD, Cobo M, Vivanco GL, del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Pereira E, Royuela A, Casarrubios M, Antón CS, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(11): 1413-22. Article. IF: 41.316; D1
- Rodríguez N, Vinal D, Rodríguez-Cobos J, de Castro J, Domínguez G. Genomic profiling in oncology clinical practice. Clin Transl Oncol. 2020; 22(9): 1430-9. Review. IF: 3.405; Q3

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Rojas AA, Collazo-Lorduy A, Remón J, Requejo OH, Jiménez-Muñarriz B, Rodríguez MCR, de Castro J. Lung adenocarcinoma during pregnancy: 11-Year Follow-Up. Case Rep Oncol. 2020; 13(2): 892-5. Article. Not Indexed
- Rosas-Alonso R, Galera R, Sánchez-Pascuala JJ, Casitas R, Burdiel M, Martínez-Cerón E, Vera O, Rodríguez-Antolín C, Pernía O, de Castro J, García-Río F, Ibáñez-de-Cáceres I. Hypermethylation of anti-oncogenic MicroRNA 7 is increased in emphysema patients. Arch Bronconeumol. 2020; 56(8): 506-13. Article. IF: 4.872; Q2
- Saini KS, de las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020; 7(6): E432-5. Editorial Material. IF: 18.959; D1
- Saini KS, de las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, García-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal O, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A. Reimagining global oncology clinical trials for the postpandemic era: A call to arms. JCO Glob Oncol. 2020; 6: 1357-62. Article. Not Indexed
- Saini KS, Lanza C, Romano M, de Azambuja E, Cortés J, de las Heras B, de Castro J, Saini ML, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020; 123(5): 694-7. Editorial Material. IF: 7.64; Q1
- Vinolas N, García-Campelo R, Majem M, Carcereny E, Isla D, Gonzáles-Larriba JL, Coves J, de-Castro J, Domine M, Lianes P, Artal A, Remón J, Felip E, Garrido P. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. BMC Psychol. 2020; 8(1): 123. Article. Not Indexed
- Rodríguez-Antolín C. Artificial intelligence will not replace health professionals, but the proper use of artificial intelligence will make health professionals better. Cancer Res. 2020; 80(10): 1912-3. Editorial Material. IF: 12.701; D1

Research projects

Burdiel Herencia M. Contrato predoctoral (FI19/00061). ISCIII. 2020-2023.

Managment centre: FIBHULP

Cruz Castellanos P. APP Respira. Boehringer Ingelheim España S. A. 2019-Ongoing.

Managment centre: FIBHULP

de Castro Carpeño J. Comite de gestión de programa: diseño, mediante inteligencia artificial, de algoritmos predictivos para la identificación de individuos en riesgo de desarrollar sobrepeso/obesidad y sus patologías asociadas: aportación del análisis genético (S2017/BMD-3773). CM. 2018-2021.

Managment centre: FIBHULP

de Castro Carpeño J. Desarrollo de las tareas necesarias para la puesta en marcha del estudio clínico ml40221 título: estudio de práctica clínica en condiciones reales para evaluarla toma de decisiones en el tratamiento de segunda línea conforme a las normas asistenciales y basado en los perfiles de foundation medicine en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con histologia de adenocarcinoma en España. Roche Farma S. A. 2018-Ongoing.

Managment centre: FIBHULP

de Castro Carpeño J. Determinación mediante inmunohistoquímica de la expresion de PDL-1 en carcinoma de célula no pequeña de pulmón. Fundación ECO. 2016-Ongoing.

Managment centre: FIBHULP

de Castro Carpeño J. Eluxa 2: estudio de fase III, abierto, aleatorizado y controlado con producto activo, multicéntrico e internacional, para evaluar la eficacia de BI1482694 frente a un doblete de quimioterapia estandar que incluye platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, con la mutación T790 M, cuya enfermedad ha progresado con el tratamiento previo con un inhibidor de la tirosina cinasa del receptor del factor de crecimiento epidérmico (EGFR-TKI). Parexel International (Irl) Limited. 2016-Ongoing.

Managment centre: FIBHULP

de Castro Carpeño J. Prestación de servicios para el desarrollo de las tareas necesarias en el estudio Estudio observacional de alectinib en pacientes con CPNM ALK+ en el programa de acceso precoz en España. Roche Farma S. A. 2018-Ongoing.

Managment centre: FIBHULP

Esteban Rodríguez MI. Proyecto para la evaluación retrospectiva de muestras pareadas de biopsia y citología para la detección de reordenamientos de ALK y expresión de PD-l1 en CPCNP. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Gil Martínez A, de Castro Carpeño J. Face Mirror. Fundación para la Innovacion y la Prospectiva en Salud en España. 2018-Ongoing.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Estudio de los mecanismos moleculares y celulares responsables de la aparición de resistencia a quimioterapia mediados MOR MAFG y su implicación como nueva diana diagnóstica y terapéutica en cancer de pulmón no microcítico (PI18/00050). ISCIII. 2019-2021.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Evalución y puesta a punto del biomarcardor epigenético MGMT en biopsia líquida como prueba no invasiva de seguimiento, en pacientes con gliomas. Cuesta Barrio, Juan. 2017-Ongoing.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. First bio-tool for exosomal normalization in liquid biopsy and its clínical applicability for lung cáncer patients stratification. Fundación Bancaria Caixa D'Estalvis I Pensions de Barcelona la Caixa. 2020-2022.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Identificación de marcadores epigenéticos para diagnóstico no invasivo en resistencia a platinos y su implicación en el uso de terapias individualizadas. Ibáñez de Cáceres, María Inmaculada. 2013-Ongoing.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Identificación y uso de microRNAas como marcadores epigenéticos de sensibilidad a cisplatino en cáncer de pulmón no microcítico: implicación en terapias individualizadas. Roche Farma S. A. 2014-Ongoing.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Papel de los exosomas en la induccion de resistencia a platino en un modelo experimental de líneas celulares de cáncer de pulmón. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Prediapt: desarrollo de un sistema predictivo de respuesta al tratamiento con derivados del platino en cáncer de pulmón basado en aptámeros (RTC-2019-007229-1). MICIU. 2020-2023.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Validación clínica del Epigen kit: un nuevo test para predecir la respuesta al ratamiento del cáncer de pulmón no microcítico (CPNM). Epigen-kit (RTC-2016-5314-1). MINECO. 2016-2020.

Managment centre: FIBHULP

Ibáñez de Cáceres MI. Validación preclínica de diferentes biomarcadores epigenéticos con potencial uso diagnóstico y predictivo,

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

en tumores sólidos tratados con derivados del platino. Nuevos retos clínicos asociados al estudio molecular de las biopsias líquidas en cáncer (PI15/00186). ISCIII. 2016-2020.

Managment centre: FIBHULP

Rodríguez Antolín C. Implementación diagnóstica del análisis de metilación dirigida en plataformas de secuenciación masiva de cáncer. Roche Farma S. A. 2019-Ongoing.

Managment centre: FIBHULP

Rosas Alonso R. Contrato Río Hortega (CM19/00100). ISCIII. 2020-2021.

Managment centre: FIBHULP

Sastre Perona A. Contrato garantía juvenil Ayudante de Investigación (PEJ-2020-AI/BMD-17846). CM. 2020-2023.

Managment centre: FIBHULP

Sastre Perona A. Contrato Miguel Servet tipo I (CP19/00063). ISCIII. 2020-2024.

Managment centre: FIBHULP

Sastre Perona A. Desarrollo de herramientas predictivas y terape ticas para combatir la resistencia a cisplatino en carcinomas escamosos de cabeza y cuello (PI20/00329). ISCIII. 2020-2023.

Managment centre: FIBHULP

Cibers and Retics

de Castro Carpeño J. Plataforma de Innovación (PT17/0005/0025). ISCIII. (31/12/2021)

Clinical trials

Cruz Castellanos, P. Estudio observacional prospectivo para identificar pacientes con CPNM avanzado/metastásico y translocación de ALK y conocer su manejo terapéutico (Estudio Idealk).

Type: Estudios, phase EPA-SP.
HULP code: Appendix 1 PI-3438.
Sponsored´s protocol code: A8081057.
Sponsored by: Pfizer S.L.U.
Signed date: 13/11/2020

de Castro Carpeño, J. Ensayo de fase III, abierto, multicéntrico de avelumab (MSB0010718C) frente al doblete con base de platino como tratamiento de primera línea del cáncer de pulmón no microcítico PD-L1+ recurrente o en estadio IV.

Type: EECC, phase III.
HULP code: Appendix 1 4889.
Sponsored´s protocol code: .
Sponsored by: Merck KGAA.
Signed date: 08/10/2020

de Castro Carpeño, J. Estudio cesto, abierto, multicéntrico, global, en fase ii con entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes ntrk1/2/3, ros1 o alk.

Type: EECC, phase II.
HULP code: Appendix 3 4648.
Sponsored´s protocol code: G040782 (RXDX-101).
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 06/02/2020

de Castro Carpeño, J. Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de met (metex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino.

Type: EECC, phase II.
HULP code: Appendix 3 4657.
Sponsored´s protocol code: MS200095-0022.
Sponsored by: Merck KGAA.
Signed date: 13/01/2020

de Castro Carpeño, J. Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadío IIIB/IV con alteraciones por omisión del exón 14 de MET (Metex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino.

Type: EECC, phase II.
HULP code: Appendix 4 4657.
Sponsored´s protocol code: MS200095-022.
Sponsored by: Merck KGAA.
Signed date: 08/09/2020

de Castro Carpeño, J. Estudio en paraguas de fase IB/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (Morpheus Pulmonar).

Type: EECC, phase I.
HULP code: 5591.
Sponsored´s protocol code: BO39610.
Sponsored by: Genentech Inc.
Signed date: 20/10/2020

de Castro Carpeño, J. Resilient: estudio aleatorizado abierto en FSE III de irinotecán liposomal inyectable (onivyde®) frente a topotecán en pacientes con cáncer de pulmón microcítico que han progresado con o después del tratamiento de primera línea basado en platino.

Type: EECC, phase III.
HULP code: Appendix 1 5330.
Sponsored´s protocol code: MM-398-01-03-04.
Sponsored by: Ipsen Bioscience Inc.
Signed date: 06/04/2020

de Castro Carpeño, J. Estudio exploratorio de los efectos biológicos y los biomarcadores de nivolumab en combinación con ipilimumab en pacientes con cáncer de pulmón no microcítico en estadio IV o recurrente sin tratamiento previo (Checkmate 592: evaluación de la vía del punto de control y de nivolumab en ensayos clínicos 592).

Type: EECC, phase IV.
HULP code: Appendix 2 5107.
Sponsored´s protocol code: CA209-592.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 13/02/2020

de Castro Carpeño, J. Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (Canopy-1).

Type: EECC, phase III.
HULP code: Appendix 1 4258.
Sponsored´s protocol code: CAC-Z885U2301.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 30/11/2020

de Castro Carpeño, J. Ensayo de plataforma de fase 2 basado en biomarcardores en pacientes con cáncer de pulmón no microcítico avanzado cuya enfermedad ha progresado durante el tratamiento con osimertinib en primera línea.

Type: EECC, phase II.
HULP code: Appendix 1 5345.
Sponsored´s protocol code: D6186C00001.
Sponsored by: Astrazeneca Farmaceutica Spain S.A.
Signed date: 04/08/2020

de Castro Carpeño, J. Estudio pantumoral para el seguimiento a largo plazo de supervivientes de cáncer que han participado en ensayos de investigación de nivolumab.

Type: EECC, phase II.

HULP code: 5551.
Sponsored´s protocol code: CA2098TT.
Sponsored by: Bristol-Myers Squibb International Corporation.
Signed date: 23/09/2020

de Castro Carpeño, J. Estudio aleatorizado de fase III de sitravatinib en combinación con nivolumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso avanzado con progresión de la enfermedad durante o después de la quimioterapia con platino y el tratamiento con inhibidor de punto de control (Sapphire).

Type: EECC, phase III.
HULP code: 5556.
Sponsored´s protocol code: 516-005.
Sponsored by: Mirati Therapeutics Inc.
Signed date: 30/09/2020

de Castro Carpeño, J. Estudio abierto, multicéntrico y global para evaluar la eficacia y la seguridad a largo plazo en pacientes que están recibiendo o que han recibido previamente durvalumab en otros protocolos (WAVE).

Type: EECC, phase IV.
HULP code: 5419.
Sponsored´s protocol code: D910FC00001.
Sponsored by: Astrazeneca Ab.
Signed date: 27/02/2020

de Castro Carpeño, J. Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar la eficacia de tak-788 como tratamiento de primera línea frente a quimioterapia a base de platino en pacientes con cáncer de pulmón no microcítico con mutaciones de EGFR por inserción en el exón 20.

Type: EECC, phase III.
HULP code: 5454.
Sponsored´s protocol code: TAK-788-3001.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 03/02/2020

de Castro Carpeño, J. Ensayo de fase 3, abierto, aleatorizado y multicéntrico que compara selpercatinib con una terapia basada en platino y pemetrexed, con o sin pembrolizumab, como tratamiento inicial del cáncer de pulmón no microcítico avanzado o metastásico, positivo para fusión de Ret.

Type: EECC, phase III.
HULP code: Appendix 1 5442.
Sponsored´s protocol code: J2G-MC-JZJC.
Sponsored by: Lilly S.A.
Signed date: 13/05/2020

de Castro Carpeño, J. Ensayo de fase 3, abierto, aleatorizado y multicéntrico que compara selpercatinib con una terapia basada en platino y pemetrexed, con o sin pembrolizumab, como tratamiento inicial del cáncer de pulmón no microcítico avanzado o metastásico, positivo para fusión de ret.

Type: EECC, phase III.
HULP code: 5442.
Sponsored´s protocol code: J2G-MC-JZJC.
Sponsored by: Lilly S.A.
Signed date: 17/02/2020

de Castro Carpeño, J. Estudio de fase III multicéntrico, aleatorizado, abierto y con control activo de AMG 510 frente a docetaxel en el tratamiento de sujetos con cpnm tratado previamente, localmente avanzado y no resecable o metastásico con la mutación P.G12C en el KRAS.

Type: EECC, phase III.
HULP code: 5545.
Sponsored´s protocol code: 20190009.
Sponsored by: Amgen S.A.
Signed date: 23/04/2020

de Castro Carpeño, J. Ensayo abierto de un solo brazo para evaluar la actividad antitumoral, la seguridad y la farmacocinética de SAR408701 utilizado en combinación con ramucirumab en pacientes con carcinoma pulmonar no microcítico no escamoso metastásico con tumores Ceacam5 positivos, tratados previamente con quimioterapia a base de platino y con un inhibidor de puntos de control inmunitario.

Type: EECC, phase II.
HULP code: 5555.
Sponsored´s protocol code: ACT16525.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 09/06/2020

de Castro Carpeño, J. Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparación con durvalumab en pacientes con cáncer de pulmón no microcítico localmente avanzado en estadio III irresecable que no han presentado progresión después de quimiorradioterapia con platino concomitante (Skyscraper-03).

Type: EECC, phase III.
HULP code: 5590.
Sponsored´s protocol code: GO41854.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

de Castro Carpeño, J. Estudio de fase III, multicéntrico, aleatorizado, abierto y controlado para evaluar la eficacia, la seguridad y la farmacocinética de atezolizumab en combinación con cabozantinib en comparación con docetaxel en monoterapia en pacientes con cáncer de pulmón no microcítico tratado previamente con un anticuerpo anti-PDL1/PD-1 y quimioterapia con platino.

Type: EECC, phase III.
HULP code: 5568.
Sponsored´s protocol code: GO41892.
Sponsored by: Roche Farma S.A.
Signed date: 28/05/2020

de Castro Carpeño, J. Estudio fase 3 abierto y aleatorizado de la combinación de la terapia amivantamab y carboplatino-pemetrexed, frente a carboplatino-pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con egfr mutado por inserciones en el Exon 20.

Type: EECC, phase III.
HULP code: 5652.
Sponsored´s protocol code: 61186372NSC3001.
Sponsored by: Janssen Cilag International N.V.
Signed date: 10/09/2020

de Castro Carpeño, J. Estudio fase 3 aleatorizado de la combinación de amivantamab y lazertinib frente a osimertinib como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación del EGFR. Mariposa.

Type: EECC, phase III.
HULP code: 5636.
Sponsored´s protocol code: 73841937NSC3003.
Sponsored by: Janssen Cilag International N.V.
Signed date: 28/08/2020

de Castro Carpeño, J. Ensayo clínico fase III de quimioterapia adyuvante versus quimoinmunoterapia en pacientes con cáncer de pulmón no microcítico estadio IB-IIIA con resección completa. Nadim Adjuvant.

Type: EECC, phase III.
HULP code: 5690.
Sponsored´s protocol code: GECP20/05.
Sponsored by: Fundación GECP.
Signed date: 03/11/2020

de Castro Carpeño, J. Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadío IIIB o IV.

Type: EECC, phase III.
HULP code: 5665.
Sponsored´s protocol code: 213400.
Sponsored by: Glaxosmithkline S.A.
Signed date: 12/11/2020

de Castro Carpeño, J. Estudio de fase II, aleatorizado, doble ciego y controlado con placebo de tiragolumab en combinación con atezolizumab más pemetrexed y carboplatino/cisplatino en comparación con pembrolizumab más pemetrexed y carboplatino/cisplatino en pacientes con cáncer de pulmón no microcítico no epidermoide avanzado no tratado previamente.

Type: EECC, phase II.
HULP code: 5702.
Sponsored´s protocol code: B042592.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 11/11/2020

de Castro Carpeño, J. Estudio en el mundo real sobre la actividad TKI en mutaciones poco frecuentes y secuenciación Giotrif.

Type: Estudios, phase EPA-OD.
HULP code: PI-3985 .
Sponsored´s protocol code: 1200-0316.
Sponsored by: Boehringer Ingelheim International Gmbh.
Signed date: 04/03/2020

Patents and trademarks

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (Publication Number pending); 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending); 2019 July 19.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene 06-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (Publication Number pending); 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Publication Number pending), PCT/EP2018/068156; 2017 September 15.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.4 Oto-Neurosurgery Research Group

Publications:	18
Impact Factor:	60.[316]
Q1:	6



Luis Lassaletta Atienza. Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz

Carolina Alfonso Carrillo. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Miryam Calvino Fernández. Investigador Adjunto Senior. FIBHULP

Javier Gavilán Bouzas. Jefe de Servicio de Otorrinolaringología. Hospital Universitario La Paz. Catedrático. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid

Alejandro Castro Calvo. Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz

Isabel García López. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Teresa González Otero. Facultativo Especialista de Área en Cirugía Maxilofacial. Hospital Universitario La Paz

José Manuel Morales Puebla. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Silvia Murillo Cuesta. Investigadora Postdoctoral. IIB "Alberto Sols"

María Fernanda Pedrero Escalas. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Carolina Peña Granero. Técnico de Laboratorio. Hospital Universitario La Paz

Rosa María Pérez Mora. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Juan Antonio Rey Herranz. Investigado Senior (Contrato MIguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Lourdes Rodríguez de la Rosa. Investigadora Postdoctoral. IIB "Alberto Sols"

Laura del Río Arroyo. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Isabel Pilar Sánchez Cuadrado. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Miguel Torres Martín. Investigador Postdoctoral. Hospital Universitario La Paz

María Isabel Varela Nieto. Profesor de Investigación. IIB "Alberto Sols"

Antonio Villalobo Polo. Profesor de Investigación. IIB "Alberto Sols"

Strategic Objective

The systematic use of magnetic resonance imaging (MRI) has dramatically increased the diagnosis of patients with vestibular schwannoma (VS). The majority of patients with VS complain of hypoacusis or tinnitus, and very few present more debilitating symptoms. Therefore, the approach with a patient with VS is complex because the treatment of the tumour is directed towards avoiding complications arising from its growth and not necessarily towards improving the patient's quality of life. Currently, there are no factors that allow us to predict the growth of vestibular schwannoma.

Recent advances in the field of oncogenetics have allowed us to better understand the development of VS.

The study of the correlation between clinical variables related to the biological beha-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

viour of VS and its genetic and epigenetic disorders aims to find the factors that predict the behaviour of VS. This will help us identify patients who need active treatment of the tumour and avoid the morbidity associated with the treatment in those who do not need it.

The cochlear implant (CI) is currently the only solution for relieving the condition in patients with severe or profound hypoacusis who do not benefit from a prosthetic adaptation with a conventional hearing aid. It is estimated that there are currently 120,000 adults in Spain with profound sensorineural hypoacusis. In recent years, new hearing implants have been developed including osseointegrated implants and active middle ear implants. It´s excellent and often spectacular results and its low rate of complications have transformed CI from an innovative technology in the experimental phase to a routine, safe and effective procedure, capable of returning deaf individuals to the hearing world and ending their isolation, increasing their quality of life. Over the past decade the relationship between hearing loss and cognitive decline in the older population has become the subject of research. We also explore the relationships between the cognitive function and the audiometric performances in patients wearing a CI.

Moderate to severe hypoacusis is one of the most prevalent medical problems. Ciliated sensory cells and neurons do not regenerate in mammals, which is the main cause of sensorineural hearing loss (SNHL). Mutations altering the levels of Insulin like growth factor type 1 (IGF-1) cause SNHL in humans and mice. IGF-1 is an essential factor in the postnatal development of mammals, and its level decreases with ageing. We are studying the participation of IGF-1 in the pathophysiology of SNHL, as well as the molecular signalling networks conferring specificity in the otic cellular response to IGF-1. We are studying the signals that regulate otic damage with the objective of identifying the key factors implicated in functional repair and regeneration of inner ear cells. In short, our work contributes to the study of auditory pathophysiology, with the ultimate objective of investigating the potential clinical usefulness of IGF-1 and downstream signalling in human sensorineural deafness.

Research lines

- Tumors of the CNS: vestibular schwannoma, meningiomas, gliomas, and other: surgery, oncogenetics, quality of life, etc.
- Auditory implants: cochlear implants, middle ear implants, bone-conduction implants: surgical aspects, telephone use, quality of life, perception of music, cognitive declive, etc.
- IGF-I deficiency: a rare syndromic human deafness.
- Neurobiology of hearing: molecular and cellular bases of hearing loss of different aetiology (genetic, noise exposure, malnutrition, and ototoxic drugs). Identification of transcriptional networks.
- Development of experimental models of deafness (genetic, noise exposure, malnutrition, ototoxic drugs and surgery associated trauma) for pre-clinical studies with potential therapeutic molecules, thus identifying possible therapeutic targets, potential markers for diagnosis and generation of vital guidelines.
- Head and Neck tumors and voice pathology.
- The role of celular senescence in the development of the inner ear and the audithory pathology.
- Studies on three systems implicated in the development of tumor metastasis: the tyrosine kinase receptors EGFR/ErbB2; the non-receptor tyrosine kinase c-Src; and the adaptor protein Grb7.

Research Activity

Publications

- Lassaletta L, Morales-Puebla JM, González-Otero T, Moraleda S, Roda JM, Gavilán J. The experience of a facial nerve unit in the treatment of patients with facial paralysis following skull base surgery. Otol Neurotol. 2020; 41(10): E1340-9. Review. IF: 2.311; Q3
- Bermúdez-Muñoz JM, Celaya AM, Hijazo-Pechero S, Wang J, Serrano M, Varela-Nieto I. G6PD overexpression protects from oxidative stress and age-related hearing loss. Aging Cell. 2020; 19(12): e13275. Article. IF: 9.304; D1
- Medina MM, Polo R, Amilibia E, Roca-Ribas F, Díaz M, Pérez M, Muriel A, Gavilán J, Cobeta I, Lassaletta L. Diagnostic accuracy of intracochlear test electrode for acoustic nerve monitoring in vestibular schwannoma surgery. Ear Hear. 2020; 41(6): 1648-59. Article. IF: 3.57; D1
- Murillo-Cuesta S, Artuch R, Asensio F, de la Villa P, Dierssen M, Enríquez JA, Fillat C, Fourcade S, Ibanez B, Montoliu L, Oliver E, Pujol A, Salido E, Vallejo M, Varela-Nieto I. The value of mouse models of rare diseases: A spanish experience. Front Genet. 2020; 11: 583932. Article. IF: 4.599; Q2
- Varela-Nieto I, Murillo-Cuesta S, Calvino M, Cediel R, Lassaletta L. Drug development for noise-induced hearing loss. Expert Opin Drug Discov. 2020; 15(12): 1457-71. Review. IF: 6.098; Q1
- Magarinos M, Barajas-Azpeleta R, Varela-Nieto I, Aburto MR. Otic neurogenesis is regulated by TGF beta in a senescence-independent manner. Front Cell Neurosci. 2020; 14: 217. Article. IF: 5.505; Q1
- García-Palmero I, Shah N, Ali NA, Daly RJ, Wilce JA, Villalobo A. Partners of wild type Grb7 and a mutant lacking its calmodulin-binding domain. Arch Biochem Biophys. 2020; 687: 108386. Article. IF: 4.013; Q2
- Munk M, Alcalde J, Lorentzen L, Villalobo A, Berchtold MW, Panina S. The impact of calmodulin on the cell cycle analyzed in a novel human cellular genetic system. Cell Calcium. 2020; 88: 102207. Article. IF: 6.817; Q1
- Alcalde J, González-Muñoz M, Villalobo A. Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of tumor cells while they enhance attachment to the substrate. Heliyon. 2020; 6(5): e03922. Article. Not Indexed

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Calvino M, Sánchez-Cuadrado I, Gavilán J, Lassaletta L. Does bimodal hearing increase self-assessed abilities and hearing outcomes when compared to unilateral cochlear implantation? Int J Audiol. 2020; 59(9): 654-60. Article. IF: 2.117; Q2
- García-López I, Pérez-Fernández CA, García-Raya P, Gavilán J. Laryngeal cleft: Diagnosis and treatment of an unusual presentation in an adult. Acta Otorrinolaringol Esp. 2020; 71(2): 122-4. Article. Not Indexed
- Lassaletta L, Morales-Puebla JM, Altuna X, Arbizu A, Aristegui M, Batuecas A, Cenjor C, Espinosa-Sánchez JM, García-Iza L, García-Raya P, González-Otero T, Manos M, Martin C, Moraleda S, Roda JM, Santiago S, Benítez J, Cavalle L, Correia V, Estévez JM, Gómez J, González R, Jiménez J, Lacosta JL, Lavilla MJ, Penarrocha J, Polo R, García-Purrinos F, Ramos F, Tomás M, Uzcanga M, Vallejo LA, Gavilán J. Facial paralysis: Clinical practice guideline of the Spanish Society of Otolaryngology. Acta Otorrinolaringol Esp. 2020; 71(2): 99-118. Article. Not Indexed
- Villalobo A, Berchtold MW. The role of calmodulin in tumor cell migration, invasiveness, and metastasis. Int J Mol Sci. 2020; 21(3): 765. Review. IF: 5.923; Q1
- Bona AB, Calcagno DQ, Ribeiro HF, Muñiz JAPC, Pinto GR, Rocha CAM, Lacreta ACC, de Assumpcao PP, Herranz JAR, Burbano RR. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Ther Adv Gastroenterol. 2020; 13: 1756284819895430. Article. IF: 4.409; Q2
- de La Rosa J, Urdiciain A, Zazpe I, Zelaya MV, Meléndez B, Rey JA, Idoate MA, Castresana JS. The synergistic effect of DZ-NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. Int J Oncol. 2020; 56(1): 283-300. Article. IF: 5.65; Q2
- Moraleda S, Hachoue Z, Abdel-Muti E, Ruiz G, Díez Sebastián J, Lassaletta L. Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A. Rehabilitacion (Madr). 2020; 54(4): 254-9. Article. Not Indexed
- Cantero D, Mollejo M, Sepulveda JM, D'Haene N, Gutiérrez-Guaman MJ, Rodríguez de Lope A, Fiano C, Castresana JS, Lebrun L, Rey JA, Salmon I, Meléndez B, Hernández-Lain A. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv. 2020; 2(1): vdz059. Article. Not Indexed
- Van de Heyning P, Atlas M, Baumgartner WD, Caversaccio M, Gavilán J, Godey B, Gstottner W, Hagen R, Yongxin L, Karltorp E, Kameswaran M, Kuzovkov V, Lassaletta L, Manoj M, Parnes L, Pillsbury H, Raine C, Rajan G, Schmutzhard J, Skarzynski H, Staecker H, Usami SI, Zernotti M. The reliability of hearing implants: report on the type and incidence of cochlear implant failures. Cochlear Implants Int. 2020; 21(4): 228-37. Article. Not Indexed

Research projects

Calvino Fernández M. Evaluación del cuestionario revisado de rehabilitación laboral WORQ MEDEL. Med-El Elektromedizinische Geräte Gesellschaft M. B. H. 2020-2021.

Managment centre: FIBHULP

García-López I. Parálisis bilateral de las cuerdas vocales: epidemiología y posibilidades terapéuticas aplicadas (PI-3780). Med-El Elektromedizinische Geräte Gesellschaft M. B. H.. 2019-Ongoing.

Managment centre: FIBHULP

Lassaletta Atienza L. Discapacidad y de la Salud en usuarios de implantes cocleares: un estudio de cohorte prospectivo multicéntric. Med-El Elektromedizinische Geräte Gesellschaft M. B. H. 2020-2022.

Managment centre: FIBHULP

Lassaletta Atienza L. Implantes cocleares y función cognitiva. Medidas de resulados auditivos, calidad de vida y calidad del sonido (PI16/00079). ISCIII. 2017-2021.

Managment centre: FIBHULP

Lassaletta Atienza L. Influencia de las estrategias de codificación y el uso de sistemas de apoyo en la percepción y uso del teléfono en pacientes adultos con implante coclear. Med-El Elektromedizinische Geräte Gesellschaft M. B. H.. 2011-Ongoing.

Managment centre: FIBHULP

Murillo Cuesta S . Delivery of antisense RNA therapeutics (CA17103). COST Action (EU). 2018-2022.

Managment centre: Biocruces Bizkaia Health Research Institute

Murillo Cuesta S. Grupo de trabajo modelos murinos para el estudio de enfermedades raras (ERP1PDI761). CIBERER. 2020-2022.

Managment centre: CIBERER

Rey Herranz JA. Contrato Miguel Servet Categoria A (CES05/027). ISCIII. 2006-2025.

Managment centre: FIBHULP

Rodríguez de la Rosa L. Análisis del mosaicismo genético mediante NGS. Aplicación en patologías raras y en modelos celulares y animales por edición genética (ER-19P5AC761). CIBERER. 2018-2020.

Managment centre: CIBERER

Rodríguez de la Rosa L. Grupo de trabajo edición genómica y terapia génica (ERP1PDI755). CIBERER. 2020-2022.

Managment centre: CIBERER

Sánchez Cuadrado IP, Lassaletta Atienza L. Análisis de las capacidades cognitivas en pacientes mayores con hipoacusia profunda con y sin implante coclear: un estudio multicéntrico prospectivo, longitudinal y comparativo. Med-El Elektromedizinische Geräte Gesellschaft M. B. H. 2016-Ongoing.

Managment centre: FIBHULP

Sánchez Cuadrado IP. Validación al español de la escala de valoración clínica eFACE y del SunnyBrook Facial Grading System (PI20/01032). ISCIII. 2020-2023.

Managment centre: FIBHULP

Varela Nieto I, Murillo Cuesta S. Scientific research and development services in the field of hearing loss (ERP17PE12). SPIRAL Therapeutix. 2017-2021.

Managment centre: CIBERER

Varela Nieto I. Ayuda para la realización de doctorado industrial para la Agencia Estatal Consejo Superior de Investigaciones Científicas y la empresa Alodia Farmaceutica S.L (IND2020/BMD-17454). Agencia Estatal CSIC. Aloda Farmaceútica S.L. 2020-2023.

Managment centre: CSIC

Varela Nieto I. Desarrollo de nuevas terapias para la prevención y tratamiento de la pérdida auditiva basadas en la identificación de parámetros genéticos, bioquímicos y moleculares (HEARCODE) (SAF2017-86107-R). Ministerio de Economía, Industria y Competitividad. 2018-2020.

Managment centre: IIBm (CSIC)

Varela Nieto I. Grupo de trabajo desarrollo de nuevas herramientas terapéuticas basadas en RNA para el tratamiento de enfermedades raras (ERP1PDI756). CIBERER. 2020-2022.

Managment centre: CIBERER

Varela Nieto I. Imagen multimodal de la respuesta terapeútica a estrategias multidiana en enfermedades neurológicas (MULTITARGET&VIEWCM) (B2017/BMD-3688). CAM. 2018-2022.

Managment centre: IIBm (CSIC)

Varela Nieto I. Prueba de concepto para determinar el efecto de la Colesteronitrona F2 en el tratamiento de la Presbiacusia (NITROPROHEAR) (0551_PSL_6_E). EU Framework programme Horizon 2020. 2020-2021.

Managment centre: CSIC

Varela Nieto I. Senescencia celular: me-

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

canismos y terapias (SENESTHERAPY) (RED2018-102698-T). Ministerio de Ciencia, Innovación y Universidades. 2018-2022.

Managment centre: Fundacio Institut de Recerca Biomedica

Cibers and Retics

Varela Nieto I. Centro de Investigación en Red de Enfermedades Raras (CB06/07/102). ISCIII. (31/12/2021)

Clinical trials

Prieto Nieto, I. Premas Study. Prevalence of malnutrition in gastrointestinal surgical oncology patients (prevalencia de la desnutrición en pacientes oncológicos sometidos a cirugía gastrointestinal).

Type: Estudios, phase No EPA.
HULP code: PI-4285 .
Sponsored´s protocol code: FRE-NUL-2020-01.
Sponsored by: Sanidad y Ediciones S.L.
Signed date: 10/09/2020

Patents and trademarks

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.5 Cancer Molecular Pathology and Therapeutic Targets Group

Publications:	23
Impact Factor:	133.^{854}
Q1:	15



David Hardisson Hernáez. Jefe de Servicio de Anatomía Patológica. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Alberto Berjón García. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Javier de Santiago García. Jefe de Servicio de Ginecológica Oncológica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

Laura Guerra Pastrián. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Jorge Martín Pérez. Investigador Científico. IIB "Alberto Sols"

Marta Mendiola Sabio. Investigadora Postdoctoral. Hospital Universitario La Paz

María Miguel Martín. Técnico de Laboratorio. Hospital Universitario La Paz

Alberto Peláez García. Investigador Postdoctoral. Hospital Universitario La Paz

Elia Pérez Fernández. Investigadora Predoctoral. Hospital Universitario La Paz

José Juan Pozo Kreilinger. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

José Ignacio Sánchez Méndez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

Laura Yébenes Gregorio. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Strategic Objective

The fundamental interest of our research group is centered in the study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.

Ovarian cancer Research Line:

The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies. Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.

Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors. The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with predictive and prognostic value for ovarian cáncer patients.

Endometrial cancer Research Line:

Endometrial carcinoma is the fourth most common cancer in women in the developed world. Histomorphologic criteria are not strongly enouygh tools to distinguish more aggressive tumors. Based on molecular characterization, risk stratification systems could be useful for decision making.

The main objective of this line of investigation, therefore, is to identify molecular markers with predictive and prognostic value for endometrial cancer patients.

Breast cancer Research Line:

C-Src is sobreexpressed and/or hyperactive in breast carcinoma biopsies and their implication in the tumorigenesis has been proved in murine models.

Our studies on genetically modified human breast cancer cells and mice can establish the relevance of the function of scaffolding of SFKs in breast cancer. In addition, our work can lead to the development of new prognosis and therapeutic tools to improve the treatment of the breast cancer.

Angiogenesis and breast cancer. Angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of evacizumab containing regimes.

Sarcomas Research Line:

Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.

Neuroendocrine tumors Research Line:


The neuroendocrine tumors (NET) include heterogeneous neoplasias, regarding morphologic and functionally features. They constitute a challenge for the medical management, mainly regarding diagnose and handling. Although we have improve the knowledge of molecular events related to their development in the last decade, we need to better known this tumors, in order to establish an early detection, that it improves the rates of survival.

In vitro 2- and 3D cell culture models for functional studies.

The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development that it improves the rates of survival.

Research lines

- Ovarian and endometrial cancer
- Breast cancer
- Sarcomas
- Neuroendocrine tumors
- New in vitro models of disease



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Publications

- Alcala S, Mayoral-Varo V, Ruiz-Canas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B. Targeting SRC kinase signaling in pancreatic cancer stem cells. Int J Mol Sci. 2020; 21(20): 7437. Article. IF: 5.923; Q1
- Casas-Arozamena C, Díaz E, Moiola CP, Alonso-Alconada L, Ferreiros A, Ábalo A, Gil CL, Oltra SS, de Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L. Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer. J Clin Med. 2020; 9(2): 585. Article. IF: 4.241; Q1
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrián L, Cantero R, del Peso L, Burgos A, Barbachano A, Muñoz A. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. Cancers. 2020; 12(8): 2302. Article. IF: 6.639; Q1
- COVIDSurg Collaborative (Sánchez-Méndez JI). Delaying surgery for patients with a previous SARS-CoV-2 infection. Br J Surg. 2020; 107(12): E601-2. Letter. IF: 6.939; D1
- del Arco CD, Muñoz LE, Manchado RB, García AP, Medina LO, Roldán EM, Fernández GS, de las Heras SGG, Acenero MJF. Prognostic role of aryl hydrocarbon receptor interacting protein (AIP) immunohistochemical expression in patients with resected gastric carcinomas. Pathol Oncol Res. 2020; 26(4): 2641-50. Article. IF: 3.201; Q2
- Escoll M, Lastra D, Pajares M, Robledinos-Antán N, Rojo AI, Fernández-Ginés R, Mendiola M, Martínez-Marín V, Esteban I, López-Larrubia P, Gargini R, Cuadrado A. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas. Redox Biol. 2020; 30: 101425. Article. IF: 11.799; D1
- Fernández-Barral A, Costales-Carrer A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrián L, Lafarga M, García-Olmo D, Cantero R, del Peso L, Batllé E, Rojo F, Muñoz A, Barbachán A. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. FEBS J. 2020; 287(1): 53-72. Article. IF: 5.542; Q1
- Garranzo-Asensio M, San Segundo-Acosta P, Poves C, Fernández-Acenero MJ, Martínez-Useros J, Montero-Calle A, Solis-Fernández G, Sánchez-Martínez M, Rodríguez N, Cerón MA, Fernández-Díez S, Domínguez G, de Los Ríos V, Peláez-García A, Guzmán-Aránguez A, Barderas R. Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis. J Proteomics. 2020; 214: 103635. Article. IF: 4.044; Q2
- Goebel EA, Hernández Bonilla S, Dong F, Dickson BC, Hoang LN, Hardisson D, Lacambra MD, Lu FI, Fletcher CDM, Crum CP, Antonescu CR, Nucci MR, Kolin DL. Uterine tumor resembling ovarian sex cord tumor (UTROSCT) a morphologic and molecular study of 26 cases confirms recurrent NCOA1-3 rearrangement. Am J Surg Pathol. 2020; 44(1): 30-42. Article. IF: 6.394; D1
- Heredia-Soto V, López-Guerrero J A, Redondo A, Mendiola M. The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. EJC Suppl. 2020; 15: 49-55. Article. IF: 9.386; D1
- Heredia-Soto V, Redondo A, Kreilinger JJP, Martínez-Marín V, Berjón A, Mendiola M. 3D culture modelling: An emerging approach for translational cancer research in sarcomas. Curr Med Chem. 2020; 27(29): 4778-88. Review. IF: 4.53; Q2
- Leskela S, Romero I, Cristóbal E, Pérez-Mies B, Rosa-Rosa JM, Gutiérrez-Pecharromán A, Santón A, González BO, López-Reig R, Hardisson D, Vera-Sempere F, Illueca C, Vieites B, López-Guerrero JA, Palacios J, Poveda A. The frequency and prognostic significance of the histologic type in early-stage ovarian carcinoma a reclassification study by the spanish group for ovarian cancer research (GEICO). Am J Surg Pathol. 2020; 44(2): 149-61. Article. IF: 6.394; D1
- López-Janeiro A, Padilla-Ansala C, de Andrea CE, Hardisson D, Melero I. Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma. A systematic review and meta-analysis. Mod Pathol. 2020; 33(8): 1458-65. Review. IF: 7.842; D1
- Martí C, Sánchez-Méndez JI. Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic. eCancerMedicalScience. 2020; 14: 1027. Article. Not Indexed
- Mayoral-Varo V, Calcabrini A, Sánchez-Bailón MP, Martínez-Costa OH, González-Páramos C, Ciordia S, Hardisson D, Aragón JJ, Fernández-Moreno MA, Martín-Pérez J. c-Src functionality controls self-renewal and glucose metabolism in MCF7 breast cancer stem cells. PLoS One. 2020; 15(7): e0235850. Article. IF: 3.24; Q2
- Nemejcova K, Kocian R, Kohler C, Jarkovsky J, Klat J, Berjón A, Pilka R, Sehnal B, Gil-Ibáñez B, Lupo E, Petiz A, Sánchez OA, Kascak P, Martínelli F, Buda A, Presl J, Barahona M, van Lonkhuijzen L, Szatkowski W, Minar L, Pakiz M, Havelka P, Zorrero C, Misiek M, Snyman LC, Wydra D, Vergote I, Vinnytska A, Redecha M, Michal M, Tingulstad S, Kipp B, Szewczyk G, Toth R, García FJD, Martín PJC, Poka R, Tamussino K, Luyckx M, Fastrez M, Staringer JC, Germanova A, Plaikner A, Bajsova S, Dundr P, Mallmann-Gottschalk N, Cibula D. Central pathology review in sENTIX, a prospective observational international study on sentinel lymph node biopsy in patients with early-stage cervical cancer (ENGOT-CX2). Cancers. 2020; 12(5): 1115. Article. IF: 6.639; Q1
- Ordulu Z, Chai HY, Peng G, McDonald AG, de Nictolis M, García-Fernández E, Hardisson D, Prat J, Li PN, Hui P, Olival E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Mod Pathol. 2020; 33(9): 1844-60. Article. IF: 7.842; D1
- Pinero-Madrona A, Ripoll-Orts F, Sánchez-Méndez JI, Chaves-Benito A, Gómez-de la Barcena MR, Calatrava-Fons A, Menjón-Beltrán S, Peg-Camara V. External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients. Breast Cancer Res Treat. 2020; 181(2): 339-45. Article. IF: 4.872; Q2
- Povedano E, Montiel VRV, Gamella M, Pedrero M, Barderas R, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Yáñez-Sedeno P, Campuzano S, Pingarrón JM. Amperometric bioplatforms to detect regional DNA methylation with single-base sensitivity. Anal Chem. 2020; 92(7): 5604-12. Article. IF: 6.986; D1
- Schaumberg AJ, Juárez-Nicanor WC, Choudhury SJ, Pastrián LG, Pritt BS, Pozuelo MP, Sánchez RS, Ho K, Zahra N, Sener BD, Yip S, Xu B, Annavarapu SR, Morini A, Jones KA, Rosado-Orozco K, Mukhopadhyay S, Miguel C, Yang HY, Rosen Y, Ali RH, Folaranmi OO, Gardner JM, Rusu C, Stayerman C, Gross J, Suleiman DE, Sirintrapun SJ, Aly M, Fuchs TJ. Interpretable multimodal deep learning for real-time pan-tissue pan-disease pathology search on social media. Mod Pathol. 2020; 33(11): 2169-85. Article. IF: 7.842; D1
- Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Vara JAF, Feliú J. Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification. Mol Cell Proteomics. 2020; 19(4): 690-700. Article. IF: 5.911; Q1
- Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros A, Gámez-Pozo A, Feliú J, Vara JAF. Comprehensi-

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

ve characterization of the mutational landscape in localized anal squamous cell carcinoma. Transl Oncol. 2020; 13(7): 100778. Article. IF: 4.243; Q2

- Vinal D, Martínez D, García-Cuesta JA, Gutierrez-Sainz L, Martínez-Recio S, Villamayor J, Martínez-Marín V, Gallego A, Ortiz-Cruz E, Mendiola M, Pozo-Kreilinger JJ, Berjón A, Belinchón B, Bernabeu D, Espinosa E, Feliú J, Redondo A. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. Clin Transl Oncol. 2020; 22(10): 1849-56. Article. IF: 3.405; Q3

Research projects

Guerra Pastrián L. Desarrollo de tareas de revisión patológica nacional del ensayo clínico Paediatric Hepatic International Tumour Trial (PHITT). Fundación para la Investigación Biomédica de Córdoba Fibico. 2019-Ongoing.

Managment centre: FIBHULP

Hardisson Hernáez D. Aplicabilidad de la proteogenómica en la progresión del carcinoma endometrioide de endometrio diagnosticado en estadios iniciales (PI17/01723). ISCIII. 2018-2021.

Managment centre: FIBHULP

Hardisson Hernáez D. Realización de las tareas necesarias para el desarrollo del ensayo clínico. A phase IB/IIA, radomized, double blind, placebo controlled, multicenter clínical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with ost-122 in patients with moderate to severe ulcerative colitis. ct-ost-122-02. Oncostellae S.L. 2020-Ongoing.

Managment centre: FIBHULP

Hardisson Hernáez D. Riesgo de recaída en pacientes con carcinoma de mama primario HER2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (Mammaprint® y Endopredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M, Hardisson Hernáez D. Identificación de biomarcadores en cáncer de pulmón no microcítico. Astrazeneca Farmacéutica Spain S. A. 2020-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Exploration of 2 and 3d models of angiosarcoma and their farcological sdreening. Grupo Español de Investigación en Sarcomas. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. Ortomedimatec. 2012-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Papel de RANKL en el sarcoma de Ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Realización de técnicas de detección de expresión proteica el IGTP. Construcción de matrices tisularees y tinciones con anticuerpos específicos. Fundacio Institut Dínvestigació én Ciéncies de la Salut Germans Trias I Pujol. 2015-Ongoing.

Managment centre: FIBHULP

Clinical trials

Hardisson Hernáez, D. Evaluación del método Osna para la detección rápida de metástasis en ganglios linfáticos en mujeres con cáncer endometrial.

Type: Estudios, phase No EPA.
HULP code: PI-4275A .
Sponsored´s protocol code: CP-OSNA-EC-210.
Sponsored by: Sysmexeurope GMBH.
Signed date: 02/10/2020

Hardisson Hernáez, D. Validación estudio Neovattl.

Type: Estudios, phase No EPA.
HULP code: PI-3692 .
Sponsored´s protocol code: GES-NEO-2019-001.
Sponsored by: Fundación Española de Senología .
Signed date: 27/01/2020

Patents and trademarks

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Introduction


Executive summary

Information Groups by Area

Associated Clinicians

3.5.6 Mechanisms of Tumour Progression Group

Publications:	20
Impact Factor:	217.734
Q1:	13



Gema Moreno Bueno. Profesora Titular. Universidad Autónoma de Madrid

David Albandea Rodríguez. Investigador Predoctoral. IIB "Alberto Sols"

Antonio Barbachano Becerril. Investigador Postdoctoral. IIB "Alberto Sols"

Pilar de la Paz Bustamante Madrid. Investigadora Predoctoral. IIB "Alberto Sols"

Alba Costales Carrera. Investigador Predoctoral. IIB "Alberto Sols"

Patricia Carrasco Ramírez. Investigadora Predoctoral. IIB "Alberto Sols"

Gemma Domínguez Muñoz. Profesora contratada. Universidad Autónoma de Madrid

Asunción Fernández Barral. Investigadora Postdoctoral. IIB "Alberto Sols"

Gemma Ferrer Mayorga. Investigadora Postdoctoral. IIB "Alberto Sols"

Alfredo Floristán Muruzúbal. Investigador Predoctoral. IIB "Alberto Sols"

Pablo García Sanz. Investigador Postdoctoral. IIB "Alberto Sols"

Patricia González Santamaría. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Marta Hergueta Redondo. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Jesús Larriba Muñoz. Científica Titular. IIB "Alberto Sols"

Ester Martín Villar. Investigadora Postdoctoral. IIB "Alberto Sols"

Saleta Morales Dolores. Técnica de Laboratorio. Universidad Autónoma de Madrid

Alba Mota Jiménez. Investigadora Predoctoral. IIB "Alberto Sols"

Alberto Muñoz Terol. Profesor de Investigación. IIB "Alberto Sols"

Eva Pérez Cuevas. Investigadora Postdoctoral. IIB "Alberto Sols"

Miguel Quintanilla Ávila. Profesor de Investigación. IIB "Alberto Sols"

José David Sarrio López. Investigador Postdoctoral. IIB-UAM- CIBERONC

Francisco Portillo Pérez. Catedrático. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

Sara Oltra Sanchís. Investigador Postdoctoral. IIB-UAM

Laura Sin Díaz. Investigador Postdoctoral. IIB-UAM

Carmen Ramos Nebot. Investigador Predoctoral. IIB-UAM- CIBERONC

Eva Díaz Martín. Técnica de Laboratorio. IIB-UAM

Alberto Vázquez Naharro. Investigador Predoctoral. IIB-UAM

Strategic Objective

Study of novel resistance mechanisms.
Analysis of tumor invasion and metastasis mechanisms in solid tumors.
Characterization of new biomarkers in breast and gynecologic carcinomas.
Design of new targeted therapies to biomarkers formerly characterized by the group.
Characterization of EMT processes in tumor metastasis.
Characterize vitamin D action in stem cells and tumor microenvironment in colorectal cancer.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Characterization of new resistance mechanism in breast tumors (HER2+).
- Intratumor heterogeneity study in different types of tumors.
- Cell plasticity and tumor metastasis.
- Study of vitamin D effects on patient-derived colon normal and cancer-associated fibroblasts and organoids.

Research Activity

Doctoral theses

Pérez López M. Implicación funcional de Gasdermina B en dos contextos biológicos: cáncer e inflamación.[dissertation]. Madrid: UAM: 2020(10/09/2020).

Directors: Moreno Bueno G, Sarrió López JD.

Publications

- Abréu M, Cabezas-Sainz P, Alonso-Alconada L, Ferreiros A, Mondelo-Macía P, Lago-Leston RM, Ábalo A, Díaz E, Palacios-Zambrano S, Rojo-Sebastián A, López-López R, Sánchez L, Moreno-Bueno G, Muinelo-Romay L. Circulating tumor cells characterization revealed TIMP1 as a potential therapeutic target in ovarian cancer. Cells. 2020; 9(5): 1218. Article. IF: 6.6; Q2
- Abréu M, Cabezas-Sainz P, Pereira-Veiga T, Falo C, Ábalo A, Morilla I, Curiel T, Cueva J, Rodríguez C, Varela-Pose V, Lago-Lestón R, Mondelo P, Palacios P, Moreno-Bueno G, Cano A, García-Caballero T, Pujana MA, Sánchez-Pinón L, Costa C, López R, Muinelo-Romay L. Looking for a better characterization of triple-negative breast cancer by means of circulating tumor cells. J Clin Med. 2020; 9(2): 353. Article. IF: 4.241; Q1
- Aguado T, García M, García A, Ferrer-Mayorga G, Martínez-Santamaria L, del Río M, Botella LM, Sánchez-Puelles JM. Raloxifene andn-acetylcysteine ameliorate TGF-signalling in fibroblasts from patients with recessive dominant epidermolysis bullosa. Cells. 2020; 9(9): 2108. Article. IF: 6.6; Q2
- Bobinski M, Okla K, Luszczki J, Bednarek W, Wawruszak A, Moreno-Bueno G, Dmoszynska-Graniczka M, Tarkowski R, Kotarski J. Isobolographic analysis demonstrates the additive and synergistic effects of gemcitabine combined with fucoidan in uterine sarcomas and carcinosarcoma cells. Cancers. 2020; 12(1): 107. Article. IF: 6.639; Q1
- Bobinski M, Okla K, Luszczki J, Bednarek W, Wawruszak A, Moreno-Bueno G, García-Sanz P, Dmoszynska-Graniczka M, Tarkowski R, Kotarski J. Gemcitabine and selected mTOR inhibitors in uterine sarcomas and carcinosarcoma cells-an isobolographic analysis. Int J Med Sci. 2020; 17(18): 2987-97. Article. IF: 3.738; Q2
- Casas-Arozamena C, Díaz E, Moiola CP, Alonso-Alconada L, Ferreiros A, Abalo A, Gil CL, Oltra SS, de Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L. Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer. J Clin Med. 2020; 9(2): 585. Article. IF: 4.241; Q1
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Domínguez O, Guerra-Pastrián L, Cantero R, del Peso L, Burgos A, Barbachano A, Muñoz A. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. Cancers. 2020; 12(8): 2302. Article. IF: 6.639; Q1
- Fernández-Barral A, Bustamante-Madrid P, Ferrer-Mayorga G, Barbachano A, Larriba MJ, Muñoz A. Vitamin D effects on cell differentiation and stemness in cancer. Cancers. 2020; 12(9): 2413. Review. IF: 6.639; Q1
- Fernández-Barral A, Costales-Carrer A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrián L, Lafarga M, García-Olmo D, Cantero R, del Peso L, Batllé E, Rojo F, Muñoz A, Barbachán A. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. Febs J. 2020; 287(1): 53-72. Article. IF: 5.542; Q1
- Garranzo-Asensio M, Guzmán-Aranguez A, Povedano E, Montiel VRV, Poves C, Fernández-Acenero MJ, Montero-Calle A, Solís-Fernández G, Fernández-Diéz S, Camps J, Arenas M, Rodríguez-Tomás E, Joven J, Sánchez-Martínez M, Rodríguez N, Domínguez G, Yáñez-Sedeno P, Pingarrón JM, Campuzano S, Barderas R. Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform. Theranostics. 2020; 10(7): 3022-34. Article. IF: 11.556; D1
- Garranzo-Asensio M, San Segundo-Acosta P, Poves C, Fernández-Acenero MJ, Martínez-Useros J, Montero-Calle A, Solís-Fernández G, Sánchez-Martínez M, Rodríguez N, Cerón MA, Fernández-Díez S, Domínguez G, de Los Ríos V, Peláez-García A, Guzmán-Aránguez A, Barderas R. Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis. J Proteomics. 2020; 214: 103635. Article. IF: 4.044; Q2
- González-Sancho JM, Larriba MJ, Muñoz A. Wnt and vitamin D at the crossroads in solid cancer. Cancers. 2020; 12(11): 3434. Review. IF: 6.639; Q1
- Grilli G, Hermida-Prado F, Álvarez-Fernández M, Allonca E, Álvarez-González M, Astudillo A, Moreno-Bueno G, Cano A, García-Pedrero JM, Rodrigo JP. Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. Oral Oncol. 2020; 110: 105003. Article. IF: 5.337; D1
- Martínez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martín MC, Moya FJ, Quintana-Bustamante O, García-Silva S, Carcaboso AM, Petazzi P, Bueno C, Mora J, Peinado H, Segovia JC, Menéndez P, Rodríguez-Perales S. In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun. 2020; 11(1): 5060. Article. IF: 14.919; D1
- Mota A, S Oltra S, Moreno-Bueno G. Insight updating of the molecular hallmarks in ovarian carcinoma. Ejc Suppl. 2020; 15: 16-26. Article. IF: 9.386; D1
- Palacios-García J, Sanz-Flores M, Asensio A, Alvarado R, Rojo-Berciano S, Stamatakis K, Paramio JM, Cano A, Nieto MA, García-Escudero R, Mayor F, Ribas C. G-protein-coupled receptor kinase 2 safeguards epithelial phenotype in head and neck squamous cell carcinomas. Int J Cancer. 2020; 147(1): 218-29. Article. IF: 7.396; Q1

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

- Portillo F, Vázquez J, Pajares MA. Protein-protein interactions involving enzymes of the mammalian methionine and homocysteine metabolism. Biochimie. 2020; 173: 33-47. Review. IF: 4.079; Q2
- Rodríguez N, Vinal D, Rodríguez-Cobos J, de Castro J, Domínguez G. Genomic profiling in oncology clinical practice. Clin Transl Oncol. 2020; 22(9): 1430-9. Review. IF: 3.405; Q3
- Rosendo-Chalma P, Antonio-Vejar V, Bigoni-Ordóñez GD, Patino-Morales CC, Cano-García A, García-Carranca A. CDH1 and SNAI1 are regulated by E7 from human papillomavirus types 16 and 18. Int J Oncol. 2020; 57(1): 301-13. Article. IF: 5.65; Q2
- Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, de Herreros AG, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang YB, Khew-Goodall Y, Levine H, Liu JS, Longmore GD, Mani SA, Massague J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing JH, Zhou BHP, Sheng GJ. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Bio. 2020; 21(6): 341-52. Review. IF: 94.444; D1

Research projects

Cano García A. Contribution of LOXL2 and LOXL3 to tumour progression and metastasis (SAF2016-76504-R). MINECO. 2014-2020.

Managment centre: UAM

Domínguez Muñoz G. Identificación de los mecanismos implicados en la diseminación peritoneal del cáncer colorrectal. Papel de Deltanp73: implicaciones diagnósticas, pronósticas y terapéuticas (PI18/00473). ISCIII. 2019-2021.

Managment centre: FIBHULP

Moreno Bueno G (IP subgrupo FMDA); Matias-Guiu X (coordinador IDIBELL). Targeting the most aggressive type of endometrial carcinoma. (GCTRA18014MATI). AECC. 2018-2024.

Managment centre: FMDA-UAM

Moreno Bueno G. Molecular characterization of Gasdermin B cytotoxic activity and its potential application for the treatment of cancer (GB-citoTOX). (PID2019-104644RB-I00). Ministerio de Ciencia e Innovación, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2020-2023.

Managment centre: UAM

Moreno Bueno G. Targeting Gasdermin-B overexpression as a new therapeutic approach in Her2+ cancers. (AECCINVEST-2019GMB). AECC. 2019-2022.

Managment centre: UAM

Muñoz Terol A, Larriba Muñoz MJ. Estudio de los efectos de la vitamina D en la fisiología y patología del colon humano usando organoides y cultivos primarios de fibroblastos derivados de pacientes (PID2019-104867RB-I00). Ministerio de Ciencia e Innovación, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2020-2023.

Managment centre: CSIC

Muñoz Terol A. Cáncer de colon: efecto de la vitamina D sobre organoides normales y tumorales derivados de pacientes y sobre el microambiente tumoral (VitDColon) (SAF2016-76377-R). Ministerio de Economía y Competitividad, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2017-2020.

Managment centre: CSIC

Rey Cuevas E. Establecimiento de prioridades de investigación de enfermería en el Hospital Universitario La Paz. Fundación Universitaria San Pablo CEU. 2019-Ongoing.

Managment centre: FIBHULP

Rey Cuevas E. Formación para enfermería en colaboración con instituciones públicas y privadas. Universidad Europea de Valencia S. L. U. 2017-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Moreno Bueno G. Networked Biomedical Research Center for Cancer (CB16/12/00295). ISCIII. (31/12/2022)

Muñoz Terol A. Networked Biomedical Research Center for Cancer (CB16/12/00273). ISCIII. (31/12/2022)

Muñoz Terol A. Red Temática de Receptores Nucleares en Cáncer, Metabolismo e Inflamación - NuRCaMeIn (SAF2017-90604-REDT). Ministerio de Ciencia, Innovación y Universidades. (30/06/2021)

Patents and trademarks

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat deLleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.

Introduction


Executive summary

Information Groups by Area

Associated Clinicians

3.5.7 Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Publications:	14
Impact Factor:	149.[29]
Q1:	9



Carmela Calés Bourdet. Profesora Titular Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

Mónica Bravo Madrigal. Investigadora Predoctoral. Universidad Autónoma de Madrid

Miguel Ramón Campanero García. Científico Titular. IIB "Alberto Sols"

Miguel Ángel Canales Albendea. Jefe de Sección de Hematología. Hospital Universitario La Paz

Raquel de Paz Arias. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Bárbara Fernández Morales. Investigadora Predoctoral. Universidad Autónoma de Madrid

Dolores Hernández Maraver. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Ana Kerguelen Fuentes. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Yenny Montenegro Medina. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Marta Morado Arias. Técnico de Laboratorio. Hospital Universitario La Paz

Gema Pérez Chacón. Investigadora Postdoctoral. IIB "Alberto Sols"

Juan Manuel Zapata Hernández. Científico Titular. IIB "Alberto Sols"

Strategic Objective

Proper homeostasis of stem cells and pluripotent progenitor is pivotal to the development of haematopoietic proliferative disorders such as myelodysplastic or myeloproliferative syndromes, leukaemia and lymphoma. It is well known that alterations in transcriptional programs lead to transformed phenotypes, which are at the basis of the insidious acquisition of stem-like phenotypes of immature cells. Our group is interested in the role of transcriptional regulators, global regulators such as c-myc, c-myb, E2F and epigenetic controllers such as PcG factors in limiting the self-renewal capacity of common myeloid and lymphoid progenitors.

Our group has two main activities: basic research aimed to unravel the molecular mechanisms responsable for the acquisition of malignant haematological phenotypes (mouse models as well as ex vivo cell models to approach the questions outlined above); and research aimed to document clinical parameters and molecular markers that may be of use to a better understanding of the progression and outcome of haematological diseases, mainly myelodysplasia, lymphoma and multiple myeloma.

Research lines

- Role of epigenetic and transcriptional regulators in myelodysplasia: cellular and animal models
- Molecular and cellular basis of lymphoid neoplasias: non Hodgkin lymphomas and chronic lymphocytic leukaemia.
- Molecular markers of haematological malignancies

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research Activity

Publications

- Bueno JL, Alegre A, López-Villar O, Querol S, Arroyo JL, Goterris R, Sureda A, García-Gala JM, Amunarriz C, Albo C, Fernández-Fuertes F, Medina L, Antelo ML, Blanquer M, Vallejo C, Canales M, Vidales-Mancha I, Duarte RF. Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document. Bone Marrow Transpl. 2020; 55(4): 811-7. Article. IF: 5.483; Q1
- de la Cruz-Benito B, Lazaro-del Campo P, Ramírez-López A, de Soto-Álvarez T, Sánchez-Vadillo I, García-Pérez E, Dos Santos-Ortas A, Humala-Barbier K, López-de la Guía A, Casado-Abad G, Jiménez-Yuste V, Canales-Albendea M. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Brit J Haematol. 2020; 191(3): 386-9. Article. IF: 6.998; Q1
- del Campo PL, Arias RD, López AR, Benito BD, Barbier KH, Vadillo IS, de la Guía AL, Álvarez TD, Yuste VJ, Albendea MC. No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19. Transfus Apher Sci. 2020; 59(6): 102921. Article. IF: 1.764; Q4
- Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cebrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, Zapata JM. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. J Hematol Oncol. 2020; 13(1): 32. Article. IF: 17.388; D1
- Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernández-Rodríguez C, Luno E, Hernández CG, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boque C, García-Gutiérrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de los Reyes-García AM, Besses C, Vicente V, Álvarez-Larrán A, Teruel-Montoya R, González-Conejero R, Martínez C. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia. 2020; 34(10): 2648-59. Article. IF: 11.528; D1
- García-Suárez J, de la Cruz J, Cedillo A, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JA, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colas-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Alaez-Uson MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Díez-Martín JL, Martínez-López J. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020; 13(1): 133. Article. IF: 17.388; D1
- Hernández-Maraver D, Viejo A, Kerguelen AE, Jiménez-Yuste V. Transfusion medicine during COVID-19 outbreak in the hotspot of Spain. Transfusion. 2020; 60(11): 2767-9. Letter. IF: 3.157; Q3
- Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma XW, Corona K, Saint-Martín JR, Chang H, Landesman Y, Joshi A, Wang HW, Shah J, Shacham S, Kauffman M, Van den Neste E, Canales MA. Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial. Lancet Haematol. 2020; 7(7): E509-22. Article. IF: 18.959; D1
- López-Sendón J, Álvarez-Ortega C, Auñón PZ, Soto AB, Lyon AR, Farmakis D, Cardinale D, Albendea MC, Batlle JF, Rodríguez IR, Fraga OR, Albaladejo A, Mediavilla G, González-Juanatey JR, Monzonis AM, Prieto PG, González-Costello J, Antolín JMS, Chamorro RC, Fernández TL. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020; 41(18): 1720-9. Article. IF: 29.983; D1
- Maia C, Puig N, Cedena MT, Goicoechea I, Valdes-Mas R, Vázquez I, Chillon MC, Aguirre P, Sarvide S, Gracia-Aznarez FJ, Alkorta G, Calasanz MJ, García-Sanz R, González M, Gutiérrez NC, Martínez-López J, Pérez JJ, Merino J, Moreno C, Burgos L, Alignani D, Botta C, Prosper F, Mataraz S, Orfao A, Oriol A, Teruel AI, de Paz RD, de Arriba F, Hernández MT, Palomera L, Martínez R, Rosinol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel JF, Paiva B. Biological and clinical signi fi cance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood. 2020; 135(26): 2375-87. Article. IF: 22.113; D1
- Oarbeascoa G, Lozano ML, Guerra LM, Amunarriz C, Saavedra CA, García-Gala JM, Viejo A, Revilla N, Fleitas CA, Arroyo JL, Revuelta EM, Galego A, Hernández-Maraver D, Kwon M, Díez-Martín JL, Pascual C. Retrospective multicenter study of extracorporeal photopheresis in steroid-refractory acute and chronic graft-versus-host disease. Biol Blood Marrow Tr. 2020; 26(4): 651-8. Article. IF: 5.742; Q1
- Pastor-Galán I, Hernández-Boluda JC, Correa JG, Álvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Vélez P, Pérez-Encinas M, Estrada N, García-Gutierrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Duran MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. Med Clin-Barcelona. 2020; 155(4): 152-8. Article. IF: 1.725; Q3
- Ramos-Tomillero I, Pérez-Chacón G, Somovilla-Crespo B, Sánchez-Madrid F, Cuevas C, Zapata JM, Domínguez JM, Rodríguez H, Albericio F. From ugi multicomponent reaction to linkers for bioconjugation. ACS Omega. 2020;5 (13): 7424-31. Article. IF: 3.512; Q2
- Sánchez JMH, Lumbreras E, Díez-Campelo M, González T, López DA, Abaigar M, del Rey M, Martín AA, de Paz R, Erquiaga S, Arrizabalaga B, Hernández-Rivas JM, Vicente AER. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. Pharmacogenomics J. 2020; 20(5): 664-71. Article. IF: 3.55; Q2

Research projects

Canales Albendea MA. Preceptorship. Derribando fronteras en el manejo de los procesos linfoproliferativos indolentes. Dendrita Health Marketing S. A. 2020-Ongoing.

Managment centre: FIBHULP

Canales Albendea MA. Programa para la investigación en neoplasias linfoides. Astellas Pharma S. A. 2008-Ongoing.

Managment centre: FIBHULP

Clinical trials

Canales Albendea, MA. Estudio adaptativo de biomarcadores de fase IB/III, doble ciego, aleatorizado, controlado con principio activo, en 3 etapas de tazemetostat o placebo en combinación con lenalidomida más rituximab en pacientes con linfoma folicular recidivante/resistente al tratamiento.

Type: EECC, phase I.
HULP code: 5671.
Sponsored´s protocol code: EZH-302.
Sponsored by: Epizyme Inc.
Signed date: 16/12/2020

Canales Albendea, MA. Estudio de fase III

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

randomizado, doble ciego y controlado con placebo, de itacitinib o placebo en combinación con corticosteroides para el tratamiento de primera línea de la enfermedad de injerto contra huésped en fase aguda.

Type: EECC, phase III.
HULP code: Appendix 1 4872.
Sponsored´s protocol code: INCB 39110-301.
Sponsored by: Incyte Corporation.
Signed date: 27/03/2020

Canales Albendea, MA. Estudio de fase III, abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de glofitamab combinado con gemcitabina más oxaliplatino en comparación con rituximab combinado con gemcitabina y oxaliplatino en pacientes con linfoma difuso de células B grandes en recaída/resistente.

Type: EECC, phase III.
HULP code: 5628.
Sponsored´s protocol code: G041944.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/09/2020

Canales Albendea, MA. Estudio en fase II/III multicéntrico y aleatorizado de rituximab-gemcitabina-dexametasona-platino con o sin selinexor, en pacientes con linfoma difuso de células B grandes recidivante/resistente.

Type: EECC, phase II.
HULP code: 5601.
Sponsored´s protocol code: XPORT-DLB-CL-030.
Sponsored by: Karyopharm Therapeutics Inc.
Signed date: 22/09/2020

Canales Albendea, MA. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo de acalabrutinib en combinación con rituximab, ciclofosfamida, doxorrubicina, vincristina y prednisona (R-CHOP) en pacientes ≤65 años con linfoma difuso de células B grandes sin centro germinal no tratado previamente.

Type: EECC, phase III.
HULP code: 5675.
Sponsored´s protocol code: ACE-LY-312.
Sponsored by: Acerta Pharma B.V.
Signed date: 29/10/2020

De Paz Arias, R. Estudio para evaluar imetelstat (GRN163l) en sujetos con síndrome mielodisplásico de riesgo ipss bajo o intermedio-1 recurrente/refractario al tratamiento con agentes estimuladores de la eritropoyesis, dependientes de las transfusiones.

Type: EECC, phase III.
HULP code: 4500.
Sponsored´s protocol code: 63935937MDS3001.
Sponsored by: Geron Corporation.
Signed date: 03/02/2020

Morado Arias, Marta. Estudio de extensión, abierto, multicéntrico de AG -348 en sujetos adultos con deficiencia de piruvato cinasa incluidos previamente en estudios con AG-348.

Type: EECC, phase III.
HULP code: Appendix 1 5237.
Sponsored´s protocol code: AG348-C-011.
Sponsored by: Agios Pharmaceuticals Inc.
Signed date: 13/01/2020

Morado Arias, Marta. Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de crovalimab frente a eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna no tratada previamente con inhibidores del complemento.

Type: EECC, phase III.
HULP code: 5707.
Sponsored´s protocol code: BO42162.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 29/12/2020

Patents and trademarks

Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees. Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees. Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.8 Research and Diagnosis of Inherited Metabolic Diseases Group

Publications:	12
Impact Factor:	53.736
Q1:	5



María Belén Pérez González. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

Patricia Alcaide Alonso. Investigadora Postdoctoral. CEDEM

Margarita Castro Reguera. Investigadora Predoctoral. CEDEM

Magdalena de Ugarte Pérez. Directora del CEDEM. CEDEM

Isaac Ferrer López. Técnico de Laboratorio. CEDEM

María Alejandra Gámez Abascal. Investigadora Senior (Contrato Ramón y Cajal). CBM "Severo Ochoa"

Fernando García Muñoz. Técnico de Laboratorio. CEDEM

Ana Jorge Finnigan. Investigadora Postdoctoral. CBM "Severo Ochoa"

Fátima Leal Pérez. Técnico de Laboratorio. CIBERER

Rosa María Navarrete López de Soria. Técnico de Laboratorio. CIBERER

Eva María Richard Rodríguez. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

Pedro Ruiz Sala. Investigador Postdoctoral. CEDEM

María Pilar Rodríguez Pombo. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

María Lourdes Ruiz Desviat. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

María Paloma Sanz Rebollo. Técnico de Laboratorio. CEDEM

Strategic Objective

- Development of genomic and metabolomic techniques aimed at improving the diagnosis of hereditary metabolic diseases.
- Study of mitochondrial dysfunction and oxidative stress as a modifier of the clinical phenotype and as a potential therapeutic target in organic acidurias.
- Development of novel therapeutic strategies: antisense therapy and pharmacological chaperone.
- Development of animal and cellular models.
- Registry of patients with hereditary metabolic diseases.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Improved diagnosis of congenital defects of glycosylation and mitochondrial defects through the application of genomic techniques (RNAseq and DNAseq of exoma and genome) and metabolomics.
- Identification of deep intronic mutations in metabolic disorders gene by transcriptional analysis. Functional validation in cellular splicing systems.
- Development of antisense therapy and pharmacological chaperones as therapeutic approaches transverse and applicable to numerous EMH.
- Evaluation of drugs aimed at the recovery of mitochondrial function and biogénesis.
- Study of oxidative stress and evaluation of common signatures of neuropathogenicity and cardiotoxicity in congenital defects of glycosylation, organic acidemias and mitochondrial diseases.
- Search for biomarkers as predictors of severity and as systems for the evaluation of pharmacological therapies.
- Characterization of pathophysiology in a murine model of propionic acidemia.
- Identification of dysregulated miRNA in propionic acidemia and characterization of its association with pathology and its usefulness as biomarkers.
- Generation of iPS from patient-derived fibroblast with organic acidemia and congenital defects of glycosylation. Differentiation to hepatocytes, neural progenitors or cardiomyocytes.

Research Activity

Doctoral theses

Alonso Barroso E. Estudios fisiopatológicos para la búsqueda de nuevas dianas terapéuticas en acidemia propiónica mediante la caracterización del modelo murino y el desarrollo de nuevos modelos celulares humanos basados en iPSCs[dissertation]. Madrid: UAM: 2020(29/10/2020).

Directors: Ruiz Desviat ML, Richard Rodríguez EM.

Fulgencio Covián A. Investigación traslacional en las cardiomiopatías asociadas a la acidemia propióninca[dissertation]. Madrid: UAM: 2020(04/12/2020).

Directors: Ruiz Desviat ML, Richard Rodríguez EM.

Briso-Montiano Pastrana A. Desarrollo de modelos para la evaluación de terapias con chaperonas farmacológicas en aciduria metilmalónica y deficiencia en fosfomanomutasa[dissertation]. Madrid: UAM: 2020(23/07/2020).

Director: Pérez González MB.

Publications

- Park KC, Krywawych S, Richard E, Desviat LR, Swietach P. Cardiac complications of propionic and other inherited organic acidemias. Front Cardiovasc Med. 2020; 7: 617451. Review. IF: 6.05; Q1
- Fulgencio-Covián A, Álvarez M, Pepers BA, López-Márquez A, Ugarte M, Pérez B, van Roon-Mom WMC, Desviat LR, Richard E. Generation of a gene-corrected human isogenic line (UA-MiO06-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology. Stem Cell Res. 2020; 49: 102055. Article. IF: 2.02; Q4
- Gámez A, Serrano M, Gallego D, Vilas A, Pérez B. New and potential strategies for the treatment of PMM2-CDG. Bba-Gen Subjects. 2020; 1864(11): 129686. Article. IF: 3.77; Q2
- Yahyaoui R, Blasco-Alonso J, Gonzalo-Marín M, Benito C, Serrano-Nieto J, González-Gallego I, Ruiz-Sala P, Pérez B, González-Lamuno D. Metabolic serendipities of expanded newborn screening. Genes (Basel). 2020; 11(9): 1018. Article. IF: 4.096; Q2
- Correa-Vela M, Lupo V, Montpeyo M, Sancho P, Marce-Grau A, Hernández-Vara J, Darling A, Jenkins A, Fernández-Rodríguez S, Tello C, Ramírez-Jiménez L, Pérez B, Sánchez-Montáñez A, Macaya A, Sobrido MJ, Martínez-Vicente M, Pérez-Dueñas B, Espinos C. Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect. Ann Clin Transl Neurol. 2020; 7(8): 1436-42. Article. IF: 4.511; Q2
- Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, Chiesa AE, Christodoulou J, Dordevic M, Desviat LR, Eliyahu A, Evers RAF, Fajkusova L, Feillet F, Bonfim-Freitas PE, Gizewska M, Gundorova P, Karall D, Kneller K, Kutsev SI, Leuzzi V, Levy HL, Lichter-Konecki U, Muntau AC, Namour F, Oltarzewski M, Paras A, Pérez B, Polak E, Polyakov AV, Porta F, Rohrbach M, Scholl-Burgi S, Specola N, Stojiljkovic M, Shen N, Santana-da Silva LC, Skouma A, van Spronsen F, Stoppioni V, Thony B, Trefz FK, Vockley J, Yu YG, Zschocke J, Hoffmann GF, Garbade SF, Blau N. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet. 2020; 107(2): 234-50. Article. IF: 11.025; D1
- Stanescu S, Belanger-Quintana A, Martín CA, Silvestre CPC, Cortes BM, Pérez BG, García-Abril CF, Blanco FA, Valverde EP, Casanova MMP. Beneficial effect of N-carbamylglutamate in a neonatal form of multiple Acyl-CoA dehydrogenase deficiency. Case Rep Pediatr. 2020: 1370293. Article. Not Indexed
- Vilas A, Yuste-Checa P, Gallego D, Desviat LR, Ugarte M, Pérez-Cerda C, Gamez A, Pérez B. Proteostasis regulators as potential rescuers of PMM2 activity. Bba-Mol Basis Dis. 2020;b1866(7):b165777. Article. IF: 5.187; Q1
- Gallego D, Leal F, Gámez A, Castro M, Navarrete R, Sánchez-Lijarcio O, Vitoria I, Bueno-Delgado M, Belanger-Quintana A, Morais A, Pedrón-Giner C, García I, Campistol J, Artuch R, Alcaide C, Cornejo V, Gil D, Yahyaoui R, Desviat LR, Ugarte M, Martinez A, Pérez B. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. Hum Mutat. 2020; 41(7): 1329-38. Article. IF: 4.878; Q2
- Fulgencio-Covián A, Alonso-Barroso E, Guenzel AJ, Rivera-Barahona A, Ugarte M, Pérez B, Barry MA, Pérez-Cerda C, Richard E, Desviat LR. Pathogenic implications of dysregulated miRNAs in propionic acidemia related cardiomyopathy. Transl Res. 2020; 218: 43-56. Article. IF: 7.012; D1
- Tamayo M, Fulgencio-Covián A, Navarro-García JA, Val-Blasco A, Ruiz-Hurtado G, Gil-Fernández M, Martín-Nunes L, López JA, Desviat LR, Delgado C, Richard E, Fernández-Velasco M. Intracellular calcium mishandling leads to cardiac dysfunction and ventricular arrhythmias in a mouse

Introduction

Executive summary

Information Groups by Area

Associated Clinicians



model of propionic acidemia. Bba-Mol Basis Dis. 2020; 1866(1): 165586. Article. IF: 5.187; Q1

- Vaes L, Tiller GE, Pérez B, Boyer SW, Berry SA, Sarafoglou K, Morava E. PMM2-CDG caused by uniparental disomy: Case report and literature review. Jimd Rep. 2020; 54(1): 16-21. Article. Not Indexed

Research projects

Pérez González MB. Bases moleculares de las enfermedades neurometabólicas y desarrollo de terapias específicas de mutación. Fundación Isabel Gemio. 2016-2021.

Managment centre: Fundación Severo Ochoa

Pérez González MB. Desarrollo de terapias con chaperonas farmacológicas para el defecto congénito de glicosilación PMM2-CDG. (ER18TRL746). Ciberer-ISCIII. 2018-2020.

Managment centre: CIBERer

Pérez González MB. Enfoque cross-ómico para el descubrimiento de la base genética de errores innatos del metabolismo y para una intervención terapéutica personalizada (PI19/01155). ISCIII. 2020-2022.

Managment centre: UAM

Pérez González MB. GenNatal, un proyecto piloto sobre secuenciación genómica en medicina neonatal y salud pública. Fundacion Ramón Areces. 2019-2020.

Managment centre: CEDEM

Pérez González MB. Raregenomicscm (B2017/BMD3721). CAM. 2018-2021.

Managment centre: UAM

Richard Rodríguez EM. Acidemia propiónica: impacto en el epigenoma y el proteoma en relación con el fenotipo cardiaco y neurológico (). Fundacion Ramón Areces. 2021-2023.

Managment centre: Fundación Severo Ochoa

Richard Rodríguez EM. Cardiomyocytes derived from induced pluripotent stem cells as a new model for therapy development in propionic acidemia. Fundación americana de acidemia propiónica. 2019-2020.

Managment centre: Fundación Severo Ochoa

Ruiz Desviat LM. Delivery of RNA therapy. European cooperation in Science and Technology (COST) (Action CA17103). EU. 2018-2022.

Managment centre: UAM

Ruiz Desviat LM. Mecanismos responsables del fenotipo patológico en enfermedades neurometabólicas raras y aproximaciones terapéuticas personalizadas (PID2019-105344RB-100). MICINN. 2020-2022.

Managment centre: UAM

Cibers and Retics

Pérez González MB. Centro de Investigación en Red de Enfermedades Raras (CB06/07/0004). ISCIII. (31/12/2020)

Patents and trademarks

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5; 2016.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.9 Regulation of Ciliary Structure and Function by Phosphoinositides Group

Publications:	2
Impact Factor:	10.691
Q1:	2



Francesc García Gonzalo. Investigador Ramón y Cajal. Universidad Autónoma de Madrid

Pablo Barbeito González. Investigador Postdoctoral. Universidad Autónoma de Madrid

Raquel Martín Morales. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Belén Sierra Rodero. Investigadora Predoctoral. Universidad Autónoma de Madrid

Strategic Objective

Cilia play important roles in human health and disease. Our goal is to better understand cilia structure and function, and how they can be manipulated to promote human health.

But what are cilia and why are they important for our health? Cilia are cell membrane protrusions with an endoskeleton consisting of nine microtubule doublets. This basic architecture, shared by both cilia and flagella, is conserved from unicellular organisms to humans. There are two kinds of cilia: motile and immotile (a.k.a. primary). Motile cilia resemble oars, displacingextracellular fluids. This is how we expel mucus from our bronchi and how sperm swim. Instead, primary cilia behave like antennae, detecting optical, mechanical or chemical signals. Our vision, hearing and smell depend on immotile cilia. Primary cilia also monitor urine flow in the kidney, act as sensors forhunger-controlling hormones in the brain, and control limb and nervous system patterning in the embryo, among many other functions.

Congenital ciliary defects cause ciliopathies, genetically and clinically diverse illnesses whose most common symptoms include mental retardation, retinal degeneration, kidney cysts, polydactyly, obesity, sterility, respiratory infections, and skeletal, heart and brain malformations. Many ciliopathies are rare syndromes (Meckel, Joubert, Bardet-Biedl, Kartagener, etc.), whereas others are more common and affect a single organ (polycystic kidney disease, retinitis pigmentosa).

Ciliopathies are not the only diseases cilia are involved in. Several cancer types, like medulloblastoma and basal cell carcinoma, arise from abnormal activation of Hedgehog signaling, a ciliary pathway essential for embryonic development and adult stem cell function. On the other hand, increasing evidence suggests that cilia modulate the progression of other diseases, such as diabetes and Alzheimer's. Given that ciliary function is critically dependent on their composition, our main strategy consists in understanding the molecular mechanisms underlying: (1) ciliary accumulation of the receptors and transducers that sensitize cilia to external stimuli, and (2) the changes in cilia composition whereby ciliary signals are relayed to the rest of the cell.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Ciliary targeting of G protein-coupled receptors (GPCRs)
- Ciliary targeting of INPP5E, a ciliopathy-associated phosphoinositide phosphatase
- Regulation of ciliary ectocytosis and disassembly by INPP5E
- Roles of B9 ciliopathy proteins at the ciliary transition zone
- Cell-based assays to test the effects of ciliopathy mutations
- Regulation of ciliogenesis and Hedgehog signaling by the transcription factor NRF2



Research Activity

Publications

- Montes-Fernández MA, Pérez-Villegas EM, García-Gonzalo FR, Pedrazza L, Rosa JL, de Toledo GA, Armengol JA. The HERC1 ubiquitin ligase regulates presynaptic membrane dynamics of central synapses. Sci Rep. 2020; 10(1): 12057. Article. IF: 4.379; Q1
- Martín-Hurtado A, Lastres-Becker I, Cuadrado A, García-Gonzalo FR. NRF2 and primary cilia: An emerging partnership. Antioxidants. 2020; 9(6): 475. Review. IF: 6.312; D1

Research projects

García Gonzalo F. Regulación de la estructura y función ciliares por fosfoinosítidos (SAF2015-66568-R). MINECO. 2016-2020.

Managment centre: UAM

García Gonzalo F. Sintonizando la antena celular: Control de la composición de cilios primarios (PID2019-104941RB-I00). MICINN. 2020-2024.

Managment centre: UAM

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.5.10 Dyslipidemias of Genetic Origin and Metabolic Diseases Group*

Sonia María Rodriguez Novoa. Facultativo Especialista de Área. Responsable del Laboratorio de Genética de Enfermedades Metabólicas. Hospital Universitario La Paz

Álvaro del Monte Vergara. Investigador Predoctoral. Hospital Universitario La Paz

Amanda Herranz Cecilia. Investigadora Predoctoral. Hospital Universitario La Paz

Ana Carazo Álvarez. Técnico de Laboratorio. Hospital Universitario La Paz

Carmen Rodríguez Jiménez. Especialista en Bioquímica Clínica. Hospital Universitario La Paz

Elena Sevilla Alonso. Investigadora Predoctoral. Hospital Universitario La Paz

Javier Sanguino Otero. Investigador Posdoctoral. Hospital Universitario La Paz



Strategic Objective

Our research is especially focused on the molecular diagnosis of dyslipidemias of genetic origin. Among dyslipidemias, Familial Hypercholesterolemia (FH) stands out for its impact on health. FH is an important risk factor in the development of early cardiovascular disease. Patients with pathogenic variants in the main genes involved in FH (LDLR, APOB, PCSK9, and LDLRAP1) are at high risk of premature coronary disease. The autosomal dominat hipercolesterolemia is caused by pathogenic variants at LDLR, APOB or PCSK9 genes. Patients with FH have a 50% of having a child with the condition. In this context, early detection of genetic alterations in patient´s relatives is essential in order to stablish an early treatment. Genetic studies of the family have proven to be cost-effective. The massively parallel sequencing technology (NGS) provide an useful tool to carry out this type of studies. However, it is important not only the detection of new variants but the characterization of them to determine their impact or pathogenicity. For this purpose, our research group has developed and validated functional in vitro studies for the characterization of genetic variants in the main genes associated with FH.

An important percentage of patients with hypercholesterolemia do not present pathogenic variants in the most frequent genes. Our group has a line of research focused on the search for new candidate genes and epigenetic causes related with altered lipid metabolism. We have developed in vitro studies to determine the impact of microRNAs on the expression of LDLR and PCSK9.

In addition to FH, we also study other genetic dyslipidemias such as familial hypertriglyceridemia and other "rare" dyslipidemias that are often not diagnosed with the usual diagnostic tools.

Research lines

- Molecular diagnosis of familial hypercholesterolemia by massive sequencing of a panel of genes. Study of the exome to detect new candidate genes.
- Functional studies of genetic variants in LDLR, PCSK9 and APOB in cellular model.
- Study of microRNAs as modulators of cholesterol regulation and their impact on familial hypercholesterolemia.
- Molecular diagnosis of hypertriglyceridemia and other "rare" dyslipidemia.
- Genetic diagnosis of metabolic diseases.


* Group recently created, december 2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.6 Surgery, Transplant and Health Technologies Area

Nuria Vilaboa Díaz

Documents:	196	IF:	651.461
Originals:	139	IF:	460.849
D1:	21	Q1:	62



3.6.1 Bone Pathophysiology and Biomaterials Group

3.6.2 Cellular Engineering Group

3.6.3 Clinical Pharmacology Group


3.6.4 Osteoarticular Surgery Research – GICOA Group

3.6.5 Research in Oral and Maxillofacial Surgery Group

3.6.6 Patients Safety and Quality Research

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

3.6 Surgery, Transplant and Health Technologies Area



Strategic Objectives	Development forecast for the coming years	Actions
Surgery, Transplant and Health Technologies Area is composed of 10 very heterogeneous groups and the absence of common activities between them make the general objectives equivalent to the sum of the research lines of each of the groups. The main objective of the area is to locate points where synergies between groups can be established.	Cellular and organ engineering, underdeveloped.	**Support researchers to continue being a reference in the national area.** **Identify and promote at international level the new research lines identifying as innovative and competitive.**
	Stem and precursor cells. This is one of the most successful lines and the one that has motivated more collaborations between them. It is certainly one of the possibilities for the future.	
	Animal models. Cellular models. They require personnel trained in cell culture techniques and who masters animal models of human disease.	
	Minimally invasive surgery: one of the most important translational fields in recent years, a permanent demand from the population and an indicator of the quality of healthcare systems.	

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.6.1 Bone Pathophysiology and Biomaterials Group

Publications:	6
Impact Factor:	40.^{556}
Q1:	4



Nuria Elda Vilaboa Díaz. Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP

Fátima Bensiamar Hadia. Técnico de Laboratorio. FIBHULP

Clara Escudero Duch. Investigadora Postdoctoral. FIBHULP

Eduardo García Cimbrelo. Doctor Emérito. Hospital Universitario La Paz. Universidad Autónoma de Madrid

Marcos de Mesa Cáceres. Ténico de Laboratorio. FIBHULP

Mabel Falguera Uceda. Investigadora Predoctoral. Hospital Universitario La Paz

Enrique Gil Garay. Jefe de Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Titular. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid

Miguel Ángel Lerma Juárez. Investigador Predoctoral. FIBHULP

Leila Maestro Paramio. Investigadora Predoctoral. FIBHULP

Carmen Martin Hervás. Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Alonso Carlos Moreno García. Facultativo Especialista de Área en Cirugía Orotopédica y Traumatología. Hospital Universitario La Paz

Laura Saldaña Quero. Investigadora Senior (Contrato Miguel Servet-Tipo I). Jefe de Laboratorio. FIBHULP

Silvia Sánchez Casanova. Investigador Predoctoral. FIBHULP

Gema Vallés Pérez. Investigadora Senior. Responsables de Cultivos Celulares y de los Laboratorios Comunes de IdiPAZ. FIBHULP

Strategic Objective

The Bone Physiopathology and Biomaterials group includes basic and clinical researchers from IdiPAZ. The group has broad experience in clinical and basic research on biomaterials for orthopaedic implants and bone tissue engineering. The principal goal of the group is to improve the clinical outcome of orthopaedic surgery through research on implants and biomaterials used for manufacturing prosthetic device.

The group is also interested in bone tissue engineering applications, developing surgical procedures that make use of allotransplants, evaluating scaffolds manufactured by collaborative partners, developing novel gene therapy strategies aimed to heal bone defects and studying the interactions of the immune and skeletal systems. Specific areas of clinical research on implants include follow-up studies on various devices in use for osteoarticular surgery.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

The main areas of interest in basic research on the biocompatibility of materials include:

a) understanding the influence of the surface biomaterial properties on the behaviour of bone-related cells

b) the study of cell reactions occurring in the vicinity of implanted materials caused by wear particles

c) the deliberate manipulation of cell responses after exposure to nanoparticles designed for gene delivery and optical hyperthermia applications.

The team is also interested in the development of transcriptional targeting strategies to ensure tight control of the expression of therapeutic proteins and their potential application in inducing an orchestrated expression of growth factors involved in bone healing.

Research lines

- Clinical research in implants for bone repair
- Biocompatibility of new materials for potential use in implants for bone repair: cell and surface interactions, cell and particle interactions
- Study of the interactions between the immune and skeletal systems
- Control of the expression of therapeutic genes using gene circuits
- Study of the physiopathology of bone diseases

Research Activity

Publications

- Escudero-Duch C, Vilaboa N. Recent efforts in the development of nanomaterials to control transgene expression. Nanomedicine. 2020; 15(21): 2019-22. Editorial Material. IF: 5.307; Q1
- García-Rey E, Sirianni R, García-Cimbrelo E, Sedel L. Total hip arthroplasty after acetabular fracture: does initial treatment make any difference to the outcome? A 5-to 23-year follow-up with clinical and radiological analysis. Hip Int. 2020; 30(3): 339-46. Article. IF: 2.135; Q3
- Nakal-Chidiac A, García O, García-Fernandez L, Martín-Saavedra FM, Sánchez-Casanova S, Escudero-Duch C, San Román J, Vilaboa N, Aguilar MR. Chitosan-stabilized silver nanoclusters with luminescent, photothermal and antibacterial properties. Carbohydr Polym. 2020; 250: 116973. Article. IF: 9.381; D1
- Sánchez-Casanova S, Martín-Saavedra FM, Escudero-Duch C, Uceda MIF, Prieto M, Arruebo M, Acebo P, Fabiilli ML, Franceschi RT, Vilaboa N. Local delivery of bone morphogenetic protein-2 from near infrared-responsive hydrogels for bone tissue regeneration. Biomaterials. 2020; 241: 119909. Article. IF: 12.479; D1
- Vallés G, Bensiamar F, Maestro-Paramio L, García-Rey E, Vilaboa N, Saldaña L. Influence of inflammatory conditions provided by macrophages on osteogenic ability of mesenchymal stem cells. Stem Cell Res Ther. 2020; 11(1): 57. Article. IF: 6.832; Q1
- Voellmy R, Bloom DC, Vilaboa N. Herpes simplex viruses whose replication can be deliberately controlled as candidate vaccines. Vaccines. 2020; 8(2): 230. Review. IF: 4.422; Q2

Research projects

Lerma Juárez MA. Contrato predoctoral (PRE2019-090430). MICIU. 2020-2024.

Managment centre: FIBHULP

Saldaña Quero L. Contrato predoctoral (PEJD-2018-PRE/BMD-7965). CM. 2019-2020.

Managment centre: FIBHULP

Saldaña Quero L. Identificación de factores moleculares implicados en la osteonecrosis idiopática: análisis del transcriptoma del tejido óseo (PI18/00643). ISCIII. 2019-2021.

Managment centre: FIBHULP

Saldaña Quero L. Preacondicionamiento inflamatorio de células madre mesenquimales para su aplicación en terapias avanzadas de regeneración ósea mediante ingeniería de tejidos (PI15/00752). ISCIII. 2016-2020.

Managment centre: FIBHULP

Vilaboa Díaz NE, Saldaña Quero L. Desarrollo de fluidos que potencien o favorezcan la osteointegración de los implantes ante distintas situaciones. Mozo-Grau S. A. 2017-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE, Saldaña Quero L. Ensayos de biocompatibilidad in vitro de Peek reforzado para prótesis de cadera. Universidad de Zaragoza. 2020-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE, Saldaña Quero L. Ensayos in vitro de un recubrimiento osteoinductor (HA) en vástagos femorales anatómicos. Universidad de Zaragoza. 2020-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE. Bone substitutes based on hydrogels responsive to near infrared light for the generation of therapeutic hyperthermia generation of therapeutic hyperthermia (NIRHYD). CIBER-BBN. 2018-2021.

Managment centre: CIBER-BBN

Vilaboa Díaz NE. Contrato Miguel Servet Categoria A (CES07/031). CM. 2007-2025.

Managment centre: FIBHULP

Vilaboa Díaz NE. Detección de activación de HSF parte II-XIV. HSF Pharmaceuticals. 2004-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE. Hidrogeles que responden a energía infrarroja y contienen adenovirus de alta capacidad. Aplicación en regeneración ósea (RTI2018-095159-B-I00). MICIU. 2019-2021.

Managment centre: FIBHULP

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Cibers and Retics

Vilaboa Díaz NE. Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine (CIBER-bbn). ISCIII (31/12/2021)

Patents and trademarks

Fabilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 62/495,501; 2016 September 16.

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees. Compounds that induce protein unfolding and a mitigated response thereto, and methods of use thereof. US 62/764,569. 2018 August 08

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees.Inhibitors of heat shock factors and uses thereof. US62/499,650. 2017 Febrary 17



Introduction


Executive summary

Information Groups by Area

Associated Clinicians

3.6.2 Cellular Engineering Group

Publications:	9
Impact Factor:	33.^{567}
Q1:	3



María Paz de Miguel González.
Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

María Pilar González-Peramato Gutiérrez.
Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Adrián Moratilla Riofrío. Investigador Predoctoral. Hospital Univerisitario Ramón y Cajal

Manuel Nistal Martín de Serrano.
Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. Universidad Autónoma de Madrid

Javier Francisco Regadera González.
Catedrático. Departamento de Histología y Neurociencia. Facultad de Medicina. Universidad Autónoma de Madrid

José Carlos Martínez Ávila. Investigador Postdoctoral. FIBHULP

Strategic Objective

To ascertain the mechanisms responsible for converting a differentiated cell into a pluripotent cell and at the same time how these establish a relationship between cellular reprogramming and oncogenic transformation, in order to use divergent pathways governing these processes as clinical early diagnostic tools and therapeutic targetsfor clinical intervention.

To develop new cell therapy approaches in diverse organs transplants.

Research lines

- Molecular mechanisms of cellular reprogramming in normal and neoplastic environments.
- New techniques and therapies in transplants.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research Activity

Publications

- Aguirre LA, Montalbán-Hernandez K, Avendaño-Ortiz J, Marín E, Lozano R, Toledano V, Sánchez-Maroto L, Terrón V, Valentín J, Pulido E, Casalvilla JC, Rubio C, Diekhorst L, Laso-García F, del Fresno C, Collazo-Lorduy A, Jiménez-Munárriz B, Gómez-Campelo P, Llanos-González E, Fernández-Velasco M, Rodríguez-Antolín C, de Diego RP, Cantero-Cid R, Hernández-Jiménez E, Álvarez E, Rosas R, López-Ayllon BD, de Castro J, Wculek SK, Cubillos-Zapata C, de Cáceres II, Díaz-Agero P, Fernández MG, de Miguel MP, Sancho D, Schulte L, Perona R, Belda-Iniesta C, Boscá L, López-Collazo E. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. Oncolmmunology. 2020; 9(1): 1773204. Article. IF: 8.11; Q1
- Barreno CP, González-Peramato P, Nistal M. Vascular and inflammatory effects of estrogen and anti-androgen therapy in the testis and epididymis of male to female transgender adults. Reprod Toxicol. 2020; 95: 37-44. Article. IF: 3.143; Q3
- Corvillo F, Nozal P, López-Lera A, de Miguel MP, Pinero-Fernández JA, de Lucas R, García-Concepcion MD, Beato MJ, Araujo-Vilar D, López-Trascasa M. Evidence of ongoing complement activation on adipose tissue from an 11-year-old girl with Barraquer-Simons syndrome. J Dermatol. 2020; 47(12): 1439-44. Article. IF: 4.005; Q2
- El Zarif M, del Barrio JLA, Arnalich-Montiel F, de Miguel MP, Makdissy N, Alio JL. Corneal stroma regeneration: New approach for the treatment of cornea disease. Asia-Pac. J Ophthalmol. 2020; 9(6): 571-9. Review. IF: 2.827; Q2
- El Zarif M, Jawad KA, del Barrio JLA, Jawad ZA, Palazon-Bru A, de Miguel MP, Saba P, Makdissy N, Alio JL. Corneal stroma cell density evolution in keratoconus corneas following the implantation of adipose mesenchymal stem cells and corneal laminas: An in vivo confocal microscopy study. Invest Ophthalmol Vis Sci. 2020; 61(4): 22. Article. IF: 4.799; Q1
- González-Peramato P. The best reviewer if the month may 2020 Pilar González Peramato. Arch Esp Urol. 2020; 73(4). Editorial Material. IF: 0.436; Q4
- Ibarra-Ramírez M, Calvo-Anguiano G, Lugo-Trampe JD, Martínez-de-Villarreal LE, Rodríguez-Torres D, Nistal M, González-Peramato P. Expression profile of microRNAs in the testes of patients with Klinefelter syndrome. Sci Rep. 2020; 10(1): 11470. Article. IF: 4.379; Q1
- Jiménez-Heffernan JA, Rodríguez-García AM, González-Peramato P, López-Ferrer P, Muñoz-Hernández P, Gordillo CH, Viguer JM, Vicandi B. Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature. Diagn Cytopathol. 2020; 48(11): 1013-20. Review. IF: 1.582; Q4
- Sánchez A, Contreras-Jurado C, Rodríguez D, Regadera J, Alemany S, Aranda A. Hematopoiesis in aged female mice devoid of thyroid hormone receptors. J Endocrinol. 2020; 244(1): 83-94. Article. IF: 4.286; Q2



Research projects

de Miguel González MP. Contrato Miguel Servet Categoria A (CP03/0007). CM. 2010-2025.

Managment centre: FIBHULP

de Miguel González MP. Contrato predoctoral (PEJD-2018-PRE/BMD-8878). CM. 2019-2021.

Managment centre: FIBHULP

de Miguel González MP. Contribución de la modificación metabólica a la reprogramación celular y la transformación oncogénica. Fundación Domingo Martínez. 2017-Ongoing.

Managment centre: FIBHULP

de Miguel González MP. Contribución de la modificación metabólica a la reprogramación celular y la transformación oncogénica. FIBHULP. 2018-Ongoing.

Managment centre: FIBHULP

de Miguel González MP. Generación de estroma corneal bio-mimético por impresión 3D de colageno y células madre mesenquimales. Stem Vision S. L. 2021-Ongoing.

Managment centre: FIBHULP

de Miguel González MP. Proveer del conocimiento técnico necesario para la implantación de láminas corneales decelularizadas y colonizadas o no con células madre mesenquimales derivadas de tejido adiposo para su uso en enfermedades corneales que involucren el estroma corneal. Optica General S. A. R. L. 2015-Ongoing.

Managment centre: FIBHULP

Patents and trademarks

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.6.3 Clinical Pharmacology Group

Publications:	23
Impact Factor:	118.[58]
Q1:	11



Jesús Frías Iniesta. Jefe de Servicio de Farmacología Clínica. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Alberto Borobia Pérez. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

Antonio Javier Carcas Sansuán. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

Irene García García. Facultativo Especialista de Área en Farmacología Clínica. Investigador Predoctoral. Hospital Universitario La Paz

Lucía Díaz García. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

María Cristina Murano. Investigador Postdoctoral. Contrato Marie Skłodowska-Curie . FIBHULP

Paloma Moraga Alapont. Investigador Predoctoral. FIBHULP

Rocío Prieto Pérez. Investigador Postdoctoral. FIBHULP

Blanca Duque Bascuñana. Responsable de Calidad. Universidad Autónoma de Madrid

Paula Prieto Pérez. Investigador Predoctoral. FIBHULP

Pablo Molina Benítez. Investigador Predoctoral. FIBHULP

Pilar Ayllón García. Técnico de Investigación. Universidad Autónoma de Madrid

Strategic Objective

Clinical pharmacology, as a scientific and professional discipline, has the objective of achieving an effective, efficacious and efficient use of drugs, at both the individual and group level. This means that Clinical Pharmacology is a cross-sectional discipline that must establish collaborations with numerous other disciplines and health professionals.

In this context and in the field of clinical research, the interests of our group are focused on two fundamental aspects:

1. Customisation of drug treatments: research and development of techniques and methods that individualise the use of drugs, improve their efficacy and reduce their risks.
2. The improvement of treatment by obtaining high quality evidence on the efficacy of clinical trials, strategies of identification, evaluation and prevention of adverse reactions to medication (pharmacovigilance programmes) and evaluation of the suitability of their use and effectiveness (studies on the use of medication).

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Research lines

- Therapeutic drug monitoring (TDM) – Development of individualised therapeutic drug monitoring programmes and pharmacogenetics.
- Getting quality evidences for the stablishment of drug efficacy, safety and adecuate use of medicines in humans

Research Activity

Publications

- Acuña-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña-Fernández C. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020; 69(3): e12683. Editorial Material. IF: 13.007; D1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Nunez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Borobia AM, Collado SG, Cardona CC, Pueyo RC, Alonso CF, Torres IP, González MC, Codesido JRC, Betegón MA, Barcela LA, Andicoechea AO, Testa AF, Colina JT, Dorribo AC, Galán CD, Ávila JCM, Lugilde ST, Sansuán AJC. Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: InMEDIATE: A randomized controlled trial in emergency departments. Ann Emerg Med. 2020; 75(3): 315-28. Article. IF: 5.721; D1
- Borobia AM, Sansuán AJC. Methoxyflurane may provide faster relief than suboptimal treatment, but not Better. Ann Emerg Med. 2020; 75(4): 551-552. Letter. IF: 5.721; D1
- Builes MM, Cuenca MV, Soler JLF, Astigarraga I, Martínez AP, Valero JMV, Tong HY, Quiroga JV, Casanova LF, López AE, Sisinni L, Blanquer M, Aguilar IM, Martínez BG, Borobia AM, Pérez-Martínez A. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020; 10(1): e029642. Article. IF: 2.692; Q2
- Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Dona I, Fernández J, García-Nunez I, García-Samaniego J, López-Rico R, Marin-Serrano E, Merida C, Moya M, Ortega-Rodríguez NR, Becerra BR, Rojas-Pérez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellon T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Invest Allergol Clin Immunol. 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Dal-Re R, Carcas AJ, Sreeharan N. The need to implement non-industry COVID-19 clinical trials in non-high-income countries. J Glob Health. 2020; 10(1): 10351. Editorial Material. IF: 4.413; Q1
- García IG, Carcas AJ, Borobia AM. Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice. Pharmacogenomics. 2020; 21(10): 647-9. Editorial Material. IF: 2.533; Q3
- García IG, Rodríguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1): 466. Letter. IF: 2.279; Q4
- González-Ramos J, Lamas C, Bellon T, Ruiz-Bravo E, Ramírez E, Lerma V, Lecumberri B. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. Indian J Dermatol Venereol Leprol. 2020; 86(5): 515-8. Article. IF: 2.545; Q3
- Jara P, Baker A, Baumann U, Borobia AM, Branchereu S, Candusso M, Carcas AJ, Chardot C, Cobas J, D'Antiga L, Ferreras C, Fitzpatrick E, Frauca E, Hernández-Oliveros F, Kalicinski P, Lindemans C, Lopes MF, López-Granados E, de Magnee C, Mota C, Muñoz JM, Ojeda JJ, Pérez-Martínez A, Perilongo G, Rascón J, Sciveres M, Stone R, Tarutis V, Toporski J, Torres JM, Wennberg L. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild. Orphanet J Rare Dis. 2020; 15(1): 16. Article. IF: 4.123; Q2
- Maseda R, Martínez-Santamaría L, Sacedón R, Butta N, de Arriba MD, García-Barcenilla S, García M, Illera N, Pérez-Conde I, Carretero M, Jiménez E, Melen G, Borobia AM, Jiménez-Yuste V, Vicente A, del Río M, de Lucas R, Escámez MJ. Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: A case report. Front Med. 2020; 7: 576558. Article. IF: 5.091; Q1
- Peña MA, Muriel J, Saiz-Rodríguez M, Borobia AM, Abad-Santos F, Frías J, Peiró AM. Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy Subjects. Clin Drug Invest. 2020; 40(7): 617-28. Article. IF: 2.859; Q3
- Prado-Velasco M, Borobia A, Carcas-Sansuán A. Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. Sci Rep. 2020; 10(1): 7542. Article. IF: 4.379; Q1
- Ramírez E, Urroz M, Rodríguez A, González-Muñoz M, Martín-Vega A, Villán Y, Seco E, Monserrat J, Frías J, Carcas AJ, Borobia AM. Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: Cautionary data. Front Pharmacol. 2020; 11: 602841. Article. IF: 5.81; Q1
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Paño-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae. Gut Pathogens. 2020; 12(1): 15. Article. IF: 4.181; Q2
- Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I, Martín-Polo L, Merino-Argos C, Rodríguez-Sotelo L, García-Veas JM, Martínez-Marín LA, Martínez-Cossiani M, Buño A, González-Valle L, Herrero

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

A, López-Sendón JL, Merino JL. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12): 2205-15. Article. IF: 15.534; D1

- Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21(1): 699. Letter. IF: 2.279; Q4
- Saborido CM, Borobia AM, Cobas J, D'Antiga L, Frauca E, Hernández-Oliveros F, Jara P, López-Granados E, Muñoz JM, Nicastro E, Ojeda JJ, Pérez-Martínez A, Torres JM, Carcas A. Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis. BMJ Open. 2020; 10(12): e037721. Review. IF: 2.692; Q2
- Saiz-Rodríguez M, Almenara S, Navares-Gómez M, Ochoa D, Román M, Zubiaur P, Koller D, Santos M, Mejia G, Borobia AM, Rodríguez-Antona C, Abad-Santos F. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020; 8(4): 94. Article. IF: 6.081; Q1
- Urbán JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martín CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutierrez RS, Santovena AZ, Hijosa MM, Camblor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frías J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? Transpl Infect Dis. 2020; 22(6): e13432. Article. IF: 2.228; Q4
- Vilchez-Sánchez F, Loli-Ausejo D, Rodríguez-Mariblanca A, Montserrat-Villatoro J, Ramírez E, Dominguez-Ortega J, González-Muñoz M. Lymphocyte transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. Allergy. 2020; 75(12): 3267-72. Letter. IF: 13.146; D1
- Villatoro JM, García IG, Bueno D, de la Cámara R, Estebánez M, de la Guía AL, Abad-Santos F, Antón C, Mejia G, Otero MJ, García ER, Iniesta JF, Carcas A, Borobia AM. Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. BMJ Open. 2020; 10(10): e037443. Article. IF: 2.692; Q2

Research projects

Borobia Pérez A. Contrato de intensificación (INT19/00055). ISCIII. 2020-2021.

Managment centre: FIBHULP

Borobia Pérez A. Coordinación del ensayo clínico Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de las estrategias antitrombóticas en adultos hospitalizados con COVID-19. New York University School of Medicine. 2020-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Corona Accelerated R&D in Europe (H2020-JTI-IMI2-2020-21-single-stage). UE. 2020-2025.

Managment centre: FIBHULP

Borobia Pérez A. Ensayo clínico aleatorizado y multicéntrico para evaluar la efectividad y la eficiencia de una estrategia de genotipado anticipado de voriconazol en pacientes con riesgo de aspergilosis (PI18/01322). ISCIII. 2019-2021.

Managment centre: FIBHULP

Borobia Pérez A. European Regimen Accelerator for Tuberculosis - ERA4TB (H2020-JTI-IMI2-2018-15). UE. 2019-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Marie Skłodowska-Curie Actions - Individual Fellow (CareInTrials). UE. 2019-2023.

Managment centre: FIBHULP

Borobia Pérez A. Puesta en marcha del estudio A randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich`s ataxia (NICOFA). ECRIN European Clínical Research Inf. 2020-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Puesta en marcha y realización del ensayo clínico. Proyecto Acanto y proyecto Facet. Fundación para la Investig Biomédica Hosopital Universitario de Getafe. 2018-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Registro de pacientes atendidos en la unidad de farmacogenética del Hospital La Paz y análisis de la actividad realizada desde su creación. Various financiers. 2017-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del ensayo clínico Treatment of high grade non-muscle invasive urothelial carcinoma of the bladder by standard number and dose of intravesical BCG instillations versus reduced number of intravesical instillations with standard dose of BCG, a european association of urology research foundation randomised phase III clínical trial- NIMBUS. Fundación para la Investigación de la Asociación Europea de Urologia. 2017-Ongoing.

Managment centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del estudio observacional Estudio de evaluación y manejo del dolor agudo en Servicios de Urgencias hospitalarias e intervención educativa: estudio Edurg17. Laboratorio Menarini S. A. 2018-Ongoing.

Managment centre: FIBHULP

Carcas Sansuán AJ. Contrato de intensificación (INT19/00082). ISCIII. 2020-2021.

Managment centre: FIBHULP

Carcas Sansuán AJ. Contrato Río Hortega (CM19/00243). ISCIII. 2019-Ongoing.

Managment centre: FIBHULP

Carcas Sansuán AJ. Identificación mediante diferentes estrategias ómicas, de biomarcadores que permitan la mejora en la individualización de tacrolimus en pacientes pediátricos con trasplante renal (PI18/00136). ISCIII. 2019-2021.

Managment centre: FIBHULP

Frías Iniesta J. Unidad clínica de Investigación y Control de Ensayos Clínicos. CM. 2011-Ongoing.

Managment centre: FIBHULP

Cibers and Retics

Frías Iniesta J. Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos (PT17/0017/0013). ISCIII. (31/12/2020)

Clinical trials

Borobia Pérez, A. Estudio fase 2a, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunacion de AD26CCOVS1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.
HULP code: 5630.
Sponsored´s protocol code: VAC-31518COV2002 VAC31518.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 08/07/2020

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Borobia Pérez, A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunacion de AD26CCOVS1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.
HULP code: Anexo 2 5630.
Sponsored´s protocol code: VAC-31518COV2001.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 31/12/2020

Borobia Pérez, A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de AD26CCOVS1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.
HULP code: Anexo 1 5630.
Sponsored´s protocol code: VAC-31518COV2002.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 20/10/2020

Borobia Pérez, A. Prevencion de enfermedad por Sars-Cov-2 (covid-19) mediante la profilaxis pre-exposición de emtricitabina / tenofovir disoproxilo e hidroxicloroquina en personal sanitario: ensayo clínico aleatorizado, controlado con placebo.

Type: EECC, phase III.
HULP code: 5576.
Sponsored´s protocol code: PREP COVID-19.
Sponsored by: Ministerio de Sanidad, Consumo y Bienestar Social.
Signed date: 03/09/2020

Borobia Pérez, A. Estudio fase I/IIA, de primera administración en humanos, aleatorizado, con observador ciego para evaluar la seguridad, reactogenicidad e inmunogenicidad de tres dosis diferentes de VAC52416 (EXPEC10V) en adultos de entre 60 y 85 años con un estado de salud estable.

Type: EECC, phase I.
HULP code: 5569.
Sponsored´s protocol code: VAC52416BAC1001.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 17/09/2020

Carcas Sansuán, AJ. Evaluación de la farmacocinética de paracetamol en pacientes pediátricos según su status ponderal evaluado mediante IMC: normopeso, sobrepeso y obesidad.

Type: EECC, phase IV.
HULP code: 5685.
Sponsored´s protocol code: PARA-OBES.
Sponsored by: Carcas Sansuán, Antonio J.
Signed date: 24/11/2020

Frías Iniesta, J. Multi-centre, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28 days in continuous regimen, versus desogestrel (Cerazet®).

Type: EECC, phase I.
Sponsored´s protocol code: LR-201.
Sponsored by: UAM.
Signed date: 30/11/2020

Frías Iniesta, J. Phase I, multi-centre, open-label clinical trial, to assess the suitability of oral calcifediol [25(OH)D] soft gelatine capsules dosage, in subjects with 25(OH)D deficiency, according to their baseline levels (POSCAL).

Type: EECC, phase I.
Sponsored´s protocol code: HIDR-0520/POS.
Sponsored by: UAM.
Signed date: 20/01/2020.

Patents and trademarks

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals. ESM 3.063.048; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus. ESM 3.063.052; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology. ESM 3.063.053; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine. ESM 3.063.049; 2013 February 12.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX. CM 13.681.614; 2015 May 28.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.6.4 Osteoarticular Surgery Research - GICOA Group

Publications:	39
Impact Factor:	99.995
Q1:	13



Enrique Gómez Barrena. Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Catedrático de Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Samuel Antuña Antuña. Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Raúl Barco Laakso. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Ana Cruz Pardos. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Marta Domínguez García-Simón. Enfermera Coordinadora de Ensayos Clínicos. Universidad Autónoma de Madrid

Eduardo García Rey. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Pablo Hernández Esteban. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Carlos Agustín Hernández Gil. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Norma Griset Padilla Eguiluz. Investigadora Predoctoral. Universidad Autónoma de Madrid

Carlos Emérito Rodríguez Merchán. Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Juan Carlos Rubio Suárez. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Strategic Objective

Orthopaedic implant studies are required to assess the results of implants, detect the causes of failure, and deepen our understanding of the prevention and solution of these failures. The medical, social, and economic relevance of orthopaedic implants, and their influence on quality of life, place this technology in the centre of translational research in orthopaedic surgery. Reconstruction based on biological strategies and biomaterials is rapidly evolving, and cutting edge research on these topics may offer an advantage in clinical translational research. The group has also developed studies on sports medicine and ligament reconstruction, with various outcome approaches and devices that may enhance surgical results. In this context, a multidisciplinary clinical and basic research group on orthopaedic surgery deepens our understanding of a wide variety of current research topics in the field and provides further progress towards clinical translation.

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

In order to contribute to new advances in the field, our main clinical and experimental objectives are addressed by a joint research line that covers issues related to bone and joint reconstruction. These issues include the following:

- Failed hip and knee prostheses, including the material, biological, and clinical mechanisms of failure. This research may lead to proposals for materials and design modifications in orthopaedic implants and reconstructive devices and techniques. Functional recovery of the patient is the ultimate goal, considering various scenarios from an experimental and clinical point of view.
- Regenerative medicine approaches to bone and joint reconstruction, to generate preclinical and clinical proposals for bone and joint regeneration and repair, both in traumatic and non-traumatic bone and soft-tissue injuries.

Research lines

- Clinical and basic research in Orthopaedics implants, and in bone and joint reconstruction

Research Activity

Publications

- Bravo E, Barco R, Rodríguez-Merchán EC. Musculo-skeletal problems of the hand in haemophilia. EFORT Open Rev. 2020; 5(6): 328-33. Article. IF: 4.618; Q1
- Carbonell-Escobar R, Vaquero-Picado A, Barco R, Antuña S. Neurologic complications after surgical management of complex elbow trauma requiring radial head replacement. J Shoulder Elbow Surg. 2020; 29(6): 1282-8. Article. IF: 3.019; Q2
- Cucchi D, Luceri F, Celli A, Menon A, Barco R, Wegmann K, Randelli P, Eygendaal D, Arrigoni P. Fracture pattern influences radial head replacement size determination among experienced elbow surgeons. Indian J Orthop. 2020; 54(5): 539-47. Article. IF: 1.251; Q4
- de la Corte-Rodríguez H, Álvarez-Román MT, Rodríguez-Merchán EC, Jiménez-Yuste V. What COVID-19 can mean for people with hemophilia beyond the infection risk. Expert Rev Hematol. 2020; 13(10): 1073-9. Review. IF: 2.929; Q3
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Jiménez-Yuste V. Intra-articular injections in people with haemophilia in the COVID-19 era. Haemophilia. 2020; 26(5): E248-50. Letter. IF: 4.287; Q1
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Martin-Salces M, Martinoli C, Jiménez-Yuste V. HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare? Blood Coagul Fibrinolysis. 2020; 31(6): 387-92. Article. IF: 1.276; Q4
- Encinas-Ullán CA, Martínez-Díez JM, Rodríguez-Merchán EC. The use of external fixation in the emergency department: applications, common errors, complications and their treatment. EFORT Open Rev. 2020; 5(4): 204-14. Article. IF: 4.618; Q1
- Gálvez-Sirvent E, Ibarzábal-Gil A, Rodríguez-Merchán EC. Treatment options for aseptic tibial diaphyseal nonunion: A review of selected studies. EFORT Open Rev. 2020; 5(11): 835-44. Review. IF: 4.618; Q1
- García-Rey E, Sirianni R, García-Cimbrelo E, Sedel L. Total hip arthroplasty after acetabular fracture: does initial treatment make any difference to the outcome? A 5-to 23-year follow-up with clinical and radiological analysis. Hip Int. 2020; 30(3): 339-46. Article. IF: 2.135; Q3
- Gómez-Barrena E, Padilla-Eguiluz N, Rosset P, Gebhard F, Hernigou P, Baldini N, Rouard H, Sensebe L, Gonzalo-Daganzo RM, Giordano R, García-Rey E, Cordero-Ampuero J, Rubio-Suárez JC, García-Simon MD, Stanovici J, Ehrnthaller C, Huber-Lang M, Flouzat-Lachaniette CH, Chevallier N, Donati DM, Spazzoli B, Ciapetti G, Fleury S, Fernández MN, Cabrera JR, Avendaño-Sola C, Montemurro T, Panaitescuk C, Veronesi E, Rojewskit MT, Lotfi R, Dominici M, Schrezenmeier H, Layrolle P. Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. Injury-Int J Care Inj. 2020; 51: S63-73. Article. IF: 2.586; Q2
- Gómez-Barrena E, Padilla-Eguiluz NG, García-Rey E, Hernandez-Esteban P, Cordero-Ampuero J, Rubio-Suárez JC. Validation of a long bone fracture non-union healing score after treatment with mesenchymal stromal cells combined to biomaterials. Injury-Int J Care Inj. 2020; 51: S55-62. Article. IF: 2.586; Q2
- Gómez-Barrena E, Padilla-Eguiluz NG, Rosset P. Frontiers in non-union research. EFORT Open Rev. 2020; 5(10): 574-83. Article. IF: 4.618; Q1
- Gómez-Barrena E, Rubio-Suárez JC, Fernández-Baillo N, Antuña S, Cruz-Pardos A, Blanco M, Ortiz-Cruz E, González-Morán G, Gil-Garay E. Limiting spread of COVID-19 in an orthopaedic department-a perspective from Spain. J Surg Case Rep. 2020; (4): rjaa095. Article. Not Indexed
- Hachem AI, D'O GC, Rondanelli SR, Rius X, Barco R. Latarjet cerclage: The metal-free fixation. Arthrosc Tec. 2020; 9(9): E1397-408. Article. Not Indexed
- Kort NP, Barrena EG, Bedard M, Donell S, Epinette JA, Gomberg B, Hirschmann MT, Indelli P, Khosravi I, Karachalios T, Liebensteiner MC, Stuyts B, Tandogan R, Violante B, Zagra L, Thaler M. Recommendations for resuming elective hip and knee arthroplasty in the setting of the SARS-CoV-2 pandemic: the European Hip Society and European Knee Associates Survey of Members. Knee Surg Sports Traumatol Arthrosc. 2020; 28(9): 2723-9. Article. IF: 4.342; Q1
- Kort NP, Barrena EG, Bedard M, Donell S, Epinette JA, Gomberg B, Hirschmann MT, Indelli P, Khosravi I, Karachalios T, Liebensteiner MC, Stuyts B, Tandogan R, Violante B, Zagra L, Thaler M. Resuming elective hip and knee arthroplasty after the first phase of the SARS-CoV-2 pandemic: the European Hip Society and European Knee Associates recommendations. Knee Surg Sports Traumatol Arthrosc. 2020; 28(9): 2730-46. Article. IF: 4.342; Q1
- Kort NP, Zagra L, Barrena EG, Tandogan RN, Thaler M, Berstock JR, Karachalios T. Resuming hip and knee arthroplasty after COVID-19: ethical implications for well-being, safety and the economy. Hip Int. 2020; 30(5): 492-9. Article. IF: 2.135; Q3
- Norooznezhad F, Rodríguez-Merchán EC, Asadi S, Norooznezhad AH. Curcumin: hopeful treatment of hemophilic arthropathy via inhibition of inflammation and angiogenesis. Expert Rev Hematol. 2020; 13(1): 5-11. Review. IF: 2.929; Q3
- Pasta G, Jannelli E, Ivone A, Mosconi M, Ferranti Calderoni E, Minen A, Benazzo F, Rodríguez-Merchán E C. The role of six biomarkers in diagnosis of hemophilic arthropathy: review of the literature. J Biol Regul Homeost Agents. 2020; 34(3 Suppl. 2): 7-13. Article. IF: 1.711; Q4
- Pérez-Chrzanowska H, Padilla-Eguiluz NG, Gómez-Barrena E. Defining the most effective patient blood management combined with tranexamic acid regime in primary uncemented total hip replacement surgery. J Clin Med. 2020; 9(6): 1952. Article. IF: 4.241; Q1
- Pérez-Chrzanowska H, Pardos AC, González MDB, Barrena EG. Preoperative correction of

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

anemia to allow a 3000 ml blood loss without transfusion in a Jehovah's witness presenting for explantation of an infected hip joint prosthesis: A case report. A A Pract. 2020; 14(6): e01196. Article. Not Indexed

- Pizones J, García-Rey E. Pelvic motion the key to understanding spine-hip interaction. EFORT Open Rev. 2020; 5(9): 522-33. Editorial Material. IF: 4.618; Q1
- Rodríguez-Merchán EC. Antibiotic-loaded bone cement in primary total knee arthroplasty: does it reduce the risk of periprosthetic joint infection? Hosp Pract (1995). 2020; 48(4): 188-95. Article. Not Indexed
- Rodríguez-Merchán EC, de la Corte-Rodríguez H. Complications of hemophilia in the elbow: current management. Expert Rev Hematol. 2020; 13(9): 991-1001. Review. IF: 2.929; Q3
- Rodríguez-Merchán EC, de la Corte-Rodríguez H. Iliopsoas hematomas in people with hemophilia: diagnosis and treatment. Expert Rev Hematol. 2020; 13(8): 803-9. Review. IF: 2.929; Q3
- Rodríguez-Merchán EC, Liddle AD. Prevention of periprosthetic joint infection in total knee arthroplasty: Main studies reported between november 2017 and january 2020. Arch Bone Jt Surg-ABJS. 2020; 8(4): 465-9. Editorial Material. Not Indexed
- Rodríguez-Merchán EC. Does Intravenous or intraarticular tranexamic acid (TXA) reduce joint bleeding following arthroscopic anterior cruciate ligament (ACL) reconstruction and arthroscopic meniscectomy? Can intraarticular use be harmful to chondrocytes? Arch Bone Jt Surg-ABJS. 2020; 8(5): 557-9. Editorial Material. Not indexed
- Rodríguez-Merchán EC. Hemophilic pseudotumors: Diagnosis and management. Arch Bone Jt Surg-ABJS. 2020; 8(2): 121-30. Review. Not Indexed
- Rodríguez-Merchán EC. Outpatient total knee arthroplasty: is it worth considering? EFORT Open Rev. 2020; 5(3): 172-9. Article. IF: 4.618; Q1
- Rodríguez-Merchán EC. Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia? Blood Rev. 2020; 41: 100642. Review. IF: 8.25; Q1
- Rodríguez-Merchán EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Rev Hematol. 2020; 13(3): 269-74. Review. IF: 2.929; Q3
- Rodríguez-Merchán EC. The present situation of patellofemoral arthroplasty in the management of solitary patellofemoral osteoarthritis. Arch Bone Jt Surg-ABJS. 2020; 8(3): 325-31. Review. Not Indexed
- Rodríguez-Merchán EC. Tranexamic acid is effective in decreasing postoperative intraarticular bleeding in arthroscopic knee surgery. Blood Coagul Fibrinolysis. 2020; 31(3): 175-8. Review. IF: 1.276; Q4
- Román MTA, Coll NB, Barcenilla SG, González LP, Collazo ID, Rodríguez HD, Garrido JAR, Salces MM, Pollmar MIR, Cebanu T, González-Zorrilla E, Acuna P, Manzano EM, Merchán ECR, Martínez RT, Banares MJB, Alvarino MG, Yuste VJ. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia. 2020; 26(5): 773-8. Article. IF: 4.287; Q1
- Román-Belmonte JM, de la Corte-Rodríguez H, Rodríguez-Merchán EC, Muñoz-de la Torre E, Vázquez-Sasot A. Strengthening with blood flow restriction: Can it be a useful option in the rehabilitation of patients with coronavirus? Arch Bone Jt Surg-ABJS. 2020; 8(4): 553-6. Letter. Not Indexed
- Rubio I, Bellostas L, García-Rey E. Radiological subsidence and acetabular erosion after tapered uncemented hemiarthroplasty in femoral neck fractures a 10-to 13-year follow-up study. Injury-Int J Care Inj. 2020; 51: S37-41. Article. IF: 2.586; Q2
- Vallés G, Bensiamar F, Maestro-Paramio L, García-Rey E, Vilaboa N, Saldaña L. Influence of inflammatory conditions provided by macrophages on osteogenic ability of mesenchymal stem cells. Stem Cell Res Ther. 2020; 11(1): 57. Article. IF: 6.832; Q1
- van Riet R P, van den Bekerom Mpj, Van Tongel A, Spross C, Barco R, Watts A C. Radial head fractures. Shoulder Elbow. 2020; 12(3): 212-23. Article. Not Indexed
- Vaquero-Picado A, Núñez-de-Armas J, Rubio-Suárez JC, Rodríguez-Merchán EC. Osteosynthesis in Schatzker V and VI tibial plateau fractures in patients older than 65 years - one or two plates? Acta Orthop Belg. 2020; 86(S1): 125-31. Article. IF: 0.5; Q4

Research projects

Antuña Antuña S. Convenio para un proyecto de investigación. Sociedad Española de Cirugia Ortopédica y Traumatología. 2008-Ongoing.

Managment centre: FIBHULP

Barco Laakso R. Artoplastía de cabeza radial anatómica versus espaciador de metal de vástago liso para traumatismo de codo. Médical Simulator S. L. 2018-Ongoing.

Managment centre: FIBHULP

Barco Laakso R. Morfología radiocapitelar, un estudio anatómico. Acumed LLC. 2018-Ongoing.

Managment centre: FIBHULP

Barco Laakso R. Terapia celular con células troncales derivadas del tejido adiposo (ASC) para mejorar el proceso de reparación en suturas tendinosas. Unión tendón-hueso (roturas del manguito rotador); unión tendón-músculo (roturas del tendón de aquiles). Sociedad Española de Cirugia Ortopédica y Traumatología. 2009-Ongoing.

Managment centre: FIBHULP

García Rey E. Identificación de factores moleculares implicados en la Osteonecrosis Idiopática: análisis del transcriptoma del tejido óseo (PI18/00643). Ministerio de Economía, Industria y Competitividad.FIS-ISCIII. 2018-Ongoing.

Managment centre: FIBHULP

Gómez Barrena E. Desinfección in vivo de implantes ortopédicos metálicos mediante calor generado por inducción electromagnética. Fundación Mutua Madrileña. 2020-Ongoing.

Managment centre: FIBHULP

Gómez Barrena E. ORTHO-3, uso de células mesenquimales de donante expandidas para la regeneración ósea en osteonecrosis de cabeza femoral desarrollada tras trasplante de médula ósea (PI17/01844). ISCIII. 2018-2022.

Managment centre: FIBHULP

Gómez Barrena E. ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs (ORTHOUNION). UE. 2017-2021.

Managment centre: FIBHULP

Patents and trademarks

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14

3.6.5 Research in Oral and Maxillofacial Surgery Group


Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Publications:	8
Impact Factor:	7.[109]
Q1:	0



José Luis Cebrián Carretero. Jefe de Sección en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Estefanía Alonso Rodríguez. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Javier González Martín-Moro. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

José Luis del Castillo Pardo de Vera. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

María José Morán Soto. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Pedro Manuel Losa Muñoz. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

Strategic Objective

Latest technologies applied to the field of planning and treatment in Head and Neck Oncology have allowed to improve the diagnosis and surgical treatment in Oral Cancer patients.

Our aim, with this project, is to stablish a work-flow in which technological and technical advances were included as a part of the protocol of treatment for oral cavity cancer patients.

Research lines

- Multidisciplinary Diagnosis and Treatment of Head and Neck Cancer
- Analysis of risk factors and prognosis in oral cavity cancer
- Diagnosis and treatment of postoperative pain
- Quality of life of the oncological patient
- Prevention of the consequences of the treatment of Head and Neck Cancer

Research Activity

Doctoral theses

Alonso Rodríguez E. Osteonecrosis de los maxilares relacionada con bifosfonatos. Aplicación de células madre derivadas de tejido adiposo en modelo experimental murino[dissertation]. Madrid: UAM: 2020(22/07/2020).

Director: Burgueño García M.

Publications

- Díaz-Sáez MC, Gil-Martínez A, González II, Lee JK, de-Vera JLDCP, Carretero JLC, Beltrán-Alacreu H. A novel mobile application to determine mandibular and tongue laterality discrimination in women with chronic temporomandibular disorder. Med Oral Patol Oral Cir Bucal. 2020; 25(6): E775-83. Article. IF: 2.407; Q3
- de Vera JLDP, Carretero JLC, Melón CG, Martín BC. Hybrid tracheotomy. A valid alternative for obese critical patients COVID-19. Rev Esp Anestesiol Reanim. 2020; 67(8): 483-4. Letter. Not indexed
- Tapia B, Garrido E, Cebrián JL, del Castillo JL, Alsina E, Gilsanz F. New techniques and recommendations in the management of free flap surgery for head and neck defects in cancer patients. Minerva Anestesiol. 2020; 86(8): 861-71. Review. IF: 3.051; Q3
- De Vera JLDP, Alcalde SR, Carretero JLC, García MB. The preventive effect of hydrocolloid dressing to prevent facial pressure and facial marks during use of medical protective equipment in the COVID-19 pandemic. Br J Oral Maxillofac Surg. 2020; 58(6): 723-5. Article. IF: 1.651; Q3
- Pampín Martínez MM, Cebrián Carretero JL, Pozo Kreilinger JJ, Burgueño García M. Pseudotumoral calcinosis of the cranial base: a case report. Rev Esp Cir Oral Maxilofac. 2020; 42(4): 175-8. Article. Not Indexed
- Sánchez Gallego-Albertos C, Guiñales Díaz de Cevallos J, del Castillo Pardo de Vera JL, Cebrián Carretero JL, Burgueño García M. Comparison of the outcomes of unilateral orbital fracture repair with and without surgical navigation system: our experience in La Paz University Hospital. Rev Esp Cir Oral Maxilofac. 2020; 42(4): 149-57. Article. Not indexed
- del Castillo Pardo de Vera JL, Cebrián Carretero JL, Guiñales Díaz de Cevallos J, Garrido Ortega P, Noguera Tomás J, Manuel Muñoz Caro J, González Otero T, Morán Soto MJ, Malet Contreras A, Sánchez Gallego-Albertos C, Figueira Iglesias JC, Asensio Martín MJ, Añón Elizalde JM, Burgueño García M. Traqueotomías en pacientes críticos durante la pandemia por COVID-19. Estudio preliminar de nuestra experiencia en el Hospital Universitario La Paz de Madrid. Rev Esp Cir Oral Maxilofac. 2020; 42(2): 60-8. Article. Not Indexed
- Monje Gil F, Cebrián Carretero J L, López-Cedrún Cembranos J L, Redondo Alamillos M, Valdés Beltrán A, Almeida Parra F, García E, Díaz-Mauriño y Garrido-Lestache J C, Tousidonis Rial M A, Ruiz-Laza L, Sastre Pérez J, Ranz Colio A, Acebal Blanco F, Rubio-Palau J, de Pedro Marina M, Redondo González L M, Pla Esparza A, Infante-Cossío P. Manejo de pacientes en cirugía oral y maxilofacial durante el periodo de crisis y de control posterior de la pandemia de COVID-19. Rev Esp Cir Oral Maxilofac. 2020; 42(2): 51-9. Article. Not Indexed

Research projects

del Castillo Pardo de Vera JL. Determinación de la relación causal entre el empleo de bifosfonatos y el desarrollo de osteonecrosis en los maxilares. Aplicación de células madre mesenquimales para su tratamiento sobre modelo experimental animal. Various Funders. 2015-Ongoing.

Managment centre: FIBHULP

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

3.6.6 Patients Safety and Quality Research Group*



Elena Ramírez García. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

Miguel Avenza Jaén. Fisioterapeuta. Hospital Universitario La Paz

José Antonio Blázquez González. Jefe de Sección de Cirugía Vascular. Hospital Universitario La Paz

Nelson Butrago Sánchez. Facultativo Especialista de Área en Radiología Pediátrica. Hospital Universitario La Paz

Luis Castro Parga. Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz

Susana Francisca Chajma Izquierdo. Facultativo Especialista en Medicina Fisica y Rehabilitación. Hospital Universitario La Paz

Pilar Durán de la Fuente. Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz

María Fernández-Velilla Peña. Facultativo Especialista en Radiología. Hospital Universitario La Paz

Miguel González Muñoz. Facultativo Especialista de Area en Inmunología. Hospital Universitario La Paz

Alberto Martín Vega. Facultativo Especialista de Area en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz

Bárbara Martínez de Miguel. Facultativo Especialista en Unidad de Radiofarmacia. Responsable del Sistema de Gestión Integrado de Calidad. Hospital Universitario La Paz

Ana Isabel Martínez Escandell. Unidad hospitalización quirúrgica. Hospital Universitario La Paz

Covadonga Mendieta Azcona. Facultativo Especialista en Cirugía Vascular. Hospital Universitario La Paz

Inés Narrillos Martín. Enfermera en Cirugía general y del Aparato digestivo. Hospital Universitario La Paz

José Jonay Ojeda Feo. Facultativo Especialista de Área en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz

Paola Andrea Parra Ramírez. Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz

Almudena Quintas Viqueira. Médico Adjunto en Medicina Preventiva. Hospital Universitario La Paz

Ana Robustillo Rodela. Jefe de Servicio de Medicina Preventiva. Hospital Universitario La Paz

Pascual Sanabría Carretero. Jefe de Sección Anestesiología Infantil. Hospital Universitario La Paz

Yuri Fabiola Villán Villan. Responsable de Seguridad del Paciente. Hospital Universitario La Paz

Strategic Objective

The ocurrence of adverse events due to unsafe care is likely one of the 10 leading causes of death and disability in the world. Research into reducing harm to patients can lead to better health outcomes, as well as significant savings in healthcare costs.

Patient safety is the health care discipline that arises with the increasing complexity of health care systems and the consequent increase in harm to patients. Its objective is to prevent and reduce the risks, errors and damages suffered by patients during the provision of healthcare. A cornerstone of the discipline is continuous improvement based on learning from mistakes and adverse events.

Research lines

- Culture of Patient Safety.
- Incident reporting system for notification and analysis of adverse events associated to Healthcare.
- Zero Infections related to Healthcare.
- Safe Surgery Saves Lives, whose purpose is to reduce the risks associated with surgery.
- Zero venous thromboembolism, in order to reduce complications attributed to hospitalization.
- Safe Medication, reduce the harm of medications.
- Safe Health Worker, Safe patients.
- Safe Transfusions, reduce adverse reactions to transfusion.
- Safe Radiations, to the right patient in the right area.
- Safe Diagnostics, reduce errors that can cause harm.
- Septicemia as a medical emergency.

* Group recently created, december 2020

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

4 Associated Clinicians

4.1 Biostatistic Group
4.2 Molecular Hepatology Group
4.3 Orthopedic Surgery and Traumatology Group
4.4 Pediatric Surgery Group
4.5 Pharmacy Group



Introduction

Executive summary

Information Groups by Area

Associated Clinicians

4.1 Biostatistic Group

Publications:	14
Impact Factor:	44.987
Q1:	4

Group Leader

Mariana Díaz Almirón

Composition

Itsaso Losantos García



Research areas

- Surgery, transplantation and health technology

Research Activity

Publications

- Barrial MA, Vilanova-Sánchez A, Gortázar S, Nava B, Serradilla J, Bueno A, Losantos I, Martínez L. Pilonidal sinus in pediatric age: primary vs. secondary closure. Cir Pediatr. 2020; 33(2): 61-4. Article. Not Indexed
- Bergón-Sendín M, Pulido-Pérez A, López FC, Díez-Sebastián J, Suárez-Fernández R. Cutaneous ultrasound for tumor thickness measurement in squamous cell carcinoma: The effect of neoadjuvant intralesional methotrexate in 40 patients. Dermatol Surg. 2020; 46(4): 530-6. Article. IF: 3.398; Q2
- Carrión DM, Rodríguez-Socarras ME, Mantica G, Pang KH, Esperto F, Mattigk A, Duijvesz D, Vásquez JL, Díez Sebastian J, Scarpa RM, Papalia R, Palou J, Gomez Rivas J. Interest and involvement of European urology residents in academic and research activities An ESRU-ESU-ESUT collaborative study. Minerva Urol Nefrol. 2020; 72(3): 384-7. Letter. IF: 3.72; Q2
- Esteban-Rodríguez I, Ruiz Bravo-Burguillos E, Rosas R, Losantos I, Rodríguez-Antolin C, de Castro J. Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data. Rev Esp Patol. 2020; 53(1): 10-8. Article. Not Indexed
- Feliú J, Jiménez-Muñárriz B, Basterretxea L, Paredero I, Llabres E, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Muñoz MD, Díaz-Almirón M, Gómez-Mediavilla J, Pinto A, Torregrosa MD, Soler G, Cruz P, Higuera O, Molina-Garrido MJ. Predicting chemotherapy toxicity in older patients with cancer: A multicenter prospective study. Oncologist. 2020; 25(10): E1516-24. Article. Not Indexed
- García-Arranz M, Alonso-Gregorio S, Fontana-Portella P, Bravo E, Sebastián JD, Fernández-Santos ME, García-Olmo D. Two phase I/

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

IIclinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells. Stem Cells Transl Med. 2020; 9(12): 1500-8. Article. IF: 6.94; Q1

- González-Diaz A, Abad-López P, Pena-Vallejo E, Caro-González MP, Calzas-Montalvo C, Gil-Moradillo J, Miranda-Utrera N, Díez-Sebastián J, Varela-Rodríguez C, Rodríguez-Antolín A, Tejido-Sánchez A. Urological surgery during SARS-CoV-2 pandemic. Descriptive analysis of the experience in a Urology Department across the pandemic phases. Actas Urol Esp. 2020; 44(10): 665-73. Article. IF: 0.994; Q4
- Gutiérrez-Zúñiga R, Alonso de Leciñana M, Delgado-Mederos R, Gallego-Cullere J, Rodríguez-Yáñez M, Martínez-Zabaleta M, Freijo M, Portilla J C, Gil-Núñez A, Díez Sebastián J, Lisbona A, Díez-Tejedor E, Fuentes B. Beyond hyperglycemia: glycaemic variability as a prognostic factor after acute ischemic stroke. Neurología (Engl Ed). 2020; 4853(20): 30272-3. Article. IF: 3.109; Q3
- Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Díez J, García-Ramírez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín- Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Sci Rep. 2020; 10(1): 17099. Article. IF: 4.379; Q1
- Moraleda S, Hachoue Z, Abdel-Muti E, Ruiz G, Díez Sebastian J, Lassaletta L. Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A. Rehabilitacion (Madr). 2020; 54(4): 254-9. Article. Not Indexed
- Pérez-Martínez A, Ferreras C, Pascual A, González-Vicent M, Alonso L, Badell I, Navarro JMF, Regueiro A, Plaza M, Hurtado JMP, Benito A, Beléndez C, Couselo JM, Fuster JL, Díaz-Almirón M, Bueno D, Mozo Y, Marsal J, López AG, Sisinni L, de Heredia CD, Díaz MA. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020; 95(1): 28-37. Article. IF: 10.047; D1
- Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, López-Vacas R, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Ferrer-Gómez M, Navarro H, Nanni P, Zamora P, Espinosa E, Main P, Vara JAF. Bayesian networks established functional differences between breast cancer subtypes. PLoS One. 2020; 15(6): e0234752. Article. IF: 3.24; Q2
- Trilla-Fuertes L, Gámez-Pozo A, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Arevalillo JM, Díaz-Almirón M, Navarro H, Main P, Espinosa E, Zamora P, Vara JAF. Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer. BMC Cancer. 2020; 20(1): 307. Article. IF: 4.43; Q2
- Varela R, Casado-Sánchez C, Zarbakhsh S, Díez J, Hernández-Godoy J, Landín L. Outcomes of DIEP flap and fluorescent angiography: A randomized controlled clinical trial. Plast Reconstr Surg. 2020; 145(1): 1-10. Article. IF: 4.73; Q1

Patents and trademarks

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending); 2019 July 19.

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

4.2 Molecular Hepatology Group


Publications:	12
Impact Factor:	139.[815]
Q1:	9

Group Leader

Javier García-Samaniego Rey

Composition

Antonio Madejón Seiz
Miriam Romero Portales
Araceli García Sánchez
Antonio Olveira Martín
Pilar Castillo Grau
Ana Isabel Gil García



Research areas

- Infectious diseases and immunity

Research Activity

Doctoral theses

Honrubia López R. Repercusión del tratamiento con antivirales de acción directa sobre la evolución clínica y calidad de vida de pacientes con hepatitis crónica C tratados en un hospital terciario[dissertation]. Madrid: UAM: 2020(2020/18/9).

Directors: García-Samaniego Rey J, Madejón Séiz A.

Publications

- López SA, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Uson C, Real Y, Rincón D, Fernández-Rodríguez CM, Banares R. A Model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis. Hepatology. 2020; 72(6): 1924-34. Article. IF: 17.425; D1
- Lens S, Miquel M, Mateos-Muñoz B, García-Samaniego J, Forns X. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol. 2020; 73(5): 1262-3. Letter. IF: 25.083; D1
- Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the spanish association for study of the liver on the treatment of hepatitis b virus infection (2020). Gastroenterol Hepatol. 2020; 43(9): 559-87. Article. IF: 2.102; Q4
- Ibáñez-Samaniego L, Bighelli F, Usón C, Caravaca C, Carrillo CF, Romero M, Barreales M, Perello C, Madejón A, Marcos AC, Albillos A, Fernández I, García-Samaniego J, Calleja JL, Banares R. Elevation of liver fibrosis index FIB-4 is associated with poor clinical outcomes in patients With COVID-19. J Infect Dis. 2020; 222(5): 726-33. Article. IF: 5.226; Q1
- Salguero S, Rojo D, Berenguer J, González-García J, Fernández-Rodríguez A, Brochado-Kith O, Díez C, Hontañón V, Virseda-Berdices A, Martínez J, Ibáñez-Samaniego L, Llop-Herrera E,

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Barbas C, Resino S, Jiménez-Sousa MA. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. Liver Int. 2020; 40(9): 2215-27. Article. IF: 5.828; Q2

- Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballeria J, Lo Iacono O, Ibáñez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Gómez MR. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol. 2020; 73(1): 17-25. Article. IF: 25.083; D1
- Meneses D, Olveira A, Corripio R, Méndez MD, Romero M, Calvo-Vinuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of noninvasive liver fibrosis scores in the morbid obese patient, same scores but different thresholds. Obes Surg. 2020; 30(7): 2538-46. Article. IF: 4.129; Q1
- Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernández-Alonso I, Castellote J, Niubo J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustín S, Conde I, Rubín A, Prieto M, Torras X, Margall N, Forns X, Marino Z, Lens S, Bonacci M, Pérez-del-Pulgar S, Londono MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martro E, Saludes V, Masnou-Ridaura H, Salmerón J, Quiles R, Carrión JA, Forne M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Nunez C, Ferri MJ, Durandez R, Saez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gómez-Alonso MJ, Rodríguez M, Deig E, Olive G, del Río O, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbes M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martín-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, di Yacovo MS, Ocana I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernandez D, Viroles S, Pamplona X, Cairo M, Ocete MD, Macías-Sánchez JF, Estebánez A, Quer JC, Mena-de-Cea A, Otero A, Castro-Iglesias A, Suárez F, Vázquez A, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fabregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martín C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, del-Campo JA, Domingo E, Esteban R, Esteban JI, Quer J. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2020; 174: 104694. Article. IF: 5.97; Q1
- Ampuero J, País R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballeria J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M, Agustín S, Jorquera F, Francés R, García-Samaniego J, Salmerón J, Fernández-Rodríguez C, Estévez P, Andrade R, Soriano G, Fernández-Bermejo M, Loste MTA, Siguenza R, Giannetti A, Maroto ED. Development and validation of hepamet fibrosis scoring system-A simple, noninvasive test to fdentify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol. 2020; 18(1): 216-25. Article. IF: 11.382; Q1
- Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Dona I, Fernández J, García-Núñez I, García-Samaniego J, López-Rico R, Marín-Serrano E, Merida C, Moya M, Ortega-Rodríguez NR, Becerra BR, Rojas-Pérez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellón T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Invest Allergol Clin Immunol. 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Palom A, Rodríguez-Tajes S, Navascues CA, García-Samaniego J, Riveiro-Barciela M, Lens S, Rodríguez M, Esteban R, Buti M. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Aliment Pharmacol Ther. 2020; 51(1): 158-66. Article. IF: 8.171; D1
- Harrison Stephen A, Goodman Zachary, Jabbar Abdul, Vemulapalli Ravi, Younes Ziad H, Freilich Bradley, Sheikh Muhammad Y, Schattenberg Jorn M, Kayali Zeid, Zivony Adam, Sheikh Aasim, García-Samaniego Javier, Satapathy Sanjaya K, Therapondos George, Mena Edward, Schuppan Detlef, Robinson James, Chan Jean L, Hagerty David T, Sanyal Arun J. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020; 72(5): 816-27-. Article. IF: 25.083; D1

Research projects

García-Samaniego Rey J. Massive HCV screening using serological tests at the points of care (POCTS) in the metropolitan area of Madrid. An approach for local elimination strategies. Gilead Sciences S.A. 2019-2022.

Managment centre: CIBERehd

Madejón Seiz A. Development of a detection system of genetic modifications with clinical implications in the development of hunman liver cancer. ARCIS Biotechnology. 2018-2021.

Managment centre: CIBERehd

Madejón Seiz A. Identification of genes related with recurrence of human liver cancer in anti-HCV treatment responder patients. ARCIS Biotechnology. 2018-2020.

Managment centre: CIBERehd

Cibers and Retics

García-Samaniego Rey J. Networked Biomedical Research Center for Hepatic and Digestive Diseases - CIBEREHD (CB06/04/0083). 31/12/2020.

Managmente Centre: FIBHULP

Clinical trials

Álvarez Maestro, M. Quimioterapia neoadyuvante versus adyuvante en carcinoma urotelial del tracto urinario superior. Ensayo clínico randomizado de viabilidad fase II. URANOS.

Type: Clinical Trial, phase II.
HULP code: 5582 .
Sponsored´s protocol code: EUOG-2016-003.
Sponsored by: European Uro-Oncology Group.
Signed date: 28/09/2020

Olveira Martin, A. Estudio multicéntrico de fase III, doble ciego, aleatorizado, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica.

Type: Clinical Trial, phase III.
HULP code: Appendix 1 4999.
Sponsored´s protocol code: 747-304.
Sponsored by: Intercept Pharmaceuticals Inc.
Signed date: 22/10/2020

Olveira Martin, A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, confirmatorio y de dos partes para evauar la eficacia y seguridad de VAY736 en pacientes con hepatitis autoinmunitaria con respuesta incompleta o intolerancia al tratamiento estándar (Amber).

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Type: Clinical Trial, phase II.
HULP code: Appendix 1 5232.
Sponsored´s protocol code: CVA-Y736B2201.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 17/06/2020

Olveira Martin, A. Estudio en fase IIB/III internacional, sin interrupciones, adaptativo, doble ciego, aleatorizado, controlado con placebo, multicéntrico, en el que se evalúa la eficacia y la seguridad de belapectin (GR-MD-02) para la prevención de las varices esofágicas en la cirrosis por EH.

Type: Clinical Trial, phase II.
HULP code: 5660.
Sponsored´s protocol code: GT-031 NASH-RX.
Sponsored by: Galectin Therapeutics Inc.
Signed date: 23/09/2020

Olveira Martin, A. Evaluación de la eficacia, la seguridad y la tolerabilidad de NGM282 (aldafermina) en un estudio fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo de pacientes con cirrosis compensada por esteatohepatitis no alcohólica (Alpine 4).

Type: Clinical Trial, phase II.
HULP code: 5547.
Sponsored´s protocol code: 282-CC-207.
Sponsored by: NGM Biopharmaceuticals Inc.
Signed date: 24/09/2020

Castillo Grau, P. Estudio clínico de fase 3/4, multinacional, multicéntrico, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de aramchol en pacientes con esteatohepatitis no alcohólica (Estudio Armor).

Type: Clinical Trial, phase III.
HULP code: 5434.
Sponsored´s protocol code: ARAM-CHOL-018.
Sponsored by: Galmed Research and Developmente Ltd.
Signed date: 14/01/2020

Patents and trademarks

Castán García P, Gil García AI, Madejón Seiz A, Montoya Miñano JJ, Sainz Martínez E, inventors; MIRNAX BIOSENS, S.L, applicants; Bivalent reverse primers. EP19382956.1 and EP20382336.4, PCT/EP2020/080999; 2019 November 04 and 2020 April 24.

Limones López GR, Madejón Seiz A, inventors; Biotools Biotechnological & Medical Laboratories, S.A., applicants; Method for the amplification by reverse transcription coupled to a nested or semi-nested reaction PCR in a single step, of a target RNA, and its applications in the identification of enterovirus and the discrimination between poliovirus and non-polio enterovirus. P200100567; 2001 March 12.

Madejón Seiz A, Vega Rocha S; inventors; Biotools Biotechnological & Medical Laboratories, S.A., applicants; Single stage amplification of DNA by semi nested PCR consists of contacting a Diana DNA fragment with a reaction mixture for pathogens identification. P200100568, 2001 March 12.

Franco de Sarabia Rosado PM, Limones López GR, Madejón Seiz A, Marín Alberdi MD; inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Procedimiento para la preparación de mezclas de reacción estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reacción y kits que las contienen. ARP020104835; 2002 December 12.

Franco de Sarabia Rosado PM, Limones López GR, Madejón Seiz A, Marín Alberdi MD, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Method for preparing stabilised reaction mixtures, which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures. P200100569, PCT/ES02/00109, AU2002246125B2, BR0204479A, BR0204479B1, CA2408857A1, EP1374827A2, EP1374827B1, IL152757A, JP2004519242A, JP4448280B2, KR20030036178A, US2003119042A1, US7919294B2; 2001 March 12.

De Grado Sanz M, Franco de Sarabia Rosado PM, Haro Castuera A, Limones López GR, Madejón Seiz A, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Stabilised composition for fluorimetric, colorimetric or chemoluminescent assays, kits containing same and production method thereof. P200300472, PCT/ES2004/000024, EP04703407.9; 2003 February 26.

Madejón Seiz A, Limones López GR, Calvo Macarro FJ, Rodríguez Gil S, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.A., applicants; Nucleic acid detection method involving the direct generation of a measurable signal. PCT/ES2005/070093, AU2005333512A1, CA2579918A1, EP1892302A1, JP2008543300A, US2007292868A1, US7919244B2; 2005 June 16

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

4.3 Orthopedic Surgery and Traumatology Group

Publications:	18
Impact Factor:	46.[33]
Q1:	4

Group Leader

Francisco Javier Sánchez Pérez-Grueso

Composition

Irene Barrientos Ruiz
Juan Cabello Blanco
Rafael Carbonell Escobar
Nicomedes Fernández-Baíllo
Gaspar González Morán
Luis Rodrigo Merino Rueda
Eduardo Ortiz Cruz
Manuel Peleteiro Pensado
Mar Pérez Martín-Buitrago
Francisco Javier Pizones Arce
Jose Miguel Sánchez Márquez
Eloy Dario Tabeayo Alvarez
Alfonso Vaquero Picado
Juan Ignacio Viñuales García



Research areas

- Surgery, transplantation and health technology

Research Activity

Publications

- Acaroglu E, Yuksel S, Ates C, Ayhan S, Bahadir S, Nabi V, Vila-Casademunt A, Pérez-Grueso FJS, Obeid I. Decision analysis in quest of the ideal treatment in adult spinal deformity adjusted for minimum clinically important difference. World Neurosurg. 2020; 142: E278-89. Article. IF: 2.104; Q3
- Bourghli A, Boissiere L, Larrieu D, Kaissar F, Cawley D, Fujishiro T, Kieser D, Gille O, Vital JM, Alanay A, Pellise F, Acaroglu E, Pérez-Grueso FJ, Kleinstuck F, Obeid I. Opioids and analgesics use after adult spinal deformity surgery correlates with sagittal alignment and preoperative analgesic pattern. Eur Spine J. 2020; 29(1): 73-84. Article. IF: 3.134; Q2
- Carbonell-Escobar R, Vaquero-Picado A, Barco R, Antuna S. Neurologic complications after surgical management of complex elbow trauma requiring radial head replacement. J Shoulder Elbow Surg. 2020; 29(6): 1282-8. Article. IF: 3.019; Q2
- Díez-Manglano J, Muñoz LB. Simplified medication regimen and survival in polypathological patients. Med Clin. 2020; 154(7): 248-53. Article. IF: 1.725; Q3
- Encinas-Ullan CA, Martínez-Díez JM, Rodríguez-Merchán EC. The use of external fixation in the emergency department: applications, common errors, complications and their treatment. EFORT Open Rev. 2020; 5(4): 204-14. Article. IF: 4.618; Q1
- Gálvez-Sirvent E, Ibarzábal-Gil A, Rodríguez-Merchán EC. Treatment options for aseptic tibial diaphyseal nonunion: A review of selected studies. EFORT Open Rev. 2020; 5(11): 835-44. Review. IF: 4.618; Q1
- García-Maya B, Pizones J, Sánchez-Márquez JM, Talavera G, Pérez-Grueso FJ, Fernández-Baillo N. Median sacral artery rupture as a complication of posterior-only approach of L4 total en bloc spondilectomy: A case report. JBJS Case Connect. 2020; 10(3): e1900427. Article. Not Indexed

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

- García-Rey E, Sirianni R, García-Cimbrelo E, Sedel L. Total hip arthroplasty after acetabular fracture: does initial treatment make any difference to the outcome? A 5-to 23-year follow-up with clinical and radiological analysis. Hip Int. 2020;30(3):339-346. Article. IF: 2,135; Q3
- Gómez-Barrena E, Padilla-Eguiluz N, Rosset P, Gebhard F, Hernigou P, Baldini N, Rouard H, Sensebe L, Gonzalo-Daganzo RM, Giordano R, García-Rey E, Cordero-Ampuero J, Rubio-Suárez JC, García-Simón MD, Stanovici J, Ehrnthaller C, Huber-Lang M, Flouzat-Lachaniette CH, Chevallier N, Donati DM, Spazzoli B, Ciapetti G, Fleury S, Fernández MN, Cabrera JR, Avendaño-Sola C, Montemurro T, Panaitescuk C, Veronesi E, Rojewskit MT, Lotfi R, Dominici M, Schrezenmeier H, Layrolle P. Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. Injury-Int J Care Inj. 2020; 51: S63-73. Article. IF: 2.586; Q2
- Gomez-Barrena E, Padilla-Eguiluz NG, García-Rey E, Hernandez-Esteban P, Cordero-Ampuero J, Rubio-Suárez JC. Validation of a long bone fracture non-union healing score after treatment with mesenchymal stromal cells combined to biomaterials. Injury-Int J Care Inj. 2020; 51: S55-62. Article. IF: 2.586; Q2
- Gómez-Barrena E, Rubio-Suárez JC, Fernández-Baillo N, Antuña S, Cruz-Pardos A, Blanco M, Ortiz-Cruz E, González-Morán G, Gil-Garay E. Limiting spread of COVID-19 in an orthopaedic department-a perspective from Spain. J Surg Case Rep. 2020; (4): . Article. Not Indexed
- Hayashi K, Boissiere L, Cawley DT, Larrieu D, Kieser D, Berjano P, Lamartina C, Gupta M, Silvestre C, Protopsaltis T, Bourghli A, Pellise F, Annis P, Papadopoulos EC, Kreichati G, Pizones J, Nakamura H, Ames CP, Obeid I. A new classification for coronal malalignment in adult spinal deformity: a validation and the role of lateral bending radiographs. Eur Spine J. 2020; 29(9): 2287-94. Article. IF: 3.134; Q2
- Pizones J, García-Rey E. Pelvic motion the key to understanding spine-hip interaction. EFORT Open Rev. 2020; 5(9): 522-33. Editorial Material. IF: 4.618; Q1
- Pizones J, Pérez-Grueso FJS, Moreno-Manzanaro L, Vila-Casademunt A, Boissiere L, Yilgor C, Fernández-Baillo N, Sánchez-Márquez JM, Talavera G, Kleinstuck F, Acaroglu ER, Alanay A, Pellise F, Obeid I. Ideal sagittal profile restoration and ideal lumbar apex positioning play an important role in postoperative mechanical complications after a lumbar PSO. Spine Deform. 2020; 8(3): 491-8. Article. IF: 2.135; Q3
- Rodríguez-Merchán EC, Encinas-Ullán CA, Gómez-Cardero P. Intra-articular tranexamic acid in primary total knee arthroplasty decreases the rate of post-operative blood transfusions in people with hemophilia: A retrospective case-control study. HSS J. 2020; 16(3): 218-21. Article. Not Indexed
- Rubio I, Bellostas L, García-Rey E. Radiological subsidence and acetabular erosion after tapered uncemented hemiarthroplasty in femoral neck fractures a 10-to 13-year follow-up study. Injury-Int J Care Inj. 2020; 51: S37-S41. Article. IF: 2.586; Q2
- Vallés G, Bensiamar F, Maestro-Paramio L, García-Rey E, Vilaboa N, Saldaña L. Influence of inflammatory conditions provided by macrophages on osteogenic ability of mesenchymal stem cells. Stem Cell Res Ther. 2020; 11(1): 57. Article. IF: 6.832; Q1
- Vaquero-Picado A, Núñez-de-Armas J, Rubio-Suárez JC, Rodríguez-Merchán EC. Osteosynthesis in Schatzker V and VI tibial plateau fractures in patients older than 65 years - one or two plates? Acta Orthop Belg. 2020; 86(S1): 125-31. Article. IF: 0.5; Q4

Research projects

Pizones Arce FJ. Clinical outcomes following conservatives and surgical treatment of adult spine deformity. Fundacio Vall d´Hebron. 2012-Ongoing.

Managment centre: FIBHULP

Vaquero Picado A. Estudio de la reproducibilidad y precisión de la reparación anatómica del ligamento colateral lateral ulnar del codo por vía artroscópica. Fundación Española de Artroscopia. 2019-Ongoing.

Managment centre: Universidad Francisco de Vitoria

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

4.4 Pediatric Surgery Group

Publications:	20
Impact Factor:	97.[393]
Q1:	7

Group Leader

Manuel López Santamaría

Composition

ISaturnino Barrena Delfa
Manuel Gámez Arance
Nuria Leal Hernando
Juan Carlos López Gutiérrez
Maria José Martínez Urrutia
Miriam Miguel Ferrero
Francisco J. Murcia Zorita
Vanessa Núñez Cerezo
Paloma E. Triana Junco
Juan José Vázquez Estévez
Alejandra Vilanova Sánchez



Research areas

- Surgery, transplantation and health technology

Research Activity

Publications

- Barrial MA, Vilanova-Sánchez A, Gortázar S, Nava B, Serradilla J, Bueno A, Losantos I Martínez L. Pilonidal sinus in pediatric age: primary vs. secondary closure. Cir Pediatr. 2020; 33(2): 61-4. Article. Not Indexed
- Carrillo-Reixach J, Torrens L, Simón-Coma M, Royo L, Domingo-Sabat M, Abril-Fornaguera J, Akers N, Sala M, Ragull S, Arnal M, Villalmanzo N, Cairo S, Villanueva A, Kappler R, Garrido M, Guerra L, Sabado C, Guillen G, Mallo M, Pineyro D, Vázquez-Vitali M, Kuchuk O, Mateos ME, Ramírez G, Santamaría ML, Mozo Y, Soriano A, Grotzer M, Branchereau S, de Andoin NG, López-Ibor B, López-Almaraz R, Salinas JA, Torres B, Hernandez F, Uriz JJ, Fabre M, Blanco J, Paris C, Bajciova V, Laureys G, Masnou H, Clos A, Beléndez C, Guettier C, Sumoy L, Planas R, Jorda M, Nonell L, Czauderna P, Morland B, Sia D, Losic B, Buendía MA, Sarrias MR, Llovet JM, Armengol C. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol. 2020; 73(2): 328-41. Article. IF: 25.083; D1
- Delgado-Miguel C, Vicente M, Serrano-Muñoz AJ, Miguel-Ferrero M, Díaz M, Triana P, López-Gutiérrez JC. Clinical factors in trunk capillary malformations in the neonate: When to suspect other associated malformations? A case-control Study. Eur J Pediatr Surg. 2020; 30(1): 122-6. Article. IF: 2.191; Q3
- Ivars M, Azana JM, Weibel L, Theiler M, Boixeda P, Norris DI, Martínez-Glez V, Agra N, Rodríguez-Laguna L, Colmenero I, Beato-Merino MJ, López-Gutiérrez JC. Capillary malformation with segmental distribution and central atrophy: A series of 7 cases. J Am Acad Dermatol. 2020; 83(1): 213-4. Letter. IF: 11.527; D1
- Ivars M, Boixeda P, Triana P, Martínez-Glez V, Rodríguez-Laguna L, Agra N, López-Gutiérrez JC. Clinical overlap between CLAPO syndrome and macrocephaly-capillary malformation syndrome. J Dtsch Dermatol Ges. 2020; 18(5):

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

479-82. Letter. IF: 5.584; Q1

- Ivars M, Boixeda P, Triana P, Martínez-Glez V, Rodríguez-Laguna L, Agra N, López-Gutiérrez JC. Klinische uberlappung zwischen CLAPO-syndrom und megalenzephalie-kapillarfehlbildungen-polymikrogyrie-syndrom. J Dtsch Dermatol Ges. 2020; 18(5): 480-4. Letter. IF: 5.584; Q1
- Ivars M, López-Gutiérrez JC, Martínez-Glez V, Redondo P. Ein asymptomatischer Fleck auf der Stirn. J Dtsch Dermatol Ges. 2020; 18(12): 1511-14. Article. IF: 5.584; Q1
- Ivars M, Triana P, López-Gutiérrez JC. Reactivation of Kasabach-Merritt phenomenon in a young adult with a congenital kaposiform hemangioendothelioma. Pediatr Dermatol. 2020; 37(5): 958-9. Article. IF: 1.588; Q3
- Marín-Manzano E, López-Gutiérrez JC. Usefulness of multidisciplinary approach in the management of diffuse venous malformations. J Vasc Surg-Venous Lymphat Dis. 2020; 8(6): 1127. Letter. IF: 2.859; Q2
- Marín-Manzano E, Mendieta-Azcona C, Riera-del-Moral L, López-Gutiérrez JC. Effectiveness and safety of 1470-nm diode laser fulguration in the management of diffuse venous malformations. J Vasc Surg-Venous Lymphat Dis. 2020; 8(3): 423-34. Article. IF: 2.859; Q2
- Navarro-Zorraquino M, Pastor C, Stringa P, Soria J, Hernández F, López-Santamaría M, García-Alvarez F. Implant of mesenchymal cells decreases acute cellular rejection in small bowel transplantation. Cir Cir. 2020; 88(5): 554-61. Article. IF: 0.361; Q4
- Rodríguez-Jiménez P, Chicharro P, Llamas-Velasco M, Moyano B, Sánchez-Carpintero I, López-Gutiérrez JC, Martínez-Glez V, Rodríguez-Laguna L, Torrelo A. A case of naevus vascularis mixtus with hypotrophy and hypotrichosis due to mosaic GNA11 mutation. J Eur Acad Dermatol Venereol. 2020; 34(8): E420-2. Letter. IF: 6.166; Q1
- Tomas-Velázquez A, López-Gutiérrez JC, Ceballos C, Núñez-Córdoba JM, Redondo P. S-100B serum protein is elevated in children with medium-to-giant congenital melanocytic nevi: An exploratory case-control study. J Am Acad Dermatol. 2020; 83(1): 222-4. Letter. IF: 11.527; D1
- Triana P, Rodríguez-Laguna L, Giacaman A, Salinas-Sanz JA, Martín-Santiago A, López-Santamaría M, Palacios E, Beato MJ, Martínez-González V, López-Gutiérrez JC. Congenital hepatic hemangiomas: Clinical, histologic, and genetic correlation. J Pediatr Surg. 2020; 55(10): 2170-6. Article. IF: 2.545; Q2
- Velayos M, Muñoz-Serrano AJ, Estefanía-Fernández K, Caldas MCS, Lapena LM, López-Santamaría M, López-Gutiérrez JC. Influence of the coronavirus 2 (SARS-Cov-2) pandemic on acute appendicitis. An Pediatr. 2020; 93(2): 118-22. Article. IF: 1.5; Q4
- Vilanova-Sánchez A, Choueiki J, Smith CA, Callicot S, Frischer JS, Levitt MA. Creating a collaborative program for the care of children with colorectal and pelvic problems. Semin Pediatr Surg. 2020; 29(6): 150985. Article. IF: 2.754; Q2
- Vilanova-Sánchez A, Halleran DR, Reck CA, McCracken K, Hewitt G, Gasior AC, Weaver L, Ahmad H, Akers A, Jaggers J, Rentea RM, Levitt MA, Wood RJ. Factors predicting the need for vaginal replacement at the time of primary reconstruction of a cloacal malformation. J Pediatr Surg. 2020; 55(1): 71-4. Article. IF: 2.545; Q2
- Vilanova-Sánchez A, Ivanov M, Halleran DR, Wagner A, Reck-Burneo CA, Ruth B, FIsher M, Ahmad H, Weaver L, Nash O, Buker D, Rentea RM, Hoover E, Maloof T, Wood RJ, Levitt MA. Total colonic Hirschsprung's disease: The hypermotility and skin rash protocol. Eur J Pediatr Surg. 2020; 30(4): 309-16. Review. IF: 2.191; Q3
- Vilanova-Sánchez A, Levitt MA. Surgical interventions for functional constipation: An update. Eur J Pediatr Surg. 2020; 30(5): 413-19. Review. IF: 2.191; Q3
- Wood RJ, Reck-Burneo CA, Vilanova-Sánchez A, Levitt MA. Organizing the care of a patient with a cloacal malformation: Key steps and decision making for pre-, intra-, and post-operative repair. Semin Pediatr Surg. 2020; 29(6): 150988. Article. IF: 2.754; Q2

Research projects

López Gutiérrez JC. Consolidation of our lymphatic anomalies program. Lymphangiomatosis & Gorham'S Disease Alliance. 2018-Ongoing.

Managment centre: FIBHULP

Vázquez Estévez JJ. Tratamientos de depuración extracorporea en pacientes criticos. De la investigación a la práctica clínica. Nikkiso America Inc. 2016-Ongoing.

Managment centre: FIBHULP

Vázquez Estévez JJ. Proyecto de investigación en tecnologías terapéuticas avanzadas del centro de simulación. Espiral Médica S. L. P. 2015-Ongoing.

Managment centre: FIBHULP

Vázquez Estévez JJ. Donación: proyecto de investigación en tecnologías terapéuticas avanzadas: dinamización del centro de simulación. Becton Dickinson S. A. 2015-Ongoing.

Managment centre: FIBHULP

Introduction

Executive summary

Information Groups by Area

Associated Clinicians

4.5 Pharmacy Group

Publications:	8
Impact Factor:	108.[214]
Q1:	3

Group Leader

Alicia Herrero Ambrosio

Composition

Luis González del Valle
Susana de Andrés Moreira
Cristina Bilbao-Gómez Martino
Gema Casado Abad
María Jesús de Domingo Gadea
Ángeles García Martín
Natalia García Vázquez
Pilar Gómez Salcedo
Maríaa Ángeles González Fernández
Inmaculada Jiménez Nacher
Carlos Jiménez Vicente
Catalina Lara Cátedra
Patricia Lucena Martínez
Marta Moreno Palomino
Francisco Moreno Ramos
Ester Pérez Andréu
Tamara Pérez Robles
Elena Rodríguez Martín
José Antonio Romero Garrido
Fátima Ros Catelar
Margarita Ruano Encinar
Luis Sánchez-Rubio Ferrández
Ana Sierra Muñoz
Carmen Sobrino Jiménez
María Luisa Testillano Tarrero
Elena Villamañán Bueno
Javier Álvarez Criado
Cristina Núñez Jiménez
Ana Belén Arancón Pardo
Macarena García-Trevijano Cabetas
Marta Ayllón Morales
Miguel Escario Gómez
Carmen Mateos Salillas
Ángela Hoyo Muñoz
Cristina Cárdenas Sarralde
Maria del Río Durango
Nuria Blázquez Ramos



Research areas

- Surgery, transplantation and health technology

Introduction
Executive summary
Information Groups by Area
Associated Clinicians

Research Activity

Doctoral theses

Sobrino Jiménez C. Estudio de utilización del concentrado de complejo protrombónico en un servicio de urgencias[dissertation]. MADRID: UCM: 2020(04/12/2020).

Directors: Romero Garrido JA, Benedi González JM.

García Vázquez MN. Validación del método de cribado automático del riesgo de desnutrición conut, su comparación con otros métodos de valoración y su capacidad de predicción de complicaciones, readmisiones y fallecimientos[dissertation]. MADRID: UAM: 2020(02/12/2020).

Directors: Gómez Candela C, Villamañán Bueno E.

Bilbao Gómez-Martino C. Snálisis de los medicamentos implicados en errores de conciliación al ingreso hospitalario[dissertation]. MADRID: UCM: 2020(16/10/2020).

Directors: Romero Garrido JA, Benedi González JM.

Publications

- Añón JM, Curto J, del Rosario Urbez M, Burnham PM, Testillano ML, de la Cerda G, Álvarez-Rojas E, García de Lorenzo A. Postintensive care syndrome and follow-up clinics: results after a two-year pilot. Minerva Anestesiol. 2020; 86(11): 1246-8. Letter. IF: 3.051; Q3
- Lazzarato I, González-Muñoz M, Heredia R, Castellar FR, de la Guía AL, Cabañas R, Fiandor A, Domínguez-Ortega J. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. Eur Ann Allergy Clin Immunol. 2020; 52(5): 235-7. Letter. Not Indexed
- Román MTA, Coll NB, Barcenilla SG, González LP, Collazo ID, Rodríguez HD, Garrido JAR, Salces MM, Pollmar MIR, Cebanu T, González-Zorrilla E, Acuña P, Manzano EM, Merchán ECR, Martínez RT, Banares MJB, Alvarino MG, Yuste VJ. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia. 2020; 26(5): 773-8. Article. IF: 4.287; Q1
- García-Vázquez N, Milla SP, López-Plaza B, Valero-Pérez M, Morato-Martínez M, Gómez-Candela C. Comparison of the CONUT method with SGA and NSA for the prediction of complications, hospital stay, readmissions, and mortality. Nutr Hosp. 2020; 37(4): 799-806. Article. IF: 1.057; Q4
- Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quirós-Roldán E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, Monforte AD, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020; 382(24): 2327-36. Article. IF: 91.245; D1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Santolaya-Perrín R, García-Martín A, Carrero-Fernández A, Torres-Santos-Olmo R. Hospital pharmacist experience in a multidisciplinary team in special care settings. Farm Hosp. 2020; 44: 36-9. Article. Not Indexed
- Villamañán E, Herrero A, Álvarez-Sala R, Quirce S. Multidisciplinary severe asthma management: The role of hospital pharmacists in accredited specialized adult asthma units in Spain. J Invest Allergol Clin Immunol. 2020; 30(4): 305-6. Letter. IF: 4.333; Q2

Research projects

Romero Garrido JA. Estudio de adherencia al tratamiento sustitutivo con factores de la coagulacion en pacientes diagnosticados de hemofilia grave en regimen de demanda y profilaxis y su relacion con los episodios de sangrado. Pfizer S.L.U. 2016-Ongoing.


Managment centre: FIBHULP

Villamañán Bueno E. Evaluación de las objeciones alegadas por un Comité Ético de Investigación Clínica a los consentimientos informados de los estudios clinicos. Amgen S.A. 2016-Ongoing.

Managment centre: FIBHULP

Scientific Report 2020

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz



SaludMadrid Hospital Universitario La Paz
Hospital Carlos III
Hospital Cantoblanco

SaludMadrid Hospital Universitario La Paz
Fundación para la Investigación Biomédica
Comunidad de Madrid

UAM
Universidad Autónoma de Madrid

SaludMadrid Hospital Universitario de Getafe

ue Universidad Europea